(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2019 (14.11.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/217890 A1

(51) International Patent Classification:
C07D 207/20 (2006.01) *C07D 487/04* (2006.01)
C07D 209/96 (2006.01) *A61P 25/00* (2006.01)
C07D 401/06 (2006.01) *A61K 31/497* (2006.01)
C07D 401/12 (2006.01) *A61K 31/4015* (2006.01)
C07D 471/10 (2006.01)

(21) International Application Number:
PCT/US2019/031824

(22) International Filing Date:
10 May 2019 (10.05.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/670,116 11 May 2018 (11.05.2018) US

(71) Applicant: **TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION** [US/US]; Broad & Montgomery Avenue, Philadelphia, PA 19122 (US).

(72) Inventors: **CANNEY, Daniel, J.**; 7 Carey Drive, Ambler, PA 19002 (US). **BLASS, Benjamin, E.**; 1029 Clark Hill Drive, Eagleville, PA 19403 (US). **BLATTNER, Kevin, M.**; 116 Cherry Lane, Folsom, PA 19033 (US). **PIPPIN, Douglas, A.**; 6 Phillips Lane, Chester Springs, PA 19425 (US).


(74) Agent: **ESPINO, Christine, G.**; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report (Art. 21(3))*

(54) **Title:** NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE



(I)





(57) **Abstract:** Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activity. A is selected from a group consisting of (group) and (group)

WO 2019/217890 A1

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

CROSS REFERENCE TO RELATED APPLICATIONS

[001] This application claims the benefit of U.S. Provisional Application No. 62/670,116, filed May 11, 2018, which is herein incorporated by reference in its entirety.

STATEMENT OF FEDERALLY FUNDED RESEARCH

[002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant number 143DK115254-01 awarded by the National Institute of Diabetes and Digestive and Kidney Disease and grant number HHSN-271-2008-00025-C awarded by the National Institute of Mental Health.

FIELD OF INVENTION

[003] Embodiments of the invention are directed to novel compounds useful as modulators of 5-hydroxytryptamine receptor 7 (5-HT_7) activity and their method of use. Embodiments are further directed to a novel chemotype useful for the treatment diseases that are associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.


BACKGROUND OF THE INVENTION

[004] Serotonin was discovered in the late 1940s and is present in both the peripheral and central nervous systems [Physiol. Res, 60 (2011) 15-25; Psychopharmacology 213 (2011) 167-169]. Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter of the indolalkylamine group that acts at synapses of nerve cells. Seven distinct families of serotonin receptors have been identified and at least 20 subpopulations have been cloned on the basis of sequence similarity, signal transduction coupling and pharmacological characteristics. The seven families of 5-HT receptor are named 5-HT_1, 5-HT_2, 5-HT_3, 5-HT_4, 5-HT_5, 5-HT_6, and 5-HT_7 and each of these receptors in turn has subfamilies or subpopulations. The signal transduction mechanism for all seven families have been studied and it is known that activation of 5-HT_1 and 5-HT_5 receptors causes a decrease in intracellular cAMP whereas activation of 5-HT_2, 5-HT_3, 5-HT_4, 5-HT_6, and 5-HT_7 results in an increase in intracellular IP3 and DAG. The 5-HT pathways in the brain are important targets for drug development in the area of CNS disorders. The

neurotransmitter binds to its a G-protein coupled receptor and is involved in a wide variety of actions including cognition, mood, anxiety, attention, appetite, cardiovascular function, vasoconstriction, sleep (ACS Medicinal Chemistry Letters, 2011, 2, 929-932; Physiological Research, 2011, 60, 15-25), inflammatory bowel disease (IBD), and intestinal inflammation (WO 2012058769, Khan, W. I., et. al. Journal of Immunology, 2013, 190, 4795-4804), epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9) among others.




SUMMARY OF THE INVENTION

[005] The present invention is directed toward novel 5-hydroxytryptamine receptor 7 (5-HT7) activity modulators, compounds of formula (I),



(I)

Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

A is selected from a group consisting of  ,  , and  ;

R^1 is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl;

R^2 is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl;

Or R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having from 5 to 7 ring atoms, optionally containing a double bond;

Or R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having from 6 to 8 ring atoms containing a moiety selected from the group consisting of O, S, SO, SO_2, and NR^7;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl, and  ;

R^4 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl and  ;

R^5 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl and  ;

R^6 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, and optionally substituted 4-pyridyl;






R^7 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, COR^8, CO_2R^9, $CONR^{10a}R^{10b}$, $SO_2NR^{10a}R^{10b}$, and SO_2R^{10c};


R^8 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^9 is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10a} is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10b} is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10c} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, $-(CH_2)_qCN$, $-(CH_2)_qSO_2R^{11}$, $-(CH_2)_qOR^{12}$,  ,  ,  ,  ,  ,



and ;

R^{11} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{12} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^{1e} are at each occurrence independently selected from the group consisting of H, OH, NO_2, halogen, CN, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, -S(C_{1-6} linear alkyl), S(C_{3-7} branched alkyl), -S(C_{3-7} cycloalkyl), COR^{13}, CO_2R^{14}, $CONR^{15a}R^{15b}$, $SO_2NR^{15a}R^{15b}$, $NR^{16a}R^{16b}$, $NR^{16a}COR^{17}$, $NR^{16a}SO_2R^{18}$, and $NR^{16a}SO_2NR^{19a}R^{19b}$;

R^{13} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{14} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{15a} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{15b} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{16a} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{16b} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{17} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{18} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{19a} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{19b} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


n is 1, 2, 3, or 4;

m is 1, 2, or 3.

[006] In embodiments, A is  . In embodiments, n is 1, 2, or 3. In embodiments, n is 1 or 2. In embodiments, n is 1. In embodiments, n is 2. In embodiments, each of R^1 and R^2 is unsubstituted C_{1-6} alkyl (e.g., each of R^1 and R^2 is methyl or each of R^1 and R^2 is ethyl). In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring (e.g., a C_3-C_8 cycloalkyl, a C_5-C_8 cycloalkenyl, or a 5- to 8-membered ring containing a ring atom that is NR^7). In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, pyrrolidinyl, or piperidinyl, wherein the nitrogen atom in said pyrrolidinyl or piperidinyl group is NR^7. In embodiments, R^7 is an alkylsulfonyl $–SO_2R^{10c}$ (e.g., $-SO_2Me$) or an acyl $–COR^8$ (e.g., acetyl). In embodiments, R^3 is phenyl or a pyridyl. In embodiments, R^3 is unsubstituted. In embodiments, R^3 is substituted (e.g., a phenyl substituted by 1, 2, 3, 4, or 5 substituents or a pyridyl substituted by 1, 2, 3, or 4 substituents). In embodiments, substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, $-O^nPr$, $-O^iPr$, $-OCF_3$, -Me, -Et, $-^nPr$, $-^iPr$, $-CF_3$, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[007] In embodiments, A is  . In embodiments, n is 1, 2, or 3. In embodiments, n is 1 or 2. In embodiments, n is 1. In embodiments, n is 2. In embodiments, each of R^1 and R^2 is unsubstituted C_{1-6} alkyl (e.g., each of R^1 and R^2 is methyl or each of R^1 and R^2 is ethyl). In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring (e.g., a C_3-C_8 cycloalkyl, a C_5-C_8 cycloalkenyl, or a 5- to 8-membered ring containing a ring atom that is NR^7). In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl,

pyrrolidinyl, or piperidinyl, wherein the nitrogen atom in said pyrrolidinyl or piperidinyl group is NR^7. In embodiments, R^7 is an alkylsulfonyl $-SO_2R^{10c}$ (e.g., $-SO_2Me$) or an acyl $-COR^8$ (e.g., acetyl). In embodiments, R^4 is phenyl or a pyridyl. In embodiments, R^4 is unsubstituted. In embodiments, R^4 is substituted (e.g., a phenyl substituted by 1, 2, 3, 4, or 5 substituents or a pyridyl substituted by 1, 2, 3, or 4 substituents). In embodiments, substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, $-O^nPr$, $-O^iPr$, $-OCF_3$, -Me, -Et, $-^nPr$, $-^iPr$, $-CF_3$, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[008] In embodiments, A is  . In embodiments, n is 1, 2, or 3. In embodiments, n is 1 or 2. In embodiments, n is 1. In embodiments, n is 2. In embodiments, each of R^1 and R^2 is unsubstituted C_{1-6} alkyl (e.g., each of R^1 and R^2 is methyl or each of R^1 and R^2 is ethyl). In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring (e.g., a C_3-C_8 cycloalkyl, a C_5-C_8 cycloalkenyl, or a 5- to 8-membered ring containing a ring atom that is NR^7). In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, pyrrolidinyl, or piperidinyl, wherein the nitrogen atom in said pyrrolidinyl or piperidinyl group is NR^7. In embodiments, R^7 is an alkylsulfonyl $-SO_2R^{10c}$ (e.g., $-SO_2Me$) or an acyl $-COR^8$ (e.g., acetyl). In embodiments, R^5 is phenyl or a pyridyl. In embodiments, R^5 is unsubstituted. In embodiments, R^5 is substituted (e.g., a phenyl substituted by 1, 2, 3, 4, or 5 substituents or a pyridyl substituted by 1, 2, 3, or 4 substituents). In embodiments, substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, $-O^nPr$, $-O^iPr$, $-OCF_3$, -Me, -Et, $-^nPr$, $-^iPr$, $-CF_3$, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[009] In embodiments, a compound is according to any formula described herein, or a pharmaceutically acceptable salt thereof. In embodiments, a compound is any compound described herein or a pharmaceutically acceptable salt thereof (e.g., a compound as described in any of Tables 1-39 described herein, or a pharmaceutically acceptable salt thereof). In embodiments, a compound is any of the compounds described in any of Tables 34-39, or a pharmaceutically acceptable salt thereof.

[010] In embodiments, a compound has the *S*-configuration at the nitrogen-substituted carbon of the lactam. In embodiments, a compound has the *R*-configuration at the nitrogen-substituted carbon of the lactam.

[011] The present invention further relates to compositions comprising:

an effective amount of one or more compounds according to the present invention and an excipient.

[012] The present invention also relates to a method for treating or preventing diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, including, for example, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury said method comprising administering to a subject an effective amount of a compound or composition according to the present invention.

[013] The present invention yet further relates to a method for treating or preventing diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, including, for example, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar, disorder inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.

[014] The present invention also relates to a method for treating or preventing diseases or conditions associated with circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome,

premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury, and diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity. Said methods comprise administering to a subject an effective amount of a compound or composition according to the present invention.

[015] The present invention yet further relates to a method for treating or preventing diseases or conditions associated with circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, and bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury, and diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.

[016] The present invention also relates to a method for treating or preventing diseases or conditions associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. Said methods comprise administering to a subject an effective amount of a compound or composition according to the present invention.

[017] The present invention yet further relates to a method for treating or preventing diseases or conditions associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.

[018] The present invention further relates to a process for preparing the 5-hydroxytryptamine receptor 7 activity modulators of the present invention.

[019] In embodiments, a disease or condition is inflammatory bowel disease (IBD).

[020] These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified.

All temperatures are in degrees Celsius (° C) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[021] There is evidence that suggests a role for the 5-HT_7 receptor in a number of medical disorders. 5-HT_7 receptor activity modulators are likely to have a beneficial effect on patients suffering from these disorders. The disorders in which 5-HT_7 dysregulation plays a role and modulation of 5-HT_7 receptor activity by a therapeutic agent may be a viable approach to therapeutic relief include, but are not limited to, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine (Vanhoenacker, P. et al. Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder (WO20100197700) attention deficit/hyperactivity disorder (ADHD) (WO20100069390), anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), intestinal inflammation (WO 2012058769, Khan, W. I., et. al. Journal of Immunology, 2013, 190, 4795-4804), epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9), breast cancer (Gautam, J. Molecular Cancer, 2016, 15, 75, 1-14, Gautam, J. Breast Cancer Research and Treatment, 2017, 161, 29-40), liver fibrosis, chronic liver injury (Halici, Z. International Immunopharmacology, 2017, 43, 227-235), hepatocellular carcinoma (Bian, Z. X. Molecular Oncology, 2016, 10, 195-212), small intestine neuroendocrine tumors (Modlin, I. M. Cancer Science, 2013, 104, 7, 844-855), and lung injury (Halici, Z. Immunology, 2013, 1271-1283.).

[022] There is a long felt need for new 5-HT_7 modulators that will provide therapeutic relief from patients suffering from diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The invention addresses the need to identify novel 5-HT7 modulators capable of treating disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The present invention addresses the need to develop new therapeutic agents for the treatment and prevention of circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic

pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury.

[023] The 5-hydroxytryptamine receptor 7 activity modulators of the present invention are capable of treating and preventing diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, for example circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury. It has been discovered that the 5-hydroxytryptamine receptor 7 play a role in a number of medical disorders, and therefore, 5-HT_7 receptor activity modulators are likely to have a beneficial effect on patients suffering from these disorders. The disorders in which 5-HT_7 dysregulation plays a role and modulation of 5-HT_7 receptor activity by a therapeutic agent may be a viable approach to therapeutic relief include, but are not limited to, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine (Vanhoenacker, P.et. al. Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder (WO20100197700) attention deficit/hyperactivity disorder (ADHD) (WO20100069390), anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), intestinal inflammation (WO 2012058769) epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9), breast cancer (Gautam, J. Molecular Cancer, 2016, 15, 75, 1-14, Gautam, J. Breast

Cancer Research and Treatment, 2017, 161, 29-40), liver fibrosis, chronic liver injury (Halici, Z. International Immunopharmacology, 2017, 43, 227-235), hepatocellular carcinoma (Bian, Z. X. Molecular Oncology, 2016, 10, 195-212), small intestine neuroendocrine tumors (Modlin, I. M. Cancer Science, 2013, 104, 7, 844-855), and lung injury (Halici, Z. Immunology, 2013, 1271-1283.).

[024] Without wishing to be limited by theory, it is believed that 5-hydroxytryptamine receptor 7 receptor activity modulators of the present invention can ameliorate, abate, otherwise cause to be controlled, diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The diseases include, but are not limited to circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury.

[025] In embodiments, a disease is depression, schizophrenia, anxiety, or bipolar disorder. In embodiments, a disease is depression. In embodiments, a disease is schizophrenia. In embodiments, a disease is anxiety. In embodiments, a disease is bipolar disorder.

[026] In embodiments, a disease is attention deficit/hyperactivity disorder.

[027] In embodiments, a disease is avoidant personality disorder.

[028] In embodiments, a disease is seasonal affective disorder.

[029] In embodiments, a disease is circadian rhythm disorder or hippocampal signaling disorder. In embodiments, a disease is circadian rhythm disorder. In embodiments, a disease is hippocampal signaling disorder.

[030] In embodiments, a disease is neurogenic inflammation.

[031] In embodiments, a disease is neuropathic pain, peripheral pain, or allodynia. In embodiments, a disease is neuropathic pain. In embodiments, a disease is peripheral pain. In embodiments, a disease is allodynia.

[032] In embodiments, a disease is migraine.

[033] In embodiments, a disease is epilepsy or a seizure disorder. In embodiments, a disease is epilepsy. In embodiments, a disease is a seizure disorder.

[034] In embodiments, a disease is a learning disorder or a memory disorder. In embodiments, a disease is a learning disorder. In embodiments, a disease is a memory disorder.

[035] In embodiments, a disease is an eating disorder.

[036] In embodiments, a disease is drug addiction or alcohol addiction.

[037] In embodiments, a disease is a sleep disorder.

[038] In embodiments, a disease is hypertension or peripheral vascular disease. In embodiments, a disease is hypertension. In embodiments, a disease is peripheral vascular disease.

[039] In embodiments, a disease is thermoregulation disorder.

[040] In embodiments, a disease is premature ejaculation.

[041] In embodiments, a disease is premenstrual syndrome or premenstrual dysphonic disorder. In embodiments, a disease is premenstrual syndrome. In embodiments, a disease is premenstrual dysphonic disorder.

[042] In embodiments, a disease is inflammatory bowel disease (IBD) or intestinal inflammation. In embodiments, a disease is inflammatory bowel disease (IBD). In embodiments, a disease is intestinal inflammation.

[043] In embodiments, a disease is breast cancer.

[044] In embodiments, a disease is liver fibrosis, chronic liver injury, or hepatocellular carcinoma. In embodiments, a disease is liver fibrosis. In embodiments, a disease is chronic liver injury. In embodiments, a disease is hepatocellular carcinoma.

[045] In embodiments, a disease is a small intestine neuroendocrine tumor.

[046] In embodiments, a disease is lung injury.

[047] In embodiments, a disease is inflammatory bowel disease (IBD).

[048] In embodiments, a compound described herein is a selective modulator of the serotonin 5HT7 receptor. In embodiments, a compound described herein can more potently bind a serotonin 5HT7 receptor as compared to other targets (e.g., other serotonin receptors). In embodiments, a compound may selectively bind a serotonin 5HT7 receptor in a particular tissue or organ.

[049] In embodiments, compounds described herein may have particularly favorable properties for effective therapy (e.g., of any of the diseases or conditions described herein). For example, in the treatment of CNS or mental disorders, a compound described herein may exhibit favorably effective blood-brain barrier permeability. Alternatively, in the treatment of non-CNS or –mental disorders, a compound described herein will not have high blood-brain barrier

permeability (e.g., off-target effects will be reduced). Without being bound by theory, molecular elements of a compound may be an effective strategy for obtaining the desired biological targeting.

[050] For example, a compound described herein may selectively bind serotonin 5HT7 receptors in the intestine of a subject. Accordingly, a compound may be used to treat or prevent inflammatory bowel disease (IBD) or intestinal inflammation.

[051] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present teachings also consist essentially of, or consist of, the recited components, and that the processes of the present teachings also consist essentially of, or consist of, the recited processing steps.

[052] In the application, where an element or component is said to be included in and/or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components and can be selected from a group consisting of two or more of the recited elements or components.

[053] The use of the singular herein includes the plural (and vice versa) unless specifically stated otherwise. In addition, where the use of the term "about" is before a quantitative value, the present teachings also include the specific quantitative value itself, unless specifically stated otherwise.

[054] It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present teachings remain operable. Moreover, two or more steps or actions can be conducted simultaneously.

[055] As used herein, the term "halogen" shall mean chlorine, bromine, fluorine and iodine.

[056] As used herein, unless otherwise noted, "alkyl" and/or "aliphatic" whether used alone or as part of a substituent group refers to straight and branched carbon chains having 1 to 20 carbon atoms or any number within this range, for example 1 to 6 carbon atoms or 1 to 4 carbon atoms. Designated numbers of carbon atoms (e.g. C_{1-6}) shall refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, *iso*-propyl, n-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, and the like. Alkyl groups can be optionally substituted. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl,

trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3-carboxypropyl, and the like. In substituent groups with multiple alkyl groups such as (C_{1-6}alkyl)$_2$amino, the alkyl groups may be the same or different.

[057] As used herein, the terms "alkenyl" and "alkynyl" groups, whether used alone or as part of a substituent group, refer to straight and branched carbon chains having 2 or more carbon atoms, preferably 2 to 20, wherein an alkenyl chain has at least one double bond in the chain and an alkynyl chain has at least one triple bond in the chain. Alkenyl and alkynyl groups can be optionally substituted. Nonlimiting examples of alkenyl groups include ethenyl, 3-propenyl, 1-propenyl (*also* 2-methylethenyl), isopropenyl (*also* 2-methylethen-2-yl), buten-4-yl, and the like. Nonlimiting examples of substituted alkenyl groups include 2-chloroethenyl (*also* 2-chlorovinyl), 4-hydroxybuten-1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, 7-hydroxy-7-methyloct-3,5-dien-2-yl, and the like. Nonlimiting examples of alkynyl groups include ethynyl, prop-2-ynyl (*also* propargyl), propyn-1-yl, and 2-methyl-hex-4-yn-1-yl. Nonlimiting examples of substituted alkynyl groups include, 5-hydroxy-5-methylhex-3-ynyl, 6-hydroxy-6-methylhept-3-yn-2-yl, 5-hydroxy-5-ethylhept-3-ynyl, and the like.

[058] As used herein, "cycloalkyl," whether used alone or as part of another group, refers to a non-aromatic carbon-containing ring including cyclized alkyl, alkenyl, and alkynyl groups, e.g., having from 3 to 14 ring carbon atoms, preferably from 3 to 7 or 3 to 6 ring carbon atoms, or even 3 to 4 ring carbon atoms, and optionally containing one or more (e.g., 1, 2, or 3) double or triple bond. Cycloalkyl groups can be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridged, and/or spiro ring systems), wherein the carbon atoms are located inside or outside of the ring system. Any suitable ring position of the cycloalkyl group can be covalently linked to the defined chemical structure. Cycloalkyl rings can be optionally substituted. Nonlimiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1*H*-indenyl, 3a,4,5,6,7,7a-hexahydro-3*H*-inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, and dodecahydro-1*H*-fluorenyl. The term "cycloalkyl" also includes carbocyclic rings which are bicyclic hydrocarbon rings, non-limiting examples of which include, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.

[059] "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen. Haloalkyl groups include perhaloalkyl groups, wherein all hydrogens of an alkyl group have been replaced with halogens (e.g., $-CF_3$, $-CF_2CF_3$). Haloalkyl groups can optionally be substituted with one or more substituents in addition to halogen. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl groups.

[060] The term "alkoxy" refers to the group –O-alkyl, wherein the alkyl group is as defined above. Alkoxy groups optionally may be substituted. The term C_3-C_6 cyclic alkoxy refers to a ring containing 3 to 6 carbon atoms and at least one oxygen atom (e.g., tetrahydrofuran, tetrahydro-2H-pyran). C_3-C_6 cyclic alkoxy groups optionally may be substituted.

[061] The term "haloalkoxy" refers to the group –O-haloalkyl, wherein the haloalkyl group is as defined above. Examples of haloalkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and pentafluoroethoxyl.

[062] The term "aryl," wherein used alone or as part of another group, is defined herein as an unsaturated, aromatic monocyclic ring of 6 carbon members or to an unsaturated, aromatic polycyclic ring of from 10 to 14 carbon members. Aryl rings can be, for example, phenyl or naphthyl ring each optionally substituted with one or more moieties capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthylen-1-yl, naphthylen-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(*N*,*N*-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-*tert*-butylphenyl, 3-methoxyphenyl, 8-hydroxynaphthylen-2-yl 4,5-dimethoxynaphthylen-1-yl, and 6-cyano-naphthylen-1-yl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl, indanyl), which can be substituted at one or more carbon atoms of the aromatic and/or saturated or partially saturated rings.

[063] The term "arylalkyl" or "aralkyl" refers to the group –alkyl-aryl, where the alkyl and aryl groups are as defined herein. Aralkyl groups of the present invention are optionally substituted. Examples of arylalkyl groups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl and the like.

[064] The terms "heterocyclic" and/or "heterocycle" and/or "heterocylyl," whether used alone or as part of another group, are defined herein as one or more ring having from 3 to 20

atoms wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O), or sulfur (S), and wherein further the ring that includes the heteroatom is non-aromatic. In heterocycle groups that include 2 or more fused rings, the non-heteroatom bearing ring may be aryl (e.g., indolinyl, tetrahydroquinolinyl, chromanyl). Exemplary heterocycle groups have from 3 to 14 ring atoms of which from 1 to 5 are heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heterocycle group can be oxidized. Heterocycle groups can be optionally substituted.

[065] Non-limiting examples of heterocyclic units having a single ring include: diazirinyl, aziridinyl, urazolyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyl oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl (valerolactam), 2,3,4,5-tetrahydro-1*H*-azepinyl, 2,3-dihydro-1*H*-indole, and 1,2,3,4-tetrahydro-quinoline. Non-limiting examples of heterocyclic units having 2 or more rings include: hexahydro-1*H*-pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-1*H*-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1*H*-indolyl, 1,2,3,4-tetrahydroquinolinyl, chromanyl, isochromanyl, indolinyl, isoindolinyl, and decahydro-1*H*-cycloocta[b]pyrrolyl.


[066] The term "heteroaryl," whether used alone or as part of another group, is defined herein as one or more rings having from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), and wherein further at least one of the rings that includes a heteroatom is aromatic. In heteroaryl groups that include 2 or more fused rings, the non-heteroatom bearing ring may be a carbocycle (e.g., 6,7-Dihydro-5*H*-cyclopentapyrimidine) or aryl (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplary heteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heteroaryl group can be oxidized. Heteroaryl groups can be substituted. Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1*H*-imidazolyl, oxazolyl, furanyl, thiopheneyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing 2 or more fused rings include: benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7*H*-purinyl, 9*H*-purinyl, 6-amino-9*H*-purinyl, 5*H*-pyrrolo[3,2-*d*]pyrimidinyl, 7*H*-pyrrolo[2,3-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1*H*-indolyl,

4,5,6,7-tetrahydro-1-*H*-indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, 1H-benzo[d]imidazol-2(3H)-onyl, 1H-benzo[d]imidazolyl, and isoquinolinyl.


[067] One non-limiting example of a heteroaryl group as described above is C_1-C_5 heteroaryl, which has 1 to 5 carbon ring atoms and at least one additional ring atom that is a heteroatom (preferably 1 to 4 additional ring atoms that are heteroatoms) independently selected from nitrogen (N), oxygen (O), or sulfur (S). Examples of C_1-C_5 heteroaryl include, but are not limited to, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1*H*-imidazol-2-yl, 1*H*-imidazol-4-yl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.

[068] Unless otherwise noted, when two substituents are taken together to form a ring having a specified number of ring atoms (e.g., R^2 and R^3 taken together with the nitrogen (N) to which they are attached to form a ring having from 3 to 7 ring members), the ring can have carbon atoms and optionally one or more (e.g., 1 to 3) additional heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). The ring can be saturated or partially saturated and can be optionally substituted.


[069] For the purposed of the present invention fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring. For example, 1,2,3,4-tetrahydroquinoline having the formula:



is, for the purposes of the present invention, considered a heterocyclic unit. 6,7-Dihydro-5*H*-cyclopentapyrimidine having the formula:



is, for the purposes of the present invention, considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both a saturated and an aryl ring, the aryl ring will predominate and determine the type of category to which the ring is assigned. For example, 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula:



is, for the purposes of the present invention, considered a heteroaryl unit.

[070] Whenever a term or either of their prefix roots appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (*e.g.*, arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl" and "aryl."

[071] The term "substituted" is used throughout the specification. The term "substituted" is defined herein as a moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several (e.g., 1 to 10) substituents as defined herein below. The substituents are capable of replacing one or two hydrogen atoms of a single moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit. For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. The term "substituted" is used throughout the present specification to indicate that a moiety can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as "substituted" any number of the hydrogen atoms may be replaced. For example, difluoromethyl is a substituted C_1 alkyl; trifluoromethyl is a substituted C_1 alkyl; 4-hydroxyphenyl is a substituted aromatic ring; (N,N-dimethyl-5-amino)octanyl is a substituted C_8 alkyl; 3-guanidinopropyl is a substituted C_3 alkyl; and 2-carboxypyridinyl is a substituted heteroaryl.

[072] The variable groups defined herein, *e.g.*, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted. Optionally substituted groups will be so indicated.

[073] The following are non-limiting examples of substituents which can substitute for hydrogen atoms on a moiety: halogen (chlorine (Cl), bromine (Br), fluorine (F) and iodine(I)), –CN, $–NO_2$, oxo (=O), $–OR^{26}$, $–SR^{26}$, $–N(R^{26})_2$, $–NR^{26}C(O)R^{26}$, $–SO_2R^{26}$, $–SO_2OR^{26}$, $–SO_2N(R^{26})_2$, $–C(O)R^{26}$, $–C(O)OR^{26}$, $–C(O)N(R^{26})_2$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{3-14} cycloalkyl, aryl, heterocycle, or heteroaryl, wherein each of the alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocycle, and heteroaryl groups is optionally substituted with 1-10 (e.g., 1-6 or 1-4) groups selected independently from halogen, –CN, $–NO_2$, oxo, and R^{26}; wherein R^{26}, at each occurrence, independently is hydrogen, $–OR^{27}$, $–SR^{27}$, $–C(O)R^{27}$, $–C(O)OR^{27}$, $–C(O)N(R^{27})_2$, $–SO_2R^{27}$, $-S(O)_2OR^{27}$, $–N(R^{27})_2$, $–NR^{27}C(O)R^{27}$, C_{1-}

$_{6}$ alkyl, C_{1-6} haloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cycloalkyl (*e.g.*, C_{3-6} cycloalkyl), aryl, heterocycle, or heteroaryl, or two R^{26} units taken together with the atom(s) to which they are bound form an optionally substituted carbocycle or heterocycle wherein said carbocycle or heterocycle has 3 to 7 ring atoms; wherein R^{27}, at each occurrence, independently is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cycloalkyl (*e.g.*, C_{3-6} cycloalkyl), aryl, heterocycle, or heteroaryl, or two R^{27} units taken together with the atom(s) to which they are bound form an optionally substituted carbocycle or heterocycle wherein said carbocycle or heterocycle preferably has 3 to 7 ring atoms.

[074] In some embodiments, the substituents are selected from

i) $-OR^{28}$; for example, $-OH$, $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2CH_3$;

ii) $-C(O)R^{28}$; for example, $-COCH_3$, $-COCH_2CH_3$, $-COCH_2CH_2CH_3$;

iii) $-C(O)OR^{28}$; for example, $-CO_2CH_3$, $-CO_2CH_2CH_3$, $-CO_2CH_2CH_2CH_3$;

iv) $-C(O)N(R^{28})_2$; for example, $-CONH_2$, $-CONHCH_3$, $-CON(CH_3)_2$;

v) $-N(R^{28})_2$; for example, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NH(CH_2CH_3)$;

vi) halogen: –F, –Cl, –Br, and –I;

vii) $-CH_eX_g$; wherein X is halogen, m is from 0 to 2, e+g =3; for example, $-CH_2F$, $-CHF_2$, $-CF_3$, $-CCl_3$, or $-CBr_3$;

viii) $-SO_2R^{28}$; for example, $-SO_2H$; $-SO_2CH_3$; $-SO_2C_6H_5$;

ix) C_1-C_6 linear, branched, or cyclic alkyl;

x) Cyano

xi) Nitro;

xii) $N(R^{28})C(O)R^{28}$;

xiii) Oxo (=O);

xiv) Heterocycle; and

xv) Heteroaryl.

wherein each R^{28} is independently hydrogen, optionally substituted C_1-C_6 linear or branched alkyl (e.g., optionally substituted C_1-C_4 linear or branched alkyl), or optionally substituted C_3-C_6 cycloalkyl (e.g optionally substituted C_3-C_4 cycloalkyl); or two R^{28} units can be taken together to form a ring comprising 3-7 ring atoms. In certain aspects, each R^{28} is independently hydrogen, C_1-C_6 linear or branched alkyl optionally substituted with halogen or C_3-C_6 cycloalkyl or C_3-C_6 cycloalkyl.

[075] At various places in the present specification, substituents of compounds are disclosed in groups or in ranges. It is specifically intended that the description include each and

every individual subcombination of the members of such groups and ranges. For example, the term "C_{1-6} alkyl" is specifically intended to individually disclose C_1, C_2, C_3, C_4, C_5, C_6, C_1-C_6, C_1-C_5, C_1-C_4, C_1-C_3, C_1-C_2, C_2-C_6, C_2-C_5, C_2-C_4, C_2-C_3, C_3-C_6, C_3-C_5, C_3-C_4, C_4-C_6, C_4-C_5, and C_5-C_6, alkyl.

[076] For the purposes of the present invention the terms "compound," "analog," and "composition of matter" stand equally well for the 5-hydroxytryptamine receptor 7 activity modulators described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms "compound," "analog," and "composition of matter" are used interchangeably throughout the present specification.

[077] Compounds described herein can contain an asymmetric atom (also referred as a chiral center), and some of the compounds can contain one or more asymmetric atoms or centers, which can thus give rise to optical isomers (enantiomers) and diastereomers. The present teachings and compounds disclosed herein include such enantiomers and diastereomers, as well as the racemic and resolved, enantiomerically pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, which include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. The present teachings also encompass cis and trans isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It is also understood that the present teachings encompass all possible regioisomers, and mixtures thereof, which can be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography.

[078] Pharmaceutically acceptable salts of compounds of the present teachings, which can have an acidic moiety, can be formed using organic and inorganic bases. Both mono and polyanionic salts are contemplated, depending on the number of acidic hydrogens available for deprotonation. Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a mono-, di-, or trihydroxy lower alkylamine (e.g., mono-, di- or triethanolamine). Specific non-limiting examples of inorganic bases include $NaHCO_3$, Na_2CO_3, $KHCO_3$, K_2CO_3, Cs_2CO_3, LiOH, NaOH, KOH, NaH_2PO_4, Na_2HPO_4, and

Na_3PO_4. Internal salts also can be formed. Similarly, when a compound disclosed herein contains a basic moiety, salts can be formed using organic and inorganic acids. For example, salts can be formed from the following acids: acetic, propionic, lactic, benzenesulfonic, benzoic, camphorsulfonic, citric, tartaric, succinic, dichloroacetic, ethenesulfonic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, malonic, mandelic, methanesulfonic, mucic, napthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, phthalic, propionic, succinic, sulfuric, tartaric, toluenesulfonic, and camphorsulfonic as well as other known pharmaceutically acceptable acids.

[079] When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence (e.g., in $N(R^9)_2$, each R^9 may be the same or different than the other). Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.


[080] The terms "treat" and "treating" and "treatment" as used herein, refer to partially or completely alleviating, inhibiting, ameliorating and/or relieving a condition from which a patient is suspected to suffer.

[081] As used herein, "therapeutically effective" and "effective dose" refer to a substance or an amount that elicits a desirable biological activity or effect.

[082] Except when noted, the terms "subject" or "patient" are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to which the compounds of the invention can be administered. In an exemplary embodiment of the present invention, to identify subject patients for treatment according to the methods of the invention, accepted screening methods are employed to determine risk factors associated with a targeted or suspected disease or condition or to determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine risk factors that may be associated with the targeted or suspected disease or condition. These and other routine methods allow the clinician to select patients in need of therapy using the methods and compounds of the present invention.



The 5-Hydroxytryptamine Receptor 7 Activity Modulators

[083] The present invention is directed toward novel 5-hydroxytryptamine receptor 7 (5-HT7) activity modulators, compounds of formula (I),



(I)

Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

A is selected from a group consisting of  , and  ;

R^1 is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl;

R^2 is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl;

Or R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having from 5 to 7 ring atoms, optionally containing a double bond;

Or R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having from 6 to 8 ring atoms containing a moiety selected from the group consisting of O, S, SO, SO_2, and NR^7;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl, and  ;

R^4 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl and  ;

R^5 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl and  ;

R^6 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, and optionally substituted 4-pyridyl;













R^7 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, COR^8, CO_2R^9, $CONR^{10a}R^{10b}$, $SO_2NR^{10a}R^{10b}$, and SO_2R^{10c};

R^8 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^9 is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10a} is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10b} is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10c} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, $-(CH_2)_qCN$, $-(CH_2)_qSO_2R^{11}$, $-(CH_2)_qOR^{12}$,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  ;

R^{11} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{12} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^{1e} are at each occurrence independently selected from the group consisting of H, OH, NO_2, halogen, CN, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, -S(C_{1-6} linear alkyl), S(C_{3-7} branched alkyl), -S(C_{3-7} cycloalkyl), COR^{13}, CO_2R^{14}, $CONR^{15a}R^{15b}$, $SO_2NR^{15a}R^{15b}$, $NR^{16a}R^{16b}$, $NR^{16a}COR^{17}$, $NR^{16a}SO_2R^{18}$, and $NR^{16a}SO_2NR^{19a}R^{19b}$;

R^{13} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{14} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{15a} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{15b} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{16a} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{16b} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{17} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{18} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{19a} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{19b} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

n is 1, 2, 3, or 4;

m is 1, 2, or 3.

[084] In embodiments,

A is  ;

each R^1 and R^2 is independently C_{1-6} linear alkyl or C_{3-7} branched alkyl; or R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring,

wherein said 5- to 8-membered ring is saturated or comprises a carbon-carbon double bond, and/or a ring atom that is O, S, SO, SO_2, or NR^7

each R^3, R^4, and R^5 is independently optionally substituted phenyl, optionally optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, or optionally substituted 4-pyridyl;

R^6 is independently optionally substituted phenyl, optionally optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, or optionally substituted 4-pyridyl;

R^7 is independently H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, COR^8, or SO_2R^{10c};

R^8 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{10c} is C_{1-6} linear alkyl or C_{3-7} branched alkyl;

n is 1, 2, 3, or 4; and

m is 1, 2, or 3.

[085] In embodiments, n is 1, 2, or 3. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 3.


[086] The embodiments of the present invention include compounds having formula **(II)**:



(II)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

[087] In embodiments, a compound has the formula **(XLII)**:



(XLII) or a pharmaceutically acceptable salt thereof.

[088] In embodiments, a compound has the formula **(XLIII)**:



(XLIII) or a pharmaceutically acceptable salt thereof.

[089] In embodiments, n is 1, 2, or 3. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 3. In embodiments, n is 1 or 2.


[090] In embodiments, each of R^1 and R^2 is unsubstituted C_{1-6} alkyl. In embodiments, each of R^1 and R^2 is ethyl. In embodiments, each of R^1 and R^2 is methyl.

[091] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring, optionally containing one carbon-carbon double bonds and/or a ring atom selected from the group consisting of O, S, SO, SO_2, and NR^7.

[092] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or a C_5-C_8 cycloalkenyl.

[093] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, and cyclooctenyl. In embodiments, said C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl is unsubstituted. In embodiments, said C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl is substituted by 1, 2, 3, or 4 substituents (e.g., 1 or 2 substituents as described herein). In embodiments, said substituents are selected from oxo (=O), hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[094] In embodiments, a compound has a structure according to formula (**XXXXIIIa**):



(XXXXIIIa) , or

a pharmaceutically acceptable salt thereof, wherein ------ represents a single or double bond.

[095] In embodiments, ------ represents a single bond.

[096] In embodiments, ------ represents a double bond.


[097] In embodiments, the lactam stereocenter substituted by nitrogen has the *R*-configuration.

[098] In embodiments, the lactam stereocenter substituted by nitrogen has the *S*-configuration.

[099] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring containing a ring atom that is NR^7. In embodiments, said 5- to 8-membered ring is not further substituted. In embodiments, said 5- to 8-membered ring further comprises 1, 2, 3, or 4 substituents (e.g., 1 or 2 substituents as described herein). In embodiments, said substituents are selected from oxo (=O), hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.


[0100] In embodiments, R^1 and R^2 are taken together to form a pyrrolidinyl or piperidinyl group where the nitrogen atom is NR^7. In embodiments, said pyrrolidinyl or piperidinyl group is not further substituted. In embodiments, said pyrrolidinyl or piperidinyl group further comprises 1, 2, 3, or 4 substituents as described herein.

[0101] In embodiments, a compound has the formula **(XLIIIb)**




(XLIIIb) , or a pharmaceutically acceptable salt thereof.

[0102] In embodiments, a compound has the formula **(XLIV)**



(XLIV) , or a pharmaceutically acceptable salt thereof.

[0103] In embodiments, a compound has the formula **(XLV)**



(XLV) , or a pharmaceutically acceptable salt thereof.

[0104] In embodiments, n is 1, 2, or 3. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 3. In embodiments, n is 1 or 2.

[0105] In embodiments, R^7 is COR^8, and R^8 is C_{1-6} linear alkyl.

[0106] In embodiments, R^7 is acetyl.

[0107] In embodiments, R^7 is SO_2R^{10c}, and R^{10c} is C_{1-6} linear alkyl.

[0108] In embodiments, R^{10c} is methyl (i.e., R^7 is SO_2Me).

[0109] In embodiments, R^3 is unsubstituted phenyl.


[0110] In embodiments, R^3 is substituted phenyl. In embodiments, R^3 is phenyl substituted by 1, 2, 3, 4, or 5 substituents (e.g., phenyl substituted by 1 or 2 substituents as described herein). In embodiments, the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0111] In embodiments, R^3 is selected from the group consisting of hydroxylphenyl, fluorophenyl, chlorophenyl, bromophenyl, cyanophenyl, tolyl, methoxylphenyl, difluorophenyl, dichlorophenyl, chloro-fluorophenyl, dimethylphenyl, trifluoromethylphenyl, di(trifluoromethyl)phenyl,

[0112] In embodiments, R^3 is selected from the group consisting of 4-hydroxyphenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-fluoro-3-chlorophenyl, 4-cyanophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl, 4-trifluoromethylphenyl, 2-morpholinophenyl, and 4-methyl-2-morpholinophenyl.

[0113] In embodiments, R^3 is 2-pyridyl. In embodiments, R^3 is 3-pyridyl. In embodiments, R^3 is 4-pyridyl. In embodiments, said pyridyl is unsubstituted. In embodiments, said pyridyl is substituted by 1, 2, 3, or 4 substituents (e.g., pyridyl substituted by 1 or 2 substituents as described herein). In embodiments, the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.


[0114] The embodiments of the present invention include compounds having formula **(IIa)**:



(IIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

[0115] The embodiments of the present invention include compounds having formula **(IIb)**:




(IIb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0116] The embodiments of the present invention include compounds having formula **(IIc)**:




(IIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0117] The embodiments of the present invention include compounds having formula **(IId)**:



(IId)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0118] The embodiments of the present invention include compounds having formula (**IId-1**):




(IId-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0119] The embodiments of the present invention include compounds having formula (**IId-2**):




(IId-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0120] The embodiments of the present invention include compounds having formula (**IId-3**):




(IId-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0121] The embodiments of the present invention include compounds having formula (**IId-4**):




(IId-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0122] The embodiments of the present invention include compounds having formula (**IId-5**):




(IId-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0123] The embodiments of the present invention include compounds having formula (**IIe**):




(IIe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy,

C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0124] The embodiments of the present invention include compounds having formula **(IIf)**:




(IIf)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0125] The embodiments of the present invention include compounds having formula **(IIg)**:




(IIg)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0126] The embodiments of the present invention include compounds having formula **(IIh)**:



(IIh)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0127] The embodiments of the present invention include compounds having formula **(IIh-1)**:




(IIh-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0128] The embodiments of the present invention include compounds having formula (**IIh-2**):




(IIh-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0129] The embodiments of the present invention include compounds having formula (**IIh-3**):




(IIh-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0130] The embodiments of the present invention include compounds having formula (**IIh-4**):




(IIh-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0131] The embodiments of the present invention include compounds having formula (**IIh-5**):




(IIh-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0132] The embodiments of the present invention include compounds having formula (**IIi**):



(IIi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

[0133] The embodiments of the present invention include compounds having formula **(IIj)**:




(IIj)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0134] The embodiments of the present invention include compounds having formula **(IIk)**:




(IIk)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0135] The embodiments of the present invention include compounds having formula **(IIL)**:



(IIL)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0136] The embodiments of the present invention include compounds having formula **(IIL-1)**:




(IIL-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0137] The embodiments of the present invention include compounds having formula **(IIL-2)**:




(IIL-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0138] The embodiments of the present invention include compounds having formula (**IIL-3**):




(IIL-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0139] The embodiments of the present invention include compounds having formula (**IIL-4**):




(IIL-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0140] The embodiments of the present invention include compounds having formula (**IIL-5**):




(IIL-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0141] The embodiments of the present invention include compounds having formula **(IIm)**:



(IIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20cd}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0142] The embodiments of the present invention include compounds having formula **(IIn)**:




(IIn)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0143] The embodiments of the present invention include compounds having formula **(IIo)**:




(IIo)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0144] The embodiments of the present invention include compounds having formula **(IIp)**:



(IIp)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0145] The embodiments of the present invention include compounds having formula (**IIp-1**):




(IIp-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0146] The embodiments of the present invention include compounds having formula (**IIp-2**):




(IIp-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0147] The embodiments of the present invention include compounds having formula (**IIp-3**):




(IIp-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0148] The embodiments of the present invention include compounds having formula (**IIp-4**):




(IIp-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0149] The embodiments of the present invention include compounds having formula (**IIp-5**):




(IIp-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0150] The embodiments of the present invention include compounds having formula (**IIq**):



(IIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6}

linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0151] The embodiments of the present invention include compounds having formula **(IIr)**:




(IIr)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0152] The embodiments of the present invention include compounds having formula **(IIs)**:




(IIs)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0153] The embodiments of the present invention include compounds having formula **(IIt)**:



(IIt)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0154] The embodiments of the present invention include compounds having formula **(IIt-1)**:




(IIt-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0155] The embodiments of the present invention include compounds having formula **(IIt-2)**:




(IIt-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0156] The embodiments of the present invention include compounds having formula (**IIt-3**):




(IIt-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0157] The embodiments of the present invention include compounds having formula (**IIt-4**):




(IIt-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0158] The embodiments of the present invention include compounds having formula (**IIt-5**):




(IIt-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0159] The embodiments of the present invention include compounds having formula **(IIu)**:



(IIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0160] The embodiments of the present invention include compounds having formula **(IIv)**:




(IIv)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0161] The embodiments of the present invention include compounds having formula **(IIw)**:




(IIw)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0162] The embodiments of the present invention include compounds having formula **(IIx)**:



(IIx)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0163] The embodiments of the present invention include compounds having formula **(IIx-1)**:




(IIx-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0164] The embodiments of the present invention include compounds having formula **(IIx-2)**:




(IIx-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0165] The embodiments of the present invention include compounds having formula (**IIx-3**):




(IIx-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0166] The embodiments of the present invention include compounds having formula (**IIx-4**):




(IIx-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0167] The embodiments of the present invention include compounds having formula (**IIx-5**):




(IIx-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0168] The embodiments of the present invention include compounds having formula **(III)**:



(III)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


[0169] The embodiments of the present invention include compounds having formula **(IIIa)**:



(IIIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

[0170] The embodiments of the present invention include compounds having formula **(IIIb)**:




(IIIb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0171] The embodiments of the present invention include compounds having formula **(IIIc)**:




(IIIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0172] The embodiments of the present invention include compounds having formula **(IIId)**:



(IIId)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0173] The embodiments of the present invention include compounds having formula **(IIId-1)**:




(IIId-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0174] The embodiments of the present invention include compounds having formula **(IIId-2)**:




(IIId-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0175] The embodiments of the present invention include compounds having formula **(IIId-3)**:




(IIId-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0176] The embodiments of the present invention include compounds having formula **(IIId-4)**:




(IIId-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0177] The embodiments of the present invention include compounds having formula **(IIId-5)**:




(IIId-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0178] The embodiments of the present invention include compounds having formula **(IIIe)**:



(IIIe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0179] The embodiments of the present invention include compounds having formula **(IIIf)**:




(IIIf)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0180] The embodiments of the present invention include compounds having formula **(IIIg)**:




(IIIg)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0181] The embodiments of the present invention include compounds having formula **(IIIh)**:



(IIIh)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0182] The embodiments of the present invention include compounds having formula **(IIIh-1)**:




(IIIh-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0183] The embodiments of the present invention include compounds having formula **(IIIh-2)**:




(IIIh-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0184] The embodiments of the present invention include compounds having formula **(IIIh-3)**:




(IIIh-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0185] The embodiments of the present invention include compounds having formula **(IIIh-4)**:




(IIIh-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0186] The embodiments of the present invention include compounds having formula **(IIIh-5)**:




(IIIh-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0187] The embodiments of the present invention include compounds having formula **(IIIi)**:



(IIIi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2,

SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

[0188] The embodiments of the present invention include compounds having formula **(IIIj)**:




(IIIj)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0189] The embodiments of the present invention include compounds having formula **(IIIk)**:




(IIIk)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0190] The embodiments of the present invention include compounds having formula **(IIIL)**:



(IIIL)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0191] The embodiments of the present invention include compounds having formula **(IIIL-1)**:




(IIIL-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0192] The embodiments of the present invention include compounds having formula **(IIIL-2)**:




(IIIL-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0193] The embodiments of the present invention include compounds having formula **(IIIL-3)**:




(IIIL-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0194] The embodiments of the present invention include compounds having formula **(IIIL-4)**:




(IIIL-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0195] The embodiments of the present invention include compounds having formula **(IIIL-5)**:




(IIIL-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0196] The embodiments of the present invention include compounds having formula **(IIIm)**:



(IIIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0197] The embodiments of the present invention include compounds having formula **(IIIn)**:




(IIIn)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0198] The embodiments of the present invention include compounds having formula **(IIIo)**:




(IIIo)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0199] The embodiments of the present invention include compounds having formula **(IIIp)**:



(IIIp)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0200] The embodiments of the present invention include compounds having formula **(IIIp-1)**:




(IIIp)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0201] The embodiments of the present invention include compounds having formula **(IIIp-2)**:




(IIIp-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0202] The embodiments of the present invention include compounds having formula **(IIIp-3)**:




(IIIp-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0203] The embodiments of the present invention include compounds having formula **(IIIp-4)**:




(IIIp-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0204] The embodiments of the present invention include compounds having formula **(IIIp-5)**:




(IIIp-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0205] The embodiments of the present invention include compounds having formula **(IIIq)**:



(IIIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched

haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0206] The embodiments of the present invention include compounds having formula **(IIIr)**:




(IIIr)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0207] The embodiments of the present invention include compounds having formula **(IIIs)**:




(IIIs)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0208] The embodiments of the present invention include compounds having formula **(IIIt)**:



(IIIt)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0209] The embodiments of the present invention include compounds having formula **(IIIt-1)**:




(IIIt-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0210] The embodiments of the present invention include compounds having formula **(IIIt-2)**:




(IIIt-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0211] The embodiments of the present invention include compounds having formula **(IIIt-3)**:




(IIIt-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0212] The embodiments of the present invention include compounds having formula **(IIIt-4)**:




(IIIt-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0213] The embodiments of the present invention include compounds having formula **(IIIt-5)**:




(IIIt-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0214] The embodiments of the present invention include compounds having formula **(IIIu)**:



(IIIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0215] The embodiments of the present invention include compounds having formula **(IIIv)**:




(IIIv)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0216] The embodiments of the present invention include compounds having formula **(IIIw)**:




(IIIw)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0217] The embodiments of the present invention include compounds having formula **(IIIx)**:



(IIIx)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0218] The embodiments of the present invention include compounds having formula **(IIIx-1)**:




(IIIx-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0219] The embodiments of the present invention include compounds having formula **(IIIx-2)**:




(IIIx-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0220] The embodiments of the present invention include compounds having formula **(IIIx-3)**:




(IIIx-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0221] The embodiments of the present invention include compounds having formula **(IIIx-4)**:




(IIIx-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0222] The embodiments of the present invention include compounds having formula **(IIIx-5)**:




(IIIx-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0223] The embodiments of the present invention include compounds having formula **(IV)**:



(IV)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

[0224] In embodiments, a compound has a structure according to Formula **(XLVII)**,



(XLVII) , or a pharmaceutically acceptable salt thereof.

[0225] In embodiments, a compound has a structure according to Formula **(XLVII)**,



(XLVII) , or a pharmaceutically acceptable salt thereof.

[0226] In embodiments, n is 1, 2, or 3. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2.

[0227] In embodiments, each of R^1 and R^2 is unsubstituted $C_{1\text{-}6}$ alkyl. In embodiments, each of R^1 and R^2 is ethyl. In embodiments, each of R^1 and R^2 is methyl.

[0228] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring, optionally containing one carbon-carbon double bonds and/or a ring atom selected from the group consisting of O, S, SO, SO_2, and NR^7.

[0229] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or a C_5-C_8 cycloalkenyl.

[0230] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, and cyclooctenyl. In embodiments, said C_3-C_8 cycloalkyl or C_5-C_8

cycloalkenyl is unsubstituted. In embodiments, said C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl is substituted by 1, 2, 3, or 4 substituents (e.g., 1 or 2 substituents as described herein). In embodiments, said substituents are selected from oxo (=O), hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0231] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring containing a ring atom that is NR^7. In embodiments, said 5- to 8-membered ring is not further substituted. In embodiments, said 5- to 8-membered ring further comprises 1, 2, 3, or 4 substituents (e.g., 1 or 2 substituents as described herein). In embodiments, said substituents are selected from oxo (=O), hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0232] In embodiments, R^1 and R^2 are taken together to form a pyrrolidinyl or piperidinyl group where the nitrogen atom is NR^7. In embodiments, said pyrrolidinyl or piperidinyl group is not further substituted. In embodiments, said pyrrolidinyl or piperidinyl group further comprises 1, 2, 3, or 4 substituents as described herein.

[0233] In embodiments, R^7 is COR^8, and R^8 is C_{1-6} linear alkyl.

[0234] In embodiments, R^7 is acetyl.

[0235] In embodiments, R^7 is SO_2R^{10c}, and R^{10c} is C_{1-6} linear alkyl.

[0236] In embodiments, R^{10c} is methyl (i.e., R^7 is SO_2Me).

[0237] In embodiments, R^4 is phenyl.


[0238] In embodiments, R^4 is substituted phenyl. In embodiments, R^4 is phenyl substituted by 1, 2, 3, 4, or 5 substituents (e.g., phenyl substituted by 1 or 2 substituents as described herein). In embodiments, the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0239] In embodiments, R^4 is selected from the group consisting of hydroxylphenyl, fluorophenyl, chlorophenyl, bromophenyl, cyanophenyl, tolyl, methoxylphenyl, difluorophenyl, dichlorophenyl, chloro-fluorophenyl, dimethylphenyl, trifluoromethylphenyl, di(trifluoromethyl)phenyl,

[0240] In embodiments, R^4 is selected from the group consisting of 4-hydroxyphenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-fluoro-3-chlorophenyl, 4-cyanophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl, 4-trifluoromethylphenyl, 2-morpholinophenyl, and 4-methyl-2-morpholinophenyl.

[0241] In embodiments, R^4 is pyridyl. In embodiments, R^4 is 2-pyridyl. In embodiments, R^4 is 3-pyridyl. In embodiments, R^4 is 4-pyridyl. In embodiments, said pyridyl is unsubstituted. In embodiments, said pyridyl is substituted by 1, 2, 3, or 4 substituents (e.g., pyridyl substituted by 1 or 2 substituents as described herein). In embodiments, the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.


[0242] The embodiments of the present invention include compounds having formula **(IVa)**:



(IVa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2,

SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

[0243] The embodiments of the present invention include compounds having formula **(IVb)**:




(IVb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0244] The embodiments of the present invention include compounds having formula **(IVc)**:




(IVc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0245] The embodiments of the present invention include compounds having formula **(IVd)**:



(IVd)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0246] The embodiments of the present invention include compounds having formula **(IVd-1)**:




(IVd-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0247] The embodiments of the present invention include compounds having formula **(IVd-2)**:




(IVd-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0248] The embodiments of the present invention include compounds having formula **(IVd-3)**:




(IVd-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0249] The embodiments of the present invention include compounds having formula **(IVd-4)**:




(IVd-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0250] The embodiments of the present invention include compounds having formula **(IVd-5)**:




(IVd-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0251] The embodiments of the present invention include compounds having formula **(IVe)**:



(IVe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0252] The embodiments of the present invention include compounds having formula **(IVf)**:




(IVf)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0253] The embodiments of the present invention include compounds having formula **(IVg)**:




(IVg)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0254] The embodiments of the present invention include compounds having formula **(IVh)**:



(IVh)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0255] The embodiments of the present invention include compounds having formula **(IVh-1)**:




(IVh-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0256] The embodiments of the present invention include compounds having formula **(IVh-2)**:




(IVh-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0257] The embodiments of the present invention include compounds having formula **(IVh-3)**:




(IVh-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0258] The embodiments of the present invention include compounds having formula **(IVh-4)**:




(IVh-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0259] The embodiments of the present invention include compounds having formula **(IVh-5)**:




(IVh-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0260] The embodiments of the present invention include compounds having formula **(IVi)**:



(IVi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

[0261] The embodiments of the present invention include compounds having formula **(IVj)**:




(IVj)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0262] The embodiments of the present invention include compounds having formula **(IVk)**:




(IVk)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0263] The embodiments of the present invention include compounds having formula **(IVL)**:



(IVL)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0264] The embodiments of the present invention include compounds having formula **(IVL-1)**:




(IVL-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0265] The embodiments of the present invention include compounds having formula **(IVL-2)**:




(IVL-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0266] The embodiments of the present invention include compounds having formula **(IVL-3)**:




(IVL-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0267] The embodiments of the present invention include compounds having formula **(IVL-4)**:




(IVL-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0268] The embodiments of the present invention include compounds having formula **(IVL-5)**:




(IVL-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0269] The embodiments of the present invention include compounds having formula **(IVm)**:



(IVm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy,

C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0270] The embodiments of the present invention include compounds having formula **(IVn)**:




(IVn)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0271] The embodiments of the present invention include compounds having formula **(IVo)**:




(IVo)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0272] The embodiments of the present invention include compounds having formula **(IVp)**:



(IVp)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0273] The embodiments of the present invention include compounds having formula **(IVp-1)**:




(IVp-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0274] The embodiments of the present invention include compounds having formula **(IVp-2)**:




(IVp-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0275] The embodiments of the present invention include compounds having formula **(IVp-3)**:




(IVp-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0276] The embodiments of the present invention include compounds having formula **(IVp-4)**:




(IVp-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0277] The embodiments of the present invention include compounds having formula **(IVp-5)**:




(IVp-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0278] The embodiments of the present invention include compounds having formula **(IVq)**:



(IVq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0279] The embodiments of the present invention include compounds having formula **(IVr)**:




(IVr)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0280] The embodiments of the present invention include compounds having formula **(IVs)**:




(IVs)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0281] The embodiments of the present invention include compounds having formula **(IVt)**:



(IVt)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0282] The embodiments of the present invention include compounds having formula (**IVt-1**):




(IVt-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0283] The embodiments of the present invention include compounds having formula (**IVt-2**):




(IVt-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0284] The embodiments of the present invention include compounds having formula (**IVt-3**):




(IVt-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0285] The embodiments of the present invention include compounds having formula (**IVt-4**):




(IVt-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0286] The embodiments of the present invention include compounds having formula (**IVt-5**):




(IVt-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0287] The embodiments of the present invention include compounds having formula **(IVu)**:



(IVu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0288] The embodiments of the present invention include compounds having formula **(IVv)**:




(IVv)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0289] The embodiments of the present invention include compounds having formula **(IVw)**:




(IVw)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0290] The embodiments of the present invention include compounds having formula **(IVx)**:



(IVx)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0291] The embodiments of the present invention include compounds having formula **(IVx-1)**:




(IVx-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0292] The embodiments of the present invention include compounds having formula **(IVx-2)**:




(IVx-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0293] The embodiments of the present invention include compounds having formula **(IVx-3)**:




(IVx-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0294] The embodiments of the present invention include compounds having formula **(IVx-4)**:




(IVx-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0295] The embodiments of the present invention include compounds having formula **(IVx-5)**:




(IVx-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0296] The embodiments of the present invention include compounds having formula **(V)**:



(V)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


[0297] The embodiments of the present invention include compounds having formula **(Va)**:



(Va)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

[0298] The embodiments of the present invention include compounds having formula **(Vb)**:




(Vb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0299] The embodiments of the present invention include compounds having formula **(Vc)**:




(Vc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0300] The embodiments of the present invention include compounds having formula **(Vd)**:



(Vd)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0301] The embodiments of the present invention include compounds having formula (**Vd-1**):




(Vd-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0302] The embodiments of the present invention include compounds having formula (**Vd-2**):




(Vd-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0303] The embodiments of the present invention include compounds having formula (**Vd-3**):




(Vd-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0304] The embodiments of the present invention include compounds having formula (**Vd-4**):




(Vd-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0305] The embodiments of the present invention include compounds having formula (**Vd-5**):




(Vd-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0306] The embodiments of the present invention include compounds having formula (**Ve**):



(Ve)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0307] The embodiments of the present invention include compounds having formula (**Vf**):




(Vf)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0308] The embodiments of the present invention include compounds having formula (**Vg**):




(Vg)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0309] The embodiments of the present invention include compounds having formula **(Vh)**:



(Vh)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0310] The embodiments of the present invention include compounds having formula **(Vh-1)**:




(Vh-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0311] The embodiments of the present invention include compounds having formula **(Vh-2)**:




(Vh-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0312] The embodiments of the present invention include compounds having formula (**Vh-3**):




(Vh-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0313] The embodiments of the present invention include compounds having formula (**Vh-4**):




(Vh-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0314] The embodiments of the present invention include compounds having formula (**Vh-5**):




(Vh-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0315] The embodiments of the present invention include compounds having formula **(Vi)**:



(Vi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

[0316] The embodiments of the present invention include compounds having formula **(Vj)**:




(Vj)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0317] The embodiments of the present invention include compounds having formula **(Vk)**:




(Vk)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0318] The embodiments of the present invention include compounds having formula **(VL)**:



(VL)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0319] The embodiments of the present invention include compounds having formula (**VL-1**):




(VL-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0320] The embodiments of the present invention include compounds having formula (**VL-2**):




(VL-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0321] The embodiments of the present invention include compounds having formula (**VL-3**):




(VL-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0322] The embodiments of the present invention include compounds having formula (**VL-4**):




(VL-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0323] The embodiments of the present invention include compounds having formula (**VL-5**):




(VL-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0324] The embodiments of the present invention include compounds having formula (**Vm**):



(Vm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, –NO_2, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0325] The embodiments of the present invention include compounds having formula **(Vn)**:




(Vn)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0326] The embodiments of the present invention include compounds having formula **(Vo)**:




(Vo)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0327] The embodiments of the present invention include compounds having formula **(Vp)**:



(Vp)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0328] The embodiments of the present invention include compounds having formula **(Vp-1)**:




(Vp-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0329] The embodiments of the present invention include compounds having formula (**Vp-2**):




(Vp-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0330] The embodiments of the present invention include compounds having formula (**Vp-3**):




(Vp-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0331] The embodiments of the present invention include compounds having formula (**Vp-4**):




(Vp-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0332] The embodiments of the present invention include compounds having formula (**Vp-5**):




(Vp-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0333] The embodiments of the present invention include compounds having formula (**Vq**):



(Vq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0334] The embodiments of the present invention include compounds having formula (**Vr**):




(Vr)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0335] The embodiments of the present invention include compounds having formula (**Vs**):




(Vs)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0336] The embodiments of the present invention include compounds having formula (**Vt**):



(Vt)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0337] The embodiments of the present invention include compounds having formula (**Vt-1**):




(Vt-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0338] The embodiments of the present invention include compounds having formula (**Vt-2**):




(Vt-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0339] The embodiments of the present invention include compounds having formula (**Vt-3**):




(Vt-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0340] The embodiments of the present invention include compounds having formula (**Vt-4**):




(Vt-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0341] The embodiments of the present invention include compounds having formula (**Vt-5**):




(Vt-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0342] The embodiments of the present invention include compounds having formula (**Vu**):



(Vu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0343] The embodiments of the present invention include compounds having formula **(Vv)**:




(Vv)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0344] The embodiments of the present invention include compounds having formula **(Vw)**:




(Vw)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0345] The embodiments of the present invention include compounds having formula **(Vx)**:



(Vx)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0346] The embodiments of the present invention include compounds having formula **(Vx-1)**:




(Vx-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0347] The embodiments of the present invention include compounds having formula (**Vx-2**):




(Vx-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0348] The embodiments of the present invention include compounds having formula (**Vx-3**):




(Vx-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0349] The embodiments of the present invention include compounds having formula (**Vx-4**):




(Vx-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0350] The embodiments of the present invention include compounds having formula **(Vx-5)**:




(Vx-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0351] The embodiments of the present invention include compounds having formula **(VI)**:



(VI)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

[0352] In embodiments, a compound has a structure according to Formula **(XLVI)**



(XLVI) , or a pharmaceutically acceptable salt thereof.

[0353] In embodiments, a compound has a structure according to Formula (**XLVIa**)



(**XLVIa**) , or a pharmaceutically acceptable salt thereof.

[0354] In embodiments, n is 1, 2, or 3. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2.

[0355] In embodiments, each of R^1 and R^2 is unsubstituted C_{1-6} alkyl. In embodiments, each of R^1 and R^2 is ethyl. In embodiments, each of R^1 and R^2 is methyl.

[0356] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring, optionally containing one carbon-carbon double bonds and/or a ring atom selected from the group consisting of O, S, SO, SO_2, and NR^7.

[0357] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or a C_5-C_8 cycloalkenyl.

[0358] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, and cyclooctenyl. In embodiments, said C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl is unsubstituted. In embodiments, said C_3-C_8 cycloalkyl or C_5-C_8 cycloalkenyl is substituted by 1, 2, 3, or 4 substituents (e.g., 1 or 2 substituents as described herein). In embodiments, said substituents are selected from oxo (=O), hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0359] In embodiments, R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring containing a ring atom that is NR^7. In embodiments, said 5- to 8-membered ring is not further substituted. In embodiments, said 5- to 8-membered ring further comprises 1, 2, 3, or 4 substituents (e.g., 1 or 2 substituents as described herein). In embodiments, said substituents are selected from oxo (=O), hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered

heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF$_3$, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF$_3$, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0360] In embodiments, R^1 and R^2 are taken together to form a pyrrolidinyl or piperidinyl group where the nitrogen atom is NR^7. In embodiments, said pyrrolidinyl or piperidinyl group is not further substituted. In embodiments, said pyrrolidinyl or piperidinyl group further comprises 1, 2, 3, or 4 substituents as described herein.

[0361] In embodiments, R^7 is COR^8, and R^8 is C_{1-6} linear alkyl.

[0362] In embodiments, R^7 is acetyl.

[0363] In embodiments, R^7 is SO_2R^{10c}, and R^{10c} is C_{1-6} linear alkyl.

[0364] In embodiments, R^{10c} is methyl (i.e., R^7 is SO_2Me).

[0365] In embodiments, R^5 is phenyl.

[0366] In embodiments, R^5 is substituted phenyl. In embodiments, R^5 is phenyl substituted by 1, 2, 3, 4, or 5 substituents (e.g., phenyl substituted by 1 or 2 substituents as described herein). In embodiments, the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF$_3$, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF$_3$, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.


[0367] In embodiments, R^5 is selected from the group consisting of hydroxylphenyl, fluorophenyl, chlorophenyl, bromophenyl, cyanophenyl, tolyl, methoxylphenyl, difluorophenyl, dichlorophenyl, chloro-fluorophenyl, dimethylphenyl, trifluoromethylphenyl, di(trifluoromethyl)phenyl,

[0368] In embodiments, R^5 is selected from the group consisting of 4-hydroxyphenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-fluoro-3-chlorophenyl, 4-cyanophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl, 4-trifluoromethylphenyl, 2-morpholinophenyl, and 4-methyl-2-morpholinophenyl.

[0369] In embodiments, R^5 is pyridyl. In embodiments, R^5 is 2-pyridyl. In embodiments, R^5 is 3-pyridyl. In embodiments, R^5 is 4-pyridyl. In embodiments, said pyridyl is unsubstituted. In embodiments, said pyridyl is substituted by 1, 2, 3, or 4 substituents (e.g., pyridyl substituted by 1 or 2 substituents as described herein). In embodiments, the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-}


7 branched alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, and 3- to 8-membered heterocylyl. In embodiments, the substituents are selected from the group consisting of –OH, -F, -Cl, -Br, -I, -CN, -OMe, -OEt, -O^{n}Pr, -O^{i}Pr, -OCF_3, -Me, -Et, -^{n}Pr, -^{i}Pr, -CF_3, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, and morpholino.

[0370] The embodiments of the present invention include compounds having formula **(VIa)**:



(VIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, -$NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

[0371] The embodiments of the present invention include compounds having formula **(VIb)**:




(VIb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0372] The embodiments of the present invention include compounds having formula **(VIc)**:




(VIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0373] The embodiments of the present invention include compounds having formula **(VId)**:



(VId)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0374] The embodiments of the present invention include compounds having formula **(Vid-1)**:




(VId-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0375] The embodiments of the present invention include compounds having formula **(Vid-2)**:




(VId-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0376] The embodiments of the present invention include compounds having formula **(Vid-3)**:




(VId-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0377] The embodiments of the present invention include compounds having formula **(Vid-4)**:




(VId-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0378] The embodiments of the present invention include compounds having formula **(Vid-5)**:




(VId-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0379] The embodiments of the present invention include compounds having formula **(VIe)**:



(VIe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0380] The embodiments of the present invention include compounds having formula **(VIf)**:




(VIf)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0381] The embodiments of the present invention include compounds having formula **(VIg)**:




(VIg)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0382] The embodiments of the present invention include compounds having formula **(VIh)**:



(VIh)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0383] The embodiments of the present invention include compounds having formula (**VIh-1**):




(VIh-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0384] The embodiments of the present invention include compounds having formula (**VIh-2**):




(VIh-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0385] The embodiments of the present invention include compounds having formula (**VIh-3**):




(VIh-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0386] The embodiments of the present invention include compounds having formula **(VIh-)**:




(VIh-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0387] The embodiments of the present invention include compounds having formula **(VIh-5)**:




(VIh-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0388] The embodiments of the present invention include compounds having formula **(VIi)**:



(VIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy,

C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

[0389] The embodiments of the present invention include compounds having formula **(VIj)**:




(VIj)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0390] The embodiments of the present invention include compounds having formula **(VIk)**:




(VIk)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0391] The embodiments of the present invention include compounds having formula **(VIL)**:



(VIL)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0392] The embodiments of the present invention include compounds having formula **(VIL-1)**:




(VIL-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0393] The embodiments of the present invention include compounds having formula **(VIL-2)**:




(VIL-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0394] The embodiments of the present invention include compounds having formula **(VIL-3)**:




(VIL-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0395] The embodiments of the present invention include compounds having formula **(VIL-4)**:




(VIL-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0396] The embodiments of the present invention include compounds having formula **(VIL-5)**:




(VIL-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0397] The embodiments of the present invention include compounds having formula **(VIm)**:



(VIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0398] The embodiments of the present invention include compounds having formula **(VIn)**:




(VIn)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0399] The embodiments of the present invention include compounds having formula **(VIo)**:




(VIo)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0400] The embodiments of the present invention include compounds having formula **(VIp)**:



(VIp)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0401] The embodiments of the present invention include compounds having formula **(VIp-1)**:




(VIp-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0402] The embodiments of the present invention include compounds having formula **(VIp-2)**:




(VIp-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0403] The embodiments of the present invention include compounds having formula (**VIp-3**):




(VIp-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0404] The embodiments of the present invention include compounds having formula (**VIp-4**):




(VIp-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0405] The embodiments of the present invention include compounds having formula (**VIp-5**):




(VIp-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0406] The embodiments of the present invention include compounds having formula **(VIq)**:



(VIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0407] The embodiments of the present invention include compounds having formula **(VIr)**:




(VIr)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0408] The embodiments of the present invention include compounds having formula **(VIs)**:




(VIs)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0409] The embodiments of the present invention include compounds having formula **(VIt)**:



(VIt)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0410] The embodiments of the present invention include compounds having formula (**VIt-1**):




(VIt-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0411] The embodiments of the present invention include compounds having formula (**VIt-2**):




(VIt-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0412] The embodiments of the present invention include compounds having formula (**VIt-3**):




(VIt-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0413] The embodiments of the present invention include compounds having formula (**VIt-4**):




(VIt-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0414] The embodiments of the present invention include compounds having formula (**VIt-5**):




(VIt-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0415] The embodiments of the present invention include compounds having formula (**VIu**):



(VIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0416] The embodiments of the present invention include compounds having formula **(VIv)**:




(VIv)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0417] The embodiments of the present invention include compounds having formula **(VIw)**:




(VIw)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0418] The embodiments of the present invention include compounds having formula **(VIx)**:



(VIx)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0419] The embodiments of the present invention include compounds having formula **(VIx-1)**:




(VIx-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0420] The embodiments of the present invention include compounds having formula (**VIx-2**):




(VIx-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0421] The embodiments of the present invention include compounds having formula (**VIx-3**):




(VIx-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0422] The embodiments of the present invention include compounds having formula (**VIx-4**):




(VIx-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0423] The embodiments of the present invention include compounds having formula **(VIx-5)**:




(VIx-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0424] The embodiments of the present invention include compounds having formula **(VII)**:



(VII)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


[0425] The embodiments of the present invention include compounds having formula **(VIIa)**:



(VIIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

[0426] The embodiments of the present invention include compounds having formula **(VIIb)**:




(VIIb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0427] The embodiments of the present invention include compounds having formula **(VIIc)**:




(VIIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0428] The embodiments of the present invention include compounds having formula **(VIId)**:



(VIId)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0429] The embodiments of the present invention include compounds having formula **(VIId-1)**:




(VIId-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0430] The embodiments of the present invention include compounds having formula **(VIId-2)**:




(VIId-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0431] The embodiments of the present invention include compounds having formula **(VIId-3)**:




(VIId-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0432] The embodiments of the present invention include compounds having formula **(VIId-4)**:




(VIId-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0433] The embodiments of the present invention include compounds having formula **(VIId-5)**:




(VIId-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0434] The embodiments of the present invention include compounds having formula **(VIIe)**:



(VIIb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2,

SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0435] The embodiments of the present invention include compounds having formula **(VIIf)**:




(VIIf)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0436] The embodiments of the present invention include compounds having formula **(VIIg)**:




(VIIg)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0437] The embodiments of the present invention include compounds having formula **(VIIh)**:



(VIIh)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0438] The embodiments of the present invention include compounds having formula **(VIIh-1)**:




(VIIh-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0439] The embodiments of the present invention include compounds having formula **(VIIh-2)**:




(VIIh-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0440] The embodiments of the present invention include compounds having formula **(VIIh-3)**:




(VIIh-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0441] The embodiments of the present invention include compounds having formula **(VIIh-4)**:




(VIIh-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0442] The embodiments of the present invention include compounds having formula **(VIIh-5)**:




(VIIh-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0443] The embodiments of the present invention include compounds having formula **(VIIi)**:



(VIIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

[0444] The embodiments of the present invention include compounds having formula **(VIIj)**:




(VIIj)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0445] The embodiments of the present invention include compounds having formula **(VIIk)**:




(VIIk)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0446] The embodiments of the present invention include compounds having formula **(VIIL)**:



(VIIL)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0447] The embodiments of the present invention include compounds having formula **(VIIL-1)**:




(VIIL-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0448] The embodiments of the present invention include compounds having formula **(VIIL-2)**:




(VIIL-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0449] The embodiments of the present invention include compounds having formula **(VIIL-3)**:




(VIIL-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0450] The embodiments of the present invention include compounds having formula **(VIIL-4)**:




(VIIL-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0451] The embodiments of the present invention include compounds having formula **(VIIL-5)**:




(VIIL-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0452] The embodiments of the present invention include compounds having formula **(VIIm)**:



(VIIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and



;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

[0453] The embodiments of the present invention include compounds having formula **(VIIn)**:




(VIIn)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0454] The embodiments of the present invention include compounds having formula **(VIIo)**:




(VIIo)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0455] The embodiments of the present invention include compounds having formula **(VIIp)**:



(VIIp)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0456] The embodiments of the present invention include compounds having formula **(VIIp-1)**:




(VIIp-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0457] The embodiments of the present invention include compounds having formula **(VIIp-2)**:




(VIIp-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0458] The embodiments of the present invention include compounds having formula **(VIIp-3)**:




(VIIp-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0459] The embodiments of the present invention include compounds having formula **(VIIp-4)**:




(VIIp-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0460] The embodiments of the present invention include compounds having formula **(VIIp-5)**:




(VIIp-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;


and Q^2 is 1 or 2.

[0461] The embodiments of the present invention include compounds having formula **(VIIq)**:



(VIIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0462] The embodiments of the present invention include compounds having formula **(VIIr)**:




(VIIr)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0463] The embodiments of the present invention include compounds having formula **(VIIs)**:




(VIIs)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0464] The embodiments of the present invention include compounds having formula **(VIIt)**:



(VIIt)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0465] The embodiments of the present invention include compounds having formula **(VIIt-1)**:




(VIIt-1)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0466] The embodiments of the present invention include compounds having formula **(VIIt-2)**:




(VIIt-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0467] The embodiments of the present invention include compounds having formula **(VIIt-3)**:




(VIIt-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0468] The embodiments of the present invention include compounds having formula **(VIIt-4)**:




(VIIt-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0469] The embodiments of the present invention include compounds having formula **(VIIt-5)**:




(VIIt-5)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


[0470] The embodiments of the present invention include compounds having formula **(VIIu)**:



(VIIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-}

$_{7}$cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

[0471] The embodiments of the present invention include compounds having formula **(VIIv)**:




(VIIv)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0472] The embodiments of the present invention include compounds having formula **(VIIw)**:




Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0473] The embodiments of the present invention include compounds having formula **(VIIx)**:




Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

X^1 is selected from the group consisting of O, S, SO, SO_2, and NR^7;

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0474] The embodiments of the present invention include compounds having formula **(VIIx-1)**:




Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0475] The embodiments of the present invention include compounds having formula **(VIIx-2)**:




(VIIx-2)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0476] The embodiments of the present invention include compounds having formula **(VIIx-3)**:




(VIIx-3)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0477] The embodiments of the present invention include compounds having formula **(VIIx-4)**:




(VIIx-4)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0478] The embodiments of the present invention include compounds having formula **(VIIx-5)**:





(VIIx-5)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.

[0479] In some embodiments A is  .

[0480] In some embodiments A is  .

[0481] In some embodiments A is  .

[0482] In some embodiments R^1 is hydrogen.

[0483] In some embodiments R^1 is C_{1-6} linear alkyl.

[0484] In some embodiments R^1 is C_{3-7} branched alkyl.

[0485] In some embodiments R^2 is hydrogen.

[0486] In some embodiments R^2 is C_{1-6} linear alkyl.

[0487] In some embodiments R^2 is C_{3-7} branched alkyl.

[0488] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 5 ring atoms.

[0489] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 5 ring atoms and containing a double bond.

[0490] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms.

[0491] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms and containing a double bond.

[0492] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms.

[0493] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms and containing a double bond.

[0494] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms containing one of which is O.

[0495] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms containing one of which is O.

[0496] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 8 ring atoms containing one of which is O.

[0497] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms containing one of which is S.

[0498] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms containing one of which is S.

[0499] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 8 ring atoms containing one of which is S.

[0500] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms containing one of which is SO.

[0501] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms containing one of which is SO.

[0502] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 8 ring atoms containing one of which is SO.

[0503] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms containing one of which is SO_2.

[0504] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms containing one of which is SO_2.

[0505] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 8 ring atoms containing one of which is SO_2.

[0506] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 6 ring atoms containing one of which is NR^7.

[0507] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 7 ring atoms containing one of which is NR^7.

[0508] In some embodiments R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having 8 ring atoms containing one of which is NR^7.

[0509] In some embodiments R^3 is optionally substituted phenyl.

[0510] In some embodiments R^3 is optionally substituted naphthylen-1-yl.

[0511] In some embodiments R^3 is optionally substituted naphthylen-2-yl.

[0512] In some embodiments R^3 is optionally substituted 2-pyridyl

[0513] In some embodiments R^3 is optionally substituted 3-pyridyl.

[0514] In some embodiments R^3 is optionally substituted 4-pyridyl.

[0515] In some embodiments R^3 is  .

[0516] In some embodiments R^4 is optionally substituted phenyl.

[0517] In some embodiments R^4 is optionally substituted naphthylen-1-yl.

[0518] In some embodiments R^4 is optionally substituted naphthylen-2-yl.

[0519] In some embodiments R^4 is optionally substituted 2-pyridyl

[0520] In some embodiments R^4 is optionally substituted 3-pyridyl.

[0521] In some embodiments R^4 is optionally substituted 4-pyridyl.

[0522] In some embodiments R^4 is  .

[0523] In some embodiments R^5 is optionally substituted phenyl.

[0524] In some embodiments R^5 is optionally substituted naphthylen-1-yl.

[0525] In some embodiments R^5 is optionally substituted naphthylen-2-yl.

[0526] In some embodiments R^5 is optionally substituted 2-pyridyl

[0527] In some embodiments R^5 is optionally substituted 3-pyridyl.

[0528] In some embodiments R^5 is optionally substituted 4-pyridyl.

[0529] In some embodiments R^5 is  .

[0530] In some embodiments R6 is optionally substituted phenyl.

[0531] In some embodiments R^6 is optionally substituted naphthylen-1-yl.

[0532] In some embodiments R^6 is optionally substituted naphthylen-2-yl.

[0533] In some embodiments R^6 is optionally substituted 2-pyridyl

[0534] In some embodiments R^6 is optionally substituted 3-pyridyl.

[0535] In some embodiments R^6 is optionally substituted 4-pyridyl.

[0536] In some embodiments R^7 is H.

[0537] In some embodiments R^7 is C_{1-6} linear alkyl.

[0538] In some embodiments R^7 is C_{3-7} branched alkyl.

[0539] In some embodiments R^7 is C_{3-7} cycloalkyl.

[0540] In some embodiments R^7 is optionally substituted phenyl.

[0541] In some embodiments R^7 is optionally substituted benzyl.

[0542] In some embodiments R^7 is COR^8.

[0543] In some embodiments R^7 is CO_2R^9.

[0544] In some embodiments R^7 is $CONR^{10a}R^{10b}$.

[0545] In some embodiments R^7 is $SO_2NR^{10a}R^{10b}$.

[0546] In some embodiments R^7 is SO_2R^{10c}.

[0547] In some embodiments R^8 is selected H.

[0548] In some embodiments R^8 is C_{1-6} linear alkyl.

[0549] In some embodiments R^8 is C_{3-7} branched alkyl

[0550] In some embodiments R^8 is C_{3-7} cycloalkyl.

[0551] In some embodiments R^9 is C_{1-6} linear alkyl.

[0552] In some embodiments R^9 is C_{3-7} branched alkyl.

[0553] In some embodiments R^9 is C_{3-7} cycloalkyl.

[0554] In some embodiments R^{10a} is H.

[0555] In some embodiments R^{10a} is C_{1-6} linear alkyl.

[0556] In some embodiments R^{10a} is C_{3-7} branched alkyl.

[0557] In some embodiments R^{10a} is C_{3-7} cycloalkyl.

[0558] In some embodiments R^{10b} is H.

[0559] In some embodiments R^{10b} is C_{1-6} linear alkyl.

[0560] In some embodiments R^{10b} is C_{3-7} branched alkyl.

[0561] In some embodiments R^{10b} is C_{3-7} cycloalkyl.

[0562] In some embodiments R^{10c} is C_{1-6} linear alkyl.

[0563] In some embodiments R^{10c} is C_{3-7} branched alkyl.

[0564] In some embodiments R^{10c} is C_{3-7} cycloalkyl.


[0565] In some embodiments R^{10c} is C_{1-6} linear haloalkyl.


[0566] In some embodiments R^{10c} is C_{3-7} branched haloalkyl.


[0567] In some embodiments R^{10c} is $-(CH_2)_qCN$.


[0568] In some embodiments R^{10c} is $-(CH_2)_qSO_2R^{11}$.


[0569] In some embodiments R^{10c} is $-(CH_2)_qOR^{12}$.


[0570] In some embodiments R^{10c} is  .


[0571] In some embodiments R^{10c} is  .


[0572] In some embodiments R^{10c} is  .


[0573] In some embodiments R^{10c} is  .


[0574] In some embodiments R^{10c} is  .


[0575] In some embodiments R^{10c} is  .


[0576] In some embodiments R^{10c} is  .

[0577] In some embodiments R^{10c} is  .

[0578] In some embodiments R^{10c} is  .

[0579] In some embodiments R^{10c} is  .

[0580] In some embodiments R^{10c} is  .

[0581] In some embodiments R^{10c} is  .

[0582] In some embodiments R^{11} is C_{1-6} linear alkyl.

[0583] In some embodiments R^{11} is C_{3-7} branched alkyl.

[0584] In some embodiments R^{11} is C_{3-7} cycloalkyl.

[0585] In some embodiments R^{12} is C_{1-6} linear alkyl.

[0586] In some embodiments R^{12} is C_{3-7} branched alkyl.

[0587] In some embodiments R^{12} is C_{3-7} cycloalkyl.

[0588] In some embodiments R^{1a} is H.

[0589] In some embodiments R^{1a} is OH

[0590] In some embodiments R^{1a} is NO_2.

[0591] In some embodiments R^{1a} is halogen.

[0592] In some embodiments R^{1a} is CN.

[0593] In some embodiments R^{1a} is C_{1-6} linear alkyl.

[0594] In some embodiments R^{1a} is C_{3-7} branched alkyl.

[0595] In some embodiments R^{1a} is C_{3-7} cycloalkyl.

[0596] In some embodiments R^{1a} is C_{1-6} linear alkoxy.

[0597] In some embodiments R^{1a} is C_{3-7} branched alkoxy.

[0598] In some embodiments R^{1a} is C_{3-7} cycloalkoxy.

[0599] In some embodiments R^{1a} is C_{1-6} linear haloalkyl.

[0600] In some embodiments R^{1a} is C_{3-7} branched haloalkyl.

[0601] In some embodiments R^{1a} is C_{1-6} linear haloalkoxy.

[0602] In some embodiments R^{1a} is -S(C_{1-6} linear alkyl).

[0603] In some embodiments R^{1a} is S(C_{3-7} branched alkyl).

[0604] In some embodiments R^{1a} is -S(C_{3-7} cycloalkyl).

[0605] In some embodiments R^{1a} is COR^{13}.

[0606] In some embodiments R^{1a} is CO_2R^{14}.

[0607] In some embodiments R^{1a} is $CONR^{15a}R^{15b}$.

[0608] In some embodiments R^{1a} is $SO_2NR^{15a}R^{15b}$.

[0609] In some embodiments R^{1a} is $NR^{16a}R^{16b}$.

[0610] In some embodiments R^{1a} is $NR^{16a}COR^{17}$.

[0611] In some embodiments R^{1a} is $NR^{16a}SO_2R^{18}$.

[0612] In some embodiments R^{1a} is $NR^{16a}SO_2NR^{19a}R^{19b}$.

[0613] In some embodiments R^{1b} is H.

[0614] In some embodiments R^{1b} is OH

[0615] In some embodiments R^{1b} is NO_2.

[0616] In some embodiments R^{1b} is halogen.

[0617] In some embodiments R^{1b} is CN.

[0618] In some embodiments R^{1b} is C_1-6 linear alkyl.

[0619] In some embodiments R^{1b} is C_3-7 branched alkyl.

[0620] In some embodiments R^{1b} is C_3-7 cycloalkyl.

[0621] In some embodiments R^{1b} is C_1-6 linear alkoxy.

[0622] In some embodiments R^{1b} is C_3-7 branched alkoxy.

[0623] In some embodiments R^{1b} is C_3-7 cycloalkoxy.

[0624] In some embodiments R^{1b} is C_1-6 linear haloalkyl.

[0625] In some embodiments R^{1b} is C_3-7 branched haloalkyl.

[0626] In some embodiments R^{1b} is C_1-6 linear haloalkoxy.

[0627] In some embodiments R^{1b} is -S(C_1-6 linear alkyl).

[0628] In some embodiments R^{1b} is S(C_3-7 branched alkyl).

[0629] In some embodiments R^{1b} is -S(C_3-7 cycloalkyl).

[0630] In some embodiments R^{1b} is COR^{13}.

[0631] In some embodiments R^{1b} is CO_2R^{14}.

[0632] In some embodiments R^{1b} is $CONR^{15a}R^{15b}$.

[0633] In some embodiments R^{1b} is $SO_2NR^{15a}R^{15b}$.

[0634] In some embodiments R^{1b} is $NR^{16a}R^{16b}$.

[0635] In some embodiments R^{1b} is $NR^{16a}COR^{17}$.

[0636] In some embodiments R^{1b} is $NR^{16a}SO_2R^{18}$.

[0637] In some embodiments R^{1b} is $NR^{16a}SO_2NR^{19a}R^{19b}$.

[0638] In some embodiments R^{1c} is H.

[0639] In some embodiments R^{1c} is OH

[0640] In some embodiments R^{1c} is NO_2.

[0641] In some embodiments R^{1c} is halogen.

[0642] In some embodiments R^{1c} is CN.

[0643] In some embodiments R^{1c} is C_{1-6} linear alkyl.

[0644] In some embodiments R^{1c} is C_{3-7} branched alkyl.

[0645] In some embodiments R^{1c} is C_{3-7} cycloalkyl.

[0646] In some embodiments R^{1c} is C_{1-6} linear alkoxy.

[0647] In some embodiments R^{1c} is C_{3-7} branched alkoxy.

[0648] In some embodiments R^{1c} is C_{3-7} cycloalkoxy.

[0649] In some embodiments R^{1c} is C_{1-6} linear haloalkyl.

[0650] In some embodiments R^{1c} is C_{3-7} branched haloalkyl.

[0651] In some embodiments R^{1c} is C_{1-6} linear haloalkoxy.

[0652] In some embodiments R^{1c} is -S(C_{1-6} linear alkyl).

[0653] In some embodiments R^{1c} is S(C_{3-7} branched alkyl).

[0654] In some embodiments R^{1c} is -S(C_{3-7} cycloalkyl).

[0655] In some embodiments R^{1c} is COR^{13}.

[0656] In some embodiments R^{1c} is CO_2R^{14}.

[0657] In some embodiments R^{1c} is $CONR^{15a}R^{15b}$.

[0658] In some embodiments R^{1c} is $SO_2NR^{15a}R^{15b}$.

[0659] In some embodiments R^{1c} is $NR^{16a}R^{16b}$.

[0660] In some embodiments R^{1c} is $NR^{16a}COR^{17}$.

[0661] In some embodiments R^{1c} is $NR^{16a}SO_2R^{18}$.

[0662] In some embodiments R^{1c} is $NR^{16a}SO_2NR^{19a}R^{19b}$.

[0663] In some embodiments R^{1d} is H.

[0664] In some embodiments R^{1d} is OH

[0665] In some embodiments R^{1d} is NO_2.

[0666] In some embodiments R^{1d} is halogen.

[0667] In some embodiments R^{1d} is CN.

[0668] In some embodiments R^{1d} is C_{1-6} linear alkyl.

[0669] In some embodiments R^{1d} is C_{3-7} branched alkyl.

[0670] In some embodiments R^{1d} is C_{3-7} cycloalkyl.

[0671] In some embodiments R^{1d} is C_{1-6} linear alkoxy.

[0672] In some embodiments R^{1d} is C_{3-7} branched alkoxy.

[0673] In some embodiments R^{1d} is C_{3-7} cycloalkoxy.

[0674] In some embodiments R^{1d} is C_{1-6} linear haloalkyl.

[0675] In some embodiments R^{1d} is C_{3-7} branched haloalkyl.

[0676] In some embodiments R^{1d} is C_{1-6} linear haloalkoxy.

[0677] In some embodiments R^{1d} is -S(C_{1-6} linear alkyl).

[0678] In some embodiments R^{1d} is S(C_{3-7} branched alkyl).

[0679] In some embodiments R^{1d} is -S(C_{3-7} cycloalkyl).

[0680] In some embodiments R^{1d} is COR^{13}.

[0681] In some embodiments R^{1d} is CO_2R^{14}.

[0682] In some embodiments R^{1d} is $CONR^{15a}R^{15b}$.

[0683] In some embodiments R^{1d} is $SO_2NR^{15a}R^{15b}$.

[0684] In some embodiments R^{1d} is $NR^{16a}R^{16b}$.

[0685] In some embodiments R^{1d} is $NR^{16a}COR^{17}$.

[0686] In some embodiments R^{1d} is $NR^{16a}SO_2R^{18}$.

[0687] In some embodiments R^{1d} is $NR^{16a}SO_2NR^{19a}R^{19b}$.

[0688] In some embodiments R^{1e} is H.

[0689] In some embodiments R^{1e} is OH

[0690] In some embodiments R^{1e} is NO_2.

[0691] In some embodiments R^{1e} is halogen.

[0692] In some embodiments R^{1e} is CN.

[0693] In some embodiments R^{1e} is C_{1-6} linear alkyl.

[0694] In some embodiments R^{1e} is C_{3-7} branched alkyl.

[0695] In some embodiments R^{1e} is C_{3-7} cycloalkyl.

[0696] In some embodiments R^{1e} is C_{1-6} linear alkoxy.

[0697] In some embodiments R^{1e} is C_{3-7} branched alkoxy.

[0698] In some embodiments R^{1e} is C_{3-7} cycloalkoxy.

[0699] In some embodiments R^{1e} is C_{1-6} linear haloalkyl.

[0700] In some embodiments R^{1e} is C_{3-7} branched haloalkyl.

[0701] In some embodiments R^{1e} is C_{1-6} linear haloalkoxy.

[0702] In some embodiments R^{1e} is -S(C_{1-6} linear alkyl).

[0703] In some embodiments R^{1e} is S(C_{3-7} branched alkyl).

[0704] In some embodiments R^{1e} is -S(C_{3-7} cycloalkyl).

[0705] In some embodiments R^{1e} is COR^{13}.

[0706] In some embodiments R^{1e} is CO_2R^{14}.

[0707] In some embodiments R^{1e} is $CONR^{15a}R^{15b}$.

[0708] In some embodiments R^{1e} is $SO_2NR^{15a}R^{15b}$.

[0709] In some embodiments R^{1e} is $NR^{16a}R^{16b}$.

[0710] In some embodiments R^{1e} is $NR^{16a}COR^{17}$.

[0711] In some embodiments R^{1e} is $NR^{16a}SO_2R^{18}$.

[0712] In some embodiments R^{1e} is $NR^{16a}SO_2NR^{19a}R^{19b}$.

[0713] In some embodiments R^{13} is H.

[0714] In some embodiments R^{13} is C_{1-6} linear alkyl.

[0715] In some embodiments R^{13} is C_{3-7} branched alkyl.

[0716] In some embodiments R^{13} is C_{3-7} cycloalkyl.

[0717] In some embodiments R^{14} is C_{1-6} linear alkyl.

[0718] In some embodiments R^{14} is C_{3-7} branched alkyl.

[0719] In some embodiments R^{14} is C_{3-7} cycloalkyl.

[0720] In some embodiments R^{15a} is H.

[0721] In some embodiments R^{15a} is C_{1-6} linear alkyl.

[0722] In some embodiments R^{15a} is C_{3-7} branched alkyl.

[0723] In some embodiments R^{15a} is C_{3-7} cycloalkyl.

[0724] In some embodiments R^{15b} is H.

[0725] In some embodiments R^{15b} is C_{1-6} linear alkyl.

[0726] In some embodiments R^{15b} is C_{3-7} branched alkyl.

[0727] In some embodiments R^{15b} is C_{3-7} cycloalkyl.

[0728] In some embodiments R^{16a} is H.

[0729] In some embodiments R^{16a} is C_{1-6} linear alkyl.

[0730] In some embodiments R^{16a} is C_{3-7} branched alkyl.

[0731] In some embodiments R^{16a} is C_{3-7} cycloalkyl.

[0732] In some embodiments R^{16b} is H.

[0733] In some embodiments R^{16b} is C_{1-6} linear alkyl.

[0734] In some embodiments R^{16b} is C_{3-7} branched alkyl.

[0735] In some embodiments R^{16b} is C_{3-7} cycloalkyl.

[0736] In some embodiments R^{17} is H.

[0737] In some embodiments R^{17} is C_{1-6} linear alkyl.

[0738] In some embodiments R^{17} is C_{3-7} branched alkyl.

[0739] In some embodiments R^{17} is C_{3-7} cycloalkyl.

[0740] In some embodiments R^{18} is C_{1-6} linear alkyl.

[0741] In some embodiments R^{18} is C_{3-7} branched alkyl.

[0742] In some embodiments R^{18} is C_{3-7} cycloalkyl.

[0743] In some embodiments R^{19a} is C_{1-6} linear alkyl.

[0744] In some embodiments R^{19a} is C_{3-7} branched alkyl.

[0745] In some embodiments R^{19a} is C_{3-7} cycloalkyl.

[0746] In some embodiments R^{19b} is C_{1-6} linear alkyl.

[0747] In some embodiments R^{19b} is C_{3-7} branched alkyl.

[0748] In some embodiments R^{19b} is C_{3-7} cycloalkyl.

[0749] In some embodiments n is 1.

[0750] In some embodiments n is 2.

[0751] In some embodiments n is 3.

[0752] In some embodiments n is 4.

[0753] In some embodiments m is 1.

[0754] In some embodiments m is 2.

[0755] In some embodiments m is 3.

[0756] In some embodiments R^{20a} is hydrogen.

[0757] In some embodiments R^{20a} is –CN.

[0758] In some embodiments R^{20a} is $–NO_2$.

[0759] In some embodiments R^{20a} is –OH.

[0760] In some embodiments R^{20a} is halogen.

[0761] In some embodiments R^{20a} is C_{1-6} linear alkyl.

[0762] In some embodiments R^{20a} is C_{3-7} branched alkyl.

[0763] In some embodiments R^{20a} is C_{3-7} cycloalkyl.

[0764] In some embodiments R^{20a} is C_{1-6} linear alkoxy.

[0765] In some embodiments R^{20a} is C_{3-7} branched alkoxy.

[0766] In some embodiments R^{20a} is C_{3-7} cycloalkoxy.

[0767] In some embodiments R^{20a} is C_{1-6} linear haloalkyl.

[0768] In some embodiments R^{20a} is C_{3-7} branched haloalkyl.

[0769] In some embodiments R^{20a} is C_{1-6} linear haloalkoxy.

[0770] In some embodiments R^{20a} is C_{3-7} branched haloalkoxy.

[0771] In some embodiments R^{20a} is SH.

[0772] In some embodiments R^{20a} is SC_{1-6} linear alkyl.

[0773] In some embodiments R^{20a} is SC_{3-7} branched alkyl.

[0774] In some embodiments R^{20a} is SC_{3-7}cycloalkyl.

[0775] In some embodiments R^{20a} is SO_2C_{1-6} linear alkyl.

[0776] In some embodiments R^{20a} is SO_2C_{3-7} branched alkyl.

[0777] In some embodiments R^{20a} is SO_2C_{3-7}cycloalkyl.

[0778] In some embodiments R^{20a} is SO_2NH_2.

[0779] In some embodiments R^{20a} is SO_2NHR^{21}.

[0780] In some embodiments R^{20a} is $NHSO_2R^{22}$.


[0781] In some embodiments R^{20a} is $-NR^{23a}R^{23b}$.

[0782] In some embodiments R^{20a} is $NHC(O)R^{24}$.

[0783] In some embodiments R^{20a} is $C(O)NHR^{24}$.

[0784] In some embodiments R^{20a} is $C(O)N(R^{24})_2$.

[0785] In some embodiments R^{20a} is morpholino.

[0786] In some embodiments R^{20a} is  .

[0787] In some embodiments R^{20b} is hydrogen.

[0788] In some embodiments R^{20b} is –CN.

[0789] In some embodiments R^{20b} is $–NO_2$.

[0790] In some embodiments R^{20b} is –OH.

[0791] In some embodiments R^{20b} is halogen.

[0792] In some embodiments R^{20b} is C_{1-6} linear alkyl.

[0793] In some embodiments R^{20b} is C_{3-7} branched alkyl.

[0794] In some embodiments R^{20b} is C_{3-7} cycloalkyl.

[0795] In some embodiments R^{20b} is C_{1-6} linear alkoxy.

[0796] In some embodiments R^{20b} is C_{3-7} branched alkoxy.

[0797] In some embodiments R^{20b} is C_{3-7} cycloalkoxy.

[0798] In some embodiments R^{20b} is C_{1-6} linear haloalkyl.

[0799] In some embodiments R^{20b} is C_{3-7} branched haloalkyl.

[0800] In some embodiments R^{20b} is C_{1-6} linear haloalkoxy.

[0801] In some embodiments R^{20b} is C_{3-7} branched haloalkoxy.

[0802] In some embodiments R^{20b} is SH.

[0803] In some embodiments R^{20b} is SC_{1-6} linear alkyl.

[0804] In some embodiments R^{20b} is SC_{3-7} branched alkyl.

[0805] In some embodiments R^{20b} is SC_{3-7}cycloalkyl.

[0806] In some embodiments R^{20b} is SO_2C_{1-6} linear alkyl.

[0807] In some embodiments R^{20b} is SO_2C_{3-7} branched alkyl.

[0808] In some embodiments R^{20b} is SO_2C_{3-7}cycloalkyl.

[0809] In some embodiments R^{20b} is SO_2NH_2.

[0810] In some embodiments R^{20b} is SO_2NHR^{21}.

[0811] In some embodiments R^{20b} is $NHSO_2R^{22}$.


[0812] In some embodiments R^{20b} is $-NR^{23a}R^{23b}$.

[0813] In some embodiments R^{20b} is $NHC(O)R^{24}$.

[0814] In some embodiments R^{20b} is $C(O)NHR^{24}$.

[0815] In some embodiments R^{20b} is $C(O)N(R^{24})_2$.

[0816] In some embodiments R^{20b} is morpholino.

[0817] In some embodiments R^{20b} is  .

[0818] In some embodiments R^{20c} is hydrogen.

[0819] In some embodiments R^{20c} is –CN.

[0820] In some embodiments R^{20c} is $–NO_2$.

[0821] In some embodiments R^{20c} is –OH.

[0822] In some embodiments R^{20c} is halogen.

[0823] In some embodiments R^{20c} is C_{1-6} linear alkyl.

[0824] In some embodiments R^{20c} is C_{3-7} branched alkyl.

[0825] In some embodiments R^{20c} is C_{3-7} cycloalkyl.

[0826] In some embodiments R^{20c} is C_{1-6} linear alkoxy.

[0827] In some embodiments R^{20c} is C_{3-7} branched alkoxy.

[0828] In some embodiments R^{20c} is C_{3-7} cycloalkoxy.

[0829] In some embodiments R^{20c} is C_{1-6} linear haloalkyl.

[0830] In some embodiments R^{20c} is C_{3-7} branched haloalkyl.

[0831] In some embodiments R^{20c} is C_{1-6} linear haloalkoxy.

[0832] In some embodiments R^{20c} is C_{3-7} branched haloalkoxy.

[0833] In some embodiments R^{20c} is SH.

[0834] In some embodiments R^{20c} is SC_{1-6} linear alkyl.

[0835] In some embodiments R^{20c} is SC_{3-7} branched alkyl.

[0836] In some embodiments R^{20c} is SC_{3-7}cycloalkyl.

[0837] In some embodiments R^{20c} is SO_2C_{1-6} linear alkyl.

[0838] In some embodiments R^{20c} is SO_2C_{3-7} branched alkyl.

[0839] In some embodiments R^{20c} is SO_2C_{3-7}cycloalkyl.

[0840] In some embodiments R^{20c} is SO_2NH_2.

[0841] In some embodiments R^{20c} is SO_2NHR^{21}.

[0842] In some embodiments R^{20c} is $NHSO_2R^{22}$.


[0843] In some embodiments R^{20c} is $-NR^{23a}R^{23b}$.

[0844] In some embodiments R^{20c} is $NHC(O)R^{24}$.

[0845] In some embodiments R^{20c} is $C(O)NHR^{24}$.

[0846] In some embodiments R^{20c} is $C(O)N(R^{24})_2$.

[0847] In some embodiments R^{20c} is morpholino.

[0848] In some embodiments R^{20c} is  .

[0849] In some embodiments R^{20d} is hydrogen.

[0850] In some embodiments R^{20d} is –CN.

[0851] In some embodiments R^{20d} is $–NO_2$.

[0852] In some embodiments R^{20d} is –OH.

[0853] In some embodiments R^{20d} is halogen.

[0854] In some embodiments R^{20d} is C_{1-6} linear alkyl.

[0855] In some embodiments R^{20d} is C_{3-7} branched alkyl.

[0856] In some embodiments R^{20d} is C_{3-7} cycloalkyl.

[0857] In some embodiments R^{20d} is C_{1-6} linear alkoxy.

[0858] In some embodiments R^{20d} is C_{3-7} branched alkoxy.

[0859] In some embodiments R^{20d} is C_{3-7} cycloalkoxy.

[0860] In some embodiments R^{20d} is C_{1-6} linear haloalkyl.

[0861] In some embodiments R^{20d} is C_{3-7} branched haloalkyl.

[0862] In some embodiments R^{20d} is C_{1-6} linear haloalkoxy.

[0863] In some embodiments R^{20d} is C_{3-7} branched haloalkoxy.

[0864] In some embodiments R^{20d} is SH.

[0865] In some embodiments R^{20d} is SC_{1-6} linear alkyl.

[0866] In some embodiments R^{20d} is SC_{3-7} branched alkyl.

[0867] In some embodiments R^{20d} is SC_{3-7}cycloalkyl.

[0868] In some embodiments R^{20d} is SO_2C_{1-6} linear alkyl.

[0869] In some embodiments R^{20d} is SO_2C_{3-7} branched alkyl.

[0870] In some embodiments R^{20d} is SO_2C_{3-7}cycloalkyl.

[0871] In some embodiments R^{20d} is SO_2NH_2.

[0872] In some embodiments R^{20d} is SO_2NHR^{21}.

[0873] In some embodiments R^{20d} is $NHSO_2R^{22}$.


[0874] In some embodiments R^{20d} is $-NR^{23a}R^{23b}$.

[0875] In some embodiments R^{20d} is $NHC(O)R^{24}$.

[0876] In some embodiments R^{20d} is $C(O)NHR^{24}$.

[0877] In some embodiments R^{20d} is $C(O)N(R^{24})_2$.

[0878] In some embodiments R^{20d} is morpholino.

[0879] In some embodiments R^{20d} is  .

[0880] In some embodiments R^{20e} is hydrogen.

[0881] In some embodiments R^{20e} is –CN.

[0882] In some embodiments R^{20e} is $–NO_2$.

[0883] In some embodiments R^{20e} is –OH.

[0884] In some embodiments R^{20e} is halogen.

[0885] In some embodiments R^{20e} is C_{1-6} linear alkyl.

[0886] In some embodiments R^{20e} is C_{3-7} branched alkyl.

[0887] In some embodiments R^{20e} is C_{3-7} cycloalkyl.

[0888] In some embodiments R^{20e} is C_{1-6} linear alkoxy.

[0889] In some embodiments R^{20e} is C_{3-7} branched alkoxy.

[0890] In some embodiments R^{20e} is C_{3-7} cycloalkoxy.

[0891] In some embodiments R^{20e} is C_{1-6} linear haloalkyl.

[0892] In some embodiments R^{20e} is C_{3-7} branched haloalkyl.

[0893] In some embodiments R^{20e} is C_{1-6} linear haloalkoxy.

[0894] In some embodiments R^{20e} is C_{3-7} branched haloalkoxy.

[0895] In some embodiments R^{20e} is SH.

[0896] In some embodiments R^{20e} is SC_{1-6} linear alkyl.

[0897] In some embodiments R^{20e} is SC_{3-7} branched alkyl.

[0898] In some embodiments R^{20e} is SC_{3-7}cycloalkyl.

[0899] In some embodiments R^{20e} is SO_2C_{1-6} linear alkyl.

[0900] In some embodiments R^{20e} is SO_2C_{3-7} branched alkyl.

[0901] In some embodiments R^{20e} is SO_2C_{3-7}cycloalkyl.

[0902] In some embodiments R^{20e} is SO_2NH_2.

[0903] In some embodiments R^{20e} is SO_2NHR^{21}.

[0904] In some embodiments R^{20e} is $NHSO_2R^{22}$.


[0905] In some embodiments R^{20e} is $-NR^{23a}R^{23b}$.

[0906] In some embodiments R^{20e} is $NHC(O)R^{24}$.

[0907] In some embodiments R^{20e} is $C(O)NHR^{24}$.

[0908] In some embodiments R^{20e} is $C(O)N(R^{24})_2$.

[0909] In some embodiments R^{20e} is morpholino.

[0910] In some embodiments R^{20e} is  .

[0911] In some embodiments R^{20f} is hydrogen.

[0912] In some embodiments R^{20f} is –CN.

[0913] In some embodiments R^{20f} is $–NO_2$.

[0914] In some embodiments R^{20f} is –OH.

[0915] In some embodiments R^{20f} is halogen.

[0916] In some embodiments R^{20f} is C_{1-6} linear alkyl.

[0917] In some embodiments R^{20f} is C_{3-7} branched alkyl.

[0918] In some embodiments R^{20f} is C_{3-7} cycloalkyl.

[0919] In some embodiments R^{20f} is C_{1-6} linear alkoxy.

[0920] In some embodiments R^{20f} is C_{3-7} branched alkoxy.

[0921] In some embodiments R^{20f} is C_{3-7} cycloalkoxy.

[0922] In some embodiments R^{20f} is C_{1-6} linear haloalkyl.

[0923] In some embodiments R^{20f} is C_{3-7} branched haloalkyl.

[0924] In some embodiments R^{20f} is C_{1-6} linear haloalkoxy.

[0925] In some embodiments R^{20f} is C_{3-7} branched haloalkoxy.

[0926] In some embodiments R^{20f} is SH.

[0927] In some embodiments R^{20f} is SC_{1-6} linear alkyl.

[0928] In some embodiments R^{20f} is SC_{3-7} branched alkyl.

[0929] In some embodiments R^{20f} is SC_{3-7}cycloalkyl.

[0930] In some embodiments R^{20f} is SO_2C_{1-6} linear alkyl.

[0931] In some embodiments R^{20f} is SO_2C_{3-7} branched alkyl.

[0932] In some embodiments R^{20f} is SO_2C_{3-7}cycloalkyl.

[0933] In some embodiments R^{20f} is SO_2NH_2.

[0934] In some embodiments R^{20f} is SO_2NHR^{21}.

[0935] In some embodiments R^{20f} is $NHSO_2R^{22}$.


[0936] In some embodiments R^{20f} is $-NR^{23a}R^{23b}$.

[0937] In some embodiments R^{20f} is $NHC(O)R^{24}$.

[0938] In some embodiments R^{20f} is $C(O)NHR^{24}$.

[0939] In some embodiments R^{20f} is $C(O)N(R^{24})_2$.

[0940] In some embodiments R^{20f} is morpholino.

[0941] In some embodiments R^{20f} is  .

[0942] In some embodiments R^{20g} is hydrogen.

[0943] In some embodiments R^{20g} is –CN.

[0944] In some embodiments R^{20g} is $–NO_2$.

[0945] In some embodiments R^{20g} is –OH.

[0946] In some embodiments R^{20g} is halogen.

[0947] In some embodiments R^{20g} is C_{1-6} linear alkyl.

[0948] In some embodiments R^{20g} is C_{3-7} branched alkyl.

[0949] In some embodiments R^{20g} is C_{3-7} cycloalkyl.

[0950] In some embodiments R^{20g} is C_{1-6} linear alkoxy.

[0951] In some embodiments R^{20g} is C_{3-7} branched alkoxy.

[0952] In some embodiments R^{20g} is C_{3-7} cycloalkoxy.

[0953] In some embodiments R^{20g} is C_{1-6} linear haloalkyl.

[0954] In some embodiments R^{20g} is C_{3-7} branched haloalkyl.

[0955] In some embodiments R^{20g} is C_{1-6} linear haloalkoxy.

[0956] In some embodiments R^{20g} is C_{3-7} branched haloalkoxy.

[0957] In some embodiments R^{20g} is SH.

[0958] In some embodiments R^{20g} is SC_{1-6} linear alkyl.

[0959] In some embodiments R^{20g} is SC_{3-7} branched alkyl.

[0960] In some embodiments R^{20g} is SC_{3-7}cycloalkyl.

[0961] In some embodiments R^{20g} is SO_2C_{1-6} linear alkyl.

[0962] In some embodiments R^{20g} is SO_2C_{3-7} branched alkyl.

[0963] In some embodiments R^{20g} is SO_2C_{3-7}cycloalkyl.

[0964] In some embodiments R^{20g} is SO_2NH_2.

[0965] In some embodiments R^{20g} is SO_2NHR^{21}.

[0966] In some embodiments R^{20g} is $NHSO_2R^{22}$.


[0967] In some embodiments R^{20g} is $-NR^{23a}R^{23b}$.

[0968] In some embodiments R^{20g} is $NHC(O)R^{24}$.

[0969] In some embodiments R^{20g} is $C(O)NHR^{24}$.

[0970] In some embodiments R^{20g} is $C(O)N(R^{24})_2$.

[0971] In some embodiments R^{20g} is morpholino.

[0972] In some embodiments R^{20g} is  .

[0973] In some embodiments R^{21} is hydrogen.

[0974] In some embodiments R^{21} is C_{1-6} linear alkyl.

[0975] In some embodiments R^{21} is C_{3-7} branched alkyl.

[0976] In some embodiments R^{21} is C_{3-7} cycloalkyl.

[0977] In some embodiments R^{22} is hydrogen.

[0978] In some embodiments R^{22} is C_{1-6} linear alkyl.

[0979] In some embodiments R^{22} is C_{3-7} branched alkyl.

[0980] In some embodiments R^{22} is C_{3-7} cycloalkyl.

[0981] In some embodiments R^{23a} is hydrogen.

[0982] In some embodiments R^{23a} is C_{1-6} linear alkyl.

[0983] In some embodiments R^{23a} is C_{3-7} branched alkyl.

[0984] In some embodiments R^{23a} is C_{3-7} cycloalkyl.

[0985] In some embodiments R^{23b} is hydrogen.

[0986] In some embodiments R^{23b} is C_{1-6} linear alkyl.

[0987] In some embodiments R^{23b} is C_{3-7} branched alkyl.

[0988] In some embodiments R^{23b} is C_{3-7} cycloalkyl.

[0989] In some embodiments R^{24} is hydrogen.

[0990] In some embodiments R^{24} is C_{1-6} linear alkyl.

[0991] In some embodiments R^{24} is C_{3-7} branched alkyl.

[0992] In some embodiments R^{24} is C_{3-7} cycloalkyl.

[0993] In some embodiments R^{25} is hydrogen.

[0994] In some embodiments R^{25} is C_{1-6} linear alkyl.

[0995] In some embodiments R^{25} is C_{3-7} branched alkyl.

[0996] In some embodiments R^{25} is C_{3-7} cycloalkyl.

[0997] In some embodiments Q^1 is 1.

[0998] In some embodiments Q^1 is 2.

[0999] In some embodiments Q^2 is 1.

[01000] In some embodiments Q^2 is 2.

[01001] In some embodiments X^1 is O.

[01002] In some embodiments X^1 is S.

[01003] In some embodiments X^1 is SO.

[01004] In some embodiments X^1 is SO_2.


[01005] In some embodiments X^1 is NR^7.

Exemplary Compounds

[01006] Exemplary compounds include any of the compounds described herein. In embodiments where the compounds or formulas described herein do not specify the configuration of the lactam stereocenter (i.e., the carbon substituted by the nitrogen of the lactam) is not indicated, said lactam stereocenter can have the *R*-configuration. In other embodiments, said lactam stereocenter can have the *S*-configuration.

[01007] In embodiments, a compound is any compound described herein or a pharmaceutically acceptable salt thereof. In embodiments, a compound that is described in any one of Tables 1-39, or a pharmaceutically acceptable salt thereof. In embodiments, a compound is a compound described in any one of Tables 34-39, or a pharmaceutically acceptable salt thereof.

[01008] Exemplary embodiments include compounds having the formula **(II)**



(II)

[01009] or a pharmaceutically acceptable salt form thereof defined herein below in Table 1.

Table 1:

Entry	R^1	R^2	n	R^3	Entry	R^1	R^2	n	R^3
1	Methyl	Methyl	1	Phenyl	177	Ethyl	Ethyl	1	Phenyl
2	Methyl	Methyl	2	Phenyl	178	Ethyl	Ethyl	2	Phenyl
3	Methyl	Methyl	3	Phenyl	179	Ethyl	Ethyl	3	Phenyl

4	Methyl	Methyl	4	Phenyl	180	Ethyl	Ethyl	4	Phenyl
5	Methyl	Methyl	1	4-OH-Phenyl	181	Ethyl	Ethyl	1	4-OH-Phenyl
6	Methyl	Methyl	2	4-OH-Phenyl	182	Ethyl	Ethyl	2	4-OH-Phenyl
7	Methyl	Methyl	3	4-OH-Phenyl	183	Ethyl	Ethyl	3	4-OH-Phenyl
8	Methyl	Methyl	4	4-OH-Phenyl	184	Ethyl	Ethyl	4	4-OH-Phenyl
9	Methyl	Methyl	1	3-OH-Phenyl	185	Ethyl	Ethyl	1	3-OH-Phenyl
10	Methyl	Methyl	2	3-OH-Phenyl	186	Ethyl	Ethyl	2	3-OH-Phenyl
11	Methyl	Methyl	3	3-OH-Phenyl	187	Ethyl	Ethyl	3	3-OH-Phenyl
12	Methyl	Methyl	4	3-OH-Phenyl	188	Ethyl	Ethyl	4	3-OH-Phenyl
13	Methyl	Methyl	1	2-OH-Phenyl	189	Ethyl	Ethyl	1	2-OH-Phenyl
14	Methyl	Methyl	2	2-OH-Phenyl	190	Ethyl	Ethyl	2	2-OH-Phenyl
15	Methyl	Methyl	3	2-OH-Phenyl	191	Ethyl	Ethyl	3	2-OH-Phenyl
16	Methyl	Methyl	4	2-OH-Phenyl	192	Ethyl	Ethyl	4	2-OH-Phenyl
17	Methyl	Methyl	1	4-OMe-Phenyl	193	Ethyl	Ethyl	1	4-OMe-Phenyl
18	Methyl	Methyl	2	4-OMe-Phenyl	194	Ethyl	Ethyl	2	4-OMe-Phenyl
19	Methyl	Methyl	3	4-OMe-Phenyl	195	Ethyl	Ethyl	3	4-OMe-Phenyl
20	Methyl	Methyl	4	4-OMe-Phenyl	196	Ethyl	Ethyl	4	4-OMe-Phenyl
21	Methyl	Methyl	1	3-OMe-Phenyl	197	Ethyl	Ethyl	1	3-OMe-Phenyl
22	Methyl	Methyl	2	3-OMe-Phenyl	198	Ethyl	Ethyl	2	3-OMe-Phenyl
23	Methyl	Methyl	3	3-OMe-Phenyl	199	Ethyl	Ethyl	3	3-OMe-Phenyl
24	Methyl	Methyl	4	3-OMe-Phenyl	200	Ethyl	Ethyl	4	3-OMe-Phenyl
25	Methyl	Methyl	1	2-OMe-Phenyl	201	Ethyl	Ethyl	1	2-OMe-Phenyl
26	Methyl	Methyl	2	2-OMe-Phenyl	202	Ethyl	Ethyl	2	2-OMe-Phenyl
27	Methyl	Methyl	3	2-OMe-Phenyl	203	Ethyl	Ethyl	3	2-OMe-Phenyl
28	Methyl	Methyl	4	2-OMe-Phenyl	204	Ethyl	Ethyl	4	2-OMe-Phenyl
29	Methyl	Methyl	1	4-CN-Phenyl	205	Ethyl	Ethyl	1	4-CN-Phenyl
30	Methyl	Methyl	2	4-CN-Phenyl	206	Ethyl	Ethyl	2	4-CN-Phenyl
31	Methyl	Methyl	3	4-CN-Phenyl	207	Ethyl	Ethyl	3	4-CN-Phenyl
32	Methyl	Methyl	4	4-CN-Phenyl	208	Ethyl	Ethyl	4	4-CN-Phenyl
33	Methyl	Methyl	1	3-CN-Phenyl	209	Ethyl	Ethyl	1	3-CN-Phenyl
34	Methyl	Methyl	2	3-CN-Phenyl	210	Ethyl	Ethyl	2	3-CN-Phenyl

35	Methyl	Methyl	3	3-CN-Phenyl	211	Ethyl	Ethyl	3	3-CN-Phenyl
36	Methyl	Methyl	4	3-CN-Phenyl	212	Ethyl	Ethyl	4	3-CN-Phenyl
37	Methyl	Methyl	1	2-CN-Phenyl	213	Ethyl	Ethyl	1	2-CN-Phenyl
38	Methyl	Methyl	2	2-CN-Phenyl	214	Ethyl	Ethyl	2	2-CN-Phenyl
39	Methyl	Methyl	3	2-CN-Phenyl	215	Ethyl	Ethyl	3	2-CN-Phenyl
40	Methyl	Methyl	4	2-CN-Phenyl	216	Ethyl	Ethyl	4	2-CN-Phenyl
41	Methyl	Methyl	1	4-Me-Phenyl	217	Ethyl	Ethyl	1	4-Me-Phenyl
42	Methyl	Methyl	2	4-Me-Phenyl	218	Ethyl	Ethyl	2	4-Me-Phenyl
43	Methyl	Methyl	3	4-Me-Phenyl	219	Ethyl	Ethyl	3	4-Me-Phenyl
44	Methyl	Methyl	4	4-Me-Phenyl	220	Ethyl	Ethyl	4	4-Me-Phenyl
45	Methyl	Methyl	1	3-Me-Phenyl	221	Ethyl	Ethyl	1	3-Me-Phenyl
46	Methyl	Methyl	2	3-Me-Phenyl	222	Ethyl	Ethyl	2	3-Me-Phenyl
47	Methyl	Methyl	3	3-Me-Phenyl	223	Ethyl	Ethyl	3	3-Me-Phenyl
48	Methyl	Methyl	4	3-Me-Phenyl	224	Ethyl	Ethyl	4	3-Me-Phenyl
49	Methyl	Methyl	1	2-Me-Phenyl	225	Ethyl	Ethyl	1	2-Me-Phenyl
50	Methyl	Methyl	2	2-Me-Phenyl	226	Ethyl	Ethyl	2	2-Me-Phenyl
51	Methyl	Methyl	3	2-Me-Phenyl	227	Ethyl	Ethyl	3	2-Me-Phenyl
52	Methyl	Methyl	4	2-Me-Phenyl	228	Ethyl	Ethyl	4	2-Me-Phenyl
53	Methyl	Methyl	1	4-F-Phenyl	229	Ethyl	Ethyl	1	4-F-Phenyl
54	Methyl	Methyl	2	4-F-Phenyl	230	Ethyl	Ethyl	2	4-F-Phenyl
55	Methyl	Methyl	3	4-F-Phenyl	231	Ethyl	Ethyl	3	4-F-Phenyl
56	Methyl	Methyl	4	4-F-Phenyl	232	Ethyl	Ethyl	4	4-F-Phenyl
57	Methyl	Methyl	1	3-F-Phenyl	233	Ethyl	Ethyl	1	3-F-Phenyl
58	Methyl	Methyl	2	3-F-Phenyl	234	Ethyl	Ethyl	2	3-F-Phenyl
59	Methyl	Methyl	3	3-F-Phenyl	235	Ethyl	Ethyl	3	3-F-Phenyl
60	Methyl	Methyl	4	3-F-Phenyl	236	Ethyl	Ethyl	4	3-F-Phenyl
61	Methyl	Methyl	1	2-F-Phenyl	237	Ethyl	Ethyl	1	2-F-Phenyl
62	Methyl	Methyl	2	2-F-Phenyl	238	Ethyl	Ethyl	2	2-F-Phenyl
63	Methyl	Methyl	3	2-F-Phenyl	239	Ethyl	Ethyl	3	2-F-Phenyl
64	Methyl	Methyl	4	2-F-Phenyl	240	Ethyl	Ethyl	4	2-F-Phenyl
65	Methyl	Methyl	1	4-Cl-Phenyl	241	Ethyl	Ethyl	1	4-Cl-Phenyl


66	Methyl	Methyl	2	4-Cl-Phenyl	242	Ethyl	Ethyl	2	4-Cl-Phenyl
67	Methyl	Methyl	3	4-Cl-Phenyl	243	Ethyl	Ethyl	3	4-Cl-Phenyl
68	Methyl	Methyl	4	4-Cl-Phenyl	244	Ethyl	Ethyl	4	4-Cl-Phenyl
69	Methyl	Methyl	1	3-Cl-Phenyl	245	Ethyl	Ethyl	1	3-Cl-Phenyl
70	Methyl	Methyl	2	3-Cl-Phenyl	246	Ethyl	Ethyl	2	3-Cl-Phenyl
71	Methyl	Methyl	3	3-Cl-Phenyl	247	Ethyl	Ethyl	3	3-Cl-Phenyl
72	Methyl	Methyl	4	3-Cl-Phenyl	248	Ethyl	Ethyl	4	3-Cl-Phenyl
73	Methyl	Methyl	1	2-Cl-Phenyl	249	Ethyl	Ethyl	1	2-Cl-Phenyl
74	Methyl	Methyl	2	2-Cl-Phenyl	250	Ethyl	Ethyl	2	2-Cl-Phenyl
75	Methyl	Methyl	3	2-Cl-Phenyl	251	Ethyl	Ethyl	3	2-Cl-Phenyl
76	Methyl	Methyl	4	2-Cl-Phenyl	252	Ethyl	Ethyl	4	2-Cl-Phenyl
77	Methyl	Methyl	1	4-Br-Phenyl	253	Ethyl	Ethyl	1	4-Br-Phenyl
78	Methyl	Methyl	2	4-Br-Phenyl	254	Ethyl	Ethyl	2	4-Br-Phenyl
79	Methyl	Methyl	3	4-Br-Phenyl	255	Ethyl	Ethyl	3	4-Br-Phenyl
80	Methyl	Methyl	4	4-Br-Phenyl	256	Ethyl	Ethyl	4	4-Br-Phenyl
81	Methyl	Methyl	1	3-Br-Phenyl	257	Ethyl	Ethyl	1	3-Br-Phenyl
82	Methyl	Methyl	2	3-Br-Phenyl	258	Ethyl	Ethyl	2	3-Br-Phenyl
83	Methyl	Methyl	3	3-Br-Phenyl	259	Ethyl	Ethyl	3	3-Br-Phenyl
84	Methyl	Methyl	4	3-Br-Phenyl	260	Ethyl	Ethyl	4	3-Br-Phenyl
85	Methyl	Methyl	1	2-Br-Phenyl	261	Ethyl	Ethyl	1	2-Br-Phenyl
86	Methyl	Methyl	2	2-Br-Phenyl	262	Ethyl	Ethyl	2	2-Br-Phenyl
87	Methyl	Methyl	3	2-Br-Phenyl	263	Ethyl	Ethyl	3	2-Br-Phenyl
88	Methyl	Methyl	4	2-Br-Phenyl	264	Ethyl	Ethyl	4	2-Br-Phenyl
89	Methyl	Methyl	1	4-CF_3-Phenyl	265	Ethyl	Ethyl	1	4-CF_3-Phenyl
90	Methyl	Methyl	2	4-CF_3-Phenyl	266	Ethyl	Ethyl	2	4-CF_3-Phenyl
91	Methyl	Methyl	3	4-CF_3-Phenyl	267	Ethyl	Ethyl	3	4-CF_3-Phenyl
92	Methyl	Methyl	4	4-CF_3-Phenyl	268	Ethyl	Ethyl	4	4-CF_3-Phenyl
93	Methyl	Methyl	1	3-CF_3-Phenyl	269	Ethyl	Ethyl	1	3-CF_3-Phenyl
94	Methyl	Methyl	2	3-CF_3-Phenyl	270	Ethyl	Ethyl	2	3-CF_3-Phenyl
95	Methyl	Methyl	3	3-CF_3-Phenyl	271	Ethyl	Ethyl	3	3-CF_3-Phenyl
96	Methyl	Methyl	4	3-CF_3-Phenyl	272	Ethyl	Ethyl	4	3-CF_3-Phenyl

97	Methyl	Methyl	1	2-CF_3-Phenyl	273	Ethyl	Ethyl	1	2-CF_3-Phenyl
98	Methyl	Methyl	2	2-CF_3-Phenyl	274	Ethyl	Ethyl	2	2-CF_3-Phenyl
99	Methyl	Methyl	3	2-CF_3-Phenyl	275	Ethyl	Ethyl	3	2-CF_3-Phenyl
100	Methyl	Methyl	4	2-CF_3-Phenyl	276	Ethyl	Ethyl	4	2-CF_3-Phenyl
101	Methyl	Methyl	1	4-iPr-Phenyl	277	Ethyl	Ethyl	1	4-iPr-Phenyl
102	Methyl	Methyl	2	4-iPr-Phenyl	278	Ethyl	Ethyl	2	4-iPr-Phenyl
103	Methyl	Methyl	3	4-iPr-Phenyl	279	Ethyl	Ethyl	3	4-iPr-Phenyl
104	Methyl	Methyl	4	4-iPr-Phenyl	280	Ethyl	Ethyl	4	4-iPr-Phenyl
105	Methyl	Methyl	1	3-iPr-Phenyl	281	Ethyl	Ethyl	1	3-iPr-Phenyl
106	Methyl	Methyl	2	3-iPr-Phenyl	282	Ethyl	Ethyl	2	3-iPr-Phenyl
107	Methyl	Methyl	3	3-iPr-Phenyl	283	Ethyl	Ethyl	3	3-iPr-Phenyl
108	Methyl	Methyl	4	3-iPr-Phenyl	284	Ethyl	Ethyl	4	3-iPr-Phenyl
109	Methyl	Methyl	1	2-iPr-Phenyl	285	Ethyl	Ethyl	1	2-iPr-Phenyl
110	Methyl	Methyl	2	2-iPr-Phenyl	286	Ethyl	Ethyl	2	2-iPr-Phenyl
111	Methyl	Methyl	3	2-iPr-Phenyl	287	Ethyl	Ethyl	3	2-iPr-Phenyl
112	Methyl	Methyl	4	2-iPr-Phenyl	288	Ethyl	Ethyl	4	2-iPr-Phenyl
113	Methyl	Methyl	1	4-NH_2-Phenyl	289	Ethyl	Ethyl	1	4-NH_2-Phenyl
114	Methyl	Methyl	2	4-NH_2-Phenyl	290	Ethyl	Ethyl	2	4-NH_2-Phenyl
115	Methyl	Methyl	3	4-NH_2-Phenyl	291	Ethyl	Ethyl	3	4-NH_2-Phenyl
116	Methyl	Methyl	4	4-NH_2-Phenyl	292	Ethyl	Ethyl	4	4-NH_2-Phenyl
117	Methyl	Methyl	1	3-NH_2-Phenyl	293	Ethyl	Ethyl	1	3-NH_2-Phenyl
118	Methyl	Methyl	2	3-NH_2-Phenyl	294	Ethyl	Ethyl	2	3-NH_2-Phenyl
119	Methyl	Methyl	3	3-NH_2-Phenyl	295	Ethyl	Ethyl	3	3-NH_2-Phenyl
120	Methyl	Methyl	4	3-NH_2-Phenyl	296	Ethyl	Ethyl	4	3-NH_2-Phenyl
121	Methyl	Methyl	1	2-NH_2-Phenyl	297	Ethyl	Ethyl	1	2-NH_2-Phenyl
122	Methyl	Methyl	2	2-NH_2-Phenyl	298	Ethyl	Ethyl	2	2-NH_2-Phenyl
123	Methyl	Methyl	3	2-NH_2-Phenyl	299	Ethyl	Ethyl	3	2-NH_2-Phenyl
124	Methyl	Methyl	4	2-NH_2-Phenyl	300	Ethyl	Ethyl	4	2-NH_2-Phenyl
125	Methyl	Methyl	1	2,3-di-Me-Phenyl	301	Ethyl	Ethyl	1	2,3-di-Me-Phenyl
126	Methyl	Methyl	2	2,3-di-Me-Phenyl	302	Ethyl	Ethyl	2	2,3-di-Me-Phenyl
127	Methyl	Methyl	3	2,3-di-Me-Phenyl	303	Ethyl	Ethyl	3	2,3-di-Me-Phenyl

128	Methyl	Methyl	4	2,3-di-Me-Phenyl	304	Ethyl	Ethyl	4	2,3-di-Me-Phenyl
129	Methyl	Methyl	1	2,4-di-Me-Phenyl	305	Ethyl	Ethyl	1	2,4-di-Me-Phenyl
130	Methyl	Methyl	2	2,4-di-Me-Phenyl	306	Ethyl	Ethyl	2	2,4-di-Me-Phenyl
131	Methyl	Methyl	3	2,4-di-Me-Phenyl	307	Ethyl	Ethyl	3	2,4-di-Me-Phenyl
132	Methyl	Methyl	4	2,4-di-Me-Phenyl	308	Ethyl	Ethyl	4	2,4-di-Me-Phenyl
133	Methyl	Methyl	1	2,5-di-Me-Phenyl	309	Ethyl	Ethyl	1	2,5-di-Me-Phenyl
134	Methyl	Methyl	2	2,5-di-Me-Phenyl	310	Ethyl	Ethyl	2	2,5-di-Me-Phenyl
135	Methyl	Methyl	3	2,5-di-Me-Phenyl	311	Ethyl	Ethyl	3	2,5-di-Me-Phenyl
136	Methyl	Methyl	4	2,5-di-Me-Phenyl	312	Ethyl	Ethyl	4	2,5-di-Me-Phenyl
137	Methyl	Methyl	1	2,6-di-Me-Phenyl	313	Ethyl	Ethyl	1	2,6-di-Me-Phenyl
138	Methyl	Methyl	2	2,6-di-Me-Phenyl	314	Ethyl	Ethyl	2	2,6-di-Me-Phenyl
139	Methyl	Methyl	3	2,6-di-Me-Phenyl	315	Ethyl	Ethyl	3	2,6-di-Me-Phenyl
140	Methyl	Methyl	4	2,6-di-Me-Phenyl	316	Ethyl	Ethyl	4	2,6-di-Me-Phenyl
141	Methyl	Methyl	1	2,6-di-iPr-Phenyl	317	Ethyl	Ethyl	1	2,6-di-iPr-Phenyl
142	Methyl	Methyl	2	2,6-di-iPr-Phenyl	318	Ethyl	Ethyl	2	2,6-di-iPr-Phenyl
143	Methyl	Methyl	3	2,6-di-iPr-Phenyl	319	Ethyl	Ethyl	3	2,6-di-iPr-Phenyl
144	Methyl	Methyl	4	2,6-di-iPr-Phenyl	320	Ethyl	Ethyl	4	2,6-di-iPr-Phenyl
145	Methyl	Methyl	1	2-morpholino-phenyl	321	Ethyl	Ethyl	1	2-morpholino-phenyl
146	Methyl	Methyl	2	2-morpholino-phenyl	322	Ethyl	Ethyl	2	2-morpholino-phenyl
147	Methyl	Methyl	3	2-morpholino-phenyl	323	Ethyl	Ethyl	3	2-morpholino-phenyl
148	Methyl	Methyl	4	2-morpholino-phenyl	324	Ethyl	Ethyl	4	2-morpholino-phenyl
149	Methyl	Methyl	1	3-morpholino-phenyl	325	Ethyl	Ethyl	1	3-morpholino-phenyl
150	Methyl	Methyl	2	3-morpholino-phenyl	326	Ethyl	Ethyl	2	3-morpholino-phenyl
151	Methyl	Methyl	3	3-morpholino-phenyl	327	Ethyl	Ethyl	3	3-morpholino-phenyl
152	Methyl	Methyl	4	3-morpholino-phenyl	328	Ethyl	Ethyl	4	3-morpholino-phenyl
153	Methyl	Methyl	1	4-morpholino-phenyl	329	Ethyl	Ethyl	1	4-morpholino-phenyl
154	Methyl	Methyl	2	4-morpholino-phenyl	330	Ethyl	Ethyl	2	4-morpholino-phenyl
155	Methyl	Methyl	3	4-morpholino-phenyl	331	Ethyl	Ethyl	3	4-morpholino-phenyl
156	Methyl	Methyl	4	4-morpholino-phenyl	332	Ethyl	Ethyl	4	4-morpholino-phenyl
157	Methyl	Methyl	1	4-CN-2-morpholino-phenyl	333	Ethyl	Ethyl	1	4-CN-2-morpholino-phenyl

158	Methyl	Methyl	2	4-CN-2-morpholino-phenyl	334	Ethyl	Ethyl	2	4-CN-2-morpholino-phenyl
159	Methyl	Methyl	3	4-CN-2-morpholino-phenyl	335	Ethyl	Ethyl	3	4-CN-2-morpholino-phenyl
160	Methyl	Methyl	4	4-CN-2-morpholino-phenyl	336	Ethyl	Ethyl	4	4-CN-2-morpholino-phenyl
161	Methyl	Methyl	1	4-CH_3-2-morpholino-phenyl	337	Ethyl	Ethyl	1	4-CH_3-2-morpholino-phenyl
162	Methyl	Methyl	2	4-CH_3-2-morpholino-phenyl	338	Ethyl	Ethyl	2	4-CH_3-2-morpholino-phenyl
163	Methyl	Methyl	3	4-CH_3-2-morpholino-phenyl	339	Ethyl	Ethyl	3	4-CH_3-2-morpholino-phenyl
164	Methyl	Methyl	4	4-CH_3-2-morpholino-phenyl	340	Ethyl	Ethyl	4	4-CH_3-2-morpholino-phenyl
165	Methyl	Methyl	1	4-OH-2-morpholino-phenyl	341	Ethyl	Ethyl	1	4-OH-2-morpholino-phenyl
166	Methyl	Methyl	2	4-OH-2-morpholino-phenyl	342	Ethyl	Ethyl	2	4-OH-2-morpholino-phenyl
167	Methyl	Methyl	3	4-OH-2-morpholino-phenyl	343	Ethyl	Ethyl	3	4-OH-2-morpholino-phenyl
168	Methyl	Methyl	4	4-OH-2-morpholino-phenyl	344	Ethyl	Ethyl	4	4-OH-2-morpholino-phenyl
169	Methyl	Methyl	1	naphthylen-1-yl	345	Ethyl	Ethyl	1	naphthylen-1-yl
170	Methyl	Methyl	2	naphthylen-1-yl	346	Ethyl	Ethyl	2	naphthylen-1-yl
171	Methyl	Methyl	3	naphthylen-1-yl	347	Ethyl	Ethyl	3	naphthylen-1-yl
172	Methyl	Methyl	4	naphthylen-1-yl	348	Ethyl	Ethyl	4	naphthylen-1-yl
173	Methyl	Methyl	1	naphthylen-2-yl	349	Ethyl	Ethyl	1	naphthylen-2-yl
174	Methyl	Methyl	2	naphthylen-2-yl	350	Ethyl	Ethyl	2	naphthylen-2-yl
175	Methyl	Methyl	3	naphthylen-2-yl	351	Ethyl	Ethyl	3	naphthylen-2-yl
176	Methyl	Methyl	4	naphthylen-2-yl	352	Ethyl	Ethyl	4	naphthylen-2-yl

[01010] Exemplary embodiments include compounds having the formula **(VIII)**



(VIII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 2.

Table 2


Entry	n	R^3	Entry	n	R^3
1	1	Phenyl	89	1	2-Br-Phenyl
2	2	Phenyl	90	2	2-Br-Phenyl
3	3	Phenyl	91	3	2-Br-Phenyl
4	4	Phenyl	92	4	2-Br-Phenyl
5	1	4-OH-Phenyl	93	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	94	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	95	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	96	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	97	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	98	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	99	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	100	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	101	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	102	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	103	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	104	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	105	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	106	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	107	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	108	4	4-iPr-Phenyl
21	1	3-OMe-	109	1	3-iPr-Phenyl

		Phenyl			
22	2	3-OMe-Phenyl	110	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	111	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	112	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	113	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	114	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	115	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	116	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	117	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	118	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	119	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	120	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	121	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	122	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	123	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	124	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	125	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	126	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	127	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	128	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	129	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	130	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	131	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	132	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	133	1	2,4-di-Me-Phenyl

46	2	3-Me-Phenyl	134	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	135	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	136	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	137	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	138	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	139	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	140	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	141	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	142	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	143	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	144	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	145	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	146	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	147	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	148	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	149	1	2-morpholino-phenyl
62	2	2-F-Phenyl	150	2	2-morpholino-phenyl
63	3	2-F-Phenyl	151	3	2-morpholino-phenyl
64	4	2-F-Phenyl	152	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	153	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	154	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	155	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	156	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	157	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	158	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	159	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	160	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	161	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	162	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	163	3	4-CN-2-morpholino-

					phenyl
76	4	2-Cl-Phenyl	164	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	165	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	166	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	167	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	168	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	169	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	170	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	171	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	172	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01011] Exemplary embodiments include compounds having the formula **(IX)**



(IX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 3.

Table 3


Entry	n	R^3	Entry	n	R^3
1	1	Phenyl	89	1	2-Br-Phenyl
2	2	Phenyl	90	2	2-Br-Phenyl
3	3	Phenyl	91	3	2-Br-Phenyl
4	4	Phenyl	92	4	2-Br-Phenyl
5	1	4-OH-Phenyl	93	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	94	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	95	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	96	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	97	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	98	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	99	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	100	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	101	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	102	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	103	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	104	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	105	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	106	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	107	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	108	4	4-iPr-Phenyl
21	1	3-OMe-	109	1	3-iPr-Phenyl

		Phenyl			
22	2	3-OMe-Phenyl	110	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	111	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	112	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	113	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	114	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	115	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	116	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	117	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	118	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	119	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	120	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	121	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	122	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	123	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	124	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	125	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	126	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	127	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	128	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	129	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	130	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	131	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	132	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	133	1	2,4-di-Me-Phenyl

46	2	3-Me-Phenyl	134	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	135	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	136	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	137	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	138	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	139	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	140	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	141	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	142	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	143	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	144	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	145	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	146	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	147	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	148	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	149	1	2-morpholino-phenyl
62	2	2-F-Phenyl	150	2	2-morpholino-phenyl
63	3	2-F-Phenyl	151	3	2-morpholino-phenyl
64	4	2-F-Phenyl	152	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	153	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	154	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	155	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	156	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	157	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	158	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	159	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	160	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	161	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	162	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	163	3	4-CN-2-morpholino-

					phenyl
76	4	2-Cl-Phenyl	164	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	165	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	166	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	167	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	168	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	169	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	170	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	171	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	172	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01012] Exemplary embodiments include compounds having the formula (**X**)



(X)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 4.

Table 4


Entry	n	R^3	Entry	n	R^3
1	1	Phenyl	89	1	2-Br-Phenyl
2	2	Phenyl	90	2	2-Br-Phenyl
3	3	Phenyl	91	3	2-Br-Phenyl
4	4	Phenyl	92	4	2-Br-Phenyl
5	1	4-OH-Phenyl	93	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	94	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	95	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	96	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	97	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	98	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	99	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	100	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	101	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	102	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	103	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	104	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	105	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	106	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	107	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	108	4	4-iPr-Phenyl
21	1	3-OMe-	109	1	3-iPr-Phenyl

		Phenyl			
22	2	3-OMe-Phenyl	110	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	111	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	112	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	113	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	114	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	115	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	116	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	117	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	118	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	119	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	120	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	121	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	122	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	123	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	124	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	125	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	126	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	127	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	128	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	129	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	130	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	131	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	132	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	133	1	2,4-di-Me-Phenyl

46	2	3-Me-Phenyl	134	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	135	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	136	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	137	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	138	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	139	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	140	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	141	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	142	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	143	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	144	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	145	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	146	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	147	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	148	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	149	1	2-morpholino-phenyl
62	2	2-F-Phenyl	150	2	2-morpholino-phenyl
63	3	2-F-Phenyl	151	3	2-morpholino-phenyl
64	4	2-F-Phenyl	152	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	153	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	154	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	155	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	156	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	157	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	158	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	159	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	160	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	161	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	162	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	163	3	4-CN-2-morpholino-

					phenyl
76	4	2-Cl-Phenyl	164	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	165	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	166	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	167	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	168	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	169	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	170	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	171	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	172	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01013] Exemplary embodiments include compounds having the formula **(XI)**



(XI)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 5.

Table 5


Entry	n	R^3	Entry	n	R^3
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-	105	1	3-iPr-Phenyl

		Phenyl			
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl

46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-

					phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01014] Exemplary embodiments include compounds having the formula **(XII)**



(XII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 6.

Table 6:

Entry	R^1	R^2	n	R^4	Entry	R^1	R^2	n	R^4
1	Methyl	Methyl	1	Phenyl	177	Ethyl	Ethyl	1	Phenyl
2	Methyl	Methyl	2	Phenyl	178	Ethyl	Ethyl	2	Phenyl
3	Methyl	Methyl	3	Phenyl	179	Ethyl	Ethyl	3	Phenyl
4	Methyl	Methyl	4	Phenyl	180	Ethyl	Ethyl	4	Phenyl
5	Methyl	Methyl	1	4-OH-Phenyl	181	Ethyl	Ethyl	1	4-OH-Phenyl
6	Methyl	Methyl	2	4-OH-Phenyl	182	Ethyl	Ethyl	2	4-OH-Phenyl
7	Methyl	Methyl	3	4-OH-Phenyl	183	Ethyl	Ethyl	3	4-OH-Phenyl
8	Methyl	Methyl	4	4-OH-Phenyl	184	Ethyl	Ethyl	4	4-OH-Phenyl
9	Methyl	Methyl	1	3-OH-Phenyl	185	Ethyl	Ethyl	1	3-OH-Phenyl
10	Methyl	Methyl	2	3-OH-Phenyl	186	Ethyl	Ethyl	2	3-OH-Phenyl
11	Methyl	Methyl	3	3-OH-Phenyl	187	Ethyl	Ethyl	3	3-OH-Phenyl
12	Methyl	Methyl	4	3-OH-Phenyl	188	Ethyl	Ethyl	4	3-OH-Phenyl
13	Methyl	Methyl	1	2-OH-Phenyl	189	Ethyl	Ethyl	1	2-OH-Phenyl
14	Methyl	Methyl	2	2-OH-Phenyl	190	Ethyl	Ethyl	2	2-OH-Phenyl
15	Methyl	Methyl	3	2-OH-Phenyl	191	Ethyl	Ethyl	3	2-OH-Phenyl
16	Methyl	Methyl	4	2-OH-Phenyl	192	Ethyl	Ethyl	4	2-OH-Phenyl
17	Methyl	Methyl	1	4-OMe-Phenyl	193	Ethyl	Ethyl	1	4-OMe-Phenyl
18	Methyl	Methyl	2	4-OMe-Phenyl	194	Ethyl	Ethyl	2	4-OMe-Phenyl
19	Methyl	Methyl	3	4-OMe-Phenyl	195	Ethyl	Ethyl	3	4-OMe-Phenyl
20	Methyl	Methyl	4	4-OMe-Phenyl	196	Ethyl	Ethyl	4	4-OMe-Phenyl
21	Methyl	Methyl	1	3-OMe-Phenyl	197	Ethyl	Ethyl	1	3-OMe-Phenyl
22	Methyl	Methyl	2	3-OMe-Phenyl	198	Ethyl	Ethyl	2	3-OMe-Phenyl
23	Methyl	Methyl	3	3-OMe-Phenyl	199	Ethyl	Ethyl	3	3-OMe-Phenyl
24	Methyl	Methyl	4	3-OMe-Phenyl	200	Ethyl	Ethyl	4	3-OMe-Phenyl
25	Methyl	Methyl	1	2-OMe-Phenyl	201	Ethyl	Ethyl	1	2-OMe-Phenyl
26	Methyl	Methyl	2	2-OMe-Phenyl	202	Ethyl	Ethyl	2	2-OMe-Phenyl
27	Methyl	Methyl	3	2-OMe-Phenyl	203	Ethyl	Ethyl	3	2-OMe-Phenyl
28	Methyl	Methyl	4	2-OMe-Phenyl	204	Ethyl	Ethyl	4	2-OMe-Phenyl
29	Methyl	Methyl	1	4-CN-Phenyl	205	Ethyl	Ethyl	1	4-CN-Phenyl

30	Methyl	Methyl	2	4-CN-Phenyl	206	Ethyl	Ethyl	2	4-CN-Phenyl
31	Methyl	Methyl	3	4-CN-Phenyl	207	Ethyl	Ethyl	3	4-CN-Phenyl
32	Methyl	Methyl	4	4-CN-Phenyl	208	Ethyl	Ethyl	4	4-CN-Phenyl
33	Methyl	Methyl	1	3-CN-Phenyl	209	Ethyl	Ethyl	1	3-CN-Phenyl
34	Methyl	Methyl	2	3-CN-Phenyl	210	Ethyl	Ethyl	2	3-CN-Phenyl
35	Methyl	Methyl	3	3-CN-Phenyl	211	Ethyl	Ethyl	3	3-CN-Phenyl
36	Methyl	Methyl	4	3-CN-Phenyl	212	Ethyl	Ethyl	4	3-CN-Phenyl
37	Methyl	Methyl	1	2-CN-Phenyl	213	Ethyl	Ethyl	1	2-CN-Phenyl
38	Methyl	Methyl	2	2-CN-Phenyl	214	Ethyl	Ethyl	2	2-CN-Phenyl
39	Methyl	Methyl	3	2-CN-Phenyl	215	Ethyl	Ethyl	3	2-CN-Phenyl
40	Methyl	Methyl	4	2-CN-Phenyl	216	Ethyl	Ethyl	4	2-CN-Phenyl
41	Methyl	Methyl	1	4-Me-Phenyl	217	Ethyl	Ethyl	1	4-Me-Phenyl
42	Methyl	Methyl	2	4-Me-Phenyl	218	Ethyl	Ethyl	2	4-Me-Phenyl
43	Methyl	Methyl	3	4-Me-Phenyl	219	Ethyl	Ethyl	3	4-Me-Phenyl
44	Methyl	Methyl	4	4-Me-Phenyl	220	Ethyl	Ethyl	4	4-Me-Phenyl
45	Methyl	Methyl	1	3-Me-Phenyl	221	Ethyl	Ethyl	1	3-Me-Phenyl
46	Methyl	Methyl	2	3-Me-Phenyl	222	Ethyl	Ethyl	2	3-Me-Phenyl
47	Methyl	Methyl	3	3-Me-Phenyl	223	Ethyl	Ethyl	3	3-Me-Phenyl
48	Methyl	Methyl	4	3-Me-Phenyl	224	Ethyl	Ethyl	4	3-Me-Phenyl
49	Methyl	Methyl	1	2-Me-Phenyl	225	Ethyl	Ethyl	1	2-Me-Phenyl
50	Methyl	Methyl	2	2-Me-Phenyl	226	Ethyl	Ethyl	2	2-Me-Phenyl
51	Methyl	Methyl	3	2-Me-Phenyl	227	Ethyl	Ethyl	3	2-Me-Phenyl
52	Methyl	Methyl	4	2-Me-Phenyl	228	Ethyl	Ethyl	4	2-Me-Phenyl
53	Methyl	Methyl	1	4-F-Phenyl	229	Ethyl	Ethyl	1	4-F-Phenyl
54	Methyl	Methyl	2	4-F-Phenyl	230	Ethyl	Ethyl	2	4-F-Phenyl
55	Methyl	Methyl	3	4-F-Phenyl	231	Ethyl	Ethyl	3	4-F-Phenyl
56	Methyl	Methyl	4	4-F-Phenyl	232	Ethyl	Ethyl	4	4-F-Phenyl
57	Methyl	Methyl	1	3-F-Phenyl	233	Ethyl	Ethyl	1	3-F-Phenyl
58	Methyl	Methyl	2	3-F-Phenyl	234	Ethyl	Ethyl	2	3-F-Phenyl
59	Methyl	Methyl	3	3-F-Phenyl	235	Ethyl	Ethyl	3	3-F-Phenyl
60	Methyl	Methyl	4	3-F-Phenyl	236	Ethyl	Ethyl	4	3-F-Phenyl

61	Methyl	Methyl	1	2-F-Phenyl	237	Ethyl	Ethyl	1	2-F-Phenyl
62	Methyl	Methyl	2	2-F-Phenyl	238	Ethyl	Ethyl	2	2-F-Phenyl
63	Methyl	Methyl	3	2-F-Phenyl	239	Ethyl	Ethyl	3	2-F-Phenyl
64	Methyl	Methyl	4	2-F-Phenyl	240	Ethyl	Ethyl	4	2-F-Phenyl
65	Methyl	Methyl	1	4-Cl-Phenyl	241	Ethyl	Ethyl	1	4-Cl-Phenyl
66	Methyl	Methyl	2	4-Cl-Phenyl	242	Ethyl	Ethyl	2	4-Cl-Phenyl
67	Methyl	Methyl	3	4-Cl-Phenyl	243	Ethyl	Ethyl	3	4-Cl-Phenyl
68	Methyl	Methyl	4	4-Cl-Phenyl	244	Ethyl	Ethyl	4	4-Cl-Phenyl
69	Methyl	Methyl	1	3-Cl-Phenyl	245	Ethyl	Ethyl	1	3-Cl-Phenyl
70	Methyl	Methyl	2	3-Cl-Phenyl	246	Ethyl	Ethyl	2	3-Cl-Phenyl
71	Methyl	Methyl	3	3-Cl-Phenyl	247	Ethyl	Ethyl	3	3-Cl-Phenyl
72	Methyl	Methyl	4	3-Cl-Phenyl	248	Ethyl	Ethyl	4	3-Cl-Phenyl
73	Methyl	Methyl	1	2-Cl-Phenyl	249	Ethyl	Ethyl	1	2-Cl-Phenyl
74	Methyl	Methyl	2	2-Cl-Phenyl	250	Ethyl	Ethyl	2	2-Cl-Phenyl
75	Methyl	Methyl	3	2-Cl-Phenyl	251	Ethyl	Ethyl	3	2-Cl-Phenyl
76	Methyl	Methyl	4	2-Cl-Phenyl	252	Ethyl	Ethyl	4	2-Cl-Phenyl
77	Methyl	Methyl	1	4-Br-Phenyl	253	Ethyl	Ethyl	1	4-Br-Phenyl
78	Methyl	Methyl	2	4-Br-Phenyl	254	Ethyl	Ethyl	2	4-Br-Phenyl
79	Methyl	Methyl	3	4-Br-Phenyl	255	Ethyl	Ethyl	3	4-Br-Phenyl
80	Methyl	Methyl	4	4-Br-Phenyl	256	Ethyl	Ethyl	4	4-Br-Phenyl
81	Methyl	Methyl	1	3-Br-Phenyl	257	Ethyl	Ethyl	1	3-Br-Phenyl
82	Methyl	Methyl	2	3-Br-Phenyl	258	Ethyl	Ethyl	2	3-Br-Phenyl
83	Methyl	Methyl	3	3-Br-Phenyl	259	Ethyl	Ethyl	3	3-Br-Phenyl
84	Methyl	Methyl	4	3-Br-Phenyl	260	Ethyl	Ethyl	4	3-Br-Phenyl
85	Methyl	Methyl	1	2-Br-Phenyl	261	Ethyl	Ethyl	1	2-Br-Phenyl
86	Methyl	Methyl	2	2-Br-Phenyl	262	Ethyl	Ethyl	2	2-Br-Phenyl
87	Methyl	Methyl	3	2-Br-Phenyl	263	Ethyl	Ethyl	3	2-Br-Phenyl
88	Methyl	Methyl	4	2-Br-Phenyl	264	Ethyl	Ethyl	4	2-Br-Phenyl
89	Methyl	Methyl	1	4-CF_3-Phenyl	265	Ethyl	Ethyl	1	4-CF_3-Phenyl
90	Methyl	Methyl	2	4-CF_3-Phenyl	266	Ethyl	Ethyl	2	4-CF_3-Phenyl
91	Methyl	Methyl	3	4-CF_3-Phenyl	267	Ethyl	Ethyl	3	4-CF_3-Phenyl


92	Methyl	Methyl	4	4-CF_3-Phenyl	268	Ethyl	Ethyl	4	4-CF_3-Phenyl
93	Methyl	Methyl	1	3-CF_3-Phenyl	269	Ethyl	Ethyl	1	3-CF_3-Phenyl
94	Methyl	Methyl	2	3-CF_3-Phenyl	270	Ethyl	Ethyl	2	3-CF_3-Phenyl
95	Methyl	Methyl	3	3-CF_3-Phenyl	271	Ethyl	Ethyl	3	3-CF_3-Phenyl
96	Methyl	Methyl	4	3-CF_3-Phenyl	272	Ethyl	Ethyl	4	3-CF_3-Phenyl
97	Methyl	Methyl	1	2-CF_3-Phenyl	273	Ethyl	Ethyl	1	2-CF_3-Phenyl
98	Methyl	Methyl	2	2-CF_3-Phenyl	274	Ethyl	Ethyl	2	2-CF_3-Phenyl
99	Methyl	Methyl	3	2-CF_3-Phenyl	275	Ethyl	Ethyl	3	2-CF_3-Phenyl
100	Methyl	Methyl	4	2-CF_3-Phenyl	276	Ethyl	Ethyl	4	2-CF_3-Phenyl
101	Methyl	Methyl	1	4-iPr-Phenyl	277	Ethyl	Ethyl	1	4-iPr-Phenyl
102	Methyl	Methyl	2	4-iPr-Phenyl	278	Ethyl	Ethyl	2	4-iPr-Phenyl
103	Methyl	Methyl	3	4-iPr-Phenyl	279	Ethyl	Ethyl	3	4-iPr-Phenyl
104	Methyl	Methyl	4	4-iPr-Phenyl	280	Ethyl	Ethyl	4	4-iPr-Phenyl
105	Methyl	Methyl	1	3-iPr-Phenyl	281	Ethyl	Ethyl	1	3-iPr-Phenyl
106	Methyl	Methyl	2	3-iPr-Phenyl	282	Ethyl	Ethyl	2	3-iPr-Phenyl
107	Methyl	Methyl	3	3-iPr-Phenyl	283	Ethyl	Ethyl	3	3-iPr-Phenyl
108	Methyl	Methyl	4	3-iPr-Phenyl	284	Ethyl	Ethyl	4	3-iPr-Phenyl
109	Methyl	Methyl	1	2-iPr-Phenyl	285	Ethyl	Ethyl	1	2-iPr-Phenyl
110	Methyl	Methyl	2	2-iPr-Phenyl	286	Ethyl	Ethyl	2	2-iPr-Phenyl
111	Methyl	Methyl	3	2-iPr-Phenyl	287	Ethyl	Ethyl	3	2-iPr-Phenyl
112	Methyl	Methyl	4	2-iPr-Phenyl	288	Ethyl	Ethyl	4	2-iPr-Phenyl
113	Methyl	Methyl	1	4-NH_2-Phenyl	289	Ethyl	Ethyl	1	4-NH_2-Phenyl
114	Methyl	Methyl	2	4-NH_2-Phenyl	290	Ethyl	Ethyl	2	4-NH_2-Phenyl
115	Methyl	Methyl	3	4-NH_2-Phenyl	291	Ethyl	Ethyl	3	4-NH_2-Phenyl
116	Methyl	Methyl	4	4-NH_2-Phenyl	292	Ethyl	Ethyl	4	4-NH_2-Phenyl
117	Methyl	Methyl	1	3-NH_2-Phenyl	293	Ethyl	Ethyl	1	3-NH_2-Phenyl
118	Methyl	Methyl	2	3-NH_2-Phenyl	294	Ethyl	Ethyl	2	3-NH_2-Phenyl
119	Methyl	Methyl	3	3-NH_2-Phenyl	295	Ethyl	Ethyl	3	3-NH_2-Phenyl
120	Methyl	Methyl	4	3-NH_2-Phenyl	296	Ethyl	Ethyl	4	3-NH_2-Phenyl
121	Methyl	Methyl	1	2-NH_2-Phenyl	297	Ethyl	Ethyl	1	2-NH_2-Phenyl
122	Methyl	Methyl	2	2-NH_2-Phenyl	298	Ethyl	Ethyl	2	2-NH_2-Phenyl

123	Methyl	Methyl	3	2-NH_2-Phenyl	299	Ethyl	Ethyl	3	2-NH_2-Phenyl
124	Methyl	Methyl	4	2-NH_2-Phenyl	300	Ethyl	Ethyl	4	2-NH_2-Phenyl
125	Methyl	Methyl	1	2,3-di-Me-Phenyl	301	Ethyl	Ethyl	1	2,3-di-Me-Phenyl
126	Methyl	Methyl	2	2,3-di-Me-Phenyl	302	Ethyl	Ethyl	2	2,3-di-Me-Phenyl
127	Methyl	Methyl	3	2,3-di-Me-Phenyl	303	Ethyl	Ethyl	3	2,3-di-Me-Phenyl
128	Methyl	Methyl	4	2,3-di-Me-Phenyl	304	Ethyl	Ethyl	4	2,3-di-Me-Phenyl
129	Methyl	Methyl	1	2,4-di-Me-Phenyl	305	Ethyl	Ethyl	1	2,4-di-Me-Phenyl
130	Methyl	Methyl	2	2,4-di-Me-Phenyl	306	Ethyl	Ethyl	2	2,4-di-Me-Phenyl
131	Methyl	Methyl	3	2,4-di-Me-Phenyl	307	Ethyl	Ethyl	3	2,4-di-Me-Phenyl
132	Methyl	Methyl	4	2,4-di-Me-Phenyl	308	Ethyl	Ethyl	4	2,4-di-Me-Phenyl
133	Methyl	Methyl	1	2,5-di-Me-Phenyl	309	Ethyl	Ethyl	1	2,5-di-Me-Phenyl
134	Methyl	Methyl	2	2,5-di-Me-Phenyl	310	Ethyl	Ethyl	2	2,5-di-Me-Phenyl
135	Methyl	Methyl	3	2,5-di-Me-Phenyl	311	Ethyl	Ethyl	3	2,5-di-Me-Phenyl
136	Methyl	Methyl	4	2,5-di-Me-Phenyl	312	Ethyl	Ethyl	4	2,5-di-Me-Phenyl
137	Methyl	Methyl	1	2,6-di-Me-Phenyl	313	Ethyl	Ethyl	1	2,6-di-Me-Phenyl
138	Methyl	Methyl	2	2,6-di-Me-Phenyl	314	Ethyl	Ethyl	2	2,6-di-Me-Phenyl
139	Methyl	Methyl	3	2,6-di-Me-Phenyl	315	Ethyl	Ethyl	3	2,6-di-Me-Phenyl
140	Methyl	Methyl	4	2,6-di-Me-Phenyl	316	Ethyl	Ethyl	4	2,6-di-Me-Phenyl
141	Methyl	Methyl	1	2,6-di-iPr-Phenyl	317	Ethyl	Ethyl	1	2,6-di-iPr-Phenyl
142	Methyl	Methyl	2	2,6-di-iPr-Phenyl	318	Ethyl	Ethyl	2	2,6-di-iPr-Phenyl
143	Methyl	Methyl	3	2,6-di-iPr-Phenyl	319	Ethyl	Ethyl	3	2,6-di-iPr-Phenyl
144	Methyl	Methyl	4	2,6-di-iPr-Phenyl	320	Ethyl	Ethyl	4	2,6-di-iPr-Phenyl
145	Methyl	Methyl	1	2-morpholino-phenyl	321	Ethyl	Ethyl	1	2-morpholino-phenyl
146	Methyl	Methyl	2	2-morpholino-phenyl	322	Ethyl	Ethyl	2	2-morpholino-phenyl
147	Methyl	Methyl	3	2-morpholino-phenyl	323	Ethyl	Ethyl	3	2-morpholino-phenyl
148	Methyl	Methyl	4	2-morpholino-phenyl	324	Ethyl	Ethyl	4	2-morpholino-phenyl
149	Methyl	Methyl	1	3-morpholino-phenyl	325	Ethyl	Ethyl	1	3-morpholino-phenyl
150	Methyl	Methyl	2	3-morpholino-phenyl	326	Ethyl	Ethyl	2	3-morpholino-phenyl
151	Methyl	Methyl	3	3-morpholino-phenyl	327	Ethyl	Ethyl	3	3-morpholino-phenyl
152	Methyl	Methyl	4	3-morpholino-phenyl	328	Ethyl	Ethyl	4	3-morpholino-phenyl
153	Methyl	Methyl	1	4-morpholino-phenyl	329	Ethyl	Ethyl	1	4-morpholino-phenyl

154	Methyl	Methyl	2	4-morpholino-phenyl	330	Ethyl	Ethyl	2	4-morpholino-phenyl
155	Methyl	Methyl	3	4-morpholino-phenyl	331	Ethyl	Ethyl	3	4-morpholino-phenyl
156	Methyl	Methyl	4	4-morpholino-phenyl	332	Ethyl	Ethyl	4	4-morpholino-phenyl
157	Methyl	Methyl	1	4-CN-2-morpholino-phenyl	333	Ethyl	Ethyl	1	4-CN-2-morpholino-phenyl
158	Methyl	Methyl	2	4-CN-2-morpholino-phenyl	334	Ethyl	Ethyl	2	4-CN-2-morpholino-phenyl
159	Methyl	Methyl	3	4-CN-2-morpholino-phenyl	335	Ethyl	Ethyl	3	4-CN-2-morpholino-phenyl
160	Methyl	Methyl	4	4-CN-2-morpholino-phenyl	336	Ethyl	Ethyl	4	4-CN-2-morpholino-phenyl
161	Methyl	Methyl	1	4-CH_3-2-morpholino-phenyl	337	Ethyl	Ethyl	1	4-CH_3-2-morpholino-phenyl
162	Methyl	Methyl	2	4-CH_3-2-morpholino-phenyl	338	Ethyl	Ethyl	2	4-CH_3-2-morpholino-phenyl
163	Methyl	Methyl	3	4-CH_3-2-morpholino-phenyl	339	Ethyl	Ethyl	3	4-CH_3-2-morpholino-phenyl
164	Methyl	Methyl	4	4-CH_3-2-morpholino-phenyl	340	Ethyl	Ethyl	4	4-CH_3-2-morpholino-phenyl
165	Methyl	Methyl	1	4-OH-2-morpholino-phenyl	341	Ethyl	Ethyl	1	4-OH-2-morpholino-phenyl
166	Methyl	Methyl	2	4-OH-2-morpholino-phenyl	342	Ethyl	Ethyl	2	4-OH-2-morpholino-phenyl
167	Methyl	Methyl	3	4-OH-2-morpholino-phenyl	343	Ethyl	Ethyl	3	4-OH-2-morpholino-phenyl
168	Methyl	Methyl	4	4-OH-2-morpholino-phenyl	344	Ethyl	Ethyl	4	4-OH-2-morpholino-phenyl
169	Methyl	Methyl	1	naphthylen-1-yl	345	Ethyl	Ethyl	1	naphthylen-1-yl
170	Methyl	Methyl	2	naphthylen-1-yl	346	Ethyl	Ethyl	2	naphthylen-1-yl
171	Methyl	Methyl	3	naphthylen-1-yl	347	Ethyl	Ethyl	3	naphthylen-1-yl
172	Methyl	Methyl	4	naphthylen-1-yl	348	Ethyl	Ethyl	4	naphthylen-2-yl
173	Methyl	Methyl	1	naphthylen-2-yl	349	Ethyl	Ethyl	1	naphthylen-2-yl

174	Methyl	Methyl	2	naphthylen-2-yl	350	Ethyl	Ethyl	2	naphthylen-2-yl
175	Methyl	Methyl	3	naphthylen-2-yl	351	Ethyl	Ethyl	3	naphthylen-2-yl
176	Methyl	Methyl	4	naphthylen-2-yl	352	Ethyl	Ethyl	4	naphthylen-2-yl

[01015] Exemplary embodiments include compounds having the formula **(XIII)**



(XIII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 7

Table 7.

Entry	n	R^4	Entry	n	R^4
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl


19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-Phenyl	105	1	3-iPr-Phenyl
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl

41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl
46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl

72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-	176	4	naphthylen-2-yl

		yl			

[01016] Exemplary embodiments include compounds having the formula **(XIV)**



(XIV)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 8.

Table 8:


Entry	n	R^4	Entry	n	R^4
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl

20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-Phenyl	105	1	3-iPr-Phenyl
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl

43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl
46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-

					phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01017] Exemplary embodiments include compounds having the formula **(XV)**



(XV)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 9.

Table 9:


Entry	n	R^4	Entry	n	R^4
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl

21	1	3-OMe-Phenyl	105	1	3-iPr-Phenyl
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl

45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl
46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl

75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01018] Exemplary embodiments include compounds having the formula **(XVI)**



(XVI)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 10.

Table 10:


Entry	n	R^4	Entry	n	R^4
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-	105	1	3-iPr-Phenyl

		Phenyl			
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl

46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-

					phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01019] Exemplary embodiments include compounds having the formula **(XVII)**



(XVII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 11.

Table 11:

Entry	R^1	R^2	n	R^5	Entry	R^1	R^2	n	R^5
1	Methyl	Methyl	1	Phenyl	177	Ethyl	Ethyl	1	Phenyl
2	Methyl	Methyl	2	Phenyl	178	Ethyl	Ethyl	2	Phenyl
3	Methyl	Methyl	3	Phenyl	179	Ethyl	Ethyl	3	Phenyl
4	Methyl	Methyl	4	Phenyl	180	Ethyl	Ethyl	4	Phenyl
5	Methyl	Methyl	1	4-OH-Phenyl	181	Ethyl	Ethyl	1	4-OH-Phenyl
6	Methyl	Methyl	2	4-OH-Phenyl	182	Ethyl	Ethyl	2	4-OH-Phenyl
7	Methyl	Methyl	3	4-OH-Phenyl	183	Ethyl	Ethyl	3	4-OH-Phenyl
8	Methyl	Methyl	4	4-OH-Phenyl	184	Ethyl	Ethyl	4	4-OH-Phenyl
9	Methyl	Methyl	1	3-OH-Phenyl	185	Ethyl	Ethyl	1	3-OH-Phenyl
10	Methyl	Methyl	2	3-OH-Phenyl	186	Ethyl	Ethyl	2	3-OH-Phenyl
11	Methyl	Methyl	3	3-OH-Phenyl	187	Ethyl	Ethyl	3	3-OH-Phenyl
12	Methyl	Methyl	4	3-OH-Phenyl	188	Ethyl	Ethyl	4	3-OH-Phenyl
13	Methyl	Methyl	1	2-OH-Phenyl	189	Ethyl	Ethyl	1	2-OH-Phenyl
14	Methyl	Methyl	2	2-OH-Phenyl	190	Ethyl	Ethyl	2	2-OH-Phenyl
15	Methyl	Methyl	3	2-OH-Phenyl	191	Ethyl	Ethyl	3	2-OH-Phenyl
16	Methyl	Methyl	4	2-OH-Phenyl	192	Ethyl	Ethyl	4	2-OH-Phenyl
17	Methyl	Methyl	1	4-OMe-Phenyl	193	Ethyl	Ethyl	1	4-OMe-Phenyl
18	Methyl	Methyl	2	4-OMe-Phenyl	194	Ethyl	Ethyl	2	4-OMe-Phenyl
19	Methyl	Methyl	3	4-OMe-Phenyl	195	Ethyl	Ethyl	3	4-OMe-Phenyl
20	Methyl	Methyl	4	4-OMe-Phenyl	196	Ethyl	Ethyl	4	4-OMe-Phenyl
21	Methyl	Methyl	1	3-OMe-Phenyl	197	Ethyl	Ethyl	1	3-OMe-Phenyl
22	Methyl	Methyl	2	3-OMe-Phenyl	198	Ethyl	Ethyl	2	3-OMe-Phenyl
23	Methyl	Methyl	3	3-OMe-Phenyl	199	Ethyl	Ethyl	3	3-OMe-Phenyl
24	Methyl	Methyl	4	3-OMe-Phenyl	200	Ethyl	Ethyl	4	3-OMe-Phenyl
25	Methyl	Methyl	1	2-OMe-Phenyl	201	Ethyl	Ethyl	1	2-OMe-Phenyl
26	Methyl	Methyl	2	2-OMe-Phenyl	202	Ethyl	Ethyl	2	2-OMe-Phenyl
27	Methyl	Methyl	3	2-OMe-Phenyl	203	Ethyl	Ethyl	3	2-OMe-Phenyl
28	Methyl	Methyl	4	2-OMe-Phenyl	204	Ethyl	Ethyl	4	2-OMe-Phenyl
29	Methyl	Methyl	1	4-CN-Phenyl	205	Ethyl	Ethyl	1	4-CN-Phenyl

30	Methyl	Methyl	2	4-CN-Phenyl	206	Ethyl	Ethyl	2	4-CN-Phenyl
31	Methyl	Methyl	3	4-CN-Phenyl	207	Ethyl	Ethyl	3	4-CN-Phenyl
32	Methyl	Methyl	4	4-CN-Phenyl	208	Ethyl	Ethyl	4	4-CN-Phenyl
33	Methyl	Methyl	1	3-CN-Phenyl	209	Ethyl	Ethyl	1	3-CN-Phenyl
34	Methyl	Methyl	2	3-CN-Phenyl	210	Ethyl	Ethyl	2	3-CN-Phenyl
35	Methyl	Methyl	3	3-CN-Phenyl	211	Ethyl	Ethyl	3	3-CN-Phenyl
36	Methyl	Methyl	4	3-CN-Phenyl	212	Ethyl	Ethyl	4	3-CN-Phenyl
37	Methyl	Methyl	1	2-CN-Phenyl	213	Ethyl	Ethyl	1	2-CN-Phenyl
38	Methyl	Methyl	2	2-CN-Phenyl	214	Ethyl	Ethyl	2	2-CN-Phenyl
39	Methyl	Methyl	3	2-CN-Phenyl	215	Ethyl	Ethyl	3	2-CN-Phenyl
40	Methyl	Methyl	4	2-CN-Phenyl	216	Ethyl	Ethyl	4	2-CN-Phenyl
41	Methyl	Methyl	1	4-Me-Phenyl	217	Ethyl	Ethyl	1	4-Me-Phenyl
42	Methyl	Methyl	2	4-Me-Phenyl	218	Ethyl	Ethyl	2	4-Me-Phenyl
43	Methyl	Methyl	3	4-Me-Phenyl	219	Ethyl	Ethyl	3	4-Me-Phenyl
44	Methyl	Methyl	4	4-Me-Phenyl	220	Ethyl	Ethyl	4	4-Me-Phenyl
45	Methyl	Methyl	1	3-Me-Phenyl	221	Ethyl	Ethyl	1	3-Me-Phenyl
46	Methyl	Methyl	2	3-Me-Phenyl	222	Ethyl	Ethyl	2	3-Me-Phenyl
47	Methyl	Methyl	3	3-Me-Phenyl	223	Ethyl	Ethyl	3	3-Me-Phenyl
48	Methyl	Methyl	4	3-Me-Phenyl	224	Ethyl	Ethyl	4	3-Me-Phenyl
49	Methyl	Methyl	1	2-Me-Phenyl	225	Ethyl	Ethyl	1	2-Me-Phenyl
50	Methyl	Methyl	2	2-Me-Phenyl	226	Ethyl	Ethyl	2	2-Me-Phenyl
51	Methyl	Methyl	3	2-Me-Phenyl	227	Ethyl	Ethyl	3	2-Me-Phenyl
52	Methyl	Methyl	4	2-Me-Phenyl	228	Ethyl	Ethyl	4	2-Me-Phenyl
53	Methyl	Methyl	1	4-F-Phenyl	229	Ethyl	Ethyl	1	4-F-Phenyl
54	Methyl	Methyl	2	4-F-Phenyl	230	Ethyl	Ethyl	2	4-F-Phenyl
55	Methyl	Methyl	3	4-F-Phenyl	231	Ethyl	Ethyl	3	4-F-Phenyl
56	Methyl	Methyl	4	4-F-Phenyl	232	Ethyl	Ethyl	4	4-F-Phenyl
57	Methyl	Methyl	1	3-F-Phenyl	233	Ethyl	Ethyl	1	3-F-Phenyl
58	Methyl	Methyl	2	3-F-Phenyl	234	Ethyl	Ethyl	2	3-F-Phenyl
59	Methyl	Methyl	3	3-F-Phenyl	235	Ethyl	Ethyl	3	3-F-Phenyl
60	Methyl	Methyl	4	3-F-Phenyl	236	Ethyl	Ethyl	4	3-F-Phenyl

61	Methyl	Methyl	1	2-F-Phenyl	237	Ethyl	Ethyl	1	2-F-Phenyl
62	Methyl	Methyl	2	2-F-Phenyl	238	Ethyl	Ethyl	2	2-F-Phenyl
63	Methyl	Methyl	3	2-F-Phenyl	239	Ethyl	Ethyl	3	2-F-Phenyl
64	Methyl	Methyl	4	2-F-Phenyl	240	Ethyl	Ethyl	4	2-F-Phenyl
65	Methyl	Methyl	1	4-Cl-Phenyl	241	Ethyl	Ethyl	1	4-Cl-Phenyl
66	Methyl	Methyl	2	4-Cl-Phenyl	242	Ethyl	Ethyl	2	4-Cl-Phenyl
67	Methyl	Methyl	3	4-Cl-Phenyl	243	Ethyl	Ethyl	3	4-Cl-Phenyl
68	Methyl	Methyl	4	4-Cl-Phenyl	244	Ethyl	Ethyl	4	4-Cl-Phenyl
69	Methyl	Methyl	1	3-Cl-Phenyl	245	Ethyl	Ethyl	1	3-Cl-Phenyl
70	Methyl	Methyl	2	3-Cl-Phenyl	246	Ethyl	Ethyl	2	3-Cl-Phenyl
71	Methyl	Methyl	3	3-Cl-Phenyl	247	Ethyl	Ethyl	3	3-Cl-Phenyl
72	Methyl	Methyl	4	3-Cl-Phenyl	248	Ethyl	Ethyl	4	3-Cl-Phenyl
73	Methyl	Methyl	1	2-Cl-Phenyl	249	Ethyl	Ethyl	1	2-Cl-Phenyl
74	Methyl	Methyl	2	2-Cl-Phenyl	250	Ethyl	Ethyl	2	2-Cl-Phenyl
75	Methyl	Methyl	3	2-Cl-Phenyl	251	Ethyl	Ethyl	3	2-Cl-Phenyl
76	Methyl	Methyl	4	2-Cl-Phenyl	252	Ethyl	Ethyl	4	2-Cl-Phenyl
77	Methyl	Methyl	1	4-Br-Phenyl	253	Ethyl	Ethyl	1	4-Br-Phenyl
78	Methyl	Methyl	2	4-Br-Phenyl	254	Ethyl	Ethyl	2	4-Br-Phenyl
79	Methyl	Methyl	3	4-Br-Phenyl	255	Ethyl	Ethyl	3	4-Br-Phenyl
80	Methyl	Methyl	4	4-Br-Phenyl	256	Ethyl	Ethyl	4	4-Br-Phenyl
81	Methyl	Methyl	1	3-Br-Phenyl	257	Ethyl	Ethyl	1	3-Br-Phenyl
82	Methyl	Methyl	2	3-Br-Phenyl	258	Ethyl	Ethyl	2	3-Br-Phenyl
83	Methyl	Methyl	3	3-Br-Phenyl	259	Ethyl	Ethyl	3	3-Br-Phenyl
84	Methyl	Methyl	4	3-Br-Phenyl	260	Ethyl	Ethyl	4	3-Br-Phenyl
85	Methyl	Methyl	1	2-Br-Phenyl	261	Ethyl	Ethyl	1	2-Br-Phenyl
86	Methyl	Methyl	2	2-Br-Phenyl	262	Ethyl	Ethyl	2	2-Br-Phenyl
87	Methyl	Methyl	3	2-Br-Phenyl	263	Ethyl	Ethyl	3	2-Br-Phenyl
88	Methyl	Methyl	4	2-Br-Phenyl	264	Ethyl	Ethyl	4	2-Br-Phenyl
89	Methyl	Methyl	1	4-CF_3-Phenyl	265	Ethyl	Ethyl	1	4-CF_3-Phenyl
90	Methyl	Methyl	2	4-CF_3-Phenyl	266	Ethyl	Ethyl	2	4-CF_3-Phenyl
91	Methyl	Methyl	3	4-CF_3-Phenyl	267	Ethyl	Ethyl	3	4-CF_3-Phenyl


92	Methyl	Methyl	4	4-CF_3-Phenyl	268	Ethyl	Ethyl	4	4-CF_3-Phenyl
93	Methyl	Methyl	1	3-CF_3-Phenyl	269	Ethyl	Ethyl	1	3-CF_3-Phenyl
94	Methyl	Methyl	2	3-CF_3-Phenyl	270	Ethyl	Ethyl	2	3-CF_3-Phenyl
95	Methyl	Methyl	3	3-CF_3-Phenyl	271	Ethyl	Ethyl	3	3-CF_3-Phenyl
96	Methyl	Methyl	4	3-CF_3-Phenyl	272	Ethyl	Ethyl	4	3-CF_3-Phenyl
97	Methyl	Methyl	1	2-CF_3-Phenyl	273	Ethyl	Ethyl	1	2-CF_3-Phenyl
98	Methyl	Methyl	2	2-CF_3-Phenyl	274	Ethyl	Ethyl	2	2-CF_3-Phenyl
99	Methyl	Methyl	3	2-CF_3-Phenyl	275	Ethyl	Ethyl	3	2-CF_3-Phenyl
100	Methyl	Methyl	4	2-CF_3-Phenyl	276	Ethyl	Ethyl	4	2-CF_3-Phenyl
101	Methyl	Methyl	1	4-iPr-Phenyl	277	Ethyl	Ethyl	1	4-iPr-Phenyl
102	Methyl	Methyl	2	4-iPr-Phenyl	278	Ethyl	Ethyl	2	4-iPr-Phenyl
103	Methyl	Methyl	3	4-iPr-Phenyl	279	Ethyl	Ethyl	3	4-iPr-Phenyl
104	Methyl	Methyl	4	4-iPr-Phenyl	280	Ethyl	Ethyl	4	4-iPr-Phenyl
105	Methyl	Methyl	1	3-iPr-Phenyl	281	Ethyl	Ethyl	1	3-iPr-Phenyl
106	Methyl	Methyl	2	3-iPr-Phenyl	282	Ethyl	Ethyl	2	3-iPr-Phenyl
107	Methyl	Methyl	3	3-iPr-Phenyl	283	Ethyl	Ethyl	3	3-iPr-Phenyl
108	Methyl	Methyl	4	3-iPr-Phenyl	284	Ethyl	Ethyl	4	3-iPr-Phenyl
109	Methyl	Methyl	1	2-iPr-Phenyl	285	Ethyl	Ethyl	1	2-iPr-Phenyl
110	Methyl	Methyl	2	2-iPr-Phenyl	286	Ethyl	Ethyl	2	2-iPr-Phenyl
111	Methyl	Methyl	3	2-iPr-Phenyl	287	Ethyl	Ethyl	3	2-iPr-Phenyl
112	Methyl	Methyl	4	2-iPr-Phenyl	288	Ethyl	Ethyl	4	2-iPr-Phenyl
113	Methyl	Methyl	1	4-NH_2-Phenyl	289	Ethyl	Ethyl	1	4-NH_2-Phenyl
114	Methyl	Methyl	2	4-NH_2-Phenyl	290	Ethyl	Ethyl	2	4-NH_2-Phenyl
115	Methyl	Methyl	3	4-NH_2-Phenyl	291	Ethyl	Ethyl	3	4-NH_2-Phenyl
116	Methyl	Methyl	4	4-NH_2-Phenyl	292	Ethyl	Ethyl	4	4-NH_2-Phenyl
117	Methyl	Methyl	1	3-NH_2-Phenyl	293	Ethyl	Ethyl	1	3-NH_2-Phenyl
118	Methyl	Methyl	2	3-NH_2-Phenyl	294	Ethyl	Ethyl	2	3-NH_2-Phenyl
119	Methyl	Methyl	3	3-NH_2-Phenyl	295	Ethyl	Ethyl	3	3-NH_2-Phenyl
120	Methyl	Methyl	4	3-NH_2-Phenyl	296	Ethyl	Ethyl	4	3-NH_2-Phenyl
121	Methyl	Methyl	1	2-NH_2-Phenyl	297	Ethyl	Ethyl	1	2-NH_2-Phenyl
122	Methyl	Methyl	2	2-NH_2-Phenyl	298	Ethyl	Ethyl	2	2-NH_2-Phenyl

123	Methyl	Methyl	3	2-NH_2-Phenyl	299	Ethyl	Ethyl	3	2-NH_2-Phenyl
124	Methyl	Methyl	4	2-NH_2-Phenyl	300	Ethyl	Ethyl	4	2-NH_2-Phenyl
125	Methyl	Methyl	1	2,3-di-Me-Phenyl	301	Ethyl	Ethyl	1	2,3-di-Me-Phenyl
126	Methyl	Methyl	2	2,3-di-Me-Phenyl	302	Ethyl	Ethyl	2	2,3-di-Me-Phenyl
127	Methyl	Methyl	3	2,3-di-Me-Phenyl	303	Ethyl	Ethyl	3	2,3-di-Me-Phenyl
128	Methyl	Methyl	4	2,3-di-Me-Phenyl	304	Ethyl	Ethyl	4	2,3-di-Me-Phenyl
129	Methyl	Methyl	1	2,4-di-Me-Phenyl	305	Ethyl	Ethyl	1	2,4-di-Me-Phenyl
130	Methyl	Methyl	2	2,4-di-Me-Phenyl	306	Ethyl	Ethyl	2	2,4-di-Me-Phenyl
131	Methyl	Methyl	3	2,4-di-Me-Phenyl	307	Ethyl	Ethyl	3	2,4-di-Me-Phenyl
132	Methyl	Methyl	4	2,4-di-Me-Phenyl	308	Ethyl	Ethyl	4	2,4-di-Me-Phenyl
133	Methyl	Methyl	1	2,5-di-Me-Phenyl	309	Ethyl	Ethyl	1	2,5-di-Me-Phenyl
134	Methyl	Methyl	2	2,5-di-Me-Phenyl	310	Ethyl	Ethyl	2	2,5-di-Me-Phenyl
135	Methyl	Methyl	3	2,5-di-Me-Phenyl	311	Ethyl	Ethyl	3	2,5-di-Me-Phenyl
136	Methyl	Methyl	4	2,5-di-Me-Phenyl	312	Ethyl	Ethyl	4	2,5-di-Me-Phenyl
137	Methyl	Methyl	1	2,6-di-Me-Phenyl	313	Ethyl	Ethyl	1	2,6-di-Me-Phenyl
138	Methyl	Methyl	2	2,6-di-Me-Phenyl	314	Ethyl	Ethyl	2	2,6-di-Me-Phenyl
139	Methyl	Methyl	3	2,6-di-Me-Phenyl	315	Ethyl	Ethyl	3	2,6-di-Me-Phenyl
140	Methyl	Methyl	4	2,6-di-Me-Phenyl	316	Ethyl	Ethyl	4	2,6-di-Me-Phenyl
141	Methyl	Methyl	1	2,6-di-iPr-Phenyl	317	Ethyl	Ethyl	1	2,6-di-iPr-Phenyl
142	Methyl	Methyl	2	2,6-di-iPr-Phenyl	318	Ethyl	Ethyl	2	2,6-di-iPr-Phenyl
143	Methyl	Methyl	3	2,6-di-iPr-Phenyl	319	Ethyl	Ethyl	3	2,6-di-iPr-Phenyl
144	Methyl	Methyl	4	2,6-di-iPr-Phenyl	320	Ethyl	Ethyl	4	2,6-di-iPr-Phenyl
145	Methyl	Methyl	1	2-morpholino-phenyl	321	Ethyl	Ethyl	1	2-morpholino-phenyl
146	Methyl	Methyl	2	2-morpholino-phenyl	322	Ethyl	Ethyl	2	2-morpholino-phenyl
147	Methyl	Methyl	3	2-morpholino-phenyl	323	Ethyl	Ethyl	3	2-morpholino-phenyl
148	Methyl	Methyl	4	2-morpholino-phenyl	324	Ethyl	Ethyl	4	2-morpholino-phenyl
149	Methyl	Methyl	1	3-morpholino-phenyl	325	Ethyl	Ethyl	1	3-morpholino-phenyl
150	Methyl	Methyl	2	3-morpholino-phenyl	326	Ethyl	Ethyl	2	3-morpholino-phenyl
151	Methyl	Methyl	3	3-morpholino-phenyl	327	Ethyl	Ethyl	3	3-morpholino-phenyl
152	Methyl	Methyl	4	3-morpholino-phenyl	328	Ethyl	Ethyl	4	3-morpholino-phenyl
153	Methyl	Methyl	1	4-morpholino-phenyl	329	Ethyl	Ethyl	1	4-morpholino-phenyl

154	Methyl	Methyl	2	4-morpholino-phenyl	330	Ethyl	Ethyl	2	4-morpholino-phenyl
155	Methyl	Methyl	3	4-morpholino-phenyl	331	Ethyl	Ethyl	3	4-morpholino-phenyl
156	Methyl	Methyl	4	4-morpholino-phenyl	332	Ethyl	Ethyl	4	4-morpholino-phenyl
157	Methyl	Methyl	1	4-CN-2-morpholino-phenyl	333	Ethyl	Ethyl	1	4-CN-2-morpholino-phenyl
158	Methyl	Methyl	2	4-CN-2-morpholino-phenyl	334	Ethyl	Ethyl	2	4-CN-2-morpholino-phenyl
159	Methyl	Methyl	3	4-CN-2-morpholino-phenyl	335	Ethyl	Ethyl	3	4-CN-2-morpholino-phenyl
160	Methyl	Methyl	4	4-CN-2-morpholino-phenyl	336	Ethyl	Ethyl	4	4-CN-2-morpholino-phenyl
161	Methyl	Methyl	1	4-CH_3-2-morpholino-phenyl	337	Ethyl	Ethyl	1	4-CH_3-2-morpholino-phenyl
162	Methyl	Methyl	2	4-CH_3-2-morpholino-phenyl	338	Ethyl	Ethyl	2	4-CH_3-2-morpholino-phenyl
163	Methyl	Methyl	3	4-CH_3-2-morpholino-phenyl	339	Ethyl	Ethyl	3	4-CH_3-2-morpholino-phenyl
164	Methyl	Methyl	4	4-CH_3-2-morpholino-phenyl	340	Ethyl	Ethyl	4	4-CH_3-2-morpholino-phenyl
165	Methyl	Methyl	1	4-OH-2-morpholino-phenyl	341	Ethyl	Ethyl	1	4-OH-2-morpholino-phenyl
166	Methyl	Methyl	2	4-OH-2-morpholino-phenyl	342	Ethyl	Ethyl	2	4-OH-2-morpholino-phenyl
167	Methyl	Methyl	3	4-OH-2-morpholino-phenyl	343	Ethyl	Ethyl	3	4-OH-2-morpholino-phenyl
168	Methyl	Methyl	4	4-OH-2-morpholino-phenyl	344	Ethyl	Ethyl	4	4-OH-2-morpholino-phenyl
169	Methyl	Methyl	1	naphthylen-1-yl	345	Ethyl	Ethyl	1	naphthylen-1-yl
170	Methyl	Methyl	2	naphthylen-1-yl	346	Ethyl	Ethyl	2	naphthylen-1-yl
171	Methyl	Methyl	3	naphthylen-1-yl	347	Ethyl	Ethyl	3	naphthylen-1-yl
172	Methyl	Methyl	4	naphthylen-1-yl	348	Ethyl	Ethyl	4	naphthylen-1-yl
173	Methyl	Methyl	1	naphthylen-2-yl	349	Ethyl	Ethyl	1	naphthylen-2-yl

174	Methyl	Methyl	2	naphthylen-2-yl	350	Ethyl	Ethyl	2	naphthylen-2-yl
175	Methyl	Methyl	3	naphthylen-2-yl	351	Ethyl	Ethyl	3	naphthylen-2-yl
176	Methyl	Methyl	4	naphthylen-2-yl	352	Ethyl	Ethyl	4	naphthylen-2-yl

[01020] Exemplary embodiments include compounds having the formula **(XVIII)**



(XVIII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 12

Table 12.

Entry	n	R^5	Entry	n	R^5
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl


19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-Phenyl	105	1	3-iPr-Phenyl
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl

41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl
46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl

72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-	176	4	naphthylen-2-yl

		yl			

[01021] Exemplary embodiments include compounds having the formula **(XIX)**



(XIX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 13.

Table 13:


Entry	n	R^5	Entry	n	R^5
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl

20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-Phenyl	105	1	3-iPr-Phenyl
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl

43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl
46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-

					phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01022] Exemplary embodiments include compounds having the formula **(XX)**



(XX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 14.

Table 14:


Entry	n	R^5	Entry	n	R^5
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl

21	1	3-OMe-Phenyl	105	1	3-iPr-Phenyl
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl

45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl
46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl

75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01023] Exemplary embodiments include compounds having the formula **(XXI)**



(XXI)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 15.

Table 15:


Entry	n	R^5	Entry	n	R^5
1	1	Phenyl	85	1	2-Br-Phenyl
2	2	Phenyl	86	2	2-Br-Phenyl
3	3	Phenyl	87	3	2-Br-Phenyl
4	4	Phenyl	88	4	2-Br-Phenyl
5	1	4-OH-Phenyl	89	1	4-CF_3-Phenyl
6	2	4-OH-Phenyl	90	2	4-CF_3-Phenyl
7	3	4-OH-Phenyl	91	3	4-CF_3-Phenyl
8	4	4-OH-Phenyl	92	4	4-CF_3-Phenyl
9	1	3-OH-Phenyl	93	1	3-CF_3-Phenyl
10	2	3-OH-Phenyl	94	2	3-CF_3-Phenyl
11	3	3-OH-Phenyl	95	3	3-CF_3-Phenyl
12	4	3-OH-Phenyl	96	4	3-CF_3-Phenyl
13	1	2-OH-Phenyl	97	1	2-CF_3-Phenyl
14	2	2-OH-Phenyl	98	2	2-CF_3-Phenyl
15	3	2-OH-Phenyl	99	3	2-CF_3-Phenyl
16	4	2-OH-Phenyl	100	4	2-CF_3-Phenyl
17	1	4-OMe-Phenyl	101	1	4-iPr-Phenyl
18	2	4-OMe-Phenyl	102	2	4-iPr-Phenyl
19	3	4-OMe-Phenyl	103	3	4-iPr-Phenyl
20	4	4-OMe-Phenyl	104	4	4-iPr-Phenyl
21	1	3-OMe-	105	1	3-iPr-Phenyl

		Phenyl			
22	2	3-OMe-Phenyl	106	2	3-iPr-Phenyl
23	3	3-OMe-Phenyl	107	3	3-iPr-Phenyl
24	4	3-OMe-Phenyl	108	4	3-iPr-Phenyl
25	1	2-OMe-Phenyl	109	1	2-iPr-Phenyl
26	2	2-OMe-Phenyl	110	2	2-iPr-Phenyl
27	3	2-OMe-Phenyl	111	3	2-iPr-Phenyl
28	4	2-OMe-Phenyl	112	4	2-iPr-Phenyl
29	1	4-CN-Phenyl	113	1	4-NH_2-Phenyl
30	2	4-CN-Phenyl	114	2	4-NH_2-Phenyl
31	3	4-CN-Phenyl	115	3	4-NH_2-Phenyl
32	4	4-CN-Phenyl	116	4	4-NH_2-Phenyl
33	1	3-CN-Phenyl	117	1	3-NH_2-Phenyl
34	2	3-CN-Phenyl	118	2	3-NH_2-Phenyl
35	3	3-CN-Phenyl	119	3	3-NH_2-Phenyl
36	4	3-CN-Phenyl	120	4	3-NH_2-Phenyl
37	1	2-CN-Phenyl	121	1	2-NH_2-Phenyl
38	2	2-CN-Phenyl	122	2	2-NH_2-Phenyl
39	3	2-CN-Phenyl	123	3	2-NH_2-Phenyl
40	4	2-CN-Phenyl	124	4	2-NH_2-Phenyl
41	1	4-Me-Phenyl	125	1	2,3-di-Me-Phenyl
42	2	4-Me-Phenyl	126	2	2,3-di-Me-Phenyl
43	3	4-Me-Phenyl	127	3	2,3-di-Me-Phenyl
44	4	4-Me-Phenyl	128	4	2,3-di-Me-Phenyl
45	1	3-Me-Phenyl	129	1	2,4-di-Me-Phenyl

46	2	3-Me-Phenyl	130	2	2,4-di-Me-Phenyl
47	3	3-Me-Phenyl	131	3	2,4-di-Me-Phenyl
48	4	3-Me-Phenyl	132	4	2,4-di-Me-Phenyl
49	1	2-Me-Phenyl	133	1	2,5-di-Me-Phenyl
50	2	2-Me-Phenyl	134	2	2,5-di-Me-Phenyl
51	3	2-Me-Phenyl	135	3	2,5-di-Me-Phenyl
52	4	2-Me-Phenyl	136	4	2,5-di-Me-Phenyl
53	1	4-F-Phenyl	137	1	2,6-di-Me-Phenyl
54	2	4-F-Phenyl	138	2	2,6-di-Me-Phenyl
55	3	4-F-Phenyl	139	3	2,6-di-Me-Phenyl
56	4	4-F-Phenyl	140	4	2,6-di-Me-Phenyl
57	1	3-F-Phenyl	141	1	2,6-di-iPr-Phenyl
58	2	3-F-Phenyl	142	2	2,6-di-iPr-Phenyl
59	3	3-F-Phenyl	143	3	2,6-di-iPr-Phenyl
60	4	3-F-Phenyl	144	4	2,6-di-iPr-Phenyl
61	1	2-F-Phenyl	145	1	2-morpholino-phenyl
62	2	2-F-Phenyl	146	2	2-morpholino-phenyl
63	3	2-F-Phenyl	147	3	2-morpholino-phenyl
64	4	2-F-Phenyl	148	4	2-morpholino-phenyl
65	1	4-Cl-Phenyl	149	1	3-morpholino-phenyl
66	2	4-Cl-Phenyl	150	2	3-morpholino-phenyl
67	3	4-Cl-Phenyl	151	3	3-morpholino-phenyl
68	4	4-Cl-Phenyl	152	4	3-morpholino-phenyl
69	1	3-Cl-Phenyl	153	1	4-morpholino-phenyl
70	2	3-Cl-Phenyl	154	2	4-morpholino-phenyl
71	3	3-Cl-Phenyl	155	3	4-morpholino-phenyl
72	4	3-Cl-Phenyl	156	4	4-morpholino-phenyl
73	1	2-Cl-Phenyl	157	1	4-CN-2-morpholino-phenyl
74	2	2-Cl-Phenyl	158	2	4-CN-2-morpholino-phenyl
75	3	2-Cl-Phenyl	159	3	4-CN-2-morpholino-

					phenyl
76	4	2-Cl-Phenyl	160	4	4-CN-2-morpholino-phenyl
77	1	4-Br-Phenyl	161	1	4-CH_3-2-morpholino-phenyl
78	2	4-Br-Phenyl	162	2	4-CH_3-2-morpholino-phenyl
79	3	4-Br-Phenyl	163	3	4-CH_3-2-morpholino-phenyl
80	4	4-Br-Phenyl	164	4	4-CH_3-2-morpholino-phenyl
81	1	3-Br-Phenyl	165	1	4-OH-2-morpholino-phenyl
82	2	3-Br-Phenyl	166	2	4-OH-2-morpholino-phenyl
83	3	3-Br-Phenyl	167	3	4-OH-2-morpholino-phenyl
84	4	3-Br-Phenyl	168	4	4-OH-2-morpholino-phenyl
85	1	naphthylen-1-yl	173	1	naphthylen-2-yl
86	2	naphthylen-1-yl	174	2	naphthylen-2-yl
87	3	naphthylen-1-yl	175	3	naphthylen-2-yl
88	4	naphthylen-1-yl	176	4	naphthylen-2-yl

[01024] Exemplary embodiments include compounds having the formula **(XXII)**



(XXII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 16.

Table 16:

Entry	n	R^7	R^3	Entry	n	R^7	R^3
1	1	H	Phenyl	779	1	H	4-OH-Phenyl
2	2	H	Phenyl	780	2	H	4-OH-Phenyl
3	3	H	Phenyl	781	3	H	4-OH-Phenyl
4	4	H	Phenyl	782	4	H	4-OH-Phenyl
5	1	Me	Phenyl	783	1	Me	4-OH-Phenyl
6	2	Me	Phenyl	784	2	Me	4-OH-Phenyl
7	3	Me	Phenyl	785	3	Me	4-OH-Phenyl
8	4	Me	Phenyl	786	4	Me	4-OH-Phenyl
9	1	CH_2Ph	Phenyl	787	1	CH_2Ph	4-OH-Phenyl
10	2	CH_2Ph	Phenyl	788	2	CH_2Ph	4-OH-Phenyl
11	3	CH_2Ph	Phenyl	789	3	CH_2Ph	4-OH-Phenyl
12	4	CH_2Ph	Phenyl	790	4	CH_2Ph	4-OH-Phenyl
13	1	COMe	Phenyl	791	1	COMe	4-OH-Phenyl
14	2	COMe	Phenyl	792	2	COMe	4-OH-Phenyl
15	3	COMe	Phenyl	793	3	COMe	4-OH-Phenyl
16	4	COMe	Phenyl	794	4	COMe	4-OH-Phenyl
17	1	CO_2Me	Phenyl	795	1	CO_2Me	4-OH-Phenyl
18	2	CO_2Me	Phenyl	796	2	CO_2Me	4-OH-Phenyl
19	3	CO_2Me	Phenyl	797	3	CO_2Me	4-OH-Phenyl
20	4	CO_2Me	Phenyl	798	4	CO_2Me	4-OH-Phenyl
21	1	CO_2tBu	Phenyl	799	1	CO_2tBu	4-OH-Phenyl
22	2	CO_2tBu	Phenyl	800	2	CO_2tBu	4-OH-Phenyl
23	3	CO_2tBu	Phenyl	801	3	CO_2tBu	4-OH-Phenyl
24	4	CO_2tBu	Phenyl	802	4	CO_2tBu	4-OH-Phenyl
25	1	CONHMe	Phenyl	803	1	CONHMe	4-OH-Phenyl

26	2	CONHMe	Phenyl	804	2	CONHMe	4-OH-Phenyl
27	3	CONHMe	Phenyl	805	3	CONHMe	4-OH-Phenyl
28	4	CONHMe	Phenyl	806	4	CONHMe	4-OH-Phenyl
29	1	SO_2Me	Phenyl	807	1	SO_2Me	4-OH-Phenyl
30	2	SO_2Me	Phenyl	808	2	SO_2Me	4-OH-Phenyl
31	3	SO_2Me	Phenyl	809	3	SO_2Me	4-OH-Phenyl
32	4	SO_2Me	Phenyl	810	4	SO_2Me	4-OH-Phenyl
33	1	SO_2NH_2	Phenyl	811	1	SO_2NH_2	4-OH-Phenyl
34	2	SO_2NH_2	Phenyl	812	2	SO_2NH_2	4-OH-Phenyl
35	3	SO_2NH_2	Phenyl	813	3	SO_2NH_2	4-OH-Phenyl
36	4	SO_2NH_2	Phenyl	814	4	SO_2NH_2	4-OH-Phenyl
37	1	H	3-OH-Phenyl	815	1	H	2-OH-Phenyl
38	2	H	3-OH-Phenyl	816	2	H	2-OH-Phenyl
39	3	H	3-OH-Phenyl	817	3	H	2-OH-Phenyl
40	4	H	3-OH-Phenyl	818	4	H	2-OH-Phenyl
41	1	Me	3-OH-Phenyl	819	1	Me	2-OH-Phenyl
42	2	Me	3-OH-Phenyl	820	2	Me	2-OH-Phenyl
43	3	Me	3-OH-Phenyl	821	3	Me	2-OH-Phenyl
44	4	Me	3-OH-Phenyl	822	4	Me	2-OH-Phenyl
45	1	CH_2Ph	3-OH-Phenyl	823	1	CH_2Ph	2-OH-Phenyl
46	2	CH_2Ph	3-OH-Phenyl	824	2	CH_2Ph	2-OH-Phenyl
47	3	CH_2Ph	3-OH-Phenyl	825	3	CH_2Ph	2-OH-Phenyl
48	4	CH_2Ph	3-OH-Phenyl	826	4	CH_2Ph	2-OH-Phenyl
49	1	COMe	3-OH-Phenyl	827	1	COMe	2-OH-Phenyl
50	2	COMe	3-OH-Phenyl	828	2	COMe	2-OH-Phenyl
51	3	COMe	3-OH-Phenyl	829	3	COMe	2-OH-Phenyl
52	4	COMe	3-OH-Phenyl	830	4	COMe	2-OH-Phenyl
53	1	CO_2Me	3-OH-Phenyl	831	1	CO_2Me	2-OH-Phenyl
54	2	CO_2Me	3-OH-Phenyl	832	2	CO_2Me	2-OH-Phenyl
55	3	CO_2Me	3-OH-Phenyl	833	3	CO_2Me	2-OH-Phenyl
56	4	CO_2Me	3-OH-Phenyl	834	4	CO_2Me	2-OH-Phenyl

57	1	CO_2tBu	3-OH-Phenyl	835	1	CO_2tBu	2-OH-Phenyl
58	2	CO_2tBu	3-OH-Phenyl	836	2	CO_2tBu	2-OH-Phenyl
59	3	CO_2tBu	3-OH-Phenyl	837	3	CO_2tBu	2-OH-Phenyl
60	4	CO_2tBu	3-OH-Phenyl	838	4	CO_2tBu	2-OH-Phenyl
61	1	CONHMe	3-OH-Phenyl	839	1	CONHMe	2-OH-Phenyl
62	2	CONHMe	3-OH-Phenyl	840	2	CONHMe	2-OH-Phenyl
63	3	CONHMe	3-OH-Phenyl	841	3	CONHMe	2-OH-Phenyl
64	4	CONHMe	3-OH-Phenyl	842	4	CONHMe	2-OH-Phenyl
65	1	SO_2Me	3-OH-Phenyl	843	1	SO_2Me	2-OH-Phenyl
66	2	SO_2Me	3-OH-Phenyl	844	2	SO_2Me	2-OH-Phenyl
67	3	SO_2Me	3-OH-Phenyl	845	3	SO_2Me	2-OH-Phenyl
68	4	SO_2Me	3-OH-Phenyl	846	4	SO_2Me	2-OH-Phenyl
69	1	SO_2NH_2	3-OH-Phenyl	847	1	SO_2NH_2	2-OH-Phenyl
70	2	SO_2NH_2	3-OH-Phenyl	848	2	SO_2NH_2	2-OH-Phenyl
71	3	SO_2NH_2	3-OH-Phenyl	849	3	SO_2NH_2	2-OH-Phenyl
72	4	SO_2NH_2	3-OH-Phenyl	850	4	SO_2NH_2	2-OH-Phenyl
73	1	H	4-NO_2-Phenyl	851	1	H	4-OMe-Phenyl
74	2	H	4-NO_2-Phenyl	852	2	H	4-OMe-Phenyl
75	3	H	4-NO_2-Phenyl	853	3	H	4-OMe-Phenyl
76	4	H	4-NO_2-Phenyl	854	4	H	4-OMe-Phenyl
77	1	Me	4-NO_2-Phenyl	855	1	Me	4-OMe-Phenyl
78	2	Me	4-NO_2-Phenyl	856	2	Me	4-OMe-Phenyl
79	3	Me	4-NO_2-Phenyl	857	3	Me	4-OMe-Phenyl
80	4	Me	4-NO_2-Phenyl	858	4	Me	4-OMe-Phenyl
81	1	CH_2Ph	4-NO_2-Phenyl	859	1	CH_2Ph	4-OMe-Phenyl
82	2	CH_2Ph	4-NO_2-Phenyl	860	2	CH_2Ph	4-OMe-Phenyl
83	3	CH_2Ph	4-NO_2-Phenyl	861	3	CH_2Ph	4-OMe-Phenyl
84	4	CH_2Ph	4-NO_2-Phenyl	862	4	CH_2Ph	4-OMe-Phenyl
85	1	COMe	4-NO_2-Phenyl	863	1	COMe	4-OMe-Phenyl
86	2	COMe	4-NO_2-Phenyl	864	2	COMe	4-OMe-Phenyl
87	3	COMe	4-NO_2-Phenyl	865	3	COMe	4-OMe-Phenyl

88	4	COMe	4-NO_2-Phenyl	866	4	COMe	4-OMe-Phenyl
89	1	CO_2Me	4-NO_2-Phenyl	867	1	CO_2Me	4-OMe-Phenyl
90	2	CO_2Me	4-NO_2-Phenyl	868	2	CO_2Me	4-OMe-Phenyl
91	3	CO_2Me	4-NO_2-Phenyl	869	3	CO_2Me	4-OMe-Phenyl
92	4	CO_2Me	4-NO_2-Phenyl	870	4	CO_2Me	4-OMe-Phenyl
93	1	CO_2tBu	4-NO_2-Phenyl	871	1	CO_2tBu	4-OMe-Phenyl
94	2	CO_2tBu	4-NO_2-Phenyl	872	2	CO_2tBu	4-OMe-Phenyl
95	3	CO_2tBu	4-NO_2-Phenyl	873	3	CO_2tBu	4-OMe-Phenyl
96	4	CO_2tBu	4-NO_2-Phenyl	874	4	CO_2tBu	4-OMe-Phenyl
97	1	CONHMe	4-NO_2-Phenyl	875	1	CONHMe	4-OMe-Phenyl
98	2	CONHMe	4-NO_2-Phenyl	876	2	CONHMe	4-OMe-Phenyl
99	3	CONHMe	4-NO_2-Phenyl	877	3	CONHMe	4-OMe-Phenyl
100	4	CONHMe	4-NO_2-Phenyl	878	4	CONHMe	4-OMe-Phenyl
101	1	SO_2Me	4-NO_2-Phenyl	879	1	SO_2Me	4-OMe-Phenyl
102	2	SO_2Me	4-NO_2-Phenyl	880	2	SO_2Me	4-OMe-Phenyl
103	3	SO_2Me	4-NO_2-Phenyl	881	3	SO_2Me	4-OMe-Phenyl
104	4	SO_2Me	4-NO_2-Phenyl	882	4	SO_2Me	4-OMe-Phenyl
105	1	SO_2NH_2	4-NO_2-Phenyl	883	1	SO_2NH_2	4-OMe-Phenyl
106	2	SO_2NH_2	4-NO_2-Phenyl	884	2	SO_2NH_2	4-OMe-Phenyl
107	3	SO_2NH_2	4-NO_2-Phenyl	885	3	SO_2NH_2	4-OMe-Phenyl
108	4	SO_2NH_2	4-NO_2-Phenyl	886	4	SO_2NH_2	4-OMe-Phenyl
109	1	H	3-OMe-Phenyl	887	1	H	2-OMe-Phenyl
110	2	H	3-OMe-Phenyl	888	2	H	2-OMe-Phenyl
111	3	H	3-OMe-Phenyl	889	3	H	2-OMe-Phenyl
112	4	H	3-OMe-Phenyl	890	4	H	2-OMe-Phenyl
113	1	Me	3-OMe-Phenyl	891	1	Me	2-OMe-Phenyl
114	2	Me	3-OMe-Phenyl	892	2	Me	2-OMe-Phenyl
115	3	Me	3-OMe-Phenyl	893	3	Me	2-OMe-Phenyl
116	4	Me	3-OMe-Phenyl	894	4	Me	2-OMe-Phenyl
117	1	CH_2Ph	3-OMe-Phenyl	895	1	CH_2Ph	2-OMe-Phenyl
118	2	CH_2Ph	3-OMe-Phenyl	896	2	CH_2Ph	2-OMe-Phenyl

119	3	CH_2Ph	3-OMe-Phenyl	897	3	CH_2Ph	2-OMe-Phenyl
120	4	CH_2Ph	3-OMe-Phenyl	898	4	CH_2Ph	2-OMe-Phenyl
121	1	COMe	3-OMe-Phenyl	899	1	COMe	2-OMe-Phenyl
122	2	COMe	3-OMe-Phenyl	900	2	COMe	2-OMe-Phenyl
123	3	COMe	3-OMe-Phenyl	901	3	COMe	2-OMe-Phenyl
124	4	COMe	3-OMe-Phenyl	902	4	COMe	2-OMe-Phenyl
125	1	CO_2Me	3-OMe-Phenyl	903	1	CO_2Me	2-OMe-Phenyl
126	2	CO_2Me	3-OMe-Phenyl	904	2	CO_2Me	2-OMe-Phenyl
127	3	CO_2Me	3-OMe-Phenyl	905	3	CO_2Me	2-OMe-Phenyl
128	4	CO_2Me	3-OMe-Phenyl	906	4	CO_2Me	2-OMe-Phenyl
129	1	CO_2tBu	3-OMe-Phenyl	907	1	CO_2tBu	2-OMe-Phenyl
130	2	CO_2tBu	3-OMe-Phenyl	908	2	CO_2tBu	2-OMe-Phenyl
131	3	CO_2tBu	3-OMe-Phenyl	909	3	CO_2tBu	2-OMe-Phenyl
132	4	CO_2tBu	3-OMe-Phenyl	910	4	CO_2tBu	2-OMe-Phenyl
133	1	CONHMe	3-OMe-Phenyl	911	1	CONHMe	2-OMe-Phenyl
134	2	CONHMe	3-OMe-Phenyl	912	2	CONHMe	2-OMe-Phenyl
135	3	CONHMe	3-OMe-Phenyl	913	3	CONHMe	2-OMe-Phenyl
136	4	CONHMe	3-OMe-Phenyl	914	4	CONHMe	2-OMe-Phenyl
137	1	SO_2Me	3-OMe-Phenyl	915	1	SO_2Me	2-OMe-Phenyl
138	2	SO_2Me	3-OMe-Phenyl	916	2	SO_2Me	2-OMe-Phenyl
139	3	SO_2Me	3-OMe-Phenyl	917	3	SO_2Me	2-OMe-Phenyl
140	4	SO_2Me	3-OMe-Phenyl	918	4	SO_2Me	2-OMe-Phenyl
141	1	SO_2NH_2	3-OMe-Phenyl	919	1	SO_2NH_2	2-OMe-Phenyl
142	2	SO_2NH_2	3-OMe-Phenyl	920	2	SO_2NH_2	2-OMe-Phenyl
143	3	SO_2NH_2	3-OMe-Phenyl	921	3	SO_2NH_2	2-OMe-Phenyl
144	4	SO_2NH_2	3-OMe-Phenyl	922	4	SO_2NH_2	2-OMe-Phenyl
145	1	H	4-CN-Phenyl	923	1	H	3-CN-Phenyl
146	2	H	4-CN-Phenyl	924	2	H	3-CN-Phenyl
147	3	H	4-CN-Phenyl	925	3	H	3-CN-Phenyl
148	4	H	4-CN-Phenyl	926	4	H	3-CN-Phenyl
149	1	Me	4-CN-Phenyl	927	1	Me	3-CN-Phenyl

150	2	Me	4-CN-Phenyl	928	2	Me	3-CN-Phenyl
151	3	Me	4-CN-Phenyl	929	3	Me	3-CN-Phenyl
152	4	Me	4-CN-Phenyl	930	4	Me	3-CN-Phenyl
153	1	CH_2Ph	4-CN-Phenyl	931	1	CH_2Ph	3-CN-Phenyl
154	2	CH_2Ph	4-CN-Phenyl	932	2	CH_2Ph	3-CN-Phenyl
155	3	CH_2Ph	4-CN-Phenyl	933	3	CH_2Ph	3-CN-Phenyl
156	4	CH_2Ph	4-CN-Phenyl	934	4	CH_2Ph	3-CN-Phenyl
157	1	COMe	4-CN-Phenyl	935	1	COMe	3-CN-Phenyl
158	2	COMe	4-CN-Phenyl	936	2	COMe	3-CN-Phenyl
159	3	COMe	4-CN-Phenyl	937	3	COMe	3-CN-Phenyl
160	4	COMe	4-CN-Phenyl	938	4	COMe	3-CN-Phenyl
161	1	CO_2Me	4-CN-Phenyl	939	1	CO_2Me	3-CN-Phenyl
162	2	CO_2Me	4-CN-Phenyl	940	2	CO_2Me	3-CN-Phenyl
163	3	CO_2Me	4-CN-Phenyl	941	3	CO_2Me	3-CN-Phenyl
164	4	CO_2Me	4-CN-Phenyl	942	4	CO_2Me	3-CN-Phenyl
165	1	CO_2tBu	4-CN-Phenyl	943	1	CO_2tBu	3-CN-Phenyl
166	2	CO_2tBu	4-CN-Phenyl	944	2	CO_2tBu	3-CN-Phenyl
167	3	CO_2tBu	4-CN-Phenyl	945	3	CO_2tBu	3-CN-Phenyl
168	4	CO_2tBu	4-CN-Phenyl	946	4	CO_2tBu	3-CN-Phenyl
169	1	CONHMe	4-CN-Phenyl	947	1	CONHMe	3-CN-Phenyl
170	2	CONHMe	4-CN-Phenyl	948	2	CONHMe	3-CN-Phenyl
171	3	CONHMe	4-CN-Phenyl	949	3	CONHMe	3-CN-Phenyl
172	4	CONHMe	4-CN-Phenyl	950	4	CONHMe	3-CN-Phenyl
173	1	SO_2Me	4-CN-Phenyl	951	1	SO_2Me	3-CN-Phenyl
174	2	SO_2Me	4-CN-Phenyl	952	2	SO_2Me	3-CN-Phenyl
175	3	SO_2Me	4-CN-Phenyl	953	3	SO_2Me	3-CN-Phenyl
176	4	SO_2Me	4-CN-Phenyl	954	4	SO_2Me	3-CN-Phenyl
177	1	SO_2NH_2	4-CN-Phenyl	955	1	SO_2NH_2	3-CN-Phenyl
178	2	SO_2NH_2	4-CN-Phenyl	956	2	SO_2NH_2	3-CN-Phenyl
179	3	SO_2NH_2	4-CN-Phenyl	957	3	SO_2NH_2	3-CN-Phenyl
180	4	SO_2NH_2	4-CN-Phenyl	958	4	SO_2NH_2	3-CN-Phenyl

181	1	H	2-CN-Phenyl	959	1	H	2-Me-Phenyl
182	2	H	2-CN-Phenyl	960	2	H	2-Me-Phenyl
183	3	H	2-CN-Phenyl	961	3	H	2-Me-Phenyl
184	4	H	2-CN-Phenyl	962	4	H	2-Me-Phenyl
185	1	Me	2-CN-Phenyl	963	1	Me	2-Me-Phenyl
186	2	Me	2-CN-Phenyl	964	2	Me	2-Me-Phenyl
187	3	Me	2-CN-Phenyl	965	3	Me	2-Me-Phenyl
188	4	Me	2-CN-Phenyl	966	4	Me	2-Me-Phenyl
189	1	CH_2Ph	2-CN-Phenyl	967	1	CH_2Ph	2-Me-Phenyl
190	2	CH_2Ph	2-CN-Phenyl	968	2	CH_2Ph	2-Me-Phenyl
191	3	CH_2Ph	2-CN-Phenyl	969	3	CH_2Ph	2-Me-Phenyl
192	4	CH_2Ph	2-CN-Phenyl	970	4	CH_2Ph	2-Me-Phenyl
193	1	COMe	2-CN-Phenyl	971	1	COMe	2-Me-Phenyl
194	2	COMe	2-CN-Phenyl	972	2	COMe	2-Me-Phenyl
195	3	COMe	2-CN-Phenyl	973	3	COMe	2-Me-Phenyl
196	4	COMe	2-CN-Phenyl	974	4	COMe	2-Me-Phenyl
197	1	CO_2Me	2-CN-Phenyl	975	1	CO_2Me	2-Me-Phenyl
198	2	CO_2Me	2-CN-Phenyl	976	2	CO_2Me	2-Me-Phenyl
199	3	CO_2Me	2-CN-Phenyl	977	3	CO_2Me	2-Me-Phenyl
200	4	CO_2Me	2-CN-Phenyl	978	4	CO_2Me	2-CN-Phenyl
201	1	CO_2tBu	2-CN-Phenyl	979	1	CO_2tBu	2-Me-Phenyl
202	2	CO_2tBu	2-CN-Phenyl	980	2	CO_2tBu	2-Me-Phenyl
203	3	CO_2tBu	2-CN-Phenyl	981	3	CO_2tBu	2-Me-Phenyl
204	4	CO_2tBu	2-CN-Phenyl	982	4	CO_2tBu	2-Me-Phenyl
205	1	CONHMe	2-CN-Phenyl	983	1	CONHMe	2-Me-Phenyl
206	2	CONHMe	2-CN-Phenyl	984	2	CONHMe	2-Me-Phenyl
207	3	CONHMe	2-CN-Phenyl	985	3	CONHMe	2-Me-Phenyl
208	4	CONHMe	2-CN-Phenyl	986	4	CONHMe	2-Me-Phenyl
209	1	SO_2Me	2-CN-Phenyl	987	1	SO_2Me	2-Me-Phenyl
210	2	SO_2Me	2-CN-Phenyl	988	2	SO_2Me	2-Me-Phenyl
211	3	SO_2Me	2-CN-Phenyl	989	3	SO_2Me	2-Me-Phenyl

212	4	SO_2Me	2-CN-Phenyl	990	4	SO_2Me	2-Me-Phenyl
213	1	SO_2NH_2	2-CN-Phenyl	991	1	SO_2NH_2	2-Me-Phenyl
214	2	SO_2NH_2	2-CN-Phenyl	992	2	SO_2NH_2	2-Me-Phenyl
215	3	SO_2NH_2	2-CN-Phenyl	993	3	SO_2NH_2	2-Me-Phenyl
216	4	SO_2NH_2	2-CN-Phenyl	994	4	SO_2NH_2	2-Me-Phenyl
217	1	H	3-Me-Phenyl	995	1	H	4-Me-Phenyl
218	2	H	3-Me-Phenyl	996	2	H	4-Me-Phenyl
219	3	H	3-Me-Phenyl	997	3	H	4-Me-Phenyl
220	4	H	3-Me-Phenyl	998	4	H	4-Me-Phenyl
221	1	Me	3-Me-Phenyl	999	1	Me	4-Me-Phenyl
222	2	Me	3-Me-Phenyl	1000	2	Me	4-Me-Phenyl
223	3	Me	3-Me-Phenyl	1001	3	Me	4-Me-Phenyl
224	4	Me	3-Me-Phenyl	1002	4	Me	4-Me-Phenyl
225	1	CH_2Ph	3-Me-Phenyl	1003	1	CH_2Ph	4-Me-Phenyl
226	2	CH_2Ph	3-Me-Phenyl	1004	2	CH_2Ph	4-Me-Phenyl
227	3	CH_2Ph	3-Me-Phenyl	1005	3	CH_2Ph	4-Me-Phenyl
228	4	CH_2Ph	3-Me-Phenyl	1006	4	CH_2Ph	4-Me-Phenyl
229	1	COMe	3-Me-Phenyl	1007	1	COMe	4-Me-Phenyl
230	2	COMe	3-Me-Phenyl	1008	2	COMe	4-Me-Phenyl
231	3	COMe	3-Me-Phenyl	1009	3	COMe	4-Me-Phenyl
232	4	COMe	3-Me-Phenyl	1010	4	COMe	4-Me-Phenyl
233	1	CO_2Me	3-Me-Phenyl	1011	1	CO_2Me	4-Me-Phenyl
234	2	CO_2Me	3-Me-Phenyl	1012	2	CO_2Me	4-Me-Phenyl
235	3	CO_2Me	3-Me-Phenyl	1013	3	CO_2Me	4-Me-Phenyl
236	4	CO_2Me	3-Me-Phenyl	1014	4	CO_2Me	4-Me-Phenyl
237	1	CO_2tBu	3-Me-Phenyl	1015	1	CO_2tBu	4-Me-Phenyl
238	2	CO_2tBu	3-Me-Phenyl	1016	2	CO_2tBu	4-Me-Phenyl
239	3	CO_2tBu	3-Me-Phenyl	1017	3	CO_2tBu	4-Me-Phenyl
240	4	CO_2tBu	3-Me-Phenyl	1018	4	CO_2tBu	4-Me-Phenyl
241	1	CONHMe	3-Me-Phenyl	1019	1	CONHMe	4-Me-Phenyl
242	2	CONHMe	3-Me-Phenyl	1020	2	CONHMe	4-Me-Phenyl

243	3	CONHMe	3-Me-Phenyl	1021	3	CONHMe	4-Me-Phenyl
244	4	CONHMe	3-Me-Phenyl	1022	4	CONHMe	4-Me-Phenyl
245	1	SO_2Me	3-Me-Phenyl	1023	1	SO_2Me	4-Me-Phenyl
246	2	SO_2Me	3-Me-Phenyl	1024	2	SO_2Me	4-Me-Phenyl
247	3	SO_2Me	3-Me-Phenyl	1025	3	SO_2Me	4-Me-Phenyl
248	4	SO_2Me	3-Me-Phenyl	1026	4	SO_2Me	4-Me-Phenyl
249	1	SO_2NH_2	3-Me-Phenyl	1027	1	SO_2NH_2	4-Me-Phenyl
250	2	SO_2NH_2	3-Me-Phenyl	1028	2	SO_2NH_2	4-Me-Phenyl
251	3	SO_2NH_2	3-Me-Phenyl	1029	3	SO_2NH_2	4-Me-Phenyl
252	4	SO_2NH_2	3-Me-Phenyl	1030	4	SO_2NH_2	4-Me-Phenyl
253	1	H	2-F-Phenyl	1031	1	H	3-F-Phenyl
254	2	H	2-F-Phenyl	1032	2	H	3-F-Phenyl
255	3	H	2-F-Phenyl	1033	3	H	3-F-Phenyl
256	4	H	2-F-Phenyl	1034	4	H	3-F-Phenyl
257	1	Me	2-F-Phenyl	1035	1	Me	3-F-Phenyl
258	2	Me	2-F-Phenyl	1036	2	Me	3-F-Phenyl
259	3	Me	2-F-Phenyl	1037	3	Me	3-F-Phenyl
260	4	Me	2-F-Phenyl	1038	4	Me	3-F-Phenyl
261	1	CH_2Ph	2-F-Phenyl	1039	1	CH_2Ph	3-F-Phenyl
262	2	CH_2Ph	2-F-Phenyl	1040	2	CH_2Ph	3-F-Phenyl
263	3	CH_2Ph	2-F-Phenyl	1041	3	CH_2Ph	3-F-Phenyl
264	4	CH_2Ph	2-F-Phenyl	1042	4	CH_2Ph	3-F-Phenyl
265	1	COMe	2-F-Phenyl	1043	1	COMe	3-F-Phenyl
266	2	COMe	2-F-Phenyl	1044	2	COMe	3-F-Phenyl
267	3	COMe	2-F-Phenyl	1045	3	COMe	3-F-Phenyl
268	4	COMe	2-F-Phenyl	1046	4	COMe	3-F-Phenyl
269	1	CO_2Me	2-F-Phenyl	1047	1	CO_2Me	3-F-Phenyl
270	2	CO_2Me	2-F-Phenyl	1048	2	CO_2Me	3-F-Phenyl
271	3	CO_2Me	2-F-Phenyl	1049	3	CO_2Me	3-F-Phenyl
272	4	CO_2Me	2-F-Phenyl	1050	4	CO_2Me	3-F-Phenyl
273	1	CO_2tBu	2-F-Phenyl	1051	1	CO_2tBu	3-F-Phenyl

274	2	CO_2tBu	2-F-Phenyl	1052	2	CO_2tBu	3-F-Phenyl
275	3	CO_2tBu	2-F-Phenyl	1053	3	CO_2tBu	3-F-Phenyl
276	4	CO_2tBu	2-F-Phenyl	1054	4	CO_2tBu	3-F-Phenyl
277	1	CONHMe	2-F-Phenyl	1055	1	CONHMe	3-F-Phenyl
278	2	CONHMe	2-F-Phenyl	1056	2	CONHMe	3-F-Phenyl
279	3	CONHMe	2-F-Phenyl	1057	3	CONHMe	3-F-Phenyl
280	4	CONHMe	2-F-Phenyl	1058	4	CONHMe	3-F-Phenyl
281	1	SO_2Me	2-F-Phenyl	1059	1	SO_2Me	3-F-Phenyl
282	2	SO_2Me	2-F-Phenyl	1060	2	SO_2Me	3-F-Phenyl
283	3	SO_2Me	2-F-Phenyl	1061	3	SO_2Me	3-F-Phenyl
284	4	SO_2Me	2-F-Phenyl	1062	4	SO_2Me	3-F-Phenyl
285	1	SO_2NH_2	2-F-Phenyl	1063	1	SO_2NH_2	3-F-Phenyl
286	2	SO_2NH_2	2-F-Phenyl	1064	2	SO_2NH_2	3-F-Phenyl
287	3	SO_2NH_2	2-F-Phenyl	1065	3	SO_2NH_2	3-F-Phenyl
288	4	SO_2NH_2	2-F-Phenyl	1066	4	SO_2NH_2	3-F-Phenyl
289	1	H	4-F-Phenyl	1067	1	H	2-Cl-Phenyl
290	2	H	4-F-Phenyl	1068	2	H	2-Cl-Phenyl
291	3	H	4-F-Phenyl	1069	3	H	2-Cl-Phenyl
292	4	H	4-F-Phenyl	1070	4	H	2-Cl-Phenyl
293	1	Me	4-F-Phenyl	1071	1	Me	2-Cl-Phenyl
294	2	Me	4-F-Phenyl	1072	2	Me	2-Cl-Phenyl
295	3	Me	4-F-Phenyl	1073	3	Me	2-Cl-Phenyl
296	4	Me	4-F-Phenyl	1074	4	Me	2-Cl-Phenyl
297	1	CH_2Ph	4-F-Phenyl	1075	1	CH_2Ph	2-Cl-Phenyl
298	2	CH_2Ph	4-F-Phenyl	1076	2	CH_2Ph	2-Cl-Phenyl
299	3	CH_2Ph	4-F-Phenyl	1077	3	CH_2Ph	2-Cl-Phenyl
300	4	CH_2Ph	4-F-Phenyl	1078	4	CH_2Ph	2-Cl-Phenyl
301	1	COMe	4-F-Phenyl	1079	1	COMe	2-Cl-Phenyl
302	2	COMe	4-F-Phenyl	1080	2	COMe	2-Cl-Phenyl
303	3	COMe	4-F-Phenyl	1081	3	COMe	2-Cl-Phenyl
304	4	COMe	4-F-Phenyl	1082	4	COMe	2-Cl-Phenyl

305	1	CO_2Me	4-F-Phenyl	1083	1	CO_2Me	2-Cl-Phenyl
306	2	CO_2Me	4-F-Phenyl	1084	2	CO_2Me	2-Cl-Phenyl
307	3	CO_2Me	4-F-Phenyl	1085	3	CO_2Me	2-Cl-Phenyl
308	4	CO_2Me	4-F-Phenyl	1086	4	CO_2Me	2-Cl-Phenyl
309	1	CO_2tBu	4-F-Phenyl	1087	1	CO_2tBu	2-Cl-Phenyl
310	2	CO_2tBu	4-F-Phenyl	1088	2	CO_2tBu	2-Cl-Phenyl
311	3	CO_2tBu	4-F-Phenyl	1089	3	CO_2tBu	2-Cl-Phenyl
312	4	CO_2tBu	4-F-Phenyl	1090	4	CO_2tBu	2-Cl-Phenyl
313	1	CONHMe	4-F-Phenyl	1091	1	CONHMe	2-Cl-Phenyl
314	2	CONHMe	4-F-Phenyl	1092	2	CONHMe	2-Cl-Phenyl
315	3	CONHMe	4-F-Phenyl	1093	3	CONHMe	2-Cl-Phenyl
316	4	CONHMe	4-F-Phenyl	1094	4	CONHMe	2-Cl-Phenyl
317	1	SO_2Me	4-F-Phenyl	1095	1	SO_2Me	2-Cl-Phenyl
318	2	SO_2Me	4-F-Phenyl	1096	2	SO_2Me	2-Cl-Phenyl
319	3	SO_2Me	4-F-Phenyl	1097	3	SO_2Me	2-Cl-Phenyl
320	4	SO_2Me	4-F-Phenyl	1098	4	SO_2Me	2-Cl-Phenyl
321	1	SO_2NH_2	4-F-Phenyl	1099	1	SO_2NH_2	2-Cl-Phenyl
322	2	SO_2NH_2	4-F-Phenyl	1100	2	SO_2NH_2	2-Cl-Phenyl
323	3	SO_2NH_2	4-F-Phenyl	1101	3	SO_2NH_2	2-Cl-Phenyl
324	4	SO_2NH_2	4-F-Phenyl	1102	4	SO_2NH_2	2-Cl-Phenyl
325	1	H	3-Cl-Phenyl	1103	1	H	4-Cl-Phenyl
326	2	H	3-Cl-Phenyl	1104	2	H	4-Cl-Phenyl
327	3	H	3-Cl-Phenyl	1105	3	H	4-Cl-Phenyl
328	4	H	3-Cl-Phenyl	1106	4	H	4-Cl-Phenyl
329	1	Me	3-Cl-Phenyl	1107	1	Me	4-Cl-Phenyl
330	2	Me	3-Cl-Phenyl	1108	2	Me	4-Cl-Phenyl
331	3	Me	3-Cl-Phenyl	1109	3	Me	4-Cl-Phenyl
332	4	Me	3-Cl-Phenyl	1110	4	Me	4-Cl-Phenyl
333	1	CH_2Ph	3-Cl-Phenyl	1111	1	CH_2Ph	4-Cl-Phenyl
334	2	CH_2Ph	3-Cl-Phenyl	1112	2	CH_2Ph	4-Cl-Phenyl
335	3	CH_2Ph	3-Cl-Phenyl	1113	3	CH_2Ph	4-Cl-Phenyl

336	4	CH_2Ph	3-Cl-Phenyl	1114	4	CH_2Ph	4-Cl-Phenyl
337	1	COMe	3-Cl-Phenyl	1115	1	COMe	4-Cl-Phenyl
338	2	COMe	3-Cl-Phenyl	1116	2	COMe	4-Cl-Phenyl
339	3	COMe	3-Cl-Phenyl	1117	3	COMe	4-Cl-Phenyl
340	4	COMe	3-Cl-Phenyl	1118	4	COMe	4-Cl-Phenyl
341	1	CO_2Me	3-Cl-Phenyl	1119	1	CO_2Me	4-Cl-Phenyl
342	2	CO_2Me	3-Cl-Phenyl	1120	2	CO_2Me	4-Cl-Phenyl
343	3	CO_2Me	3-Cl-Phenyl	1121	3	CO_2Me	4-Cl-Phenyl
344	4	CO_2Me	3-Cl-Phenyl	1122	4	CO_2Me	4-Cl-Phenyl
345	1	CO_2tBu	3-Cl-Phenyl	1123	1	CO_2tBu	4-Cl-Phenyl
346	2	CO_2tBu	3-Cl-Phenyl	1124	2	CO_2tBu	4-Cl-Phenyl
347	3	CO_2tBu	3-Cl-Phenyl	1125	3	CO_2tBu	4-Cl-Phenyl
348	4	CO_2tBu	3-Cl-Phenyl	1126	4	CO_2tBu	4-Cl-Phenyl
349	1	CONHMe	3-Cl-Phenyl	1127	1	CONHMe	4-Cl-Phenyl
350	2	CONHMe	3-Cl-Phenyl	1128	2	CONHMe	4-Cl-Phenyl
351	3	CONHMe	3-Cl-Phenyl	1129	3	CONHMe	4-Cl-Phenyl
352	4	CONHMe	3-Cl-Phenyl	1130	4	CONHMe	4-Cl-Phenyl
353	1	SO_2Me	3-Cl-Phenyl	1131	1	SO_2Me	4-Cl-Phenyl
354	2	SO_2Me	3-Cl-Phenyl	1132	2	SO_2Me	4-Cl-Phenyl
355	3	SO_2Me	3-Cl-Phenyl	1133	3	SO_2Me	4-Cl-Phenyl
356	4	SO_2Me	3-Cl-Phenyl	1134	4	SO_2Me	4-Cl-Phenyl
357	1	SO_2NH_2	3-Cl-Phenyl	1135	1	SO_2NH_2	4-Cl-Phenyl
358	2	SO_2NH_2	3-Cl-Phenyl	1136	2	SO_2NH_2	4-Cl-Phenyl
359	3	SO_2NH_2	3-Cl-Phenyl	1137	3	SO_2NH_2	4-Cl-Phenyl
360	4	SO_2NH_2	3-Cl-Phenyl	1138	4	SO_2NH_2	4-Cl-Phenyl
361	1	H	2-Br-Phenyl	1139	1	H	3-Br-Phenyl
362	2	H	2-Br-Phenyl	1140	2	H	3-Br-Phenyl
363	3	H	2-Br-Phenyl	1141	3	H	3-Br-Phenyl
364	4	H	2-Br-Phenyl	1142	4	H	3-Br-Phenyl
365	1	Me	2-Br-Phenyl	1143	1	Me	3-Br-Phenyl
366	2	Me	2-Br-Phenyl	1144	2	Me	3-Br-Phenyl

367	3	Me	2-Br-Phenyl	1145	3	Me	3-Br-Phenyl
368	4	Me	2-Br-Phenyl	1146	4	Me	3-Br-Phenyl
369	1	CH_2Ph	2-Br-Phenyl	1147	1	CH_2Ph	3-Br-Phenyl
370	2	CH_2Ph	2-Br-Phenyl	1148	2	CH_2Ph	3-Br-Phenyl
371	3	CH_2Ph	2-Br-Phenyl	1149	3	CH_2Ph	3-Br-Phenyl
372	4	CH_2Ph	2-Br-Phenyl	1150	4	CH_2Ph	3-Br-Phenyl
373	1	COMe	2-Br-Phenyl	1151	1	COMe	3-Br-Phenyl
374	2	COMe	2-Br-Phenyl	1152	2	COMe	3-Br-Phenyl
375	3	COMe	2-Br-Phenyl	1153	3	COMe	3-Br-Phenyl
376	4	COMe	2-Br-Phenyl	1154	4	COMe	3-Br-Phenyl
377	1	CO_2Me	2-Br-Phenyl	1155	1	CO_2Me	3-Br-Phenyl
378	2	CO_2Me	2-Br-Phenyl	1156	2	CO_2Me	3-Br-Phenyl
379	3	CO_2Me	2-Br-Phenyl	1157	3	CO_2Me	3-Br-Phenyl
380	4	CO_2Me	2-Br-Phenyl	1158	4	CO_2Me	3-Br-Phenyl
381	1	CO_2tBu	2-Br-Phenyl	1159	1	CO_2tBu	3-Br-Phenyl
382	2	CO_2tBu	2-Br-Phenyl	1160	2	CO_2tBu	3-Br-Phenyl
383	3	CO_2tBu	2-Br-Phenyl	1161	3	CO_2tBu	3-Br-Phenyl
384	4	CO_2tBu	2-Br-Phenyl	1162	4	CO_2tBu	3-Br-Phenyl
385	1	CONHMe	2-Br-Phenyl	1163	1	CONHMe	3-Br-Phenyl
386	2	CONHMe	2-Br-Phenyl	1164	2	CONHMe	3-Br-Phenyl
387	3	CONHMe	2-Br-Phenyl	1165	3	CONHMe	3-Br-Phenyl
388	4	CONHMe	2-Br-Phenyl	1166	4	CONHMe	3-Br-Phenyl
389	1	SO_2Me	2-Br-Phenyl	1167	1	SO_2Me	3-Br-Phenyl
390	2	SO_2Me	2-Br-Phenyl	1168	2	SO_2Me	3-Br-Phenyl
391	3	SO_2Me	2-Br-Phenyl	1169	3	SO_2Me	3-Br-Phenyl
392	4	SO_2Me	2-Br-Phenyl	1170	4	SO_2Me	3-Br-Phenyl
393	1	SO_2NH_2	2-Br-Phenyl	1171	1	SO_2NH_2	3-Br-Phenyl
394	2	SO_2NH_2	2-Br-Phenyl	1172	2	SO_2NH_2	3-Br-Phenyl
395	3	SO_2NH_2	2-Br-Phenyl	1173	3	SO_2NH_2	3-Br-Phenyl
396	4	SO_2NH_2	2-Br-Phenyl	1174	4	SO_2NH_2	3-Br-Phenyl
397	1	H	4-Br-Phenyl	1175	1	H	2-CF_3-Phenyl

398	2	H	4-Br-Phenyl	1176	2	H	2-CF_3-Phenyl
399	3	H	4-Br-Phenyl	1177	3	H	2-CF_3-Phenyl
400	4	H	4-Br-Phenyl	1178	4	H	2-CF_3-Phenyl
401	1	Me	4-Br-Phenyl	1179	1	Me	2-CF_3-Phenyl
402	2	Me	4-Br-Phenyl	1180	2	Me	2-CF_3-Phenyl
403	3	Me	4-Br-Phenyl	1181	3	Me	2-CF_3-Phenyl
404	4	Me	4-Br-Phenyl	1182	4	Me	2-CF_3-Phenyl
405	1	CH_2Ph	4-Br-Phenyl	1183	1	CH_2Ph	2-CF_3-Phenyl
406	2	CH_2Ph	4-Br-Phenyl	1184	2	CH_2Ph	2-CF_3-Phenyl
407	3	CH_2Ph	4-Br-Phenyl	1185	3	CH_2Ph	2-CF_3-Phenyl
408	4	CH_2Ph	4-Br-Phenyl	1186	4	CH_2Ph	2-CF_3-Phenyl
409	1	COMe	4-Br-Phenyl	1187	1	COMe	2-CF_3-Phenyl
410	2	COMe	4-Br-Phenyl	1188	2	COMe	2-CF_3-Phenyl
411	3	COMe	4-Br-Phenyl	1189	3	COMe	2-CF_3-Phenyl
412	4	COMe	4-Br-Phenyl	1190	4	COMe	2-CF_3-Phenyl
413	1	CO_2Me	4-Br-Phenyl	1191	1	CO_2Me	2-CF_3-Phenyl
414	2	CO_2Me	4-Br-Phenyl	1192	2	CO_2Me	2-CF_3-Phenyl
415	3	CO_2Me	4-Br-Phenyl	1193	3	CO_2Me	2-CF_3-Phenyl
416	4	CO_2Me	4-Br-Phenyl	1194	4	CO_2Me	2-CF_3-Phenyl
417	1	CO_2tBu	4-Br-Phenyl	1195	1	CO_2tBu	2-CF_3-Phenyl
418	2	CO_2tBu	4-Br-Phenyl	1196	2	CO_2tBu	2-CF_3-Phenyl
419	3	CO_2tBu	4-Br-Phenyl	1197	3	CO_2tBu	2-CF_3-Phenyl
420	4	CO_2tBu	4-Br-Phenyl	1198	4	CO_2tBu	2-CF_3-Phenyl
421	1	CONHMe	4-Br-Phenyl	1199	1	CONHMe	2-CF_3-Phenyl
422	2	CONHMe	4-Br-Phenyl	1200	2	CONHMe	2-CF_3-Phenyl
423	3	CONHMe	4-Br-Phenyl	1201	3	CONHMe	2-CF_3-Phenyl
424	4	CONHMe	4-Br-Phenyl	1202	4	CONHMe	2-CF_3-Phenyl
425	1	SO_2Me	4-Br-Phenyl	1203	1	SO_2Me	2-CF_3-Phenyl
426	2	SO_2Me	4-Br-Phenyl	1204	2	SO_2Me	2-CF_3-Phenyl
427	3	SO_2Me	4-Br-Phenyl	1205	3	SO_2Me	2-CF_3-Phenyl
428	4	SO_2Me	4-Br-Phenyl	1206	4	SO_2Me	2-CF_3-Phenyl

429	1	SO_2NH_2	4-Br-Phenyl	1207	1	SO_2NH_2	2-CF_3-Phenyl
430	2	SO_2NH_2	4-Br-Phenyl	1208	2	SO_2NH_2	2-CF_3-Phenyl
431	3	SO_2NH_2	4-Br-Phenyl	1209	3	SO_2NH_2	2-CF_3-Phenyl
432	4	SO_2NH_2	4-Br-Phenyl	1210	4	SO_2NH_2	2-CF_3-Phenyl
433	1	H	3-CF_3-Phenyl	1211	1	H	4-CF_3-Phenyl
434	2	H	3-CF_3-Phenyl	1212	2	H	4-CF_3-Phenyl
435	3	H	3-CF_3-Phenyl	1213	3	H	4-CF_3-Phenyl
436	4	H	3-CF_3-Phenyl	1214	4	H	4-CF_3-Phenyl
437	1	Me	3-CF_3-Phenyl	1215	1	Me	4-CF_3-Phenyl
438	2	Me	3-CF_3-Phenyl	1216	2	Me	4-CF_3-Phenyl
439	3	Me	3-CF_3-Phenyl	1217	3	Me	4-CF_3-Phenyl
440	4	Me	3-CF_3-Phenyl	1218	4	Me	4-CF_3-Phenyl
441	1	CH_2Ph	3-CF_3-Phenyl	1219	1	CH_2Ph	4-CF_3-Phenyl
442	2	CH_2Ph	3-CF_3-Phenyl	1220	2	CH_2Ph	4-CF_3-Phenyl
443	3	CH_2Ph	3-CF_3-Phenyl	1221	3	CH_2Ph	4-CF_3-Phenyl
444	4	CH_2Ph	3-CF_3-Phenyl	1222	4	CH_2Ph	4-CF_3-Phenyl
445	1	COMe	3-CF_3-Phenyl	1223	1	COMe	4-CF_3-Phenyl
446	2	COMe	3-CF_3-Phenyl	1224	2	COMe	4-CF_3-Phenyl
447	3	COMe	3-CF_3-Phenyl	1225	3	COMe	4-CF_3-Phenyl
448	4	COMe	3-CF_3-Phenyl	1226	4	COMe	4-CF_3-Phenyl
449	1	CO_2Me	3-CF_3-Phenyl	1227	1	CO_2Me	4-CF_3-Phenyl
450	2	CO_2Me	3-CF_3-Phenyl	1228	2	CO_2Me	4-CF_3-Phenyl
451	3	CO_2Me	3-CF_3-Phenyl	1229	3	CO_2Me	4-CF_3-Phenyl
452	4	CO_2Me	3-CF_3-Phenyl	1230	4	CO_2Me	4-CF_3-Phenyl
453	1	CO_2tBu	3-CF_3-Phenyl	1231	1	CO_2tBu	4-CF_3-Phenyl
454	2	CO_2tBu	3-CF_3-Phenyl	1232	2	CO_2tBu	4-CF_3-Phenyl
455	3	CO_2tBu	3-CF_3-Phenyl	1233	3	CO_2tBu	4-CF_3-Phenyl
456	4	CO_2tBu	3-CF_3-Phenyl	1234	4	CO_2tBu	4-CF_3-Phenyl
457	1	CONHMe	3-CF_3-Phenyl	1235	1	CONHMe	4-CF_3-Phenyl
458	2	CONHMe	3-CF_3-Phenyl	1236	2	CONHMe	4-CF_3-Phenyl
459	3	CONHMe	3-CF_3-Phenyl	1237	3	CONHMe	4-CF_3-Phenyl

460	4	CONHMe	3-CF_3-Phenyl	1238	4	CONHMe	4-CF_3-Phenyl
461	1	SO_2Me	3-CF_3-Phenyl	1239	1	SO_2Me	4-CF_3-Phenyl
462	2	SO_2Me	3-CF_3-Phenyl	1240	2	SO_2Me	4-CF_3-Phenyl
463	3	SO_2Me	3-CF_3-Phenyl	1241	3	SO_2Me	4-CF_3-Phenyl
464	4	SO_2Me	3-CF_3-Phenyl	1242	4	SO_2Me	4-CF_3-Phenyl
465	1	SO_2NH_2	3-CF_3-Phenyl	1243	1	SO_2NH_2	4-CF_3-Phenyl
466	2	SO_2NH_2	3-CF_3-Phenyl	1244	2	SO_2NH_2	4-CF_3-Phenyl
467	3	SO_2NH_2	3-CF_3-Phenyl	1245	3	SO_2NH_2	4-CF_3-Phenyl
468	4	SO_2NH_2	3-CF_3-Phenyl	1246	4	SO_2NH_2	4-CF_3-Phenyl
469	1	H	2-iPr-Phenyl	1247	1	H	3-iPr-Phenyl
470	2	H	2-iPr-Phenyl	1248	2	H	3-iPr-Phenyl
471	3	H	2-iPr-Phenyl	1249	3	H	3-iPr-Phenyl
472	4	H	2-iPr-Phenyl	1250	4	H	3-iPr-Phenyl
473	1	Me	2-iPr-Phenyl	1251	1	Me	3-iPr-Phenyl
474	2	Me	2-iPr-Phenyl	1252	2	Me	3-iPr-Phenyl
475	3	Me	2-iPr-Phenyl	1253	3	Me	3-iPr-Phenyl
476	4	Me	2-iPr-Phenyl	1254	4	Me	3-iPr-Phenyl
477	1	CH_2Ph	2-iPr-Phenyl	1255	1	CH_2Ph	3-iPr-Phenyl
478	2	CH_2Ph	2-iPr-Phenyl	1256	2	CH_2Ph	3-iPr-Phenyl
479	3	CH_2Ph	2-iPr-Phenyl	1257	3	CH_2Ph	3-iPr-Phenyl
480	4	CH_2Ph	2-iPr-Phenyl	1258	4	CH_2Ph	3-iPr-Phenyl
481	1	COMe	2-iPr-Phenyl	1259	1	COMe	3-iPr-Phenyl
482	2	COMe	2-iPr-Phenyl	1260	2	COMe	3-iPr-Phenyl
483	3	COMe	2-iPr-Phenyl	1261	3	COMe	3-iPr-Phenyl
484	4	COMe	2-iPr-Phenyl	1262	4	COMe	3-iPr-Phenyl
485	1	CO_2Me	2-iPr-Phenyl	1263	1	CO_2Me	3-iPr-Phenyl
486	2	CO_2Me	2-iPr-Phenyl	1264	2	CO_2Me	3-iPr-Phenyl
487	3	CO_2Me	2-iPr-Phenyl	1265	3	CO_2Me	3-iPr-Phenyl
488	4	CO_2Me	2-iPr-Phenyl	1266	4	CO_2Me	3-iPr-Phenyl
489	1	CO_2tBu	2-iPr-Phenyl	1267	1	CO_2tBu	3-iPr-Phenyl
490	2	CO_2tBu	2-iPr-Phenyl	1268	2	CO_2tBu	3-iPr-Phenyl

491	3	CO_2tBu	2-iPr-Phenyl	1269	3	CO_2tBu	3-iPr-Phenyl
492	4	CO_2tBu	2-iPr-Phenyl	1270	4	CO_2tBu	3-iPr-Phenyl
493	1	CONHMe	2-iPr-Phenyl	1271	1	CONHMe	3-iPr-Phenyl
494	2	CONHMe	2-iPr-Phenyl	1272	2	CONHMe	3-iPr-Phenyl
495	3	CONHMe	2-iPr-Phenyl	1273	3	CONHMe	3-iPr-Phenyl
496	4	CONHMe	2-iPr-Phenyl	1274	4	CONHMe	3-iPr-Phenyl
497	1	SO_2Me	2-iPr-Phenyl	1275	1	SO_2Me	3-iPr-Phenyl
498	2	SO_2Me	2-iPr-Phenyl	1276	2	SO_2Me	3-iPr-Phenyl
499	3	SO_2Me	2-iPr-Phenyl	1277	3	SO_2Me	3-iPr-Phenyl
500	4	SO_2Me	2-iPr-Phenyl	1278	4	SO_2Me	3-iPr-Phenyl
501	1	SO_2NH_2	2-iPr-Phenyl	1279	1	SO_2NH_2	3-iPr-Phenyl
502	2	SO_2NH_2	2-iPr-Phenyl	1280	2	SO_2NH_2	3-iPr-Phenyl
503	3	SO_2NH_2	2-iPr-Phenyl	1281	3	SO_2NH_2	3-iPr-Phenyl
504	4	SO_2NH_2	2-iPr-Phenyl	1282	4	SO_2NH_2	3-iPr-Phenyl
505	1	H	4-iPr-Phenyl	1283	1	H	4-NH_2-Phenyl
506	2	H	4-iPr-Phenyl	1284	2	H	4-NH_2-Phenyl
507	3	H	4-iPr-Phenyl	1285	3	H	4-NH_2-Phenyl
508	4	H	4-iPr-Phenyl	1286	4	H	4-NH_2-Phenyl
509	1	Me	4-iPr-Phenyl	1287	1	Me	4-NH_2-Phenyl
510	2	Me	4-iPr-Phenyl	1288	2	Me	4-NH_2-Phenyl
511	3	Me	4-iPr-Phenyl	1289	3	Me	4-NH_2-Phenyl
512	4	Me	4-iPr-Phenyl	1290	4	Me	4-NH_2-Phenyl
513	1	CH_2Ph	4-iPr-Phenyl	1291	1	CH_2Ph	4-NH_2-Phenyl
514	2	CH_2Ph	4-iPr-Phenyl	1292	2	CH_2Ph	4-NH_2-Phenyl
515	3	CH_2Ph	4-iPr-Phenyl	1293	3	CH_2Ph	4-NH_2-Phenyl
516	4	CH_2Ph	4-iPr-Phenyl	1294	4	CH_2Ph	4-NH_2-Phenyl
517	1	COMe	4-iPr-Phenyl	1295	1	COMe	4-NH_2-Phenyl
518	2	COMe	4-iPr-Phenyl	1296	2	COMe	4-NH_2-Phenyl
519	3	COMe	4-iPr-Phenyl	1297	3	COMe	4-NH_2-Phenyl
520	4	COMe	4-iPr-Phenyl	1298	4	COMe	4-NH_2-Phenyl
521	1	CO_2Me	4-iPr-Phenyl	1299	1	CO_2Me	4-NH_2-Phenyl

522	2	CO_2Me	4-iPr-Phenyl	1300	2	CO_2Me	4-NH_2-Phenyl
523	3	CO_2Me	4-iPr-Phenyl	1301	3	CO_2Me	4-NH_2-Phenyl
524	4	CO_2Me	4-iPr-Phenyl	1302	4	CO_2Me	4-NH_2-Phenyl
525	1	CO_2tBu	4-iPr-Phenyl	1303	1	CO_2tBu	4-NH_2-Phenyl
526	2	CO_2tBu	4-iPr-Phenyl	1304	2	CO_2tBu	4-NH_2-Phenyl
527	3	CO_2tBu	4-iPr-Phenyl	1305	3	CO_2tBu	4-NH_2-Phenyl
528	4	CO_2tBu	4-iPr-Phenyl	1306	4	CO_2tBu	4-NH_2-Phenyl
529	1	CONHMe	4-iPr-Phenyl	1307	1	CONHMe	4-NH_2-Phenyl
530	2	CONHMe	4-iPr-Phenyl	1308	2	CONHMe	4-NH_2-Phenyl
531	3	CONHMe	4-iPr-Phenyl	1309	3	CONHMe	4-NH_2-Phenyl
532	4	CONHMe	4-iPr-Phenyl	1310	4	CONHMe	4-NH_2-Phenyl
533	1	SO_2Me	4-iPr-Phenyl	1311	1	SO_2Me	4-NH_2-Phenyl
534	2	SO_2Me	4-iPr-Phenyl	1312	2	SO_2Me	4-NH_2-Phenyl
535	3	SO_2Me	4-iPr-Phenyl	1313	3	SO_2Me	4-NH_2-Phenyl
536	4	SO_2Me	4-iPr-Phenyl	1314	4	SO_2Me	4-NH_2-Phenyl
537	1	SO_2NH_2	4-iPr-Phenyl	1315	1	SO_2NH_2	4-NH_2-Phenyl
538	2	SO_2NH_2	4-iPr-Phenyl	1316	2	SO_2NH_2	4-NH_2-Phenyl
539	3	SO_2NH_2	4-iPr-Phenyl	1317	3	SO_2NH_2	4-NH_2-Phenyl
540	4	SO_2NH_2	4-iPr-Phenyl	1318	4	SO_2NH_2	4-NH_2-Phenyl
541	1	H	3-NH_2-Phenyl	1319	1	H	2-NH_2-Phenyl
542	2	H	3-NH_2-Phenyl	1320	2	H	2-NH_2-Phenyl
543	3	H	3-NH_2-Phenyl	1321	3	H	2-NH_2-Phenyl
544	4	H	3-NH_2-Phenyl	1322	4	H	2-NH_2-Phenyl
545	1	Me	3-NH_2-Phenyl	1323	1	Me	2-NH_2-Phenyl
546	2	Me	3-NH_2-Phenyl	1324	2	Me	2-NH_2-Phenyl
547	3	Me	3-NH_2-Phenyl	1325	3	Me	2-NH_2-Phenyl
548	4	Me	3-NH_2-Phenyl	1326	4	Me	2-NH_2-Phenyl
549	1	CH_2Ph	3-NH_2-Phenyl	1327	1	CH_2Ph	2-NH_2-Phenyl
550	2	CH_2Ph	3-NH_2-Phenyl	1328	2	CH_2Ph	2-NH_2-Phenyl
551	3	CH_2Ph	3-NH_2-Phenyl	1329	3	CH_2Ph	2-NH_2-Phenyl
552	4	CH_2Ph	3-NH_2-Phenyl	1330	4	CH_2Ph	2-NH_2-Phenyl

553	1	COMe	3-NH_2-Phenyl	1331	1	COMe	2-NH_2-Phenyl
554	2	COMe	3-NH_2-Phenyl	1332	2	COMe	2-NH_2-Phenyl
555	3	COMe	3-NH_2-Phenyl	1333	3	COMe	2-NH_2-Phenyl
556	4	COMe	3-NH_2-Phenyl	1334	4	COMe	2-NH_2-Phenyl
557	1	CO_2Me	3-NH_2-Phenyl	1335	1	CO_2Me	2-NH_2-Phenyl
558	2	CO_2Me	3-NH_2-Phenyl	1336	2	CO_2Me	2-NH_2-Phenyl
559	3	CO_2Me	3-NH_2-Phenyl	1337	3	CO_2Me	2-NH_2-Phenyl
560	4	CO_2Me	3-NH_2-Phenyl	1338	4	CO_2Me	2-NH_2-Phenyl
561	1	CO_2tBu	3-NH_2-Phenyl	1339	1	CO_2tBu	2-NH_2-Phenyl
562	2	CO_2tBu	3-NH_2-Phenyl	1340	2	CO_2tBu	2-NH_2-Phenyl
563	3	CO_2tBu	3-NH_2-Phenyl	1341	3	CO_2tBu	2-NH_2-Phenyl
564	4	CO_2tBu	3-NH_2-Phenyl	1342	4	CO_2tBu	2-NH_2-Phenyl
565	1	CONHMe	3-NH_2-Phenyl	1343	1	CONHMe	2-NH_2-Phenyl
566	2	CONHMe	3-NH_2-Phenyl	1344	2	CONHMe	2-NH_2-Phenyl
567	3	CONHMe	3-NH_2-Phenyl	1345	3	CONHMe	2-NH_2-Phenyl
568	4	CONHMe	3-NH_2-Phenyl	1346	4	CONHMe	2-NH_2-Phenyl
569	1	SO_2Me	3-NH_2-Phenyl	1347	1	SO_2Me	2-NH_2-Phenyl
570	2	SO_2Me	3-NH_2-Phenyl	1348	2	SO_2Me	2-NH_2-Phenyl
571	3	SO_2Me	3-NH_2-Phenyl	1349	3	SO_2Me	2-NH_2-Phenyl
572	4	SO_2Me	3-NH_2-Phenyl	1350	4	SO_2Me	2-NH_2-Phenyl
573	1	SO_2NH_2	3-NH_2-Phenyl	1351	1	SO_2NH_2	2-NH_2-Phenyl
574	2	SO_2NH_2	3-NH_2-Phenyl	1352	2	SO_2NH_2	2-NH_2-Phenyl
575	3	SO_2NH_2	3-NH_2-Phenyl	1353	3	SO_2NH_2	2-NH_2-Phenyl
576	4	SO_2NH_2	3-NH_2-Phenyl	1354	4	SO_2NH_2	2-NH_2-Phenyl
577	1	H	2,4-di-Me-Phenyl	1355	1	H	2,6-di-Me-Phenyl
578	2	H	2,4-di-Me-Phenyl	1356	2	H	2,6-di-Me-Phenyl
579	3	H	2,4-di-Me-Phenyl	1357	3	H	2,6-di-Me-Phenyl
580	4	H	2,4-di-Me-Phenyl	1358	4	H	2,6-di-Me-Phenyl
581	1	Me	2,4-di-Me-Phenyl	1359	1	Me	2,6-di-Me-Phenyl
582	2	Me	2,4-di-Me-Phenyl	1360	2	Me	2,6-di-Me-Phenyl
583	3	Me	2,4-di-Me-Phenyl	1361	3	Me	2,6-di-Me-Phenyl

584	4	Me	2,4-di-Me-Phenyl	1362	4	Me	2,6-di-Me-Phenyl
585	1	CH_2Ph	2,4-di-Me-Phenyl	1363	1	CH_2Ph	2,6-di-Me-Phenyl
586	2	CH_2Ph	2,4-di-Me-Phenyl	1364	2	CH_2Ph	2,6-di-Me-Phenyl
587	3	CH_2Ph	2,4-di-Me-Phenyl	1365	3	CH_2Ph	2,6-di-Me-Phenyl
588	4	CH_2Ph	2,4-di-Me-Phenyl	1366	4	CH_2Ph	2,6-di-Me-Phenyl
589	1	COMe	2,4-di-Me-Phenyl	1367	1	COMe	2,6-di-Me-Phenyl
590	2	COMe	2,4-di-Me-Phenyl	1368	2	COMe	2,6-di-Me-Phenyl
591	3	COMe	2,4-di-Me-Phenyl	1369	3	COMe	2,6-di-Me-Phenyl
592	4	COMe	2,4-di-Me-Phenyl	1370	4	COMe	2,6-di-Me-Phenyl
593	1	CO_2Me	2,4-di-Me-Phenyl	1371	1	CO_2Me	2,6-di-Me-Phenyl
594	2	CO_2Me	2,4-di-Me-Phenyl	1372	2	CO_2Me	2,6-di-Me-Phenyl
595	3	CO_2Me	2,4-di-Me-Phenyl	1373	3	CO_2Me	2,6-di-Me-Phenyl
596	4	CO_2Me	2,4-di-Me-Phenyl	1374	4	CO_2Me	2,6-di-Me-Phenyl
597	1	CO_2tBu	2,4-di-Me-Phenyl	1375	1	CO_2tBu	2,6-di-Me-Phenyl
598	2	CO_2tBu	2,4-di-Me-Phenyl	1376	2	CO_2tBu	2,6-di-Me-Phenyl
599	3	CO_2tBu	2,4-di-Me-Phenyl	1377	3	CO_2tBu	2,6-di-Me-Phenyl
600	4	CO_2tBu	2,4-di-Me-Phenyl	1378	4	CO_2tBu	2,6-di-Me-Phenyl
601	1	CONHMe	2,4-di-Me-Phenyl	1379	1	CONHMe	2,6-di-Me-Phenyl
602	2	CONHMe	2,4-di-Me-Phenyl	1380	2	CONHMe	2,6-di-Me-Phenyl
603	3	CONHMe	2,4-di-Me-Phenyl	1381	3	CONHMe	2,6-di-Me-Phenyl
604	4	CONHMe	2,4-di-Me-Phenyl	1382	4	CONHMe	2,6-di-Me-Phenyl
605	1	SO_2Me	2,4-di-Me-Phenyl	1383	1	SO_2Me	2,6-di-Me-Phenyl
606	2	SO_2Me	2,4-di-Me-Phenyl	1384	2	SO_2Me	2,6-di-Me-Phenyl
607	3	SO_2Me	2,4-di-Me-Phenyl	1385	3	SO_2Me	2,6-di-Me-Phenyl
608	4	SO_2Me	2,4-di-Me-Phenyl	1386	4	SO_2Me	2,6-di-Me-Phenyl
609	1	SO_2NH_2	2,4-di-Me-Phenyl	1387	1	SO_2NH_2	2,6-di-Me-Phenyl
610	2	SO_2NH_2	2,4-di-Me-Phenyl	1388	2	SO_2NH_2	2,6-di-Me-Phenyl
611	3	SO_2NH_2	2,4-di-Me-Phenyl	1389	3	SO_2NH_2	2,6-di-Me-Phenyl
612	4	SO_2NH_2	2,4-di-Me-Phenyl	1390	4	SO_2NH_2	2,6-di-Me-Phenyl
613	1	H	2,6-di-iPr-Phenyl	1391	1	H	2-Ph-Phenyl
614	2	H	2,6-di-iPr-Phenyl	1392	2	H	2-Ph-Phenyl

615	3	H	2,6-di-iPr-Phenyl	1393	3	H	2-Ph-Phenyl
616	4	H	2,6-di-iPr-Phenyl	1394	4	H	2-Ph-Phenyl
617	1	Me	2,6-di-iPr-Phenyl	1395	1	Me	2-Ph-Phenyl
618	2	Me	2,6-di-iPr-Phenyl	1396	2	Me	2-Ph-Phenyl
619	3	Me	2,6-di-iPr-Phenyl	1397	3	Me	2-Ph-Phenyl
620	4	Me	2,6-di-iPr-Phenyl	1398	4	Me	2-Ph-Phenyl
621	1	CH_2Ph	2,6-di-iPr-Phenyl	1399	1	CH_2Ph	2-Ph-Phenyl
622	2	CH_2Ph	2,6-di-iPr-Phenyl	1400	2	CH_2Ph	2-Ph-Phenyl
623	3	CH_2Ph	2,6-di-iPr-Phenyl	1401	3	CH_2Ph	2-Ph-Phenyl
624	3	CH_2Ph	2,6-di-iPr-Phenyl	1402	4	CH_2Ph	2-Ph-Phenyl
625	1	COMe	2,6-di-iPr-Phenyl	1403	1	COMe	2-Ph-Phenyl
626	2	COMe	2,6-di-iPr-Phenyl	1404	2	COMe	2-Ph-Phenyl
627	3	COMe	2,6-di-iPr-Phenyl	1405	3	COMe	2-Ph-Phenyl
628	4	COMe	2,6-di-iPr-Phenyl	1406	4	COMe	2-Ph-Phenyl
629	1	CO_2Me	2,6-di-iPr-Phenyl	1407	1	CO_2Me	2-Ph-Phenyl
630	2	CO_2Me	2,6-di-iPr-Phenyl	1408	2	CO_2Me	2-Ph-Phenyl
631	3	CO_2Me	2,6-di-iPr-Phenyl	1409	3	CO_2Me	2-Ph-Phenyl
632	4	CO_2Me	2,6-di-iPr-Phenyl	1410	4	CO_2Me	2-Ph-Phenyl
633	1	CO_2tBu	2,6-di-iPr-Phenyl	1411	1	CO_2tBu	2-Ph-Phenyl
634	2	CO_2tBu	2,6-di-iPr-Phenyl	1412	2	CO_2tBu	2-Ph-Phenyl
635	3	CO_2tBu	2,6-di-iPr-Phenyl	1413	3	CO_2tBu	2-Ph-Phenyl
636	4	CO_2tBu	2,6-di-iPr-Phenyl	1414	4	CO_2tBu	2-Ph-Phenyl
637	1	CONHMe	2,6-di-iPr-Phenyl	1415	1	CONHMe	2-Ph-Phenyl
638	2	CONHMe	2,6-di-iPr-Phenyl	1416	2	CONHMe	2-Ph-Phenyl
639	3	CONHMe	2,6-di-iPr-Phenyl	1417	3	CONHMe	2-Ph-Phenyl
640	4	CONHMe	2,6-di-iPr-Phenyl	1418	4	CONHMe	2-Ph-Phenyl
641	1	SO_2Me	2,6-di-iPr-Phenyl	1419	1	SO_2Me	2-Ph-Phenyl
642	2	SO_2Me	2,6-di-iPr-Phenyl	1420	2	SO_2Me	2-Ph-Phenyl
643	3	SO_2Me	2,6-di-iPr-Phenyl	1421	3	SO_2Me	2-Ph-Phenyl
644	4	SO_2Me	2,6-di-iPr-Phenyl	1422	4	SO_2Me	2-Ph-Phenyl
645	1	SO_2NH_2	2,6-di-iPr-Phenyl	1423	1	SO_2NH_2	2-Ph-Phenyl

646	2	SO_2NH_2	2,6-di-iPr-Phenyl	1424	2	SO_2NH_2	2-Ph-Phenyl
647	3	SO_2NH_2	2,6-di-iPr-Phenyl	1425	3	SO_2NH_2	2-Ph-Phenyl
648	4	SO_2NH_2	2,6-di-iPr-Phenyl	1426	4	SO_2NH_2	2-Ph-Phenyl
649	1	H	3-Ph-Phenyl	1427	1	H	4-Ph-Phenyl
650	2	H	3-Ph-Phenyl	1428	2	H	4-Ph-Phenyl
651	3	H	3-Ph-Phenyl	1429	3	H	4-Ph-Phenyl
652	4	H	3-Ph-Phenyl	1430	4	H	4-Ph-Phenyl
653	1	Me	3-Ph-Phenyl	1431	1	Me	4-Ph-Phenyl
654	2	Me	3-Ph-Phenyl	1432	2	Me	4-Ph-Phenyl
655	3	Me	3-Ph-Phenyl	1433	3	Me	4-Ph-Phenyl
656	4	Me	3-Ph-Phenyl	1434	4	Me	4-Ph-Phenyl
657	1	CH_2Ph	3-Ph-Phenyl	1435	1	CH_2Ph	4-Ph-Phenyl
658	2	CH_2Ph	3-Ph-Phenyl	1436	2	CH_2Ph	4-Ph-Phenyl
659	3	CH_2Ph	3-Ph-Phenyl	1437	3	CH_2Ph	4-Ph-Phenyl
660	4	CH_2Ph	3-Ph-Phenyl	1438	4	CH_2Ph	4-Ph-Phenyl
661	1	COMe	3-Ph-Phenyl	1439	1	COMe	4-Ph-Phenyl
662	2	COMe	3-Ph-Phenyl	1440	2	COMe	4-Ph-Phenyl
663	3	COMe	3-Ph-Phenyl	1441	3	COMe	4-Ph-Phenyl
664	4	COMe	3-Ph-Phenyl	1442	4	COMe	4-Ph-Phenyl
665	1	CO_2Me	3-Ph-Phenyl	1443	1	CO_2Me	4-Ph-Phenyl
666	2	CO_2Me	3-Ph-Phenyl	1444	2	CO_2Me	4-Ph-Phenyl
667	3	CO_2Me	3-Ph-Phenyl	1445	3	CO_2Me	4-Ph-Phenyl
668	4	CO_2Me	3-Ph-Phenyl	1446	4	CO_2Me	4-Ph-Phenyl
669	1	CO_2tBu	3-Ph-Phenyl	1447	1	CO_2tBu	4-Ph-Phenyl
670	2	CO_2tBu	3-Ph-Phenyl	1448	2	CO_2tBu	4-Ph-Phenyl
671	3	CO_2tBu	3-Ph-Phenyl	1449	3	CO_2tBu	4-Ph-Phenyl
672	4	CO_2tBu	3-Ph-Phenyl	1450	4	CO_2tBu	4-Ph-Phenyl
673	1	CONHMe	3-Ph-Phenyl	1451	1	CONHMe	4-Ph-Phenyl
674	2	CONHMe	3-Ph-Phenyl	1452	2	CONHMe	4-Ph-Phenyl
675	3	CONHMe	3-Ph-Phenyl	1453	3	CONHMe	4-Ph-Phenyl
676	4	CONHMe	3-Ph-Phenyl	1454	4	CONHMe	4-Ph-Phenyl

677	1	SO_2Me	3-Ph-Phenyl	1455	1	SO_2Me	4-Ph-Phenyl
678	2	SO_2Me	3-Ph-Phenyl	1456	2	SO_2Me	4-Ph-Phenyl
679	3	SO_2Me	3-Ph-Phenyl	1457	3	SO_2Me	4-Ph-Phenyl
680	4	SO_2Me	3-Ph-Phenyl	1458	4	SO_2Me	4-Ph-Phenyl
681	1	SO_2NH_2	3-Ph-Phenyl	1459	1	SO_2NH_2	4-Ph-Phenyl
682	2	SO_2NH_2	3-Ph-Phenyl	1460	2	SO_2NH_2	4-Ph-Phenyl
683	3	SO_2NH_2	3-Ph-Phenyl	1461	3	SO_2NH_2	4-Ph-Phenyl
684	4	SO_2NH_2	3-Ph-Phenyl	1462	4	SO_2NH_2	4-Ph-Phenyl
685	1	H	2-morpholino-phenyl	1463	1	H	3-morpholino-phenyl
686	2	H	2-morpholino-phenyl	1464	2	H	3-morpholino-phenyl
687	3	H	2-morpholino-phenyl	1465	3	H	3-morpholino-phenyl
688	4	H	2-morpholino-phenyl	1466	4	H	3-morpholino-phenyl
689	1	Me	2-morpholino-phenyl	1467	1	Me	3-morpholino-phenyl
690	2	Me	2-morpholino-phenyl	1468	2	Me	3-morpholino-phenyl
691	3	Me	2-morpholino-phenyl	1469	3	Me	3-morpholino-phenyl
692	4	Me	2-morpholino-phenyl	1470	4	Me	3-morpholino-phenyl
693	1	CH_2Ph	2-morpholino-phenyl	1471	1	CH_2Ph	3-morpholino-phenyl
694	2	CH_2Ph	2-morpholino-phenyl	1472	2	CH_2Ph	3-morpholino-phenyl
695	3	CH_2Ph	2-morpholino-phenyl	1473	3	CH_2Ph	3-morpholino-phenyl
696	4	CH_2Ph	2-morpholino-phenyl	1474	4	CH_2Ph	3-morpholino-phenyl


697	1	COMe	2-morpholino-phenyl	1475	1	COMe	3-morpholino-phenyl
698	2	COMe	2-morpholino-phenyl	1476	2	COMe	3-morpholino-phenyl
699	3	COMe	2-morpholino-phenyl	1477	3	COMe	3-morpholino-phenyl
700	4	COMe	2-morpholino-phenyl	1478	4	COMe	3-morpholino-phenyl
701	1	CO_2Me	2-morpholino-phenyl	1479	1	CO_2Me	3-morpholino-phenyl
702	2	CO_2Me	2-morpholino-phenyl	1480	2	CO_2Me	3-morpholino-phenyl
703	3	CO_2Me	2-morpholino-phenyl	1481	3	CO_2Me	3-morpholino-phenyl
704	4	CO_2Me	2-morpholino-phenyl	1482	4	CO_2Me	3-morpholino-phenyl
705	1	CO_2tBu	2-morpholino-phenyl	1483	1	CO_2tBu	3-morpholino-phenyl
706	2	CO_2tBu	2-morpholino-phenyl	1484	2	CO_2tBu	3-morpholino-phenyl
707	3	CO_2tBu	2-morpholino-phenyl	1485	3	CO_2tBu	3-morpholino-phenyl
708	4	CO_2tBu	2-morpholino-phenyl	1486	4	CO_2tBu	3-morpholino-phenyl
709	1	CONHMe	2-morpholino-phenyl	1487	1	CONHMe	3-morpholino-phenyl
710	2	CONHMe	2-morpholino-phenyl	1488	2	CONHMe	3-morpholino-phenyl
711	3	CONHMe	2-morpholino-phenyl	1489	3	CONHMe	3-morpholino-phenyl
712	4	CONHMe	2-morpholino-phenyl	1490	4	CONHMe	3-morpholino-phenyl

713	1	SO_2Me	2-morpholino-phenyl	1491	1	SO_2Me	3-morpholino-phenyl
714	2	SO_2Me	2-morpholino-phenyl	1492	2	SO_2Me	3-morpholino-phenyl
715	3	SO_2Me	2-morpholino-phenyl	1493	3	SO_2Me	3-morpholino-phenyl
716	4	SO_2Me	2-morpholino-phenyl	1494	4	SO_2Me	3-morpholino-phenyl
717	1	SO_2NH_2	2-morpholino-phenyl	1495	1	SO_2NH_2	3-morpholino-phenyl
718	2	SO_2NH_2	2-morpholino-phenyl	1496	2	SO_2NH_2	3-morpholino-phenyl
719	3	SO_2NH_2	2-morpholino-phenyl	1497	3	SO_2NH_2	3-morpholino-phenyl
720	4	SO_2NH_2	2-morpholino-phenyl	1498	4	SO_2NH_2	3-morpholino-phenyl
721	1	H	4-morpholino-phenyl	1499	1	Me	4-morpholino-phenyl
722	2	H	4-morpholino-phenyl	1500	2	Me	4-morpholino-phenyl
723	3	H	4-morpholino-phenyl	1501	3	Me	4-morpholino-phenyl
724	4	H	4-morpholino-phenyl	1502	4	Me	4-morpholino-phenyl
725	1	CH_2Ph	4-morpholino-phenyl	103	1	COMe	4-morpholino-phenyl
726	2	CH_2Ph	4-morpholino-phenyl	1504	2	COMe	4-morpholino-phenyl
727	3	CH_2Ph	4-morpholino-phenyl	1505	3	COMe	4-morpholino-phenyl
728	4	CH_2Ph	4-morpholino-phenyl	1506	4	COMe	4-morpholino-phenyl

729	1	CO_2Me	4-morpholino-phenyl	1507	1	CO_2tBu	4-morpholino-phenyl
730	2	CO_2Me	4-morpholino-phenyl	1508	2	CO_2tBu	4-morpholino-phenyl
731	3	CO_2Me	4-morpholino-phenyl	1509	3	CO_2tBu	4-morpholino-phenyl
732	4	CO_2Me	4-morpholino-phenyl	1510	4	CO_2tBu	4-morpholino-phenyl
733	1	CONHMe	4-morpholino-phenyl	1511	1	SO_2Me	4-morpholino-phenyl
734	2	CONHMe	4-morpholino-phenyl	1512	2	SO_2Me	4-morpholino-phenyl
735	3	CONHMe	4-morpholino-phenyl	1513	3	SO_2Me	4-morpholino-phenyl
736	4	CONHMe	4-morpholino-phenyl	1514	4	SO_2Me	4-morpholino-phenyl
737	1	SO_2NH_2	4-morpholino-phenyl	1516	1	H	naphthylen-2-yl
738	2	SO_2NH_2	4-morpholino-phenyl	1517	2	H	naphthylen-2-yl
739	3	SO_2NH_2	4-morpholino-phenyl	1518	3	H	naphthylen-2-yl
740	1	H	naphthylen-1-yl	1519	4	H	naphthylen-2-yl
741	2	H	naphthylen-1-yl	1520	1	Me	naphthylen-2-yl
742	3	H	naphthylen-1-yl	1521	2	Me	naphthylen-2-yl
743	4	H	naphthylen-1-yl	1522	3	Me	naphthylen-2-yl
744	1	Me	naphthylen-1-yl	1523	4	Me	naphthylen-2-yl
745	2	Me	naphthylen-1-yl	1524	1	CH_2Ph	naphthylen-2-yl
746	3	Me	naphthylen-1-yl	1525	2	CH_2Ph	naphthylen-2-yl
747	4	Me	naphthylen-1-yl	1526	3	CH_2Ph	naphthylen-2-yl
748	1	CH_2Ph	naphthylen-1-yl	1527	4	CH_2Ph	naphthylen-2-yl
749	2	CH_2Ph	naphthylen-1-yl	1528	1	COMe	naphthylen-2-yl

750	3	CH_2Ph	naphthylen-1-yl	1529	2	COMe	naphthylen-2-yl
751	4	CH_2Ph	naphthylen-1-yl	1530	3	COMe	naphthylen-2-yl
752	1	COMe	naphthylen-1-yl	1531	4	COMe	naphthylen-2-yl
753	2	COMe	naphthylen-1-yl	1532	1	CO_2Me	naphthylen-2-yl
754	3	COMe	naphthylen-1-yl	1533	2	CO_2Me	naphthylen-2-yl
755	4	COMe	naphthylen-1-yl	1534	3	CO_2Me	naphthylen-2-yl
756	1	CO_2Me	naphthylen-1-yl	1535	4	CO_2Me	naphthylen-2-yl
757	2	CO_2Me	naphthylen-1-yl	1536	1	CO_2tBu	naphthylen-2-yl
758	3	CO_2Me	naphthylen-1-yl	1537	2	CO_2tBu	naphthylen-2-yl
759	4	CO_2Me	naphthylen-1-yl	1538	3	CO_2tBu	naphthylen-2-yl
760	1	CO_2tBu	naphthylen-1-yl	1539	4	CO_2tBu	naphthylen-2-yl
761	2	CO_2tBu	naphthylen-1-yl	1540	1	CONHMe	naphthylen-2-yl
762	3	CO_2tBu	naphthylen-1-yl	1541	2	CONHMe	naphthylen-2-yl
763	4	CO_2tBu	naphthylen-1-yl	1542	3	CONHMe	naphthylen-2-yl
764	1	CONHMe	naphthylen-1-yl	1543	4	CONHMe	naphthylen-2-yl
765	2	CONHMe	naphthylen-1-yl	1544	1	SO_2Me	naphthylen-2-yl
767	3	CONHMe	naphthylen-1-yl	1545	2	SO_2Me	naphthylen-2-yl
768	4	CONHMe	naphthylen-1-yl	1546	3	SO_2Me	naphthylen-2-yl
769	1	SO_2Me	naphthylen-1-yl	1547	4	SO_2Me	naphthylen-2-yl
770	2	SO_2Me	naphthylen-1-yl	1548	1	SO_2NH_2	naphthylen-2-yl
771	3	SO_2Me	naphthylen-1-yl	1549	2	SO_2NH_2	naphthylen-2-yl
772	4	SO_2Me	naphthylen-1-yl	1550	3	SO_2NH_2	naphthylen-2-yl
773	1	SO_2NH_2	naphthylen-1-yl	1551	4	SO_2NH_2	naphthylen-2-yl
774	2	SO_2NH_2	naphthylen-1-yl				
775	3	SO_2NH_2	naphthylen-1-yl				
778	4	SO_2NH_2	naphthylen-1-yl				

[01025] Exemplary embodiments include compounds having the formula **(XXIII)**



(XXIII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 17.

Table 17

Entry	n	R^7	R^3	Entry	n	R^7	R^3
1	1	H	Phenyl	779	1	H	4-OH-Phenyl
2	2	H	Phenyl	780	2	H	4-OH-Phenyl
3	3	H	Phenyl	781	3	H	4-OH-Phenyl
4	4	H	Phenyl	782	4	H	4-OH-Phenyl
5	1	Me	Phenyl	783	1	Me	4-OH-Phenyl
6	2	Me	Phenyl	784	2	Me	4-OH-Phenyl
7	3	Me	Phenyl	785	3	Me	4-OH-Phenyl
8	4	Me	Phenyl	786	4	Me	4-OH-Phenyl
9	1	CH_2Ph	Phenyl	787	1	CH_2Ph	4-OH-Phenyl
10	2	CH_2Ph	Phenyl	788	2	CH_2Ph	4-OH-Phenyl
11	3	CH_2Ph	Phenyl	789	3	CH_2Ph	4-OH-Phenyl
12	4	CH_2Ph	Phenyl	790	4	CH_2Ph	4-OH-Phenyl
13	1	COMe	Phenyl	791	1	COMe	4-OH-Phenyl
14	2	COMe	Phenyl	792	2	COMe	4-OH-Phenyl
15	3	COMe	Phenyl	793	3	COMe	4-OH-Phenyl
16	4	COMe	Phenyl	794	4	COMe	4-OH-Phenyl
17	1	CO_2Me	Phenyl	795	1	CO_2Me	4-OH-Phenyl
18	2	CO_2Me	Phenyl	796	2	CO_2Me	4-OH-Phenyl
19	3	CO_2Me	Phenyl	797	3	CO_2Me	4-OH-Phenyl
20	4	CO_2Me	Phenyl	798	4	CO_2Me	4-OH-Phenyl
21	1	CO_2tBu	Phenyl	799	1	CO_2tBu	4-OH-Phenyl
22	2	CO_2tBu	Phenyl	800	2	CO_2tBu	4-OH-Phenyl
23	3	CO_2tBu	Phenyl	801	3	CO_2tBu	4-OH-Phenyl
24	4	CO_2tBu	Phenyl	802	4	CO_2tBu	4-OH-Phenyl
25	1	CONHMe	Phenyl	803	1	CONHMe	4-OH-Phenyl
26	2	CONHMe	Phenyl	804	2	CONHMe	4-OH-Phenyl
27	3	CONHMe	Phenyl	805	3	CONHMe	4-OH-Phenyl
28	4	CONHMe	Phenyl	806	4	CONHMe	4-OH-Phenyl
29	1	SO_2Me	Phenyl	807	1	SO_2Me	4-OH-Phenyl

30	2	SO_2Me	Phenyl	808	2	SO_2Me	4-OH-Phenyl
31	3	SO_2Me	Phenyl	809	3	SO_2Me	4-OH-Phenyl
32	4	SO_2Me	Phenyl	810	4	SO_2Me	4-OH-Phenyl
33	1	SO_2NH_2	Phenyl	811	1	SO_2NH_2	4-OH-Phenyl
34	2	SO_2NH_2	Phenyl	812	2	SO_2NH_2	4-OH-Phenyl
35	3	SO_2NH_2	Phenyl	813	3	SO_2NH_2	4-OH-Phenyl
36	4	SO_2NH_2	Phenyl	814	4	SO_2NH_2	4-OH-Phenyl
37	1	H	3-OH-Phenyl	815	1	H	2-OH-Phenyl
38	2	H	3-OH-Phenyl	816	2	H	2-OH-Phenyl
39	3	H	3-OH-Phenyl	817	3	H	2-OH-Phenyl
40	4	H	3-OH-Phenyl	818	4	H	2-OH-Phenyl
41	1	Me	3-OH-Phenyl	819	1	Me	2-OH-Phenyl
42	2	Me	3-OH-Phenyl	820	2	Me	2-OH-Phenyl
43	3	Me	3-OH-Phenyl	821	3	Me	2-OH-Phenyl
44	4	Me	3-OH-Phenyl	822	4	Me	2-OH-Phenyl
45	1	CH_2Ph	3-OH-Phenyl	823	1	CH_2Ph	2-OH-Phenyl
46	2	CH_2Ph	3-OH-Phenyl	824	2	CH_2Ph	2-OH-Phenyl
47	3	CH_2Ph	3-OH-Phenyl	825	3	CH_2Ph	2-OH-Phenyl
48	4	CH_2Ph	3-OH-Phenyl	826	4	CH_2Ph	2-OH-Phenyl
49	1	COMe	3-OH-Phenyl	827	1	COMe	2-OH-Phenyl
50	2	COMe	3-OH-Phenyl	828	2	COMe	2-OH-Phenyl
51	3	COMe	3-OH-Phenyl	829	3	COMe	2-OH-Phenyl
52	4	COMe	3-OH-Phenyl	830	4	COMe	2-OH-Phenyl
53	1	CO_2Me	3-OH-Phenyl	831	1	CO_2Me	2-OH-Phenyl
54	2	CO_2Me	3-OH-Phenyl	832	2	CO_2Me	2-OH-Phenyl
55	3	CO_2Me	3-OH-Phenyl	833	3	CO_2Me	2-OH-Phenyl
56	4	CO_2Me	3-OH-Phenyl	834	4	CO_2Me	2-OH-Phenyl
57	1	CO_2tBu	3-OH-Phenyl	835	1	CO_2tBu	2-OH-Phenyl
58	2	CO_2tBu	3-OH-Phenyl	836	2	CO_2tBu	2-OH-Phenyl
59	3	CO_2tBu	3-OH-Phenyl	837	3	CO_2tBu	2-OH-Phenyl
60	4	CO_2tBu	3-OH-Phenyl	838	4	CO_2tBu	2-OH-Phenyl

61	1	CONHMe	3-OH-Phenyl	839	1	CONHMe	2-OH-Phenyl
62	2	CONHMe	3-OH-Phenyl	840	2	CONHMe	2-OH-Phenyl
63	3	CONHMe	3-OH-Phenyl	841	3	CONHMe	2-OH-Phenyl
64	4	CONHMe	3-OH-Phenyl	842	4	CONHMe	2-OH-Phenyl
65	1	SO_2Me	3-OH-Phenyl	843	1	SO_2Me	2-OH-Phenyl
66	2	SO_2Me	3-OH-Phenyl	844	2	SO_2Me	2-OH-Phenyl
67	3	SO_2Me	3-OH-Phenyl	845	3	SO_2Me	2-OH-Phenyl
68	4	SO_2Me	3-OH-Phenyl	846	4	SO_2Me	2-OH-Phenyl
69	1	SO_2NH_2	3-OH-Phenyl	847	1	SO_2NH_2	2-OH-Phenyl
70	2	SO_2NH_2	3-OH-Phenyl	848	2	SO_2NH_2	2-OH-Phenyl
71	3	SO_2NH_2	3-OH-Phenyl	849	3	SO_2NH_2	2-OH-Phenyl
72	4	SO_2NH_2	3-OH-Phenyl	850	4	SO_2NH_2	2-OH-Phenyl
73	1	H	4-NO_2-Phenyl	851	1	H	4-OMe-Phenyl
74	2	H	4-NO_2-Phenyl	852	2	H	4-OMe-Phenyl
75	3	H	4-NO_2-Phenyl	853	3	H	4-OMe-Phenyl
76	4	H	4-NO_2-Phenyl	854	4	H	4-OMe-Phenyl
77	1	Me	4-NO_2-Phenyl	855	1	Me	4-OMe-Phenyl
78	2	Me	4-NO_2-Phenyl	856	2	Me	4-OMe-Phenyl
79	3	Me	4-NO_2-Phenyl	857	3	Me	4-OMe-Phenyl
80	4	Me	4-NO_2-Phenyl	858	4	Me	4-OMe-Phenyl
81	1	CH_2Ph	4-NO_2-Phenyl	859	1	CH_2Ph	4-OMe-Phenyl
82	2	CH_2Ph	4-NO_2-Phenyl	860	2	CH_2Ph	4-OMe-Phenyl
83	3	CH_2Ph	4-NO_2-Phenyl	861	3	CH_2Ph	4-OMe-Phenyl
84	4	CH_2Ph	4-NO_2-Phenyl	862	4	CH_2Ph	4-OMe-Phenyl
85	1	COMe	4-NO_2-Phenyl	863	1	COMe	4-OMe-Phenyl
86	2	COMe	4-NO_2-Phenyl	864	2	COMe	4-OMe-Phenyl
87	3	COMe	4-NO_2-Phenyl	865	3	COMe	4-OMe-Phenyl
88	4	COMe	4-NO_2-Phenyl	866	4	COMe	4-OMe-Phenyl
89	1	CO_2Me	4-NO_2-Phenyl	867	1	CO_2Me	4-OMe-Phenyl
90	2	CO_2Me	4-NO_2-Phenyl	868	2	CO_2Me	4-OMe-Phenyl
91	3	CO_2Me	4-NO_2-Phenyl	869	3	CO_2Me	4-OMe-Phenyl

92	4	CO_2Me	4-NO_2-Phenyl	870	4	CO_2Me	4-OMe-Phenyl
93	1	CO_2tBu	4-NO_2-Phenyl	871	1	CO_2tBu	4-OMe-Phenyl
94	2	CO_2tBu	4-NO_2-Phenyl	872	2	CO_2tBu	4-OMe-Phenyl
95	3	CO_2tBu	4-NO_2-Phenyl	873	3	CO_2tBu	4-OMe-Phenyl
96	4	CO_2tBu	4-NO_2-Phenyl	874	4	CO_2tBu	4-OMe-Phenyl
97	1	CONHMe	4-NO_2-Phenyl	875	1	CONHMe	4-OMe-Phenyl
98	2	CONHMe	4-NO_2-Phenyl	876	2	CONHMe	4-OMe-Phenyl
99	3	CONHMe	4-NO_2-Phenyl	877	3	CONHMe	4-OMe-Phenyl
100	4	CONHMe	4-NO_2-Phenyl	878	4	CONHMe	4-OMe-Phenyl
101	1	SO_2Me	4-NO_2-Phenyl	879	1	SO_2Me	4-OMe-Phenyl
102	2	SO_2Me	4-NO_2-Phenyl	880	2	SO_2Me	4-OMe-Phenyl
103	3	SO_2Me	4-NO_2-Phenyl	881	3	SO_2Me	4-OMe-Phenyl
104	4	SO_2Me	4-NO_2-Phenyl	882	4	SO_2Me	4-OMe-Phenyl
105	1	SO_2NH_2	4-NO_2-Phenyl	883	1	SO_2NH_2	4-OMe-Phenyl
106	2	SO_2NH_2	4-NO_2-Phenyl	884	2	SO_2NH_2	4-OMe-Phenyl
107	3	SO_2NH_2	4-NO_2-Phenyl	885	3	SO_2NH_2	4-OMe-Phenyl
108	4	SO_2NH_2	4-NO_2-Phenyl	886	4	SO_2NH_2	4-OMe-Phenyl
109	1	H	3-OMe-Phenyl	887	1	H	2-OMe-Phenyl
110	2	H	3-OMe-Phenyl	888	2	H	2-OMe-Phenyl
111	3	H	3-OMe-Phenyl	889	3	H	2-OMe-Phenyl
112	4	H	3-OMe-Phenyl	890	4	H	2-OMe-Phenyl
113	1	Me	3-OMe-Phenyl	891	1	Me	2-OMe-Phenyl
114	2	Me	3-OMe-Phenyl	892	2	Me	2-OMe-Phenyl
115	3	Me	3-OMe-Phenyl	893	3	Me	2-OMe-Phenyl
116	4	Me	3-OMe-Phenyl	894	4	Me	2-OMe-Phenyl
117	1	CH_2Ph	3-OMe-Phenyl	895	1	CH_2Ph	2-OMe-Phenyl
118	2	CH_2Ph	3-OMe-Phenyl	896	2	CH_2Ph	2-OMe-Phenyl
119	3	CH_2Ph	3-OMe-Phenyl	897	3	CH_2Ph	2-OMe-Phenyl
120	4	CH_2Ph	3-OMe-Phenyl	898	4	CH_2Ph	2-OMe-Phenyl
121	1	COMe	3-OMe-Phenyl	899	1	COMe	2-OMe-Phenyl
122	2	COMe	3-OMe-Phenyl	900	2	COMe	2-OMe-Phenyl

123	3	COMe	3-OMe-Phenyl	901	3	COMe	2-OMe-Phenyl
124	4	COMe	3-OMe-Phenyl	902	4	COMe	2-OMe-Phenyl
125	1	CO_2Me	3-OMe-Phenyl	903	1	CO_2Me	2-OMe-Phenyl
126	2	CO_2Me	3-OMe-Phenyl	904	2	CO_2Me	2-OMe-Phenyl
127	3	CO_2Me	3-OMe-Phenyl	905	3	CO_2Me	2-OMe-Phenyl
128	4	CO_2Me	3-OMe-Phenyl	906	4	CO_2Me	2-OMe-Phenyl
129	1	CO_2tBu	3-OMe-Phenyl	907	1	CO_2tBu	2-OMe-Phenyl
130	2	CO_2tBu	3-OMe-Phenyl	908	2	CO_2tBu	2-OMe-Phenyl
131	3	CO_2tBu	3-OMe-Phenyl	909	3	CO_2tBu	2-OMe-Phenyl
132	4	CO_2tBu	3-OMe-Phenyl	910	4	CO_2tBu	2-OMe-Phenyl
133	1	CONHMe	3-OMe-Phenyl	911	1	CONHMe	2-OMe-Phenyl
134	2	CONHMe	3-OMe-Phenyl	912	2	CONHMe	2-OMe-Phenyl
135	3	CONHMe	3-OMe-Phenyl	913	3	CONHMe	2-OMe-Phenyl
136	4	CONHMe	3-OMe-Phenyl	914	4	CONHMe	2-OMe-Phenyl
137	1	SO_2Me	3-OMe-Phenyl	915	1	SO_2Me	2-OMe-Phenyl
138	2	SO_2Me	3-OMe-Phenyl	916	2	SO_2Me	2-OMe-Phenyl
139	3	SO_2Me	3-OMe-Phenyl	917	3	SO_2Me	2-OMe-Phenyl
140	4	SO_2Me	3-OMe-Phenyl	918	4	SO_2Me	2-OMe-Phenyl
141	1	SO_2NH_2	3-OMe-Phenyl	919	1	SO_2NH_2	2-OMe-Phenyl
142	2	SO_2NH_2	3-OMe-Phenyl	920	2	SO_2NH_2	2-OMe-Phenyl
143	3	SO_2NH_2	3-OMe-Phenyl	921	3	SO_2NH_2	2-OMe-Phenyl
144	4	SO_2NH_2	3-OMe-Phenyl	922	4	SO_2NH_2	2-OMe-Phenyl
145	1	H	4-CN-Phenyl	923	1	H	3-CN-Phenyl
146	2	H	4-CN-Phenyl	924	2	H	3-CN-Phenyl
147	3	H	4-CN-Phenyl	925	3	H	3-CN-Phenyl
148	4	H	4-CN-Phenyl	926	4	H	3-CN-Phenyl
149	1	Me	4-CN-Phenyl	927	1	Me	3-CN-Phenyl
150	2	Me	4-CN-Phenyl	928	2	Me	3-CN-Phenyl
151	3	Me	4-CN-Phenyl	929	3	Me	3-CN-Phenyl
152	4	Me	4-CN-Phenyl	930	4	Me	3-CN-Phenyl
153	1	CH_2Ph	4-CN-Phenyl	931	1	CH_2Ph	3-CN-Phenyl

154	2	CH_2Ph	4-CN-Phenyl	932	2	CH_2Ph	3-CN-Phenyl
155	3	CH_2Ph	4-CN-Phenyl	933	3	CH_2Ph	3-CN-Phenyl
156	4	CH_2Ph	4-CN-Phenyl	934	4	CH_2Ph	3-CN-Phenyl
157	1	COMe	4-CN-Phenyl	935	1	COMe	3-CN-Phenyl
158	2	COMe	4-CN-Phenyl	936	2	COMe	3-CN-Phenyl
159	3	COMe	4-CN-Phenyl	937	3	COMe	3-CN-Phenyl
160	4	COMe	4-CN-Phenyl	938	4	COMe	3-CN-Phenyl
161	1	CO_2Me	4-CN-Phenyl	939	1	CO_2Me	3-CN-Phenyl
162	2	CO_2Me	4-CN-Phenyl	940	2	CO_2Me	3-CN-Phenyl
163	3	CO_2Me	4-CN-Phenyl	941	3	CO_2Me	3-CN-Phenyl
164	4	CO_2Me	4-CN-Phenyl	942	4	CO_2Me	3-CN-Phenyl
165	1	CO_2tBu	4-CN-Phenyl	943	1	CO_2tBu	3-CN-Phenyl
166	2	CO_2tBu	4-CN-Phenyl	944	2	CO_2tBu	3-CN-Phenyl
167	3	CO_2tBu	4-CN-Phenyl	945	3	CO_2tBu	3-CN-Phenyl
168	4	CO_2tBu	4-CN-Phenyl	946	4	CO_2tBu	3-CN-Phenyl
169	1	CONHMe	4-CN-Phenyl	947	1	CONHMe	3-CN-Phenyl
170	2	CONHMe	4-CN-Phenyl	948	2	CONHMe	3-CN-Phenyl
171	3	CONHMe	4-CN-Phenyl	949	3	CONHMe	3-CN-Phenyl
172	4	CONHMe	4-CN-Phenyl	950	4	CONHMe	3-CN-Phenyl
173	1	SO_2Me	4-CN-Phenyl	951	1	SO_2Me	3-CN-Phenyl
174	2	SO_2Me	4-CN-Phenyl	952	2	SO_2Me	3-CN-Phenyl
175	3	SO_2Me	4-CN-Phenyl	953	3	SO_2Me	3-CN-Phenyl
176	4	SO_2Me	4-CN-Phenyl	954	4	SO_2Me	3-CN-Phenyl
177	1	SO_2NH_2	4-CN-Phenyl	955	1	SO_2NH_2	3-CN-Phenyl
178	2	SO_2NH_2	4-CN-Phenyl	956	2	SO_2NH_2	3-CN-Phenyl
179	3	SO_2NH_2	4-CN-Phenyl	957	3	SO_2NH_2	3-CN-Phenyl
180	4	SO_2NH_2	4-CN-Phenyl	958	4	SO_2NH_2	3-CN-Phenyl
181	1	H	2-CN-Phenyl	959	1	H	2-Me-Phenyl
182	2	H	2-CN-Phenyl	960	2	H	2-Me-Phenyl
183	3	H	2-CN-Phenyl	961	3	H	2-Me-Phenyl
184	4	H	2-CN-Phenyl	962	4	H	2-Me-Phenyl

185	1	Me	2-CN-Phenyl	963	1	Me	2-Me-Phenyl
186	2	Me	2-CN-Phenyl	964	2	Me	2-Me-Phenyl
187	3	Me	2-CN-Phenyl	965	3	Me	2-Me-Phenyl
188	4	Me	2-CN-Phenyl	966	4	Me	2-Me-Phenyl
189	1	CH_2Ph	2-CN-Phenyl	967	1	CH_2Ph	2-Me-Phenyl
190	2	CH_2Ph	2-CN-Phenyl	968	2	CH_2Ph	2-Me-Phenyl
191	3	CH_2Ph	2-CN-Phenyl	969	3	CH_2Ph	2-Me-Phenyl
192	4	CH_2Ph	2-CN-Phenyl	970	4	CH_2Ph	2-Me-Phenyl
193	1	COMe	2-CN-Phenyl	971	1	COMe	2-Me-Phenyl
194	2	COMe	2-CN-Phenyl	972	2	COMe	2-Me-Phenyl
195	3	COMe	2-CN-Phenyl	973	3	COMe	2-Me-Phenyl
196	4	COMe	2-CN-Phenyl	974	4	COMe	2-Me-Phenyl
197	1	CO_2Me	2-CN-Phenyl	975	1	CO_2Me	2-Me-Phenyl
198	2	CO_2Me	2-CN-Phenyl	976	2	CO_2Me	2-Me-Phenyl
199	3	CO_2Me	2-CN-Phenyl	977	3	CO_2Me	2-Me-Phenyl
200	4	CO_2Me	2-CN-Phenyl	978	4	CO_2Me	2-CN-Phenyl
201	1	CO_2tBu	2-CN-Phenyl	979	1	CO_2tBu	2-Me-Phenyl
202	2	CO_2tBu	2-CN-Phenyl	980	2	CO_2tBu	2-Me-Phenyl
203	3	CO_2tBu	2-CN-Phenyl	981	3	CO_2tBu	2-Me-Phenyl
204	4	CO_2tBu	2-CN-Phenyl	982	4	CO_2tBu	2-Me-Phenyl
205	1	CONHMe	2-CN-Phenyl	983	1	CONHMe	2-Me-Phenyl
206	2	CONHMe	2-CN-Phenyl	984	2	CONHMe	2-Me-Phenyl
207	3	CONHMe	2-CN-Phenyl	985	3	CONHMe	2-Me-Phenyl
208	4	CONHMe	2-CN-Phenyl	986	4	CONHMe	2-Me-Phenyl
209	1	SO_2Me	2-CN-Phenyl	987	1	SO_2Me	2-Me-Phenyl
210	2	SO_2Me	2-CN-Phenyl	988	2	SO_2Me	2-Me-Phenyl
211	3	SO_2Me	2-CN-Phenyl	989	3	SO_2Me	2-Me-Phenyl
212	4	SO_2Me	2-CN-Phenyl	990	4	SO_2Me	2-Me-Phenyl
213	1	SO_2NH_2	2-CN-Phenyl	991	1	SO_2NH_2	2-Me-Phenyl
214	2	SO_2NH_2	2-CN-Phenyl	992	2	SO_2NH_2	2-Me-Phenyl
215	3	SO_2NH_2	2-CN-Phenyl	993	3	SO_2NH_2	2-Me-Phenyl

216	4	SO_2NH_2	2-CN-Phenyl	994	4	SO_2NH_2	2-Me-Phenyl
217	1	H	3-Me-Phenyl	995	1	H	4-Me-Phenyl
218	2	H	3-Me-Phenyl	996	2	H	4-Me-Phenyl
219	3	H	3-Me-Phenyl	997	3	H	4-Me-Phenyl
220	4	H	3-Me-Phenyl	998	4	H	4-Me-Phenyl
221	1	Me	3-Me-Phenyl	999	1	Me	4-Me-Phenyl
222	2	Me	3-Me-Phenyl	1000	2	Me	4-Me-Phenyl
223	3	Me	3-Me-Phenyl	1001	3	Me	4-Me-Phenyl
224	4	Me	3-Me-Phenyl	1002	4	Me	4-Me-Phenyl
225	1	CH_2Ph	3-Me-Phenyl	1003	1	CH_2Ph	4-Me-Phenyl
226	2	CH_2Ph	3-Me-Phenyl	1004	2	CH_2Ph	4-Me-Phenyl
227	3	CH_2Ph	3-Me-Phenyl	1005	3	CH_2Ph	4-Me-Phenyl
228	4	CH_2Ph	3-Me-Phenyl	1006	4	CH_2Ph	4-Me-Phenyl
229	1	COMe	3-Me-Phenyl	1007	1	COMe	4-Me-Phenyl
230	2	COMe	3-Me-Phenyl	1008	2	COMe	4-Me-Phenyl
231	3	COMe	3-Me-Phenyl	1009	3	COMe	4-Me-Phenyl
232	4	COMe	3-Me-Phenyl	1010	4	COMe	4-Me-Phenyl
233	1	CO_2Me	3-Me-Phenyl	1011	1	CO_2Me	4-Me-Phenyl
234	2	CO_2Me	3-Me-Phenyl	1012	2	CO_2Me	4-Me-Phenyl
235	3	CO_2Me	3-Me-Phenyl	1013	3	CO_2Me	4-Me-Phenyl
236	4	CO_2Me	3-Me-Phenyl	1014	4	CO_2Me	4-Me-Phenyl
237	1	CO_2tBu	3-Me-Phenyl	1015	1	CO_2tBu	4-Me-Phenyl
238	2	CO_2tBu	3-Me-Phenyl	1016	2	CO_2tBu	4-Me-Phenyl
239	3	CO_2tBu	3-Me-Phenyl	1017	3	CO_2tBu	4-Me-Phenyl
240	4	CO_2tBu	3-Me-Phenyl	1018	4	CO_2tBu	4-Me-Phenyl
241	1	CONHMe	3-Me-Phenyl	1019	1	CONHMe	4-Me-Phenyl
242	2	CONHMe	3-Me-Phenyl	1020	2	CONHMe	4-Me-Phenyl
243	3	CONHMe	3-Me-Phenyl	1021	3	CONHMe	4-Me-Phenyl
244	4	CONHMe	3-Me-Phenyl	1022	4	CONHMe	4-Me-Phenyl
245	1	SO_2Me	3-Me-Phenyl	1023	1	SO_2Me	4-Me-Phenyl
246	2	SO_2Me	3-Me-Phenyl	1024	2	SO_2Me	4-Me-Phenyl

247	3	SO_2Me	3-Me-Phenyl	1025	3	SO_2Me	4-Me-Phenyl
248	4	SO_2Me	3-Me-Phenyl	1026	4	SO_2Me	4-Me-Phenyl
249	1	SO_2NH_2	3-Me-Phenyl	1027	1	SO_2NH_2	4-Me-Phenyl
250	2	SO_2NH_2	3-Me-Phenyl	1028	2	SO_2NH_2	4-Me-Phenyl
251	3	SO_2NH_2	3-Me-Phenyl	1029	3	SO_2NH_2	4-Me-Phenyl
252	4	SO_2NH_2	3-Me-Phenyl	1030	4	SO_2NH_2	4-Me-Phenyl
253	1	H	2-F-Phenyl	1031	1	H	3-F-Phenyl
254	2	H	2-F-Phenyl	1032	2	H	3-F-Phenyl
255	3	H	2-F-Phenyl	1033	3	H	3-F-Phenyl
256	4	H	2-F-Phenyl	1034	4	H	3-F-Phenyl
257	1	Me	2-F-Phenyl	1035	1	Me	3-F-Phenyl
258	2	Me	2-F-Phenyl	1036	2	Me	3-F-Phenyl
259	3	Me	2-F-Phenyl	1037	3	Me	3-F-Phenyl
260	4	Me	2-F-Phenyl	1038	4	Me	3-F-Phenyl
261	1	CH_2Ph	2-F-Phenyl	1039	1	CH_2Ph	3-F-Phenyl
262	2	CH_2Ph	2-F-Phenyl	1040	2	CH_2Ph	3-F-Phenyl
263	3	CH_2Ph	2-F-Phenyl	1041	3	CH_2Ph	3-F-Phenyl
264	4	CH_2Ph	2-F-Phenyl	1042	4	CH_2Ph	3-F-Phenyl
265	1	COMe	2-F-Phenyl	1043	1	COMe	3-F-Phenyl
266	2	COMe	2-F-Phenyl	1044	2	COMe	3-F-Phenyl
267	3	COMe	2-F-Phenyl	1045	3	COMe	3-F-Phenyl
268	4	COMe	2-F-Phenyl	1046	4	COMe	3-F-Phenyl
269	1	CO_2Me	2-F-Phenyl	1047	1	CO_2Me	3-F-Phenyl
270	2	CO_2Me	2-F-Phenyl	1048	2	CO_2Me	3-F-Phenyl
271	3	CO_2Me	2-F-Phenyl	1049	3	CO_2Me	3-F-Phenyl
272	4	CO_2Me	2-F-Phenyl	1050	4	CO_2Me	3-F-Phenyl
273	1	CO_2tBu	2-F-Phenyl	1051	1	CO_2tBu	3-F-Phenyl
274	2	CO_2tBu	2-F-Phenyl	1052	2	CO_2tBu	3-F-Phenyl
275	3	CO_2tBu	2-F-Phenyl	1053	3	CO_2tBu	3-F-Phenyl
276	4	CO_2tBu	2-F-Phenyl	1054	4	CO_2tBu	3-F-Phenyl
277	1	CONHMe	2-F-Phenyl	1055	1	CONHMe	3-F-Phenyl

278	2	CONHMe	2-F-Phenyl	1056	2	CONHMe	3-F-Phenyl
279	3	CONHMe	2-F-Phenyl	1057	3	CONHMe	3-F-Phenyl
280	4	CONHMe	2-F-Phenyl	1058	4	CONHMe	3-F-Phenyl
281	1	SO_2Me	2-F-Phenyl	1059	1	SO_2Me	3-F-Phenyl
282	2	SO_2Me	2-F-Phenyl	1060	2	SO_2Me	3-F-Phenyl
283	3	SO_2Me	2-F-Phenyl	1061	3	SO_2Me	3-F-Phenyl
284	4	SO_2Me	2-F-Phenyl	1062	4	SO_2Me	3-F-Phenyl
285	1	SO_2NH_2	2-F-Phenyl	1063	1	SO_2NH_2	3-F-Phenyl
286	2	SO_2NH_2	2-F-Phenyl	1064	2	SO_2NH_2	3-F-Phenyl
287	3	SO_2NH_2	2-F-Phenyl	1065	3	SO_2NH_2	3-F-Phenyl
288	4	SO_2NH_2	2-F-Phenyl	1066	4	SO_2NH_2	3-F-Phenyl
289	1	H	4-F-Phenyl	1067	1	H	2-Cl-Phenyl
290	2	H	4-F-Phenyl	1068	2	H	2-Cl-Phenyl
291	3	H	4-F-Phenyl	1069	3	H	2-Cl-Phenyl
292	4	H	4-F-Phenyl	1070	4	H	2-Cl-Phenyl
293	1	Me	4-F-Phenyl	1071	1	Me	2-Cl-Phenyl
294	2	Me	4-F-Phenyl	1072	2	Me	2-Cl-Phenyl
295	3	Me	4-F-Phenyl	1073	3	Me	2-Cl-Phenyl
296	4	Me	4-F-Phenyl	1074	4	Me	2-Cl-Phenyl
297	1	CH_2Ph	4-F-Phenyl	1075	1	CH_2Ph	2-Cl-Phenyl
298	2	CH_2Ph	4-F-Phenyl	1076	2	CH_2Ph	2-Cl-Phenyl
299	3	CH_2Ph	4-F-Phenyl	1077	3	CH_2Ph	2-Cl-Phenyl
300	4	CH_2Ph	4-F-Phenyl	1078	4	CH_2Ph	2-Cl-Phenyl
301	1	COMe	4-F-Phenyl	1079	1	COMe	2-Cl-Phenyl
302	2	COMe	4-F-Phenyl	1080	2	COMe	2-Cl-Phenyl
303	3	COMe	4-F-Phenyl	1081	3	COMe	2-Cl-Phenyl
304	4	COMe	4-F-Phenyl	1082	4	COMe	2-Cl-Phenyl
305	1	CO_2Me	4-F-Phenyl	1083	1	CO_2Me	2-Cl-Phenyl
306	2	CO_2Me	4-F-Phenyl	1084	2	CO_2Me	2-Cl-Phenyl
307	3	CO_2Me	4-F-Phenyl	1085	3	CO_2Me	2-Cl-Phenyl
308	4	CO_2Me	4-F-Phenyl	1086	4	CO_2Me	2-Cl-Phenyl

309	1	CO_2tBu	4-F-Phenyl	1087	1	CO_2tBu	2-Cl-Phenyl
310	2	CO_2tBu	4-F-Phenyl	1088	2	CO_2tBu	2-Cl-Phenyl
311	3	CO_2tBu	4-F-Phenyl	1089	3	CO_2tBu	2-Cl-Phenyl
312	4	CO_2tBu	4-F-Phenyl	1090	4	CO_2tBu	2-Cl-Phenyl
313	1	CONHMe	4-F-Phenyl	1091	1	CONHMe	2-Cl-Phenyl
314	2	CONHMe	4-F-Phenyl	1092	2	CONHMe	2-Cl-Phenyl
315	3	CONHMe	4-F-Phenyl	1093	3	CONHMe	2-Cl-Phenyl
316	4	CONHMe	4-F-Phenyl	1094	4	CONHMe	2-Cl-Phenyl
317	1	SO_2Me	4-F-Phenyl	1095	1	SO_2Me	2-Cl-Phenyl
318	2	SO_2Me	4-F-Phenyl	1096	2	SO_2Me	2-Cl-Phenyl
319	3	SO_2Me	4-F-Phenyl	1097	3	SO_2Me	2-Cl-Phenyl
320	4	SO_2Me	4-F-Phenyl	1098	4	SO_2Me	2-Cl-Phenyl
321	1	SO_2NH_2	4-F-Phenyl	1099	1	SO_2NH_2	2-Cl-Phenyl
322	2	SO_2NH_2	4-F-Phenyl	1100	2	SO_2NH_2	2-Cl-Phenyl
323	3	SO_2NH_2	4-F-Phenyl	1101	3	SO_2NH_2	2-Cl-Phenyl
324	4	SO_2NH_2	4-F-Phenyl	1102	4	SO_2NH_2	2-Cl-Phenyl
325	1	H	3-Cl-Phenyl	1103	1	H	4-Cl-Phenyl
326	2	H	3-Cl-Phenyl	1104	2	H	4-Cl-Phenyl
327	3	H	3-Cl-Phenyl	1105	3	H	4-Cl-Phenyl
328	4	H	3-Cl-Phenyl	1106	4	H	4-Cl-Phenyl
329	1	Me	3-Cl-Phenyl	1107	1	Me	4-Cl-Phenyl
330	2	Me	3-Cl-Phenyl	1108	2	Me	4-Cl-Phenyl
331	3	Me	3-Cl-Phenyl	1109	3	Me	4-Cl-Phenyl
332	4	Me	3-Cl-Phenyl	1110	4	Me	4-Cl-Phenyl
333	1	CH_2Ph	3-Cl-Phenyl	1111	1	CH_2Ph	4-Cl-Phenyl
334	2	CH_2Ph	3-Cl-Phenyl	1112	2	CH_2Ph	4-Cl-Phenyl
335	3	CH_2Ph	3-Cl-Phenyl	1113	3	CH_2Ph	4-Cl-Phenyl
336	4	CH_2Ph	3-Cl-Phenyl	1114	4	CH_2Ph	4-Cl-Phenyl
337	1	COMe	3-Cl-Phenyl	1115	1	COMe	4-Cl-Phenyl
338	2	COMe	3-Cl-Phenyl	1116	2	COMe	4-Cl-Phenyl
339	3	COMe	3-Cl-Phenyl	1117	3	COMe	4-Cl-Phenyl

340	4	COMe	3-Cl-Phenyl	1118	4	COMe	4-Cl-Phenyl
341	1	CO_2Me	3-Cl-Phenyl	1119	1	CO_2Me	4-Cl-Phenyl
342	2	CO_2Me	3-Cl-Phenyl	1120	2	CO_2Me	4-Cl-Phenyl
343	3	CO_2Me	3-Cl-Phenyl	1121	3	CO_2Me	4-Cl-Phenyl
344	4	CO_2Me	3-Cl-Phenyl	1122	4	CO_2Me	4-Cl-Phenyl
345	1	CO_2tBu	3-Cl-Phenyl	1123	1	CO_2tBu	4-Cl-Phenyl
346	2	CO_2tBu	3-Cl-Phenyl	1124	2	CO_2tBu	4-Cl-Phenyl
347	3	CO_2tBu	3-Cl-Phenyl	1125	3	CO_2tBu	4-Cl-Phenyl
348	4	CO_2tBu	3-Cl-Phenyl	1126	4	CO_2tBu	4-Cl-Phenyl
349	1	CONHMe	3-Cl-Phenyl	1127	1	CONHMe	4-Cl-Phenyl
350	2	CONHMe	3-Cl-Phenyl	1128	2	CONHMe	4-Cl-Phenyl
351	3	CONHMe	3-Cl-Phenyl	1129	3	CONHMe	4-Cl-Phenyl
352	4	CONHMe	3-Cl-Phenyl	1130	4	CONHMe	4-Cl-Phenyl
353	1	SO_2Me	3-Cl-Phenyl	1131	1	SO_2Me	4-Cl-Phenyl
354	2	SO_2Me	3-Cl-Phenyl	1132	2	SO_2Me	4-Cl-Phenyl
355	3	SO_2Me	3-Cl-Phenyl	1133	3	SO_2Me	4-Cl-Phenyl
356	4	SO_2Me	3-Cl-Phenyl	1134	4	SO_2Me	4-Cl-Phenyl
357	1	SO_2NH_2	3-Cl-Phenyl	1135	1	SO_2NH_2	4-Cl-Phenyl
358	2	SO_2NH_2	3-Cl-Phenyl	1136	2	SO_2NH_2	4-Cl-Phenyl
359	3	SO_2NH_2	3-Cl-Phenyl	1137	3	SO_2NH_2	4-Cl-Phenyl
360	4	SO_2NH_2	3-Cl-Phenyl	1138	4	SO_2NH_2	4-Cl-Phenyl
361	1	H	2-Br-Phenyl	1139	1	H	3-Br-Phenyl
362	2	H	2-Br-Phenyl	1140	2	H	3-Br-Phenyl
363	3	H	2-Br-Phenyl	1141	3	H	3-Br-Phenyl
364	4	H	2-Br-Phenyl	1142	4	H	3-Br-Phenyl
365	1	Me	2-Br-Phenyl	1143	1	Me	3-Br-Phenyl
366	2	Me	2-Br-Phenyl	1144	2	Me	3-Br-Phenyl
367	3	Me	2-Br-Phenyl	1145	3	Me	3-Br-Phenyl
368	4	Me	2-Br-Phenyl	1146	4	Me	3-Br-Phenyl
369	1	CH_2Ph	2-Br-Phenyl	1147	1	CH_2Ph	3-Br-Phenyl
370	2	CH_2Ph	2-Br-Phenyl	1148	2	CH_2Ph	3-Br-Phenyl

371	3	CH_2Ph	2-Br-Phenyl	1149	3	CH_2Ph	3-Br-Phenyl
372	4	CH_2Ph	2-Br-Phenyl	1150	4	CH_2Ph	3-Br-Phenyl
373	1	COMe	2-Br-Phenyl	1151	1	COMe	3-Br-Phenyl
374	2	COMe	2-Br-Phenyl	1152	2	COMe	3-Br-Phenyl
375	3	COMe	2-Br-Phenyl	1153	3	COMe	3-Br-Phenyl
376	4	COMe	2-Br-Phenyl	1154	4	COMe	3-Br-Phenyl
377	1	CO_2Me	2-Br-Phenyl	1155	1	CO_2Me	3-Br-Phenyl
378	2	CO_2Me	2-Br-Phenyl	1156	2	CO_2Me	3-Br-Phenyl
379	3	CO_2Me	2-Br-Phenyl	1157	3	CO_2Me	3-Br-Phenyl
380	4	CO_2Me	2-Br-Phenyl	1158	4	CO_2Me	3-Br-Phenyl
381	1	CO_2tBu	2-Br-Phenyl	1159	1	CO_2tBu	3-Br-Phenyl
382	2	CO_2tBu	2-Br-Phenyl	1160	2	CO_2tBu	3-Br-Phenyl
383	3	CO_2tBu	2-Br-Phenyl	1161	3	CO_2tBu	3-Br-Phenyl
384	4	CO_2tBu	2-Br-Phenyl	1162	4	CO_2tBu	3-Br-Phenyl
385	1	CONHMe	2-Br-Phenyl	1163	1	CONHMe	3-Br-Phenyl
386	2	CONHMe	2-Br-Phenyl	1164	2	CONHMe	3-Br-Phenyl
387	3	CONHMe	2-Br-Phenyl	1165	3	CONHMe	3-Br-Phenyl
388	4	CONHMe	2-Br-Phenyl	1166	4	CONHMe	3-Br-Phenyl
389	1	SO_2Me	2-Br-Phenyl	1167	1	SO_2Me	3-Br-Phenyl
390	2	SO_2Me	2-Br-Phenyl	1168	2	SO_2Me	3-Br-Phenyl
391	3	SO_2Me	2-Br-Phenyl	1169	3	SO_2Me	3-Br-Phenyl
392	4	SO_2Me	2-Br-Phenyl	1170	4	SO_2Me	3-Br-Phenyl
393	1	SO_2NH_2	2-Br-Phenyl	1171	1	SO_2NH_2	3-Br-Phenyl
394	2	SO_2NH_2	2-Br-Phenyl	1172	2	SO_2NH_2	3-Br-Phenyl
395	3	SO_2NH_2	2-Br-Phenyl	1173	3	SO_2NH_2	3-Br-Phenyl
396	4	SO_2NH_2	2-Br-Phenyl	1174	4	SO_2NH_2	3-Br-Phenyl
397	1	H	4-Br-Phenyl	1175	1	H	2-CF_3-Phenyl
398	2	H	4-Br-Phenyl	1176	2	H	2-CF_3-Phenyl
399	3	H	4-Br-Phenyl	1177	3	H	2-CF_3-Phenyl
400	4	H	4-Br-Phenyl	1178	4	H	2-CF_3-Phenyl
401	1	Me	4-Br-Phenyl	1179	1	Me	2-CF_3-Phenyl

402	2	Me	4-Br-Phenyl	1180	2	Me	2-CF_3-Phenyl
403	3	Me	4-Br-Phenyl	1181	3	Me	2-CF_3-Phenyl
404	4	Me	4-Br-Phenyl	1182	4	Me	2-CF_3-Phenyl
405	1	CH_2Ph	4-Br-Phenyl	1183	1	CH_2Ph	2-CF_3-Phenyl
406	2	CH_2Ph	4-Br-Phenyl	1184	2	CH_2Ph	2-CF_3-Phenyl
407	3	CH_2Ph	4-Br-Phenyl	1185	3	CH_2Ph	2-CF_3-Phenyl
408	4	CH_2Ph	4-Br-Phenyl	1186	4	CH_2Ph	2-CF_3-Phenyl
409	1	COMe	4-Br-Phenyl	1187	1	COMe	2-CF_3-Phenyl
410	2	COMe	4-Br-Phenyl	1188	2	COMe	2-CF_3-Phenyl
411	3	COMe	4-Br-Phenyl	1189	3	COMe	2-CF_3-Phenyl
412	4	COMe	4-Br-Phenyl	1190	4	COMe	2-CF_3-Phenyl
413	1	CO_2Me	4-Br-Phenyl	1191	1	CO_2Me	2-CF_3-Phenyl
414	2	CO_2Me	4-Br-Phenyl	1192	2	CO_2Me	2-CF_3-Phenyl
415	3	CO_2Me	4-Br-Phenyl	1193	3	CO_2Me	2-CF_3-Phenyl
416	4	CO_2Me	4-Br-Phenyl	1194	4	CO_2Me	2-CF_3-Phenyl
417	1	CO_2tBu	4-Br-Phenyl	1195	1	CO_2tBu	2-CF_3-Phenyl
418	2	CO_2tBu	4-Br-Phenyl	1196	2	CO_2tBu	2-CF_3-Phenyl
419	3	CO_2tBu	4-Br-Phenyl	1197	3	CO_2tBu	2-CF_3-Phenyl
420	4	CO_2tBu	4-Br-Phenyl	1198	4	CO_2tBu	2-CF_3-Phenyl
421	1	CONHMe	4-Br-Phenyl	1199	1	CONHMe	2-CF_3-Phenyl
422	2	CONHMe	4-Br-Phenyl	1200	2	CONHMe	2-CF_3-Phenyl
423	3	CONHMe	4-Br-Phenyl	1201	3	CONHMe	2-CF_3-Phenyl
424	4	CONHMe	4-Br-Phenyl	1202	4	CONHMe	2-CF_3-Phenyl
425	1	SO_2Me	4-Br-Phenyl	1203	1	SO_2Me	2-CF_3-Phenyl
426	2	SO_2Me	4-Br-Phenyl	1204	2	SO_2Me	2-CF_3-Phenyl
427	3	SO_2Me	4-Br-Phenyl	1205	3	SO_2Me	2-CF_3-Phenyl
428	4	SO_2Me	4-Br-Phenyl	1206	4	SO_2Me	2-CF_3-Phenyl
429	1	SO_2NH_2	4-Br-Phenyl	1207	1	SO_2NH_2	2-CF_3-Phenyl
430	2	SO_2NH_2	4-Br-Phenyl	1208	2	SO_2NH_2	2-CF_3-Phenyl
431	3	SO_2NH_2	4-Br-Phenyl	1209	3	SO_2NH_2	2-CF_3-Phenyl
432	4	SO_2NH_2	4-Br-Phenyl	1210	4	SO_2NH_2	2-CF_3-Phenyl

433	1	H	3-CF_3-Phenyl	1211	1	H	4-CF_3-Phenyl
434	2	H	3-CF_3-Phenyl	1212	2	H	4-CF_3-Phenyl
435	3	H	3-CF_3-Phenyl	1213	3	H	4-CF_3-Phenyl
436	4	H	3-CF_3-Phenyl	1214	4	H	4-CF_3-Phenyl
437	1	Me	3-CF_3-Phenyl	1215	1	Me	4-CF_3-Phenyl
438	2	Me	3-CF_3-Phenyl	1216	2	Me	4-CF_3-Phenyl
439	3	Me	3-CF_3-Phenyl	1217	3	Me	4-CF_3-Phenyl
440	4	Me	3-CF_3-Phenyl	1218	4	Me	4-CF_3-Phenyl
441	1	CH_2Ph	3-CF_3-Phenyl	1219	1	CH_2Ph	4-CF_3-Phenyl
442	2	CH_2Ph	3-CF_3-Phenyl	1220	2	CH_2Ph	4-CF_3-Phenyl
443	3	CH_2Ph	3-CF_3-Phenyl	1221	3	CH_2Ph	4-CF_3-Phenyl
444	4	CH_2Ph	3-CF_3-Phenyl	1222	4	CH_2Ph	4-CF_3-Phenyl
445	1	COMe	3-CF_3-Phenyl	1223	1	COMe	4-CF_3-Phenyl
446	2	COMe	3-CF_3-Phenyl	1224	2	COMe	4-CF_3-Phenyl
447	3	COMe	3-CF_3-Phenyl	1225	3	COMe	4-CF_3-Phenyl
448	4	COMe	3-CF_3-Phenyl	1226	4	COMe	4-CF_3-Phenyl
449	1	CO_2Me	3-CF_3-Phenyl	1227	1	CO_2Me	4-CF_3-Phenyl
450	2	CO_2Me	3-CF_3-Phenyl	1228	2	CO_2Me	4-CF_3-Phenyl
451	3	CO_2Me	3-CF_3-Phenyl	1229	3	CO_2Me	4-CF_3-Phenyl
452	4	CO_2Me	3-CF_3-Phenyl	1230	4	CO_2Me	4-CF_3-Phenyl
453	1	CO_2tBu	3-CF_3-Phenyl	1231	1	CO_2tBu	4-CF_3-Phenyl
454	2	CO_2tBu	3-CF_3-Phenyl	1232	2	CO_2tBu	4-CF_3-Phenyl
455	3	CO_2tBu	3-CF_3-Phenyl	1233	3	CO_2tBu	4-CF_3-Phenyl
456	4	CO_2tBu	3-CF_3-Phenyl	1234	4	CO_2tBu	4-CF_3-Phenyl
457	1	CONHMe	3-CF_3-Phenyl	1235	1	CONHMe	4-CF_3-Phenyl
458	2	CONHMe	3-CF_3-Phenyl	1236	2	CONHMe	4-CF_3-Phenyl
459	3	CONHMe	3-CF_3-Phenyl	1237	3	CONHMe	4-CF_3-Phenyl
460	4	CONHMe	3-CF_3-Phenyl	1238	4	CONHMe	4-CF_3-Phenyl
461	1	SO_2Me	3-CF_3-Phenyl	1239	1	SO_2Me	4-CF_3-Phenyl
462	2	SO_2Me	3-CF_3-Phenyl	1240	2	SO_2Me	4-CF_3-Phenyl
463	3	SO_2Me	3-CF_3-Phenyl	1241	3	SO_2Me	4-CF_3-Phenyl

464	4	SO_2Me	3-CF_3-Phenyl	1242	4	SO_2Me	4-CF_3-Phenyl
465	1	SO_2NH_2	3-CF_3-Phenyl	1243	1	SO_2NH_2	4-CF_3-Phenyl
466	2	SO_2NH_2	3-CF_3-Phenyl	1244	2	SO_2NH_2	4-CF_3-Phenyl
467	3	SO_2NH_2	3-CF_3-Phenyl	1245	3	SO_2NH_2	4-CF_3-Phenyl
468	4	SO_2NH_2	3-CF_3-Phenyl	1246	4	SO_2NH_2	4-CF_3-Phenyl
469	1	H	2-iPr-Phenyl	1247	1	H	3-iPr-Phenyl
470	2	H	2-iPr-Phenyl	1248	2	H	3-iPr-Phenyl
471	3	H	2-iPr-Phenyl	1249	3	H	3-iPr-Phenyl
472	4	H	2-iPr-Phenyl	1250	4	H	3-iPr-Phenyl
473	1	Me	2-iPr-Phenyl	1251	1	Me	3-iPr-Phenyl
474	2	Me	2-iPr-Phenyl	1252	2	Me	3-iPr-Phenyl
475	3	Me	2-iPr-Phenyl	1253	3	Me	3-iPr-Phenyl
476	4	Me	2-iPr-Phenyl	1254	4	Me	3-iPr-Phenyl
477	1	CH_2Ph	2-iPr-Phenyl	1255	1	CH_2Ph	3-iPr-Phenyl
478	2	CH_2Ph	2-iPr-Phenyl	1256	2	CH_2Ph	3-iPr-Phenyl
479	3	CH_2Ph	2-iPr-Phenyl	1257	3	CH_2Ph	3-iPr-Phenyl
480	4	CH_2Ph	2-iPr-Phenyl	1258	4	CH_2Ph	3-iPr-Phenyl
481	1	COMe	2-iPr-Phenyl	1259	1	COMe	3-iPr-Phenyl
482	2	COMe	2-iPr-Phenyl	1260	2	COMe	3-iPr-Phenyl
483	3	COMe	2-iPr-Phenyl	1261	3	COMe	3-iPr-Phenyl
484	4	COMe	2-iPr-Phenyl	1262	4	COMe	3-iPr-Phenyl
485	1	CO_2Me	2-iPr-Phenyl	1263	1	CO_2Me	3-iPr-Phenyl
486	2	CO_2Me	2-iPr-Phenyl	1264	2	CO_2Me	3-iPr-Phenyl
487	3	CO_2Me	2-iPr-Phenyl	1265	3	CO_2Me	3-iPr-Phenyl
488	4	CO_2Me	2-iPr-Phenyl	1266	4	CO_2Me	3-iPr-Phenyl
489	1	CO_2tBu	2-iPr-Phenyl	1267	1	CO_2tBu	3-iPr-Phenyl
490	2	CO_2tBu	2-iPr-Phenyl	1268	2	CO_2tBu	3-iPr-Phenyl
491	3	CO_2tBu	2-iPr-Phenyl	1269	3	CO_2tBu	3-iPr-Phenyl
492	4	CO_2tBu	2-iPr-Phenyl	1270	4	CO_2tBu	3-iPr-Phenyl
493	1	CONHMe	2-iPr-Phenyl	1271	1	CONHMe	3-iPr-Phenyl
494	2	CONHMe	2-iPr-Phenyl	1272	2	CONHMe	3-iPr-Phenyl

495	3	CONHMe	2-iPr-Phenyl	1273	3	CONHMe	3-iPr-Phenyl
496	4	CONHMe	2-iPr-Phenyl	1274	4	CONHMe	3-iPr-Phenyl
497	1	SO_2Me	2-iPr-Phenyl	1275	1	SO_2Me	3-iPr-Phenyl
498	2	SO_2Me	2-iPr-Phenyl	1276	2	SO_2Me	3-iPr-Phenyl
499	3	SO_2Me	2-iPr-Phenyl	1277	3	SO_2Me	3-iPr-Phenyl
500	4	SO_2Me	2-iPr-Phenyl	1278	4	SO_2Me	3-iPr-Phenyl
501	1	SO_2NH_2	2-iPr-Phenyl	1279	1	SO_2NH_2	3-iPr-Phenyl
502	2	SO_2NH_2	2-iPr-Phenyl	1280	2	SO_2NH_2	3-iPr-Phenyl
503	3	SO_2NH_2	2-iPr-Phenyl	1281	3	SO_2NH_2	3-iPr-Phenyl
504	4	SO_2NH_2	2-iPr-Phenyl	1282	4	SO_2NH_2	3-iPr-Phenyl
505	1	H	4-iPr-Phenyl	1283	1	H	4-NH_2-Phenyl
506	2	H	4-iPr-Phenyl	1284	2	H	4-NH_2-Phenyl
507	3	H	4-iPr-Phenyl	1285	3	H	4-NH_2-Phenyl
508	4	H	4-iPr-Phenyl	1286	4	H	4-NH_2-Phenyl
509	1	Me	4-iPr-Phenyl	1287	1	Me	4-NH_2-Phenyl
510	2	Me	4-iPr-Phenyl	1288	2	Me	4-NH_2-Phenyl
511	3	Me	4-iPr-Phenyl	1289	3	Me	4-NH_2-Phenyl
512	4	Me	4-iPr-Phenyl	1290	4	Me	4-NH_2-Phenyl
513	1	CH_2Ph	4-iPr-Phenyl	1291	1	CH_2Ph	4-NH_2-Phenyl
514	2	CH_2Ph	4-iPr-Phenyl	1292	2	CH_2Ph	4-NH_2-Phenyl
515	3	CH_2Ph	4-iPr-Phenyl	1293	3	CH_2Ph	4-NH_2-Phenyl
516	4	CH_2Ph	4-iPr-Phenyl	1294	4	CH_2Ph	4-NH_2-Phenyl
517	1	COMe	4-iPr-Phenyl	1295	1	COMe	4-NH_2-Phenyl
518	2	COMe	4-iPr-Phenyl	1296	2	COMe	4-NH_2-Phenyl
519	3	COMe	4-iPr-Phenyl	1297	3	COMe	4-NH_2-Phenyl
520	4	COMe	4-iPr-Phenyl	1298	4	COMe	4-NH_2-Phenyl
521	1	CO_2Me	4-iPr-Phenyl	1299	1	CO_2Me	4-NH_2-Phenyl
522	2	CO_2Me	4-iPr-Phenyl	1300	2	CO_2Me	4-NH_2-Phenyl
523	3	CO_2Me	4-iPr-Phenyl	1301	3	CO_2Me	4-NH_2-Phenyl
524	4	CO_2Me	4-iPr-Phenyl	1302	4	CO_2Me	4-NH_2-Phenyl
525	1	CO_2tBu	4-iPr-Phenyl	1303	1	CO_2tBu	4-NH_2-Phenyl

526	2	CO_2tBu	4-iPr-Phenyl	1304	2	CO_2tBu	4-NH_2-Phenyl
527	3	CO_2tBu	4-iPr-Phenyl	1305	3	CO_2tBu	4-NH_2-Phenyl
528	4	CO_2tBu	4-iPr-Phenyl	1306	4	CO_2tBu	4-NH_2-Phenyl
529	1	CONHMe	4-iPr-Phenyl	1307	1	CONHMe	4-NH_2-Phenyl
530	2	CONHMe	4-iPr-Phenyl	1308	2	CONHMe	4-NH_2-Phenyl
531	3	CONHMe	4-iPr-Phenyl	1309	3	CONHMe	4-NH_2-Phenyl
532	4	CONHMe	4-iPr-Phenyl	1310	4	CONHMe	4-NH_2-Phenyl
533	1	SO_2Me	4-iPr-Phenyl	1311	1	SO_2Me	4-NH_2-Phenyl
534	2	SO_2Me	4-iPr-Phenyl	1312	2	SO_2Me	4-NH_2-Phenyl
535	3	SO_2Me	4-iPr-Phenyl	1313	3	SO_2Me	4-NH_2-Phenyl
536	4	SO_2Me	4-iPr-Phenyl	1314	4	SO_2Me	4-NH_2-Phenyl
537	1	SO_2NH_2	4-iPr-Phenyl	1315	1	SO_2NH_2	4-NH_2-Phenyl
538	2	SO_2NH_2	4-iPr-Phenyl	1316	2	SO_2NH_2	4-NH_2-Phenyl
539	3	SO_2NH_2	4-iPr-Phenyl	1317	3	SO_2NH_2	4-NH_2-Phenyl
540	4	SO_2NH_2	4-iPr-Phenyl	1318	4	SO_2NH_2	4-NH_2-Phenyl
541	1	H	3-NH_2-Phenyl	1319	1	H	2-NH_2-Phenyl
542	2	H	3-NH_2-Phenyl	1320	2	H	2-NH_2-Phenyl
543	3	H	3-NH_2-Phenyl	1321	3	H	2-NH_2-Phenyl
544	4	H	3-NH_2-Phenyl	1322	4	H	2-NH_2-Phenyl
545	1	Me	3-NH_2-Phenyl	1323	1	Me	2-NH_2-Phenyl
546	2	Me	3-NH_2-Phenyl	1324	2	Me	2-NH_2-Phenyl
547	3	Me	3-NH_2-Phenyl	1325	3	Me	2-NH_2-Phenyl
548	4	Me	3-NH_2-Phenyl	1326	4	Me	2-NH_2-Phenyl
549	1	CH_2Ph	3-NH_2-Phenyl	1327	1	CH_2Ph	2-NH_2-Phenyl
550	2	CH_2Ph	3-NH_2-Phenyl	1328	2	CH_2Ph	2-NH_2-Phenyl
551	3	CH_2Ph	3-NH_2-Phenyl	1329	3	CH_2Ph	2-NH_2-Phenyl
552	4	CH_2Ph	3-NH_2-Phenyl	1330	4	CH_2Ph	2-NH_2-Phenyl
553	1	COMe	3-NH_2-Phenyl	1331	1	COMe	2-NH_2-Phenyl
554	2	COMe	3-NH_2-Phenyl	1332	2	COMe	2-NH_2-Phenyl
555	3	COMe	3-NH_2-Phenyl	1333	3	COMe	2-NH_2-Phenyl
556	4	COMe	3-NH_2-Phenyl	1334	4	COMe	2-NH_2-Phenyl

557	1	CO_2Me	3-NH_2-Phenyl	1335	1	CO_2Me	2-NH_2-Phenyl
558	2	CO_2Me	3-NH_2-Phenyl	1336	2	CO_2Me	2-NH_2-Phenyl
559	3	CO_2Me	3-NH_2-Phenyl	1337	3	CO_2Me	2-NH_2-Phenyl
560	4	CO_2Me	3-NH_2-Phenyl	1338	4	CO_2Me	2-NH_2-Phenyl
561	1	CO_2tBu	3-NH_2-Phenyl	1339	1	CO_2tBu	2-NH_2-Phenyl
562	2	CO_2tBu	3-NH_2-Phenyl	1340	2	CO_2tBu	2-NH_2-Phenyl
563	3	CO_2tBu	3-NH_2-Phenyl	1341	3	CO_2tBu	2-NH_2-Phenyl
564	4	CO_2tBu	3-NH_2-Phenyl	1342	4	CO_2tBu	2-NH_2-Phenyl
565	1	CONHMe	3-NH_2-Phenyl	1343	1	CONHMe	2-NH_2-Phenyl
566	2	CONHMe	3-NH_2-Phenyl	1344	2	CONHMe	2-NH_2-Phenyl
567	3	CONHMe	3-NH_2-Phenyl	1345	3	CONHMe	2-NH_2-Phenyl
568	4	CONHMe	3-NH_2-Phenyl	1346	4	CONHMe	2-NH_2-Phenyl
569	1	SO_2Me	3-NH_2-Phenyl	1347	1	SO_2Me	2-NH_2-Phenyl
570	2	SO_2Me	3-NH_2-Phenyl	1348	2	SO_2Me	2-NH_2-Phenyl
571	3	SO_2Me	3-NH_2-Phenyl	1349	3	SO_2Me	2-NH_2-Phenyl
572	4	SO_2Me	3-NH_2-Phenyl	1350	4	SO_2Me	2-NH_2-Phenyl
573	1	SO_2NH_2	3-NH_2-Phenyl	1351	1	SO_2NH_2	2-NH_2-Phenyl
574	2	SO_2NH_2	3-NH_2-Phenyl	1352	2	SO_2NH_2	2-NH_2-Phenyl
575	3	SO_2NH_2	3-NH_2-Phenyl	1353	3	SO_2NH_2	2-NH_2-Phenyl
576	4	SO_2NH_2	3-NH_2-Phenyl	1354	4	SO_2NH_2	2-NH_2-Phenyl
577	1	H	2,4-di-Me-Phenyl	1355	1	H	2,6-di-Me-Phenyl
578	2	H	2,4-di-Me-Phenyl	1356	2	H	2,6-di-Me-Phenyl
579	3	H	2,4-di-Me-Phenyl	1357	3	H	2,6-di-Me-Phenyl
580	4	H	2,4-di-Me-Phenyl	1358	4	H	2,6-di-Me-Phenyl
581	1	Me	2,4-di-Me-Phenyl	1359	1	Me	2,6-di-Me-Phenyl
582	2	Me	2,4-di-Me-Phenyl	1360	2	Me	2,6-di-Me-Phenyl
583	3	Me	2,4-di-Me-Phenyl	1361	3	Me	2,6-di-Me-Phenyl
584	4	Me	2,4-di-Me-Phenyl	1362	4	Me	2,6-di-Me-Phenyl
585	1	CH_2Ph	2,4-di-Me-Phenyl	1363	1	CH_2Ph	2,6-di-Me-Phenyl
586	2	CH_2Ph	2,4-di-Me-Phenyl	1364	2	CH_2Ph	2,6-di-Me-Phenyl
587	3	CH_2Ph	2,4-di-Me-Phenyl	1365	3	CH_2Ph	2,6-di-Me-Phenyl

588	4	CH_2Ph	2,4-di-Me-Phenyl	1366	4	CH_2Ph	2,6-di-Me-Phenyl
589	1	COMe	2,4-di-Me-Phenyl	1367	1	COMe	2,6-di-Me-Phenyl
590	2	COMe	2,4-di-Me-Phenyl	1368	2	COMe	2,6-di-Me-Phenyl
591	3	COMe	2,4-di-Me-Phenyl	1369	3	COMe	2,6-di-Me-Phenyl
592	4	COMe	2,4-di-Me-Phenyl	1370	4	COMe	2,6-di-Me-Phenyl
593	1	CO_2Me	2,4-di-Me-Phenyl	1371	1	CO_2Me	2,6-di-Me-Phenyl
594	2	CO_2Me	2,4-di-Me-Phenyl	1372	2	CO_2Me	2,6-di-Me-Phenyl
595	3	CO_2Me	2,4-di-Me-Phenyl	1373	3	CO_2Me	2,6-di-Me-Phenyl
596	4	CO_2Me	2,4-di-Me-Phenyl	1374	4	CO_2Me	2,6-di-Me-Phenyl
597	1	CO_2tBu	2,4-di-Me-Phenyl	1375	1	CO_2tBu	2,6-di-Me-Phenyl
598	2	CO_2tBu	2,4-di-Me-Phenyl	1376	2	CO_2tBu	2,6-di-Me-Phenyl
599	3	CO_2tBu	2,4-di-Me-Phenyl	1377	3	CO_2tBu	2,6-di-Me-Phenyl
600	4	CO_2tBu	2,4-di-Me-Phenyl	1378	4	CO_2tBu	2,6-di-Me-Phenyl
601	1	CONHMe	2,4-di-Me-Phenyl	1379	1	CONHMe	2,6-di-Me-Phenyl
602	2	CONHMe	2,4-di-Me-Phenyl	1380	2	CONHMe	2,6-di-Me-Phenyl
603	3	CONHMe	2,4-di-Me-Phenyl	1381	3	CONHMe	2,6-di-Me-Phenyl
604	4	CONHMe	2,4-di-Me-Phenyl	1382	4	CONHMe	2,6-di-Me-Phenyl
605	1	SO_2Me	2,4-di-Me-Phenyl	1383	1	SO_2Me	2,6-di-Me-Phenyl
606	2	SO_2Me	2,4-di-Me-Phenyl	1384	2	SO_2Me	2,6-di-Me-Phenyl
607	3	SO_2Me	2,4-di-Me-Phenyl	1385	3	SO_2Me	2,6-di-Me-Phenyl
608	4	SO_2Me	2,4-di-Me-Phenyl	1386	4	SO_2Me	2,6-di-Me-Phenyl
609	1	SO_2NH_2	2,4-di-Me-Phenyl	1387	1	SO_2NH_2	2,6-di-Me-Phenyl
610	2	SO_2NH_2	2,4-di-Me-Phenyl	1388	2	SO_2NH_2	2,6-di-Me-Phenyl
611	3	SO_2NH_2	2,4-di-Me-Phenyl	1389	3	SO_2NH_2	2,6-di-Me-Phenyl
612	4	SO_2NH_2	2,4-di-Me-Phenyl	1390	4	SO_2NH_2	2,6-di-Me-Phenyl
613	1	H	2,6-di-iPr-Phenyl	1391	1	H	2-Ph-Phenyl
614	2	H	2,6-di-iPr-Phenyl	1392	2	H	2-Ph-Phenyl
615	3	H	2,6-di-iPr-Phenyl	1393	3	H	2-Ph-Phenyl
616	4	H	2,6-di-iPr-Phenyl	1394	4	H	2-Ph-Phenyl
617	1	Me	2,6-di-iPr-Phenyl	1395	1	Me	2-Ph-Phenyl
618	2	Me	2,6-di-iPr-Phenyl	1396	2	Me	2-Ph-Phenyl

619	3	Me	2,6-di-iPr-Phenyl	1397	3	Me	2-Ph-Phenyl
620	4	Me	2,6-di-iPr-Phenyl	1398	4	Me	2-Ph-Phenyl
621	1	CH_2Ph	2,6-di-iPr-Phenyl	1399	1	CH_2Ph	2-Ph-Phenyl
622	2	CH_2Ph	2,6-di-iPr-Phenyl	1400	2	CH_2Ph	2-Ph-Phenyl
623	3	CH_2Ph	2,6-di-iPr-Phenyl	1401	3	CH_2Ph	2-Ph-Phenyl
624	3	CH_2Ph	2,6-di-iPr-Phenyl	1402	4	CH_2Ph	2-Ph-Phenyl
625	1	COMe	2,6-di-iPr-Phenyl	1403	1	COMe	2-Ph-Phenyl
626	2	COMe	2,6-di-iPr-Phenyl	1404	2	COMe	2-Ph-Phenyl
627	3	COMe	2,6-di-iPr-Phenyl	1405	3	COMe	2-Ph-Phenyl
628	4	COMe	2,6-di-iPr-Phenyl	1406	4	COMe	2-Ph-Phenyl
629	1	CO_2Me	2,6-di-iPr-Phenyl	1407	1	CO_2Me	2-Ph-Phenyl
630	2	CO_2Me	2,6-di-iPr-Phenyl	1408	2	CO_2Me	2-Ph-Phenyl
631	3	CO_2Me	2,6-di-iPr-Phenyl	1409	3	CO_2Me	2-Ph-Phenyl
632	4	CO_2Me	2,6-di-iPr-Phenyl	1410	4	CO_2Me	2-Ph-Phenyl
633	1	CO_2tBu	2,6-di-iPr-Phenyl	1411	1	CO_2tBu	2-Ph-Phenyl
634	2	CO_2tBu	2,6-di-iPr-Phenyl	1412	2	CO_2tBu	2-Ph-Phenyl
635	3	CO_2tBu	2,6-di-iPr-Phenyl	1413	3	CO_2tBu	2-Ph-Phenyl
636	4	CO_2tBu	2,6-di-iPr-Phenyl	1414	4	CO_2tBu	2-Ph-Phenyl
637	1	CONHMe	2,6-di-iPr-Phenyl	1415	1	CONHMe	2-Ph-Phenyl
638	2	CONHMe	2,6-di-iPr-Phenyl	1416	2	CONHMe	2-Ph-Phenyl
639	3	CONHMe	2,6-di-iPr-Phenyl	1417	3	CONHMe	2-Ph-Phenyl
640	4	CONHMe	2,6-di-iPr-Phenyl	1418	4	CONHMe	2-Ph-Phenyl
641	1	SO_2Me	2,6-di-iPr-Phenyl	1419	1	SO_2Me	2-Ph-Phenyl
642	2	SO_2Me	2,6-di-iPr-Phenyl	1420	2	SO_2Me	2-Ph-Phenyl
643	3	SO_2Me	2,6-di-iPr-Phenyl	1421	3	SO_2Me	2-Ph-Phenyl
644	4	SO_2Me	2,6-di-iPr-Phenyl	1422	4	SO_2Me	2-Ph-Phenyl
645	1	SO_2NH_2	2,6-di-iPr-Phenyl	1423	1	SO_2NH_2	2-Ph-Phenyl
646	2	SO_2NH_2	2,6-di-iPr-Phenyl	1424	2	SO_2NH_2	2-Ph-Phenyl
647	3	SO_2NH_2	2,6-di-iPr-Phenyl	1425	3	SO_2NH_2	2-Ph-Phenyl
648	4	SO_2NH_2	2,6-di-iPr-Phenyl	1426	4	SO_2NH_2	2-Ph-Phenyl
649	1	H	3-Ph-Phenyl	1427	1	H	4-Ph-Phenyl

650	2	H	3-Ph-Phenyl	1428	2	H	4-Ph-Phenyl
651	3	H	3-Ph-Phenyl	1429	3	H	4-Ph-Phenyl
652	4	H	3-Ph-Phenyl	1430	4	H	4-Ph-Phenyl
653	1	Me	3-Ph-Phenyl	1431	1	Me	4-Ph-Phenyl
654	2	Me	3-Ph-Phenyl	1432	2	Me	4-Ph-Phenyl
655	3	Me	3-Ph-Phenyl	1433	3	Me	4-Ph-Phenyl
656	4	Me	3-Ph-Phenyl	1434	4	Me	4-Ph-Phenyl
657	1	CH_2Ph	3-Ph-Phenyl	1435	1	CH_2Ph	4-Ph-Phenyl
658	2	CH_2Ph	3-Ph-Phenyl	1436	2	CH_2Ph	4-Ph-Phenyl
659	3	CH_2Ph	3-Ph-Phenyl	1437	3	CH_2Ph	4-Ph-Phenyl
660	4	CH_2Ph	3-Ph-Phenyl	1438	4	CH_2Ph	4-Ph-Phenyl
661	1	COMe	3-Ph-Phenyl	1439	1	COMe	4-Ph-Phenyl
662	2	COMe	3-Ph-Phenyl	1440	2	COMe	4-Ph-Phenyl
663	3	COMe	3-Ph-Phenyl	1441	3	COMe	4-Ph-Phenyl
664	4	COMe	3-Ph-Phenyl	1442	4	COMe	4-Ph-Phenyl
665	1	CO_2Me	3-Ph-Phenyl	1443	1	CO_2Me	4-Ph-Phenyl
666	2	CO_2Me	3-Ph-Phenyl	1444	2	CO_2Me	4-Ph-Phenyl
667	3	CO_2Me	3-Ph-Phenyl	1445	3	CO_2Me	4-Ph-Phenyl
668	4	CO_2Me	3-Ph-Phenyl	1446	4	CO_2Me	4-Ph-Phenyl
669	1	CO_2tBu	3-Ph-Phenyl	1447	1	CO_2tBu	4-Ph-Phenyl
670	2	CO_2tBu	3-Ph-Phenyl	1448	2	CO_2tBu	4-Ph-Phenyl
671	3	CO_2tBu	3-Ph-Phenyl	1449	3	CO_2tBu	4-Ph-Phenyl
672	4	CO_2tBu	3-Ph-Phenyl	1450	4	CO_2tBu	4-Ph-Phenyl
673	1	CONHMe	3-Ph-Phenyl	1451	1	CONHMe	4-Ph-Phenyl
674	2	CONHMe	3-Ph-Phenyl	1452	2	CONHMe	4-Ph-Phenyl
675	3	CONHMe	3-Ph-Phenyl	1453	3	CONHMe	4-Ph-Phenyl
676	4	CONHMe	3-Ph-Phenyl	1454	4	CONHMe	4-Ph-Phenyl
677	1	SO_2Me	3-Ph-Phenyl	1455	1	SO_2Me	4-Ph-Phenyl
678	2	SO_2Me	3-Ph-Phenyl	1456	2	SO_2Me	4-Ph-Phenyl
679	3	SO_2Me	3-Ph-Phenyl	1457	3	SO_2Me	4-Ph-Phenyl
680	4	SO_2Me	3-Ph-Phenyl	1458	4	SO_2Me	4-Ph-Phenyl

681	1	SO_2NH_2	3-Ph-Phenyl	1459	1	SO_2NH_2	4-Ph-Phenyl
682	2	SO_2NH_2	3-Ph-Phenyl	1460	2	SO_2NH_2	4-Ph-Phenyl
683	3	SO_2NH_2	3-Ph-Phenyl	1461	3	SO_2NH_2	4-Ph-Phenyl
684	4	SO_2NH_2	3-Ph-Phenyl	1462	4	SO_2NH_2	4-Ph-Phenyl
685	1	H	2-morpholino-phenyl	1463	1	H	3-morpholino-phenyl
686	2	H	2-morpholino-phenyl	1464	2	H	3-morpholino-phenyl
687	3	H	2-morpholino-phenyl	1465	3	H	3-morpholino-phenyl
688	4	H	2-morpholino-phenyl	1466	4	H	3-morpholino-phenyl
689	1	Me	2-morpholino-phenyl	1467	1	Me	3-morpholino-phenyl
690	2	Me	2-morpholino-phenyl	1468	2	Me	3-morpholino-phenyl
691	3	Me	2-morpholino-phenyl	1469	3	Me	3-morpholino-phenyl
692	4	Me	2-morpholino-phenyl	1470	4	Me	3-morpholino-phenyl
693	1	CH_2Ph	2-morpholino-phenyl	1471	1	CH_2Ph	3-morpholino-phenyl
694	2	CH_2Ph	2-morpholino-phenyl	1472	2	CH_2Ph	3-morpholino-phenyl
695	3	CH_2Ph	2-morpholino-phenyl	1473	3	CH_2Ph	3-morpholino-phenyl
696	4	CH_2Ph	2-morpholino-phenyl	1474	4	CH_2Ph	3-morpholino-phenyl
697	1	COMe	2-morpholino-phenyl	1475	1	COMe	3-morpholino-phenyl
698	2	COMe	2-morpholino-phenyl	1476	2	COMe	3-morpholino-phenyl


699	3	COMe	2-morpholino-phenyl	1477	3	COMe	3-morpholino-phenyl
700	4	COMe	2-morpholino-phenyl	1478	4	COMe	3-morpholino-phenyl
701	1	CO_2Me	2-morpholino-phenyl	1479	1	CO_2Me	3-morpholino-phenyl
702	2	CO_2Me	2-morpholino-phenyl	1480	2	CO_2Me	3-morpholino-phenyl
703	3	CO_2Me	2-morpholino-phenyl	1481	3	CO_2Me	3-morpholino-phenyl
704	4	CO_2Me	2-morpholino-phenyl	1482	4	CO_2Me	3-morpholino-phenyl
705	1	CO_2tBu	2-morpholino-phenyl	1483	1	CO_2tBu	3-morpholino-phenyl
706	2	CO_2tBu	2-morpholino-phenyl	1484	2	CO_2tBu	3-morpholino-phenyl
707	3	CO_2tBu	2-morpholino-phenyl	1485	3	CO_2tBu	3-morpholino-phenyl
708	4	CO_2tBu	2-morpholino-phenyl	1486	4	CO_2tBu	3-morpholino-phenyl
709	1	CONHMe	2-morpholino-phenyl	1487	1	CONHMe	3-morpholino-phenyl
710	2	CONHMe	2-morpholino-phenyl	1488	2	CONHMe	3-morpholino-phenyl
711	3	CONHMe	2-morpholino-phenyl	1489	3	CONHMe	3-morpholino-phenyl
712	4	CONHMe	2-morpholino-phenyl	1490	4	CONHMe	3-morpholino-phenyl
713	1	SO_2Me	2-morpholino-phenyl	1491	1	SO_2Me	3-morpholino-phenyl
714	2	SO_2Me	2-morpholino-phenyl	1492	2	SO_2Me	3-morpholino-phenyl

715	3	SO_2Me	2-morpholino-phenyl	1493	3	SO_2Me	3-morpholino-phenyl
716	4	SO_2Me	2-morpholino-phenyl	1494	4	SO_2Me	3-morpholino-phenyl
717	1	SO_2NH_2	2-morpholino-phenyl	1495	1	SO_2NH_2	3-morpholino-phenyl
718	2	SO_2NH_2	2-morpholino-phenyl	1496	2	SO_2NH_2	3-morpholino-phenyl
719	3	SO_2NH_2	2-morpholino-phenyl	1497	3	SO_2NH_2	3-morpholino-phenyl
720	4	SO_2NH_2	2-morpholino-phenyl	1498	4	**SO_2NH_2**	3-morpholino-phenyl
721	1	H	4-morpholino-phenyl	1499	1	Me	4-morpholino-phenyl
722	2	H	4-morpholino-phenyl	1500	2	Me	4-morpholino-phenyl
723	3	H	4-morpholino-phenyl	1501	3	Me	4-morpholino-phenyl
724	4	H	4-morpholino-phenyl	1502	4	Me	4-morpholino-phenyl
725	1	CH_2Ph	4-morpholino-phenyl	103	1	COMe	4-morpholino-phenyl
726	2	CH_2Ph	4-morpholino-phenyl	1504	2	COMe	4-morpholino-phenyl
727	3	CH_2Ph	4-morpholino-phenyl	1505	3	COMe	4-morpholino-phenyl
728	4	CH_2Ph	4-morpholino-phenyl	1506	4	COMe	4-morpholino-phenyl
729	1	CO_2Me	4-morpholino-phenyl	1507	1	CO_2tBu	4-morpholino-phenyl
730	2	CO_2Me	4-morpholino-phenyl	1508	2	CO_2tBu	4-morpholino-phenyl

731	3	CO_2Me	4-morpholino-phenyl	1509	3	CO_2tBu	4-morpholino-phenyl
732	4	CO_2Me	4-morpholino-phenyl	1510	4	CO_2tBu	4-morpholino-phenyl
733	1	CONHMe	4-morpholino-phenyl	1511	1	SO_2Me	4-morpholino-phenyl
734	2	CONHMe	4-morpholino-phenyl	1512	2	SO_2Me	4-morpholino-phenyl
735	3	CONHMe	4-morpholino-phenyl	1513	3	SO_2Me	4-morpholino-phenyl
736	4	CONHMe	4-morpholino-phenyl	1514	4	SO_2Me	4-morpholino-phenyl
737	1	SO_2NH_2	4-morpholino-phenyl	1516	1	H	naphthylen-2-yl
738	2	SO_2NH_2	4-morpholino-phenyl	1517	2	H	naphthylen-2-yl
739	3	SO_2NH_2	4-morpholino-phenyl	1518	3	H	naphthylen-2-yl
740	1	H	naphthylen-1-yl	1519	4	H	naphthylen-2-yl
741	2	H	naphthylen-1-yl	1520	1	Me	naphthylen-2-yl
742	3	H	naphthylen-1-yl	1521	2	Me	naphthylen-2-yl
743	4	H	naphthylen-1-yl	1522	3	Me	naphthylen-2-yl
744	1	Me	naphthylen-1-yl	1523	4	Me	naphthylen-2-yl
745	2	Me	naphthylen-1-yl	1524	1	CH_2Ph	naphthylen-2-yl
746	3	Me	naphthylen-1-yl	1525	2	CH_2Ph	naphthylen-2-yl
747	4	Me	naphthylen-1-yl	1526	3	CH_2Ph	naphthylen-2-yl
748	1	CH_2Ph	naphthylen-1-yl	1527	4	CH_2Ph	naphthylen-2-yl
749	2	CH_2Ph	naphthylen-1-yl	1528	1	COMe	naphthylen-2-yl
750	3	CH_2Ph	naphthylen-1-yl	1529	2	COMe	naphthylen-2-yl
751	4	CH_2Ph	naphthylen-1-yl	1530	3	COMe	naphthylen-2-yl
752	1	COMe	naphthylen-1-yl	1531	4	COMe	naphthylen-2-yl
753	2	COMe	naphthylen-1-yl	1532	1	CO_2Me	naphthylen-2-yl

754	3	COMe	naphthylen-1-yl	1533	2	CO_2Me	naphthylen-2-yl
755	4	COMe	naphthylen-1-yl	1534	3	CO_2Me	naphthylen-2-yl
756	1	CO_2Me	naphthylen-1-yl	1535	4	CO_2Me	naphthylen-2-yl
757	2	CO_2Me	naphthylen-1-yl	1536	1	CO_2tBu	naphthylen-2-yl
758	3	CO_2Me	naphthylen-1-yl	1537	2	CO_2tBu	naphthylen-2-yl
759	4	CO_2Me	naphthylen-1-yl	1538	3	CO_2tBu	naphthylen-2-yl
760	1	CO_2tBu	naphthylen-1-yl	1539	4	CO_2tBu	naphthylen-2-yl
761	2	CO_2tBu	naphthylen-1-yl	1540	1	CONHMe	naphthylen-2-yl
762	3	CO_2tBu	naphthylen-1-yl	1541	2	CONHMe	naphthylen-2-yl
763	4	CO_2tBu	naphthylen-1-yl	1542	3	CONHMe	naphthylen-2-yl
764	1	CONHMe	naphthylen-1-yl	1543	4	CONHMe	naphthylen-2-yl
765	2	CONHMe	naphthylen-1-yl	1544	1	SO_2Me	naphthylen-2-yl
767	3	CONHMe	naphthylen-1-yl	1545	2	SO_2Me	naphthylen-2-yl
768	4	CONHMe	naphthylen-1-yl	1546	3	SO_2Me	naphthylen-2-yl
769	1	SO_2Me	naphthylen-1-yl	1547	4	SO_2Me	naphthylen-2-yl
770	2	SO_2Me	naphthylen-1-yl	1548	1	SO_2NH_2	naphthylen-2-yl
771	3	SO_2Me	naphthylen-1-yl	1549	2	SO_2NH_2	naphthylen-2-yl
772	4	SO_2Me	naphthylen-1-yl	1550	3	SO_2NH_2	naphthylen-2-yl
773	1	SO_2NH_2	naphthylen-1-yl	1551	4	SO_2NH_2	naphthylen-2-yl
774	2	SO_2NH_2	naphthylen-1-yl				
775	3	SO_2NH_2	naphthylen-1-yl				
778	4	SO_2NH_2	naphthylen-1-yl				

[01026] Exemplary embodiments include compounds having the formula **(XXIV)**



or a pharmaceutically acceptable salt form thereof defined herein below in Table 18.

Table 18:

Entry	n	R^7	R^3	Entry	n	R^7	R^3

1	1	H	Phenyl	779	1	H	4-OH-Phenyl
2	2	H	Phenyl	780	2	H	4-OH-Phenyl
3	3	H	Phenyl	781	3	H	4-OH-Phenyl
4	4	H	Phenyl	782	4	H	4-OH-Phenyl
5	1	Me	Phenyl	783	1	Me	4-OH-Phenyl
6	2	Me	Phenyl	784	2	Me	4-OH-Phenyl
7	3	Me	Phenyl	785	3	Me	4-OH-Phenyl
8	4	Me	Phenyl	786	4	Me	4-OH-Phenyl
9	1	CH_2Ph	Phenyl	787	1	CH_2Ph	4-OH-Phenyl
10	2	CH_2Ph	Phenyl	788	2	CH_2Ph	4-OH-Phenyl
11	3	CH_2Ph	Phenyl	789	3	CH_2Ph	4-OH-Phenyl
12	4	CH_2Ph	Phenyl	790	4	CH_2Ph	4-OH-Phenyl
13	1	COMe	Phenyl	791	1	COMe	4-OH-Phenyl
14	2	COMe	Phenyl	792	2	COMe	4-OH-Phenyl
15	3	COMe	Phenyl	793	3	COMe	4-OH-Phenyl
16	4	COMe	Phenyl	794	4	COMe	4-OH-Phenyl
17	1	CO_2Me	Phenyl	795	1	CO_2Me	4-OH-Phenyl
18	2	CO_2Me	Phenyl	796	2	CO_2Me	4-OH-Phenyl
19	3	CO_2Me	Phenyl	797	3	CO_2Me	4-OH-Phenyl
20	4	CO_2Me	Phenyl	798	4	CO_2Me	4-OH-Phenyl
21	1	CO_2tBu	Phenyl	799	1	CO_2tBu	4-OH-Phenyl
22	2	CO_2tBu	Phenyl	800	2	CO_2tBu	4-OH-Phenyl
23	3	CO_2tBu	Phenyl	801	3	CO_2tBu	4-OH-Phenyl
24	4	CO_2tBu	Phenyl	802	4	CO_2tBu	4-OH-Phenyl
25	1	CONHMe	Phenyl	803	1	CONHMe	4-OH-Phenyl
26	2	CONHMe	Phenyl	804	2	CONHMe	4-OH-Phenyl
27	3	CONHMe	Phenyl	805	3	CONHMe	4-OH-Phenyl
28	4	CONHMe	Phenyl	806	4	CONHMe	4-OH-Phenyl
29	1	SO_2Me	Phenyl	807	1	SO_2Me	4-OH-Phenyl
30	2	SO_2Me	Phenyl	808	2	SO_2Me	4-OH-Phenyl
31	3	SO_2Me	Phenyl	809	3	SO_2Me	4-OH-Phenyl

32	4	SO_2Me	Phenyl	810	4	SO_2Me	4-OH-Phenyl
33	1	SO_2NH_2	Phenyl	811	1	SO_2NH_2	4-OH-Phenyl
34	2	SO_2NH_2	Phenyl	812	2	SO_2NH_2	4-OH-Phenyl
35	3	SO_2NH_2	Phenyl	813	3	SO_2NH_2	4-OH-Phenyl
36	4	SO_2NH_2	Phenyl	814	4	SO_2NH_2	4-OH-Phenyl
37	1	H	3-OH-Phenyl	815	1	H	2-OH-Phenyl
38	2	H	3-OH-Phenyl	816	2	H	2-OH-Phenyl
39	3	H	3-OH-Phenyl	817	3	H	2-OH-Phenyl
40	4	H	3-OH-Phenyl	818	4	H	2-OH-Phenyl
41	1	Me	3-OH-Phenyl	819	1	Me	2-OH-Phenyl
42	2	Me	3-OH-Phenyl	820	2	Me	2-OH-Phenyl
43	3	Me	3-OH-Phenyl	821	3	Me	2-OH-Phenyl
44	4	Me	3-OH-Phenyl	822	4	Me	2-OH-Phenyl
45	1	CH_2Ph	3-OH-Phenyl	823	1	CH_2Ph	2-OH-Phenyl
46	2	CH_2Ph	3-OH-Phenyl	824	2	CH_2Ph	2-OH-Phenyl
47	3	CH_2Ph	3-OH-Phenyl	825	3	CH_2Ph	2-OH-Phenyl
48	4	CH_2Ph	3-OH-Phenyl	826	4	CH_2Ph	2-OH-Phenyl
49	1	COMe	3-OH-Phenyl	827	1	COMe	2-OH-Phenyl
50	2	COMe	3-OH-Phenyl	828	2	COMe	2-OH-Phenyl
51	3	COMe	3-OH-Phenyl	829	3	COMe	2-OH-Phenyl
52	4	COMe	3-OH-Phenyl	830	4	COMe	2-OH-Phenyl
53	1	CO_2Me	3-OH-Phenyl	831	1	CO_2Me	2-OH-Phenyl
54	2	CO_2Me	3-OH-Phenyl	832	2	CO_2Me	2-OH-Phenyl
55	3	CO_2Me	3-OH-Phenyl	833	3	CO_2Me	2-OH-Phenyl
56	4	CO_2Me	3-OH-Phenyl	834	4	CO_2Me	2-OH-Phenyl
57	1	CO_2tBu	3-OH-Phenyl	835	1	CO_2tBu	2-OH-Phenyl
58	2	CO_2tBu	3-OH-Phenyl	836	2	CO_2tBu	2-OH-Phenyl
59	3	CO_2tBu	3-OH-Phenyl	837	3	CO_2tBu	2-OH-Phenyl
60	4	CO_2tBu	3-OH-Phenyl	838	4	CO_2tBu	2-OH-Phenyl
61	1	CONHMe	3-OH-Phenyl	839	1	CONHMe	2-OH-Phenyl
62	2	CONHMe	3-OH-Phenyl	840	2	CONHMe	2-OH-Phenyl

63	3	CONHMe	3-OH-Phenyl	841	3	CONHMe	2-OH-Phenyl
64	4	CONHMe	3-OH-Phenyl	842	4	CONHMe	2-OH-Phenyl
65	1	SO_2Me	3-OH-Phenyl	843	1	SO_2Me	2-OH-Phenyl
66	2	SO_2Me	3-OH-Phenyl	844	2	SO_2Me	2-OH-Phenyl
67	3	SO_2Me	3-OH-Phenyl	845	3	SO_2Me	2-OH-Phenyl
68	4	SO_2Me	3-OH-Phenyl	846	4	SO_2Me	2-OH-Phenyl
69	1	SO_2NH_2	3-OH-Phenyl	847	1	SO_2NH_2	2-OH-Phenyl
70	2	SO_2NH_2	3-OH-Phenyl	848	2	SO_2NH_2	2-OH-Phenyl
71	3	SO_2NH_2	3-OH-Phenyl	849	3	SO_2NH_2	2-OH-Phenyl
72	4	SO_2NH_2	3-OH-Phenyl	850	4	SO_2NH_2	2-OH-Phenyl
73	1	H	4-NO_2-Phenyl	851	1	H	4-OMe-Phenyl
74	2	H	4-NO_2-Phenyl	852	2	H	4-OMe-Phenyl
75	3	H	4-NO_2-Phenyl	853	3	H	4-OMe-Phenyl
76	4	H	4-NO_2-Phenyl	854	4	H	4-OMe-Phenyl
77	1	Me	4-NO_2-Phenyl	855	1	Me	4-OMe-Phenyl
78	2	Me	4-NO_2-Phenyl	856	2	Me	4-OMe-Phenyl
79	3	Me	4-NO_2-Phenyl	857	3	Me	4-OMe-Phenyl
80	4	Me	4-NO_2-Phenyl	858	4	Me	4-OMe-Phenyl
81	1	CH_2Ph	4-NO_2-Phenyl	859	1	CH_2Ph	4-OMe-Phenyl
82	2	CH_2Ph	4-NO_2-Phenyl	860	2	CH_2Ph	4-OMe-Phenyl
83	3	CH_2Ph	4-NO_2-Phenyl	861	3	CH_2Ph	4-OMe-Phenyl
84	4	CH_2Ph	4-NO_2-Phenyl	862	4	CH_2Ph	4-OMe-Phenyl
85	1	COMe	4-NO_2-Phenyl	863	1	COMe	4-OMe-Phenyl
86	2	COMe	4-NO_2-Phenyl	864	2	COMe	4-OMe-Phenyl
87	3	COMe	4-NO_2-Phenyl	865	3	COMe	4-OMe-Phenyl
88	4	COMe	4-NO_2-Phenyl	866	4	COMe	4-OMe-Phenyl
89	1	CO_2Me	4-NO_2-Phenyl	867	1	CO_2Me	4-OMe-Phenyl
90	2	CO_2Me	4-NO_2-Phenyl	868	2	CO_2Me	4-OMe-Phenyl
91	3	CO_2Me	4-NO_2-Phenyl	869	3	CO_2Me	4-OMe-Phenyl
92	4	CO_2Me	4-NO_2-Phenyl	870	4	CO_2Me	4-OMe-Phenyl
93	1	CO_2tBu	4-NO_2-Phenyl	871	1	CO_2tBu	4-OMe-Phenyl

94	2	CO_2tBu	4-NO_2-Phenyl	872	2	CO_2tBu	4-OMe-Phenyl
95	3	CO_2tBu	4-NO_2-Phenyl	873	3	CO_2tBu	4-OMe-Phenyl
96	4	CO_2tBu	4-NO_2-Phenyl	874	4	CO_2tBu	4-OMe-Phenyl
97	1	CONHMe	4-NO_2-Phenyl	875	1	CONHMe	4-OMe-Phenyl
98	2	CONHMe	4-NO_2-Phenyl	876	2	CONHMe	4-OMe-Phenyl
99	3	CONHMe	4-NO_2-Phenyl	877	3	CONHMe	4-OMe-Phenyl
100	4	CONHMe	4-NO_2-Phenyl	878	4	CONHMe	4-OMe-Phenyl
101	1	SO_2Me	4-NO_2-Phenyl	879	1	SO_2Me	4-OMe-Phenyl
102	2	SO_2Me	4-NO_2-Phenyl	880	2	SO_2Me	4-OMe-Phenyl
103	3	SO_2Me	4-NO_2-Phenyl	881	3	SO_2Me	4-OMe-Phenyl
104	4	SO_2Me	4-NO_2-Phenyl	882	4	SO_2Me	4-OMe-Phenyl
105	1	SO_2NH_2	4-NO_2-Phenyl	883	1	SO_2NH_2	4-OMe-Phenyl
106	2	SO_2NH_2	4-NO_2-Phenyl	884	2	SO_2NH_2	4-OMe-Phenyl
107	3	SO_2NH_2	4-NO_2-Phenyl	885	3	SO_2NH_2	4-OMe-Phenyl
108	4	SO_2NH_2	4-NO_2-Phenyl	886	4	SO_2NH_2	4-OMe-Phenyl
109	1	H	3-OMe-Phenyl	887	1	H	2-OMe-Phenyl
110	2	H	3-OMe-Phenyl	888	2	H	2-OMe-Phenyl
111	3	H	3-OMe-Phenyl	889	3	H	2-OMe-Phenyl
112	4	H	3-OMe-Phenyl	890	4	H	2-OMe-Phenyl
113	1	Me	3-OMe-Phenyl	891	1	Me	2-OMe-Phenyl
114	2	Me	3-OMe-Phenyl	892	2	Me	2-OMe-Phenyl
115	3	Me	3-OMe-Phenyl	893	3	Me	2-OMe-Phenyl
116	4	Me	3-OMe-Phenyl	894	4	Me	2-OMe-Phenyl
117	1	CH_2Ph	3-OMe-Phenyl	895	1	CH_2Ph	2-OMe-Phenyl
118	2	CH_2Ph	3-OMe-Phenyl	896	2	CH_2Ph	2-OMe-Phenyl
119	3	CH_2Ph	3-OMe-Phenyl	897	3	CH_2Ph	2-OMe-Phenyl
120	4	CH_2Ph	3-OMe-Phenyl	898	4	CH_2Ph	2-OMe-Phenyl
121	1	COMe	3-OMe-Phenyl	899	1	COMe	2-OMe-Phenyl
122	2	COMe	3-OMe-Phenyl	900	2	COMe	2-OMe-Phenyl
123	3	COMe	3-OMe-Phenyl	901	3	COMe	2-OMe-Phenyl
124	4	COMe	3-OMe-Phenyl	902	4	COMe	2-OMe-Phenyl

125	1	CO_2Me	3-OMe-Phenyl	903	1	CO_2Me	2-OMe-Phenyl
126	2	CO_2Me	3-OMe-Phenyl	904	2	CO_2Me	2-OMe-Phenyl
127	3	CO_2Me	3-OMe-Phenyl	905	3	CO_2Me	2-OMe-Phenyl
128	4	CO_2Me	3-OMe-Phenyl	906	4	CO_2Me	2-OMe-Phenyl
129	1	CO_2tBu	3-OMe-Phenyl	907	1	CO_2tBu	2-OMe-Phenyl
130	2	CO_2tBu	3-OMe-Phenyl	908	2	CO_2tBu	2-OMe-Phenyl
131	3	CO_2tBu	3-OMe-Phenyl	909	3	CO_2tBu	2-OMe-Phenyl
132	4	CO_2tBu	3-OMe-Phenyl	910	4	CO_2tBu	2-OMe-Phenyl
133	1	CONHMe	3-OMe-Phenyl	911	1	CONHMe	2-OMe-Phenyl
134	2	CONHMe	3-OMe-Phenyl	912	2	CONHMe	2-OMe-Phenyl
135	3	CONHMe	3-OMe-Phenyl	913	3	CONHMe	2-OMe-Phenyl
136	4	CONHMe	3-OMe-Phenyl	914	4	CONHMe	2-OMe-Phenyl
137	1	SO_2Me	3-OMe-Phenyl	915	1	SO_2Me	2-OMe-Phenyl
138	2	SO_2Me	3-OMe-Phenyl	916	2	SO_2Me	2-OMe-Phenyl
139	3	SO_2Me	3-OMe-Phenyl	917	3	SO_2Me	2-OMe-Phenyl
140	4	SO_2Me	3-OMe-Phenyl	918	4	SO_2Me	2-OMe-Phenyl
141	1	SO_2NH_2	3-OMe-Phenyl	919	1	SO_2NH_2	2-OMe-Phenyl
142	2	SO_2NH_2	3-OMe-Phenyl	920	2	SO_2NH_2	2-OMe-Phenyl
143	3	SO_2NH_2	3-OMe-Phenyl	921	3	SO_2NH_2	2-OMe-Phenyl
144	4	SO_2NH_2	3-OMe-Phenyl	922	4	SO_2NH_2	2-OMe-Phenyl
145	1	H	4-CN-Phenyl	923	1	H	3-CN-Phenyl
146	2	H	4-CN-Phenyl	924	2	H	3-CN-Phenyl
147	3	H	4-CN-Phenyl	925	3	H	3-CN-Phenyl
148	4	H	4-CN-Phenyl	926	4	H	3-CN-Phenyl
149	1	Me	4-CN-Phenyl	927	1	Me	3-CN-Phenyl
150	2	Me	4-CN-Phenyl	928	2	Me	3-CN-Phenyl
151	3	Me	4-CN-Phenyl	929	3	Me	3-CN-Phenyl
152	4	Me	4-CN-Phenyl	930	4	Me	3-CN-Phenyl
153	1	CH_2Ph	4-CN-Phenyl	931	1	CH_2Ph	3-CN-Phenyl
154	2	CH_2Ph	4-CN-Phenyl	932	2	CH_2Ph	3-CN-Phenyl
155	3	CH_2Ph	4-CN-Phenyl	933	3	CH_2Ph	3-CN-Phenyl

156	4	CH_2Ph	4-CN-Phenyl	934	4	CH_2Ph	3-CN-Phenyl
157	1	COMe	4-CN-Phenyl	935	1	COMe	3-CN-Phenyl
158	2	COMe	4-CN-Phenyl	936	2	COMe	3-CN-Phenyl
159	3	COMe	4-CN-Phenyl	937	3	COMe	3-CN-Phenyl
160	4	COMe	4-CN-Phenyl	938	4	COMe	3-CN-Phenyl
161	1	CO_2Me	4-CN-Phenyl	939	1	CO_2Me	3-CN-Phenyl
162	2	CO_2Me	4-CN-Phenyl	940	2	CO_2Me	3-CN-Phenyl
163	3	CO_2Me	4-CN-Phenyl	941	3	CO_2Me	3-CN-Phenyl
164	4	CO_2Me	4-CN-Phenyl	942	4	CO_2Me	3-CN-Phenyl
165	1	CO_2tBu	4-CN-Phenyl	943	1	CO_2tBu	3-CN-Phenyl
166	2	CO_2tBu	4-CN-Phenyl	944	2	CO_2tBu	3-CN-Phenyl
167	3	CO_2tBu	4-CN-Phenyl	945	3	CO_2tBu	3-CN-Phenyl
168	4	CO_2tBu	4-CN-Phenyl	946	4	CO_2tBu	3-CN-Phenyl
169	1	CONHMe	4-CN-Phenyl	947	1	CONHMe	3-CN-Phenyl
170	2	CONHMe	4-CN-Phenyl	948	2	CONHMe	3-CN-Phenyl
171	3	CONHMe	4-CN-Phenyl	949	3	CONHMe	3-CN-Phenyl
172	4	CONHMe	4-CN-Phenyl	950	4	CONHMe	3-CN-Phenyl
173	1	SO_2Me	4-CN-Phenyl	951	1	SO_2Me	3-CN-Phenyl
174	2	SO_2Me	4-CN-Phenyl	952	2	SO_2Me	3-CN-Phenyl
175	3	SO_2Me	4-CN-Phenyl	953	3	SO_2Me	3-CN-Phenyl
176	4	SO_2Me	4-CN-Phenyl	954	4	SO_2Me	3-CN-Phenyl
177	1	SO_2NH_2	4-CN-Phenyl	955	1	SO_2NH_2	3-CN-Phenyl
178	2	SO_2NH_2	4-CN-Phenyl	956	2	SO_2NH_2	3-CN-Phenyl
179	3	SO_2NH_2	4-CN-Phenyl	957	3	SO_2NH_2	3-CN-Phenyl
180	4	SO_2NH_2	4-CN-Phenyl	958	4	SO_2NH_2	3-CN-Phenyl
181	1	H	2-CN-Phenyl	959	1	H	2-Me-Phenyl
182	2	H	2-CN-Phenyl	960	2	H	2-Me-Phenyl
183	3	H	2-CN-Phenyl	961	3	H	2-Me-Phenyl
184	4	H	2-CN-Phenyl	962	4	H	2-Me-Phenyl
185	1	Me	2-CN-Phenyl	963	1	Me	2-Me-Phenyl
186	2	Me	2-CN-Phenyl	964	2	Me	2-Me-Phenyl

187	3	Me	2-CN-Phenyl	965	3	Me	2-Me-Phenyl
188	4	Me	2-CN-Phenyl	966	4	Me	2-Me-Phenyl
189	1	CH_2Ph	2-CN-Phenyl	967	1	CH_2Ph	2-Me-Phenyl
190	2	CH_2Ph	2-CN-Phenyl	968	2	CH_2Ph	2-Me-Phenyl
191	3	CH_2Ph	2-CN-Phenyl	969	3	CH_2Ph	2-Me-Phenyl
192	4	CH_2Ph	2-CN-Phenyl	970	4	CH_2Ph	2-Me-Phenyl
193	1	COMe	2-CN-Phenyl	971	1	COMe	2-Me-Phenyl
194	2	COMe	2-CN-Phenyl	972	2	COMe	2-Me-Phenyl
195	3	COMe	2-CN-Phenyl	973	3	COMe	2-Me-Phenyl
196	4	COMe	2-CN-Phenyl	974	4	COMe	2-Me-Phenyl
197	1	CO_2Me	2-CN-Phenyl	975	1	CO_2Me	2-Me-Phenyl
198	2	CO_2Me	2-CN-Phenyl	976	2	CO_2Me	2-Me-Phenyl
199	3	CO_2Me	2-CN-Phenyl	977	3	CO_2Me	2-Me-Phenyl
200	4	CO_2Me	2-CN-Phenyl	978	4	CO_2Me	2-CN-Phenyl
201	1	CO_2tBu	2-CN-Phenyl	979	1	CO_2tBu	2-Me-Phenyl
202	2	CO_2tBu	2-CN-Phenyl	980	2	CO_2tBu	2-Me-Phenyl
203	3	CO_2tBu	2-CN-Phenyl	981	3	CO_2tBu	2-Me-Phenyl
204	4	CO_2tBu	2-CN-Phenyl	982	4	CO_2tBu	2-Me-Phenyl
205	1	CONHMe	2-CN-Phenyl	983	1	CONHMe	2-Me-Phenyl
206	2	CONHMe	2-CN-Phenyl	984	2	CONHMe	2-Me-Phenyl
207	3	CONHMe	2-CN-Phenyl	985	3	CONHMe	2-Me-Phenyl
208	4	CONHMe	2-CN-Phenyl	986	4	CONHMe	2-Me-Phenyl
209	1	SO_2Me	2-CN-Phenyl	987	1	SO_2Me	2-Me-Phenyl
210	2	SO_2Me	2-CN-Phenyl	988	2	SO_2Me	2-Me-Phenyl
211	3	SO_2Me	2-CN-Phenyl	989	3	SO_2Me	2-Me-Phenyl
212	4	SO_2Me	2-CN-Phenyl	990	4	SO_2Me	2-Me-Phenyl
213	1	SO_2NH_2	2-CN-Phenyl	991	1	SO_2NH_2	2-Me-Phenyl
214	2	SO_2NH_2	2-CN-Phenyl	992	2	SO_2NH_2	2-Me-Phenyl
215	3	SO_2NH_2	2-CN-Phenyl	993	3	SO_2NH_2	2-Me-Phenyl
216	4	SO_2NH_2	2-CN-Phenyl	994	4	SO_2NH_2	2-Me-Phenyl
217	1	H	3-Me-Phenyl	995	1	H	4-Me-Phenyl

218	2	H	3-Me-Phenyl	996	2	H	4-Me-Phenyl
219	3	H	3-Me-Phenyl	997	3	H	4-Me-Phenyl
220	4	H	3-Me-Phenyl	998	4	H	4-Me-Phenyl
221	1	Me	3-Me-Phenyl	999	1	Me	4-Me-Phenyl
222	2	Me	3-Me-Phenyl	1000	2	Me	4-Me-Phenyl
223	3	Me	3-Me-Phenyl	1001	3	Me	4-Me-Phenyl
224	4	Me	3-Me-Phenyl	1002	4	Me	4-Me-Phenyl
225	1	CH_2Ph	3-Me-Phenyl	1003	1	CH_2Ph	4-Me-Phenyl
226	2	CH_2Ph	3-Me-Phenyl	1004	2	CH_2Ph	4-Me-Phenyl
227	3	CH_2Ph	3-Me-Phenyl	1005	3	CH_2Ph	4-Me-Phenyl
228	4	CH_2Ph	3-Me-Phenyl	1006	4	CH_2Ph	4-Me-Phenyl
229	1	COMe	3-Me-Phenyl	1007	1	COMe	4-Me-Phenyl
230	2	COMe	3-Me-Phenyl	1008	2	COMe	4-Me-Phenyl
231	3	COMe	3-Me-Phenyl	1009	3	COMe	4-Me-Phenyl
232	4	COMe	3-Me-Phenyl	1010	4	COMe	4-Me-Phenyl
233	1	CO_2Me	3-Me-Phenyl	1011	1	CO_2Me	4-Me-Phenyl
234	2	CO_2Me	3-Me-Phenyl	1012	2	CO_2Me	4-Me-Phenyl
235	3	CO_2Me	3-Me-Phenyl	1013	3	CO_2Me	4-Me-Phenyl
236	4	CO_2Me	3-Me-Phenyl	1014	4	CO_2Me	4-Me-Phenyl
237	1	CO_2tBu	3-Me-Phenyl	1015	1	CO_2tBu	4-Me-Phenyl
238	2	CO_2tBu	3-Me-Phenyl	1016	2	CO_2tBu	4-Me-Phenyl
239	3	CO_2tBu	3-Me-Phenyl	1017	3	CO_2tBu	4-Me-Phenyl
240	4	CO_2tBu	3-Me-Phenyl	1018	4	CO_2tBu	4-Me-Phenyl
241	1	CONHMe	3-Me-Phenyl	1019	1	CONHMe	4-Me-Phenyl
242	2	CONHMe	3-Me-Phenyl	1020	2	CONHMe	4-Me-Phenyl
243	3	CONHMe	3-Me-Phenyl	1021	3	CONHMe	4-Me-Phenyl
244	4	CONHMe	3-Me-Phenyl	1022	4	CONHMe	4-Me-Phenyl
245	1	SO_2Me	3-Me-Phenyl	1023	1	SO_2Me	4-Me-Phenyl
246	2	SO_2Me	3-Me-Phenyl	1024	2	SO_2Me	4-Me-Phenyl
247	3	SO_2Me	3-Me-Phenyl	1025	3	SO_2Me	4-Me-Phenyl
248	4	SO_2Me	3-Me-Phenyl	1026	4	SO_2Me	4-Me-Phenyl

249	1	SO_2NH_2	3-Me-Phenyl	1027	1	SO_2NH_2	4-Me-Phenyl
250	2	SO_2NH_2	3-Me-Phenyl	1028	2	SO_2NH_2	4-Me-Phenyl
251	3	SO_2NH_2	3-Me-Phenyl	1029	3	SO_2NH_2	4-Me-Phenyl
252	4	SO_2NH_2	3-Me-Phenyl	1030	4	SO_2NH_2	4-Me-Phenyl
253	1	H	2-F-Phenyl	1031	1	H	3-F-Phenyl
254	2	H	2-F-Phenyl	1032	2	H	3-F-Phenyl
255	3	H	2-F-Phenyl	1033	3	H	3-F-Phenyl
256	4	H	2-F-Phenyl	1034	4	H	3-F-Phenyl
257	1	Me	2-F-Phenyl	1035	1	Me	3-F-Phenyl
258	2	Me	2-F-Phenyl	1036	2	Me	3-F-Phenyl
259	3	Me	2-F-Phenyl	1037	3	Me	3-F-Phenyl
260	4	Me	2-F-Phenyl	1038	4	Me	3-F-Phenyl
261	1	CH_2Ph	2-F-Phenyl	1039	1	CH_2Ph	3-F-Phenyl
262	2	CH_2Ph	2-F-Phenyl	1040	2	CH_2Ph	3-F-Phenyl
263	3	CH_2Ph	2-F-Phenyl	1041	3	CH_2Ph	3-F-Phenyl
264	4	CH_2Ph	2-F-Phenyl	1042	4	CH_2Ph	3-F-Phenyl
265	1	COMe	2-F-Phenyl	1043	1	COMe	3-F-Phenyl
266	2	COMe	2-F-Phenyl	1044	2	COMe	3-F-Phenyl
267	3	COMe	2-F-Phenyl	1045	3	COMe	3-F-Phenyl
268	4	COMe	2-F-Phenyl	1046	4	COMe	3-F-Phenyl
269	1	CO_2Me	2-F-Phenyl	1047	1	CO_2Me	3-F-Phenyl
270	2	CO_2Me	2-F-Phenyl	1048	2	CO_2Me	3-F-Phenyl
271	3	CO_2Me	2-F-Phenyl	1049	3	CO_2Me	3-F-Phenyl
272	4	CO_2Me	2-F-Phenyl	1050	4	CO_2Me	3-F-Phenyl
273	1	CO_2tBu	2-F-Phenyl	1051	1	CO_2tBu	3-F-Phenyl
274	2	CO_2tBu	2-F-Phenyl	1052	2	CO_2tBu	3-F-Phenyl
275	3	CO_2tBu	2-F-Phenyl	1053	3	CO_2tBu	3-F-Phenyl
276	4	CO_2tBu	2-F-Phenyl	1054	4	CO_2tBu	3-F-Phenyl
277	1	CONHMe	2-F-Phenyl	1055	1	CONHMe	3-F-Phenyl
278	2	CONHMe	2-F-Phenyl	1056	2	CONHMe	3-F-Phenyl
279	3	CONHMe	2-F-Phenyl	1057	3	CONHMe	3-F-Phenyl

280	4	CONHMe	2-F-Phenyl	1058	4	CONHMe	3-F-Phenyl
281	1	SO_2Me	2-F-Phenyl	1059	1	SO_2Me	3-F-Phenyl
282	2	SO_2Me	2-F-Phenyl	1060	2	SO_2Me	3-F-Phenyl
283	3	SO_2Me	2-F-Phenyl	1061	3	SO_2Me	3-F-Phenyl
284	4	SO_2Me	2-F-Phenyl	1062	4	SO_2Me	3-F-Phenyl
285	1	SO_2NH_2	2-F-Phenyl	1063	1	SO_2NH_2	3-F-Phenyl
286	2	SO_2NH_2	2-F-Phenyl	1064	2	SO_2NH_2	3-F-Phenyl
287	3	SO_2NH_2	2-F-Phenyl	1065	3	SO_2NH_2	3-F-Phenyl
288	4	SO_2NH_2	2-F-Phenyl	1066	4	SO_2NH_2	3-F-Phenyl
289	1	H	4-F-Phenyl	1067	1	H	2-Cl-Phenyl
290	2	H	4-F-Phenyl	1068	2	H	2-Cl-Phenyl
291	3	H	4-F-Phenyl	1069	3	H	2-Cl-Phenyl
292	4	H	4-F-Phenyl	1070	4	H	2-Cl-Phenyl
293	1	Me	4-F-Phenyl	1071	1	Me	2-Cl-Phenyl
294	2	Me	4-F-Phenyl	1072	2	Me	2-Cl-Phenyl
295	3	Me	4-F-Phenyl	1073	3	Me	2-Cl-Phenyl
296	4	Me	4-F-Phenyl	1074	4	Me	2-Cl-Phenyl
297	1	CH_2Ph	4-F-Phenyl	1075	1	CH_2Ph	2-Cl-Phenyl
298	2	CH_2Ph	4-F-Phenyl	1076	2	CH_2Ph	2-Cl-Phenyl
299	3	CH_2Ph	4-F-Phenyl	1077	3	CH_2Ph	2-Cl-Phenyl
300	4	CH_2Ph	4-F-Phenyl	1078	4	CH_2Ph	2-Cl-Phenyl
301	1	COMe	4-F-Phenyl	1079	1	COMe	2-Cl-Phenyl
302	2	COMe	4-F-Phenyl	1080	2	COMe	2-Cl-Phenyl
303	3	COMe	4-F-Phenyl	1081	3	COMe	2-Cl-Phenyl
304	4	COMe	4-F-Phenyl	1082	4	COMe	2-Cl-Phenyl
305	1	CO_2Me	4-F-Phenyl	1083	1	CO_2Me	2-Cl-Phenyl
306	2	CO_2Me	4-F-Phenyl	1084	2	CO_2Me	2-Cl-Phenyl
307	3	CO_2Me	4-F-Phenyl	1085	3	CO_2Me	2-Cl-Phenyl
308	4	CO_2Me	4-F-Phenyl	1086	4	CO_2Me	2-Cl-Phenyl
309	1	CO_2tBu	4-F-Phenyl	1087	1	CO_2tBu	2-Cl-Phenyl
310	2	CO_2tBu	4-F-Phenyl	1088	2	CO_2tBu	2-Cl-Phenyl

311	3	CO_2tBu	4-F-Phenyl	1089	3	CO_2tBu	2-Cl-Phenyl
312	4	CO_2tBu	4-F-Phenyl	1090	4	CO_2tBu	2-Cl-Phenyl
313	1	CONHMe	4-F-Phenyl	1091	1	CONHMe	2-Cl-Phenyl
314	2	CONHMe	4-F-Phenyl	1092	2	CONHMe	2-Cl-Phenyl
315	3	CONHMe	4-F-Phenyl	1093	3	CONHMe	2-Cl-Phenyl
316	4	CONHMe	4-F-Phenyl	1094	4	CONHMe	2-Cl-Phenyl
317	1	SO_2Me	4-F-Phenyl	1095	1	SO_2Me	2-Cl-Phenyl
318	2	SO_2Me	4-F-Phenyl	1096	2	SO_2Me	2-Cl-Phenyl
319	3	SO_2Me	4-F-Phenyl	1097	3	SO_2Me	2-Cl-Phenyl
320	4	SO_2Me	4-F-Phenyl	1098	4	SO_2Me	2-Cl-Phenyl
321	1	SO_2NH_2	4-F-Phenyl	1099	1	SO_2NH_2	2-Cl-Phenyl
322	2	SO_2NH_2	4-F-Phenyl	1100	2	SO_2NH_2	2-Cl-Phenyl
323	3	SO_2NH_2	4-F-Phenyl	1101	3	SO_2NH_2	2-Cl-Phenyl
324	4	SO_2NH_2	4-F-Phenyl	1102	4	SO_2NH_2	2-Cl-Phenyl
325	1	H	3-Cl-Phenyl	1103	1	H	4-Cl-Phenyl
326	2	H	3-Cl-Phenyl	1104	2	H	4-Cl-Phenyl
327	3	H	3-Cl-Phenyl	1105	3	H	4-Cl-Phenyl
328	4	H	3-Cl-Phenyl	1106	4	H	4-Cl-Phenyl
329	1	Me	3-Cl-Phenyl	1107	1	Me	4-Cl-Phenyl
330	2	Me	3-Cl-Phenyl	1108	2	Me	4-Cl-Phenyl
331	3	Me	3-Cl-Phenyl	1109	3	Me	4-Cl-Phenyl
332	4	Me	3-Cl-Phenyl	1110	4	Me	4-Cl-Phenyl
333	1	CH_2Ph	3-Cl-Phenyl	1111	1	CH_2Ph	4-Cl-Phenyl
334	2	CH_2Ph	3-Cl-Phenyl	1112	2	CH_2Ph	4-Cl-Phenyl
335	3	CH_2Ph	3-Cl-Phenyl	1113	3	CH_2Ph	4-Cl-Phenyl
336	4	CH_2Ph	3-Cl-Phenyl	1114	4	CH_2Ph	4-Cl-Phenyl
337	1	COMe	3-Cl-Phenyl	1115	1	COMe	4-Cl-Phenyl
338	2	COMe	3-Cl-Phenyl	1116	2	COMe	4-Cl-Phenyl
339	3	COMe	3-Cl-Phenyl	1117	3	COMe	4-Cl-Phenyl
340	4	COMe	3-Cl-Phenyl	1118	4	COMe	4-Cl-Phenyl
341	1	CO_2Me	3-Cl-Phenyl	1119	1	CO_2Me	4-Cl-Phenyl

342	2	CO_2Me	3-Cl-Phenyl	1120	2	CO_2Me	4-Cl-Phenyl
343	3	CO_2Me	3-Cl-Phenyl	1121	3	CO_2Me	4-Cl-Phenyl
344	4	CO_2Me	3-Cl-Phenyl	1122	4	CO_2Me	4-Cl-Phenyl
345	1	CO_2tBu	3-Cl-Phenyl	1123	1	CO_2tBu	4-Cl-Phenyl
346	2	CO_2tBu	3-Cl-Phenyl	1124	2	CO_2tBu	4-Cl-Phenyl
347	3	CO_2tBu	3-Cl-Phenyl	1125	3	CO_2tBu	4-Cl-Phenyl
348	4	CO_2tBu	3-Cl-Phenyl	1126	4	CO_2tBu	4-Cl-Phenyl
349	1	CONHMe	3-Cl-Phenyl	1127	1	CONHMe	4-Cl-Phenyl
350	2	CONHMe	3-Cl-Phenyl	1128	2	CONHMe	4-Cl-Phenyl
351	3	CONHMe	3-Cl-Phenyl	1129	3	CONHMe	4-Cl-Phenyl
352	4	CONHMe	3-Cl-Phenyl	1130	4	CONHMe	4-Cl-Phenyl
353	1	SO_2Me	3-Cl-Phenyl	1131	1	SO_2Me	4-Cl-Phenyl
354	2	SO_2Me	3-Cl-Phenyl	1132	2	SO_2Me	4-Cl-Phenyl
355	3	SO_2Me	3-Cl-Phenyl	1133	3	SO_2Me	4-Cl-Phenyl
356	4	SO_2Me	3-Cl-Phenyl	1134	4	SO_2Me	4-Cl-Phenyl
357	1	SO_2NH_2	3-Cl-Phenyl	1135	1	SO_2NH_2	4-Cl-Phenyl
358	2	SO_2NH_2	3-Cl-Phenyl	1136	2	SO_2NH_2	4-Cl-Phenyl
359	3	SO_2NH_2	3-Cl-Phenyl	1137	3	SO_2NH_2	4-Cl-Phenyl
360	4	SO_2NH_2	3-Cl-Phenyl	1138	4	SO_2NH_2	4-Cl-Phenyl
361	1	H	2-Br-Phenyl	1139	1	H	3-Br-Phenyl
362	2	H	2-Br-Phenyl	1140	2	H	3-Br-Phenyl
363	3	H	2-Br-Phenyl	1141	3	H	3-Br-Phenyl
364	4	H	2-Br-Phenyl	1142	4	H	3-Br-Phenyl
365	1	Me	2-Br-Phenyl	1143	1	Me	3-Br-Phenyl
366	2	Me	2-Br-Phenyl	1144	2	Me	3-Br-Phenyl
367	3	Me	2-Br-Phenyl	1145	3	Me	3-Br-Phenyl
368	4	Me	2-Br-Phenyl	1146	4	Me	3-Br-Phenyl
369	1	CH_2Ph	2-Br-Phenyl	1147	1	CH_2Ph	3-Br-Phenyl
370	2	CH_2Ph	2-Br-Phenyl	1148	2	CH_2Ph	3-Br-Phenyl
371	3	CH_2Ph	2-Br-Phenyl	1149	3	CH_2Ph	3-Br-Phenyl
372	4	CH_2Ph	2-Br-Phenyl	1150	4	CH_2Ph	3-Br-Phenyl

373	1	COMe	2-Br-Phenyl	1151	1	COMe	3-Br-Phenyl
374	2	COMe	2-Br-Phenyl	1152	2	COMe	3-Br-Phenyl
375	3	COMe	2-Br-Phenyl	1153	3	COMe	3-Br-Phenyl
376	4	COMe	2-Br-Phenyl	1154	4	COMe	3-Br-Phenyl
377	1	CO_2Me	2-Br-Phenyl	1155	1	CO_2Me	3-Br-Phenyl
378	2	CO_2Me	2-Br-Phenyl	1156	2	CO_2Me	3-Br-Phenyl
379	3	CO_2Me	2-Br-Phenyl	1157	3	CO_2Me	3-Br-Phenyl
380	4	CO_2Me	2-Br-Phenyl	1158	4	CO_2Me	3-Br-Phenyl
381	1	CO_2tBu	2-Br-Phenyl	1159	1	CO_2tBu	3-Br-Phenyl
382	2	CO_2tBu	2-Br-Phenyl	1160	2	CO_2tBu	3-Br-Phenyl
383	3	CO_2tBu	2-Br-Phenyl	1161	3	CO_2tBu	3-Br-Phenyl
384	4	CO_2tBu	2-Br-Phenyl	1162	4	CO_2tBu	3-Br-Phenyl
385	1	CONHMe	2-Br-Phenyl	1163	1	CONHMe	3-Br-Phenyl
386	2	CONHMe	2-Br-Phenyl	1164	2	CONHMe	3-Br-Phenyl
387	3	CONHMe	2-Br-Phenyl	1165	3	CONHMe	3-Br-Phenyl
388	4	CONHMe	2-Br-Phenyl	1166	4	CONHMe	3-Br-Phenyl
389	1	SO_2Me	2-Br-Phenyl	1167	1	SO_2Me	3-Br-Phenyl
390	2	SO_2Me	2-Br-Phenyl	1168	2	SO_2Me	3-Br-Phenyl
391	3	SO_2Me	2-Br-Phenyl	1169	3	SO_2Me	3-Br-Phenyl
392	4	SO_2Me	2-Br-Phenyl	1170	4	SO_2Me	3-Br-Phenyl
393	1	SO_2NH_2	2-Br-Phenyl	1171	1	SO_2NH_2	3-Br-Phenyl
394	2	SO_2NH_2	2-Br-Phenyl	1172	2	SO_2NH_2	3-Br-Phenyl
395	3	SO_2NH_2	2-Br-Phenyl	1173	3	SO_2NH_2	3-Br-Phenyl
396	4	SO_2NH_2	2-Br-Phenyl	1174	4	SO_2NH_2	3-Br-Phenyl
397	1	H	4-Br-Phenyl	1175	1	H	2-CF_3-Phenyl
398	2	H	4-Br-Phenyl	1176	2	H	2-CF_3-Phenyl
399	3	H	4-Br-Phenyl	1177	3	H	2-CF_3-Phenyl
400	4	H	4-Br-Phenyl	1178	4	H	2-CF_3-Phenyl
401	1	Me	4-Br-Phenyl	1179	1	Me	2-CF_3-Phenyl
402	2	Me	4-Br-Phenyl	1180	2	Me	2-CF_3-Phenyl
403	3	Me	4-Br-Phenyl	1181	3	Me	2-CF_3-Phenyl

404	4	Me	4-Br-Phenyl	1182	4	Me	2-CF_3-Phenyl
405	1	CH_2Ph	4-Br-Phenyl	1183	1	CH_2Ph	2-CF_3-Phenyl
406	2	CH_2Ph	4-Br-Phenyl	1184	2	CH_2Ph	2-CF_3-Phenyl
407	3	CH_2Ph	4-Br-Phenyl	1185	3	CH_2Ph	2-CF_3-Phenyl
408	4	CH_2Ph	4-Br-Phenyl	1186	4	CH_2Ph	2-CF_3-Phenyl
409	1	COMe	4-Br-Phenyl	1187	1	COMe	2-CF_3-Phenyl
410	2	COMe	4-Br-Phenyl	1188	2	COMe	2-CF_3-Phenyl
411	3	COMe	4-Br-Phenyl	1189	3	COMe	2-CF_3-Phenyl
412	4	COMe	4-Br-Phenyl	1190	4	COMe	2-CF_3-Phenyl
413	1	CO_2Me	4-Br-Phenyl	1191	1	CO_2Me	2-CF_3-Phenyl
414	2	CO_2Me	4-Br-Phenyl	1192	2	CO_2Me	2-CF_3-Phenyl
415	3	CO_2Me	4-Br-Phenyl	1193	3	CO_2Me	2-CF_3-Phenyl
416	4	CO_2Me	4-Br-Phenyl	1194	4	CO_2Me	2-CF_3-Phenyl
417	1	CO_2tBu	4-Br-Phenyl	1195	1	CO_2tBu	2-CF_3-Phenyl
418	2	CO_2tBu	4-Br-Phenyl	1196	2	CO_2tBu	2-CF_3-Phenyl
419	3	CO_2tBu	4-Br-Phenyl	1197	3	CO_2tBu	2-CF_3-Phenyl
420	4	CO_2tBu	4-Br-Phenyl	1198	4	CO_2tBu	2-CF_3-Phenyl
421	1	CONHMe	4-Br-Phenyl	1199	1	CONHMe	2-CF_3-Phenyl
422	2	CONHMe	4-Br-Phenyl	1200	2	CONHMe	2-CF_3-Phenyl
423	3	CONHMe	4-Br-Phenyl	1201	3	CONHMe	2-CF_3-Phenyl
424	4	CONHMe	4-Br-Phenyl	1202	4	CONHMe	2-CF_3-Phenyl
425	1	SO_2Me	4-Br-Phenyl	1203	1	SO_2Me	2-CF_3-Phenyl
426	2	SO_2Me	4-Br-Phenyl	1204	2	SO_2Me	2-CF_3-Phenyl
427	3	SO_2Me	4-Br-Phenyl	1205	3	SO_2Me	2-CF_3-Phenyl
428	4	SO_2Me	4-Br-Phenyl	1206	4	SO_2Me	2-CF_3-Phenyl
429	1	SO_2NH_2	4-Br-Phenyl	1207	1	SO_2NH_2	2-CF_3-Phenyl
430	2	SO_2NH_2	4-Br-Phenyl	1208	2	SO_2NH_2	2-CF_3-Phenyl
431	3	SO_2NH_2	4-Br-Phenyl	1209	3	SO_2NH_2	2-CF_3-Phenyl
432	4	SO_2NH_2	4-Br-Phenyl	1210	4	SO_2NH_2	2-CF_3-Phenyl
433	1	H	3-CF_3-Phenyl	1211	1	H	4-CF_3-Phenyl
434	2	H	3-CF_3-Phenyl	1212	2	H	4-CF_3-Phenyl

435	3	H	3-CF_3-Phenyl	1213	3	H	4-CF_3-Phenyl
436	4	H	3-CF_3-Phenyl	1214	4	H	4-CF_3-Phenyl
437	1	Me	3-CF_3-Phenyl	1215	1	Me	4-CF_3-Phenyl
438	2	Me	3-CF_3-Phenyl	1216	2	Me	4-CF_3-Phenyl
439	3	Me	3-CF_3-Phenyl	1217	3	Me	4-CF_3-Phenyl
440	4	Me	3-CF_3-Phenyl	1218	4	Me	4-CF_3-Phenyl
441	1	CH_2Ph	3-CF_3-Phenyl	1219	1	CH_2Ph	4-CF_3-Phenyl
442	2	CH_2Ph	3-CF_3-Phenyl	1220	2	CH_2Ph	4-CF_3-Phenyl
443	3	CH_2Ph	3-CF_3-Phenyl	1221	3	CH_2Ph	4-CF_3-Phenyl
444	4	CH_2Ph	3-CF_3-Phenyl	1222	4	CH_2Ph	4-CF_3-Phenyl
445	1	COMe	3-CF_3-Phenyl	1223	1	COMe	4-CF_3-Phenyl
446	2	COMe	3-CF_3-Phenyl	1224	2	COMe	4-CF_3-Phenyl
447	3	COMe	3-CF_3-Phenyl	1225	3	COMe	4-CF_3-Phenyl
448	4	COMe	3-CF_3-Phenyl	1226	4	COMe	4-CF_3-Phenyl
449	1	CO_2Me	3-CF_3-Phenyl	1227	1	CO_2Me	4-CF_3-Phenyl
450	2	CO_2Me	3-CF_3-Phenyl	1228	2	CO_2Me	4-CF_3-Phenyl
451	3	CO_2Me	3-CF_3-Phenyl	1229	3	CO_2Me	4-CF_3-Phenyl
452	4	CO_2Me	3-CF_3-Phenyl	1230	4	CO_2Me	4-CF_3-Phenyl
453	1	CO_2tBu	3-CF_3-Phenyl	1231	1	CO_2tBu	4-CF_3-Phenyl
454	2	CO_2tBu	3-CF_3-Phenyl	1232	2	CO_2tBu	4-CF_3-Phenyl
455	3	CO_2tBu	3-CF_3-Phenyl	1233	3	CO_2tBu	4-CF_3-Phenyl
456	4	CO_2tBu	3-CF_3-Phenyl	1234	4	CO_2tBu	4-CF_3-Phenyl
457	1	CONHMe	3-CF_3-Phenyl	1235	1	CONHMe	4-CF_3-Phenyl
458	2	CONHMe	3-CF_3-Phenyl	1236	2	CONHMe	4-CF_3-Phenyl
459	3	CONHMe	3-CF_3-Phenyl	1237	3	CONHMe	4-CF_3-Phenyl
460	4	CONHMe	3-CF_3-Phenyl	1238	4	CONHMe	4-CF_3-Phenyl
461	1	SO_2Me	3-CF_3-Phenyl	1239	1	SO_2Me	4-CF_3-Phenyl
462	2	SO_2Me	3-CF_3-Phenyl	1240	2	SO_2Me	4-CF_3-Phenyl
463	3	SO_2Me	3-CF_3-Phenyl	1241	3	SO_2Me	4-CF_3-Phenyl
464	4	SO_2Me	3-CF_3-Phenyl	1242	4	SO_2Me	4-CF_3-Phenyl
465	1	SO_2NH_2	3-CF_3-Phenyl	1243	1	SO_2NH_2	4-CF_3-Phenyl

466	2	SO_2NH_2	3-CF_3-Phenyl	1244	2	SO_2NH_2	4-CF_3-Phenyl
467	3	SO_2NH_2	3-CF_3-Phenyl	1245	3	SO_2NH_2	4-CF_3-Phenyl
468	4	SO_2NH_2	3-CF_3-Phenyl	1246	4	SO_2NH_2	4-CF_3-Phenyl
469	1	H	2-iPr-Phenyl	1247	1	H	3-iPr-Phenyl
470	2	H	2-iPr-Phenyl	1248	2	H	3-iPr-Phenyl
471	3	H	2-iPr-Phenyl	1249	3	H	3-iPr-Phenyl
472	4	H	2-iPr-Phenyl	1250	4	H	3-iPr-Phenyl
473	1	Me	2-iPr-Phenyl	1251	1	Me	3-iPr-Phenyl
474	2	Me	2-iPr-Phenyl	1252	2	Me	3-iPr-Phenyl
475	3	Me	2-iPr-Phenyl	1253	3	Me	3-iPr-Phenyl
476	4	Me	2-iPr-Phenyl	1254	4	Me	3-iPr-Phenyl
477	1	CH_2Ph	2-iPr-Phenyl	1255	1	CH_2Ph	3-iPr-Phenyl
478	2	CH_2Ph	2-iPr-Phenyl	1256	2	CH_2Ph	3-iPr-Phenyl
479	3	CH_2Ph	2-iPr-Phenyl	1257	3	CH_2Ph	3-iPr-Phenyl
480	4	CH_2Ph	2-iPr-Phenyl	1258	4	CH_2Ph	3-iPr-Phenyl
481	1	COMe	2-iPr-Phenyl	1259	1	COMe	3-iPr-Phenyl
482	2	COMe	2-iPr-Phenyl	1260	2	COMe	3-iPr-Phenyl
483	3	COMe	2-iPr-Phenyl	1261	3	COMe	3-iPr-Phenyl
484	4	COMe	2-iPr-Phenyl	1262	4	COMe	3-iPr-Phenyl
485	1	CO_2Me	2-iPr-Phenyl	1263	1	CO_2Me	3-iPr-Phenyl
486	2	CO_2Me	2-iPr-Phenyl	1264	2	CO_2Me	3-iPr-Phenyl
487	3	CO_2Me	2-iPr-Phenyl	1265	3	CO_2Me	3-iPr-Phenyl
488	4	CO_2Me	2-iPr-Phenyl	1266	4	CO_2Me	3-iPr-Phenyl
489	1	CO_2tBu	2-iPr-Phenyl	1267	1	CO_2tBu	3-iPr-Phenyl
490	2	CO_2tBu	2-iPr-Phenyl	1268	2	CO_2tBu	3-iPr-Phenyl
491	3	CO_2tBu	2-iPr-Phenyl	1269	3	CO_2tBu	3-iPr-Phenyl
492	4	CO_2tBu	2-iPr-Phenyl	1270	4	CO_2tBu	3-iPr-Phenyl
493	1	CONHMe	2-iPr-Phenyl	1271	1	CONHMe	3-iPr-Phenyl
494	2	CONHMe	2-iPr-Phenyl	1272	2	CONHMe	3-iPr-Phenyl
495	3	CONHMe	2-iPr-Phenyl	1273	3	CONHMe	3-iPr-Phenyl
496	4	CONHMe	2-iPr-Phenyl	1274	4	CONHMe	3-iPr-Phenyl

497	1	SO_2Me	2-iPr-Phenyl	1275	1	SO_2Me	3-iPr-Phenyl
498	2	SO_2Me	2-iPr-Phenyl	1276	2	SO_2Me	3-iPr-Phenyl
499	3	SO_2Me	2-iPr-Phenyl	1277	3	SO_2Me	3-iPr-Phenyl
500	4	SO_2Me	2-iPr-Phenyl	1278	4	SO_2Me	3-iPr-Phenyl
501	1	SO_2NH_2	2-iPr-Phenyl	1279	1	SO_2NH_2	3-iPr-Phenyl
502	2	SO_2NH_2	2-iPr-Phenyl	1280	2	SO_2NH_2	3-iPr-Phenyl
503	3	SO_2NH_2	2-iPr-Phenyl	1281	3	SO_2NH_2	3-iPr-Phenyl
504	4	SO_2NH_2	2-iPr-Phenyl	1282	4	SO_2NH_2	3-iPr-Phenyl
505	1	H	4-iPr-Phenyl	1283	1	H	4-NH_2-Phenyl
506	2	H	4-iPr-Phenyl	1284	2	H	4-NH_2-Phenyl
507	3	H	4-iPr-Phenyl	1285	3	H	4-NH_2-Phenyl
508	4	H	4-iPr-Phenyl	1286	4	H	4-NH_2-Phenyl
509	1	Me	4-iPr-Phenyl	1287	1	Me	4-NH_2-Phenyl
510	2	Me	4-iPr-Phenyl	1288	2	Me	4-NH_2-Phenyl
511	3	Me	4-iPr-Phenyl	1289	3	Me	4-NH_2-Phenyl
512	4	Me	4-iPr-Phenyl	1290	4	Me	4-NH_2-Phenyl
513	1	CH_2Ph	4-iPr-Phenyl	1291	1	CH_2Ph	4-NH_2-Phenyl
514	2	CH_2Ph	4-iPr-Phenyl	1292	2	CH_2Ph	4-NH_2-Phenyl
515	3	CH_2Ph	4-iPr-Phenyl	1293	3	CH_2Ph	4-NH_2-Phenyl
516	4	CH_2Ph	4-iPr-Phenyl	1294	4	CH_2Ph	4-NH_2-Phenyl
517	1	COMe	4-iPr-Phenyl	1295	1	COMe	4-NH_2-Phenyl
518	2	COMe	4-iPr-Phenyl	1296	2	COMe	4-NH_2-Phenyl
519	3	COMe	4-iPr-Phenyl	1297	3	COMe	4-NH_2-Phenyl
520	4	COMe	4-iPr-Phenyl	1298	4	COMe	4-NH_2-Phenyl
521	1	CO_2Me	4-iPr-Phenyl	1299	1	CO_2Me	4-NH_2-Phenyl
522	2	CO_2Me	4-iPr-Phenyl	1300	2	CO_2Me	4-NH_2-Phenyl
523	3	CO_2Me	4-iPr-Phenyl	1301	3	CO_2Me	4-NH_2-Phenyl
524	4	CO_2Me	4-iPr-Phenyl	1302	4	CO_2Me	4-NH_2-Phenyl
525	1	CO_2tBu	4-iPr-Phenyl	1303	1	CO_2tBu	4-NH_2-Phenyl
526	2	CO_2tBu	4-iPr-Phenyl	1304	2	CO_2tBu	4-NH_2-Phenyl
527	3	CO_2tBu	4-iPr-Phenyl	1305	3	CO_2tBu	4-NH_2-Phenyl

528	4	CO_2tBu	4-iPr-Phenyl	1306	4	CO_2tBu	4-NH_2-Phenyl
529	1	CONHMe	4-iPr-Phenyl	1307	1	CONHMe	4-NH_2-Phenyl
530	2	CONHMe	4-iPr-Phenyl	1308	2	CONHMe	4-NH_2-Phenyl
531	3	CONHMe	4-iPr-Phenyl	1309	3	CONHMe	4-NH_2-Phenyl
532	4	CONHMe	4-iPr-Phenyl	1310	4	CONHMe	4-NH_2-Phenyl
533	1	SO_2Me	4-iPr-Phenyl	1311	1	SO_2Me	4-NH_2-Phenyl
534	2	SO_2Me	4-iPr-Phenyl	1312	2	SO_2Me	4-NH_2-Phenyl
535	3	SO_2Me	4-iPr-Phenyl	1313	3	SO_2Me	4-NH_2-Phenyl
536	4	SO_2Me	4-iPr-Phenyl	1314	4	SO_2Me	4-NH_2-Phenyl
537	1	SO_2NH_2	4-iPr-Phenyl	1315	1	SO_2NH_2	4-NH_2-Phenyl
538	2	SO_2NH_2	4-iPr-Phenyl	1316	2	SO_2NH_2	4-NH_2-Phenyl
539	3	SO_2NH_2	4-iPr-Phenyl	1317	3	SO_2NH_2	4-NH_2-Phenyl
540	4	SO_2NH_2	4-iPr-Phenyl	1318	4	SO_2NH_2	4-NH_2-Phenyl
541	1	H	3-NH_2-Phenyl	1319	1	H	2-NH_2-Phenyl
542	2	H	3-NH_2-Phenyl	1320	2	H	2-NH_2-Phenyl
543	3	H	3-NH_2-Phenyl	1321	3	H	2-NH_2-Phenyl
544	4	H	3-NH_2-Phenyl	1322	4	H	2-NH_2-Phenyl
545	1	Me	3-NH_2-Phenyl	1323	1	Me	2-NH_2-Phenyl
546	2	Me	3-NH_2-Phenyl	1324	2	Me	2-NH_2-Phenyl
547	3	Me	3-NH_2-Phenyl	1325	3	Me	2-NH_2-Phenyl
548	4	Me	3-NH_2-Phenyl	1326	4	Me	2-NH_2-Phenyl
549	1	CH_2Ph	3-NH_2-Phenyl	1327	1	CH_2Ph	2-NH_2-Phenyl
550	2	CH_2Ph	3-NH_2-Phenyl	1328	2	CH_2Ph	2-NH_2-Phenyl
551	3	CH_2Ph	3-NH_2-Phenyl	1329	3	CH_2Ph	2-NH_2-Phenyl
552	4	CH_2Ph	3-NH_2-Phenyl	1330	4	CH_2Ph	2-NH_2-Phenyl
553	1	COMe	3-NH_2-Phenyl	1331	1	COMe	2-NH_2-Phenyl
554	2	COMe	3-NH_2-Phenyl	1332	2	COMe	2-NH_2-Phenyl
555	3	COMe	3-NH_2-Phenyl	1333	3	COMe	2-NH_2-Phenyl
556	4	COMe	3-NH_2-Phenyl	1334	4	COMe	2-NH_2-Phenyl
557	1	CO_2Me	3-NH_2-Phenyl	1335	1	CO_2Me	2-NH_2-Phenyl
558	2	CO_2Me	3-NH_2-Phenyl	1336	2	CO_2Me	2-NH_2-Phenyl

559	3	CO_2Me	3-NH_2-Phenyl	1337	3	CO_2Me	2-NH_2-Phenyl
560	4	CO_2Me	3-NH_2-Phenyl	1338	4	CO_2Me	2-NH_2-Phenyl
561	1	CO_2tBu	3-NH_2-Phenyl	1339	1	CO_2tBu	2-NH_2-Phenyl
562	2	CO_2tBu	3-NH_2-Phenyl	1340	2	CO_2tBu	2-NH_2-Phenyl
563	3	CO_2tBu	3-NH_2-Phenyl	1341	3	CO_2tBu	2-NH_2-Phenyl
564	4	CO_2tBu	3-NH_2-Phenyl	1342	4	CO_2tBu	2-NH_2-Phenyl
565	1	CONHMe	3-NH_2-Phenyl	1343	1	CONHMe	2-NH_2-Phenyl
566	2	CONHMe	3-NH_2-Phenyl	1344	2	CONHMe	2-NH_2-Phenyl
567	3	CONHMe	3-NH_2-Phenyl	1345	3	CONHMe	2-NH_2-Phenyl
568	4	CONHMe	3-NH_2-Phenyl	1346	4	CONHMe	2-NH_2-Phenyl
569	1	SO_2Me	3-NH_2-Phenyl	1347	1	SO_2Me	2-NH_2-Phenyl
570	2	SO_2Me	3-NH_2-Phenyl	1348	2	SO_2Me	2-NH_2-Phenyl
571	3	SO_2Me	3-NH_2-Phenyl	1349	3	SO_2Me	2-NH_2-Phenyl
572	4	SO_2Me	3-NH_2-Phenyl	1350	4	SO_2Me	2-NH_2-Phenyl
573	1	SO_2NH_2	3-NH_2-Phenyl	1351	1	SO_2NH_2	2-NH_2-Phenyl
574	2	SO_2NH_2	3-NH_2-Phenyl	1352	2	SO_2NH_2	2-NH_2-Phenyl
575	3	SO_2NH_2	3-NH_2-Phenyl	1353	3	SO_2NH_2	2-NH_2-Phenyl
576	4	SO_2NH_2	3-NH_2-Phenyl	1354	4	SO_2NH_2	2-NH_2-Phenyl
577	1	H	2,4-di-Me-Phenyl	1355	1	H	2,6-di-Me-Phenyl
578	2	H	2,4-di-Me-Phenyl	1356	2	H	2,6-di-Me-Phenyl
579	3	H	2,4-di-Me-Phenyl	1357	3	H	2,6-di-Me-Phenyl
580	4	H	2,4-di-Me-Phenyl	1358	4	H	2,6-di-Me-Phenyl
581	1	Me	2,4-di-Me-Phenyl	1359	1	Me	2,6-di-Me-Phenyl
582	2	Me	2,4-di-Me-Phenyl	1360	2	Me	2,6-di-Me-Phenyl
583	3	Me	2,4-di-Me-Phenyl	1361	3	Me	2,6-di-Me-Phenyl
584	4	Me	2,4-di-Me-Phenyl	1362	4	Me	2,6-di-Me-Phenyl
585	1	CH_2Ph	2,4-di-Me-Phenyl	1363	1	CH_2Ph	2,6-di-Me-Phenyl
586	2	CH_2Ph	2,4-di-Me-Phenyl	1364	2	CH_2Ph	2,6-di-Me-Phenyl
587	3	CH_2Ph	2,4-di-Me-Phenyl	1365	3	CH_2Ph	2,6-di-Me-Phenyl
588	4	CH_2Ph	2,4-di-Me-Phenyl	1366	4	CH_2Ph	2,6-di-Me-Phenyl
589	1	COMe	2,4-di-Me-Phenyl	1367	1	COMe	2,6-di-Me-Phenyl

590	2	COMe	2,4-di-Me-Phenyl	1368	2	COMe	2,6-di-Me-Phenyl
591	3	COMe	2,4-di-Me-Phenyl	1369	3	COMe	2,6-di-Me-Phenyl
592	4	COMe	2,4-di-Me-Phenyl	1370	4	COMe	2,6-di-Me-Phenyl
593	1	CO_2Me	2,4-di-Me-Phenyl	1371	1	CO_2Me	2,6-di-Me-Phenyl
594	2	CO_2Me	2,4-di-Me-Phenyl	1372	2	CO_2Me	2,6-di-Me-Phenyl
595	3	CO_2Me	2,4-di-Me-Phenyl	1373	3	CO_2Me	2,6-di-Me-Phenyl
596	4	CO_2Me	2,4-di-Me-Phenyl	1374	4	CO_2Me	2,6-di-Me-Phenyl
597	1	CO_2tBu	2,4-di-Me-Phenyl	1375	1	CO_2tBu	2,6-di-Me-Phenyl
598	2	CO_2tBu	2,4-di-Me-Phenyl	1376	2	CO_2tBu	2,6-di-Me-Phenyl
599	3	CO_2tBu	2,4-di-Me-Phenyl	1377	3	CO_2tBu	2,6-di-Me-Phenyl
600	4	CO_2tBu	2,4-di-Me-Phenyl	1378	4	CO_2tBu	2,6-di-Me-Phenyl
601	1	CONHMe	2,4-di-Me-Phenyl	1379	1	CONHMe	2,6-di-Me-Phenyl
602	2	CONHMe	2,4-di-Me-Phenyl	1380	2	CONHMe	2,6-di-Me-Phenyl
603	3	CONHMe	2,4-di-Me-Phenyl	1381	3	CONHMe	2,6-di-Me-Phenyl
604	4	CONHMe	2,4-di-Me-Phenyl	1382	4	CONHMe	2,6-di-Me-Phenyl
605	1	SO_2Me	2,4-di-Me-Phenyl	1383	1	SO_2Me	2,6-di-Me-Phenyl
606	2	SO_2Me	2,4-di-Me-Phenyl	1384	2	SO_2Me	2,6-di-Me-Phenyl
607	3	SO_2Me	2,4-di-Me-Phenyl	1385	3	SO_2Me	2,6-di-Me-Phenyl
608	4	SO_2Me	2,4-di-Me-Phenyl	1386	4	SO_2Me	2,6-di-Me-Phenyl
609	1	SO_2NH_2	2,4-di-Me-Phenyl	1387	1	SO_2NH_2	2,6-di-Me-Phenyl
610	2	SO_2NH_2	2,4-di-Me-Phenyl	1388	2	SO_2NH_2	2,6-di-Me-Phenyl
611	3	SO_2NH_2	2,4-di-Me-Phenyl	1389	3	SO_2NH_2	2,6-di-Me-Phenyl
612	4	SO_2NH_2	2,4-di-Me-Phenyl	1390	4	SO_2NH_2	2,6-di-Me-Phenyl
613	1	H	2,6-di-iPr-Phenyl	1391	1	H	2-Ph-Phenyl
614	2	H	2,6-di-iPr-Phenyl	1392	2	H	2-Ph-Phenyl
615	3	H	2,6-di-iPr-Phenyl	1393	3	H	2-Ph-Phenyl
616	4	H	2,6-di-iPr-Phenyl	1394	4	H	2-Ph-Phenyl
617	1	Me	2,6-di-iPr-Phenyl	1395	1	Me	2-Ph-Phenyl
618	2	Me	2,6-di-iPr-Phenyl	1396	2	Me	2-Ph-Phenyl
619	3	Me	2,6-di-iPr-Phenyl	1397	3	Me	2-Ph-Phenyl
620	4	Me	2,6-di-iPr-Phenyl	1398	4	Me	2-Ph-Phenyl

621	1	CH_2Ph	2,6-di-iPr-Phenyl	1399	1	CH_2Ph	2-Ph-Phenyl
622	2	CH_2Ph	2,6-di-iPr-Phenyl	1400	2	CH_2Ph	2-Ph-Phenyl
623	3	CH_2Ph	2,6-di-iPr-Phenyl	1401	3	CH_2Ph	2-Ph-Phenyl
624	3	CH_2Ph	2,6-di-iPr-Phenyl	1402	4	CH_2Ph	2-Ph-Phenyl
625	1	COMe	2,6-di-iPr-Phenyl	1403	1	COMe	2-Ph-Phenyl
626	2	COMe	2,6-di-iPr-Phenyl	1404	2	COMe	2-Ph-Phenyl
627	3	COMe	2,6-di-iPr-Phenyl	1405	3	COMe	2-Ph-Phenyl
628	4	COMe	2,6-di-iPr-Phenyl	1406	4	COMe	2-Ph-Phenyl
629	1	CO_2Me	2,6-di-iPr-Phenyl	1407	1	CO_2Me	2-Ph-Phenyl
630	2	CO_2Me	2,6-di-iPr-Phenyl	1408	2	CO_2Me	2-Ph-Phenyl
631	3	CO_2Me	2,6-di-iPr-Phenyl	1409	3	CO_2Me	2-Ph-Phenyl
632	4	CO_2Me	2,6-di-iPr-Phenyl	1410	4	CO_2Me	2-Ph-Phenyl
633	1	CO_2tBu	2,6-di-iPr-Phenyl	1411	1	CO_2tBu	2-Ph-Phenyl
634	2	CO_2tBu	2,6-di-iPr-Phenyl	1412	2	CO_2tBu	2-Ph-Phenyl
635	3	CO_2tBu	2,6-di-iPr-Phenyl	1413	3	CO_2tBu	2-Ph-Phenyl
636	4	CO_2tBu	2,6-di-iPr-Phenyl	1414	4	CO_2tBu	2-Ph-Phenyl
637	1	CONHMe	2,6-di-iPr-Phenyl	1415	1	CONHMe	2-Ph-Phenyl
638	2	CONHMe	2,6-di-iPr-Phenyl	1416	2	CONHMe	2-Ph-Phenyl
639	3	CONHMe	2,6-di-iPr-Phenyl	1417	3	CONHMe	2-Ph-Phenyl
640	4	CONHMe	2,6-di-iPr-Phenyl	1418	4	CONHMe	2-Ph-Phenyl
641	1	SO_2Me	2,6-di-iPr-Phenyl	1419	1	SO_2Me	2-Ph-Phenyl
642	2	SO_2Me	2,6-di-iPr-Phenyl	1420	2	SO_2Me	2-Ph-Phenyl
643	3	SO_2Me	2,6-di-iPr-Phenyl	1421	3	SO_2Me	2-Ph-Phenyl
644	4	SO_2Me	2,6-di-iPr-Phenyl	1422	4	SO_2Me	2-Ph-Phenyl
645	1	SO_2NH_2	2,6-di-iPr-Phenyl	1423	1	SO_2NH_2	2-Ph-Phenyl
646	2	SO_2NH_2	2,6-di-iPr-Phenyl	1424	2	SO_2NH_2	2-Ph-Phenyl
647	3	SO_2NH_2	2,6-di-iPr-Phenyl	1425	3	SO_2NH_2	2-Ph-Phenyl
648	4	SO_2NH_2	2,6-di-iPr-Phenyl	1426	4	SO_2NH_2	2-Ph-Phenyl
649	1	H	3-Ph-Phenyl	1427	1	H	4-Ph-Phenyl
650	2	H	3-Ph-Phenyl	1428	2	H	4-Ph-Phenyl
651	3	H	3-Ph-Phenyl	1429	3	H	4-Ph-Phenyl

652	4	H	3-Ph-Phenyl	1430	4	H	4-Ph-Phenyl
653	1	Me	3-Ph-Phenyl	1431	1	Me	4-Ph-Phenyl
654	2	Me	3-Ph-Phenyl	1432	2	Me	4-Ph-Phenyl
655	3	Me	3-Ph-Phenyl	1433	3	Me	4-Ph-Phenyl
656	4	Me	3-Ph-Phenyl	1434	4	Me	4-Ph-Phenyl
657	1	CH_2Ph	3-Ph-Phenyl	1435	1	CH_2Ph	4-Ph-Phenyl
658	2	CH_2Ph	3-Ph-Phenyl	1436	2	CH_2Ph	4-Ph-Phenyl
659	3	CH_2Ph	3-Ph-Phenyl	1437	3	CH_2Ph	4-Ph-Phenyl
660	4	CH_2Ph	3-Ph-Phenyl	1438	4	CH_2Ph	4-Ph-Phenyl
661	1	COMe	3-Ph-Phenyl	1439	1	COMe	4-Ph-Phenyl
662	2	COMe	3-Ph-Phenyl	1440	2	COMe	4-Ph-Phenyl
663	3	COMe	3-Ph-Phenyl	1441	3	COMe	4-Ph-Phenyl
664	4	COMe	3-Ph-Phenyl	1442	4	COMe	4-Ph-Phenyl
665	1	CO_2Me	3-Ph-Phenyl	1443	1	CO_2Me	4-Ph-Phenyl
666	2	CO_2Me	3-Ph-Phenyl	1444	2	CO_2Me	4-Ph-Phenyl
667	3	CO_2Me	3-Ph-Phenyl	1445	3	CO_2Me	4-Ph-Phenyl
668	4	CO_2Me	3-Ph-Phenyl	1446	4	CO_2Me	4-Ph-Phenyl
669	1	CO_2tBu	3-Ph-Phenyl	1447	1	CO_2tBu	4-Ph-Phenyl
670	2	CO_2tBu	3-Ph-Phenyl	1448	2	CO_2tBu	4-Ph-Phenyl
671	3	CO_2tBu	3-Ph-Phenyl	1449	3	CO_2tBu	4-Ph-Phenyl
672	4	CO_2tBu	3-Ph-Phenyl	1450	4	CO_2tBu	4-Ph-Phenyl
673	1	CONHMe	3-Ph-Phenyl	1451	1	CONHMe	4-Ph-Phenyl
674	2	CONHMe	3-Ph-Phenyl	1452	2	CONHMe	4-Ph-Phenyl
675	3	CONHMe	3-Ph-Phenyl	1453	3	CONHMe	4-Ph-Phenyl
676	4	CONHMe	3-Ph-Phenyl	1454	4	CONHMe	4-Ph-Phenyl
677	1	SO_2Me	3-Ph-Phenyl	1455	1	SO_2Me	4-Ph-Phenyl
678	2	SO_2Me	3-Ph-Phenyl	1456	2	SO_2Me	4-Ph-Phenyl
679	3	SO_2Me	3-Ph-Phenyl	1457	3	SO_2Me	4-Ph-Phenyl
680	4	SO_2Me	3-Ph-Phenyl	1458	4	SO_2Me	4-Ph-Phenyl
681	1	SO_2NH_2	3-Ph-Phenyl	1459	1	SO_2NH_2	4-Ph-Phenyl
682	2	SO_2NH_2	3-Ph-Phenyl	1460	2	SO_2NH_2	4-Ph-Phenyl

683	3	SO_2NH_2	3-Ph-Phenyl	1461	3	SO_2NH_2	4-Ph-Phenyl
684	4	SO_2NH_2	3-Ph-Phenyl	1462	4	SO_2NH_2	4-Ph-Phenyl
685	1	H	2-morpholino-phenyl	1463	1	H	3-morpholino-phenyl
686	2	H	2-morpholino-phenyl	1464	2	H	3-morpholino-phenyl
687	3	H	2-morpholino-phenyl	1465	3	H	3-morpholino-phenyl
688	4	H	2-morpholino-phenyl	1466	4	H	3-morpholino-phenyl
689	1	Me	2-morpholino-phenyl	1467	1	Me	3-morpholino-phenyl
690	2	Me	2-morpholino-phenyl	1468	2	Me	3-morpholino-phenyl
691	3	Me	2-morpholino-phenyl	1469	3	Me	3-morpholino-phenyl
692	4	Me	2-morpholino-phenyl	1470	4	Me	3-morpholino-phenyl
693	1	CH_2Ph	2-morpholino-phenyl	1471	1	CH_2Ph	3-morpholino-phenyl
694	2	CH_2Ph	2-morpholino-phenyl	1472	2	CH_2Ph	3-morpholino-phenyl
695	3	CH_2Ph	2-morpholino-phenyl	1473	3	CH_2Ph	3-morpholino-phenyl
696	4	CH_2Ph	2-morpholino-phenyl	1474	4	CH_2Ph	3-morpholino-phenyl
697	1	COMe	2-morpholino-phenyl	1475	1	COMe	3-morpholino-phenyl
698	2	COMe	2-morpholino-phenyl	1476	2	COMe	3-morpholino-phenyl
699	3	COMe	2-morpholino-phenyl	1477	3	COMe	3-morpholino-phenyl


700	4	COMe	2-morpholino-phenyl	1478	4	COMe	3-morpholino-phenyl
701	1	CO_2Me	2-morpholino-phenyl	1479	1	CO_2Me	3-morpholino-phenyl
702	2	CO_2Me	2-morpholino-phenyl	1480	2	CO_2Me	3-morpholino-phenyl
703	3	CO_2Me	2-morpholino-phenyl	1481	3	CO_2Me	3-morpholino-phenyl
704	4	CO_2Me	2-morpholino-phenyl	1482	4	CO_2Me	3-morpholino-phenyl
705	1	CO_2tBu	2-morpholino-phenyl	1483	1	CO_2tBu	3-morpholino-phenyl
706	2	CO_2tBu	2-morpholino-phenyl	1484	2	CO_2tBu	3-morpholino-phenyl
707	3	CO_2tBu	2-morpholino-phenyl	1485	3	CO_2tBu	3-morpholino-phenyl
708	4	CO_2tBu	2-morpholino-phenyl	1486	4	CO_2tBu	3-morpholino-phenyl
709	1	CONHMe	2-morpholino-phenyl	1487	1	CONHMe	3-morpholino-phenyl
710	2	CONHMe	2-morpholino-phenyl	1488	2	CONHMe	3-morpholino-phenyl
711	3	CONHMe	2-morpholino-phenyl	1489	3	CONHMe	3-morpholino-phenyl
712	4	CONHMe	2-morpholino-phenyl	1490	4	CONHMe	3-morpholino-phenyl
713	1	SO_2Me	2-morpholino-phenyl	1491	1	SO_2Me	3-morpholino-phenyl
714	2	SO_2Me	2-morpholino-phenyl	1492	2	SO_2Me	3-morpholino-phenyl
715	3	SO_2Me	2-morpholino-phenyl	1493	3	SO_2Me	3-morpholino-phenyl

716	4	SO_2Me	2-morpholino-phenyl	1494	4	SO_2Me	3-morpholino-phenyl
717	1	SO_2NH_2	2-morpholino-phenyl	1495	1	SO_2NH_2	3-morpholino-phenyl
718	2	SO_2NH_2	2-morpholino-phenyl	1496	2	SO_2NH_2	3-morpholino-phenyl
719	3	SO_2NH_2	2-morpholino-phenyl	1497	3	SO_2NH_2	3-morpholino-phenyl
720	4	SO_2NH_2	2-morpholino-phenyl	1498	4	**SO_2NH_2**	3-morpholino-phenyl
721	1	H	4-morpholino-phenyl	1499	1	Me	4-morpholino-phenyl
722	2	H	4-morpholino-phenyl	1500	2	Me	4-morpholino-phenyl
723	3	H	4-morpholino-phenyl	1501	3	Me	4-morpholino-phenyl
724	4	H	4-morpholino-phenyl	1502	4	Me	4-morpholino-phenyl
725	1	CH_2Ph	4-morpholino-phenyl	103	1	COMe	4-morpholino-phenyl
726	2	CH_2Ph	4-morpholino-phenyl	1504	2	COMe	4-morpholino-phenyl
727	3	CH_2Ph	4-morpholino-phenyl	1505	3	COMe	4-morpholino-phenyl
728	4	CH_2Ph	4-morpholino-phenyl	1506	4	COMe	4-morpholino-phenyl
729	1	CO_2Me	4-morpholino-phenyl	1507	1	CO_2tBu	4-morpholino-phenyl
730	2	CO_2Me	4-morpholino-phenyl	1508	2	CO_2tBu	4-morpholino-phenyl
731	3	CO_2Me	4-morpholino-phenyl	1509	3	CO_2tBu	4-morpholino-phenyl

732	4	CO_2Me	4-morpholino-phenyl	1510	4	CO_2tBu	4-morpholino-phenyl
733	1	CONHMe	4-morpholino-phenyl	1511	1	SO_2Me	4-morpholino-phenyl
734	2	CONHMe	4-morpholino-phenyl	1512	2	SO_2Me	4-morpholino-phenyl
735	3	CONHMe	4-morpholino-phenyl	1513	3	SO_2Me	4-morpholino-phenyl
736	4	CONHMe	4-morpholino-phenyl	1514	4	SO_2Me	4-morpholino-phenyl
737	1	SO_2NH_2	4-morpholino-phenyl	1516	1	H	naphthylen-2-yl
738	2	SO_2NH_2	4-morpholino-phenyl	1517	2	H	naphthylen-2-yl
739	3	SO_2NH_2	4-morpholino-phenyl	1518	3	H	naphthylen-2-yl
740	1	H	naphthylen-1-yl	1519	4	H	naphthylen-2-yl
741	2	H	naphthylen-1-yl	1520	1	Me	naphthylen-2-yl
742	3	H	naphthylen-1-yl	1521	2	Me	naphthylen-2-yl
743	4	H	naphthylen-1-yl	1522	3	Me	naphthylen-2-yl
744	1	Me	naphthylen-1-yl	1523	4	Me	naphthylen-2-yl
745	2	Me	naphthylen-1-yl	1524	1	CH_2Ph	naphthylen-2-yl
746	3	Me	naphthylen-1-yl	1525	2	CH_2Ph	naphthylen-2-yl
747	4	Me	naphthylen-1-yl	1526	3	CH_2Ph	naphthylen-2-yl
748	1	CH_2Ph	naphthylen-1-yl	1527	4	CH_2Ph	naphthylen-2-yl
749	2	CH_2Ph	naphthylen-1-yl	1528	1	COMe	naphthylen-2-yl
750	3	CH_2Ph	naphthylen-1-yl	1529	2	COMe	naphthylen-2-yl
751	4	CH_2Ph	naphthylen-1-yl	1530	3	COMe	naphthylen-2-yl
752	1	COMe	naphthylen-1-yl	1531	4	COMe	naphthylen-2-yl
753	2	COMe	naphthylen-1-yl	1532	1	CO_2Me	naphthylen-2-yl
754	3	COMe	naphthylen-1-yl	1533	2	CO_2Me	naphthylen-2-yl
755	4	COMe	naphthylen-1-yl	1534	3	CO_2Me	naphthylen-2-yl

756	1	CO_2Me	naphthylen-1-yl	1535	4	CO_2Me	naphthylen-2-yl
757	2	CO_2Me	naphthylen-1-yl	1536	1	CO_2tBu	naphthylen-2-yl
758	3	CO_2Me	naphthylen-1-yl	1537	2	CO_2tBu	naphthylen-2-yl
759	4	CO_2Me	naphthylen-1-yl	1538	3	CO_2tBu	naphthylen-2-yl
760	1	CO_2tBu	naphthylen-1-yl	1539	4	CO_2tBu	naphthylen-2-yl
761	2	CO_2tBu	naphthylen-1-yl	1540	1	CONHMe	naphthylen-2-yl
762	3	CO_2tBu	naphthylen-1-yl	1541	2	CONHMe	naphthylen-2-yl
763	4	CO_2tBu	naphthylen-1-yl	1542	3	CONHMe	naphthylen-2-yl
764	1	CONHMe	naphthylen-1-yl	1543	4	CONHMe	naphthylen-2-yl
765	2	CONHMe	naphthylen-1-yl	1544	1	SO_2Me	naphthylen-2-yl
767	3	CONHMe	naphthylen-1-yl	1545	2	SO_2Me	naphthylen-2-yl
768	4	CONHMe	naphthylen-1-yl	1546	3	SO_2Me	naphthylen-2-yl
769	1	SO_2Me	naphthylen-1-yl	1547	4	SO_2Me	naphthylen-2-yl
770	2	SO_2Me	naphthylen-1-yl	1548	1	SO_2NH_2	naphthylen-2-yl
771	3	SO_2Me	naphthylen-1-yl	1549	2	SO_2NH_2	naphthylen-2-yl
772	4	SO_2Me	naphthylen-1-yl	1550	3	SO_2NH_2	naphthylen-2-yl
773	1	SO_2NH_2	naphthylen-1-yl	1551	4	SO_2NH_2	naphthylen-2-yl
774	2	SO_2NH_2	naphthylen-1-yl				
775	3	SO_2NH_2	naphthylen-1-yl				
778	4	SO_2NH_2	naphthylen-1-yl				

[01027] Exemplary embodiments include compounds having the formula **(XXV)**



(XXV)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 19.

Table 19

Entry	n	R^7	R^{20a}	R^{20b}	R^{20c}	R^{20d}
1	1	H	H	H	H	H
2	2	H	H	H	H	H

3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H

34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H

65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H

96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H

127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H

158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H

189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H

220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H

251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H

282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	OH	H	H
290	2	H	H	OH	H	H
291	3	H	H	OH	H	H
292	4	H	H	OH	H	H
293	1	Me	H	OH	H	H
294	2	Me	H	OH	H	H
295	3	Me	H	OH	H	H
296	4	Me	H	OH	H	H
297	1	CH_2Ph	H	OH	H	H
298	2	CH_2Ph	H	OH	H	H
299	3	CH_2Ph	H	OH	H	H
300	4	CH_2Ph	H	OH	H	H
301	1	COMe	H	OH	H	H
302	2	COMe	H	OH	H	H
303	3	COMe	H	OH	H	H
304	4	COMe	H	OH	H	H
305	1	CO_2Me	H	OH	H	H
306	2	CO_2Me	H	OH	H	H
307	3	CO_2Me	H	OH	H	H
308	4	CO_2Me	H	OH	H	H
309	1	CO_2tBu	H	OH	H	H
310	2	CO_2tBu	H	OH	H	H
311	3	CO_2tBu	H	OH	H	H
312	4	CO_2tBu	H	OH	H	H

313	1	CONHMe	H	OH	H	H
314	2	CONHMe	H	OH	H	H
315	3	CONHMe	H	OH	H	H
316	4	CONHMe	H	OH	H	H
317	1	SO_2Me	H	OH	H	H
318	2	SO_2Me	H	OH	H	H
319	3	SO_2Me	H	OH	H	H
320	4	SO_2Me	H	OH	H	H
321	1	SO_2NH_2	H	OH	H	H
322	2	SO_2NH_2	H	OH	H	H
323	3	SO_2NH_2	H	OH	H	H
324	4	SO_2NH_2	H	OH	H	H
325	1	H	H	OMe	H	H
326	2	H	H	OMe	H	H
327	3	H	H	OMe	H	H
328	4	H	H	OMe	H	H
329	1	Me	H	OMe	H	H
330	2	Me	H	OMe	H	H
331	3	Me	H	OMe	H	H
332	4	Me	H	OMe	H	H
333	1	CH_2Ph	H	OMe	H	H
334	2	CH_2Ph	H	OMe	H	H
335	3	CH_2Ph	H	OMe	H	H
336	4	CH_2Ph	H	OMe	H	H
337	1	COMe	H	OMe	H	H
338	2	COMe	H	OMe	H	H
339	3	COMe	H	OMe	H	H
340	4	COMe	H	OMe	H	H
341	1	CO_2Me	H	OMe	H	H
342	2	CO_2Me	H	OMe	H	H
343	3	CO_2Me	H	OMe	H	H

344	4	CO_2Me	H	OMe	H	H
345	1	CO_2tBu	H	OMe	H	H
346	2	CO_2tBu	H	OMe	H	H
347	3	CO_2tBu	H	OMe	H	H
348	4	CO_2tBu	H	OMe	H	H
349	1	CONHMe	H	OMe	H	H
350	2	CONHMe	H	OMe	H	H
351	3	CONHMe	H	OMe	H	H
352	4	CONHMe	H	OMe	H	H
353	1	SO_2Me	H	OMe	H	H
354	2	SO_2Me	H	OMe	H	H
355	3	SO_2Me	H	OMe	H	H
356	4	SO_2Me	H	OMe	H	H
357	1	SO_2NH_2	H	OMe	H	H
358	2	SO_2NH_2	H	OMe	H	H
359	3	SO_2NH_2	H	OMe	H	H
360	4	SO_2NH_2	H	OMe	H	H
361	1	H	H	Me	H	H
362	2	H	H	Me	H	H
363	3	H	H	Me	H	H
364	4	H	H	Me	H	H
365	1	Me	H	Me	H	H
366	2	Me	H	Me	H	H
367	3	Me	H	Me	H	H
368	4	Me	H	Me	H	H
369	1	CH_2Ph	H	Me	H	H
370	2	CH_2Ph	H	Me	H	H
371	3	CH_2Ph	H	Me	H	H
372	4	CH_2Ph	H	Me	H	H
373	1	COMe	H	Me	H	H
374	2	COMe	H	Me	H	H

375	3	COMe	H	Me	H	H
376	4	COMe	H	Me	H	H
377	1	CO_2Me	H	Me	H	H
378	2	CO_2Me	H	Me	H	H
379	3	CO_2Me	H	Me	H	H
380	4	CO_2Me	H	Me	H	H
381	1	CO_2tBu	H	Me	H	H
382	2	CO_2tBu	H	Me	H	H
383	3	CO_2tBu	H	Me	H	H
384	4	CO_2tBu	H	Me	H	H
385	1	CONHMe	H	Me	H	H
386	2	CONHMe	H	Me	H	H
387	3	CONHMe	H	Me	H	H
388	4	CONHMe	H	Me	H	H
389	1	SO_2Me	H	Me	H	H
390	2	SO_2Me	H	Me	H	H
391	3	SO_2Me	H	Me	H	H
392	4	SO_2Me	H	Me	H	H
393	1	SO_2NH_2	H	Me	H	H
394	2	SO_2NH_2	H	Me	H	H
395	3	SO_2NH_2	H	Me	H	H
396	4	SO_2NH_2	H	Me	H	H
397	1	H	H	CF_3	H	H
398	2	H	H	CF_3	H	H
399	3	H	H	CF_3	H	H
400	4	H	H	CF_3	H	H
401	1	Me	H	CF_3	H	H
402	2	Me	H	CF_3	H	H
403	3	Me	H	CF_3	H	H
404	4	Me	H	CF_3	H	H
405	1	CH_2Ph	H	CF_3	H	H

406	2	CH_2Ph	H	CF_3	H	H
407	3	CH_2Ph	H	CF_3	H	H
408	4	CH_2Ph	H	CF_3	H	H
409	1	COMe	H	CF_3	H	H
410	2	COMe	H	CF_3	H	H
411	3	COMe	H	CF_3	H	H
412	4	COMe	H	CF_3	H	H
413	1	CO_2Me	H	CF_3	H	H
414	2	CO_2Me	H	CF_3	H	H
415	3	CO_2Me	H	CF_3	H	H
416	4	CO_2Me	H	CF_3	H	H
417	1	CO_2tBu	H	CF_3	H	H
418	2	CO_2tBu	H	CF_3	H	H
419	3	CO_2tBu	H	CF_3	H	H
420	4	CO_2tBu	H	CF_3	H	H
421	1	CONHMe	H	CF_3	H	H
422	2	CONHMe	H	CF_3	H	H
423	3	CONHMe	H	CF_3	H	H
424	4	CONHMe	H	CF_3	H	H
425	1	SO_2Me	H	CF_3	H	H
426	2	SO_2Me	H	CF_3	H	H
427	3	SO_2Me	H	CF_3	H	H
428	4	SO_2Me	H	CF_3	H	H
429	1	SO_2NH_2	H	CF_3	H	H
430	2	SO_2NH_2	H	CF_3	H	H
431	3	SO_2NH_2	H	CF_3	H	H
432	4	SO_2NH_2	H	CF_3	H	H
433	1	H	H	F	H	H
434	2	H	H	F	H	H
435	3	H	H	F	H	H
436	3	H	H	F	H	H

437	1	Me	H	F	H	H
438	2	Me	H	F	H	H
439	3	Me	H	F	H	H
440	4	Me	H	F	H	H
441	1	CH_2Ph	H	F	H	H
442	2	CH_2Ph	H	F	H	H
443	3	CH_2Ph	H	F	H	H
444	4	CH_2Ph	H	F	H	H
445	1	COMe	H	F	H	H
446	2	COMe	H	F	H	H
447	3	COMe	H	F	H	H
448	4	COMe	H	F	H	H
449	1	CO_2Me	H	F	H	H
450	2	CO_2Me	H	F	H	H
451	3	CO_2Me	H	F	H	H
452	4	CO_2Me	H	F	H	H
453	1	CO_2tBu	H	F	H	H
454	2	CO_2tBu	H	F	H	H
455	3	CO_2tBu	H	F	H	H
456	4	CO_2tBu	H	F	H	H
457	1	CONHMe	H	F	H	H
458	2	CONHMe	H	F	H	H
459	3	CONHMe	H	F	H	H
460	4	CONHMe	H	F	H	H
461	1	SO_2Me	H	F	H	H
462	2	SO_2Me	H	F	H	H
463	3	SO_2Me	H	F	H	H
464	4	SO_2Me	H	F	H	H
465	1	SO_2NH_2	H	F	H	H
466	2	SO_2NH_2	H	F	H	H
467	3	SO_2NH_2	H	F	H	H

468	4	SO_2NH_2	H	F	H	H
469	1	H	H	Cl	H	H
470	2	H	H	Cl	H	H
471	3	H	H	Cl	H	H
472	4	H	H	Cl	H	H
473	1	Me	H	Cl	H	H
474	2	Me	H	Cl	H	H
475	3	Me	H	Cl	H	H
476	4	Me	H	Cl	H	H
477	1	CH_2Ph	H	Cl	H	H
478	2	CH_2Ph	H	Cl	H	H
479	3	CH_2Ph	H	Cl	H	H
480	4	CH_2Ph	H	Cl	H	H
481	1	COMe	H	Cl	H	H
482	2	COMe	H	Cl	H	H
483	3	COMe	H	Cl	H	H
484	4	COMe	H	Cl	H	H
485	1	CO_2Me	H	Cl	H	H
486	2	CO_2Me	H	Cl	H	H
487	3	CO_2Me	H	Cl	H	H
488	4	CO_2Me	H	Cl	H	H
489	1	CO_2tBu	H	Cl	H	H
490	2	CO_2tBu	H	Cl	H	H
491	3	CO_2tBu	H	Cl	H	H
492	4	CO_2tBu	H	Cl	H	H
493	1	CONHMe	H	Cl	H	H
494	2	CONHMe	H	Cl	H	H
495	3	CONHMe	H	Cl	H	H
496	4	CONHMe	H	Cl	H	H
497	1	SO_2Me	H	Cl	H	H
498	2	SO_2Me	H	Cl	H	H

499	3	SO_2Me	H	Cl	H	H
500	4	SO_2Me	H	Cl	H	H
501	1	SO_2NH_2	H	Cl	H	H
502	2	SO_2NH_2	H	Cl	H	H
503	3	SO_2NH_2	H	Cl	H	H
504	4	SO_2NH_2	H	Cl	H	H
505	1	H	H	CN	H	H
506	2	H	H	CN	H	H
507	3	H	H	CN	H	H
508	4	H	H	CN	H	H
509	1	Me	H	CN	H	H
510	2	Me	H	CN	H	H
511	3	Me	H	CN	H	H
512	4	Me	H	CN	H	H
513	1	CH_2Ph	H	CN	H	H
514	2	CH_2Ph	H	CN	H	H
515	3	CH_2Ph	H	CN	H	H
516	4	CH_2Ph	H	CN	H	H
517	1	COMe	H	CN	H	H
518	2	COMe	H	CN	H	H
519	3	COMe	H	CN	H	H
520	4	COMe	H	CN	H	H
521	1	CO_2Me	H	CN	H	H
522	2	CO_2Me	H	CN	H	H
523	3	CO_2Me	H	CN	H	H
524	4	CO_2Me	H	CN	H	H
525	1	CO_2tBu	H	CN	H	H
526	2	CO_2tBu	H	CN	H	H
527	3	CO_2tBu	H	CN	H	H
528	4	CO_2tBu	H	CN	H	H
529	1	CONHMe	H	CN	H	H

530	2	CONHMe	H	CN	H	H
531	3	CONHMe	H	CN	H	H
532	4	CONHMe	H	CN	H	H
533	1	SO_2Me	H	CN	H	H
534	2	SO_2Me	H	CN	H	H
535	3	SO_2Me	H	CN	H	H
536	4	SO_2Me	H	CN	H	H
537	1	SO_2NH_2	H	CN	H	H
538	2	SO_2NH_2	H	CN	H	H
539	3	SO_2NH_2	H	CN	H	H
540	4	SO_2NH_2	H	CN	H	H
541	1	H	OH	H	H	H
542	2	H	OH	H	H	H
543	3	H	OH	H	H	H
544	4	H	OH	H	H	H
545	1	Me	OH	H	H	H
546	2	Me	OH	H	H	H
547	3	Me	OH	H	H	H
548	4	Me	OH	H	H	H
549	1	CH_2Ph	OH	H	H	H
550	2	CH_2Ph	OH	H	H	H
551	3	CH_2Ph	OH	H	H	H
552	4	CH_2Ph	OH	H	H	H
553	1	COMe	OH	H	H	H
554	2	COMe	OH	H	H	H
555	3	COMe	OH	H	H	H
556	4	COMe	OH	H	H	H
557	1	CO_2Me	OH	H	H	H
558	2	CO_2Me	OH	H	H	H
559	3	CO_2Me	OH	H	H	H
560	4	CO_2Me	OH	H	H	H

561	1	CO_2tBu	OH	H	H	H
562	2	CO_2tBu	OH	H	H	H
563	3	CO_2tBu	OH	H	H	H
564	4	CO_2tBu	OH	H	H	H
565	1	CONHMe	OH	H	H	H
566	2	CONHMe	OH	H	H	H
567	3	CONHMe	OH	H	H	H
568	4	CONHMe	OH	H	H	H
569	1	SO_2Me	OH	H	H	H
570	2	SO_2Me	OH	H	H	H
571	3	SO_2Me	OH	H	H	H
572	4	SO_2Me	OH	H	H	H
573	1	SO_2NH_2	OH	H	H	H
574	2	SO_2NH_2	OH	H	H	H
575	3	SO_2NH_2	OH	H	H	H
576	4	SO_2NH_2	OH	H	H	H
577	1	H	OMe	H	H	H
578	2	H	OMe	H	H	H
579	3	H	OMe	H	H	H
580	4	H	OMe	H	H	H
581	1	Me	OMe	H	H	H
582	2	Me	OMe	H	H	H
583	3	Me	OMe	H	H	H
584	4	Me	OMe	H	H	H
585	1	CH_2Ph	OMe	H	H	H
586	2	CH_2Ph	OMe	H	H	H
587	3	CH_2Ph	OMe	H	H	H
588	4	CH_2Ph	OMe	H	H	H
589	1	COMe	OMe	H	H	H
590	2	COMe	OMe	H	H	H
591	3	COMe	OMe	H	H	H

592	4	COMe	OMe	H	H	H
593	1	CO_2Me	OMe	H	H	H
594	2	CO_2Me	OMe	H	H	H
595	3	CO_2Me	OMe	H	H	H
596	4	CO_2Me	OMe	H	H	H
597	1	CO_2tBu	OMe	H	H	H
598	2	CO_2tBu	OMe	H	H	H
599	3	CO_2tBu	OMe	H	H	H
600	4	CO_2tBu	OMe	H	H	H
601	1	CONHMe	OMe	H	H	H
602	2	CONHMe	OMe	H	H	H
603	3	CONHMe	OMe	H	H	H
604	4	CONHMe	OMe	H	H	H
605	1	SO_2Me	OMe	H	H	H
606	2	SO_2Me	OMe	H	H	H
607	3	SO_2Me	OMe	H	H	H
608	4	SO_2Me	OMe	H	H	H
609	1	SO_2NH_2	OMe	H	H	H
610	2	SO_2NH_2	OMe	H	H	H
611	3	SO_2NH_2	OMe	H	H	H
612	4	SO_2NH_2	OMe	H	H	H
613	1	H	Me	H	H	H
614	2	H	Me	H	H	H
615	3	H	Me	H	H	H
616	4	H	Me	H	H	H
617	1	Me	Me	H	H	H
618	2	Me	Me	H	H	H
619	3	Me	Me	H	H	H
620	4	Me	Me	H	H	H
621	1	CH_2Ph	Me	H	H	H
622	2	CH_2Ph	Me	H	H	H

623	3	CH_2Ph	Me	H	H	H
624	4	CH_2Ph	Me	H	H	H
625	1	COMe	Me	H	H	H
626	2	COMe	Me	H	H	H
627	3	COMe	Me	H	H	H
628	4	COMe	Me	H	H	H
629	1	CO_2Me	Me	H	H	H
630	2	CO_2Me	Me	H	H	H
631	3	CO_2Me	Me	H	H	H
632	4	CO_2Me	Me	H	H	H
633	1	CO_2tBu	Me	H	H	H
634	2	CO_2tBu	Me	H	H	H
635	3	CO_2tBu	Me	H	H	H
636	4	CO_2tBu	Me	H	H	H
637	1	CONHMe	Me	H	H	H
638	2	CONHMe	Me	H	H	H
639	3	CONHMe	Me	H	H	H
640	4	CONHMe	Me	H	H	H
641	1	SO_2Me	Me	H	H	H
642	2	SO_2Me	Me	H	H	H
643	3	SO_2Me	Me	H	H	H
644	4	SO_2Me	Me	H	H	H
645	1	SO_2NH_2	Me	H	H	H
646	2	SO_2NH_2	Me	H	H	H
647	3	SO_2NH_2	Me	H	H	H
648	4	SO_2NH_2	Me	H	H	H
649	1	H	CF_3	H	H	H
650	2	H	CF_3	H	H	H
651	3	H	CF_3	H	H	H
652	4	H	CF_3	H	H	H
653	1	Me	CF_3	H	H	H

654	2	Me	CF_3	H	H	H
655	3	Me	CF_3	H	H	H
656	4	Me	CF_3	H	H	H
657	1	CH_2Ph	CF_3	H	H	H
658	2	CH_2Ph	CF_3	H	H	H
659	3	CH_2Ph	CF_3	H	H	H
660	4	CH_2Ph	CF_3	H	H	H
661	1	COMe	CF_3	H	H	H
662	2	COMe	CF_3	H	H	H
663	3	COMe	CF_3	H	H	H
664	4	COMe	CF_3	H	H	H
665	1	CO_2Me	CF_3	H	H	H
666	2	CO_2Me	CF_3	H	H	H
667	3	CO_2Me	CF_3	H	H	H
668	4	CO_2Me	CF_3	H	H	H
669	1	CO_2tBu	CF_3	H	H	H
670	2	CO_2tBu	CF_3	H	H	H
671	3	CO_2tBu	CF_3	H	H	H
672	4	CO_2tBu	CF_3	H	H	H
673	1	CONHMe	CF_3	H	H	H
674	2	CONHMe	CF_3	H	H	H
675	3	CONHMe	CF_3	H	H	H
676	4	CONHMe	CF_3	H	H	H
677	1	SO_2Me	CF_3	H	H	H
678	2	SO_2Me	CF_3	H	H	H
679	3	SO_2Me	CF_3	H	H	H
680	4	SO_2Me	CF_3	H	H	H
681	1	SO_2NH_2	CF_3	H	H	H
682	2	SO_2NH_2	CF_3	H	H	H
683	3	SO_2NH_2	CF_3	H	H	H
684	4	SO_2NH_2	CF_3	H	H	H

685	1	H	F	H	H	H
686	2	H	F	H	H	H
687	3	H	F	H	H	H
688	3	H	F	H	H	H
689	1	Me	F	H	H	H
690	2	Me	F	H	H	H
691	3	Me	F	H	H	H
692	4	Me	F	H	H	H
693	1	CH_2Ph	F	H	H	H
694	2	CH_2Ph	F	H	H	H
695	3	CH_2Ph	F	H	H	H
696	4	CH_2Ph	F	H	H	H
697	1	COMe	F	H	H	H
698	2	COMe	F	H	H	H
699	3	COMe	F	H	H	H
700	4	COMe	F	H	H	H
701	1	CO_2Me	F	H	H	H
702	2	CO_2Me	F	H	H	H
703	3	CO_2Me	F	H	H	H
704	4	CO_2Me	F	H	H	H
705	1	CO_2tBu	F	H	H	H
706	2	CO_2tBu	F	H	H	H
707	3	CO_2tBu	F	H	H	H
708	4	CO_2tBu	F	H	H	H
709	1	CONHMe	F	H	H	H
710	2	CONHMe	F	H	H	H
711	3	CONHMe	F	H	H	H
712	4	CONHMe	F	H	H	H
713	1	SO_2Me	F	H	H	H
714	2	SO_2Me	F	H	H	H
715	3	SO_2Me	F	H	H	H

716	4	SO_2Me	F	H	H	H
717	1	SO_2NH_2	F	H	H	H
718	2	SO_2NH_2	F	H	H	H
719	3	SO_2NH_2	F	H	H	H
720	4	SO_2NH_2	F	H	H	H
721	1	H	Cl	H	H	H
722	2	H	Cl	H	H	H
723	3	H	Cl	H	H	H
724	4	H	Cl	H	H	H
725	1	Me	Cl	H	H	H
726	2	Me	Cl	H	H	H
727	3	Me	Cl	H	H	H
728	4	Me	Cl	H	H	H
729	1	CH_2Ph	Cl	H	H	H
730	2	CH_2Ph	Cl	H	H	H
731	3	CH_2Ph	Cl	H	H	H
732	4	CH_2Ph	Cl	H	H	H
733	1	COMe	Cl	H	H	H
734	2	COMe	Cl	H	H	H
735	3	COMe	Cl	H	H	H
736	4	COMe	Cl	H	H	H
737	1	CO_2Me	Cl	H	H	H
738	2	CO_2Me	Cl	H	H	H
739	3	CO_2Me	Cl	H	H	H
740	4	CO_2Me	Cl	H	H	H
741	1	CO_2tBu	Cl	H	H	H
742	2	CO_2tBu	Cl	H	H	H
743	3	CO_2tBu	Cl	H	H	H
744	4	CO_2tBu	Cl	H	H	H
745	1	CONHMe	Cl	H	H	H
746	2	CONHMe	Cl	H	H	H

747	3	CONHMe	Cl	H	H	H
748	4	CONHMe	Cl	H	H	H
749	1	SO_2Me	Cl	H	H	H
750	2	SO_2Me	Cl	H	H	H
751	3	SO_2Me	Cl	H	H	H
752	4	SO_2Me	Cl	H	H	H
753	1	SO_2NH_2	Cl	H	H	H
754	2	SO_2NH_2	Cl	H	H	H
755	3	SO_2NH_2	Cl	H	H	H
756	4	SO_2NH_2	Cl	H	H	H
757	1	H	CN	H	H	H
758	2	H	CN	H	H	H
759	3	H	CN	H	H	H
760	4	H	CN	H	H	H
761	1	Me	CN	H	H	H
762	2	Me	CN	H	H	H
763	3	Me	CN	H	H	H
764	4	Me	CN	H	H	H
765	1	CH_2Ph	CN	H	H	H
766	2	CH_2Ph	CN	H	H	H
767	3	CH_2Ph	CN	H	H	H
768	4	CH_2Ph	CN	H	H	H
769	1	COMe	CN	H	H	H
770	2	COMe	CN	H	H	H
771	3	COMe	CN	H	H	H
772	4	COMe	CN	H	H	H
773	1	CO_2Me	CN	H	H	H
774	2	CO_2Me	CN	H	H	H
775	3	CO_2Me	CN	H	H	H
776	4	CO_2Me	CN	H	H	H
777	1	CO_2tBu	CN	H	H	H

778	2	CO_2tBu	CN	H	H	H
779	3	CO_2tBu	CN	H	H	H
780	4	CO_2tBu	CN	H	H	H
781	1	CONHMe	CN	H	H	H
782	2	CONHMe	CN	H	H	H
783	3	CONHMe	CN	H	H	H
784	4	CONHMe	CN	H	H	H
785	1	SO_2Me	CN	H	H	H
786	2	SO_2Me	CN	H	H	H
787	3	SO_2Me	CN	H	H	H
788	4	SO_2Me	CN	H	H	H
789	1	SO_2NH_2	CN	H	H	H
790	2	SO_2NH_2	CN	H	H	H
791	3	SO_2NH_2	CN	H	H	H
792	4	SO_2NH_2	CN	H	H	H
793	1	H	H	H	H	OH
794	2	H	H	H	H	OH
795	3	H	H	H	H	OH
796	4	H	H	H	H	OH
797	1	Me	H	H	H	OH
798	2	Me	H	H	H	OH
799	3	Me	H	H	H	OH
800	4	Me	H	H	H	OH
801	1	CH_2Ph	H	H	H	OH
802	2	CH_2Ph	H	H	H	OH
803	3	CH_2Ph	H	H	H	OH
804	4	CH_2Ph	H	H	H	OH
805	1	COMe	H	H	H	OH
806	2	COMe	H	H	H	OH
807	3	COMe	H	H	H	OH
808	4	COMe	H	H	H	OH

809	1	CO_2Me	H	H	H	OH
810	2	CO_2Me	H	H	H	OH
811	3	CO_2Me	H	H	H	OH
812	4	CO_2Me	H	H	H	OH
813	1	CO_2tBu	H	H	H	OH
814	2	CO_2tBu	H	H	H	OH
815	3	CO_2tBu	H	H	H	OH
816	4	CO_2tBu	H	H	H	OH
817	1	CONHMe	H	H	H	OH
818	2	CONHMe	H	H	H	OH
819	3	CONHMe	H	H	H	OH
820	4	CONHMe	H	H	H	OH
821	1	SO_2Me	H	H	H	OH
822	2	SO_2Me	H	H	H	OH
823	3	SO_2Me	H	H	H	OH
824	4	SO_2Me	H	H	H	OH
825	1	SO_2NH_2	H	H	H	OH
826	2	SO_2NH_2	H	H	H	OH
827	3	SO_2NH_2	H	H	H	OH
828	4	SO_2NH_2	H	H	H	OH
829	1	H	H	H	H	OMe
830	2	H	H	H	H	OMe
831	3	H	H	H	H	OMe
832	4	H	H	H	H	OMe
833	1	Me	H	H	H	OMe
834	2	Me	H	H	H	OMe
835	3	Me	H	H	H	OMe
836	4	Me	H	H	H	OMe
837	1	CH_2Ph	H	H	H	OMe
838	2	CH_2Ph	H	H	H	OMe
839	3	CH_2Ph	H	H	H	OMe

840	4	CH_2Ph	H	H	H	OMe
841	1	COMe	H	H	H	OMe
842	2	COMe	H	H	H	OMe
843	3	COMe	H	H	H	OMe
844	4	COMe	H	H	H	OMe
845	1	CO_2Me	H	H	H	OMe
846	2	CO_2Me	H	H	H	OMe
847	3	CO_2Me	H	H	H	OMe
848	4	CO_2Me	H	H	H	OMe
849	1	CO_2tBu	H	H	H	OMe
850	2	CO_2tBu	H	H	H	OMe
851	3	CO_2tBu	H	H	H	OMe
852	4	CO_2tBu	H	H	H	OMe
853	1	CONHMe	H	H	H	OMe
854	2	CONHMe	H	H	H	OMe
855	3	CONHMe	H	H	H	OMe
856	4	CONHMe	H	H	H	OMe
857	1	SO_2Me	H	H	H	OMe
858	2	SO_2Me	H	H	H	OMe
859	3	SO_2Me	H	H	H	OMe
860	4	SO_2Me	H	H	H	OMe
861	1	SO_2NH_2	H	H	H	OMe
862	2	SO_2NH_2	H	H	H	OMe
863	3	SO_2NH_2	H	H	H	OMe
864	4	SO_2NH_2	H	H	H	OMe
865	1	H	H	H	H	Me
866	2	H	H	H	H	Me
867	3	H	H	H	H	Me
868	4	H	H	H	H	Me
869	1	Me	H	H	H	Me
870	2	Me	H	H	H	Me

871	3	Me	H	H	H	Me
872	4	Me	H	H	H	Me
873	1	CH_2Ph	H	H	H	Me
874	2	CH_2Ph	H	H	H	Me
875	3	CH_2Ph	H	H	H	Me
876	4	CH_2Ph	H	H	H	Me
877	1	COMe	H	H	H	Me
878	2	COMe	H	H	H	Me
879	3	COMe	H	H	H	Me
880	4	COMe	H	H	H	Me
881	1	CO_2Me	H	H	H	Me
882	2	CO_2Me	H	H	H	Me
883	3	CO_2Me	H	H	H	Me
884	4	CO_2Me	H	H	H	Me
885	1	CO_2tBu	H	H	H	Me
886	2	CO_2tBu	H	H	H	Me
887	3	CO_2tBu	H	H	H	Me
888	4	CO_2tBu	H	H	H	Me
889	1	CONHMe	H	H	H	Me
890	2	CONHMe	H	H	H	Me
891	3	CONHMe	H	H	H	Me
892	4	CONHMe	H	H	H	Me
893	1	SO_2Me	H	H	H	Me
894	2	SO_2Me	H	H	H	Me
895	3	SO_2Me	H	H	H	Me
896	4	SO_2Me	H	H	H	Me
897	1	SO_2NH_2	H	H	H	Me
898	2	SO_2NH_2	H	H	H	Me
899	3	SO_2NH_2	H	H	H	Me
900	4	SO_2NH_2	H	H	H	Me
901	1	H	H	H	H	CF_3

902	2	H	H	H	H	CF_3
903	3	H	H	H	H	CF_3
904	4	H	H	H	H	CF_3
905	1	Me	H	H	H	CF_3
906	2	Me	H	H	H	CF_3
907	3	Me	H	H	H	CF_3
908	4	Me	H	H	H	CF_3
909	1	CH_2Ph	H	H	H	CF_3
910	2	CH_2Ph	H	H	H	CF_3
911	3	CH_2Ph	H	H	H	CF_3
912	4	CH_2Ph	H	H	H	CF_3
913	1	COMe	H	H	H	CF_3
914	2	COMe	H	H	H	CF_3
915	3	COMe	H	H	H	CF_3
916	4	COMe	H	H	H	CF_3
917	1	CO_2Me	H	H	H	CF_3
918	2	CO_2Me	H	H	H	CF_3
919	3	CO_2Me	H	H	H	CF_3
920	4	CO_2Me	H	H	H	CF_3
921	1	CO_2tBu	H	H	H	CF_3
922	2	CO_2tBu	H	H	H	CF_3
923	3	CO_2tBu	H	H	H	CF_3
924	4	CO_2tBu	H	H	H	CF_3
925	1	CONHMe	H	H	H	CF_3
926	2	CONHMe	H	H	H	CF_3
927	3	CONHMe	H	H	H	CF_3
928	4	CONHMe	H	H	H	CF_3
929	1	SO_2Me	H	H	H	CF_3
930	2	SO_2Me	H	H	H	CF_3
931	3	SO_2Me	H	H	H	CF_3
932	4	SO_2Me	H	H	H	CF_3


933	1	SO_2NH_2	H	H	H	CF_3
934	2	SO_2NH_2	H	H	H	CF_3
935	3	SO_2NH_2	H	H	H	CF_3
936	4	SO_2NH_2	H	H	H	CF_3
937	1	H	H	H	H	F
938	2	H	H	H	H	F
939	3	H	H	H	H	F
940	3	H	H	H	H	F
941	1	Me	H	H	H	F
942	2	Me	H	H	H	F
943	3	Me	H	H	H	F
944	4	Me	H	H	H	F
945	1	CH_2Ph	H	H	H	F
946	2	CH_2Ph	H	H	H	F
947	3	CH_2Ph	H	H	H	F
948	4	CH_2Ph	H	H	H	F
949	1	COMe	H	H	H	F
950	2	COMe	H	H	H	F
951	3	COMe	H	H	H	F
952	4	COMe	H	H	H	F
953	1	CO_2Me	H	H	H	F
954	2	CO_2Me	H	H	H	F
955	3	CO_2Me	H	H	H	F
956	4	CO_2Me	H	H	H	F
957	1	CO_2tBu	H	H	H	F
958	2	CO_2tBu	H	H	H	F
959	3	CO_2tBu	H	H	H	F
960	4	CO_2tBu	H	H	H	F
961	1	CONHMe	H	H	H	F
962	2	CONHMe	H	H	H	F
963	3	CONHMe	H	H	H	F

964	4	CONHMe	H	H	H	F
965	1	SO_2Me	H	H	H	F
966	2	SO_2Me	H	H	H	F
967	3	SO_2Me	H	H	H	F
968	4	SO_2Me	H	H	H	F
969	1	SO_2NH_2	H	H	H	F
970	2	SO_2NH_2	H	H	H	F
971	3	SO_2NH_2	H	H	H	F
972	4	SO_2NH_2	H	H	H	F
973	1	H	H	H	H	Cl
974	2	H	H	H	H	Cl
975	3	H	H	H	H	Cl
976	4	H	H	H	H	Cl
977	1	Me	H	H	H	Cl
978	2	Me	H	H	H	Cl
979	3	Me	H	H	H	Cl
980	4	Me	H	H	H	Cl
981	1	CH_2Ph	H	H	H	Cl
982	2	CH_2Ph	H	H	H	Cl
983	3	CH_2Ph	H	H	H	Cl
984	4	CH_2Ph	H	H	H	Cl
985	1	COMe	H	H	H	Cl
986	2	COMe	H	H	H	Cl
987	3	COMe	H	H	H	Cl
988	4	COMe	H	H	H	Cl
989	1	CO_2Me	H	H	H	Cl
990	2	CO_2Me	H	H	H	Cl
991	3	CO_2Me	H	H	H	Cl
992	4	CO_2Me	H	H	H	Cl
993	1	CO_2tBu	H	H	H	Cl
994	2	CO_2tBu	H	H	H	Cl

995	3	CO_2tBu	H	H	H	Cl
996	4	CO_2tBu	H	H	H	Cl
997	1	CONHMe	H	H	H	Cl
998	2	CONHMe	H	H	H	Cl
999	3	CONHMe	H	H	H	Cl
1000	4	CONHMe	H	H	H	Cl
1001	1	SO_2Me	H	H	H	Cl
1002	2	SO_2Me	H	H	H	Cl
1003	3	SO_2Me	H	H	H	Cl
1004	4	SO_2Me	H	H	H	Cl
1005	1	SO_2NH_2	H	H	H	Cl
1006	2	SO_2NH_2	H	H	H	Cl
1007	3	SO_2NH_2	H	H	H	Cl
1008	4	SO_2NH_2	H	H	H	Cl
1009	1	H	H	H	H	CN
1010	2	H	H	H	H	CN
1011	3	H	H	H	H	CN
1012	4	H	H	H	H	CN
1013	1	Me	H	H	H	CN
1014	2	Me	H	H	H	CN
1015	3	Me	H	H	H	CN
1016	4	Me	H	H	H	CN
1017	1	CH_2Ph	H	H	H	CN
1018	2	CH_2Ph	H	H	H	CN
1019	3	CH_2Ph	H	H	H	CN
1020	4	CH_2Ph	H	H	H	CN
1021	1	COMe	H	H	H	CN
1022	2	COMe	H	H	H	CN
1023	3	COMe	H	H	H	CN
1024	4	COMe	H	H	H	CN
1025	1	CO_2Me	H	H	H	CN

1026	2	CO_2Me	H	H	H	CN
1027	3	CO_2Me	H	H	H	CN
1028	4	CO_2Me	H	H	H	CN
1029	1	CO_2tBu	H	H	H	CN
1030	2	CO_2tBu	H	H	H	CN
1031	3	CO_2tBu	H	H	H	CN
1032	4	CO_2tBu	H	H	H	CN
1033	1	CONHMe	H	H	H	CN
1034	2	CONHMe	H	H	H	CN
1035	3	CONHMe	H	H	H	CN
1036	4	CONHMe	H	H	H	CN
1037	1	SO_2Me	H	H	H	CN
1038	2	SO_2Me	H	H	H	CN
1039	3	SO_2Me	H	H	H	CN
1040	4	SO_2Me	H	H	H	CN
1041	1	SO_2NH_2	H	H	H	CN
1042	2	SO_2NH_2	H	H	H	CN
1043	3	SO_2NH_2	H	H	H	CN
1044	4	SO_2NH_2	H	H	H	CN

[01028] Exemplary embodiments include compounds having the formula **(XXVI)**



or a pharmaceutically acceptable salt form thereof defined herein below in Table 20.

Table 20

Entry	n	R^7	R^{20a}	R^{20b}	R^{20c}	R^{20d}
1	1	H	H	H	H	H
2	2	H	H	H	H	H

3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H

34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H

65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H

96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H

127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H

158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H

189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H

220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H

251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H

282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	OH	H	H
290	2	H	H	OH	H	H
291	3	H	H	OH	H	H
292	4	H	H	OH	H	H
293	1	Me	H	OH	H	H
294	2	Me	H	OH	H	H
295	3	Me	H	OH	H	H
296	4	Me	H	OH	H	H
297	1	CH_2Ph	H	OH	H	H
298	2	CH_2Ph	H	OH	H	H
299	3	CH_2Ph	H	OH	H	H
300	4	CH_2Ph	H	OH	H	H
301	1	COMe	H	OH	H	H
302	2	COMe	H	OH	H	H
303	3	COMe	H	OH	H	H
304	4	COMe	H	OH	H	H
305	1	CO_2Me	H	OH	H	H
306	2	CO_2Me	H	OH	H	H
307	3	CO_2Me	H	OH	H	H
308	4	CO_2Me	H	OH	H	H
309	1	CO_2tBu	H	OH	H	H
310	2	CO_2tBu	H	OH	H	H
311	3	CO_2tBu	H	OH	H	H
312	4	CO_2tBu	H	OH	H	H

313	1	CONHMe	H	OH	H	H
314	2	CONHMe	H	OH	H	H
315	3	CONHMe	H	OH	H	H
316	4	CONHMe	H	OH	H	H
317	1	SO_2Me	H	OH	H	H
318	2	SO_2Me	H	OH	H	H
319	3	SO_2Me	H	OH	H	H
320	4	SO_2Me	H	OH	H	H
321	1	SO_2NH_2	H	OH	H	H
322	2	SO_2NH_2	H	OH	H	H
323	3	SO_2NH_2	H	OH	H	H
324	4	SO_2NH_2	H	OH	H	H
325	1	H	H	OMe	H	H
326	2	H	H	OMe	H	H
327	3	H	H	OMe	H	H
328	4	H	H	OMe	H	H
329	1	Me	H	OMe	H	H
330	2	Me	H	OMe	H	H
331	3	Me	H	OMe	H	H
332	4	Me	H	OMe	H	H
333	1	CH_2Ph	H	OMe	H	H
334	2	CH_2Ph	H	OMe	H	H
335	3	CH_2Ph	H	OMe	H	H
336	4	CH_2Ph	H	OMe	H	H
337	1	COMe	H	OMe	H	H
338	2	COMe	H	OMe	H	H
339	3	COMe	H	OMe	H	H
340	4	COMe	H	OMe	H	H
341	1	CO_2Me	H	OMe	H	H
342	2	CO_2Me	H	OMe	H	H
343	3	CO_2Me	H	OMe	H	H

344	4	CO_2Me	H	OMe	H	H
345	1	CO_2tBu	H	OMe	H	H
346	2	CO_2tBu	H	OMe	H	H
347	3	CO_2tBu	H	OMe	H	H
348	4	CO_2tBu	H	OMe	H	H
349	1	CONHMe	H	OMe	H	H
350	2	CONHMe	H	OMe	H	H
351	3	CONHMe	H	OMe	H	H
352	4	CONHMe	H	OMe	H	H
353	1	SO_2Me	H	OMe	H	H
354	2	SO_2Me	H	OMe	H	H
355	3	SO_2Me	H	OMe	H	H
356	4	SO_2Me	H	OMe	H	H
357	1	SO_2NH_2	H	OMe	H	H
358	2	SO_2NH_2	H	OMe	H	H
359	3	SO_2NH_2	H	OMe	H	H
360	4	SO_2NH_2	H	OMe	H	H
361	1	H	H	Me	H	H
362	2	H	H	Me	H	H
363	3	H	H	Me	H	H
364	4	H	H	Me	H	H
365	1	Me	H	Me	H	H
366	2	Me	H	Me	H	H
367	3	Me	H	Me	H	H
368	4	Me	H	Me	H	H
369	1	CH_2Ph	H	Me	H	H
370	2	CH_2Ph	H	Me	H	H
371	3	CH_2Ph	H	Me	H	H
372	4	CH_2Ph	H	Me	H	H
373	1	COMe	H	Me	H	H
374	2	COMe	H	Me	H	H

375	3	COMe	H	Me	H	H
376	4	COMe	H	Me	H	H
377	1	CO_2Me	H	Me	H	H
378	2	CO_2Me	H	Me	H	H
379	3	CO_2Me	H	Me	H	H
380	4	CO_2Me	H	Me	H	H
381	1	CO_2tBu	H	Me	H	H
382	2	CO_2tBu	H	Me	H	H
383	3	CO_2tBu	H	Me	H	H
384	4	CO_2tBu	H	Me	H	H
385	1	CONHMe	H	Me	H	H
386	2	CONHMe	H	Me	H	H
387	3	CONHMe	H	Me	H	H
388	4	CONHMe	H	Me	H	H
389	1	SO_2Me	H	Me	H	H
390	2	SO_2Me	H	Me	H	H
391	3	SO_2Me	H	Me	H	H
392	4	SO_2Me	H	Me	H	H
393	1	SO_2NH_2	H	Me	H	H
394	2	SO_2NH_2	H	Me	H	H
395	3	SO_2NH_2	H	Me	H	H
396	4	SO_2NH_2	H	Me	H	H
397	1	H	H	CF_3	H	H
398	2	H	H	CF_3	H	H
399	3	H	H	CF_3	H	H
400	4	H	H	CF_3	H	H
401	1	Me	H	CF_3	H	H
402	2	Me	H	CF_3	H	H
403	3	Me	H	CF_3	H	H
404	4	Me	H	CF_3	H	H
405	1	CH_2Ph	H	CF_3	H	H

406	2	CH_2Ph	H	CF_3	H	H
407	3	CH_2Ph	H	CF_3	H	H
408	4	CH_2Ph	H	CF_3	H	H
409	1	COMe	H	CF_3	H	H
410	2	COMe	H	CF_3	H	H
411	3	COMe	H	CF_3	H	H
412	4	COMe	H	CF_3	H	H
413	1	CO_2Me	H	CF_3	H	H
414	2	CO_2Me	H	CF_3	H	H
415	3	CO_2Me	H	CF_3	H	H
416	4	CO_2Me	H	CF_3	H	H
417	1	CO_2tBu	H	CF_3	H	H
418	2	CO_2tBu	H	CF_3	H	H
419	3	CO_2tBu	H	CF_3	H	H
420	4	CO_2tBu	H	CF_3	H	H
421	1	CONHMe	H	CF_3	H	H
422	2	CONHMe	H	CF_3	H	H
423	3	CONHMe	H	CF_3	H	H
424	4	CONHMe	H	CF_3	H	H
425	1	SO_2Me	H	CF_3	H	H
426	2	SO_2Me	H	CF_3	H	H
427	3	SO_2Me	H	CF_3	H	H
428	4	SO_2Me	H	CF_3	H	H
429	1	SO_2NH_2	H	CF_3	H	H
430	2	SO_2NH_2	H	CF_3	H	H
431	3	SO_2NH_2	H	CF_3	H	H
432	4	SO_2NH_2	H	CF_3	H	H
433	1	H	H	F	H	H
434	2	H	H	F	H	H
435	3	H	H	F	H	H
436	3	H	H	F	H	H

437	1	Me	H	F	H	H
438	2	Me	H	F	H	H
439	3	Me	H	F	H	H
440	4	Me	H	F	H	H
441	1	CH_2Ph	H	F	H	H
442	2	CH_2Ph	H	F	H	H
443	3	CH_2Ph	H	F	H	H
444	4	CH_2Ph	H	F	H	H
445	1	COMe	H	F	H	H
446	2	COMe	H	F	H	H
447	3	COMe	H	F	H	H
448	4	COMe	H	F	H	H
449	1	CO_2Me	H	F	H	H
450	2	CO_2Me	H	F	H	H
451	3	CO_2Me	H	F	H	H
452	4	CO_2Me	H	F	H	H
453	1	CO_2tBu	H	F	H	H
454	2	CO_2tBu	H	F	H	H
455	3	CO_2tBu	H	F	H	H
456	4	CO_2tBu	H	F	H	H
457	1	CONHMe	H	F	H	H
458	2	CONHMe	H	F	H	H
459	3	CONHMe	H	F	H	H
460	4	CONHMe	H	F	H	H
461	1	SO_2Me	H	F	H	H
462	2	SO_2Me	H	F	H	H
463	3	SO_2Me	H	F	H	H
464	4	SO_2Me	H	F	H	H
465	1	SO_2NH_2	H	F	H	H
466	2	SO_2NH_2	H	F	H	H
467	3	SO_2NH_2	H	F	H	H

468	4	SO_2NH_2	H	F	H	H
469	1	H	H	Cl	H	H
470	2	H	H	Cl	H	H
471	3	H	H	Cl	H	H
472	4	H	H	Cl	H	H
473	1	Me	H	Cl	H	H
474	2	Me	H	Cl	H	H
475	3	Me	H	Cl	H	H
476	4	Me	H	Cl	H	H
477	1	CH_2Ph	H	Cl	H	H
478	2	CH_2Ph	H	Cl	H	H
479	3	CH_2Ph	H	Cl	H	H
480	4	CH_2Ph	H	Cl	H	H
481	1	COMe	H	Cl	H	H
482	2	COMe	H	Cl	H	H
483	3	COMe	H	Cl	H	H
484	4	COMe	H	Cl	H	H
485	1	CO_2Me	H	Cl	H	H
486	2	CO_2Me	H	Cl	H	H
487	3	CO_2Me	H	Cl	H	H
488	4	CO_2Me	H	Cl	H	H
489	1	CO_2tBu	H	Cl	H	H
490	2	CO_2tBu	H	Cl	H	H
491	3	CO_2tBu	H	Cl	H	H
492	4	CO_2tBu	H	Cl	H	H
493	1	CONHMe	H	Cl	H	H
494	2	CONHMe	H	Cl	H	H
495	3	CONHMe	H	Cl	H	H
496	4	CONHMe	H	Cl	H	H
497	1	SO_2Me	H	Cl	H	H
498	2	SO_2Me	H	Cl	H	H

499	3	SO_2Me	H	Cl	H	H
500	4	SO_2Me	H	Cl	H	H
501	1	SO_2NH_2	H	Cl	H	H
502	2	SO_2NH_2	H	Cl	H	H
503	3	SO_2NH_2	H	Cl	H	H
504	4	SO_2NH_2	H	Cl	H	H
505	1	H	H	CN	H	H
506	2	H	H	CN	H	H
507	3	H	H	CN	H	H
508	4	H	H	CN	H	H
509	1	Me	H	CN	H	H
510	2	Me	H	CN	H	H
511	3	Me	H	CN	H	H
512	4	Me	H	CN	H	H
513	1	CH_2Ph	H	CN	H	H
514	2	CH_2Ph	H	CN	H	H
515	3	CH_2Ph	H	CN	H	H
516	4	CH_2Ph	H	CN	H	H
517	1	COMe	H	CN	H	H
518	2	COMe	H	CN	H	H
519	3	COMe	H	CN	H	H
520	4	COMe	H	CN	H	H
521	1	CO_2Me	H	CN	H	H
522	2	CO_2Me	H	CN	H	H
523	3	CO_2Me	H	CN	H	H
524	4	CO_2Me	H	CN	H	H
525	1	CO_2tBu	H	CN	H	H
526	2	CO_2tBu	H	CN	H	H
527	3	CO_2tBu	H	CN	H	H
528	4	CO_2tBu	H	CN	H	H
529	1	CONHMe	H	CN	H	H

530	2	CONHMe	H	CN	H	H
531	3	CONHMe	H	CN	H	H
532	4	CONHMe	H	CN	H	H
533	1	SO_2Me	H	CN	H	H
534	2	SO_2Me	H	CN	H	H
535	3	SO_2Me	H	CN	H	H
536	4	SO_2Me	H	CN	H	H
537	1	SO_2NH_2	H	CN	H	H
538	2	SO_2NH_2	H	CN	H	H
539	3	SO_2NH_2	H	CN	H	H
540	4	SO_2NH_2	H	CN	H	H
541	1	H	OH	H	H	H
542	2	H	OH	H	H	H
543	3	H	OH	H	H	H
544	4	H	OH	H	H	H
545	1	Me	OH	H	H	H
546	2	Me	OH	H	H	H
547	3	Me	OH	H	H	H
548	4	Me	OH	H	H	H
549	1	CH_2Ph	OH	H	H	H
550	2	CH_2Ph	OH	H	H	H
551	3	CH_2Ph	OH	H	H	H
552	4	CH_2Ph	OH	H	H	H
553	1	COMe	OH	H	H	H
554	2	COMe	OH	H	H	H
555	3	COMe	OH	H	H	H
556	4	COMe	OH	H	H	H
557	1	CO_2Me	OH	H	H	H
558	2	CO_2Me	OH	H	H	H
559	3	CO_2Me	OH	H	H	H
560	4	CO_2Me	OH	H	H	H

561	1	CO_2tBu	OH	H	H	H
562	2	CO_2tBu	OH	H	H	H
563	3	CO_2tBu	OH	H	H	H
564	4	CO_2tBu	OH	H	H	H
565	1	CONHMe	OH	H	H	H
566	2	CONHMe	OH	H	H	H
567	3	CONHMe	OH	H	H	H
568	4	CONHMe	OH	H	H	H
569	1	SO_2Me	OH	H	H	H
570	2	SO_2Me	OH	H	H	H
571	3	SO_2Me	OH	H	H	H
572	4	SO_2Me	OH	H	H	H
573	1	SO_2NH_2	OH	H	H	H
574	2	SO_2NH_2	OH	H	H	H
575	3	SO_2NH_2	OH	H	H	H
576	4	SO_2NH_2	OH	H	H	H
577	1	H	OMe	H	H	H
578	2	H	OMe	H	H	H
579	3	H	OMe	H	H	H
580	4	H	OMe	H	H	H
581	1	Me	OMe	H	H	H
582	2	Me	OMe	H	H	H
583	3	Me	OMe	H	H	H
584	4	Me	OMe	H	H	H
585	1	CH_2Ph	OMe	H	H	H
586	2	CH_2Ph	OMe	H	H	H
587	3	CH_2Ph	OMe	H	H	H
588	4	CH_2Ph	OMe	H	H	H
589	1	COMe	OMe	H	H	H
590	2	COMe	OMe	H	H	H
591	3	COMe	OMe	H	H	H

592	4	COMe	OMe	H	H	H
593	1	CO_2Me	OMe	H	H	H
594	2	CO_2Me	OMe	H	H	H
595	3	CO_2Me	OMe	H	H	H
596	4	CO_2Me	OMe	H	H	H
597	1	CO_2tBu	OMe	H	H	H
598	2	CO_2tBu	OMe	H	H	H
599	3	CO_2tBu	OMe	H	H	H
600	4	CO_2tBu	OMe	H	H	H
601	1	CONHMe	OMe	H	H	H
602	2	CONHMe	OMe	H	H	H
603	3	CONHMe	OMe	H	H	H
604	4	CONHMe	OMe	H	H	H
605	1	SO_2Me	OMe	H	H	H
606	2	SO_2Me	OMe	H	H	H
607	3	SO_2Me	OMe	H	H	H
608	4	SO_2Me	OMe	H	H	H
609	1	SO_2NH_2	OMe	H	H	H
610	2	SO_2NH_2	OMe	H	H	H
611	3	SO_2NH_2	OMe	H	H	H
612	4	SO_2NH_2	OMe	H	H	H
613	1	H	Me	H	H	H
614	2	H	Me	H	H	H
615	3	H	Me	H	H	H
616	4	H	Me	H	H	H
617	1	Me	Me	H	H	H
618	2	Me	Me	H	H	H
619	3	Me	Me	H	H	H
620	4	Me	Me	H	H	H
621	1	CH_2Ph	Me	H	H	H
622	2	CH_2Ph	Me	H	H	H

623	3	CH_2Ph	Me	H	H	H
624	4	CH_2Ph	Me	H	H	H
625	1	COMe	Me	H	H	H
626	2	COMe	Me	H	H	H
627	3	COMe	Me	H	H	H
628	4	COMe	Me	H	H	H
629	1	CO_2Me	Me	H	H	H
630	2	CO_2Me	Me	H	H	H
631	3	CO_2Me	Me	H	H	H
632	4	CO_2Me	Me	H	H	H
633	1	CO_2tBu	Me	H	H	H
634	2	CO_2tBu	Me	H	H	H
635	3	CO_2tBu	Me	H	H	H
636	4	CO_2tBu	Me	H	H	H
637	1	CONHMe	Me	H	H	H
638	2	CONHMe	Me	H	H	H
639	3	CONHMe	Me	H	H	H
640	4	CONHMe	Me	H	H	H
641	1	SO_2Me	Me	H	H	H
642	2	SO_2Me	Me	H	H	H
643	3	SO_2Me	Me	H	H	H
644	4	SO_2Me	Me	H	H	H
645	1	SO_2NH_2	Me	H	H	H
646	2	SO_2NH_2	Me	H	H	H
647	3	SO_2NH_2	Me	H	H	H
648	4	SO_2NH_2	Me	H	H	H
649	1	H	CF_3	H	H	H
650	2	H	CF_3	H	H	H
651	3	H	CF_3	H	H	H
652	4	H	CF_3	H	H	H
653	1	Me	CF_3	H	H	H

654	2	Me	CF_3	H	H	H
655	3	Me	CF_3	H	H	H
656	4	Me	CF_3	H	H	H
657	1	CH_2Ph	CF_3	H	H	H
658	2	CH_2Ph	CF_3	H	H	H
659	3	CH_2Ph	CF_3	H	H	H
660	4	CH_2Ph	CF_3	H	H	H
661	1	COMe	CF_3	H	H	H
662	2	COMe	CF_3	H	H	H
663	3	COMe	CF_3	H	H	H
664	4	COMe	CF_3	H	H	H
665	1	CO_2Me	CF_3	H	H	H
666	2	CO_2Me	CF_3	H	H	H
667	3	CO_2Me	CF_3	H	H	H
668	4	CO_2Me	CF_3	H	H	H
669	1	CO_2tBu	CF_3	H	H	H
670	2	CO_2tBu	CF_3	H	H	H
671	3	CO_2tBu	CF_3	H	H	H
672	4	CO_2tBu	CF_3	H	H	H
673	1	CONHMe	CF_3	H	H	H
674	2	CONHMe	CF_3	H	H	H
675	3	CONHMe	CF_3	H	H	H
676	4	CONHMe	CF_3	H	H	H
677	1	SO_2Me	CF_3	H	H	H
678	2	SO_2Me	CF_3	H	H	H
679	3	SO_2Me	CF_3	H	H	H
680	4	SO_2Me	CF_3	H	H	H
681	1	SO_2NH_2	CF_3	H	H	H
682	2	SO_2NH_2	CF_3	H	H	H
683	3	SO_2NH_2	CF_3	H	H	H
684	4	SO_2NH_2	CF_3	H	H	H

685	1	H	F	H	H	H
686	2	H	F	H	H	H
687	3	H	F	H	H	H
688	3	H	F	H	H	H
689	1	Me	F	H	H	H
690	2	Me	F	H	H	H
691	3	Me	F	H	H	H
692	4	Me	F	H	H	H
693	1	CH_2Ph	F	H	H	H
694	2	CH_2Ph	F	H	H	H
695	3	CH_2Ph	F	H	H	H
696	4	CH_2Ph	F	H	H	H
697	1	COMe	F	H	H	H
698	2	COMe	F	H	H	H
699	3	COMe	F	H	H	H
700	4	COMe	F	H	H	H
701	1	CO_2Me	F	H	H	H
702	2	CO_2Me	F	H	H	H
703	3	CO_2Me	F	H	H	H
704	4	CO_2Me	F	H	H	H
705	1	CO_2tBu	F	H	H	H
706	2	CO_2tBu	F	H	H	H
707	3	CO_2tBu	F	H	H	H
708	4	CO_2tBu	F	H	H	H
709	1	CONHMe	F	H	H	H
710	2	CONHMe	F	H	H	H
711	3	CONHMe	F	H	H	H
712	4	CONHMe	F	H	H	H
713	1	SO_2Me	F	H	H	H
714	2	SO_2Me	F	H	H	H
715	3	SO_2Me	F	H	H	H

716	4	SO_2Me	F	H	H	H
717	1	SO_2NH_2	F	H	H	H
718	2	SO_2NH_2	F	H	H	H
719	3	SO_2NH_2	F	H	H	H
720	4	SO_2NH_2	F	H	H	H
721	1	H	Cl	H	H	H
722	2	H	Cl	H	H	H
723	3	H	Cl	H	H	H
724	4	H	Cl	H	H	H
725	1	Me	Cl	H	H	H
726	2	Me	Cl	H	H	H
727	3	Me	Cl	H	H	H
728	4	Me	Cl	H	H	H
729	1	CH_2Ph	Cl	H	H	H
730	2	CH_2Ph	Cl	H	H	H
731	3	CH_2Ph	Cl	H	H	H
732	4	CH_2Ph	Cl	H	H	H
733	1	COMe	Cl	H	H	H
734	2	COMe	Cl	H	H	H
735	3	COMe	Cl	H	H	H
736	4	COMe	Cl	H	H	H
737	1	CO_2Me	Cl	H	H	H
738	2	CO_2Me	Cl	H	H	H
739	3	CO_2Me	Cl	H	H	H
740	4	CO_2Me	Cl	H	H	H
741	1	CO_2tBu	Cl	H	H	H
742	2	CO_2tBu	Cl	H	H	H
743	3	CO_2tBu	Cl	H	H	H
744	4	CO_2tBu	Cl	H	H	H
745	1	CONHMe	Cl	H	H	H
746	2	CONHMe	Cl	H	H	H

747	3	CONHMe	Cl	H	H	H
748	4	CONHMe	Cl	H	H	H
749	1	SO_2Me	Cl	H	H	H
750	2	SO_2Me	Cl	H	H	H
751	3	SO_2Me	Cl	H	H	H
752	4	SO_2Me	Cl	H	H	H
753	1	SO_2NH_2	Cl	H	H	H
754	2	SO_2NH_2	Cl	H	H	H
755	3	SO_2NH_2	Cl	H	H	H
756	4	SO_2NH_2	Cl	H	H	H
757	1	H	CN	H	H	H
758	2	H	CN	H	H	H
759	3	H	CN	H	H	H
760	4	H	CN	H	H	H
761	1	Me	CN	H	H	H
762	2	Me	CN	H	H	H
763	3	Me	CN	H	H	H
764	4	Me	CN	H	H	H
765	1	CH_2Ph	CN	H	H	H
766	2	CH_2Ph	CN	H	H	H
767	3	CH_2Ph	CN	H	H	H
768	4	CH_2Ph	CN	H	H	H
769	1	COMe	CN	H	H	H
770	2	COMe	CN	H	H	H
771	3	COMe	CN	H	H	H
772	4	COMe	CN	H	H	H
773	1	CO_2Me	CN	H	H	H
774	2	CO_2Me	CN	H	H	H
775	3	CO_2Me	CN	H	H	H
776	4	CO_2Me	CN	H	H	H
777	1	CO_2tBu	CN	H	H	H

778	2	CO_2tBu	CN	H	H	H
779	3	CO_2tBu	CN	H	H	H
780	4	CO_2tBu	CN	H	H	H
781	1	CONHMe	CN	H	H	H
782	2	CONHMe	CN	H	H	H
783	3	CONHMe	CN	H	H	H
784	4	CONHMe	CN	H	H	H
785	1	SO_2Me	CN	H	H	H
786	2	SO_2Me	CN	H	H	H
787	3	SO_2Me	CN	H	H	H
788	4	SO_2Me	CN	H	H	H
789	1	SO_2NH_2	CN	H	H	H
790	2	SO_2NH_2	CN	H	H	H
791	3	SO_2NH_2	CN	H	H	H
792	4	SO_2NH_2	CN	H	H	H
793	1	H	H	H	H	OH
794	2	H	H	H	H	OH
795	3	H	H	H	H	OH
796	4	H	H	H	H	OH
797	1	Me	H	H	H	OH
798	2	Me	H	H	H	OH
799	3	Me	H	H	H	OH
800	4	Me	H	H	H	OH
801	1	CH_2Ph	H	H	H	OH
802	2	CH_2Ph	H	H	H	OH
803	3	CH_2Ph	H	H	H	OH
804	4	CH_2Ph	H	H	H	OH
805	1	COMe	H	H	H	OH
806	2	COMe	H	H	H	OH
807	3	COMe	H	H	H	OH
808	4	COMe	H	H	H	OH

809	1	CO_2Me	H	H	H	OH
810	2	CO_2Me	H	H	H	OH
811	3	CO_2Me	H	H	H	OH
812	4	CO_2Me	H	H	H	OH
813	1	CO_2tBu	H	H	H	OH
814	2	CO_2tBu	H	H	H	OH
815	3	CO_2tBu	H	H	H	OH
816	4	CO_2tBu	H	H	H	OH
817	1	CONHMe	H	H	H	OH
818	2	CONHMe	H	H	H	OH
819	3	CONHMe	H	H	H	OH
820	4	CONHMe	H	H	H	OH
821	1	SO_2Me	H	H	H	OH
822	2	SO_2Me	H	H	H	OH
823	3	SO_2Me	H	H	H	OH
824	4	SO_2Me	H	H	H	OH
825	1	SO_2NH_2	H	H	H	OH
826	2	SO_2NH_2	H	H	H	OH
827	3	SO_2NH_2	H	H	H	OH
828	4	SO_2NH_2	H	H	H	OH
829	1	H	H	H	H	OMe
830	2	H	H	H	H	OMe
831	3	H	H	H	H	OMe
832	4	H	H	H	H	OMe
833	1	Me	H	H	H	OMe
834	2	Me	H	H	H	OMe
835	3	Me	H	H	H	OMe
836	4	Me	H	H	H	OMe
837	1	CH_2Ph	H	H	H	OMe
838	2	CH_2Ph	H	H	H	OMe
839	3	CH_2Ph	H	H	H	OMe

840	4	CH_2Ph	H	H	H	OMe
841	1	COMe	H	H	H	OMe
842	2	COMe	H	H	H	OMe
843	3	COMe	H	H	H	OMe
844	4	COMe	H	H	H	OMe
845	1	CO_2Me	H	H	H	OMe
846	2	CO_2Me	H	H	H	OMe
847	3	CO_2Me	H	H	H	OMe
848	4	CO_2Me	H	H	H	OMe
849	1	CO_2tBu	H	H	H	OMe
850	2	CO_2tBu	H	H	H	OMe
851	3	CO_2tBu	H	H	H	OMe
852	4	CO_2tBu	H	H	H	OMe
853	1	CONHMe	H	H	H	OMe
854	2	CONHMe	H	H	H	OMe
855	3	CONHMe	H	H	H	OMe
856	4	CONHMe	H	H	H	OMe
857	1	SO_2Me	H	H	H	OMe
858	2	SO_2Me	H	H	H	OMe
859	3	SO_2Me	H	H	H	OMe
860	4	SO_2Me	H	H	H	OMe
861	1	SO_2NH_2	H	H	H	OMe
862	2	SO_2NH_2	H	H	H	OMe
863	3	SO_2NH_2	H	H	H	OMe
864	4	SO_2NH_2	H	H	H	OMe
865	1	H	H	H	H	Me
866	2	H	H	H	H	Me
867	3	H	H	H	H	Me
868	4	H	H	H	H	Me
869	1	Me	H	H	H	Me
870	2	Me	H	H	H	Me

871	3	Me	H	H	H	Me
872	4	Me	H	H	H	Me
873	1	CH_2Ph	H	H	H	Me
874	2	CH_2Ph	H	H	H	Me
875	3	CH_2Ph	H	H	H	Me
876	4	CH_2Ph	H	H	H	Me
877	1	COMe	H	H	H	Me
878	2	COMe	H	H	H	Me
879	3	COMe	H	H	H	Me
880	4	COMe	H	H	H	Me
881	1	CO_2Me	H	H	H	Me
882	2	CO_2Me	H	H	H	Me
883	3	CO_2Me	H	H	H	Me
884	4	CO_2Me	H	H	H	Me
885	1	CO_2tBu	H	H	H	Me
886	2	CO_2tBu	H	H	H	Me
887	3	CO_2tBu	H	H	H	Me
888	4	CO_2tBu	H	H	H	Me
889	1	CONHMe	H	H	H	Me
890	2	CONHMe	H	H	H	Me
891	3	CONHMe	H	H	H	Me
892	4	CONHMe	H	H	H	Me
893	1	SO_2Me	H	H	H	Me
894	2	SO_2Me	H	H	H	Me
895	3	SO_2Me	H	H	H	Me
896	4	SO_2Me	H	H	H	Me
897	1	SO_2NH_2	H	H	H	Me
898	2	SO_2NH_2	H	H	H	Me
899	3	SO_2NH_2	H	H	H	Me
900	4	SO_2NH_2	H	H	H	Me
901	1	H	H	H	H	CF_3

902	2	H	H	H	H	CF_3
903	3	H	H	H	H	CF_3
904	4	H	H	H	H	CF_3
905	1	Me	H	H	H	CF_3
906	2	Me	H	H	H	CF_3
907	3	Me	H	H	H	CF_3
908	4	Me	H	H	H	CF_3
909	1	CH_2Ph	H	H	H	CF_3
910	2	CH_2Ph	H	H	H	CF_3
911	3	CH_2Ph	H	H	H	CF_3
912	4	CH_2Ph	H	H	H	CF_3
913	1	COMe	H	H	H	CF_3
914	2	COMe	H	H	H	CF_3
915	3	COMe	H	H	H	CF_3
916	4	COMe	H	H	H	CF_3
917	1	CO_2Me	H	H	H	CF_3
918	2	CO_2Me	H	H	H	CF_3
919	3	CO_2Me	H	H	H	CF_3
920	4	CO_2Me	H	H	H	CF_3
921	1	CO_2tBu	H	H	H	CF_3
922	2	CO_2tBu	H	H	H	CF_3
923	3	CO_2tBu	H	H	H	CF_3
924	4	CO_2tBu	H	H	H	CF_3
925	1	CONHMe	H	H	H	CF_3
926	2	CONHMe	H	H	H	CF_3
927	3	CONHMe	H	H	H	CF_3
928	4	CONHMe	H	H	H	CF_3
929	1	SO_2Me	H	H	H	CF_3
930	2	SO_2Me	H	H	H	CF_3
931	3	SO_2Me	H	H	H	CF_3
932	4	SO_2Me	H	H	H	CF_3


933	1	SO_2NH_2	H	H	H	CF_3
934	2	SO_2NH_2	H	H	H	CF_3
935	3	SO_2NH_2	H	H	H	CF_3
936	4	SO_2NH_2	H	H	H	CF_3
937	1	H	H	H	H	F
938	2	H	H	H	H	F
939	3	H	H	H	H	F
940	3	H	H	H	H	F
941	1	Me	H	H	H	F
942	2	Me	H	H	H	F
943	3	Me	H	H	H	F
944	4	Me	H	H	H	F
945	1	CH_2Ph	H	H	H	F
946	2	CH_2Ph	H	H	H	F
947	3	CH_2Ph	H	H	H	F
948	4	CH_2Ph	H	H	H	F
949	1	COMe	H	H	H	F
950	2	COMe	H	H	H	F
951	3	COMe	H	H	H	F
952	4	COMe	H	H	H	F
953	1	CO_2Me	H	H	H	F
954	2	CO_2Me	H	H	H	F
955	3	CO_2Me	H	H	H	F
956	4	CO_2Me	H	H	H	F
957	1	CO_2tBu	H	H	H	F
958	2	CO_2tBu	H	H	H	F
959	3	CO_2tBu	H	H	H	F
960	4	CO_2tBu	H	H	H	F
961	1	CONHMe	H	H	H	F
962	2	CONHMe	H	H	H	F
963	3	CONHMe	H	H	H	F

964	4	CONHMe	H	H	H	F
965	1	SO_2Me	H	H	H	F
966	2	SO_2Me	H	H	H	F
967	3	SO_2Me	H	H	H	F
968	4	SO_2Me	H	H	H	F
969	1	SO_2NH_2	H	H	H	F
970	2	SO_2NH_2	H	H	H	F
971	3	SO_2NH_2	H	H	H	F
972	4	SO_2NH_2	H	H	H	F
973	1	H	H	H	H	Cl
974	2	H	H	H	H	Cl
975	3	H	H	H	H	Cl
976	4	H	H	H	H	Cl
977	1	Me	H	H	H	Cl
978	2	Me	H	H	H	Cl
979	3	Me	H	H	H	Cl
980	4	Me	H	H	H	Cl
981	1	CH_2Ph	H	H	H	Cl
982	2	CH_2Ph	H	H	H	Cl
983	3	CH_2Ph	H	H	H	Cl
984	4	CH_2Ph	H	H	H	Cl
985	1	COMe	H	H	H	Cl
986	2	COMe	H	H	H	Cl
987	3	COMe	H	H	H	Cl
988	4	COMe	H	H	H	Cl
989	1	CO_2Me	H	H	H	Cl
990	2	CO_2Me	H	H	H	Cl
991	3	CO_2Me	H	H	H	Cl
992	4	CO_2Me	H	H	H	Cl
993	1	CO_2tBu	H	H	H	Cl
994	2	CO_2tBu	H	H	H	Cl

995	3	CO_2tBu	H	H	H	Cl
996	4	CO_2tBu	H	H	H	Cl
997	1	CONHMe	H	H	H	Cl
998	2	CONHMe	H	H	H	Cl
999	3	CONHMe	H	H	H	Cl
1000	4	CONHMe	H	H	H	Cl
1001	1	SO_2Me	H	H	H	Cl
1002	2	SO_2Me	H	H	H	Cl
1003	3	SO_2Me	H	H	H	Cl
1004	4	SO_2Me	H	H	H	Cl
1005	1	SO_2NH_2	H	H	H	Cl
1006	2	SO_2NH_2	H	H	H	Cl
1007	3	SO_2NH_2	H	H	H	Cl
1008	4	SO_2NH_2	H	H	H	Cl
1009	1	H	H	H	H	CN
1010	2	H	H	H	H	CN
1011	3	H	H	H	H	CN
1012	4	H	H	H	H	CN
1013	1	Me	H	H	H	CN
1014	2	Me	H	H	H	CN
1015	3	Me	H	H	H	CN
1016	4	Me	H	H	H	CN
1017	1	CH_2Ph	H	H	H	CN
1018	2	CH_2Ph	H	H	H	CN
1019	3	CH_2Ph	H	H	H	CN
1020	4	CH_2Ph	H	H	H	CN
1021	1	COMe	H	H	H	CN
1022	2	COMe	H	H	H	CN
1023	3	COMe	H	H	H	CN
1024	4	COMe	H	H	H	CN
1025	1	CO_2Me	H	H	H	CN

1026	2	CO_2Me	H	H	H	CN
1027	3	CO_2Me	H	H	H	CN
1028	4	CO_2Me	H	H	H	CN
1029	1	CO_2tBu	H	H	H	CN
1030	2	CO_2tBu	H	H	H	CN
1031	3	CO_2tBu	H	H	H	CN
1032	4	CO_2tBu	H	H	H	CN
1033	1	CONHMe	H	H	H	CN
1034	2	CONHMe	H	H	H	CN
1035	3	CONHMe	H	H	H	CN
1036	4	CONHMe	H	H	H	CN
1037	1	SO_2Me	H	H	H	CN
1038	2	SO_2Me	H	H	H	CN
1039	3	SO_2Me	H	H	H	CN
1040	4	SO_2Me	H	H	H	CN
1041	1	SO_2NH_2	H	H	H	CN
1042	2	SO_2NH_2	H	H	H	CN
1043	3	SO_2NH_2	H	H	H	CN
1044	4	SO_2NH_2	H	H	H	CN

[01029] Exemplary embodiments include compounds having the formula **(XXVII)**



(XXVII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 21.

Table 21

Entry	n	R^7	R^{20a}	R^{20b}	R^{20c}	R^{20d}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H

4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H

35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H

66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H

97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H

128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H

159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H

190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H

221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H

252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H

283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	OH	H	H
290	2	H	H	OH	H	H
291	3	H	H	OH	H	H
292	4	H	H	OH	H	H
293	1	Me	H	OH	H	H
294	2	Me	H	OH	H	H
295	3	Me	H	OH	H	H
296	4	Me	H	OH	H	H
297	1	CH_2Ph	H	OH	H	H
298	2	CH_2Ph	H	OH	H	H
299	3	CH_2Ph	H	OH	H	H
300	4	CH_2Ph	H	OH	H	H
301	1	COMe	H	OH	H	H
302	2	COMe	H	OH	H	H
303	3	COMe	H	OH	H	H
304	4	COMe	H	OH	H	H
305	1	CO_2Me	H	OH	H	H
306	2	CO_2Me	H	OH	H	H
307	3	CO_2Me	H	OH	H	H
308	4	CO_2Me	H	OH	H	H
309	1	CO_2tBu	H	OH	H	H
310	2	CO_2tBu	H	OH	H	H
311	3	CO_2tBu	H	OH	H	H
312	4	CO_2tBu	H	OH	H	H
313	1	CONHMe	H	OH	H	H

314	2	CONHMe	H	OH	H	H
315	3	CONHMe	H	OH	H	H
316	4	CONHMe	H	OH	H	H
317	1	SO_2Me	H	OH	H	H
318	2	SO_2Me	H	OH	H	H
319	3	SO_2Me	H	OH	H	H
320	4	SO_2Me	H	OH	H	H
321	1	SO_2NH_2	H	OH	H	H
322	2	SO_2NH_2	H	OH	H	H
323	3	SO_2NH_2	H	OH	H	H
324	4	SO_2NH_2	H	OH	H	H
325	1	H	H	OMe	H	H
326	2	H	H	OMe	H	H
327	3	H	H	OMe	H	H
328	4	H	H	OMe	H	H
329	1	Me	H	OMe	H	H
330	2	Me	H	OMe	H	H
331	3	Me	H	OMe	H	H
332	4	Me	H	OMe	H	H
333	1	CH_2Ph	H	OMe	H	H
334	2	CH_2Ph	H	OMe	H	H
335	3	CH_2Ph	H	OMe	H	H
336	4	CH_2Ph	H	OMe	H	H
337	1	COMe	H	OMe	H	H
338	2	COMe	H	OMe	H	H
339	3	COMe	H	OMe	H	H
340	4	COMe	H	OMe	H	H
341	1	CO_2Me	H	OMe	H	H
342	2	CO_2Me	H	OMe	H	H
343	3	CO_2Me	H	OMe	H	H
344	4	CO_2Me	H	OMe	H	H

345	1	CO_2tBu	H	OMe	H	H
346	2	CO_2tBu	H	OMe	H	H
347	3	CO_2tBu	H	OMe	H	H
348	4	CO_2tBu	H	OMe	H	H
349	1	CONHMe	H	OMe	H	H
350	2	CONHMe	H	OMe	H	H
351	3	CONHMe	H	OMe	H	H
352	4	CONHMe	H	OMe	H	H
353	1	SO_2Me	H	OMe	H	H
354	2	SO_2Me	H	OMe	H	H
355	3	SO_2Me	H	OMe	H	H
356	4	SO_2Me	H	OMe	H	H
357	1	SO_2NH_2	H	OMe	H	H
358	2	SO_2NH_2	H	OMe	H	H
359	3	SO_2NH_2	H	OMe	H	H
360	4	SO_2NH_2	H	OMe	H	H
361	1	H	H	Me	H	H
362	2	H	H	Me	H	H
363	3	H	H	Me	H	H
364	4	H	H	Me	H	H
365	1	Me	H	Me	H	H
366	2	Me	H	Me	H	H
367	3	Me	H	Me	H	H
368	4	Me	H	Me	H	H
369	1	CH_2Ph	H	Me	H	H
370	2	CH_2Ph	H	Me	H	H
371	3	CH_2Ph	H	Me	H	H
372	4	CH_2Ph	H	Me	H	H
373	1	COMe	H	Me	H	H
374	2	COMe	H	Me	H	H
375	3	COMe	H	Me	H	H

376	4	COMe	H	Me	H	H
377	1	CO_2Me	H	Me	H	H
378	2	CO_2Me	H	Me	H	H
379	3	CO_2Me	H	Me	H	H
380	4	CO_2Me	H	Me	H	H
381	1	CO_2tBu	H	Me	H	H
382	2	CO_2tBu	H	Me	H	H
383	3	CO_2tBu	H	Me	H	H
384	4	CO_2tBu	H	Me	H	H
385	1	CONHMe	H	Me	H	H
386	2	CONHMe	H	Me	H	H
387	3	CONHMe	H	Me	H	H
388	4	CONHMe	H	Me	H	H
389	1	SO_2Me	H	Me	H	H
390	2	SO_2Me	H	Me	H	H
391	3	SO_2Me	H	Me	H	H
392	4	SO_2Me	H	Me	H	H
393	1	SO_2NH_2	H	Me	H	H
394	2	SO_2NH_2	H	Me	H	H
395	3	SO_2NH_2	H	Me	H	H
396	4	SO_2NH_2	H	Me	H	H
397	1	H	H	CF_3	H	H
398	2	H	H	CF_3	H	H
399	3	H	H	CF_3	H	H
400	4	H	H	CF_3	H	H
401	1	Me	H	CF_3	H	H
402	2	Me	H	CF_3	H	H
403	3	Me	H	CF_3	H	H
404	4	Me	H	CF_3	H	H
405	1	CH_2Ph	H	CF_3	H	H
406	2	CH_2Ph	H	CF_3	H	H

407	3	CH_2Ph	H	CF_3	H	H
408	4	CH_2Ph	H	CF_3	H	H
409	1	COMe	H	CF_3	H	H
410	2	COMe	H	CF_3	H	H
411	3	COMe	H	CF_3	H	H
412	4	COMe	H	CF_3	H	H
413	1	CO_2Me	H	CF_3	H	H
414	2	CO_2Me	H	CF_3	H	H
415	3	CO_2Me	H	CF_3	H	H
416	4	CO_2Me	H	CF_3	H	H
417	1	CO_2tBu	H	CF_3	H	H
418	2	CO_2tBu	H	CF_3	H	H
419	3	CO_2tBu	H	CF_3	H	H
420	4	CO_2tBu	H	CF_3	H	H
421	1	CONHMe	H	CF_3	H	H
422	2	CONHMe	H	CF_3	H	H
423	3	CONHMe	H	CF_3	H	H
424	4	CONHMe	H	CF_3	H	H
425	1	SO_2Me	H	CF_3	H	H
426	2	SO_2Me	H	CF_3	H	H
427	3	SO_2Me	H	CF_3	H	H
428	4	SO_2Me	H	CF_3	H	H
429	1	SO_2NH_2	H	CF_3	H	H
430	2	SO_2NH_2	H	CF_3	H	H
431	3	SO_2NH_2	H	CF_3	H	H
432	4	SO_2NH_2	H	CF_3	H	H
433	1	H	H	F	H	H
434	2	H	H	F	H	H
435	3	H	H	F	H	H
436	3	H	H	F	H	H
437	1	Me	H	F	H	H

438	2	Me	H	F	H	H
439	3	Me	H	F	H	H
440	4	Me	H	F	H	H
441	1	CH_2Ph	H	F	H	H
442	2	CH_2Ph	H	F	H	H
443	3	CH_2Ph	H	F	H	H
444	4	CH_2Ph	H	F	H	H
445	1	COMe	H	F	H	H
446	2	COMe	H	F	H	H
447	3	COMe	H	F	H	H
448	4	COMe	H	F	H	H
449	1	CO_2Me	H	F	H	H
450	2	CO_2Me	H	F	H	H
451	3	CO_2Me	H	F	H	H
452	4	CO_2Me	H	F	H	H
453	1	CO_2tBu	H	F	H	H
454	2	CO_2tBu	H	F	H	H
455	3	CO_2tBu	H	F	H	H
456	4	CO_2tBu	H	F	H	H
457	1	CONHMe	H	F	H	H
458	2	CONHMe	H	F	H	H
459	3	CONHMe	H	F	H	H
460	4	CONHMe	H	F	H	H
461	1	SO_2Me	H	F	H	H
462	2	SO_2Me	H	F	H	H
463	3	SO_2Me	H	F	H	H
464	4	SO_2Me	H	F	H	H
465	1	SO_2NH_2	H	F	H	H
466	2	SO_2NH_2	H	F	H	H
467	3	SO_2NH_2	H	F	H	H
468	4	SO_2NH_2	H	F	H	H

469	1	H	H	Cl	H	H
470	2	H	H	Cl	H	H
471	3	H	H	Cl	H	H
472	4	H	H	Cl	H	H
473	1	Me	H	Cl	H	H
474	2	Me	H	Cl	H	H
475	3	Me	H	Cl	H	H
476	4	Me	H	Cl	H	H
477	1	CH_2Ph	H	Cl	H	H
478	2	CH_2Ph	H	Cl	H	H
479	3	CH_2Ph	H	Cl	H	H
480	4	CH_2Ph	H	Cl	H	H
481	1	COMe	H	Cl	H	H
482	2	COMe	H	Cl	H	H
483	3	COMe	H	Cl	H	H
484	4	COMe	H	Cl	H	H
485	1	CO_2Me	H	Cl	H	H
486	2	CO_2Me	H	Cl	H	H
487	3	CO_2Me	H	Cl	H	H
488	4	CO_2Me	H	Cl	H	H
489	1	CO_2tBu	H	Cl	H	H
490	2	CO_2tBu	H	Cl	H	H
491	3	CO_2tBu	H	Cl	H	H
492	4	CO_2tBu	H	Cl	H	H
493	1	CONHMe	H	Cl	H	H
494	2	CONHMe	H	Cl	H	H
495	3	CONHMe	H	Cl	H	H
496	4	CONHMe	H	Cl	H	H
497	1	SO_2Me	H	Cl	H	H
498	2	SO_2Me	H	Cl	H	H
499	3	SO_2Me	H	Cl	H	H

500	4	SO_2Me	H	Cl	H	H
501	1	SO_2NH_2	H	Cl	H	H
502	2	SO_2NH_2	H	Cl	H	H
503	3	SO_2NH_2	H	Cl	H	H
504	4	SO_2NH_2	H	Cl	H	H
505	1	H	H	CN	H	H
506	2	H	H	CN	H	H
507	3	H	H	CN	H	H
508	4	H	H	CN	H	H
509	1	Me	H	CN	H	H
510	2	Me	H	CN	H	H
511	3	Me	H	CN	H	H
512	4	Me	H	CN	H	H
513	1	CH_2Ph	H	CN	H	H
514	2	CH_2Ph	H	CN	H	H
515	3	CH_2Ph	H	CN	H	H
516	4	CH_2Ph	H	CN	H	H
517	1	COMe	H	CN	H	H
518	2	COMe	H	CN	H	H
519	3	COMe	H	CN	H	H
520	4	COMe	H	CN	H	H
521	1	CO_2Me	H	CN	H	H
522	2	CO_2Me	H	CN	H	H
523	3	CO_2Me	H	CN	H	H
524	4	CO_2Me	H	CN	H	H
525	1	CO_2tBu	H	CN	H	H
526	2	CO_2tBu	H	CN	H	H
527	3	CO_2tBu	H	CN	H	H
528	4	CO_2tBu	H	CN	H	H
529	1	CONHMe	H	CN	H	H
530	2	CONHMe	H	CN	H	H

531	3	CONHMe	H	CN	H	H
532	4	CONHMe	H	CN	H	H
533	1	SO_2Me	H	CN	H	H
534	2	SO_2Me	H	CN	H	H
535	3	SO_2Me	H	CN	H	H
536	4	SO_2Me	H	CN	H	H
537	1	SO_2NH_2	H	CN	H	H
538	2	SO_2NH_2	H	CN	H	H
539	3	SO_2NH_2	H	CN	H	H
540	4	SO_2NH_2	H	CN	H	H
541	1	H	OH	H	H	H
542	2	H	OH	H	H	H
543	3	H	OH	H	H	H
544	4	H	OH	H	H	H
545	1	Me	OH	H	H	H
546	2	Me	OH	H	H	H
547	3	Me	OH	H	H	H
548	4	Me	OH	H	H	H
549	1	CH_2Ph	OH	H	H	H
550	2	CH_2Ph	OH	H	H	H
551	3	CH_2Ph	OH	H	H	H
552	4	CH_2Ph	OH	H	H	H
553	1	COMe	OH	H	H	H
554	2	COMe	OH	H	H	H
555	3	COMe	OH	H	H	H
556	4	COMe	OH	H	H	H
557	1	CO_2Me	OH	H	H	H
558	2	CO_2Me	OH	H	H	H
559	3	CO_2Me	OH	H	H	H
560	4	CO_2Me	OH	H	H	H
561	1	CO_2tBu	OH	H	H	H

562	2	CO_2tBu	OH	H	H	H
563	3	CO_2tBu	OH	H	H	H
564	4	CO_2tBu	OH	H	H	H
565	1	CONHMe	OH	H	H	H
566	2	CONHMe	OH	H	H	H
567	3	CONHMe	OH	H	H	H
568	4	CONHMe	OH	H	H	H
569	1	SO_2Me	OH	H	H	H
570	2	SO_2Me	OH	H	H	H
571	3	SO_2Me	OH	H	H	H
572	4	SO_2Me	OH	H	H	H
573	1	SO_2NH_2	OH	H	H	H
574	2	SO_2NH_2	OH	H	H	H
575	3	SO_2NH_2	OH	H	H	H
576	4	SO_2NH_2	OH	H	H	H
577	1	H	OMe	H	H	H
578	2	H	OMe	H	H	H
579	3	H	OMe	H	H	H
580	4	H	OMe	H	H	H
581	1	Me	OMe	H	H	H
582	2	Me	OMe	H	H	H
583	3	Me	OMe	H	H	H
584	4	Me	OMe	H	H	H
585	1	CH_2Ph	OMe	H	H	H
586	2	CH_2Ph	OMe	H	H	H
587	3	CH_2Ph	OMe	H	H	H
588	4	CH_2Ph	OMe	H	H	H
589	1	COMe	OMe	H	H	H
590	2	COMe	OMe	H	H	H
591	3	COMe	OMe	H	H	H
592	4	COMe	OMe	H	H	H

593	1	CO_2Me	OMe	H	H	H
594	2	CO_2Me	OMe	H	H	H
595	3	CO_2Me	OMe	H	H	H
596	4	CO_2Me	OMe	H	H	H
597	1	CO_2tBu	OMe	H	H	H
598	2	CO_2tBu	OMe	H	H	H
599	3	CO_2tBu	OMe	H	H	H
600	4	CO_2tBu	OMe	H	H	H
601	1	CONHMe	OMe	H	H	H
602	2	CONHMe	OMe	H	H	H
603	3	CONHMe	OMe	H	H	H
604	4	CONHMe	OMe	H	H	H
605	1	SO_2Me	OMe	H	H	H
606	2	SO_2Me	OMe	H	H	H
607	3	SO_2Me	OMe	H	H	H
608	4	SO_2Me	OMe	H	H	H
609	1	SO_2NH_2	OMe	H	H	H
610	2	SO_2NH_2	OMe	H	H	H
611	3	SO_2NH_2	OMe	H	H	H
612	4	SO_2NH_2	OMe	H	H	H
613	1	H	Me	H	H	H
614	2	H	Me	H	H	H
615	3	H	Me	H	H	H
616	4	H	Me	H	H	H
617	1	Me	Me	H	H	H
618	2	Me	Me	H	H	H
619	3	Me	Me	H	H	H
620	4	Me	Me	H	H	H
621	1	CH_2Ph	Me	H	H	H
622	2	CH_2Ph	Me	H	H	H
623	3	CH_2Ph	Me	H	H	H

624	4	CH_2Ph	Me	H	H	H
625	1	COMe	Me	H	H	H
626	2	COMe	Me	H	H	H
627	3	COMe	Me	H	H	H
628	4	COMe	Me	H	H	H
629	1	CO_2Me	Me	H	H	H
630	2	CO_2Me	Me	H	H	H
631	3	CO_2Me	Me	H	H	H
632	4	CO_2Me	Me	H	H	H
633	1	CO_2tBu	Me	H	H	H
634	2	CO_2tBu	Me	H	H	H
635	3	CO_2tBu	Me	H	H	H
636	4	CO_2tBu	Me	H	H	H
637	1	CONHMe	Me	H	H	H
638	2	CONHMe	Me	H	H	H
639	3	CONHMe	Me	H	H	H
640	4	CONHMe	Me	H	H	H
641	1	SO_2Me	Me	H	H	H
642	2	SO_2Me	Me	H	H	H
643	3	SO_2Me	Me	H	H	H
644	4	SO_2Me	Me	H	H	H
645	1	SO_2NH_2	Me	H	H	H
646	2	SO_2NH_2	Me	H	H	H
647	3	SO_2NH_2	Me	H	H	H
648	4	SO_2NH_2	Me	H	H	H
649	1	H	CF_3	H	H	H
650	2	H	CF_3	H	H	H
651	3	H	CF_3	H	H	H
652	4	H	CF_3	H	H	H
653	1	Me	CF_3	H	H	H
654	2	Me	CF_3	H	H	H

655	3	Me	CF_3	H	H	H
656	4	Me	CF_3	H	H	H
657	1	CH_2Ph	CF_3	H	H	H
658	2	CH_2Ph	CF_3	H	H	H
659	3	CH_2Ph	CF_3	H	H	H
660	4	CH_2Ph	CF_3	H	H	H
661	1	COMe	CF_3	H	H	H
662	2	COMe	CF_3	H	H	H
663	3	COMe	CF_3	H	H	H
664	4	COMe	CF_3	H	H	H
665	1	CO_2Me	CF_3	H	H	H
666	2	CO_2Me	CF_3	H	H	H
667	3	CO_2Me	CF_3	H	H	H
668	4	CO_2Me	CF_3	H	H	H
669	1	CO_2tBu	CF_3	H	H	H
670	2	CO_2tBu	CF_3	H	H	H
671	3	CO_2tBu	CF_3	H	H	H
672	4	CO_2tBu	CF_3	H	H	H
673	1	CONHMe	CF_3	H	H	H
674	2	CONHMe	CF_3	H	H	H
675	3	CONHMe	CF_3	H	H	H
676	4	CONHMe	CF_3	H	H	H
677	1	SO_2Me	CF_3	H	H	H
678	2	SO_2Me	CF_3	H	H	H
679	3	SO_2Me	CF_3	H	H	H
680	4	SO_2Me	CF_3	H	H	H
681	1	SO_2NH_2	CF_3	H	H	H
682	2	SO_2NH_2	CF_3	H	H	H
683	3	SO_2NH_2	CF_3	H	H	H
684	4	SO_2NH_2	CF_3	H	H	H
685	1	H	F	H	H	H

686	2	H	F	H	H	H
687	3	H	F	H	H	H
688	3	H	F	H	H	H
689	1	Me	F	H	H	H
690	2	Me	F	H	H	H
691	3	Me	F	H	H	H
692	4	Me	F	H	H	H
693	1	CH_2Ph	F	H	H	H
694	2	CH_2Ph	F	H	H	H
695	3	CH_2Ph	F	H	H	H
696	4	CH_2Ph	F	H	H	H
697	1	COMe	F	H	H	H
698	2	COMe	F	H	H	H
699	3	COMe	F	H	H	H
700	4	COMe	F	H	H	H
701	1	CO_2Me	F	H	H	H
702	2	CO_2Me	F	H	H	H
703	3	CO_2Me	F	H	H	H
704	4	CO_2Me	F	H	H	H
705	1	CO_2tBu	F	H	H	H
706	2	CO_2tBu	F	H	H	H
707	3	CO_2tBu	F	H	H	H
708	4	CO_2tBu	F	H	H	H
709	1	CONHMe	F	H	H	H
710	2	CONHMe	F	H	H	H
711	3	CONHMe	F	H	H	H
712	4	CONHMe	F	H	H	H
713	1	SO_2Me	F	H	H	H
714	2	SO_2Me	F	H	H	H
715	3	SO_2Me	F	H	H	H
716	4	SO_2Me	F	H	H	H

717	1	SO_2NH_2	F	H	H	H
718	2	SO_2NH_2	F	H	H	H
719	3	SO_2NH_2	F	H	H	H
720	4	SO_2NH_2	F	H	H	H
721	1	H	Cl	H	H	H
722	2	H	Cl	H	H	H
723	3	H	Cl	H	H	H
724	4	H	Cl	H	H	H
725	1	Me	Cl	H	H	H
726	2	Me	Cl	H	H	H
727	3	Me	Cl	H	H	H
728	4	Me	Cl	H	H	H
729	1	CH_2Ph	Cl	H	H	H
730	2	CH_2Ph	Cl	H	H	H
731	3	CH_2Ph	Cl	H	H	H
732	4	CH_2Ph	Cl	H	H	H
733	1	COMe	Cl	H	H	H
734	2	COMe	Cl	H	H	H
735	3	COMe	Cl	H	H	H
736	4	COMe	Cl	H	H	H
737	1	CO_2Me	Cl	H	H	H
738	2	CO_2Me	Cl	H	H	H
739	3	CO_2Me	Cl	H	H	H
740	4	CO_2Me	Cl	H	H	H
741	1	CO_2tBu	Cl	H	H	H
742	2	CO_2tBu	Cl	H	H	H
743	3	CO_2tBu	Cl	H	H	H
744	4	CO_2tBu	Cl	H	H	H
745	1	CONHMe	Cl	H	H	H
746	2	CONHMe	Cl	H	H	H
747	3	CONHMe	Cl	H	H	H

748	4	CONHMe	Cl	H	H	H
749	1	SO_2Me	Cl	H	H	H
750	2	SO_2Me	Cl	H	H	H
751	3	SO_2Me	Cl	H	H	H
752	4	SO_2Me	Cl	H	H	H
753	1	SO_2NH_2	Cl	H	H	H
754	2	SO_2NH_2	Cl	H	H	H
755	3	SO_2NH_2	Cl	H	H	H
756	4	SO_2NH_2	Cl	H	H	H
757	1	H	CN	H	H	H
758	2	H	CN	H	H	H
759	3	H	CN	H	H	H
760	4	H	CN	H	H	H
761	1	Me	CN	H	H	H
762	2	Me	CN	H	H	H
763	3	Me	CN	H	H	H
764	4	Me	CN	H	H	H
765	1	CH_2Ph	CN	H	H	H
766	2	CH_2Ph	CN	H	H	H
767	3	CH_2Ph	CN	H	H	H
768	4	CH_2Ph	CN	H	H	H
769	1	COMe	CN	H	H	H
770	2	COMe	CN	H	H	H
771	3	COMe	CN	H	H	H
772	4	COMe	CN	H	H	H
773	1	CO_2Me	CN	H	H	H
774	2	CO_2Me	CN	H	H	H
775	3	CO_2Me	CN	H	H	H
776	4	CO_2Me	CN	H	H	H
777	1	CO_2tBu	CN	H	H	H
778	2	CO_2tBu	CN	H	H	H

779	3	CO_2tBu	CN	H	H	H
780	4	CO_2tBu	CN	H	H	H
781	1	CONHMe	CN	H	H	H
782	2	CONHMe	CN	H	H	H
783	3	CONHMe	CN	H	H	H
784	4	CONHMe	CN	H	H	H
785	1	SO_2Me	CN	H	H	H
786	2	SO_2Me	CN	H	H	H
787	3	SO_2Me	CN	H	H	H
788	4	SO_2Me	CN	H	H	H
789	1	SO_2NH_2	CN	H	H	H
790	2	SO_2NH_2	CN	H	H	H
791	3	SO_2NH_2	CN	H	H	H
792	4	SO_2NH_2	CN	H	H	H
793	1	H	H	H	H	OH
794	2	H	H	H	H	OH
795	3	H	H	H	H	OH
796	4	H	H	H	H	OH
797	1	Me	H	H	H	OH
798	2	Me	H	H	H	OH
799	3	Me	H	H	H	OH
800	4	Me	H	H	H	OH
801	1	CH_2Ph	H	H	H	OH
802	2	CH_2Ph	H	H	H	OH
803	3	CH_2Ph	H	H	H	OH
804	4	CH_2Ph	H	H	H	OH
805	1	COMe	H	H	H	OH
806	2	COMe	H	H	H	OH
807	3	COMe	H	H	H	OH
808	4	COMe	H	H	H	OH
809	1	CO_2Me	H	H	H	OH

810	2	CO_2Me	H	H	H	OH
811	3	CO_2Me	H	H	H	OH
812	4	CO_2Me	H	H	H	OH
813	1	CO_2tBu	H	H	H	OH
814	2	CO_2tBu	H	H	H	OH
815	3	CO_2tBu	H	H	H	OH
816	4	CO_2tBu	H	H	H	OH
817	1	CONHMe	H	H	H	OH
818	2	CONHMe	H	H	H	OH
819	3	CONHMe	H	H	H	OH
820	4	CONHMe	H	H	H	OH
821	1	SO_2Me	H	H	H	OH
822	2	SO_2Me	H	H	H	OH
823	3	SO_2Me	H	H	H	OH
824	4	SO_2Me	H	H	H	OH
825	1	SO_2NH_2	H	H	H	OH
826	2	SO_2NH_2	H	H	H	OH
827	3	SO_2NH_2	H	H	H	OH
828	4	SO_2NH_2	H	H	H	OH
829	1	H	H	H	H	OMe
830	2	H	H	H	H	OMe
831	3	H	H	H	H	OMe
832	4	H	H	H	H	OMe
833	1	Me	H	H	H	OMe
834	2	Me	H	H	H	OMe
835	3	Me	H	H	H	OMe
836	4	Me	H	H	H	OMe
837	1	CH_2Ph	H	H	H	OMe
838	2	CH_2Ph	H	H	H	OMe
839	3	CH_2Ph	H	H	H	OMe
840	4	CH_2Ph	H	H	H	OMe

841	1	COMe	H	H	H	OMe
842	2	COMe	H	H	H	OMe
843	3	COMe	H	H	H	OMe
844	4	COMe	H	H	H	OMe
845	1	CO_2Me	H	H	H	OMe
846	2	CO_2Me	H	H	H	OMe
847	3	CO_2Me	H	H	H	OMe
848	4	CO_2Me	H	H	H	OMe
849	1	CO_2tBu	H	H	H	OMe
850	2	CO_2tBu	H	H	H	OMe
851	3	CO_2tBu	H	H	H	OMe
852	4	CO_2tBu	H	H	H	OMe
853	1	CONHMe	H	H	H	OMe
854	2	CONHMe	H	H	H	OMe
855	3	CONHMe	H	H	H	OMe
856	4	CONHMe	H	H	H	OMe
857	1	SO_2Me	H	H	H	OMe
858	2	SO_2Me	H	H	H	OMe
859	3	SO_2Me	H	H	H	OMe
860	4	SO_2Me	H	H	H	OMe
861	1	SO_2NH_2	H	H	H	OMe
862	2	SO_2NH_2	H	H	H	OMe
863	3	SO_2NH_2	H	H	H	OMe
864	4	SO_2NH_2	H	H	H	OMe
865	1	H	H	H	H	Me
866	2	H	H	H	H	Me
867	3	H	H	H	H	Me
868	4	H	H	H	H	Me
869	1	Me	H	H	H	Me
870	2	Me	H	H	H	Me
871	3	Me	H	H	H	Me

872	4	Me	H	H	H	Me
873	1	CH_2Ph	H	H	H	Me
874	2	CH_2Ph	H	H	H	Me
875	3	CH_2Ph	H	H	H	Me
876	4	CH_2Ph	H	H	H	Me
877	1	COMe	H	H	H	Me
878	2	COMe	H	H	H	Me
879	3	COMe	H	H	H	Me
880	4	COMe	H	H	H	Me
881	1	CO_2Me	H	H	H	Me
882	2	CO_2Me	H	H	H	Me
883	3	CO_2Me	H	H	H	Me
884	4	CO_2Me	H	H	H	Me
885	1	CO_2tBu	H	H	H	Me
886	2	CO_2tBu	H	H	H	Me
887	3	CO_2tBu	H	H	H	Me
888	4	CO_2tBu	H	H	H	Me
889	1	CONHMe	H	H	H	Me
890	2	CONHMe	H	H	H	Me
891	3	CONHMe	H	H	H	Me
892	4	CONHMe	H	H	H	Me
893	1	SO_2Me	H	H	H	Me
894	2	SO_2Me	H	H	H	Me
895	3	SO_2Me	H	H	H	Me
896	4	SO_2Me	H	H	H	Me
897	1	SO_2NH_2	H	H	H	Me
898	2	SO_2NH_2	H	H	H	Me
899	3	SO_2NH_2	H	H	H	Me
900	4	SO_2NH_2	H	H	H	Me
901	1	H	H	H	H	CF_3
902	2	H	H	H	H	CF_3

903	3	H	H	H	H	CF_3
904	4	H	H	H	H	CF_3
905	1	Me	H	H	H	CF_3
906	2	Me	H	H	H	CF_3
907	3	Me	H	H	H	CF_3
908	4	Me	H	H	H	CF_3
909	1	CH_2Ph	H	H	H	CF_3
910	2	CH_2Ph	H	H	H	CF_3
911	3	CH_2Ph	H	H	H	CF_3
912	4	CH_2Ph	H	H	H	CF_3
913	1	COMe	H	H	H	CF_3
914	2	COMe	H	H	H	CF_3
915	3	COMe	H	H	H	CF_3
916	4	COMe	H	H	H	CF_3
917	1	CO_2Me	H	H	H	CF_3
918	2	CO_2Me	H	H	H	CF_3
919	3	CO_2Me	H	H	H	CF_3
920	4	CO_2Me	H	H	H	CF_3
921	1	CO_2tBu	H	H	H	CF_3
922	2	CO_2tBu	H	H	H	CF_3
923	3	CO_2tBu	H	H	H	CF_3
924	4	CO_2tBu	H	H	H	CF_3
925	1	CONHMe	H	H	H	CF_3
926	2	CONHMe	H	H	H	CF_3
927	3	CONHMe	H	H	H	CF_3
928	4	CONHMe	H	H	H	CF_3
929	1	SO_2Me	H	H	H	CF_3
930	2	SO_2Me	H	H	H	CF_3
931	3	SO_2Me	H	H	H	CF_3
932	4	SO_2Me	H	H	H	CF_3
933	1	SO_2NH_2	H	H	H	CF_3


934	2	SO_2NH_2	H	H	H	CF_3
935	3	SO_2NH_2	H	H	H	CF_3
936	4	SO_2NH_2	H	H	H	CF_3
937	1	H	H	H	H	F
938	2	H	H	H	H	F
939	3	H	H	H	H	F
940	3	H	H	H	H	F
941	1	Me	H	H	H	F
942	2	Me	H	H	H	F
943	3	Me	H	H	H	F
944	4	Me	H	H	H	F
945	1	CH_2Ph	H	H	H	F
946	2	CH_2Ph	H	H	H	F
947	3	CH_2Ph	H	H	H	F
948	4	CH_2Ph	H	H	H	F
949	1	COMe	H	H	H	F
950	2	COMe	H	H	H	F
951	3	COMe	H	H	H	F
952	4	COMe	H	H	H	F
953	1	CO_2Me	H	H	H	F
954	2	CO_2Me	H	H	H	F
955	3	CO_2Me	H	H	H	F
956	4	CO_2Me	H	H	H	F
957	1	CO_2tBu	H	H	H	F
958	2	CO_2tBu	H	H	H	F
959	3	CO_2tBu	H	H	H	F
960	4	CO_2tBu	H	H	H	F
961	1	CONHMe	H	H	H	F
962	2	CONHMe	H	H	H	F
963	3	CONHMe	H	H	H	F
964	4	CONHMe	H	H	H	F

965	1	SO_2Me	H	H	H	F
966	2	SO_2Me	H	H	H	F
967	3	SO_2Me	H	H	H	F
968	4	SO_2Me	H	H	H	F
969	1	SO_2NH_2	H	H	H	F
970	2	SO_2NH_2	H	H	H	F
971	3	SO_2NH_2	H	H	H	F
972	4	SO_2NH_2	H	H	H	F
973	1	H	H	H	H	Cl
974	2	H	H	H	H	Cl
975	3	H	H	H	H	Cl
976	4	H	H	H	H	Cl
977	1	Me	H	H	H	Cl
978	2	Me	H	H	H	Cl
979	3	Me	H	H	H	Cl
980	4	Me	H	H	H	Cl
981	1	CH_2Ph	H	H	H	Cl
982	2	CH_2Ph	H	H	H	Cl
983	3	CH_2Ph	H	H	H	Cl
984	4	CH_2Ph	H	H	H	Cl
985	1	COMe	H	H	H	Cl
986	2	COMe	H	H	H	Cl
987	3	COMe	H	H	H	Cl
988	4	COMe	H	H	H	Cl
989	1	CO_2Me	H	H	H	Cl
990	2	CO_2Me	H	H	H	Cl
991	3	CO_2Me	H	H	H	Cl
992	4	CO_2Me	H	H	H	Cl
993	1	CO_2tBu	H	H	H	Cl
994	2	CO_2tBu	H	H	H	Cl
995	3	CO_2tBu	H	H	H	Cl

996	4	CO_2tBu	H	H	H	Cl
997	1	CONHMe	H	H	H	Cl
998	2	CONHMe	H	H	H	Cl
999	3	CONHMe	H	H	H	Cl
1000	4	CONHMe	H	H	H	Cl
1001	1	SO_2Me	H	H	H	Cl
1002	2	SO_2Me	H	H	H	Cl
1003	3	SO_2Me	H	H	H	Cl
1004	4	SO_2Me	H	H	H	Cl
1005	1	SO_2NH_2	H	H	H	Cl
1006	2	SO_2NH_2	H	H	H	Cl
1007	3	SO_2NH_2	H	H	H	Cl
1008	4	SO_2NH_2	H	H	H	Cl
1009	1	H	H	H	H	CN
1010	2	H	H	H	H	CN
1011	3	H	H	H	H	CN
1012	4	H	H	H	H	CN
1013	1	Me	H	H	H	CN
1014	2	Me	H	H	H	CN
1015	3	Me	H	H	H	CN
1016	4	Me	H	H	H	CN
1017	1	CH_2Ph	H	H	H	CN
1018	2	CH_2Ph	H	H	H	CN
1019	3	CH_2Ph	H	H	H	CN
1020	4	CH_2Ph	H	H	H	CN
1021	1	COMe	H	H	H	CN
1022	2	COMe	H	H	H	CN
1023	3	COMe	H	H	H	CN
1024	4	COMe	H	H	H	CN
1025	1	CO_2Me	H	H	H	CN
1026	2	CO_2Me	H	H	H	CN

1027	3	CO_2Me	H	H	H	CN
1028	4	CO_2Me	H	H	H	CN
1029	1	CO_2tBu	H	H	H	CN
1030	2	CO_2tBu	H	H	H	CN
1031	3	CO_2tBu	H	H	H	CN
1032	4	CO_2tBu	H	H	H	CN
1033	1	CONHMe	H	H	H	CN
1034	2	CONHMe	H	H	H	CN
1035	3	CONHMe	H	H	H	CN
1036	4	CONHMe	H	H	H	CN
1037	1	SO_2Me	H	H	H	CN
1038	2	SO_2Me	H	H	H	CN
1039	3	SO_2Me	H	H	H	CN
1040	4	SO_2Me	H	H	H	CN
1041	1	SO_2NH_2	H	H	H	CN
1042	2	SO_2NH_2	H	H	H	CN
1043	3	SO_2NH_2	H	H	H	CN
1044	4	SO_2NH_2	H	H	H	CN

[01030] Exemplary embodiments include compounds having the formula **(XXVIII)**



(XXVIII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 22.

Table 22

Entry	n	R^7	R^{20a}	R^{20b}	R^{20c}	R^{20e}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H
4	4	H	H	H	H	H

5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H

36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H

67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H

98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H

129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H

160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H

191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H

222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H

253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H

284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	OH	H	H
290	2	H	H	OH	H	H
291	3	H	H	OH	H	H
292	4	H	H	OH	H	H
293	1	Me	H	OH	H	H
294	2	Me	H	OH	H	H
295	3	Me	H	OH	H	H
296	4	Me	H	OH	H	H
297	1	CH_2Ph	H	OH	H	H
298	2	CH_2Ph	H	OH	H	H
299	3	CH_2Ph	H	OH	H	H
300	4	CH_2Ph	H	OH	H	H
301	1	COMe	H	OH	H	H
302	2	COMe	H	OH	H	H
303	3	COMe	H	OH	H	H
304	4	COMe	H	OH	H	H
305	1	CO_2Me	H	OH	H	H
306	2	CO_2Me	H	OH	H	H
307	3	CO_2Me	H	OH	H	H
308	4	CO_2Me	H	OH	H	H
309	1	CO_2tBu	H	OH	H	H
310	2	CO_2tBu	H	OH	H	H
311	3	CO_2tBu	H	OH	H	H
312	4	CO_2tBu	H	OH	H	H
313	1	CONHMe	H	OH	H	H
314	2	CONHMe	H	OH	H	H

315	3	CONHMe	H	OH	H	H
316	4	CONHMe	H	OH	H	H
317	1	SO_2Me	H	OH	H	H
318	2	SO_2Me	H	OH	H	H
319	3	SO_2Me	H	OH	H	H
320	4	SO_2Me	H	OH	H	H
321	1	SO_2NH_2	H	OH	H	H
322	2	SO_2NH_2	H	OH	H	H
323	3	SO_2NH_2	H	OH	H	H
324	4	SO_2NH_2	H	OH	H	H
325	1	H	H	OMe	H	H
326	2	H	H	OMe	H	H
327	3	H	H	OMe	H	H
328	4	H	H	OMe	H	H
329	1	Me	H	OMe	H	H
330	2	Me	H	OMe	H	H
331	3	Me	H	OMe	H	H
332	4	Me	H	OMe	H	H
333	1	CH_2Ph	H	OMe	H	H
334	2	CH_2Ph	H	OMe	H	H
335	3	CH_2Ph	H	OMe	H	H
336	4	CH_2Ph	H	OMe	H	H
337	1	COMe	H	OMe	H	H
338	2	COMe	H	OMe	H	H
339	3	COMe	H	OMe	H	H
340	4	COMe	H	OMe	H	H
341	1	CO_2Me	H	OMe	H	H
342	2	CO_2Me	H	OMe	H	H
343	3	CO_2Me	H	OMe	H	H
344	4	CO_2Me	H	OMe	H	H
345	1	CO_2tBu	H	OMe	H	H

346	2	CO_2tBu	H	OMe	H	H
347	3	CO_2tBu	H	OMe	H	H
348	4	CO_2tBu	H	OMe	H	H
349	1	CONHMe	H	OMe	H	H
350	2	CONHMe	H	OMe	H	H
351	3	CONHMe	H	OMe	H	H
352	4	CONHMe	H	OMe	H	H
353	1	SO_2Me	H	OMe	H	H
354	2	SO_2Me	H	OMe	H	H
355	3	SO_2Me	H	OMe	H	H
356	4	SO_2Me	H	OMe	H	H
357	1	SO_2NH_2	H	OMe	H	H
358	2	SO_2NH_2	H	OMe	H	H
359	3	SO_2NH_2	H	OMe	H	H
360	4	SO_2NH_2	H	OMe	H	H
361	1	H	H	Me	H	H
362	2	H	H	Me	H	H
363	3	H	H	Me	H	H
364	4	H	H	Me	H	H
365	1	Me	H	Me	H	H
366	2	Me	H	Me	H	H
367	3	Me	H	Me	H	H
368	4	Me	H	Me	H	H
369	1	CH_2Ph	H	Me	H	H
370	2	CH_2Ph	H	Me	H	H
371	3	CH_2Ph	H	Me	H	H
372	4	CH_2Ph	H	Me	H	H
373	1	COMe	H	Me	H	H
374	2	COMe	H	Me	H	H
375	3	COMe	H	Me	H	H
376	4	COMe	H	Me	H	H

377	1	CO_2Me	H	Me	H	H
378	2	CO_2Me	H	Me	H	H
379	3	CO_2Me	H	Me	H	H
380	4	CO_2Me	H	Me	H	H
381	1	CO_2tBu	H	Me	H	H
382	2	CO_2tBu	H	Me	H	H
383	3	CO_2tBu	H	Me	H	H
384	4	CO_2tBu	H	Me	H	H
385	1	CONHMe	H	Me	H	H
386	2	CONHMe	H	Me	H	H
387	3	CONHMe	H	Me	H	H
388	4	CONHMe	H	Me	H	H
389	1	SO_2Me	H	Me	H	H
390	2	SO_2Me	H	Me	H	H
391	3	SO_2Me	H	Me	H	H
392	4	SO_2Me	H	Me	H	H
393	1	SO_2NH_2	H	Me	H	H
394	2	SO_2NH_2	H	Me	H	H
395	3	SO_2NH_2	H	Me	H	H
396	4	SO_2NH_2	H	Me	H	H
397	1	H	H	CF_3	H	H
398	2	H	H	CF_3	H	H
399	3	H	H	CF_3	H	H
400	4	H	H	CF_3	H	H
401	1	Me	H	CF_3	H	H
402	2	Me	H	CF_3	H	H
403	3	Me	H	CF_3	H	H
404	4	Me	H	CF_3	H	H
405	1	CH_2Ph	H	CF_3	H	H
406	2	CH_2Ph	H	CF_3	H	H
407	3	CH_2Ph	H	CF_3	H	H

408	4	CH_2Ph	H	CF_3	H	H
409	1	COMe	H	CF_3	H	H
410	2	COMe	H	CF_3	H	H
411	3	COMe	H	CF_3	H	H
412	4	COMe	H	CF_3	H	H
413	1	CO_2Me	H	CF_3	H	H
414	2	CO_2Me	H	CF_3	H	H
415	3	CO_2Me	H	CF_3	H	H
416	4	CO_2Me	H	CF_3	H	H
417	1	CO_2tBu	H	CF_3	H	H
418	2	CO_2tBu	H	CF_3	H	H
419	3	CO_2tBu	H	CF_3	H	H
420	4	CO_2tBu	H	CF_3	H	H
421	1	CONHMe	H	CF_3	H	H
422	2	CONHMe	H	CF_3	H	H
423	3	CONHMe	H	CF_3	H	H
424	4	CONHMe	H	CF_3	H	H
425	1	SO_2Me	H	CF_3	H	H
426	2	SO_2Me	H	CF_3	H	H
427	3	SO_2Me	H	CF_3	H	H
428	4	SO_2Me	H	CF_3	H	H
429	1	SO_2NH_2	H	CF_3	H	H
430	2	SO_2NH_2	H	CF_3	H	H
431	3	SO_2NH_2	H	CF_3	H	H
432	4	SO_2NH_2	H	CF_3	H	H
433	1	H	H	F	H	H
434	2	H	H	F	H	H
435	3	H	H	F	H	H
436	3	H	H	F	H	H
437	1	Me	H	F	H	H
438	2	Me	H	F	H	H

439	3	Me	H	F	H	H
440	4	Me	H	F	H	H
441	1	CH_2Ph	H	F	H	H
442	2	CH_2Ph	H	F	H	H
443	3	CH_2Ph	H	F	H	H
444	4	CH_2Ph	H	F	H	H
445	1	COMe	H	F	H	H
446	2	COMe	H	F	H	H
447	3	COMe	H	F	H	H
448	4	COMe	H	F	H	H
449	1	CO_2Me	H	F	H	H
450	2	CO_2Me	H	F	H	H
451	3	CO_2Me	H	F	H	H
452	4	CO_2Me	H	F	H	H
453	1	CO_2tBu	H	F	H	H
454	2	CO_2tBu	H	F	H	H
455	3	CO_2tBu	H	F	H	H
456	4	CO_2tBu	H	F	H	H
457	1	CONHMe	H	F	H	H
458	2	CONHMe	H	F	H	H
459	3	CONHMe	H	F	H	H
460	4	CONHMe	H	F	H	H
461	1	SO_2Me	H	F	H	H
462	2	SO_2Me	H	F	H	H
463	3	SO_2Me	H	F	H	H
464	4	SO_2Me	H	F	H	H
465	1	SO_2NH_2	H	F	H	H
466	2	SO_2NH_2	H	F	H	H
467	3	SO_2NH_2	H	F	H	H
468	4	SO_2NH_2	H	F	H	H
469	1	H	H	Cl	H	H

470	2	H	H	Cl	H	H
471	3	H	H	Cl	H	H
472	4	H	H	Cl	H	H
473	1	Me	H	Cl	H	H
474	2	Me	H	Cl	H	H
475	3	Me	H	Cl	H	H
476	4	Me	H	Cl	H	H
477	1	CH_2Ph	H	Cl	H	H
478	2	CH_2Ph	H	Cl	H	H
479	3	CH_2Ph	H	Cl	H	H
480	4	CH_2Ph	H	Cl	H	H
481	1	COMe	H	Cl	H	H
482	2	COMe	H	Cl	H	H
483	3	COMe	H	Cl	H	H
484	4	COMe	H	Cl	H	H
485	1	CO_2Me	H	Cl	H	H
486	2	CO_2Me	H	Cl	H	H
487	3	CO_2Me	H	Cl	H	H
488	4	CO_2Me	H	Cl	H	H
489	1	CO_2tBu	H	Cl	H	H
490	2	CO_2tBu	H	Cl	H	H
491	3	CO_2tBu	H	Cl	H	H
492	4	CO_2tBu	H	Cl	H	H
493	1	CONHMe	H	Cl	H	H
494	2	CONHMe	H	Cl	H	H
495	3	CONHMe	H	Cl	H	H
496	4	CONHMe	H	Cl	H	H
497	1	SO_2Me	H	Cl	H	H
498	2	SO_2Me	H	Cl	H	H
499	3	SO_2Me	H	Cl	H	H
500	4	SO_2Me	H	Cl	H	H

501	1	SO_2NH_2	H	Cl	H	H
502	2	SO_2NH_2	H	Cl	H	H
503	3	SO_2NH_2	H	Cl	H	H
504	4	SO_2NH_2	H	Cl	H	H
505	1	H	H	CN	H	H
506	2	H	H	CN	H	H
507	3	H	H	CN	H	H
508	4	H	H	CN	H	H
509	1	Me	H	CN	H	H
510	2	Me	H	CN	H	H
511	3	Me	H	CN	H	H
512	4	Me	H	CN	H	H
513	1	CH_2Ph	H	CN	H	H
514	2	CH_2Ph	H	CN	H	H
515	3	CH_2Ph	H	CN	H	H
516	4	CH_2Ph	H	CN	H	H
517	1	COMe	H	CN	H	H
518	2	COMe	H	CN	H	H
519	3	COMe	H	CN	H	H
520	4	COMe	H	CN	H	H
521	1	CO_2Me	H	CN	H	H
522	2	CO_2Me	H	CN	H	H
523	3	CO_2Me	H	CN	H	H
524	4	CO_2Me	H	CN	H	H
525	1	CO_2tBu	H	CN	H	H
526	2	CO_2tBu	H	CN	H	H
527	3	CO_2tBu	H	CN	H	H
528	4	CO_2tBu	H	CN	H	H
529	1	CONHMe	H	CN	H	H
530	2	CONHMe	H	CN	H	H
531	3	CONHMe	H	CN	H	H

532	4	CONHMe	H	CN	H	H
533	1	SO_2Me	H	CN	H	H
534	2	SO_2Me	H	CN	H	H
535	3	SO_2Me	H	CN	H	H
536	4	SO_2Me	H	CN	H	H
537	1	SO_2NH_2	H	CN	H	H
538	2	SO_2NH_2	H	CN	H	H
539	3	SO_2NH_2	H	CN	H	H
540	4	SO_2NH_2	H	CN	H	H
541	1	H	OH	H	H	H
542	2	H	OH	H	H	H
543	3	H	OH	H	H	H
544	4	H	OH	H	H	H
545	1	Me	OH	H	H	H
546	2	Me	OH	H	H	H
547	3	Me	OH	H	H	H
548	4	Me	OH	H	H	H
549	1	CH_2Ph	OH	H	H	H
550	2	CH_2Ph	OH	H	H	H
551	3	CH_2Ph	OH	H	H	H
552	4	CH_2Ph	OH	H	H	H
553	1	COMe	OH	H	H	H
554	2	COMe	OH	H	H	H
555	3	COMe	OH	H	H	H
556	4	COMe	OH	H	H	H
557	1	CO_2Me	OH	H	H	H
558	2	CO_2Me	OH	H	H	H
559	3	CO_2Me	OH	H	H	H
560	4	CO_2Me	OH	H	H	H
561	1	CO_2tBu	OH	H	H	H
562	2	CO_2tBu	OH	H	H	H

563	3	CO_2tBu	OH	H	H	H
564	4	CO_2tBu	OH	H	H	H
565	1	CONHMe	OH	H	H	H
566	2	CONHMe	OH	H	H	H
567	3	CONHMe	OH	H	H	H
568	4	CONHMe	OH	H	H	H
569	1	SO_2Me	OH	H	H	H
570	2	SO_2Me	OH	H	H	H
571	3	SO_2Me	OH	H	H	H
572	4	SO_2Me	OH	H	H	H
573	1	SO_2NH_2	OH	H	H	H
574	2	SO_2NH_2	OH	H	H	H
575	3	SO_2NH_2	OH	H	H	H
576	4	SO_2NH_2	OH	H	H	H
577	1	H	OMe	H	H	H
578	2	H	OMe	H	H	H
579	3	H	OMe	H	H	H
580	4	H	OMe	H	H	H
581	1	Me	OMe	H	H	H
582	2	Me	OMe	H	H	H
583	3	Me	OMe	H	H	H
584	4	Me	OMe	H	H	H
585	1	CH_2Ph	OMe	H	H	H
586	2	CH_2Ph	OMe	H	H	H
587	3	CH_2Ph	OMe	H	H	H
588	4	CH_2Ph	OMe	H	H	H
589	1	COMe	OMe	H	H	H
590	2	COMe	OMe	H	H	H
591	3	COMe	OMe	H	H	H
592	4	COMe	OMe	H	H	H
593	1	CO_2Me	OMe	H	H	H

594	2	CO_2Me	OMe	H	H	H
595	3	CO_2Me	OMe	H	H	H
596	4	CO_2Me	OMe	H	H	H
597	1	CO_2tBu	OMe	H	H	H
598	2	CO_2tBu	OMe	H	H	H
599	3	CO_2tBu	OMe	H	H	H
600	4	CO_2tBu	OMe	H	H	H
601	1	CONHMe	OMe	H	H	H
602	2	CONHMe	OMe	H	H	H
603	3	CONHMe	OMe	H	H	H
604	4	CONHMe	OMe	H	H	H
605	1	SO_2Me	OMe	H	H	H
606	2	SO_2Me	OMe	H	H	H
607	3	SO_2Me	OMe	H	H	H
608	4	SO_2Me	OMe	H	H	H
609	1	SO_2NH_2	OMe	H	H	H
610	2	SO_2NH_2	OMe	H	H	H
611	3	SO_2NH_2	OMe	H	H	H
612	4	SO_2NH_2	OMe	H	H	H
613	1	H	Me	H	H	H
614	2	H	Me	H	H	H
615	3	H	Me	H	H	H
616	4	H	Me	H	H	H
617	1	Me	Me	H	H	H
618	2	Me	Me	H	H	H
619	3	Me	Me	H	H	H
620	4	Me	Me	H	H	H
621	1	CH_2Ph	Me	H	H	H
622	2	CH_2Ph	Me	H	H	H
623	3	CH_2Ph	Me	H	H	H
624	4	CH_2Ph	Me	H	H	H

625	1	COMe	Me	H	H	H
626	2	COMe	Me	H	H	H
627	3	COMe	Me	H	H	H
628	4	COMe	Me	H	H	H
629	1	CO_2Me	Me	H	H	H
630	2	CO_2Me	Me	H	H	H
631	3	CO_2Me	Me	H	H	H
632	4	CO_2Me	Me	H	H	H
633	1	CO_2tBu	Me	H	H	H
634	2	CO_2tBu	Me	H	H	H
635	3	CO_2tBu	Me	H	H	H
636	4	CO_2tBu	Me	H	H	H
637	1	CONHMe	Me	H	H	H
638	2	CONHMe	Me	H	H	H
639	3	CONHMe	Me	H	H	H
640	4	CONHMe	Me	H	H	H
641	1	SO_2Me	Me	H	H	H
642	2	SO_2Me	Me	H	H	H
643	3	SO_2Me	Me	H	H	H
644	4	SO_2Me	Me	H	H	H
645	1	SO_2NH_2	Me	H	H	H
646	2	SO_2NH_2	Me	H	H	H
647	3	SO_2NH_2	Me	H	H	H
648	4	SO_2NH_2	Me	H	H	H
649	1	H	CF_3	H	H	H
650	2	H	CF_3	H	H	H
651	3	H	CF_3	H	H	H
652	4	H	CF_3	H	H	H
653	1	Me	CF_3	H	H	H
654	2	Me	CF_3	H	H	H
655	3	Me	CF_3	H	H	H

656	4	Me	CF_3	H	H	H
657	1	CH_2Ph	CF_3	H	H	H
658	2	CH_2Ph	CF_3	H	H	H
659	3	CH_2Ph	CF_3	H	H	H
660	4	CH_2Ph	CF_3	H	H	H
661	1	COMe	CF_3	H	H	H
662	2	COMe	CF_3	H	H	H
663	3	COMe	CF_3	H	H	H
664	4	COMe	CF_3	H	H	H
665	1	CO_2Me	CF_3	H	H	H
666	2	CO_2Me	CF_3	H	H	H
667	3	CO_2Me	CF_3	H	H	H
668	4	CO_2Me	CF_3	H	H	H
669	1	CO_2tBu	CF_3	H	H	H
670	2	CO_2tBu	CF_3	H	H	H
671	3	CO_2tBu	CF_3	H	H	H
672	4	CO_2tBu	CF_3	H	H	H
673	1	CONHMe	CF_3	H	H	H
674	2	CONHMe	CF_3	H	H	H
675	3	CONHMe	CF_3	H	H	H
676	4	CONHMe	CF_3	H	H	H
677	1	SO_2Me	CF_3	H	H	H
678	2	SO_2Me	CF_3	H	H	H
679	3	SO_2Me	CF_3	H	H	H
680	4	SO_2Me	CF_3	H	H	H
681	1	SO_2NH_2	CF_3	H	H	H
682	2	SO_2NH_2	CF_3	H	H	H
683	3	SO_2NH_2	CF_3	H	H	H
684	4	SO_2NH_2	CF_3	H	H	H
685	1	H	F	H	H	H
686	2	H	F	H	H	H

687	3	H	F	H	H	H
688	3	H	F	H	H	H
689	1	Me	F	H	H	H
690	2	Me	F	H	H	H
691	3	Me	F	H	H	H
692	4	Me	F	H	H	H
693	1	CH_2Ph	F	H	H	H
694	2	CH_2Ph	F	H	H	H
695	3	CH_2Ph	F	H	H	H
696	4	CH_2Ph	F	H	H	H
697	1	COMe	F	H	H	H
698	2	COMe	F	H	H	H
699	3	COMe	F	H	H	H
700	4	COMe	F	H	H	H
701	1	CO_2Me	F	H	H	H
702	2	CO_2Me	F	H	H	H
703	3	CO_2Me	F	H	H	H
704	4	CO_2Me	F	H	H	H
705	1	CO_2tBu	F	H	H	H
706	2	CO_2tBu	F	H	H	H
707	3	CO_2tBu	F	H	H	H
708	4	CO_2tBu	F	H	H	H
709	1	CONHMe	F	H	H	H
710	2	CONHMe	F	H	H	H
711	3	CONHMe	F	H	H	H
712	4	CONHMe	F	H	H	H
713	1	SO_2Me	F	H	H	H
714	2	SO_2Me	F	H	H	H
715	3	SO_2Me	F	H	H	H
716	4	SO_2Me	F	H	H	H
717	1	SO_2NH_2	F	H	H	H

718	2	SO_2NH_2	F	H	H	H
719	3	SO_2NH_2	F	H	H	H
720	4	SO_2NH_2	F	H	H	H
721	1	H	Cl	H	H	H
722	2	H	Cl	H	H	H
723	3	H	Cl	H	H	H
724	4	H	Cl	H	H	H
725	1	Me	Cl	H	H	H
726	2	Me	Cl	H	H	H
727	3	Me	Cl	H	H	H
728	4	Me	Cl	H	H	H
729	1	CH_2Ph	Cl	H	H	H
730	2	CH_2Ph	Cl	H	H	H
731	3	CH_2Ph	Cl	H	H	H
732	4	CH_2Ph	Cl	H	H	H
733	1	COMe	Cl	H	H	H
734	2	COMe	Cl	H	H	H
735	3	COMe	Cl	H	H	H
736	4	COMe	Cl	H	H	H
737	1	CO_2Me	Cl	H	H	H
738	2	CO_2Me	Cl	H	H	H
739	3	CO_2Me	Cl	H	H	H
740	4	CO_2Me	Cl	H	H	H
741	1	CO_2tBu	Cl	H	H	H
742	2	CO_2tBu	Cl	H	H	H
743	3	CO_2tBu	Cl	H	H	H
744	4	CO_2tBu	Cl	H	H	H
745	1	CONHMe	Cl	H	H	H
746	2	CONHMe	Cl	H	H	H
747	3	CONHMe	Cl	H	H	H
748	4	CONHMe	Cl	H	H	H

749	1	SO_2Me	Cl	H	H	H
750	2	SO_2Me	Cl	H	H	H
751	3	SO_2Me	Cl	H	H	H
752	4	SO_2Me	Cl	H	H	H
753	1	SO_2NH_2	Cl	H	H	H
754	2	SO_2NH_2	Cl	H	H	H
755	3	SO_2NH_2	Cl	H	H	H
756	4	SO_2NH_2	Cl	H	H	H
757	1	H	CN	H	H	H
758	2	H	CN	H	H	H
759	3	H	CN	H	H	H
760	4	H	CN	H	H	H
761	1	Me	CN	H	H	H
762	2	Me	CN	H	H	H
763	3	Me	CN	H	H	H
764	4	Me	CN	H	H	H
765	1	CH_2Ph	CN	H	H	H
766	2	CH_2Ph	CN	H	H	H
767	3	CH_2Ph	CN	H	H	H
768	4	CH_2Ph	CN	H	H	H
769	1	COMe	CN	H	H	H
770	2	COMe	CN	H	H	H
771	3	COMe	CN	H	H	H
772	4	COMe	CN	H	H	H
773	1	CO_2Me	CN	H	H	H
774	2	CO_2Me	CN	H	H	H
775	3	CO_2Me	CN	H	H	H
776	4	CO_2Me	CN	H	H	H
777	1	CO_2tBu	CN	H	H	H
778	2	CO_2tBu	CN	H	H	H
779	3	CO_2tBu	CN	H	H	H

780	4	CO_2tBu	CN	H	H	H
781	1	CONHMe	CN	H	H	H
782	2	CONHMe	CN	H	H	H
783	3	CONHMe	CN	H	H	H
784	4	CONHMe	CN	H	H	H
785	1	SO_2Me	CN	H	H	H
786	2	SO_2Me	CN	H	H	H
787	3	SO_2Me	CN	H	H	H
788	4	SO_2Me	CN	H	H	H
789	1	SO_2NH_2	CN	H	H	H
790	2	SO_2NH_2	CN	H	H	H
791	3	SO_2NH_2	CN	H	H	H
792	4	SO_2NH_2	CN	H	H	H
793	1	H	H	H	H	OH
794	2	H	H	H	H	OH
795	3	H	H	H	H	OH
796	4	H	H	H	H	OH
797	1	Me	H	H	H	OH
798	2	Me	H	H	H	OH
799	3	Me	H	H	H	OH
800	4	Me	H	H	H	OH
801	1	CH_2Ph	H	H	H	OH
802	2	CH_2Ph	H	H	H	OH
803	3	CH_2Ph	H	H	H	OH
804	4	CH_2Ph	H	H	H	OH
805	1	COMe	H	H	H	OH
806	2	COMe	H	H	H	OH
807	3	COMe	H	H	H	OH
808	4	COMe	H	H	H	OH
809	1	CO_2Me	H	H	H	OH
810	2	CO_2Me	H	H	H	OH

811	3	CO_2Me	H	H	H	OH
812	4	CO_2Me	H	H	H	OH
813	1	CO_2tBu	H	H	H	OH
814	2	CO_2tBu	H	H	H	OH
815	3	CO_2tBu	H	H	H	OH
816	4	CO_2tBu	H	H	H	OH
817	1	CONHMe	H	H	H	OH
818	2	CONHMe	H	H	H	OH
819	3	CONHMe	H	H	H	OH
820	4	CONHMe	H	H	H	OH
821	1	SO_2Me	H	H	H	OH
822	2	SO_2Me	H	H	H	OH
823	3	SO_2Me	H	H	H	OH
824	4	SO_2Me	H	H	H	OH
825	1	SO_2NH_2	H	H	H	OH
826	2	SO_2NH_2	H	H	H	OH
827	3	SO_2NH_2	H	H	H	OH
828	4	SO_2NH_2	H	H	H	OH
829	1	H	H	H	H	OMe
830	2	H	H	H	H	OMe
831	3	H	H	H	H	OMe
832	4	H	H	H	H	OMe
833	1	Me	H	H	H	OMe
834	2	Me	H	H	H	OMe
835	3	Me	H	H	H	OMe
836	4	Me	H	H	H	OMe
837	1	CH_2Ph	H	H	H	OMe
838	2	CH_2Ph	H	H	H	OMe
839	3	CH_2Ph	H	H	H	OMe
840	4	CH_2Ph	H	H	H	OMe
841	1	COMe	H	H	H	OMe

842	2	COMe	H	H	H	OMe
843	3	COMe	H	H	H	OMe
844	4	COMe	H	H	H	OMe
845	1	CO_2Me	H	H	H	OMe
846	2	CO_2Me	H	H	H	OMe
847	3	CO_2Me	H	H	H	OMe
848	4	CO_2Me	H	H	H	OMe
849	1	CO_2tBu	H	H	H	OMe
850	2	CO_2tBu	H	H	H	OMe
851	3	CO_2tBu	H	H	H	OMe
852	4	CO_2tBu	H	H	H	OMe
853	1	CONHMe	H	H	H	OMe
854	2	CONHMe	H	H	H	OMe
855	3	CONHMe	H	H	H	OMe
856	4	CONHMe	H	H	H	OMe
857	1	SO_2Me	H	H	H	OMe
858	2	SO_2Me	H	H	H	OMe
859	3	SO_2Me	H	H	H	OMe
860	4	SO_2Me	H	H	H	OMe
861	1	SO_2NH_2	H	H	H	OMe
862	2	SO_2NH_2	H	H	H	OMe
863	3	SO_2NH_2	H	H	H	OMe
864	4	SO_2NH_2	H	H	H	OMe
865	1	H	H	H	H	Me
866	2	H	H	H	H	Me
867	3	H	H	H	H	Me
868	4	H	H	H	H	Me
869	1	Me	H	H	H	Me
870	2	Me	H	H	H	Me
871	3	Me	H	H	H	Me
872	4	Me	H	H	H	Me

873	1	CH_2Ph	H	H	H	Me
874	2	CH_2Ph	H	H	H	Me
875	3	CH_2Ph	H	H	H	Me
876	4	CH_2Ph	H	H	H	Me
877	1	COMe	H	H	H	Me
878	2	COMe	H	H	H	Me
879	3	COMe	H	H	H	Me
880	4	COMe	H	H	H	Me
881	1	CO_2Me	H	H	H	Me
882	2	CO_2Me	H	H	H	Me
883	3	CO_2Me	H	H	H	Me
884	4	CO_2Me	H	H	H	Me
885	1	CO_2tBu	H	H	H	Me
886	2	CO_2tBu	H	H	H	Me
887	3	CO_2tBu	H	H	H	Me
888	4	CO_2tBu	H	H	H	Me
889	1	CONHMe	H	H	H	Me
890	2	CONHMe	H	H	H	Me
891	3	CONHMe	H	H	H	Me
892	4	CONHMe	H	H	H	Me
893	1	SO_2Me	H	H	H	Me
894	2	SO_2Me	H	H	H	Me
895	3	SO_2Me	H	H	H	Me
896	4	SO_2Me	H	H	H	Me
897	1	SO_2NH_2	H	H	H	Me
898	2	SO_2NH_2	H	H	H	Me
899	3	SO_2NH_2	H	H	H	Me
900	4	SO_2NH_2	H	H	H	Me
901	1	H	H	H	H	CF_3
902	2	H	H	H	H	CF_3
903	3	H	H	H	H	CF_3

904	4	H	H	H	H	CF_3
905	1	Me	H	H	H	CF_3
906	2	Me	H	H	H	CF_3
907	3	Me	H	H	H	CF_3
908	4	Me	H	H	H	CF_3
909	1	CH_2Ph	H	H	H	CF_3
910	2	CH_2Ph	H	H	H	CF_3
911	3	CH_2Ph	H	H	H	CF_3
912	4	CH_2Ph	H	H	H	CF_3
913	1	COMe	H	H	H	CF_3
914	2	COMe	H	H	H	CF_3
915	3	COMe	H	H	H	CF_3
916	4	COMe	H	H	H	CF_3
917	1	CO_2Me	H	H	H	CF_3
918	2	CO_2Me	H	H	H	CF_3
919	3	CO_2Me	H	H	H	CF_3
920	4	CO_2Me	H	H	H	CF_3
921	1	CO_2tBu	H	H	H	CF_3
922	2	CO_2tBu	H	H	H	CF_3
923	3	CO_2tBu	H	H	H	CF_3
924	4	CO_2tBu	H	H	H	CF_3
925	1	CONHMe	H	H	H	CF_3
926	2	CONHMe	H	H	H	CF_3
927	3	CONHMe	H	H	H	CF_3
928	4	CONHMe	H	H	H	CF_3
929	1	SO_2Me	H	H	H	CF_3
930	2	SO_2Me	H	H	H	CF_3
931	3	SO_2Me	H	H	H	CF_3
932	4	SO_2Me	H	H	H	CF_3
933	1	SO_2NH_2	H	H	H	CF_3
934	2	SO_2NH_2	H	H	H	CF_3


935	3	SO_2NH_2	H	H	H	CF_3
936	4	SO_2NH_2	H	H	H	CF_3
937	1	H	H	H	H	F
938	2	H	H	H	H	F
939	3	H	H	H	H	F
940	3	H	H	H	H	F
941	1	Me	H	H	H	F
942	2	Me	H	H	H	F
943	3	Me	H	H	H	F
944	4	Me	H	H	H	F
945	1	CH_2Ph	H	H	H	F
946	2	CH_2Ph	H	H	H	F
947	3	CH_2Ph	H	H	H	F
948	4	CH_2Ph	H	H	H	F
949	1	COMe	H	H	H	F
950	2	COMe	H	H	H	F
951	3	COMe	H	H	H	F
952	4	COMe	H	H	H	F
953	1	CO_2Me	H	H	H	F
954	2	CO_2Me	H	H	H	F
955	3	CO_2Me	H	H	H	F
956	4	CO_2Me	H	H	H	F
957	1	CO_2tBu	H	H	H	F
958	2	CO_2tBu	H	H	H	F
959	3	CO_2tBu	H	H	H	F
960	4	CO_2tBu	H	H	H	F
961	1	CONHMe	H	H	H	F
962	2	CONHMe	H	H	H	F
963	3	CONHMe	H	H	H	F
964	4	CONHMe	H	H	H	F
965	1	SO_2Me	H	H	H	F

966	2	SO_2Me	H	H	H	F
967	3	SO_2Me	H	H	H	F
968	4	SO_2Me	H	H	H	F
969	1	SO_2NH_2	H	H	H	F
970	2	SO_2NH_2	H	H	H	F
971	3	SO_2NH_2	H	H	H	F
972	4	SO_2NH_2	H	H	H	F
973	1	H	H	H	H	Cl
974	2	H	H	H	H	Cl
975	3	H	H	H	H	Cl
976	4	H	H	H	H	Cl
977	1	Me	H	H	H	Cl
978	2	Me	H	H	H	Cl
979	3	Me	H	H	H	Cl
980	4	Me	H	H	H	Cl
981	1	CH_2Ph	H	H	H	Cl
982	2	CH_2Ph	H	H	H	Cl
983	3	CH_2Ph	H	H	H	Cl
984	4	CH_2Ph	H	H	H	Cl
985	1	COMe	H	H	H	Cl
986	2	COMe	H	H	H	Cl
987	3	COMe	H	H	H	Cl
988	4	COMe	H	H	H	Cl
989	1	CO_2Me	H	H	H	Cl
990	2	CO_2Me	H	H	H	Cl
991	3	CO_2Me	H	H	H	Cl
992	4	CO_2Me	H	H	H	Cl
993	1	CO_2tBu	H	H	H	Cl
994	2	CO_2tBu	H	H	H	Cl
995	3	CO_2tBu	H	H	H	Cl
996	4	CO_2tBu	H	H	H	Cl

997	1	CONHMe	H	H	H	Cl
998	2	CONHMe	H	H	H	Cl
999	3	CONHMe	H	H	H	Cl
1000	4	CONHMe	H	H	H	Cl
1001	1	SO_2Me	H	H	H	Cl
1002	2	SO_2Me	H	H	H	Cl
1003	3	SO_2Me	H	H	H	Cl
1004	4	SO_2Me	H	H	H	Cl
1005	1	SO_2NH_2	H	H	H	Cl
1006	2	SO_2NH_2	H	H	H	Cl
1007	3	SO_2NH_2	H	H	H	Cl
1008	4	SO_2NH_2	H	H	H	Cl
1009	1	H	H	H	H	CN
1010	2	H	H	H	H	CN
1011	3	H	H	H	H	CN
1012	4	H	H	H	H	CN
1013	1	Me	H	H	H	CN
1014	2	Me	H	H	H	CN
1015	3	Me	H	H	H	CN
1016	4	Me	H	H	H	CN
1017	1	CH_2Ph	H	H	H	CN
1018	2	CH_2Ph	H	H	H	CN
1019	3	CH_2Ph	H	H	H	CN
1020	4	CH_2Ph	H	H	H	CN
1021	1	COMe	H	H	H	CN
1022	2	COMe	H	H	H	CN
1023	3	COMe	H	H	H	CN
1024	4	COMe	H	H	H	CN
1025	1	CO_2Me	H	H	H	CN
1026	2	CO_2Me	H	H	H	CN
1027	3	CO_2Me	H	H	H	CN

1028	4	CO_2Me	H	H	H	CN
1029	1	CO_2tBu	H	H	H	CN
1030	2	CO_2tBu	H	H	H	CN
1031	3	CO_2tBu	H	H	H	CN
1032	4	CO_2tBu	H	H	H	CN
1033	1	CONHMe	H	H	H	CN
1034	2	CONHMe	H	H	H	CN
1035	3	CONHMe	H	H	H	CN
1036	4	CONHMe	H	H	H	CN
1037	1	SO_2Me	H	H	H	CN
1038	2	SO_2Me	H	H	H	CN
1039	3	SO_2Me	H	H	H	CN
1040	4	SO_2Me	H	H	H	CN
1041	1	SO_2NH_2	H	H	H	CN
1042	2	SO_2NH_2	H	H	H	CN
1043	3	SO_2NH_2	H	H	H	CN
1044	4	SO_2NH_2	H	H	H	CN

[01031] Exemplary embodiments include compounds having the formula **(XXIX)**



(XXIX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 23.

Table 23

Entry	n	R^7	R^{20a}	R^{20b}	R^{20c}	R^{20e}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H

6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H

37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H

68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H

99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H

130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H

161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H

192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H

223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H

254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H

285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	OH	H	H
290	2	H	H	OH	H	H
291	3	H	H	OH	H	H
292	4	H	H	OH	H	H
293	1	Me	H	OH	H	H
294	2	Me	H	OH	H	H
295	3	Me	H	OH	H	H
296	4	Me	H	OH	H	H
297	1	CH_2Ph	H	OH	H	H
298	2	CH_2Ph	H	OH	H	H
299	3	CH_2Ph	H	OH	H	H
300	4	CH_2Ph	H	OH	H	H
301	1	COMe	H	OH	H	H
302	2	COMe	H	OH	H	H
303	3	COMe	H	OH	H	H
304	4	COMe	H	OH	H	H
305	1	CO_2Me	H	OH	H	H
306	2	CO_2Me	H	OH	H	H
307	3	CO_2Me	H	OH	H	H
308	4	CO_2Me	H	OH	H	H
309	1	CO_2tBu	H	OH	H	H
310	2	CO_2tBu	H	OH	H	H
311	3	CO_2tBu	H	OH	H	H
312	4	CO_2tBu	H	OH	H	H
313	1	CONHMe	H	OH	H	H
314	2	CONHMe	H	OH	H	H
315	3	CONHMe	H	OH	H	H

316	4	CONHMe	H	OH	H	H
317	1	SO_2Me	H	OH	H	H
318	2	SO_2Me	H	OH	H	H
319	3	SO_2Me	H	OH	H	H
320	4	SO_2Me	H	OH	H	H
321	1	SO_2NH_2	H	OH	H	H
322	2	SO_2NH_2	H	OH	H	H
323	3	SO_2NH_2	H	OH	H	H
324	4	SO_2NH_2	H	OH	H	H
325	1	H	H	OMe	H	H
326	2	H	H	OMe	H	H
327	3	H	H	OMe	H	H
328	4	H	H	OMe	H	H
329	1	Me	H	OMe	H	H
330	2	Me	H	OMe	H	H
331	3	Me	H	OMe	H	H
332	4	Me	H	OMe	H	H
333	1	CH_2Ph	H	OMe	H	H
334	2	CH_2Ph	H	OMe	H	H
335	3	CH_2Ph	H	OMe	H	H
336	4	CH_2Ph	H	OMe	H	H
337	1	COMe	H	OMe	H	H
338	2	COMe	H	OMe	H	H
339	3	COMe	H	OMe	H	H
340	4	COMe	H	OMe	H	H
341	1	CO_2Me	H	OMe	H	H
342	2	CO_2Me	H	OMe	H	H
343	3	CO_2Me	H	OMe	H	H
344	4	CO_2Me	H	OMe	H	H
345	1	CO_2tBu	H	OMe	H	H
346	2	CO_2tBu	H	OMe	H	H

347	3	CO_2tBu	H	OMe	H	H
348	4	CO_2tBu	H	OMe	H	H
349	1	CONHMe	H	OMe	H	H
350	2	CONHMe	H	OMe	H	H
351	3	CONHMe	H	OMe	H	H
352	4	CONHMe	H	OMe	H	H
353	1	SO_2Me	H	OMe	H	H
354	2	SO_2Me	H	OMe	H	H
355	3	SO_2Me	H	OMe	H	H
356	4	SO_2Me	H	OMe	H	H
357	1	SO_2NH_2	H	OMe	H	H
358	2	SO_2NH_2	H	OMe	H	H
359	3	SO_2NH_2	H	OMe	H	H
360	4	SO_2NH_2	H	OMe	H	H
361	1	H	H	Me	H	H
362	2	H	H	Me	H	H
363	3	H	H	Me	H	H
364	4	H	H	Me	H	H
365	1	Me	H	Me	H	H
366	2	Me	H	Me	H	H
367	3	Me	H	Me	H	H
368	4	Me	H	Me	H	H
369	1	CH_2Ph	H	Me	H	H
370	2	CH_2Ph	H	Me	H	H
371	3	CH_2Ph	H	Me	H	H
372	4	CH_2Ph	H	Me	H	H
373	1	COMe	H	Me	H	H
374	2	COMe	H	Me	H	H
375	3	COMe	H	Me	H	H
376	4	COMe	H	Me	H	H
377	1	CO_2Me	H	Me	H	H

378	2	CO_2Me	H	Me	H	H
379	3	CO_2Me	H	Me	H	H
380	4	CO_2Me	H	Me	H	H
381	1	CO_2tBu	H	Me	H	H
382	2	CO_2tBu	H	Me	H	H
383	3	CO_2tBu	H	Me	H	H
384	4	CO_2tBu	H	Me	H	H
385	1	CONHMe	H	Me	H	H
386	2	CONHMe	H	Me	H	H
387	3	CONHMe	H	Me	H	H
388	4	CONHMe	H	Me	H	H
389	1	SO_2Me	H	Me	H	H
390	2	SO_2Me	H	Me	H	H
391	3	SO_2Me	H	Me	H	H
392	4	SO_2Me	H	Me	H	H
393	1	SO_2NH_2	H	Me	H	H
394	2	SO_2NH_2	H	Me	H	H
395	3	SO_2NH_2	H	Me	H	H
396	4	SO_2NH_2	H	Me	H	H
397	1	H	H	CF_3	H	H
398	2	H	H	CF_3	H	H
399	3	H	H	CF_3	H	H
400	4	H	H	CF_3	H	H
401	1	Me	H	CF_3	H	H
402	2	Me	H	CF_3	H	H
403	3	Me	H	CF_3	H	H
404	4	Me	H	CF_3	H	H
405	1	CH_2Ph	H	CF_3	H	H
406	2	CH_2Ph	H	CF_3	H	H
407	3	CH_2Ph	H	CF_3	H	H
408	4	CH_2Ph	H	CF_3	H	H

409	1	COMe	H	CF_3	H	H
410	2	COMe	H	CF_3	H	H
411	3	COMe	H	CF_3	H	H
412	4	COMe	H	CF_3	H	H
413	1	CO_2Me	H	CF_3	H	H
414	2	CO_2Me	H	CF_3	H	H
415	3	CO_2Me	H	CF_3	H	H
416	4	CO_2Me	H	CF_3	H	H
417	1	CO_2tBu	H	CF_3	H	H
418	2	CO_2tBu	H	CF_3	H	H
419	3	CO_2tBu	H	CF_3	H	H
420	4	CO_2tBu	H	CF_3	H	H
421	1	CONHMe	H	CF_3	H	H
422	2	CONHMe	H	CF_3	H	H
423	3	CONHMe	H	CF_3	H	H
424	4	CONHMe	H	CF_3	H	H
425	1	SO_2Me	H	CF_3	H	H
426	2	SO_2Me	H	CF_3	H	H
427	3	SO_2Me	H	CF_3	H	H
428	4	SO_2Me	H	CF_3	H	H
429	1	SO_2NH_2	H	CF_3	H	H
430	2	SO_2NH_2	H	CF_3	H	H
431	3	SO_2NH_2	H	CF_3	H	H
432	4	SO_2NH_2	H	CF_3	H	H
433	1	H	H	F	H	H
434	2	H	H	F	H	H
435	3	H	H	F	H	H
436	3	H	H	F	H	H
437	1	Me	H	F	H	H
438	2	Me	H	F	H	H
439	3	Me	H	F	H	H

440	4	Me	H	F	H	H
441	1	CH_2Ph	H	F	H	H
442	2	CH_2Ph	H	F	H	H
443	3	CH_2Ph	H	F	H	H
444	4	CH_2Ph	H	F	H	H
445	1	COMe	H	F	H	H
446	2	COMe	H	F	H	H
447	3	COMe	H	F	H	H
448	4	COMe	H	F	H	H
449	1	CO_2Me	H	F	H	H
450	2	CO_2Me	H	F	H	H
451	3	CO_2Me	H	F	H	H
452	4	CO_2Me	H	F	H	H
453	1	CO_2tBu	H	F	H	H
454	2	CO_2tBu	H	F	H	H
455	3	CO_2tBu	H	F	H	H
456	4	CO_2tBu	H	F	H	H
457	1	CONHMe	H	F	H	H
458	2	CONHMe	H	F	H	H
459	3	CONHMe	H	F	H	H
460	4	CONHMe	H	F	H	H
461	1	SO_2Me	H	F	H	H
462	2	SO_2Me	H	F	H	H
463	3	SO_2Me	H	F	H	H
464	4	SO_2Me	H	F	H	H
465	1	SO_2NH_2	H	F	H	H
466	2	SO_2NH_2	H	F	H	H
467	3	SO_2NH_2	H	F	H	H
468	4	SO_2NH_2	H	F	H	H
469	1	H	H	Cl	H	H
470	2	H	H	Cl	H	H

471	3	H	H	Cl	H	H
472	4	H	H	Cl	H	H
473	1	Me	H	Cl	H	H
474	2	Me	H	Cl	H	H
475	3	Me	H	Cl	H	H
476	4	Me	H	Cl	H	H
477	1	CH_2Ph	H	Cl	H	H
478	2	CH_2Ph	H	Cl	H	H
479	3	CH_2Ph	H	Cl	H	H
480	4	CH_2Ph	H	Cl	H	H
481	1	COMe	H	Cl	H	H
482	2	COMe	H	Cl	H	H
483	3	COMe	H	Cl	H	H
484	4	COMe	H	Cl	H	H
485	1	CO_2Me	H	Cl	H	H
486	2	CO_2Me	H	Cl	H	H
487	3	CO_2Me	H	Cl	H	H
488	4	CO_2Me	H	Cl	H	H
489	1	CO_2tBu	H	Cl	H	H
490	2	CO_2tBu	H	Cl	H	H
491	3	CO_2tBu	H	Cl	H	H
492	4	CO_2tBu	H	Cl	H	H
493	1	CONHMe	H	Cl	H	H
494	2	CONHMe	H	Cl	H	H
495	3	CONHMe	H	Cl	H	H
496	4	CONHMe	H	Cl	H	H
497	1	SO_2Me	H	Cl	H	H
498	2	SO_2Me	H	Cl	H	H
499	3	SO_2Me	H	Cl	H	H
500	4	SO_2Me	H	Cl	H	H
501	1	SO_2NH_2	H	Cl	H	H

502	2	SO_2NH_2	H	Cl	H	H
503	3	SO_2NH_2	H	Cl	H	H
504	4	SO_2NH_2	H	Cl	H	H
505	1	H	H	CN	H	H
506	2	H	H	CN	H	H
507	3	H	H	CN	H	H
508	4	H	H	CN	H	H
509	1	Me	H	CN	H	H
510	2	Me	H	CN	H	H
511	3	Me	H	CN	H	H
512	4	Me	H	CN	H	H
513	1	CH_2Ph	H	CN	H	H
514	2	CH_2Ph	H	CN	H	H
515	3	CH_2Ph	H	CN	H	H
516	4	CH_2Ph	H	CN	H	H
517	1	COMe	H	CN	H	H
518	2	COMe	H	CN	H	H
519	3	COMe	H	CN	H	H
520	4	COMe	H	CN	H	H
521	1	CO_2Me	H	CN	H	H
522	2	CO_2Me	H	CN	H	H
523	3	CO_2Me	H	CN	H	H
524	4	CO_2Me	H	CN	H	H
525	1	CO_2tBu	H	CN	H	H
526	2	CO_2tBu	H	CN	H	H
527	3	CO_2tBu	H	CN	H	H
528	4	CO_2tBu	H	CN	H	H
529	1	CONHMe	H	CN	H	H
530	2	CONHMe	H	CN	H	H
531	3	CONHMe	H	CN	H	H
532	4	CONHMe	H	CN	H	H

533	1	SO_2Me	H	CN	H	H
534	2	SO_2Me	H	CN	H	H
535	3	SO_2Me	H	CN	H	H
536	4	SO_2Me	H	CN	H	H
537	1	SO_2NH_2	H	CN	H	H
538	2	SO_2NH_2	H	CN	H	H
539	3	SO_2NH_2	H	CN	H	H
540	4	SO_2NH_2	H	CN	H	H
541	1	H	OH	H	H	H
542	2	H	OH	H	H	H
543	3	H	OH	H	H	H
544	4	H	OH	H	H	H
545	1	Me	OH	H	H	H
546	2	Me	OH	H	H	H
547	3	Me	OH	H	H	H
548	4	Me	OH	H	H	H
549	1	CH_2Ph	OH	H	H	H
550	2	CH_2Ph	OH	H	H	H
551	3	CH_2Ph	OH	H	H	H
552	4	CH_2Ph	OH	H	H	H
553	1	COMe	OH	H	H	H
554	2	COMe	OH	H	H	H
555	3	COMe	OH	H	H	H
556	4	COMe	OH	H	H	H
557	1	CO_2Me	OH	H	H	H
558	2	CO_2Me	OH	H	H	H
559	3	CO_2Me	OH	H	H	H
560	4	CO_2Me	OH	H	H	H
561	1	CO_2tBu	OH	H	H	H
562	2	CO_2tBu	OH	H	H	H
563	3	CO_2tBu	OH	H	H	H

564	4	CO_2tBu	OH	H	H	H
565	1	CONHMe	OH	H	H	H
566	2	CONHMe	OH	H	H	H
567	3	CONHMe	OH	H	H	H
568	4	CONHMe	OH	H	H	H
569	1	SO_2Me	OH	H	H	H
570	2	SO_2Me	OH	H	H	H
571	3	SO_2Me	OH	H	H	H
572	4	SO_2Me	OH	H	H	H
573	1	SO_2NH_2	OH	H	H	H
574	2	SO_2NH_2	OH	H	H	H
575	3	SO_2NH_2	OH	H	H	H
576	4	SO_2NH_2	OH	H	H	H
577	1	H	OMe	H	H	H
578	2	H	OMe	H	H	H
579	3	H	OMe	H	H	H
580	4	H	OMe	H	H	H
581	1	Me	OMe	H	H	H
582	2	Me	OMe	H	H	H
583	3	Me	OMe	H	H	H
584	4	Me	OMe	H	H	H
585	1	CH_2Ph	OMe	H	H	H
586	2	CH_2Ph	OMe	H	H	H
587	3	CH_2Ph	OMe	H	H	H
588	4	CH_2Ph	OMe	H	H	H
589	1	COMe	OMe	H	H	H
590	2	COMe	OMe	H	H	H
591	3	COMe	OMe	H	H	H
592	4	COMe	OMe	H	H	H
593	1	CO_2Me	OMe	H	H	H
594	2	CO_2Me	OMe	H	H	H

595	3	CO_2Me	OMe	H	H	H
596	4	CO_2Me	OMe	H	H	H
597	1	CO_2tBu	OMe	H	H	H
598	2	CO_2tBu	OMe	H	H	H
599	3	CO_2tBu	OMe	H	H	H
600	4	CO_2tBu	OMe	H	H	H
601	1	CONHMe	OMe	H	H	H
602	2	CONHMe	OMe	H	H	H
603	3	CONHMe	OMe	H	H	H
604	4	CONHMe	OMe	H	H	H
605	1	SO_2Me	OMe	H	H	H
606	2	SO_2Me	OMe	H	H	H
607	3	SO_2Me	OMe	H	H	H
608	4	SO_2Me	OMe	H	H	H
609	1	SO_2NH_2	OMe	H	H	H
610	2	SO_2NH_2	OMe	H	H	H
611	3	SO_2NH_2	OMe	H	H	H
612	4	SO_2NH_2	OMe	H	H	H
613	1	H	Me	H	H	H
614	2	H	Me	H	H	H
615	3	H	Me	H	H	H
616	4	H	Me	H	H	H
617	1	Me	Me	H	H	H
618	2	Me	Me	H	H	H
619	3	Me	Me	H	H	H
620	4	Me	Me	H	H	H
621	1	CH_2Ph	Me	H	H	H
622	2	CH_2Ph	Me	H	H	H
623	3	CH_2Ph	Me	H	H	H
624	4	CH_2Ph	Me	H	H	H
625	1	COMe	Me	H	H	H

626	2	COMe	Me	H	H	H
627	3	COMe	Me	H	H	H
628	4	COMe	Me	H	H	H
629	1	CO_2Me	Me	H	H	H
630	2	CO_2Me	Me	H	H	H
631	3	CO_2Me	Me	H	H	H
632	4	CO_2Me	Me	H	H	H
633	1	CO_2tBu	Me	H	H	H
634	2	CO_2tBu	Me	H	H	H
635	3	CO_2tBu	Me	H	H	H
636	4	CO_2tBu	Me	H	H	H
637	1	CONHMe	Me	H	H	H
638	2	CONHMe	Me	H	H	H
639	3	CONHMe	Me	H	H	H
640	4	CONHMe	Me	H	H	H
641	1	SO_2Me	Me	H	H	H
642	2	SO_2Me	Me	H	H	H
643	3	SO_2Me	Me	H	H	H
644	4	SO_2Me	Me	H	H	H
645	1	SO_2NH_2	Me	H	H	H
646	2	SO_2NH_2	Me	H	H	H
647	3	SO_2NH_2	Me	H	H	H
648	4	SO_2NH_2	Me	H	H	H
649	1	H	CF_3	H	H	H
650	2	H	CF_3	H	H	H
651	3	H	CF_3	H	H	H
652	4	H	CF_3	H	H	H
653	1	Me	CF_3	H	H	H
654	2	Me	CF_3	H	H	H
655	3	Me	CF_3	H	H	H
656	4	Me	CF_3	H	H	H

657	1	CH_2Ph	CF_3	H	H	H
658	2	CH_2Ph	CF_3	H	H	H
659	3	CH_2Ph	CF_3	H	H	H
660	4	CH_2Ph	CF_3	H	H	H
661	1	COMe	CF_3	H	H	H
662	2	COMe	CF_3	H	H	H
663	3	COMe	CF_3	H	H	H
664	4	COMe	CF_3	H	H	H
665	1	CO_2Me	CF_3	H	H	H
666	2	CO_2Me	CF_3	H	H	H
667	3	CO_2Me	CF_3	H	H	H
668	4	CO_2Me	CF_3	H	H	H
669	1	CO_2tBu	CF_3	H	H	H
670	2	CO_2tBu	CF_3	H	H	H
671	3	CO_2tBu	CF_3	H	H	H
672	4	CO_2tBu	CF_3	H	H	H
673	1	CONHMe	CF_3	H	H	H
674	2	CONHMe	CF_3	H	H	H
675	3	CONHMe	CF_3	H	H	H
676	4	CONHMe	CF_3	H	H	H
677	1	SO_2Me	CF_3	H	H	H
678	2	SO_2Me	CF_3	H	H	H
679	3	SO_2Me	CF_3	H	H	H
680	4	SO_2Me	CF_3	H	H	H
681	1	SO_2NH_2	CF_3	H	H	H
682	2	SO_2NH_2	CF_3	H	H	H
683	3	SO_2NH_2	CF_3	H	H	H
684	4	SO_2NH_2	CF_3	H	H	H
685	1	H	F	H	H	H
686	2	H	F	H	H	H
687	3	H	F	H	H	H

688	3	H	F	H	H	H
689	1	Me	F	H	H	H
690	2	Me	F	H	H	H
691	3	Me	F	H	H	H
692	4	Me	F	H	H	H
693	1	CH_2Ph	F	H	H	H
694	2	CH_2Ph	F	H	H	H
695	3	CH_2Ph	F	H	H	H
696	4	CH_2Ph	F	H	H	H
697	1	COMe	F	H	H	H
698	2	COMe	F	H	H	H
699	3	COMe	F	H	H	H
700	4	COMe	F	H	H	H
701	1	CO_2Me	F	H	H	H
702	2	CO_2Me	F	H	H	H
703	3	CO_2Me	F	H	H	H
704	4	CO_2Me	F	H	H	H
705	1	CO_2tBu	F	H	H	H
706	2	CO_2tBu	F	H	H	H
707	3	CO_2tBu	F	H	H	H
708	4	CO_2tBu	F	H	H	H
709	1	CONHMe	F	H	H	H
710	2	CONHMe	F	H	H	H
711	3	CONHMe	F	H	H	H
712	4	CONHMe	F	H	H	H
713	1	SO_2Me	F	H	H	H
714	2	SO_2Me	F	H	H	H
715	3	SO_2Me	F	H	H	H
716	4	SO_2Me	F	H	H	H
717	1	SO_2NH_2	F	H	H	H
718	2	SO_2NH_2	F	H	H	H

719	3	SO_2NH_2	F	H	H	H
720	4	SO_2NH_2	F	H	H	H
721	1	H	Cl	H	H	H
722	2	H	Cl	H	H	H
723	3	H	Cl	H	H	H
724	4	H	Cl	H	H	H
725	1	Me	Cl	H	H	H
726	2	Me	Cl	H	H	H
727	3	Me	Cl	H	H	H
728	4	Me	Cl	H	H	H
729	1	CH_2Ph	Cl	H	H	H
730	2	CH_2Ph	Cl	H	H	H
731	3	CH_2Ph	Cl	H	H	H
732	4	CH_2Ph	Cl	H	H	H
733	1	COMe	Cl	H	H	H
734	2	COMe	Cl	H	H	H
735	3	COMe	Cl	H	H	H
736	4	COMe	Cl	H	H	H
737	1	CO_2Me	Cl	H	H	H
738	2	CO_2Me	Cl	H	H	H
739	3	CO_2Me	Cl	H	H	H
740	4	CO_2Me	Cl	H	H	H
741	1	CO_2tBu	Cl	H	H	H
742	2	CO_2tBu	Cl	H	H	H
743	3	CO_2tBu	Cl	H	H	H
744	4	CO_2tBu	Cl	H	H	H
745	1	CONHMe	Cl	H	H	H
746	2	CONHMe	Cl	H	H	H
747	3	CONHMe	Cl	H	H	H
748	4	CONHMe	Cl	H	H	H
749	1	SO_2Me	Cl	H	H	H

750	2	SO_2Me	Cl	H	H	H
751	3	SO_2Me	Cl	H	H	H
752	4	SO_2Me	Cl	H	H	H
753	1	SO_2NH_2	Cl	H	H	H
754	2	SO_2NH_2	Cl	H	H	H
755	3	SO_2NH_2	Cl	H	H	H
756	4	SO_2NH_2	Cl	H	H	H
757	1	H	CN	H	H	H
758	2	H	CN	H	H	H
759	3	H	CN	H	H	H
760	4	H	CN	H	H	H
761	1	Me	CN	H	H	H
762	2	Me	CN	H	H	H
763	3	Me	CN	H	H	H
764	4	Me	CN	H	H	H
765	1	CH_2Ph	CN	H	H	H
766	2	CH_2Ph	CN	H	H	H
767	3	CH_2Ph	CN	H	H	H
768	4	CH_2Ph	CN	H	H	H
769	1	COMe	CN	H	H	H
770	2	COMe	CN	H	H	H
771	3	COMe	CN	H	H	H
772	4	COMe	CN	H	H	H
773	1	CO_2Me	CN	H	H	H
774	2	CO_2Me	CN	H	H	H
775	3	CO_2Me	CN	H	H	H
776	4	CO_2Me	CN	H	H	H
777	1	CO_2tBu	CN	H	H	H
778	2	CO_2tBu	CN	H	H	H
779	3	CO_2tBu	CN	H	H	H
780	4	CO_2tBu	CN	H	H	H

781	1	CONHMe	CN	H	H	H
782	2	CONHMe	CN	H	H	H
783	3	CONHMe	CN	H	H	H
784	4	CONHMe	CN	H	H	H
785	1	SO_2Me	CN	H	H	H
786	2	SO_2Me	CN	H	H	H
787	3	SO_2Me	CN	H	H	H
788	4	SO_2Me	CN	H	H	H
789	1	SO_2NH_2	CN	H	H	H
790	2	SO_2NH_2	CN	H	H	H
791	3	SO_2NH_2	CN	H	H	H
792	4	SO_2NH_2	CN	H	H	H
793	1	H	H	H	H	OH
794	2	H	H	H	H	OH
795	3	H	H	H	H	OH
796	4	H	H	H	H	OH
797	1	Me	H	H	H	OH
798	2	Me	H	H	H	OH
799	3	Me	H	H	H	OH
800	4	Me	H	H	H	OH
801	1	CH_2Ph	H	H	H	OH
802	2	CH_2Ph	H	H	H	OH
803	3	CH_2Ph	H	H	H	OH
804	4	CH_2Ph	H	H	H	OH
805	1	COMe	H	H	H	OH
806	2	COMe	H	H	H	OH
807	3	COMe	H	H	H	OH
808	4	COMe	H	H	H	OH
809	1	CO_2Me	H	H	H	OH
810	2	CO_2Me	H	H	H	OH
811	3	CO_2Me	H	H	H	OH

812	4	CO_2Me	H	H	H	OH
813	1	CO_2tBu	H	H	H	OH
814	2	CO_2tBu	H	H	H	OH
815	3	CO_2tBu	H	H	H	OH
816	4	CO_2tBu	H	H	H	OH
817	1	CONHMe	H	H	H	OH
818	2	CONHMe	H	H	H	OH
819	3	CONHMe	H	H	H	OH
820	4	CONHMe	H	H	H	OH
821	1	SO_2Me	H	H	H	OH
822	2	SO_2Me	H	H	H	OH
823	3	SO_2Me	H	H	H	OH
824	4	SO_2Me	H	H	H	OH
825	1	SO_2NH_2	H	H	H	OH
826	2	SO_2NH_2	H	H	H	OH
827	3	SO_2NH_2	H	H	H	OH
828	4	SO_2NH_2	H	H	H	OH
829	1	H	H	H	H	OMe
830	2	H	H	H	H	OMe
831	3	H	H	H	H	OMe
832	4	H	H	H	H	OMe
833	1	Me	H	H	H	OMe
834	2	Me	H	H	H	OMe
835	3	Me	H	H	H	OMe
836	4	Me	H	H	H	OMe
837	1	CH_2Ph	H	H	H	OMe
838	2	CH_2Ph	H	H	H	OMe
839	3	CH_2Ph	H	H	H	OMe
840	4	CH_2Ph	H	H	H	OMe
841	1	COMe	H	H	H	OMe
842	2	COMe	H	H	H	OMe

843	3	COMe	H	H	H	OMe
844	4	COMe	H	H	H	OMe
845	1	CO_2Me	H	H	H	OMe
846	2	CO_2Me	H	H	H	OMe
847	3	CO_2Me	H	H	H	OMe
848	4	CO_2Me	H	H	H	OMe
849	1	CO_2tBu	H	H	H	OMe
850	2	CO_2tBu	H	H	H	OMe
851	3	CO_2tBu	H	H	H	OMe
852	4	CO_2tBu	H	H	H	OMe
853	1	CONHMe	H	H	H	OMe
854	2	CONHMe	H	H	H	OMe
855	3	CONHMe	H	H	H	OMe
856	4	CONHMe	H	H	H	OMe
857	1	SO_2Me	H	H	H	OMe
858	2	SO_2Me	H	H	H	OMe
859	3	SO_2Me	H	H	H	OMe
860	4	SO_2Me	H	H	H	OMe
861	1	SO_2NH_2	H	H	H	OMe
862	2	SO_2NH_2	H	H	H	OMe
863	3	SO_2NH_2	H	H	H	OMe
864	4	SO_2NH_2	H	H	H	OMe
865	1	H	H	H	H	Me
866	2	H	H	H	H	Me
867	3	H	H	H	H	Me
868	4	H	H	H	H	Me
869	1	Me	H	H	H	Me
870	2	Me	H	H	H	Me
871	3	Me	H	H	H	Me
872	4	Me	H	H	H	Me
873	1	CH_2Ph	H	H	H	Me

874	2	CH_2Ph	H	H	H	Me
875	3	CH_2Ph	H	H	H	Me
876	4	CH_2Ph	H	H	H	Me
877	1	COMe	H	H	H	Me
878	2	COMe	H	H	H	Me
879	3	COMe	H	H	H	Me
880	4	COMe	H	H	H	Me
881	1	CO_2Me	H	H	H	Me
882	2	CO_2Me	H	H	H	Me
883	3	CO_2Me	H	H	H	Me
884	4	CO_2Me	H	H	H	Me
885	1	CO_2tBu	H	H	H	Me
886	2	CO_2tBu	H	H	H	Me
887	3	CO_2tBu	H	H	H	Me
888	4	CO_2tBu	H	H	H	Me
889	1	CONHMe	H	H	H	Me
890	2	CONHMe	H	H	H	Me
891	3	CONHMe	H	H	H	Me
892	4	CONHMe	H	H	H	Me
893	1	SO_2Me	H	H	H	Me
894	2	SO_2Me	H	H	H	Me
895	3	SO_2Me	H	H	H	Me
896	4	SO_2Me	H	H	H	Me
897	1	SO_2NH_2	H	H	H	Me
898	2	SO_2NH_2	H	H	H	Me
899	3	SO_2NH_2	H	H	H	Me
900	4	SO_2NH_2	H	H	H	Me
901	1	H	H	H	H	CF_3
902	2	H	H	H	H	CF_3
903	3	H	H	H	H	CF_3
904	4	H	H	H	H	CF_3

905	1	Me	H	H	H	CF_3
906	2	Me	H	H	H	CF_3
907	3	Me	H	H	H	CF_3
908	4	Me	H	H	H	CF_3
909	1	CH_2Ph	H	H	H	CF_3
910	2	CH_2Ph	H	H	H	CF_3
911	3	CH_2Ph	H	H	H	CF_3
912	4	CH_2Ph	H	H	H	CF_3
913	1	COMe	H	H	H	CF_3
914	2	COMe	H	H	H	CF_3
915	3	COMe	H	H	H	CF_3
916	4	COMe	H	H	H	CF_3
917	1	CO_2Me	H	H	H	CF_3
918	2	CO_2Me	H	H	H	CF_3
919	3	CO_2Me	H	H	H	CF_3
920	4	CO_2Me	H	H	H	CF_3
921	1	CO_2tBu	H	H	H	CF_3
922	2	CO_2tBu	H	H	H	CF_3
923	3	CO_2tBu	H	H	H	CF_3
924	4	CO_2tBu	H	H	H	CF_3
925	1	CONHMe	H	H	H	CF_3
926	2	CONHMe	H	H	H	CF_3
927	3	CONHMe	H	H	H	CF_3
928	4	CONHMe	H	H	H	CF_3
929	1	SO_2Me	H	H	H	CF_3
930	2	SO_2Me	H	H	H	CF_3
931	3	SO_2Me	H	H	H	CF_3
932	4	SO_2Me	H	H	H	CF_3
933	1	SO_2NH_2	H	H	H	CF_3
934	2	SO_2NH_2	H	H	H	CF_3
935	3	SO_2NH_2	H	H	H	CF_3


936	4	SO_2NH_2	H	H	H	CF_3
937	1	H	H	H	H	F
938	2	H	H	H	H	F
939	3	H	H	H	H	F
940	3	H	H	H	H	F
941	1	Me	H	H	H	F
942	2	Me	H	H	H	F
943	3	Me	H	H	H	F
944	4	Me	H	H	H	F
945	1	CH_2Ph	H	H	H	F
946	2	CH_2Ph	H	H	H	F
947	3	CH_2Ph	H	H	H	F
948	4	CH_2Ph	H	H	H	F
949	1	COMe	H	H	H	F
950	2	COMe	H	H	H	F
951	3	COMe	H	H	H	F
952	4	COMe	H	H	H	F
953	1	CO_2Me	H	H	H	F
954	2	CO_2Me	H	H	H	F
955	3	CO_2Me	H	H	H	F
956	4	CO_2Me	H	H	H	F
957	1	CO_2tBu	H	H	H	F
958	2	CO_2tBu	H	H	H	F
959	3	CO_2tBu	H	H	H	F
960	4	CO_2tBu	H	H	H	F
961	1	CONHMe	H	H	H	F
962	2	CONHMe	H	H	H	F
963	3	CONHMe	H	H	H	F
964	4	CONHMe	H	H	H	F
965	1	SO_2Me	H	H	H	F
966	2	SO_2Me	H	H	H	F

967	3	SO_2Me	H	H	H	F
968	4	SO_2Me	H	H	H	F
969	1	SO_2NH_2	H	H	H	F
970	2	SO_2NH_2	H	H	H	F
971	3	SO_2NH_2	H	H	H	F
972	4	SO_2NH_2	H	H	H	F
973	1	H	H	H	H	Cl
974	2	H	H	H	H	Cl
975	3	H	H	H	H	Cl
976	4	H	H	H	H	Cl
977	1	Me	H	H	H	Cl
978	2	Me	H	H	H	Cl
979	3	Me	H	H	H	Cl
980	4	Me	H	H	H	Cl
981	1	CH_2Ph	H	H	H	Cl
982	2	CH_2Ph	H	H	H	Cl
983	3	CH_2Ph	H	H	H	Cl
984	4	CH_2Ph	H	H	H	Cl
985	1	COMe	H	H	H	Cl
986	2	COMe	H	H	H	Cl
987	3	COMe	H	H	H	Cl
988	4	COMe	H	H	H	Cl
989	1	CO_2Me	H	H	H	Cl
990	2	CO_2Me	H	H	H	Cl
991	3	CO_2Me	H	H	H	Cl
992	4	CO_2Me	H	H	H	Cl
993	1	CO_2tBu	H	H	H	Cl
994	2	CO_2tBu	H	H	H	Cl
995	3	CO_2tBu	H	H	H	Cl
996	4	CO_2tBu	H	H	H	Cl
997	1	CONHMe	H	H	H	Cl

998	2	CONHMe	H	H	H	Cl
999	3	CONHMe	H	H	H	Cl
1000	4	CONHMe	H	H	H	Cl
1001	1	SO_2Me	H	H	H	Cl
1002	2	SO_2Me	H	H	H	Cl
1003	3	SO_2Me	H	H	H	Cl
1004	4	SO_2Me	H	H	H	Cl
1005	1	SO_2NH_2	H	H	H	Cl
1006	2	SO_2NH_2	H	H	H	Cl
1007	3	SO_2NH_2	H	H	H	Cl
1008	4	SO_2NH_2	H	H	H	Cl
1009	1	H	H	H	H	CN
1010	2	H	H	H	H	CN
1011	3	H	H	H	H	CN
1012	4	H	H	H	H	CN
1013	1	Me	H	H	H	CN
1014	2	Me	H	H	H	CN
1015	3	Me	H	H	H	CN
1016	4	Me	H	H	H	CN
1017	1	CH_2Ph	H	H	H	CN
1018	2	CH_2Ph	H	H	H	CN
1019	3	CH_2Ph	H	H	H	CN
1020	4	CH_2Ph	H	H	H	CN
1021	1	COMe	H	H	H	CN
1022	2	COMe	H	H	H	CN
1023	3	COMe	H	H	H	CN
1024	4	COMe	H	H	H	CN
1025	1	CO_2Me	H	H	H	CN
1026	2	CO_2Me	H	H	H	CN
1027	3	CO_2Me	H	H	H	CN
1028	4	CO_2Me	H	H	H	CN

1029	1	CO_2tBu	H	H	H	CN
1030	2	CO_2tBu	H	H	H	CN
1031	3	CO_2tBu	H	H	H	CN
1032	4	CO_2tBu	H	H	H	CN
1033	1	CONHMe	H	H	H	CN
1034	2	CONHMe	H	H	H	CN
1035	3	CONHMe	H	H	H	CN
1036	4	CONHMe	H	H	H	CN
1037	1	SO_2Me	H	H	H	CN
1038	2	SO_2Me	H	H	H	CN
1039	3	SO_2Me	H	H	H	CN
1040	4	SO_2Me	H	H	H	CN
1041	1	SO_2NH_2	H	H	H	CN
1042	2	SO_2NH_2	H	H	H	CN
1043	3	SO_2NH_2	H	H	H	CN
1044	4	SO_2NH_2	H	H	H	CN

[01032] Exemplary embodiments include compounds having the formula **(XXX)**



(XXX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 24.

Table 24

Entry	n	R^7	R^{20a}	R^{20b}	R^{20c}	R^{20e}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H

7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H

38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H

69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H

100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H

131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H

162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H

193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H

224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H

255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H

286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	OH	H	H
290	2	H	H	OH	H	H
291	3	H	H	OH	H	H
292	4	H	H	OH	H	H
293	1	Me	H	OH	H	H
294	2	Me	H	OH	H	H
295	3	Me	H	OH	H	H
296	4	Me	H	OH	H	H
297	1	CH_2Ph	H	OH	H	H
298	2	CH_2Ph	H	OH	H	H
299	3	CH_2Ph	H	OH	H	H
300	4	CH_2Ph	H	OH	H	H
301	1	COMe	H	OH	H	H
302	2	COMe	H	OH	H	H
303	3	COMe	H	OH	H	H
304	4	COMe	H	OH	H	H
305	1	CO_2Me	H	OH	H	H
306	2	CO_2Me	H	OH	H	H
307	3	CO_2Me	H	OH	H	H
308	4	CO_2Me	H	OH	H	H
309	1	CO_2tBu	H	OH	H	H
310	2	CO_2tBu	H	OH	H	H
311	3	CO_2tBu	H	OH	H	H
312	4	CO_2tBu	H	OH	H	H
313	1	CONHMe	H	OH	H	H
314	2	CONHMe	H	OH	H	H
315	3	CONHMe	H	OH	H	H
316	4	CONHMe	H	OH	H	H

317	1	SO_2Me	H	OH	H	H
318	2	SO_2Me	H	OH	H	H
319	3	SO_2Me	H	OH	H	H
320	4	SO_2Me	H	OH	H	H
321	1	SO_2NH_2	H	OH	H	H
322	2	SO_2NH_2	H	OH	H	H
323	3	SO_2NH_2	H	OH	H	H
324	4	SO_2NH_2	H	OH	H	H
325	1	H	H	OMe	H	H
326	2	H	H	OMe	H	H
327	3	H	H	OMe	H	H
328	4	H	H	OMe	H	H
329	1	Me	H	OMe	H	H
330	2	Me	H	OMe	H	H
331	3	Me	H	OMe	H	H
332	4	Me	H	OMe	H	H
333	1	CH_2Ph	H	OMe	H	H
334	2	CH_2Ph	H	OMe	H	H
335	3	CH_2Ph	H	OMe	H	H
336	4	CH_2Ph	H	OMe	H	H
337	1	COMe	H	OMe	H	H
338	2	COMe	H	OMe	H	H
339	3	COMe	H	OMe	H	H
340	4	COMe	H	OMe	H	H
341	1	CO_2Me	H	OMe	H	H
342	2	CO_2Me	H	OMe	H	H
343	3	CO_2Me	H	OMe	H	H
344	4	CO_2Me	H	OMe	H	H
345	1	CO_2tBu	H	OMe	H	H
346	2	CO_2tBu	H	OMe	H	H
347	3	CO_2tBu	H	OMe	H	H

348	4	CO_2tBu	H	OMe	H	H
349	1	CONHMe	H	OMe	H	H
350	2	CONHMe	H	OMe	H	H
351	3	CONHMe	H	OMe	H	H
352	4	CONHMe	H	OMe	H	H
353	1	SO_2Me	H	OMe	H	H
354	2	SO_2Me	H	OMe	H	H
355	3	SO_2Me	H	OMe	H	H
356	4	SO_2Me	H	OMe	H	H
357	1	SO_2NH_2	H	OMe	H	H
358	2	SO_2NH_2	H	OMe	H	H
359	3	SO_2NH_2	H	OMe	H	H
360	4	SO_2NH_2	H	OMe	H	H
361	1	H	H	Me	H	H
362	2	H	H	Me	H	H
363	3	H	H	Me	H	H
364	4	H	H	Me	H	H
365	1	Me	H	Me	H	H
366	2	Me	H	Me	H	H
367	3	Me	H	Me	H	H
368	4	Me	H	Me	H	H
369	1	CH_2Ph	H	Me	H	H
370	2	CH_2Ph	H	Me	H	H
371	3	CH_2Ph	H	Me	H	H
372	4	CH_2Ph	H	Me	H	H
373	1	COMe	H	Me	H	H
374	2	COMe	H	Me	H	H
375	3	COMe	H	Me	H	H
376	4	COMe	H	Me	H	H
377	1	CO_2Me	H	Me	H	H
378	2	CO_2Me	H	Me	H	H

379	3	CO_2Me	H	Me	H	H
380	4	CO_2Me	H	Me	H	H
381	1	CO_2tBu	H	Me	H	H
382	2	CO_2tBu	H	Me	H	H
383	3	CO_2tBu	H	Me	H	H
384	4	CO_2tBu	H	Me	H	H
385	1	CONHMe	H	Me	H	H
386	2	CONHMe	H	Me	H	H
387	3	CONHMe	H	Me	H	H
388	4	CONHMe	H	Me	H	H
389	1	SO_2Me	H	Me	H	H
390	2	SO_2Me	H	Me	H	H
391	3	SO_2Me	H	Me	H	H
392	4	SO_2Me	H	Me	H	H
393	1	SO_2NH_2	H	Me	H	H
394	2	SO_2NH_2	H	Me	H	H
395	3	SO_2NH_2	H	Me	H	H
396	4	SO_2NH_2	H	Me	H	H
397	1	H	H	CF_3	H	H
398	2	H	H	CF_3	H	H
399	3	H	H	CF_3	H	H
400	4	H	H	CF_3	H	H
401	1	Me	H	CF_3	H	H
402	2	Me	H	CF_3	H	H
403	3	Me	H	CF_3	H	H
404	4	Me	H	CF_3	H	H
405	1	CH_2Ph	H	CF_3	H	H
406	2	CH_2Ph	H	CF_3	H	H
407	3	CH_2Ph	H	CF_3	H	H
408	4	CH_2Ph	H	CF_3	H	H
409	1	COMe	H	CF_3	H	H

410	2	COMe	H	CF_3	H	H
411	3	COMe	H	CF_3	H	H
412	4	COMe	H	CF_3	H	H
413	1	CO_2Me	H	CF_3	H	H
414	2	CO_2Me	H	CF_3	H	H
415	3	CO_2Me	H	CF_3	H	H
416	4	CO_2Me	H	CF_3	H	H
417	1	CO_2tBu	H	CF_3	H	H
418	2	CO_2tBu	H	CF_3	H	H
419	3	CO_2tBu	H	CF_3	H	H
420	4	CO_2tBu	H	CF_3	H	H
421	1	CONHMe	H	CF_3	H	H
422	2	CONHMe	H	CF_3	H	H
423	3	CONHMe	H	CF_3	H	H
424	4	CONHMe	H	CF_3	H	H
425	1	SO_2Me	H	CF_3	H	H
426	2	SO_2Me	H	CF_3	H	H
427	3	SO_2Me	H	CF_3	H	H
428	4	SO_2Me	H	CF_3	H	H
429	1	SO_2NH_2	H	CF_3	H	H
430	2	SO_2NH_2	H	CF_3	H	H
431	3	SO_2NH_2	H	CF_3	H	H
432	4	SO_2NH_2	H	CF_3	H	H
433	1	H	H	F	H	H
434	2	H	H	F	H	H
435	3	H	H	F	H	H
436	3	H	H	F	H	H
437	1	Me	H	F	H	H
438	2	Me	H	F	H	H
439	3	Me	H	F	H	H
440	4	Me	H	F	H	H

441	1	CH_2Ph	H	F	H	H
442	2	CH_2Ph	H	F	H	H
443	3	CH_2Ph	H	F	H	H
444	4	CH_2Ph	H	F	H	H
445	1	COMe	H	F	H	H
446	2	COMe	H	F	H	H
447	3	COMe	H	F	H	H
448	4	COMe	H	F	H	H
449	1	CO_2Me	H	F	H	H
450	2	CO_2Me	H	F	H	H
451	3	CO_2Me	H	F	H	H
452	4	CO_2Me	H	F	H	H
453	1	CO_2tBu	H	F	H	H
454	2	CO_2tBu	H	F	H	H
455	3	CO_2tBu	H	F	H	H
456	4	CO_2tBu	H	F	H	H
457	1	CONHMe	H	F	H	H
458	2	CONHMe	H	F	H	H
459	3	CONHMe	H	F	H	H
460	4	CONHMe	H	F	H	H
461	1	SO_2Me	H	F	H	H
462	2	SO_2Me	H	F	H	H
463	3	SO_2Me	H	F	H	H
464	4	SO_2Me	H	F	H	H
465	1	SO_2NH_2	H	F	H	H
466	2	SO_2NH_2	H	F	H	H
467	3	SO_2NH_2	H	F	H	H
468	4	SO_2NH_2	H	F	H	H
469	1	H	H	Cl	H	H
470	2	H	H	Cl	H	H
471	3	H	H	Cl	H	H

472	4	H	H	Cl	H	H
473	1	Me	H	Cl	H	H
474	2	Me	H	Cl	H	H
475	3	Me	H	Cl	H	H
476	4	Me	H	Cl	H	H
477	1	CH_2Ph	H	Cl	H	H
478	2	CH_2Ph	H	Cl	H	H
479	3	CH_2Ph	H	Cl	H	H
480	4	CH_2Ph	H	Cl	H	H
481	1	COMe	H	Cl	H	H
482	2	COMe	H	Cl	H	H
483	3	COMe	H	Cl	H	H
484	4	COMe	H	Cl	H	H
485	1	CO_2Me	H	Cl	H	H
486	2	CO_2Me	H	Cl	H	H
487	3	CO_2Me	H	Cl	H	H
488	4	CO_2Me	H	Cl	H	H
489	1	CO_2tBu	H	Cl	H	H
490	2	CO_2tBu	H	Cl	H	H
491	3	CO_2tBu	H	Cl	H	H
492	4	CO_2tBu	H	Cl	H	H
493	1	CONHMe	H	Cl	H	H
494	2	CONHMe	H	Cl	H	H
495	3	CONHMe	H	Cl	H	H
496	4	CONHMe	H	Cl	H	H
497	1	SO_2Me	H	Cl	H	H
498	2	SO_2Me	H	Cl	H	H
499	3	SO_2Me	H	Cl	H	H
500	4	SO_2Me	H	Cl	H	H
501	1	SO_2NH_2	H	Cl	H	H
502	2	SO_2NH_2	H	Cl	H	H

503	3	SO_2NH_2	H	Cl	H	H
504	4	SO_2NH_2	H	Cl	H	H
505	1	H	H	CN	H	H
506	2	H	H	CN	H	H
507	3	H	H	CN	H	H
508	4	H	H	CN	H	H
509	1	Me	H	CN	H	H
510	2	Me	H	CN	H	H
511	3	Me	H	CN	H	H
512	4	Me	H	CN	H	H
513	1	CH_2Ph	H	CN	H	H
514	2	CH_2Ph	H	CN	H	H
515	3	CH_2Ph	H	CN	H	H
516	4	CH_2Ph	H	CN	H	H
517	1	COMe	H	CN	H	H
518	2	COMe	H	CN	H	H
519	3	COMe	H	CN	H	H
520	4	COMe	H	CN	H	H
521	1	CO_2Me	H	CN	H	H
522	2	CO_2Me	H	CN	H	H
523	3	CO_2Me	H	CN	H	H
524	4	CO_2Me	H	CN	H	H
525	1	CO_2tBu	H	CN	H	H
526	2	CO_2tBu	H	CN	H	H
527	3	CO_2tBu	H	CN	H	H
528	4	CO_2tBu	H	CN	H	H
529	1	CONHMe	H	CN	H	H
530	2	CONHMe	H	CN	H	H
531	3	CONHMe	H	CN	H	H
532	4	CONHMe	H	CN	H	H
533	1	SO_2Me	H	CN	H	H

534	2	SO_2Me	H	CN	H	H
535	3	SO_2Me	H	CN	H	H
536	4	SO_2Me	H	CN	H	H
537	1	SO_2NH_2	H	CN	H	H
538	2	SO_2NH_2	H	CN	H	H
539	3	SO_2NH_2	H	CN	H	H
540	4	SO_2NH_2	H	CN	H	H
541	1	H	OH	H	H	H
542	2	H	OH	H	H	H
543	3	H	OH	H	H	H
544	4	H	OH	H	H	H
545	1	Me	OH	H	H	H
546	2	Me	OH	H	H	H
547	3	Me	OH	H	H	H
548	4	Me	OH	H	H	H
549	1	CH_2Ph	OH	H	H	H
550	2	CH_2Ph	OH	H	H	H
551	3	CH_2Ph	OH	H	H	H
552	4	CH_2Ph	OH	H	H	H
553	1	COMe	OH	H	H	H
554	2	COMe	OH	H	H	H
555	3	COMe	OH	H	H	H
556	4	COMe	OH	H	H	H
557	1	CO_2Me	OH	H	H	H
558	2	CO_2Me	OH	H	H	H
559	3	CO_2Me	OH	H	H	H
560	4	CO_2Me	OH	H	H	H
561	1	CO_2tBu	OH	H	H	H
562	2	CO_2tBu	OH	H	H	H
563	3	CO_2tBu	OH	H	H	H
564	4	CO_2tBu	OH	H	H	H

565	1	CONHMe	OH	H	H	H
566	2	CONHMe	OH	H	H	H
567	3	CONHMe	OH	H	H	H
568	4	CONHMe	OH	H	H	H
569	1	SO_2Me	OH	H	H	H
570	2	SO_2Me	OH	H	H	H
571	3	SO_2Me	OH	H	H	H
572	4	SO_2Me	OH	H	H	H
573	1	SO_2NH_2	OH	H	H	H
574	2	SO_2NH_2	OH	H	H	H
575	3	SO_2NH_2	OH	H	H	H
576	4	SO_2NH_2	OH	H	H	H
577	1	H	OMe	H	H	H
578	2	H	OMe	H	H	H
579	3	H	OMe	H	H	H
580	4	H	OMe	H	H	H
581	1	Me	OMe	H	H	H
582	2	Me	OMe	H	H	H
583	3	Me	OMe	H	H	H
584	4	Me	OMe	H	H	H
585	1	CH_2Ph	OMe	H	H	H
586	2	CH_2Ph	OMe	H	H	H
587	3	CH_2Ph	OMe	H	H	H
588	4	CH_2Ph	OMe	H	H	H
589	1	COMe	OMe	H	H	H
590	2	COMe	OMe	H	H	H
591	3	COMe	OMe	H	H	H
592	4	COMe	OMe	H	H	H
593	1	CO_2Me	OMe	H	H	H
594	2	CO_2Me	OMe	H	H	H
595	3	CO_2Me	OMe	H	H	H

596	4	CO_2Me	OMe	H	H	H
597	1	CO_2tBu	OMe	H	H	H
598	2	CO_2tBu	OMe	H	H	H
599	3	CO_2tBu	OMe	H	H	H
600	4	CO_2tBu	OMe	H	H	H
601	1	CONHMe	OMe	H	H	H
602	2	CONHMe	OMe	H	H	H
603	3	CONHMe	OMe	H	H	H
604	4	CONHMe	OMe	H	H	H
605	1	SO_2Me	OMe	H	H	H
606	2	SO_2Me	OMe	H	H	H
607	3	SO_2Me	OMe	H	H	H
608	4	SO_2Me	OMe	H	H	H
609	1	SO_2NH_2	OMe	H	H	H
610	2	SO_2NH_2	OMe	H	H	H
611	3	SO_2NH_2	OMe	H	H	H
612	4	SO_2NH_2	OMe	H	H	H
613	1	H	Me	H	H	H
614	2	H	Me	H	H	H
615	3	H	Me	H	H	H
616	4	H	Me	H	H	H
617	1	Me	Me	H	H	H
618	2	Me	Me	H	H	H
619	3	Me	Me	H	H	H
620	4	Me	Me	H	H	H
621	1	CH_2Ph	Me	H	H	H
622	2	CH_2Ph	Me	H	H	H
623	3	CH_2Ph	Me	H	H	H
624	4	CH_2Ph	Me	H	H	H
625	1	COMe	Me	H	H	H
626	2	COMe	Me	H	H	H

627	3	COMe	Me	H	H	H
628	4	COMe	Me	H	H	H
629	1	CO_2Me	Me	H	H	H
630	2	CO_2Me	Me	H	H	H
631	3	CO_2Me	Me	H	H	H
632	4	CO_2Me	Me	H	H	H
633	1	CO_2tBu	Me	H	H	H
634	2	CO_2tBu	Me	H	H	H
635	3	CO_2tBu	Me	H	H	H
636	4	CO_2tBu	Me	H	H	H
637	1	CONHMe	Me	H	H	H
638	2	CONHMe	Me	H	H	H
639	3	CONHMe	Me	H	H	H
640	4	CONHMe	Me	H	H	H
641	1	SO_2Me	Me	H	H	H
642	2	SO_2Me	Me	H	H	H
643	3	SO_2Me	Me	H	H	H
644	4	SO_2Me	Me	H	H	H
645	1	SO_2NH_2	Me	H	H	H
646	2	SO_2NH_2	Me	H	H	H
647	3	SO_2NH_2	Me	H	H	H
648	4	SO_2NH_2	Me	H	H	H
649	1	H	CF_3	H	H	H
650	2	H	CF_3	H	H	H
651	3	H	CF_3	H	H	H
652	4	H	CF_3	H	H	H
653	1	Me	CF_3	H	H	H
654	2	Me	CF_3	H	H	H
655	3	Me	CF_3	H	H	H
656	4	Me	CF_3	H	H	H
657	1	CH_2Ph	CF_3	H	H	H

658	2	CH_2Ph	CF_3	H	H	H
659	3	CH_2Ph	CF_3	H	H	H
660	4	CH_2Ph	CF_3	H	H	H
661	1	COMe	CF_3	H	H	H
662	2	COMe	CF_3	H	H	H
663	3	COMe	CF_3	H	H	H
664	4	COMe	CF_3	H	H	H
665	1	CO_2Me	CF_3	H	H	H
666	2	CO_2Me	CF_3	H	H	H
667	3	CO_2Me	CF_3	H	H	H
668	4	CO_2Me	CF_3	H	H	H
669	1	CO_2tBu	CF_3	H	H	H
670	2	CO_2tBu	CF_3	H	H	H
671	3	CO_2tBu	CF_3	H	H	H
672	4	CO_2tBu	CF_3	H	H	H
673	1	CONHMe	CF_3	H	H	H
674	2	CONHMe	CF_3	H	H	H
675	3	CONHMe	CF_3	H	H	H
676	4	CONHMe	CF_3	H	H	H
677	1	SO_2Me	CF_3	H	H	H
678	2	SO_2Me	CF_3	H	H	H
679	3	SO_2Me	CF_3	H	H	H
680	4	SO_2Me	CF_3	H	H	H
681	1	SO_2NH_2	CF_3	H	H	H
682	2	SO_2NH_2	CF_3	H	H	H
683	3	SO_2NH_2	CF_3	H	H	H
684	4	SO_2NH_2	CF_3	H	H	H
685	1	H	F	H	H	H
686	2	H	F	H	H	H
687	3	H	F	H	H	H
688	3	H	F	H	H	H

689	1	Me	F	H	H	H
690	2	Me	F	H	H	H
691	3	Me	F	H	H	H
692	4	Me	F	H	H	H
693	1	CH_2Ph	F	H	H	H
694	2	CH_2Ph	F	H	H	H
695	3	CH_2Ph	F	H	H	H
696	4	CH_2Ph	F	H	H	H
697	1	COMe	F	H	H	H
698	2	COMe	F	H	H	H
699	3	COMe	F	H	H	H
700	4	COMe	F	H	H	H
701	1	CO_2Me	F	H	H	H
702	2	CO_2Me	F	H	H	H
703	3	CO_2Me	F	H	H	H
704	4	CO_2Me	F	H	H	H
705	1	CO_2tBu	F	H	H	H
706	2	CO_2tBu	F	H	H	H
707	3	CO_2tBu	F	H	H	H
708	4	CO_2tBu	F	H	H	H
709	1	CONHMe	F	H	H	H
710	2	CONHMe	F	H	H	H
711	3	CONHMe	F	H	H	H
712	4	CONHMe	F	H	H	H
713	1	SO_2Me	F	H	H	H
714	2	SO_2Me	F	H	H	H
715	3	SO_2Me	F	H	H	H
716	4	SO_2Me	F	H	H	H
717	1	SO_2NH_2	F	H	H	H
718	2	SO_2NH_2	F	H	H	H
719	3	SO_2NH_2	F	H	H	H

720	4	SO_2NH_2	F	H	H	H
721	1	H	Cl	H	H	H
722	2	H	Cl	H	H	H
723	3	H	Cl	H	H	H
724	4	H	Cl	H	H	H
725	1	Me	Cl	H	H	H
726	2	Me	Cl	H	H	H
727	3	Me	Cl	H	H	H
728	4	Me	Cl	H	H	H
729	1	CH_2Ph	Cl	H	H	H
730	2	CH_2Ph	Cl	H	H	H
731	3	CH_2Ph	Cl	H	H	H
732	4	CH_2Ph	Cl	H	H	H
733	1	COMe	Cl	H	H	H
734	2	COMe	Cl	H	H	H
735	3	COMe	Cl	H	H	H
736	4	COMe	Cl	H	H	H
737	1	CO_2Me	Cl	H	H	H
738	2	CO_2Me	Cl	H	H	H
739	3	CO_2Me	Cl	H	H	H
740	4	CO_2Me	Cl	H	H	H
741	1	CO_2tBu	Cl	H	H	H
742	2	CO_2tBu	Cl	H	H	H
743	3	CO_2tBu	Cl	H	H	H
744	4	CO_2tBu	Cl	H	H	H
745	1	CONHMe	Cl	H	H	H
746	2	CONHMe	Cl	H	H	H
747	3	CONHMe	Cl	H	H	H
748	4	CONHMe	Cl	H	H	H
749	1	SO_2Me	Cl	H	H	H
750	2	SO_2Me	Cl	H	H	H

751	3	SO_2Me	Cl	H	H	H
752	4	SO_2Me	Cl	H	H	H
753	1	SO_2NH_2	Cl	H	H	H
754	2	SO_2NH_2	Cl	H	H	H
755	3	SO_2NH_2	Cl	H	H	H
756	4	SO_2NH_2	Cl	H	H	H
757	1	H	CN	H	H	H
758	2	H	CN	H	H	H
759	3	H	CN	H	H	H
760	4	H	CN	H	H	H
761	1	Me	CN	H	H	H
762	2	Me	CN	H	H	H
763	3	Me	CN	H	H	H
764	4	Me	CN	H	H	H
765	1	CH_2Ph	CN	H	H	H
766	2	CH_2Ph	CN	H	H	H
767	3	CH_2Ph	CN	H	H	H
768	4	CH_2Ph	CN	H	H	H
769	1	COMe	CN	H	H	H
770	2	COMe	CN	H	H	H
771	3	COMe	CN	H	H	H
772	4	COMe	CN	H	H	H
773	1	CO_2Me	CN	H	H	H
774	2	CO_2Me	CN	H	H	H
775	3	CO_2Me	CN	H	H	H
776	4	CO_2Me	CN	H	H	H
777	1	CO_2tBu	CN	H	H	H
778	2	CO_2tBu	CN	H	H	H
779	3	CO_2tBu	CN	H	H	H
780	4	CO_2tBu	CN	H	H	H
781	1	CONHMe	CN	H	H	H

782	2	CONHMe	CN	H	H	H
783	3	CONHMe	CN	H	H	H
784	4	CONHMe	CN	H	H	H
785	1	SO_2Me	CN	H	H	H
786	2	SO_2Me	CN	H	H	H
787	3	SO_2Me	CN	H	H	H
788	4	SO_2Me	CN	H	H	H
789	1	SO_2NH_2	CN	H	H	H
790	2	SO_2NH_2	CN	H	H	H
791	3	SO_2NH_2	CN	H	H	H
792	4	SO_2NH_2	CN	H	H	H
793	1	H	H	H	H	OH
794	2	H	H	H	H	OH
795	3	H	H	H	H	OH
796	4	H	H	H	H	OH
797	1	Me	H	H	H	OH
798	2	Me	H	H	H	OH
799	3	Me	H	H	H	OH
800	4	Me	H	H	H	OH
801	1	CH_2Ph	H	H	H	OH
802	2	CH_2Ph	H	H	H	OH
803	3	CH_2Ph	H	H	H	OH
804	4	CH_2Ph	H	H	H	OH
805	1	COMe	H	H	H	OH
806	2	COMe	H	H	H	OH
807	3	COMe	H	H	H	OH
808	4	COMe	H	H	H	OH
809	1	CO_2Me	H	H	H	OH
810	2	CO_2Me	H	H	H	OH
811	3	CO_2Me	H	H	H	OH
812	4	CO_2Me	H	H	H	OH

813	1	CO_2tBu	H	H	H	OH
814	2	CO_2tBu	H	H	H	OH
815	3	CO_2tBu	H	H	H	OH
816	4	CO_2tBu	H	H	H	OH
817	1	CONHMe	H	H	H	OH
818	2	CONHMe	H	H	H	OH
819	3	CONHMe	H	H	H	OH
820	4	CONHMe	H	H	H	OH
821	1	SO_2Me	H	H	H	OH
822	2	SO_2Me	H	H	H	OH
823	3	SO_2Me	H	H	H	OH
824	4	SO_2Me	H	H	H	OH
825	1	SO_2NH_2	H	H	H	OH
826	2	SO_2NH_2	H	H	H	OH
827	3	SO_2NH_2	H	H	H	OH
828	4	SO_2NH_2	H	H	H	OH
829	1	H	H	H	H	OMe
830	2	H	H	H	H	OMe
831	3	H	H	H	H	OMe
832	4	H	H	H	H	OMe
833	1	Me	H	H	H	OMe
834	2	Me	H	H	H	OMe
835	3	Me	H	H	H	OMe
836	4	Me	H	H	H	OMe
837	1	CH_2Ph	H	H	H	OMe
838	2	CH_2Ph	H	H	H	OMe
839	3	CH_2Ph	H	H	H	OMe
840	4	CH_2Ph	H	H	H	OMe
841	1	COMe	H	H	H	OMe
842	2	COMe	H	H	H	OMe
843	3	COMe	H	H	H	OMe

844	4	COMe	H	H	H	OMe
845	1	CO_2Me	H	H	H	OMe
846	2	CO_2Me	H	H	H	OMe
847	3	CO_2Me	H	H	H	OMe
848	4	CO_2Me	H	H	H	OMe
849	1	CO_2tBu	H	H	H	OMe
850	2	CO_2tBu	H	H	H	OMe
851	3	CO_2tBu	H	H	H	OMe
852	4	CO_2tBu	H	H	H	OMe
853	1	CONHMe	H	H	H	OMe
854	2	CONHMe	H	H	H	OMe
855	3	CONHMe	H	H	H	OMe
856	4	CONHMe	H	H	H	OMe
857	1	SO_2Me	H	H	H	OMe
858	2	SO_2Me	H	H	H	OMe
859	3	SO_2Me	H	H	H	OMe
860	4	SO_2Me	H	H	H	OMe
861	1	SO_2NH_2	H	H	H	OMe
862	2	SO_2NH_2	H	H	H	OMe
863	3	SO_2NH_2	H	H	H	OMe
864	4	SO_2NH_2	H	H	H	OMe
865	1	H	H	H	H	Me
866	2	H	H	H	H	Me
867	3	H	H	H	H	Me
868	4	H	H	H	H	Me
869	1	Me	H	H	H	Me
870	2	Me	H	H	H	Me
871	3	Me	H	H	H	Me
872	4	Me	H	H	H	Me
873	1	CH_2Ph	H	H	H	Me
874	2	CH_2Ph	H	H	H	Me

875	3	CH_2Ph	H	H	H	Me
876	4	CH_2Ph	H	H	H	Me
877	1	COMe	H	H	H	Me
878	2	COMe	H	H	H	Me
879	3	COMe	H	H	H	Me
880	4	COMe	H	H	H	Me
881	1	CO_2Me	H	H	H	Me
882	2	CO_2Me	H	H	H	Me
883	3	CO_2Me	H	H	H	Me
884	4	CO_2Me	H	H	H	Me
885	1	CO_2tBu	H	H	H	Me
886	2	CO_2tBu	H	H	H	Me
887	3	CO_2tBu	H	H	H	Me
888	4	CO_2tBu	H	H	H	Me
889	1	CONHMe	H	H	H	Me
890	2	CONHMe	H	H	H	Me
891	3	CONHMe	H	H	H	Me
892	4	CONHMe	H	H	H	Me
893	1	SO_2Me	H	H	H	Me
894	2	SO_2Me	H	H	H	Me
895	3	SO_2Me	H	H	H	Me
896	4	SO_2Me	H	H	H	Me
897	1	SO_2NH_2	H	H	H	Me
898	2	SO_2NH_2	H	H	H	Me
899	3	SO_2NH_2	H	H	H	Me
900	4	SO_2NH_2	H	H	H	Me
901	1	H	H	H	H	CF_3
902	2	H	H	H	H	CF_3
903	3	H	H	H	H	CF_3
904	4	H	H	H	H	CF_3
905	1	Me	H	H	H	CF_3

906	2	Me	H	H	H	CF_3
907	3	Me	H	H	H	CF_3
908	4	Me	H	H	H	CF_3
909	1	CH_2Ph	H	H	H	CF_3
910	2	CH_2Ph	H	H	H	CF_3
911	3	CH_2Ph	H	H	H	CF_3
912	4	CH_2Ph	H	H	H	CF_3
913	1	COMe	H	H	H	CF_3
914	2	COMe	H	H	H	CF_3
915	3	COMe	H	H	H	CF_3
916	4	COMe	H	H	H	CF_3
917	1	CO_2Me	H	H	H	CF_3
918	2	CO_2Me	H	H	H	CF_3
919	3	CO_2Me	H	H	H	CF_3
920	4	CO_2Me	H	H	H	CF_3
921	1	CO_2tBu	H	H	H	CF_3
922	2	CO_2tBu	H	H	H	CF_3
923	3	CO_2tBu	H	H	H	CF_3
924	4	CO_2tBu	H	H	H	CF_3
925	1	CONHMe	H	H	H	CF_3
926	2	CONHMe	H	H	H	CF_3
927	3	CONHMe	H	H	H	CF_3
928	4	CONHMe	H	H	H	CF_3
929	1	SO_2Me	H	H	H	CF_3
930	2	SO_2Me	H	H	H	CF_3
931	3	SO_2Me	H	H	H	CF_3
932	4	SO_2Me	H	H	H	CF_3
933	1	SO_2NH_2	H	H	H	CF_3
934	2	SO_2NH_2	H	H	H	CF_3
935	3	SO_2NH_2	H	H	H	CF_3
936	4	SO_2NH_2	H	H	H	CF_3


937	1	H	H	H	H	F
938	2	H	H	H	H	F
939	3	H	H	H	H	F
940	3	H	H	H	H	F
941	1	Me	H	H	H	F
942	2	Me	H	H	H	F
943	3	Me	H	H	H	F
944	4	Me	H	H	H	F
945	1	CH_2Ph	H	H	H	F
946	2	CH_2Ph	H	H	H	F
947	3	CH_2Ph	H	H	H	F
948	4	CH_2Ph	H	H	H	F
949	1	COMe	H	H	H	F
950	2	COMe	H	H	H	F
951	3	COMe	H	H	H	F
952	4	COMe	H	H	H	F
953	1	CO_2Me	H	H	H	F
954	2	CO_2Me	H	H	H	F
955	3	CO_2Me	H	H	H	F
956	4	CO_2Me	H	H	H	F
957	1	CO_2tBu	H	H	H	F
958	2	CO_2tBu	H	H	H	F
959	3	CO_2tBu	H	H	H	F
960	4	CO_2tBu	H	H	H	F
961	1	CONHMe	H	H	H	F
962	2	CONHMe	H	H	H	F
963	3	CONHMe	H	H	H	F
964	4	CONHMe	H	H	H	F
965	1	SO_2Me	H	H	H	F
966	2	SO_2Me	H	H	H	F
967	3	SO_2Me	H	H	H	F

968	4	SO_2Me	H	H	H	F
969	1	SO_2NH_2	H	H	H	F
970	2	SO_2NH_2	H	H	H	F
971	3	SO_2NH_2	H	H	H	F
972	4	SO_2NH_2	H	H	H	F
973	1	H	H	H	H	Cl
974	2	H	H	H	H	Cl
975	3	H	H	H	H	Cl
976	4	H	H	H	H	Cl
977	1	Me	H	H	H	Cl
978	2	Me	H	H	H	Cl
979	3	Me	H	H	H	Cl
980	4	Me	H	H	H	Cl
981	1	CH_2Ph	H	H	H	Cl
982	2	CH_2Ph	H	H	H	Cl
983	3	CH_2Ph	H	H	H	Cl
984	4	CH_2Ph	H	H	H	Cl
985	1	COMe	H	H	H	Cl
986	2	COMe	H	H	H	Cl
987	3	COMe	H	H	H	Cl
988	4	COMe	H	H	H	Cl
989	1	CO_2Me	H	H	H	Cl
990	2	CO_2Me	H	H	H	Cl
991	3	CO_2Me	H	H	H	Cl
992	4	CO_2Me	H	H	H	Cl
993	1	CO_2tBu	H	H	H	Cl
994	2	CO_2tBu	H	H	H	Cl
995	3	CO_2tBu	H	H	H	Cl
996	4	CO_2tBu	H	H	H	Cl
997	1	CONHMe	H	H	H	Cl
998	2	CONHMe	H	H	H	Cl

999	3	CONHMe	H	H	H	Cl
1000	4	CONHMe	H	H	H	Cl
1001	1	SO_2Me	H	H	H	Cl
1002	2	SO_2Me	H	H	H	Cl
1003	3	SO_2Me	H	H	H	Cl
1004	4	SO_2Me	H	H	H	Cl
1005	1	SO_2NH_2	H	H	H	Cl
1006	2	SO_2NH_2	H	H	H	Cl
1007	3	SO_2NH_2	H	H	H	Cl
1008	4	SO_2NH_2	H	H	H	Cl
1009	1	H	H	H	H	CN
1010	2	H	H	H	H	CN
1011	3	H	H	H	H	CN
1012	4	H	H	H	H	CN
1013	1	Me	H	H	H	CN
1014	2	Me	H	H	H	CN
1015	3	Me	H	H	H	CN
1016	4	Me	H	H	H	CN
1017	1	CH_2Ph	H	H	H	CN
1018	2	CH_2Ph	H	H	H	CN
1019	3	CH_2Ph	H	H	H	CN
1020	4	CH_2Ph	H	H	H	CN
1021	1	COMe	H	H	H	CN
1022	2	COMe	H	H	H	CN
1023	3	COMe	H	H	H	CN
1024	4	COMe	H	H	H	CN
1025	1	CO_2Me	H	H	H	CN
1026	2	CO_2Me	H	H	H	CN
1027	3	CO_2Me	H	H	H	CN
1028	4	CO_2Me	H	H	H	CN
1029	1	CO_2tBu	H	H	H	CN

1030	2	CO_2tBu	H	H	H	CN
1031	3	CO_2tBu	H	H	H	CN
1032	4	CO_2tBu	H	H	H	CN
1033	1	CONHMe	H	H	H	CN
1034	2	CONHMe	H	H	H	CN
1035	3	CONHMe	H	H	H	CN
1036	4	CONHMe	H	H	H	CN
1037	1	SO_2Me	H	H	H	CN
1038	2	SO_2Me	H	H	H	CN
1039	3	SO_2Me	H	H	H	CN
1040	4	SO_2Me	H	H	H	CN
1041	1	SO_2NH_2	H	H	H	CN
1042	2	SO_2NH_2	H	H	H	CN
1043	3	SO_2NH_2	H	H	H	CN
1044	4	SO_2NH_2	H	H	H	CN

[01033] Exemplary embodiments include compounds having the formula **(XXXI)**



(XXXI)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 25.

Table 25

Entry	n	R^7	R^{20a}	R^{20b}	R^{20d}	R^{20e}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H

8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H

39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H

70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H

101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H

132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H

163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H

194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H

225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H

256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H

287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	H	H	OH
290	2	H	H	H	H	OH
291	3	H	H	H	H	OH
292	4	H	H	H	H	OH
293	1	Me	H	H	H	OH
294	2	Me	H	H	H	OH
295	3	Me	H	H	H	OH
296	4	Me	H	H	H	OH
297	1	CH_2Ph	H	H	H	OH
298	2	CH_2Ph	H	H	H	OH
299	3	CH_2Ph	H	H	H	OH
300	4	CH_2Ph	H	H	H	OH
301	1	COMe	H	H	H	OH
302	2	COMe	H	H	H	OH
303	3	COMe	H	H	H	OH
304	4	COMe	H	H	H	OH
305	1	CO_2Me	H	H	H	OH
306	2	CO_2Me	H	H	H	OH
307	3	CO_2Me	H	H	H	OH
308	4	CO_2Me	H	H	H	OH
309	1	CO_2tBu	H	H	H	OH
310	2	CO_2tBu	H	H	H	OH
311	3	CO_2tBu	H	H	H	OH
312	4	CO_2tBu	H	H	H	OH
313	1	CONHMe	H	H	H	OH
314	2	CONHMe	H	H	H	OH
315	3	CONHMe	H	H	H	OH
316	4	CONHMe	H	H	H	OH
317	1	SO_2Me	H	H	H	OH

318	2	SO_2Me	H	H	H	OH
319	3	SO_2Me	H	H	H	OH
320	4	SO_2Me	H	H	H	OH
321	1	SO_2NH_2	H	H	H	OH
322	2	SO_2NH_2	H	H	H	OH
323	3	SO_2NH_2	H	H	H	OH
324	4	SO_2NH_2	H	H	H	OH
325	1	H	H	H	H	OMe
326	2	H	H	H	H	OMe
327	3	H	H	H	H	OMe
328	4	H	H	H	H	OMe
329	1	Me	H	H	H	OMe
330	2	Me	H	H	H	OMe
331	3	Me	H	H	H	OMe
332	4	Me	H	H	H	OMe
333	1	CH_2Ph	H	H	H	OMe
334	2	CH_2Ph	H	H	H	OMe
335	3	CH_2Ph	H	H	H	OMe
336	4	CH_2Ph	H	H	H	OMe
337	1	COMe	H	H	H	OMe
338	2	COMe	H	H	H	OMe
339	3	COMe	H	H	H	OMe
340	4	COMe	H	H	H	OMe
341	1	CO_2Me	H	H	H	OMe
342	2	CO_2Me	H	H	H	OMe
343	3	CO_2Me	H	H	H	OMe
344	4	CO_2Me	H	H	H	OMe
345	1	CO_2tBu	H	H	H	OMe
346	2	CO_2tBu	H	H	H	OMe
347	3	CO_2tBu	H	H	H	OMe
348	4	CO_2tBu	H	H	H	OMe

349	1	CONHMe	H	H	H	OMe
350	2	CONHMe	H	H	H	OMe
351	3	CONHMe	H	H	H	OMe
352	4	CONHMe	H	H	H	OMe
353	1	SO_2Me	H	H	H	OMe
354	2	SO_2Me	H	H	H	OMe
355	3	SO_2Me	H	H	H	OMe
356	4	SO_2Me	H	H	H	OMe
357	1	SO_2NH_2	H	H	H	OMe
358	2	SO_2NH_2	H	H	H	OMe
359	3	SO_2NH_2	H	H	H	OMe
360	4	SO_2NH_2	H	H	H	OMe
361	1	H	H	H	H	Me
362	2	H	H	H	H	Me
363	3	H	H	H	H	Me
364	4	H	H	H	H	Me
365	1	Me	H	H	H	Me
366	2	Me	H	H	H	Me
367	3	Me	H	H	H	Me
368	4	Me	H	H	H	Me
369	1	CH_2Ph	H	H	H	Me
370	2	CH_2Ph	H	H	H	Me
371	3	CH_2Ph	H	H	H	Me
372	4	CH_2Ph	H	H	H	Me
373	1	COMe	H	H	H	Me
374	2	COMe	H	H	H	Me
375	3	COMe	H	H	H	Me
376	4	COMe	H	H	H	Me
377	1	CO_2Me	H	H	H	Me
378	2	CO_2Me	H	H	H	Me
379	3	CO_2Me	H	H	H	Me

380	4	CO_2Me	H	H	H	Me
381	1	CO_2tBu	H	H	H	Me
382	2	CO_2tBu	H	H	H	Me
383	3	CO_2tBu	H	H	H	Me
384	4	CO_2tBu	H	H	H	Me
385	1	CONHMe	H	H	H	Me
386	2	CONHMe	H	H	H	Me
387	3	CONHMe	H	H	H	Me
388	4	CONHMe	H	H	H	Me
389	1	SO_2Me	H	H	H	Me
390	2	SO_2Me	H	H	H	Me
391	3	SO_2Me	H	H	H	Me
392	4	SO_2Me	H	H	H	Me
393	1	SO_2NH_2	H	H	H	Me
394	2	SO_2NH_2	H	H	H	Me
395	3	SO_2NH_2	H	H	H	Me
396	4	SO_2NH_2	H	H	H	Me
397	1	H	H	H	H	CF_3
398	2	H	H	H	H	CF_3
399	3	H	H	H	H	CF_3
400	4	H	H	H	H	CF_3
401	1	Me	H	H	H	CF_3
402	2	Me	H	H	H	CF_3
403	3	Me	H	H	H	CF_3
404	4	Me	H	H	H	CF_3
405	1	CH_2Ph	H	H	H	CF_3
406	2	CH_2Ph	H	H	H	CF_3
407	3	CH_2Ph	H	H	H	CF_3
408	4	CH_2Ph	H	H	H	CF_3
409	1	COMe	H	H	H	CF_3
410	2	COMe	H	H	H	CF_3

411	3	COMe	H	H	H	CF_3
412	4	COMe	H	H	H	CF_3
413	1	CO_2Me	H	H	H	CF_3
414	2	CO_2Me	H	H	H	CF_3
415	3	CO_2Me	H	H	H	CF_3
416	4	CO_2Me	H	H	H	CF_3
417	1	CO_2tBu	H	H	H	CF_3
418	2	CO_2tBu	H	H	H	CF_3
419	3	CO_2tBu	H	H	H	CF_3
420	4	CO_2tBu	H	H	H	CF_3
421	1	CONHMe	H	H	H	CF_3
422	2	CONHMe	H	H	H	CF_3
423	3	CONHMe	H	H	H	CF_3
424	4	CONHMe	H	H	H	CF_3
425	1	SO_2Me	H	H	H	CF_3
426	2	SO_2Me	H	H	H	CF_3
427	3	SO_2Me	H	H	H	CF_3
428	4	SO_2Me	H	H	H	CF_3
429	1	SO_2NH_2	H	H	H	CF_3
430	2	SO_2NH_2	H	H	H	CF_3
431	3	SO_2NH_2	H	H	H	CF_3
432	4	SO_2NH_2	H	H	H	CF_3
433	1	H	H	H	H	F
434	2	H	H	H	H	F
435	3	H	H	H	H	F
436	3	H	H	H	H	F
437	1	Me	H	H	H	F
438	2	Me	H	H	H	F
439	3	Me	H	H	H	F
440	4	Me	H	H	H	F
441	1	CH_2Ph	H	H	H	F


442	2	CH_2Ph	H	H	H	F
443	3	CH_2Ph	H	H	H	F
444	4	CH_2Ph	H	H	H	F
445	1	COMe	H	H	H	F
446	2	COMe	H	H	H	F
447	3	COMe	H	H	H	F
448	4	COMe	H	H	H	F
449	1	CO_2Me	H	H	H	F
450	2	CO_2Me	H	H	H	F
451	3	CO_2Me	H	H	H	F
452	4	CO_2Me	H	H	H	F
453	1	CO_2tBu	H	H	H	F
454	2	CO_2tBu	H	H	H	F
455	3	CO_2tBu	H	H	H	F
456	4	CO_2tBu	H	H	H	F
457	1	CONHMe	H	H	H	F
458	2	CONHMe	H	H	H	F
459	3	CONHMe	H	H	H	F
460	4	CONHMe	H	H	H	F
461	1	SO_2Me	H	H	H	F
462	2	SO_2Me	H	H	H	F
463	3	SO_2Me	H	H	H	F
464	4	SO_2Me	H	H	H	F
465	1	SO_2NH_2	H	H	H	F
466	2	SO_2NH_2	H	H	H	F
467	3	SO_2NH_2	H	H	H	F
468	4	SO_2NH_2	H	H	H	F
469	1	H	H	H	H	Cl
470	2	H	H	H	H	Cl
471	3	H	H	H	H	Cl
472	4	H	H	H	H	Cl

473	1	Me	H	H	H	Cl
474	2	Me	H	H	H	Cl
475	3	Me	H	H	H	Cl
476	4	Me	H	H	H	Cl
477	1	CH_2Ph	H	H	H	Cl
478	2	CH_2Ph	H	H	H	Cl
479	3	CH_2Ph	H	H	H	Cl
480	4	CH_2Ph	H	H	H	Cl
481	1	COMe	H	H	H	Cl
482	2	COMe	H	H	H	Cl
483	3	COMe	H	H	H	Cl
484	4	COMe	H	H	H	Cl
485	1	CO_2Me	H	H	H	Cl
486	2	CO_2Me	H	H	H	Cl
487	3	CO_2Me	H	H	H	Cl
488	4	CO_2Me	H	H	H	Cl
489	1	CO_2tBu	H	H	H	Cl
490	2	CO_2tBu	H	H	H	Cl
491	3	CO_2tBu	H	H	H	Cl
492	4	CO_2tBu	H	H	H	Cl
493	1	CONHMe	H	H	H	Cl
494	2	CONHMe	H	H	H	Cl
495	3	CONHMe	H	H	H	Cl
496	4	CONHMe	H	H	H	Cl
497	1	SO_2Me	H	H	H	Cl
498	2	SO_2Me	H	H	H	Cl
499	3	SO_2Me	H	H	H	Cl
500	4	SO_2Me	H	H	H	Cl
501	1	SO_2NH_2	H	H	H	Cl
502	2	SO_2NH_2	H	H	H	Cl
503	3	SO_2NH_2	H	H	H	Cl

504	4	SO_2NH_2	H	H	H	Cl
505	1	H	H	H	H	CN
506	2	H	H	H	H	CN
507	3	H	H	H	H	CN
508	4	H	H	H	H	CN
509	1	Me	H	H	H	CN
510	2	Me	H	H	H	CN
511	3	Me	H	H	H	CN
512	4	Me	H	H	H	CN
513	1	CH_2Ph	H	H	H	CN
514	2	CH_2Ph	H	H	H	CN
515	3	CH_2Ph	H	H	H	CN
516	4	CH_2Ph	H	H	H	CN
517	1	COMe	H	H	H	CN
518	2	COMe	H	H	H	CN
519	3	COMe	H	H	H	CN
520	4	COMe	H	H	H	CN
521	1	CO_2Me	H	H	H	CN
522	2	CO_2Me	H	H	H	CN
523	3	CO_2Me	H	H	H	CN
524	4	CO_2Me	H	H	H	CN
525	1	CO_2tBu	H	H	H	CN
526	2	CO_2tBu	H	H	H	CN
527	3	CO_2tBu	H	H	H	CN
528	4	CO_2tBu	H	H	H	CN
529	1	CONHMe	H	H	H	CN
530	2	CONHMe	H	H	H	CN
531	3	CONHMe	H	H	H	CN
532	4	CONHMe	H	H	H	CN
533	1	SO_2Me	H	H	H	CN
534	2	SO_2Me	H	H	H	CN

535	3	SO_2Me	H	H	H	CN
536	4	SO_2Me	H	H	H	CN
537	1	SO_2NH_2	H	H	H	CN
538	2	SO_2NH_2	H	H	H	CN
539	3	SO_2NH_2	H	H	H	CN
540	4	SO_2NH_2	H	H	H	CN

[01034] Exemplary embodiments include compounds having the formula **(XXXII)**



(XXXII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 26.

Table 26

Entry	n	R^7	R^{20a}	R^{20b}	R^{20d}	R^{20e}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H

17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H
25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H

48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H
56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H

79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H
87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H

110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H
118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H

141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H
149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H

172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H
180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H

203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H
211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H

234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H
242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H

265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H
273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	H	H	OH
290	2	H	H	H	H	OH
291	3	H	H	H	H	OH
292	4	H	H	H	H	OH
293	1	Me	H	H	H	OH
294	2	Me	H	H	H	OH
295	3	Me	H	H	H	OH

296	4	Me	H	H	H	OH
297	1	CH_2Ph	H	H	H	OH
298	2	CH_2Ph	H	H	H	OH
299	3	CH_2Ph	H	H	H	OH
300	4	CH_2Ph	H	H	H	OH
301	1	COMe	H	H	H	OH
302	2	COMe	H	H	H	OH
303	3	COMe	H	H	H	OH
304	4	COMe	H	H	H	OH
305	1	CO_2Me	H	H	H	OH
306	2	CO_2Me	H	H	H	OH
307	3	CO_2Me	H	H	H	OH
308	4	CO_2Me	H	H	H	OH
309	1	CO_2tBu	H	H	H	OH
310	2	CO_2tBu	H	H	H	OH
311	3	CO_2tBu	H	H	H	OH
312	4	CO_2tBu	H	H	H	OH
313	1	CONHMe	H	H	H	OH
314	2	CONHMe	H	H	H	OH
315	3	CONHMe	H	H	H	OH
316	4	CONHMe	H	H	H	OH
317	1	SO_2Me	H	H	H	OH
318	2	SO_2Me	H	H	H	OH
319	3	SO_2Me	H	H	H	OH
320	4	SO_2Me	H	H	H	OH
321	1	SO_2NH_2	H	H	H	OH
322	2	SO_2NH_2	H	H	H	OH
323	3	SO_2NH_2	H	H	H	OH
324	4	SO_2NH_2	H	H	H	OH
325	1	H	H	H	H	OMe
326	2	H	H	H	H	OMe

327	3	H	H	H	H	OMe
328	4	H	H	H	H	OMe
329	1	Me	H	H	H	OMe
330	2	Me	H	H	H	OMe
331	3	Me	H	H	H	OMe
332	4	Me	H	H	H	OMe
333	1	CH_2Ph	H	H	H	OMe
334	2	CH_2Ph	H	H	H	OMe
335	3	CH_2Ph	H	H	H	OMe
336	4	CH_2Ph	H	H	H	OMe
337	1	COMe	H	H	H	OMe
338	2	COMe	H	H	H	OMe
339	3	COMe	H	H	H	OMe
340	4	COMe	H	H	H	OMe
341	1	CO_2Me	H	H	H	OMe
342	2	CO_2Me	H	H	H	OMe
343	3	CO_2Me	H	H	H	OMe
344	4	CO_2Me	H	H	H	OMe
345	1	CO_2tBu	H	H	H	OMe
346	2	CO_2tBu	H	H	H	OMe
347	3	CO_2tBu	H	H	H	OMe
348	4	CO_2tBu	H	H	H	OMe
349	1	CONHMe	H	H	H	OMe
350	2	CONHMe	H	H	H	OMe
351	3	CONHMe	H	H	H	OMe
352	4	CONHMe	H	H	H	OMe
353	1	SO_2Me	H	H	H	OMe
354	2	SO_2Me	H	H	H	OMe
355	3	SO_2Me	H	H	H	OMe
356	4	SO_2Me	H	H	H	OMe
357	1	SO_2NH_2	H	H	H	OMe

358	2	SO_2NH_2	H	H	H	OMe
359	3	SO_2NH_2	H	H	H	OMe
360	4	SO_2NH_2	H	H	H	OMe
361	1	H	H	H	H	Me
362	2	H	H	H	H	Me
363	3	H	H	H	H	Me
364	4	H	H	H	H	Me
365	1	Me	H	H	H	Me
366	2	Me	H	H	H	Me
367	3	Me	H	H	H	Me
368	4	Me	H	H	H	Me
369	1	CH_2Ph	H	H	H	Me
370	2	CH_2Ph	H	H	H	Me
371	3	CH_2Ph	H	H	H	Me
372	4	CH_2Ph	H	H	H	Me
373	1	COMe	H	H	H	Me
374	2	COMe	H	H	H	Me
375	3	COMe	H	H	H	Me
376	4	COMe	H	H	H	Me
377	1	CO_2Me	H	H	H	Me
378	2	CO_2Me	H	H	H	Me
379	3	CO_2Me	H	H	H	Me
380	4	CO_2Me	H	H	H	Me
381	1	CO_2tBu	H	H	H	Me
382	2	CO_2tBu	H	H	H	Me
383	3	CO_2tBu	H	H	H	Me
384	4	CO_2tBu	H	H	H	Me
385	1	CONHMe	H	H	H	Me
386	2	CONHMe	H	H	H	Me
387	3	CONHMe	H	H	H	Me
388	4	CONHMe	H	H	H	Me

389	1	SO_2Me	H	H	H	Me
390	2	SO_2Me	H	H	H	Me
391	3	SO_2Me	H	H	H	Me
392	4	SO_2Me	H	H	H	Me
393	1	SO_2NH_2	H	H	H	Me
394	2	SO_2NH_2	H	H	H	Me
395	3	SO_2NH_2	H	H	H	Me
396	4	SO_2NH_2	H	H	H	Me
397	1	H	H	H	H	CF_3
398	2	H	H	H	H	CF_3
399	3	H	H	H	H	CF_3
400	4	H	H	H	H	CF_3
401	1	Me	H	H	H	CF_3
402	2	Me	H	H	H	CF_3
403	3	Me	H	H	H	CF_3
404	4	Me	H	H	H	CF_3
405	1	CH_2Ph	H	H	H	CF_3
406	2	CH_2Ph	H	H	H	CF_3
407	3	CH_2Ph	H	H	H	CF_3
408	4	CH_2Ph	H	H	H	CF_3
409	1	COMe	H	H	H	CF_3
410	2	COMe	H	H	H	CF_3
411	3	COMe	H	H	H	CF_3
412	4	COMe	H	H	H	CF_3
413	1	CO_2Me	H	H	H	CF_3
414	2	CO_2Me	H	H	H	CF_3
415	3	CO_2Me	H	H	H	CF_3
416	4	CO_2Me	H	H	H	CF_3
417	1	CO_2tBu	H	H	H	CF_3
418	2	CO_2tBu	H	H	H	CF_3
419	3	CO_2tBu	H	H	H	CF_3


420	4	CO_2tBu	H	H	H	CF_3
421	1	CONHMe	H	H	H	CF_3
422	2	CONHMe	H	H	H	CF_3
423	3	CONHMe	H	H	H	CF_3
424	4	CONHMe	H	H	H	CF_3
425	1	SO_2Me	H	H	H	CF_3
426	2	SO_2Me	H	H	H	CF_3
427	3	SO_2Me	H	H	H	CF_3
428	4	SO_2Me	H	H	H	CF_3
429	1	SO_2NH_2	H	H	H	CF_3
430	2	SO_2NH_2	H	H	H	CF_3
431	3	SO_2NH_2	H	H	H	CF_3
432	4	SO_2NH_2	H	H	H	CF_3
433	1	H	H	H	H	F
434	2	H	H	H	H	F
435	3	H	H	H	H	F
436	3	H	H	H	H	F
437	1	Me	H	H	H	F
438	2	Me	H	H	H	F
439	3	Me	H	H	H	F
440	4	Me	H	H	H	F
441	1	CH_2Ph	H	H	H	F
442	2	CH_2Ph	H	H	H	F
443	3	CH_2Ph	H	H	H	F
444	4	CH_2Ph	H	H	H	F
445	1	COMe	H	H	H	F
446	2	COMe	H	H	H	F
447	3	COMe	H	H	H	F
448	4	COMe	H	H	H	F
449	1	CO_2Me	H	H	H	F
450	2	CO_2Me	H	H	H	F

451	3	CO_2Me	H	H	H	F
452	4	CO_2Me	H	H	H	F
453	1	CO_2tBu	H	H	H	F
454	2	CO_2tBu	H	H	H	F
455	3	CO_2tBu	H	H	H	F
456	4	CO_2tBu	H	H	H	F
457	1	CONHMe	H	H	H	F
458	2	CONHMe	H	H	H	F
459	3	CONHMe	H	H	H	F
460	4	CONHMe	H	H	H	F
461	1	SO_2Me	H	H	H	F
462	2	SO_2Me	H	H	H	F
463	3	SO_2Me	H	H	H	F
464	4	SO_2Me	H	H	H	F
465	1	SO_2NH_2	H	H	H	F
466	2	SO_2NH_2	H	H	H	F
467	3	SO_2NH_2	H	H	H	F
468	4	SO_2NH_2	H	H	H	F
469	1	H	H	H	H	Cl
470	2	H	H	H	H	Cl
471	3	H	H	H	H	Cl
472	4	H	H	H	H	Cl
473	1	Me	H	H	H	Cl
474	2	Me	H	H	H	Cl
475	3	Me	H	H	H	Cl
476	4	Me	H	H	H	Cl
477	1	CH_2Ph	H	H	H	Cl
478	2	CH_2Ph	H	H	H	Cl
479	3	CH_2Ph	H	H	H	Cl
480	4	CH_2Ph	H	H	H	Cl
481	1	COMe	H	H	H	Cl

482	2	COMe	H	H	H	Cl
483	3	COMe	H	H	H	Cl
484	4	COMe	H	H	H	Cl
485	1	CO_2Me	H	H	H	Cl
486	2	CO_2Me	H	H	H	Cl
487	3	CO_2Me	H	H	H	Cl
488	4	CO_2Me	H	H	H	Cl
489	1	CO_2tBu	H	H	H	Cl
490	2	CO_2tBu	H	H	H	Cl
491	3	CO_2tBu	H	H	H	Cl
492	4	CO_2tBu	H	H	H	Cl
493	1	CONHMe	H	H	H	Cl
494	2	CONHMe	H	H	H	Cl
495	3	CONHMe	H	H	H	Cl
496	4	CONHMe	H	H	H	Cl
497	1	SO_2Me	H	H	H	Cl
498	2	SO_2Me	H	H	H	Cl
499	3	SO_2Me	H	H	H	Cl
500	4	SO_2Me	H	H	H	Cl
501	1	SO_2NH_2	H	H	H	Cl
502	2	SO_2NH_2	H	H	H	Cl
503	3	SO_2NH_2	H	H	H	Cl
504	4	SO_2NH_2	H	H	H	Cl
505	1	H	H	H	H	CN
506	2	H	H	H	H	CN
507	3	H	H	H	H	CN
508	4	H	H	H	H	CN
509	1	Me	H	H	H	CN
510	2	Me	H	H	H	CN
511	3	Me	H	H	H	CN
512	4	Me	H	H	H	CN

513	1	CH_2Ph	H	H	H	CN
514	2	CH_2Ph	H	H	H	CN
515	3	CH_2Ph	H	H	H	CN
516	4	CH_2Ph	H	H	H	CN
517	1	COMe	H	H	H	CN
518	2	COMe	H	H	H	CN
519	3	COMe	H	H	H	CN
520	4	COMe	H	H	H	CN
521	1	CO_2Me	H	H	H	CN
522	2	CO_2Me	H	H	H	CN
523	3	CO_2Me	H	H	H	CN
524	4	CO_2Me	H	H	H	CN
525	1	CO_2tBu	H	H	H	CN
526	2	CO_2tBu	H	H	H	CN
527	3	CO_2tBu	H	H	H	CN
528	4	CO_2tBu	H	H	H	CN
529	1	CONHMe	H	H	H	CN
530	2	CONHMe	H	H	H	CN
531	3	CONHMe	H	H	H	CN
532	4	CONHMe	H	H	H	CN
533	1	SO_2Me	H	H	H	CN
534	2	SO_2Me	H	H	H	CN
535	3	SO_2Me	H	H	H	CN
536	4	SO_2Me	H	H	H	CN
537	1	SO_2NH_2	H	H	H	CN
538	2	SO_2NH_2	H	H	H	CN
539	3	SO_2NH_2	H	H	H	CN
540	4	SO_2NH_2	H	H	H	CN

[01035] Exemplary embodiments include compounds having the formula **(XXXIV)**



(XXXIV)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 27.

Table 27

Entry	n	R^7	R^{20a}	R^{20b}	R^{20d}	R^{20e}
1	1	H	H	H	H	H
2	2	H	H	H	H	H
3	3	H	H	H	H	H
4	4	H	H	H	H	H
5	1	Me	H	H	H	H
6	2	Me	H	H	H	H
7	3	Me	H	H	H	H
8	4	Me	H	H	H	H
9	1	CH_2Ph	H	H	H	H
10	2	CH_2Ph	H	H	H	H
11	3	CH_2Ph	H	H	H	H
12	4	CH_2Ph	H	H	H	H
13	1	COMe	H	H	H	H
14	2	COMe	H	H	H	H
15	3	COMe	H	H	H	H
16	4	COMe	H	H	H	H
17	1	CO_2Me	H	H	H	H
18	2	CO_2Me	H	H	H	H
19	3	CO_2Me	H	H	H	H
20	4	CO_2Me	H	H	H	H
21	1	CO_2tBu	H	H	H	H
22	2	CO_2tBu	H	H	H	H
23	3	CO_2tBu	H	H	H	H
24	4	CO_2tBu	H	H	H	H

25	1	CONHMe	H	H	H	H
26	2	CONHMe	H	H	H	H
27	3	CONHMe	H	H	H	H
28	4	CONHMe	H	H	H	H
29	1	SO_2Me	H	H	H	H
30	2	SO_2Me	H	H	H	H
31	3	SO_2Me	H	H	H	H
32	4	SO_2Me	H	H	H	H
33	1	SO_2NH_2	H	H	H	H
34	2	SO_2NH_2	H	H	H	H
35	3	SO_2NH_2	H	H	H	H
36	4	SO_2NH_2	H	H	H	H
37	1	H	H	H	OH	H
38	2	H	H	H	OH	H
39	3	H	H	H	OH	H
40	4	H	H	H	OH	H
41	1	Me	H	H	OH	H
42	2	Me	H	H	OH	H
43	3	Me	H	H	OH	H
44	4	Me	H	H	OH	H
45	1	CH_2Ph	H	H	OH	H
46	2	CH_2Ph	H	H	OH	H
47	3	CH_2Ph	H	H	OH	H
48	4	CH_2Ph	H	H	OH	H
49	1	COMe	H	H	OH	H
50	2	COMe	H	H	OH	H
51	3	COMe	H	H	OH	H
52	4	COMe	H	H	OH	H
53	1	CO_2Me	H	H	OH	H
54	2	CO_2Me	H	H	OH	H
55	3	CO_2Me	H	H	OH	H

56	4	CO_2Me	H	H	OH	H
57	1	CO_2tBu	H	H	OH	H
58	2	CO_2tBu	H	H	OH	H
59	3	CO_2tBu	H	H	OH	H
60	4	CO_2tBu	H	H	OH	H
61	1	CONHMe	H	H	OH	H
62	2	CONHMe	H	H	OH	H
63	3	CONHMe	H	H	OH	H
64	4	CONHMe	H	H	OH	H
65	1	SO_2Me	H	H	OH	H
66	2	SO_2Me	H	H	OH	H
67	3	SO_2Me	H	H	OH	H
68	4	SO_2Me	H	H	OH	H
69	1	SO_2NH_2	H	H	OH	H
70	2	SO_2NH_2	H	H	OH	H
71	3	SO_2NH_2	H	H	OH	H
72	4	SO_2NH_2	H	H	OH	H
73	1	H	H	H	OMe	H
74	2	H	H	H	OMe	H
75	3	H	H	H	OMe	H
76	4	H	H	H	OMe	H
77	1	Me	H	H	OMe	H
78	2	Me	H	H	OMe	H
79	3	Me	H	H	OMe	H
80	4	Me	H	H	OMe	H
81	1	CH_2Ph	H	H	OMe	H
82	2	CH_2Ph	H	H	OMe	H
83	3	CH_2Ph	H	H	OMe	H
84	4	CH_2Ph	H	H	OMe	H
85	1	COMe	H	H	OMe	H
86	2	COMe	H	H	OMe	H

87	3	COMe	H	H	OMe	H
88	4	COMe	H	H	OMe	H
89	1	CO_2Me	H	H	OMe	H
90	2	CO_2Me	H	H	OMe	H
91	3	CO_2Me	H	H	OMe	H
92	4	CO_2Me	H	H	OMe	H
93	1	CO_2tBu	H	H	OMe	H
94	2	CO_2tBu	H	H	OMe	H
95	3	CO_2tBu	H	H	OMe	H
96	1	CO_2tBu	H	H	OMe	H
97	1	CONHMe	H	H	OMe	H
98	2	CONHMe	H	H	OMe	H
99	3	CONHMe	H	H	OMe	H
100	4	CONHMe	H	H	OMe	H
101	1	SO_2Me	H	H	OMe	H
102	2	SO_2Me	H	H	OMe	H
103	3	SO_2Me	H	H	OMe	H
104	4	SO_2Me	H	H	OMe	H
105	1	SO_2NH_2	H	H	OMe	H
106	2	SO_2NH_2	H	H	OMe	H
107	3	SO_2NH_2	H	H	OMe	H
108	4	SO_2NH_2	H	H	OMe	H
109	1	H	H	H	Me	H
110	2	H	H	H	Me	H
111	3	H	H	H	Me	H
112	4	H	H	H	Me	H
113	1	Me	H	H	Me	H
114	2	Me	H	H	Me	H
115	3	Me	H	H	Me	H
116	4	Me	H	H	Me	H
117	1	CH_2Ph	H	H	Me	H

118	2	CH_2Ph	H	H	Me	H
119	3	CH_2Ph	H	H	Me	H
120	4	CH_2Ph	H	H	Me	H
121	1	COMe	H	H	Me	H
122	2	COMe	H	H	Me	H
123	3	COMe	H	H	Me	H
124	4	COMe	H	H	Me	H
125	1	CO_2Me	H	H	Me	H
126	2	CO_2Me	H	H	Me	H
127	3	CO_2Me	H	H	Me	H
128	4	CO_2Me	H	H	Me	H
129	1	CO_2tBu	H	H	Me	H
130	2	CO_2tBu	H	H	Me	H
131	3	CO_2tBu	H	H	Me	H
132	4	CO_2tBu	H	H	Me	H
133	1	CONHMe	H	H	Me	H
134	2	CONHMe	H	H	Me	H
135	3	CONHMe	H	H	Me	H
136	4	CONHMe	H	H	Me	H
137	1	SO_2Me	H	H	Me	H
138	2	SO_2Me	H	H	Me	H
139	3	SO_2Me	H	H	Me	H
140	4	SO_2Me	H	H	Me	H
141	1	SO_2NH_2	H	H	Me	H
142	2	SO_2NH_2	H	H	Me	H
143	3	SO_2NH_2	H	H	Me	H
144	4	SO_2NH_2	H	H	Me	H
145	1	H	H	H	CF_3	H
146	2	H	H	H	CF_3	H
147	3	H	H	H	CF_3	H
148	4	H	H	H	CF_3	H

149	1	Me	H	H	CF_3	H
150	2	Me	H	H	CF_3	H
151	3	Me	H	H	CF_3	H
152	4	Me	H	H	CF_3	H
153	1	CH_2Ph	H	H	CF_3	H
154	2	CH_2Ph	H	H	CF_3	H
155	3	CH_2Ph	H	H	CF_3	H
156	4	CH_2Ph	H	H	CF_3	H
157	1	COMe	H	H	CF_3	H
158	2	COMe	H	H	CF_3	H
159	3	COMe	H	H	CF_3	H
160	4	COMe	H	H	CF_3	H
161	1	CO_2Me	H	H	CF_3	H
162	2	CO_2Me	H	H	CF_3	H
163	3	CO_2Me	H	H	CF_3	H
164	4	CO_2Me	H	H	CF_3	H
165	1	CO_2tBu	H	H	CF_3	H
166	2	CO_2tBu	H	H	CF_3	H
167	3	CO_2tBu	H	H	CF_3	H
168	4	CO_2tBu	H	H	CF_3	H
169	1	CONHMe	H	H	CF_3	H
170	2	CONHMe	H	H	CF_3	H
171	3	CONHMe	H	H	CF_3	H
172	4	CONHMe	H	H	CF_3	H
173	1	SO_2Me	H	H	CF_3	H
174	2	SO_2Me	H	H	CF_3	H
175	3	SO_2Me	H	H	CF_3	H
176	4	SO_2Me	H	H	CF_3	H
177	1	SO_2NH_2	H	H	CF_3	H
178	2	SO_2NH_2	H	H	CF_3	H
179	3	SO_2NH_2	H	H	CF_3	H

180	4	SO_2NH_2	H	H	CF_3	H
181	1	H	H	H	F	H
182	2	H	H	H	F	H
183	3	H	H	H	F	H
184	4	H	H	H	F	H
185	1	Me	H	H	F	H
186	2	Me	H	H	F	H
187	3	Me	H	H	F	H
188	4	Me	H	H	F	H
189	1	CH_2Ph	H	H	F	H
190	2	CH_2Ph	H	H	F	H
191	3	CH_2Ph	H	H	F	H
192	4	CH_2Ph	H	H	F	H
193	1	COMe	H	H	F	H
194	2	COMe	H	H	F	H
195	3	COMe	H	H	F	H
196	4	COMe	H	H	F	H
197	1	CO_2Me	H	H	F	H
198	2	CO_2Me	H	H	F	H
199	3	CO_2Me	H	H	F	H
200	4	CO_2Me	H	H	F	H
201	1	CO_2tBu	H	H	F	H
202	2	CO_2tBu	H	H	F	H
203	3	CO_2tBu	H	H	F	H
204	4	CO_2tBu	H	H	F	H
205	1	CONHMe	H	H	F	H
206	2	CONHMe	H	H	F	H
207	3	CONHMe	H	H	F	H
208	4	CONHMe	H	H	F	H
209	1	SO_2Me	H	H	F	H
210	2	SO_2Me	H	H	F	H

211	3	SO_2Me	H	H	F	H
212	4	SO_2Me	H	H	F	H
213	1	SO_2NH_2	H	H	F	H
214	2	SO_2NH_2	H	H	F	H
215	3	SO_2NH_2	H	H	F	H
216	4	SO_2NH_2	H	H	F	H
217	1	H	H	H	Cl	H
218	2	H	H	H	Cl	H
219	3	H	H	H	Cl	H
220	4	H	H	H	Cl	H
221	1	Me	H	H	Cl	H
222	2	Me	H	H	Cl	H
223	3	Me	H	H	Cl	H
224	4	Me	H	H	Cl	H
225	1	CH_2Ph	H	H	Cl	H
226	2	CH_2Ph	H	H	Cl	H
227	3	CH_2Ph	H	H	Cl	H
228	4	CH_2Ph	H	H	Cl	H
229	1	COMe	H	H	Cl	H
230	2	COMe	H	H	Cl	H
231	3	COMe	H	H	Cl	H
232	4	COMe	H	H	Cl	H
233	1	CO_2Me	H	H	Cl	H
234	2	CO_2Me	H	H	Cl	H
235	3	CO_2Me	H	H	Cl	H
236	4	CO_2Me	H	H	Cl	H
237	1	CO_2tBu	H	H	Cl	H
238	2	CO_2tBu	H	H	Cl	H
239	3	CO_2tBu	H	H	Cl	H
240	4	CO_2tBu	H	H	Cl	H
241	1	CONHMe	H	H	Cl	H

242	2	CONHMe	H	H	Cl	H
243	3	CONHMe	H	H	Cl	H
244	4	CONHMe	H	H	Cl	H
245	1	SO_2Me	H	H	Cl	H
246	2	SO_2Me	H	H	Cl	H
247	3	SO_2Me	H	H	Cl	H
248	4	SO_2Me	H	H	Cl	H
249	1	SO_2NH_2	H	H	Cl	H
250	2	SO_2NH_2	H	H	Cl	H
251	3	SO_2NH_2	H	H	Cl	H
252	4	SO_2NH_2	H	H	Cl	H
253	1	H	H	H	CN	H
254	2	H	H	H	CN	H
255	3	H	H	H	CN	H
256	4	H	H	H	CN	H
257	1	Me	H	H	CN	H
258	2	Me	H	H	CN	H
259	3	Me	H	H	CN	H
260	4	Me	H	H	CN	H
261	1	CH_2Ph	H	H	CN	H
262	2	CH_2Ph	H	H	CN	H
263	3	CH_2Ph	H	H	CN	H
264	4	CH_2Ph	H	H	CN	H
265	1	COMe	H	H	CN	H
266	2	COMe	H	H	CN	H
267	3	COMe	H	H	CN	H
268	4	COMe	H	H	CN	H
269	1	CO_2Me	H	H	CN	H
270	2	CO_2Me	H	H	CN	H
271	3	CO_2Me	H	H	CN	H
272	4	CO_2Me	H	H	CN	H

273	1	CO_2tBu	H	H	CN	H
274	2	CO_2tBu	H	H	CN	H
275	3	CO_2tBu	H	H	CN	H
276	4	CO_2tBu	H	H	CN	H
277	1	CONHMe	H	H	CN	H
278	2	CONHMe	H	H	CN	H
279	3	CONHMe	H	H	CN	H
280	4	CONHMe	H	H	CN	H
281	1	SO_2Me	H	H	CN	H
282	2	SO_2Me	H	H	CN	H
283	3	SO_2Me	H	H	CN	H
284	4	SO_2Me	H	H	CN	H
285	1	SO_2NH_2	H	H	CN	H
286	2	SO_2NH_2	H	H	CN	H
287	3	SO_2NH_2	H	H	CN	H
288	4	SO_2NH_2	H	H	CN	H
289	1	H	H	H	H	OH
290	2	H	H	H	H	OH
291	3	H	H	H	H	OH
292	4	H	H	H	H	OH
293	1	Me	H	H	H	OH
294	2	Me	H	H	H	OH
295	3	Me	H	H	H	OH
296	4	Me	H	H	H	OH
297	1	CH_2Ph	H	H	H	OH
298	2	CH_2Ph	H	H	H	OH
299	3	CH_2Ph	H	H	H	OH
300	4	CH_2Ph	H	H	H	OH
301	1	COMe	H	H	H	OH
302	2	COMe	H	H	H	OH
303	3	COMe	H	H	H	OH

304	4	COMe	H	H	H	OH
305	1	CO_2Me	H	H	H	OH
306	2	CO_2Me	H	H	H	OH
307	3	CO_2Me	H	H	H	OH
308	4	CO_2Me	H	H	H	OH
309	1	CO_2tBu	H	H	H	OH
310	2	CO_2tBu	H	H	H	OH
311	3	CO_2tBu	H	H	H	OH
312	4	CO_2tBu	H	H	H	OH
313	1	CONHMe	H	H	H	OH
314	2	CONHMe	H	H	H	OH
315	3	CONHMe	H	H	H	OH
316	4	CONHMe	H	H	H	OH
317	1	SO_2Me	H	H	H	OH
318	2	SO_2Me	H	H	H	OH
319	3	SO_2Me	H	H	H	OH
320	4	SO_2Me	H	H	H	OH
321	1	SO_2NH_2	H	H	H	OH
322	2	SO_2NH_2	H	H	H	OH
323	3	SO_2NH_2	H	H	H	OH
324	4	SO_2NH_2	H	H	H	OH
325	1	H	H	H	H	OMe
326	2	H	H	H	H	OMe
327	3	H	H	H	H	OMe
328	4	H	H	H	H	OMe
329	1	Me	H	H	H	OMe
330	2	Me	H	H	H	OMe
331	3	Me	H	H	H	OMe
332	4	Me	H	H	H	OMe
333	1	CH_2Ph	H	H	H	OMe
334	2	CH_2Ph	H	H	H	OMe

335	3	CH_2Ph	H	H	H	OMe
336	4	CH_2Ph	H	H	H	OMe
337	1	COMe	H	H	H	OMe
338	2	COMe	H	H	H	OMe
339	3	COMe	H	H	H	OMe
340	4	COMe	H	H	H	OMe
341	1	CO_2Me	H	H	H	OMe
342	2	CO_2Me	H	H	H	OMe
343	3	CO_2Me	H	H	H	OMe
344	4	CO_2Me	H	H	H	OMe
345	1	CO_2tBu	H	H	H	OMe
346	2	CO_2tBu	H	H	H	OMe
347	3	CO_2tBu	H	H	H	OMe
348	4	CO_2tBu	H	H	H	OMe
349	1	CONHMe	H	H	H	OMe
350	2	CONHMe	H	H	H	OMe
351	3	CONHMe	H	H	H	OMe
352	4	CONHMe	H	H	H	OMe
353	1	SO_2Me	H	H	H	OMe
354	2	SO_2Me	H	H	H	OMe
355	3	SO_2Me	H	H	H	OMe
356	4	SO_2Me	H	H	H	OMe
357	1	SO_2NH_2	H	H	H	OMe
358	2	SO_2NH_2	H	H	H	OMe
359	3	SO_2NH_2	H	H	H	OMe
360	4	SO_2NH_2	H	H	H	OMe
361	1	H	H	H	H	Me
362	2	H	H	H	H	Me
363	3	H	H	H	H	Me
364	4	H	H	H	H	Me
365	1	Me	H	H	H	Me

366	2	Me	H	H	H	Me
367	3	Me	H	H	H	Me
368	4	Me	H	H	H	Me
369	1	CH_2Ph	H	H	H	Me
370	2	CH_2Ph	H	H	H	Me
371	3	CH_2Ph	H	H	H	Me
372	4	CH_2Ph	H	H	H	Me
373	1	COMe	H	H	H	Me
374	2	COMe	H	H	H	Me
375	3	COMe	H	H	H	Me
376	4	COMe	H	H	H	Me
377	1	CO_2Me	H	H	H	Me
378	2	CO_2Me	H	H	H	Me
379	3	CO_2Me	H	H	H	Me
380	4	CO_2Me	H	H	H	Me
381	1	CO_2tBu	H	H	H	Me
382	2	CO_2tBu	H	H	H	Me
383	3	CO_2tBu	H	H	H	Me
384	4	CO_2tBu	H	H	H	Me
385	1	CONHMe	H	H	H	Me
386	2	CONHMe	H	H	H	Me
387	3	CONHMe	H	H	H	Me
388	4	CONHMe	H	H	H	Me
389	1	SO_2Me	H	H	H	Me
390	2	SO_2Me	H	H	H	Me
391	3	SO_2Me	H	H	H	Me
392	4	SO_2Me	H	H	H	Me
393	1	SO_2NH_2	H	H	H	Me
394	2	SO_2NH_2	H	H	H	Me
395	3	SO_2NH_2	H	H	H	Me
396	4	SO_2NH_2	H	H	H	Me

397	1	H	H	H	H	CF_3
398	2	H	H	H	H	CF_3
399	3	H	H	H	H	CF_3
400	4	H	H	H	H	CF_3
401	1	Me	H	H	H	CF_3
402	2	Me	H	H	H	CF_3
403	3	Me	H	H	H	CF_3
404	4	Me	H	H	H	CF_3
405	1	CH_2Ph	H	H	H	CF_3
406	2	CH_2Ph	H	H	H	CF_3
407	3	CH_2Ph	H	H	H	CF_3
408	4	CH_2Ph	H	H	H	CF_3
409	1	COMe	H	H	H	CF_3
410	2	COMe	H	H	H	CF_3
411	3	COMe	H	H	H	CF_3
412	4	COMe	H	H	H	CF_3
413	1	CO_2Me	H	H	H	CF_3
414	2	CO_2Me	H	H	H	CF_3
415	3	CO_2Me	H	H	H	CF_3
416	4	CO_2Me	H	H	H	CF_3
417	1	CO_2tBu	H	H	H	CF_3
418	2	CO_2tBu	H	H	H	CF_3
419	3	CO_2tBu	H	H	H	CF_3
420	4	CO_2tBu	H	H	H	CF_3
421	1	CONHMe	H	H	H	CF_3
422	2	CONHMe	H	H	H	CF_3
423	3	CONHMe	H	H	H	CF_3
424	4	CONHMe	H	H	H	CF_3
425	1	SO_2Me	H	H	H	CF_3
426	2	SO_2Me	H	H	H	CF_3
427	3	SO_2Me	H	H	H	CF_3


428	4	SO_2Me	H	H	H	CF_3
429	1	SO_2NH_2	H	H	H	CF_3
430	2	SO_2NH_2	H	H	H	CF_3
431	3	SO_2NH_2	H	H	H	CF_3
432	4	SO_2NH_2	H	H	H	CF_3
433	1	H	H	H	H	F
434	2	H	H	H	H	F
435	3	H	H	H	H	F
436	3	H	H	H	H	F
437	1	Me	H	H	H	F
438	2	Me	H	H	H	F
439	3	Me	H	H	H	F
440	4	Me	H	H	H	F
441	1	CH_2Ph	H	H	H	F
442	2	CH_2Ph	H	H	H	F
443	3	CH_2Ph	H	H	H	F
444	4	CH_2Ph	H	H	H	F
445	1	COMe	H	H	H	F
446	2	COMe	H	H	H	F
447	3	COMe	H	H	H	F
448	4	COMe	H	H	H	F
449	1	CO_2Me	H	H	H	F
450	2	CO_2Me	H	H	H	F
451	3	CO_2Me	H	H	H	F
452	4	CO_2Me	H	H	H	F
453	1	CO_2tBu	H	H	H	F
454	2	CO_2tBu	H	H	H	F
455	3	CO_2tBu	H	H	H	F
456	4	CO_2tBu	H	H	H	F
457	1	CONHMe	H	H	H	F
458	2	CONHMe	H	H	H	F

459	3	CONHMe	H	H	H	F
460	4	CONHMe	H	H	H	F
461	1	SO_2Me	H	H	H	F
462	2	SO_2Me	H	H	H	F
463	3	SO_2Me	H	H	H	F
464	4	SO_2Me	H	H	H	F
465	1	SO_2NH_2	H	H	H	F
466	2	SO_2NH_2	H	H	H	F
467	3	SO_2NH_2	H	H	H	F
468	4	SO_2NH_2	H	H	H	F
469	1	H	H	H	H	Cl
470	2	H	H	H	H	Cl
471	3	H	H	H	H	Cl
472	4	H	H	H	H	Cl
473	1	Me	H	H	H	Cl
474	2	Me	H	H	H	Cl
475	3	Me	H	H	H	Cl
476	4	Me	H	H	H	Cl
477	1	CH_2Ph	H	H	H	Cl
478	2	CH_2Ph	H	H	H	Cl
479	3	CH_2Ph	H	H	H	Cl
480	4	CH_2Ph	H	H	H	Cl
481	1	COMe	H	H	H	Cl
482	2	COMe	H	H	H	Cl
483	3	COMe	H	H	H	Cl
484	4	COMe	H	H	H	Cl
485	1	CO_2Me	H	H	H	Cl
486	2	CO_2Me	H	H	H	Cl
487	3	CO_2Me	H	H	H	Cl
488	4	CO_2Me	H	H	H	Cl
489	1	CO_2tBu	H	H	H	Cl

490	2	CO_2tBu	H	H	H	Cl
491	3	CO_2tBu	H	H	H	Cl
492	4	CO_2tBu	H	H	H	Cl
493	1	CONHMe	H	H	H	Cl
494	2	CONHMe	H	H	H	Cl
495	3	CONHMe	H	H	H	Cl
496	4	CONHMe	H	H	H	Cl
497	1	SO_2Me	H	H	H	Cl
498	2	SO_2Me	H	H	H	Cl
499	3	SO_2Me	H	H	H	Cl
500	4	SO_2Me	H	H	H	Cl
501	1	SO_2NH_2	H	H	H	Cl
502	2	SO_2NH_2	H	H	H	Cl
503	3	SO_2NH_2	H	H	H	Cl
504	4	SO_2NH_2	H	H	H	Cl
505	1	H	H	H	H	CN
506	2	H	H	H	H	CN
507	3	H	H	H	H	CN
508	4	H	H	H	H	CN
509	1	Me	H	H	H	CN
510	2	Me	H	H	H	CN
511	3	Me	H	H	H	CN
512	4	Me	H	H	H	CN
513	1	CH_2Ph	H	H	H	CN
514	2	CH_2Ph	H	H	H	CN
515	3	CH_2Ph	H	H	H	CN
516	4	CH_2Ph	H	H	H	CN
517	1	COMe	H	H	H	CN
518	2	COMe	H	H	H	CN
519	3	COMe	H	H	H	CN
520	4	COMe	H	H	H	CN

521	1	CO_2Me	H	H	H	CN
522	2	CO_2Me	H	H	H	CN
523	3	CO_2Me	H	H	H	CN
524	4	CO_2Me	H	H	H	CN
525	1	CO_2tBu	H	H	H	CN
526	2	CO_2tBu	H	H	H	CN
527	3	CO_2tBu	H	H	H	CN
528	4	CO_2tBu	H	H	H	CN
529	1	CONHMe	H	H	H	CN
530	2	CONHMe	H	H	H	CN
531	3	CONHMe	H	H	H	CN
532	4	CONHMe	H	H	H	CN
533	1	SO_2Me	H	H	H	CN
534	2	SO_2Me	H	H	H	CN
535	3	SO_2Me	H	H	H	CN
536	4	SO_2Me	H	H	H	CN
537	1	SO_2NH_2	H	H	H	CN
538	2	SO_2NH_2	H	H	H	CN
539	3	SO_2NH_2	H	H	H	CN
540	4	SO_2NH_2	H	H	H	CN

[01036] Exemplary embodiments include compounds having the formula **(XXXV)**



(XXXV)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 28.

Table 28

Entry	n	X	R^3	Entry	n	X	R^3
1	1	O	Phenyl	344	1	O	4-OH-Phenyl
2	2	O	Phenyl	345	2	O	4-OH-Phenyl

3	3	O	Phenyl	346	3	O	4-OH-Phenyl
4	4	O	Phenyl	347	4	O	4-OH-Phenyl
5	1	S	Phenyl	348	1	S	4-OH-Phenyl
6	2	S	Phenyl	349	2	S	4-OH-Phenyl
7	3	S	Phenyl	350	3	S	4-OH-Phenyl
8	4	S	Phenyl	351	4	S	4-OH-Phenyl
9	1	SO	Phenyl	352	1	SO	4-OH-Phenyl
10	2	SO	Phenyl	353	2	SO	4-OH-Phenyl
11	3	SO	Phenyl	354	3	SO	4-OH-Phenyl
12	4	SO	Phenyl	355	4	SO	4-OH-Phenyl
13	1	SO_2	Phenyl	356	1	SO_2	4-OH-Phenyl
14	2	SO_2	Phenyl	357	2	SO_2	4-OH-Phenyl
15	3	SO_2	Phenyl	358	3	SO_2	4-OH-Phenyl
16	4	SO_2	Phenyl	359	4	SO_2	4-OH-Phenyl
17	1	O	3-OH-Phenyl	360	1	O	2-OH-Phenyl
18	2	O	3-OH-Phenyl	361	2	O	2-OH-Phenyl
19	3	O	3-OH-Phenyl	362	3	O	2-OH-Phenyl
20	4	O	3-OH-Phenyl	363	4	O	2-OH-Phenyl
21	1	S	3-OH-Phenyl	364	1	S	2-OH-Phenyl
22	2	S	3-OH-Phenyl	365	2	S	2-OH-Phenyl
23	3	S	3-OH-Phenyl	366	3	S	2-OH-Phenyl
24	4	S	3-OH-Phenyl	367	4	S	2-OH-Phenyl
25	1	SO	3-OH-Phenyl	368	1	SO	2-OH-Phenyl
26	2	SO	3-OH-Phenyl	369	2	SO	2-OH-Phenyl
27	3	SO	3-OH-Phenyl	370	3	SO	2-OH-Phenyl
28	4	SO	3-OH-Phenyl	371	4	SO	2-OH-Phenyl
29	1	SO_2	3-OH-Phenyl	372	1	SO_2	2-OH-Phenyl
30	2	SO_2	3-OH-Phenyl	373	2	SO_2	2-OH-Phenyl
31	3	SO_2	3-OH-Phenyl	374	3	SO_2	2-OH-Phenyl
32	4	SO_2	3-OH-Phenyl	375	4	SO_2	2-OH-Phenyl
33	1	O	4-NO_2-Phenyl	376	1	O	4-OMe-Phenyl

34	2	O	4-NO_2-Phenyl	377	2	O	4-OMe-Phenyl
35	3	O	4-NO_2-Phenyl	378	3	O	4-OMe-Phenyl
36	4	O	4-NO_2-Phenyl	379	4	O	4-OMe-Phenyl
37	1	S	4-NO_2-Phenyl	380	1	S	4-OMe-Phenyl
38	2	S	4-NO_2-Phenyl	381	2	S	4-OMe-Phenyl
39	3	S	4-NO_2-Phenyl	382	3	S	4-OMe-Phenyl
40	4	S	4-NO_2-Phenyl	383	4	S	4-OMe-Phenyl
41	1	SO	4-NO_2-Phenyl	384	1	SO	4-OMe-Phenyl
42	2	SO	4-NO_2-Phenyl	385	2	SO	4-OMe-Phenyl
43	3	SO	4-NO_2-Phenyl	386	3	SO	4-OMe-Phenyl
44	4	SO	4-NO_2-Phenyl	387	4	SO	4-OMe-Phenyl
45	1	SO_2	4-NO_2-Phenyl	388	1	SO_2	4-OMe-Phenyl
46	2	SO_2	4-NO_2-Phenyl	389	2	SO_2	4-OMe-Phenyl
47	3	SO_2	4-NO_2-Phenyl	390	3	SO_2	4-OMe-Phenyl
48	4	SO_2	4-NO_2-Phenyl	391	4	SO_2	4-OMe-Phenyl
49	1	O	3-OMe-Phenyl	392	1	O	2-OMe-Phenyl
50	2	O	3-OMe-Phenyl	393	2	O	2-OMe-Phenyl
51	3	O	3-OMe-Phenyl	394	3	O	2-OMe-Phenyl
52	4	O	3-OMe-Phenyl	395	4	O	2-OMe-Phenyl
53	1	S	3-OMe-Phenyl	396	1	S	2-OMe-Phenyl
54	2	S	3-OMe-Phenyl	397	2	S	2-OMe-Phenyl
55	3	S	3-OMe-Phenyl	398	3	S	2-OMe-Phenyl
56	4	S	3-OMe-Phenyl	399	4	S	2-OMe-Phenyl
57	1	SO	3-OMe-Phenyl	400	1	SO	2-OMe-Phenyl
58	2	SO	3-OMe-Phenyl	401	2	SO	2-OMe-Phenyl
59	3	SO	3-OMe-Phenyl	402	3	SO	2-OMe-Phenyl
60	4	SO	3-OMe-Phenyl	403	4	SO	2-OMe-Phenyl
61	1	SO_2	3-OMe-Phenyl	404	1	SO_2	2-OMe-Phenyl
62	2	SO_2	3-OMe-Phenyl	405	2	SO_2	2-OMe-Phenyl
63	3	SO_2	3-OMe-Phenyl	406	3	SO_2	2-OMe-Phenyl
64	4	SO_2	3-OMe-Phenyl	407	4	SO_2	2-OMe-Phenyl

65	1	O	4-CN-Phenyl	408	1	O	3-CN-Phenyl
66	2	O	4-CN-Phenyl	409	2	O	3-CN-Phenyl
67	3	O	4-CN-Phenyl	410	3	O	3-CN-Phenyl
68	4	O	4-CN-Phenyl	411	4	O	3-CN-Phenyl
69	1	S	4-CN-Phenyl	412	1	S	3-CN-Phenyl
70	2	S	4-CN-Phenyl	413	2	S	3-CN-Phenyl
71	3	S	4-CN-Phenyl	414	3	S	3-CN-Phenyl
72	4	S	4-CN-Phenyl	415	4	S	3-CN-Phenyl
73	1	SO	4-CN-Phenyl	416	1	SO	3-CN-Phenyl
74	2	SO	4-CN-Phenyl	417	2	SO	3-CN-Phenyl
75	3	SO	4-CN-Phenyl	418	3	SO	3-CN-Phenyl
76	4	SO	4-CN-Phenyl	419	4	SO	3-CN-Phenyl
77	1	SO_2	4-CN-Phenyl	420	1	SO_2	3-CN-Phenyl
78	2	SO_2	4-CN-Phenyl	421	2	SO_2	3-CN-Phenyl
79	3	SO_2	4-CN-Phenyl	422	3	SO_2	3-CN-Phenyl
80	4	SO_2	4-CN-Phenyl	423	4	SO_2	3-CN-Phenyl
81	1	O	2-CN-Phenyl	424	1	O	2-Me-Phenyl
82	2	O	2-CN-Phenyl	425	2	O	2-Me-Phenyl
83	3	O	2-CN-Phenyl	426	3	O	2-Me-Phenyl
84	4	O	2-CN-Phenyl	427	4	O	2-Me-Phenyl
85	1	S	2-CN-Phenyl	428	1	S	2-Me-Phenyl
86	2	S	2-CN-Phenyl	429	2	S	2-Me-Phenyl
87	3	S	2-CN-Phenyl	430	3	S	2-Me-Phenyl
88	4	S	2-CN-Phenyl	431	4	S	2-Me-Phenyl
89	1	SO	2-CN-Phenyl	432	1	SO	2-Me-Phenyl
90	2	SO	2-CN-Phenyl	433	2	SO	2-Me-Phenyl
91	3	SO	2-CN-Phenyl	434	3	SO	2-Me-Phenyl
92	4	SO	2-CN-Phenyl	435	4	SO	2-Me-Phenyl
93	1	SO_2	2-CN-Phenyl	436	1	SO_2	2-Me-Phenyl
94	2	SO_2	2-CN-Phenyl	437	2	SO_2	2-Me-Phenyl
95	3	SO_2	2-CN-Phenyl	438	3	SO_2	2-Me-Phenyl

96	4	SO_2	2-CN-Phenyl	439	4	SO_2	2-Me-Phenyl
97	1	O	3-Me-Phenyl	440	1	O	4-Me-Phenyl
98	2	O	3-Me-Phenyl	441	2	O	4-Me-Phenyl
99	3	O	3-Me-Phenyl	442	3	O	4-Me-Phenyl
100	4	O	3-Me-Phenyl	443	4	O	4-Me-Phenyl
101	1	S	3-Me-Phenyl	444	1	S	4-Me-Phenyl
102	2	S	3-Me-Phenyl	445	2	S	4-Me-Phenyl
103	3	S	3-Me-Phenyl	446	3	S	4-Me-Phenyl
104	4	S	3-Me-Phenyl	447	4	S	4-Me-Phenyl
105	1	SO	3-Me-Phenyl	448	1	SO	4-Me-Phenyl
106	2	SO	3-Me-Phenyl	449	2	SO	4-Me-Phenyl
107	3	SO	3-Me-Phenyl	450	3	SO	4-Me-Phenyl
108	4	SO	3-Me-Phenyl	451	4	SO	4-Me-Phenyl
109	1	SO_2	3-Me-Phenyl	452	1	SO_2	4-Me-Phenyl
110	2	SO_2	3-Me-Phenyl	453	2	SO_2	4-Me-Phenyl
111	3	SO_2	3-Me-Phenyl	454	3	SO_2	4-Me-Phenyl
112	4	SO_2	3-Me-Phenyl	455	4	SO_2	4-Me-Phenyl
113	1	O	2-F-Phenyl	456	1	O	3-F-Phenyl
114	2	O	2-F-Phenyl	457	2	O	3-F-Phenyl
115	3	O	2-F-Phenyl	458	3	O	3-F-Phenyl
116	4	O	2-F-Phenyl	459	4	O	3-F-Phenyl
117	1	S	2-F-Phenyl	460	1	S	3-F-Phenyl
118	2	S	2-F-Phenyl	461	2	S	3-F-Phenyl
119	3	S	2-F-Phenyl	462	3	S	3-F-Phenyl
120	4	S	2-F-Phenyl	463	4	S	3-F-Phenyl
121	1	SO	2-F-Phenyl	464	1	SO	3-F-Phenyl
122	2	SO	2-F-Phenyl	465	2	SO	3-F-Phenyl
123	3	SO	2-F-Phenyl	466	3	SO	3-F-Phenyl
124	4	SO	2-F-Phenyl	467	4	SO	3-F-Phenyl
125	1	SO_2	2-F-Phenyl	468	1	SO_2	3-F-Phenyl
126	2	SO_2	2-F-Phenyl	469	2	SO_2	3-F-Phenyl

127	3	SO_2	2-F-Phenyl	470	3	SO_2	3-F-Phenyl
128	4	SO_2	2-F-Phenyl	471	4	SO_2	3-F-Phenyl
129	1	O	4-F-Phenyl	472	1	O	2-Cl-Phenyl
130	2	O	4-F-Phenyl	473	2	O	2-Cl-Phenyl
131	3	O	4-F-Phenyl	474	3	O	2-Cl-Phenyl
132	4	O	4-F-Phenyl	475	4	O	2-Cl-Phenyl
133	1	S	4-F-Phenyl	476	1	S	2-Cl-Phenyl
134	2	S	4-F-Phenyl	477	2	S	2-Cl-Phenyl
135	3	S	4-F-Phenyl	478	3	S	2-Cl-Phenyl
136	4	S	4-F-Phenyl	479	4	S	2-Cl-Phenyl
137	1	SO	4-F-Phenyl	480	1	SO	2-Cl-Phenyl
138	2	SO	4-F-Phenyl	481	2	SO	2-Cl-Phenyl
139	3	SO	4-F-Phenyl	482	3	SO	2-Cl-Phenyl
140	4	SO	4-F-Phenyl	483	4	SO	2-Cl-Phenyl
141	1	SO_2	4-F-Phenyl	484	1	SO_2	2-Cl-Phenyl
142	2	SO_2	4-F-Phenyl	485	2	SO_2	2-Cl-Phenyl
143	3	SO_2	4-F-Phenyl	486	3	SO_2	2-Cl-Phenyl
144	4	SO_2	4-F-Phenyl	487	4	SO_2	2-Cl-Phenyl
145	1	O	3-Cl-Phenyl	488	1	O	4-Cl-Phenyl
146	2	O	3-Cl-Phenyl	489	2	O	4-Cl-Phenyl
147	3	O	3-Cl-Phenyl	490	3	O	4-Cl-Phenyl
148	4	O	3-Cl-Phenyl	491	4	O	4-Cl-Phenyl
149	1	S	3-Cl-Phenyl	492	1	S	4-Cl-Phenyl
150	2	S	3-Cl-Phenyl	493	2	S	4-Cl-Phenyl
151	3	S	3-Cl-Phenyl	494	3	S	4-Cl-Phenyl
152	4	S	3-Cl-Phenyl	495	4	S	4-Cl-Phenyl
153	1	SO	3-Cl-Phenyl	496	1	SO	4-Cl-Phenyl
154	2	SO	3-Cl-Phenyl	497	2	SO	4-Cl-Phenyl
155	3	SO	3-Cl-Phenyl	498	3	SO	4-Cl-Phenyl
156	4	SO	3-Cl-Phenyl	499	4	SO	4-Cl-Phenyl
157	1	SO_2	3-Cl-Phenyl	500	1	SO_2	4-Cl-Phenyl

158	2	SO_2	3-Cl-Phenyl	501	2	SO_2	4-Cl-Phenyl
159	3	SO_2	3-Cl-Phenyl	502	3	SO_2	4-Cl-Phenyl
160	4	SO_2	3-Cl-Phenyl	503	4	SO_2	4-Cl-Phenyl
161	1	O	2-Br-Phenyl	504	1	O	3-Br-Phenyl
162	2	O	2-Br-Phenyl	505	2	O	3-Br-Phenyl
163	3	O	2-Br-Phenyl	506	3	O	3-Br-Phenyl
164	4	O	2-Br-Phenyl	507	4	O	3-Br-Phenyl
165	1	S	2-Br-Phenyl	508	1	S	3-Br-Phenyl
166	2	S	2-Br-Phenyl	509	2	S	3-Br-Phenyl
167	3	S	2-Br-Phenyl	510	3	S	3-Br-Phenyl
168	4	S	2-Br-Phenyl	511	4	S	3-Br-Phenyl
169	1	SO	2-Br-Phenyl	512	1	SO	3-Br-Phenyl
170	2	SO	2-Br-Phenyl	513	2	SO	3-Br-Phenyl
171	3	SO	2-Br-Phenyl	514	3	SO	3-Br-Phenyl
172	4	SO	2-Br-Phenyl	515	4	SO	3-Br-Phenyl
173	1	SO_2	2-Br-Phenyl	516	1	SO_2	3-Br-Phenyl
174	2	SO_2	2-Br-Phenyl	517	2	SO_2	3-Br-Phenyl
175	3	SO_2	2-Br-Phenyl	518	3	SO_2	3-Br-Phenyl
176	4	SO_2	2-Br-Phenyl	519	4	SO_2	3-Br-Phenyl
177	1	O	4-Br-Phenyl	520	1	O	2-CF_3-Phenyl
178	2	O	4-Br-Phenyl	521	2	O	2-CF_3-Phenyl
179	3	O	4-Br-Phenyl	522	3	O	2-CF_3-Phenyl
180	4	O	4-Br-Phenyl	523	4	O	2-CF_3-Phenyl
181	1	S	4-Br-Phenyl	524	1	S	2-CF_3-Phenyl
182	2	S	4-Br-Phenyl	525	2	S	2-CF_3-Phenyl
183	3	S	4-Br-Phenyl	526	3	S	2-CF_3-Phenyl
184	4	S	4-Br-Phenyl	527	4	S	2-CF_3-Phenyl
185	1	SO	4-Br-Phenyl	528	1	SO	2-CF_3-Phenyl
186	2	SO	4-Br-Phenyl	529	2	SO	2-CF_3-Phenyl
187	3	SO	4-Br-Phenyl	530	3	SO	2-CF_3-Phenyl
188	4	SO	4-Br-Phenyl	531	4	SO	2-CF_3-Phenyl

189	1	SO_2	4-Br-Phenyl	532	1	SO_2	2-CF_3-Phenyl
190	2	SO_2	4-Br-Phenyl	533	2	SO_2	2-CF_3-Phenyl
191	3	SO_2	4-Br-Phenyl	534	3	SO_2	2-CF_3-Phenyl
192	4	SO_2	4-Br-Phenyl	535	4	SO_2	2-CF_3-Phenyl
193	1	O	3-CF_3-Phenyl	536	1	O	4-CF_3-Phenyl
194	2	O	3-CF_3-Phenyl	537	2	O	4-CF_3-Phenyl
195	3	O	3-CF_3-Phenyl	538	3	O	4-CF_3-Phenyl
196	4	O	3-CF_3-Phenyl	539	4	O	4-CF_3-Phenyl
197	1	S	3-CF_3-Phenyl	540	1	S	4-CF_3-Phenyl
198	2	S	3-CF_3-Phenyl	541	2	S	4-CF_3-Phenyl
199	3	S	3-CF_3-Phenyl	542	3	S	4-CF_3-Phenyl
200	4	S	3-CF_3-Phenyl	543	4	S	4-CF_3-Phenyl
201	1	SO	3-CF_3-Phenyl	544	1	SO	4-CF_3-Phenyl
202	2	SO	3-CF_3-Phenyl	545	2	SO	4-CF_3-Phenyl
203	3	SO	3-CF_3-Phenyl	546	3	SO	4-CF_3-Phenyl
204	4	SO	3-CF_3-Phenyl	547	4	SO	3-CF_3-Phenyl
205	1	SO_2	3-CF_3-Phenyl	548	1	SO_2	4-CF_3-Phenyl
206	2	SO_2	3-CF_3-Phenyl	549	2	SO_2	4-CF_3-Phenyl
207	3	SO_2	3-CF_3-Phenyl	550	3	SO_2	4-CF_3-Phenyl
208	4	SO_2	3-CF_3-Phenyl	551	4	SO_2	4-CF_3-Phenyl
209	1	O	2-iPr-Phenyl	552	1	O	3-iPr-Phenyl
210	2	O	2-iPr-Phenyl	553	2	O	3-iPr-Phenyl
211	3	O	2-iPr-Phenyl	554	3	O	3-iPr-Phenyl
212	4	O	2-iPr-Phenyl	555	4	O	3-iPr-Phenyl
213	1	S	2-iPr-Phenyl	556	1	S	3-iPr-Phenyl
214	2	S	2-iPr-Phenyl	557	2	S	3-iPr-Phenyl
215	3	S	2-iPr-Phenyl	558	3	S	3-iPr-Phenyl
216	4	S	2-iPr-Phenyl	559	4	S	3-iPr-Phenyl
217	1	SO	2-iPr-Phenyl	560	1	SO	3-iPr-Phenyl
218	2	SO	2-iPr-Phenyl	561	2	SO	3-iPr-Phenyl
219	3	SO	2-iPr-Phenyl	562	3	SO	3-iPr-Phenyl

220	4	SO	2-iPr-Phenyl	563	4	SO	3-iPr-Phenyl
221	1	SO_2	2-iPr-Phenyl	564	1	SO_2	3-iPr-Phenyl
222	2	SO_2	2-iPr-Phenyl	565	2	SO_2	3-iPr-Phenyl
223	3	SO_2	2-iPr-Phenyl	566	3	SO_2	3-iPr-Phenyl
224	4	SO_2	2-iPr-Phenyl	567	4	SO_2	3-iPr-Phenyl
225	1	O	4-iPr-Phenyl	568	1	O	4-NH_2-Phenyl
226	2	O	4-iPr-Phenyl	569	2	O	4-NH_2-Phenyl
227	3	O	4-iPr-Phenyl	570	3	O	4-NH_2-Phenyl
228	4	O	4-iPr-Phenyl	571	4	O	4-NH_2-Phenyl
229	1	S	4-iPr-Phenyl	572	1	S	4-NH_2-Phenyl
230	2	S	4-iPr-Phenyl	573	2	S	4-NH_2-Phenyl
231	3	S	4-iPr-Phenyl	574	3	S	4-NH_2-Phenyl
232	4	S	4-iPr-Phenyl	575	4	S	4-NH_2-Phenyl
233	1	SO	4-iPr-Phenyl	576	1	SO	4-NH_2-Phenyl
234	2	SO	4-iPr-Phenyl	577	2	SO	4-NH_2-Phenyl
235	3	SO	4-iPr-Phenyl	578	3	SO	4-NH_2-Phenyl
236	4	SO	4-iPr-Phenyl	579	4	SO	4-NH_2-Phenyl
237	1	SO_2	4-iPr-Phenyl	580	1	SO_2	4-NH_2-Phenyl
238	2	SO_2	4-iPr-Phenyl	581	2	SO_2	4-NH_2-Phenyl
239	3	SO_2	4-iPr-Phenyl	582	3	SO_2	4-NH_2-Phenyl
240	4	SO_2	4-iPr-Phenyl	583	4	SO_2	4-NH_2-Phenyl
241	1	O	3-NH_2-Phenyl	584	1	O	2-NH_2-Phenyl
242	2	O	3-NH_2-Phenyl	585	2	O	2-NH_2-Phenyl
243	3	O	3-NH_2-Phenyl	586	3	O	2-NH_2-Phenyl
244	4	O	3-NH_2-Phenyl	587	4	O	2-NH_2-Phenyl
245	1	S	3-NH_2-Phenyl	588	1	S	2-NH_2-Phenyl
246	2	S	3-NH_2-Phenyl	589	2	S	2-NH_2-Phenyl
247	3	S	3-NH_2-Phenyl	590	3	S	2-NH_2-Phenyl
248	1	SO	3-NH_2-Phenyl	591	1	SO	2-NH_2-Phenyl
249	2	SO	3-NH_2-Phenyl	592	2	SO	2-NH_2-Phenyl
250	3	SO	3-NH_2-Phenyl	593	3	SO	2-NH_2-Phenyl


251	4	SO	3-NH_2-Phenyl	594	4	SO	2-NH_2-Phenyl
252	1	SO_2	3-NH_2-Phenyl	595	1	SO_2	2-NH_2-Phenyl
253	2	SO_2	3-NH_2-Phenyl	596	2	SO_2	2-NH_2-Phenyl
254	3	SO_2	3-NH_2-Phenyl	597	3	SO_2	2-NH_2-Phenyl
255	4	SO_2	3-NH_2-Phenyl	598	4	SO_2	2-NH_2-Phenyl
256	1	O	2,4-di-Me-Phenyl	599	1	O	2,6-di-Me-Phenyl
257	2	O	2,4-di-Me-Phenyl	600	2	O	2,6-di-Me-Phenyl
258	3	O	2,4-di-Me-Phenyl	601	3	O	2,6-di-Me-Phenyl
259	4	O	2,4-di-Me-Phenyl	602	4	O	2,6-di-Me-Phenyl
260	1	S	2,4-di-Me-Phenyl	603	1	S	2,6-di-Me-Phenyl
261	2	S	2,4-di-Me-Phenyl	604	2	S	2,6-di-Me-Phenyl
262	3	S	2,4-di-Me-Phenyl	605	3	S	2,6-di-Me-Phenyl
263	4	S	2,4-di-Me-Phenyl	606	4	S	2,6-di-Me-Phenyl
264	1	SO	2,4-di-Me-Phenyl	607	1	SO	2,6-di-Me-Phenyl
265	2	SO	2,4-di-Me-Phenyl	608	2	SO	2,6-di-Me-Phenyl
266	3	SO	2,4-di-Me-Phenyl	609	3	SO	2,6-di-Me-Phenyl
267	4	SO	2,4-di-Me-Phenyl	610	4	SO	2,6-di-Me-Phenyl
268	1	SO_2	2,4-di-Me-Phenyl	611	1	SO_2	2,6-di-Me-Phenyl
269	2	SO_2	2,4-di-Me-Phenyl	612	2	SO_2	2,6-di-Me-Phenyl
270	3	SO_2	2,4-di-Me-Phenyl	613	3	SO_2	2,6-di-Me-Phenyl
271	4	SO_2	2,4-di-Me-Phenyl	614	4	SO_2	2,6-di-Me-Phenyl
272	1	O	2,6-di-iPr-Phenyl	615	1	O	2-Ph-Phenyl
273	2	O	2,6-di-iPr-Phenyl	616	2	O	2-Ph-Phenyl
274	3	O	2,6-di-iPr-Phenyl	617	3	O	2-Ph-Phenyl
275	4	O	2,6-di-iPr-Phenyl	618	4	O	2-Ph-Phenyl
276	1	S	2,6-di-iPr-Phenyl	619	1	S	2-Ph-Phenyl
277	2	S	2,6-di-iPr-Phenyl	620	2	S	2-Ph-Phenyl
278	3	S	2,6-di-iPr-Phenyl	621	3	S	2-Ph-Phenyl
279	4	S	2,6-di-iPr-Phenyl	622	4	S	2-Ph-Phenyl
280	1	SO	2,6-di-iPr-Phenyl	623	1	SO	2-Ph-Phenyl
281	2	SO	2,6-di-iPr-Phenyl	624	2	SO	2-Ph-Phenyl

282	3	SO	2,6-di-iPr-Phenyl	625	3	SO	2-Ph-Phenyl
283	4	SO	2,6-di-iPr-Phenyl	626	4	SO	2-Ph-Phenyl
284	1	SO_2	2,6-di-iPr-Phenyl	627	1	SO_2	2-Ph-Phenyl
285	2	SO_2	2,6-di-iPr-Phenyl	628	2	SO_2	2-Ph-Phenyl
286	3	SO_2	2,6-di-iPr-Phenyl	629	3	SO_2	2-Ph-Phenyl
287	4	SO_2	2,6-di-iPr-Phenyl	630	4	SO_2	2-Ph-Phenyl
288	1	O	3-Ph-Phenyl	631	1	O	4-Ph-Phenyl
289	2	O	3-Ph-Phenyl	632	2	O	4-Ph-Phenyl
290	3	O	3-Ph-Phenyl	633	3	O	4-Ph-Phenyl
291	4	O	3-Ph-Phenyl	634	4	O	4-Ph-Phenyl
292	1	S	3-Ph-Phenyl	635	1	S	4-Ph-Phenyl
293	2	S	3-Ph-Phenyl	636	2	S	4-Ph-Phenyl
294	3	S	3-Ph-Phenyl	637	3	S	4-Ph-Phenyl
295	4	S	3-Ph-Phenyl	638	4	S	4-Ph-Phenyl
296	1	SO	3-Ph-Phenyl	639	1	SO	4-Ph-Phenyl
297	2	SO	3-Ph-Phenyl	640	2	SO	4-Ph-Phenyl
298	3	SO	3-Ph-Phenyl	641	3	SO	4-Ph-Phenyl
299	4	SO	3-Ph-Phenyl	642	4	SO	4-Ph-Phenyl
300	1	SO_2	3-Ph-Phenyl	643	1	SO_2	4-Ph-Phenyl
301	2	SO_2	3-Ph-Phenyl	644	2	SO_2	4-Ph-Phenyl
302	3	SO_2	3-Ph-Phenyl	645	3	SO_2	4-Ph-Phenyl
303	4	SO_2	3-Ph-Phenyl	646	4	SO_2	4-Ph-Phenyl
304	1	O	2-morpholino-phenyl	647	1	O	3-morpholino-phenyl
305	2	O	2-morpholino-phenyl	648	2	O	3-morpholino-phenyl
306	3	O	2-morpholino-phenyl	649	3	O	3-morpholino-phenyl
307	4	O	2-morpholino-phenyl	650	4	O	3-morpholino-phenyl
308	1	S	2-morpholino-	651	1	S	3-morpholino-

			phenyl				phenyl
309	2	S	2-morpholino-phenyl	652	2	S	3-morpholino-phenyl
310	3	S	2-morpholino-phenyl	653	3	S	3-morpholino-phenyl
311	4	S	2-morpholino-phenyl	654	4	S	3-morpholino-phenyl
312	1	SO	2-morpholino-phenyl	655	1	SO	3-morpholino-phenyl
313	2	SO	2-morpholino-phenyl	656	2	SO	3-morpholino-phenyl
314	3	SO	2-morpholino-phenyl	657	3	SO	3-morpholino-phenyl
315	4	SO	2-morpholino-phenyl	658	4	SO	3-morpholino-phenyl
316	1	SO_2	2-morpholino-phenyl	659	1	SO_2	3-morpholino-phenyl
317	2	SO_2	2-morpholino-phenyl	660	2	SO_2	3-morpholino-phenyl
318	3	SO_2	2-morpholino-phenyl	661	3	SO_2	3-morpholino-phenyl
319	4	SO_2	2-morpholino-phenyl	662	4	SO_2	3-morpholino-phenyl
320	1	O	4-morpholino-phenyl	663	1	S	4-morpholino-phenyl
321	2	O	4-morpholino-phenyl	664	2	S	4-morpholino-phenyl
322	3	O	4-morpholino-phenyl	665	3	S	4-morpholino-phenyl
323	4	O	4-morpholino-phenyl	667	4	S	4-morpholino-phenyl

324	1	SO	4-morpholino-phenyl	668	1	SO_2	4-morpholino-phenyl
325	2	SO	4-morpholino-phenyl	669	2	SO_2	4-morpholino-phenyl
326	3	SO	4-morpholino-phenyl	670	3	SO_2	4-morpholino-phenyl
327	4	SO	4-morpholino-phenyl	671	4	SO_2	4-morpholino-phenyl
328	1	O	naphthylen-1-yl	672	1	O	naphthylen-2-yl
329	2	O	naphthylen-1-yl	673	2	O	naphthylen-2-yl
330	3	O	naphthylen-1-yl	674	3	O	naphthylen-2-yl
331	4	O	naphthylen-1-yl	675	4	O	naphthylen-2-yl
332	1	S	naphthylen-1-yl	676	1	S	naphthylen-2-yl
333	2	S	naphthylen-1-yl	678	2	S	naphthylen-2-yl
334	3	S	naphthylen-1-yl	679	3	S	naphthylen-2-yl
335	4	S	naphthylen-1-yl	680	4	S	naphthylen-2-yl
336	1	SO	naphthylen-1-yl	681	1	SO	naphthylen-2-yl
337	2	SO	naphthylen-1-yl	682	2	SO	naphthylen-2-yl
338	3	SO	naphthylen-1-yl	683	3	SO	naphthylen-2-yl
339	4	SO	naphthylen-1-yl	684	4	SO	naphthylen-2-yl
340	1	SO_2	naphthylen-1-yl	685	1	SO_2	naphthylen-2-yl
341	2	SO_2	naphthylen-1-yl	686	2	SO_2	naphthylen-2-yl
342	3	SO_2	naphthylen-1-yl	687	3	SO_2	naphthylen-2-yl
343	4	SO_2	naphthylen-1-yl	688	4	SO_2	naphthylen-2-yl

[01037] Exemplary embodiments include compounds having the formula **(XXXVI)**



(XXXVI)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 29.

Table 29

Entry	n	X	R^3	Entry	n	X	R^3
1	1	O	Phenyl	344	1	O	4-OH-Phenyl
2	2	O	Phenyl	345	2	O	4-OH-Phenyl
3	3	O	Phenyl	346	3	O	4-OH-Phenyl
4	4	O	Phenyl	347	4	O	4-OH-Phenyl
5	1	S	Phenyl	348	1	S	4-OH-Phenyl
6	2	S	Phenyl	349	2	S	4-OH-Phenyl
7	3	S	Phenyl	350	3	S	4-OH-Phenyl
8	4	S	Phenyl	351	4	S	4-OH-Phenyl
9	1	SO	Phenyl	352	1	SO	4-OH-Phenyl
10	2	SO	Phenyl	353	2	SO	4-OH-Phenyl
11	3	SO	Phenyl	354	3	SO	4-OH-Phenyl
12	4	SO	Phenyl	355	4	SO	4-OH-Phenyl
13	1	SO_2	Phenyl	356	1	SO_2	4-OH-Phenyl
14	2	SO_2	Phenyl	357	2	SO_2	4-OH-Phenyl
15	3	SO_2	Phenyl	358	3	SO_2	4-OH-Phenyl
16	4	SO_2	Phenyl	359	4	SO_2	4-OH-Phenyl
17	1	O	3-OH-Phenyl	360	1	O	2-OH-Phenyl
18	2	O	3-OH-Phenyl	361	2	O	2-OH-Phenyl
19	3	O	3-OH-Phenyl	362	3	O	2-OH-Phenyl
20	4	O	3-OH-Phenyl	363	4	O	2-OH-Phenyl
21	1	S	3-OH-Phenyl	364	1	S	2-OH-Phenyl
22	2	S	3-OH-Phenyl	365	2	S	2-OH-Phenyl
23	3	S	3-OH-Phenyl	366	3	S	2-OH-Phenyl
24	4	S	3-OH-Phenyl	367	4	S	2-OH-Phenyl
25	1	SO	3-OH-Phenyl	368	1	SO	2-OH-Phenyl
26	2	SO	3-OH-Phenyl	369	2	SO	2-OH-Phenyl
27	3	SO	3-OH-Phenyl	370	3	SO	2-OH-Phenyl
28	4	SO	3-OH-Phenyl	371	4	SO	2-OH-Phenyl
29	1	SO_2	3-OH-Phenyl	372	1	SO_2	2-OH-Phenyl
30	2	SO_2	3-OH-Phenyl	373	2	SO_2	2-OH-Phenyl

31	3	SO_2	3-OH-Phenyl	374	3	SO_2	2-OH-Phenyl
32	4	SO_2	3-OH-Phenyl	375	4	SO_2	2-OH-Phenyl
33	1	O	4-NO_2-Phenyl	376	1	O	4-OMe-Phenyl
34	2	O	4-NO_2-Phenyl	377	2	O	4-OMe-Phenyl
35	3	O	4-NO_2-Phenyl	378	3	O	4-OMe-Phenyl
36	4	O	4-NO_2-Phenyl	379	4	O	4-OMe-Phenyl
37	1	S	4-NO_2-Phenyl	380	1	S	4-OMe-Phenyl
38	2	S	4-NO_2-Phenyl	381	2	S	4-OMe-Phenyl
39	3	S	4-NO_2-Phenyl	382	3	S	4-OMe-Phenyl
40	4	S	4-NO_2-Phenyl	383	4	S	4-OMe-Phenyl
41	1	SO	4-NO_2-Phenyl	384	1	SO	4-OMe-Phenyl
42	2	SO	4-NO_2-Phenyl	385	2	SO	4-OMe-Phenyl
43	3	SO	4-NO_2-Phenyl	386	3	SO	4-OMe-Phenyl
44	4	SO	4-NO_2-Phenyl	387	4	SO	4-OMe-Phenyl
45	1	SO_2	4-NO_2-Phenyl	388	1	SO_2	4-OMe-Phenyl
46	2	SO_2	4-NO_2-Phenyl	389	2	SO_2	4-OMe-Phenyl
47	3	SO_2	4-NO_2-Phenyl	390	3	SO_2	4-OMe-Phenyl
48	4	SO_2	4-NO_2-Phenyl	391	4	SO_2	4-OMe-Phenyl
49	1	O	3-OMe-Phenyl	392	1	O	2-OMe-Phenyl
50	2	O	3-OMe-Phenyl	393	2	O	2-OMe-Phenyl
51	3	O	3-OMe-Phenyl	394	3	O	2-OMe-Phenyl
52	4	O	3-OMe-Phenyl	395	4	O	2-OMe-Phenyl
53	1	S	3-OMe-Phenyl	396	1	S	2-OMe-Phenyl
54	2	S	3-OMe-Phenyl	397	2	S	2-OMe-Phenyl
55	3	S	3-OMe-Phenyl	398	3	S	2-OMe-Phenyl
56	4	S	3-OMe-Phenyl	399	4	S	2-OMe-Phenyl
57	1	SO	3-OMe-Phenyl	400	1	SO	2-OMe-Phenyl
58	2	SO	3-OMe-Phenyl	401	2	SO	2-OMe-Phenyl
59	3	SO	3-OMe-Phenyl	402	3	SO	2-OMe-Phenyl
60	4	SO	3-OMe-Phenyl	403	4	SO	2-OMe-Phenyl
61	1	SO_2	3-OMe-Phenyl	404	1	SO_2	2-OMe-Phenyl

62	2	SO_2	3-OMe-Phenyl	405	2	SO_2	2-OMe-Phenyl
63	3	SO_2	3-OMe-Phenyl	406	3	SO_2	2-OMe-Phenyl
64	4	SO_2	3-OMe-Phenyl	407	4	SO_2	2-OMe-Phenyl
65	1	O	4-CN-Phenyl	408	1	O	3-CN-Phenyl
66	2	O	4-CN-Phenyl	409	2	O	3-CN-Phenyl
67	3	O	4-CN-Phenyl	410	3	O	3-CN-Phenyl
68	4	O	4-CN-Phenyl	411	4	O	3-CN-Phenyl
69	1	S	4-CN-Phenyl	412	1	S	3-CN-Phenyl
70	2	S	4-CN-Phenyl	413	2	S	3-CN-Phenyl
71	3	S	4-CN-Phenyl	414	3	S	3-CN-Phenyl
72	4	S	4-CN-Phenyl	415	4	S	3-CN-Phenyl
73	1	SO	4-CN-Phenyl	416	1	SO	3-CN-Phenyl
74	2	SO	4-CN-Phenyl	417	2	SO	3-CN-Phenyl
75	3	SO	4-CN-Phenyl	418	3	SO	3-CN-Phenyl
76	4	SO	4-CN-Phenyl	419	4	SO	3-CN-Phenyl
77	1	SO_2	4-CN-Phenyl	420	1	SO_2	3-CN-Phenyl
78	2	SO_2	4-CN-Phenyl	421	2	SO_2	3-CN-Phenyl
79	3	SO_2	4-CN-Phenyl	422	3	SO_2	3-CN-Phenyl
80	4	SO_2	4-CN-Phenyl	423	4	SO_2	3-CN-Phenyl
81	1	O	2-CN-Phenyl	424	1	O	2-Me-Phenyl
82	2	O	2-CN-Phenyl	425	2	O	2-Me-Phenyl
83	3	O	2-CN-Phenyl	426	3	O	2-Me-Phenyl
84	4	O	2-CN-Phenyl	427	4	O	2-Me-Phenyl
85	1	S	2-CN-Phenyl	428	1	S	2-Me-Phenyl
86	2	S	2-CN-Phenyl	429	2	S	2-Me-Phenyl
87	3	S	2-CN-Phenyl	430	3	S	2-Me-Phenyl
88	4	S	2-CN-Phenyl	431	4	S	2-Me-Phenyl
89	1	SO	2-CN-Phenyl	432	1	SO	2-Me-Phenyl
90	2	SO	2-CN-Phenyl	433	2	SO	2-Me-Phenyl
91	3	SO	2-CN-Phenyl	434	3	SO	2-Me-Phenyl
92	4	SO	2-CN-Phenyl	435	4	SO	2-Me-Phenyl

93	1	SO_2	2-CN-Phenyl	436	1	SO_2	2-Me-Phenyl
94	2	SO_2	2-CN-Phenyl	437	2	SO_2	2-Me-Phenyl
95	3	SO_2	2-CN-Phenyl	438	3	SO_2	2-Me-Phenyl
96	4	SO_2	2-CN-Phenyl	439	4	SO_2	2-Me-Phenyl
97	1	O	3-Me-Phenyl	440	1	O	4-Me-Phenyl
98	2	O	3-Me-Phenyl	441	2	O	4-Me-Phenyl
99	3	O	3-Me-Phenyl	442	3	O	4-Me-Phenyl
100	4	O	3-Me-Phenyl	443	4	O	4-Me-Phenyl
101	1	S	3-Me-Phenyl	444	1	S	4-Me-Phenyl
102	2	S	3-Me-Phenyl	445	2	S	4-Me-Phenyl
103	3	S	3-Me-Phenyl	446	3	S	4-Me-Phenyl
104	4	S	3-Me-Phenyl	447	4	S	4-Me-Phenyl
105	1	SO	3-Me-Phenyl	448	1	SO	4-Me-Phenyl
106	2	SO	3-Me-Phenyl	449	2	SO	4-Me-Phenyl
107	3	SO	3-Me-Phenyl	450	3	SO	4-Me-Phenyl
108	4	SO	3-Me-Phenyl	451	4	SO	4-Me-Phenyl
109	1	SO_2	3-Me-Phenyl	452	1	SO_2	4-Me-Phenyl
110	2	SO_2	3-Me-Phenyl	453	2	SO_2	4-Me-Phenyl
111	3	SO_2	3-Me-Phenyl	454	3	SO_2	4-Me-Phenyl
112	4	SO_2	3-Me-Phenyl	455	4	SO_2	4-Me-Phenyl
113	1	O	2-F-Phenyl	456	1	O	3-F-Phenyl
114	2	O	2-F-Phenyl	457	2	O	3-F-Phenyl
115	3	O	2-F-Phenyl	458	3	O	3-F-Phenyl
116	4	O	2-F-Phenyl	459	4	O	3-F-Phenyl
117	1	S	2-F-Phenyl	460	1	S	3-F-Phenyl
118	2	S	2-F-Phenyl	461	2	S	3-F-Phenyl
119	3	S	2-F-Phenyl	462	3	S	3-F-Phenyl
120	4	S	2-F-Phenyl	463	4	S	3-F-Phenyl
121	1	SO	2-F-Phenyl	464	1	SO	3-F-Phenyl
122	2	SO	2-F-Phenyl	465	2	SO	3-F-Phenyl
123	3	SO	2-F-Phenyl	466	3	SO	3-F-Phenyl

124	4	SO	2-F-Phenyl	467	4	SO	3-F-Phenyl
125	1	SO_2	2-F-Phenyl	468	1	SO_2	3-F-Phenyl
126	2	SO_2	2-F-Phenyl	469	2	SO_2	3-F-Phenyl
127	3	SO_2	2-F-Phenyl	470	3	SO_2	3-F-Phenyl
128	4	SO_2	2-F-Phenyl	471	4	SO_2	3-F-Phenyl
129	1	O	4-F-Phenyl	472	1	O	2-Cl-Phenyl
130	2	O	4-F-Phenyl	473	2	O	2-Cl-Phenyl
131	3	O	4-F-Phenyl	474	3	O	2-Cl-Phenyl
132	4	O	4-F-Phenyl	475	4	O	2-Cl-Phenyl
133	1	S	4-F-Phenyl	476	1	S	2-Cl-Phenyl
134	2	S	4-F-Phenyl	477	2	S	2-Cl-Phenyl
135	3	S	4-F-Phenyl	478	3	S	2-Cl-Phenyl
136	4	S	4-F-Phenyl	479	4	S	2-Cl-Phenyl
137	1	SO	4-F-Phenyl	480	1	SO	2-Cl-Phenyl
138	2	SO	4-F-Phenyl	481	2	SO	2-Cl-Phenyl
139	3	SO	4-F-Phenyl	482	3	SO	2-Cl-Phenyl
140	4	SO	4-F-Phenyl	483	4	SO	2-Cl-Phenyl
141	1	SO_2	4-F-Phenyl	484	1	SO_2	2-Cl-Phenyl
142	2	SO_2	4-F-Phenyl	485	2	SO_2	2-Cl-Phenyl
143	3	SO_2	4-F-Phenyl	486	3	SO_2	2-Cl-Phenyl
144	4	SO_2	4-F-Phenyl	487	4	SO_2	2-Cl-Phenyl
145	1	O	3-Cl-Phenyl	488	1	O	4-Cl-Phenyl
146	2	O	3-Cl-Phenyl	489	2	O	4-Cl-Phenyl
147	3	O	3-Cl-Phenyl	490	3	O	4-Cl-Phenyl
148	4	O	3-Cl-Phenyl	491	4	O	4-Cl-Phenyl
149	1	S	3-Cl-Phenyl	492	1	S	4-Cl-Phenyl
150	2	S	3-Cl-Phenyl	493	2	S	4-Cl-Phenyl
151	3	S	3-Cl-Phenyl	494	3	S	4-Cl-Phenyl
152	4	S	3-Cl-Phenyl	495	4	S	4-Cl-Phenyl
153	1	SO	3-Cl-Phenyl	496	1	SO	4-Cl-Phenyl
154	2	SO	3-Cl-Phenyl	497	2	SO	4-Cl-Phenyl

155	3	SO	3-Cl-Phenyl	498	3	SO	4-Cl-Phenyl
156	4	SO	3-Cl-Phenyl	499	4	SO	4-Cl-Phenyl
157	1	SO_2	3-Cl-Phenyl	500	1	SO_2	4-Cl-Phenyl
158	2	SO_2	3-Cl-Phenyl	501	2	SO_2	4-Cl-Phenyl
159	3	SO_2	3-Cl-Phenyl	502	3	SO_2	4-Cl-Phenyl
160	4	SO_2	3-Cl-Phenyl	503	4	SO_2	4-Cl-Phenyl
161	1	O	2-Br-Phenyl	504	1	O	3-Br-Phenyl
162	2	O	2-Br-Phenyl	505	2	O	3-Br-Phenyl
163	3	O	2-Br-Phenyl	506	3	O	3-Br-Phenyl
164	4	O	2-Br-Phenyl	507	4	O	3-Br-Phenyl
165	1	S	2-Br-Phenyl	508	1	S	3-Br-Phenyl
166	2	S	2-Br-Phenyl	509	2	S	3-Br-Phenyl
167	3	S	2-Br-Phenyl	510	3	S	3-Br-Phenyl
168	4	S	2-Br-Phenyl	511	4	S	3-Br-Phenyl
169	1	SO	2-Br-Phenyl	512	1	SO	3-Br-Phenyl
170	2	SO	2-Br-Phenyl	513	2	SO	3-Br-Phenyl
171	3	SO	2-Br-Phenyl	514	3	SO	3-Br-Phenyl
172	4	SO	2-Br-Phenyl	515	4	SO	3-Br-Phenyl
173	1	SO_2	2-Br-Phenyl	516	1	SO_2	3-Br-Phenyl
174	2	SO_2	2-Br-Phenyl	517	2	SO_2	3-Br-Phenyl
175	3	SO_2	2-Br-Phenyl	518	3	SO_2	3-Br-Phenyl
176	4	SO_2	2-Br-Phenyl	519	4	SO_2	3-Br-Phenyl
177	1	O	4-Br-Phenyl	520	1	O	2-CF_3-Phenyl
178	2	O	4-Br-Phenyl	521	2	O	2-CF_3-Phenyl
179	3	O	4-Br-Phenyl	522	3	O	2-CF_3-Phenyl
180	4	O	4-Br-Phenyl	523	4	O	2-CF_3-Phenyl
181	1	S	4-Br-Phenyl	524	1	S	2-CF_3-Phenyl
182	2	S	4-Br-Phenyl	525	2	S	2-CF_3-Phenyl
183	3	S	4-Br-Phenyl	526	3	S	2-CF_3-Phenyl
184	4	S	4-Br-Phenyl	527	4	S	2-CF_3-Phenyl
185	1	SO	4-Br-Phenyl	528	1	SO	2-CF_3-Phenyl

186	2	SO	4-Br-Phenyl	529	2	SO	2-CF_3-Phenyl
187	3	SO	4-Br-Phenyl	530	3	SO	2-CF_3-Phenyl
188	4	SO	4-Br-Phenyl	531	4	SO	2-CF_3-Phenyl
189	1	SO_2	4-Br-Phenyl	532	1	SO_2	2-CF_3-Phenyl
190	2	SO_2	4-Br-Phenyl	533	2	SO_2	2-CF_3-Phenyl
191	3	SO_2	4-Br-Phenyl	534	3	SO_2	2-CF_3-Phenyl
192	4	SO_2	4-Br-Phenyl	535	4	SO_2	2-CF_3-Phenyl
193	1	O	3-CF_3-Phenyl	536	1	O	4-CF_3-Phenyl
194	2	O	3-CF_3-Phenyl	537	2	O	4-CF_3-Phenyl
195	3	O	3-CF_3-Phenyl	538	3	O	4-CF_3-Phenyl
196	4	O	3-CF_3-Phenyl	539	4	O	4-CF_3-Phenyl
197	1	S	3-CF_3-Phenyl	540	1	S	4-CF_3-Phenyl
198	2	S	3-CF_3-Phenyl	541	2	S	4-CF_3-Phenyl
199	3	S	3-CF_3-Phenyl	542	3	S	4-CF_3-Phenyl
200	4	S	3-CF_3-Phenyl	543	4	S	4-CF_3-Phenyl
201	1	SO	3-CF_3-Phenyl	544	1	SO	4-CF_3-Phenyl
202	2	SO	3-CF_3-Phenyl	545	2	SO	4-CF_3-Phenyl
203	3	SO	3-CF_3-Phenyl	546	3	SO	4-CF_3-Phenyl
204	4	SO	3-CF_3-Phenyl	547	4	SO	3-CF_3-Phenyl
205	1	SO_2	3-CF_3-Phenyl	548	1	SO_2	4-CF_3-Phenyl
206	2	SO_2	3-CF_3-Phenyl	549	2	SO_2	4-CF_3-Phenyl
207	3	SO_2	3-CF_3-Phenyl	550	3	SO_2	4-CF_3-Phenyl
208	4	SO_2	3-CF_3-Phenyl	551	4	SO_2	4-CF_3-Phenyl
209	1	O	2-iPr-Phenyl	552	1	O	3-iPr-Phenyl
210	2	O	2-iPr-Phenyl	553	2	O	3-iPr-Phenyl
211	3	O	2-iPr-Phenyl	554	3	O	3-iPr-Phenyl
212	4	O	2-iPr-Phenyl	555	4	O	3-iPr-Phenyl
213	1	S	2-iPr-Phenyl	556	1	S	3-iPr-Phenyl
214	2	S	2-iPr-Phenyl	557	2	S	3-iPr-Phenyl
215	3	S	2-iPr-Phenyl	558	3	S	3-iPr-Phenyl
216	4	S	2-iPr-Phenyl	559	4	S	3-iPr-Phenyl

217	1	SO	2-iPr-Phenyl	560	1	SO	3-iPr-Phenyl
218	2	SO	2-iPr-Phenyl	561	2	SO	3-iPr-Phenyl
219	3	SO	2-iPr-Phenyl	562	3	SO	3-iPr-Phenyl
220	4	SO	2-iPr-Phenyl	563	4	SO	3-iPr-Phenyl
221	1	SO_2	2-iPr-Phenyl	564	1	SO_2	3-iPr-Phenyl
222	2	SO_2	2-iPr-Phenyl	565	2	SO_2	3-iPr-Phenyl
223	3	SO_2	2-iPr-Phenyl	566	3	SO_2	3-iPr-Phenyl
224	4	SO_2	2-iPr-Phenyl	567	4	SO_2	3-iPr-Phenyl
225	1	O	4-iPr-Phenyl	568	1	O	4-NH_2-Phenyl
226	2	O	4-iPr-Phenyl	569	2	O	4-NH_2-Phenyl
227	3	O	4-iPr-Phenyl	570	3	O	4-NH_2-Phenyl
228	4	O	4-iPr-Phenyl	571	4	O	4-NH_2-Phenyl
229	1	S	4-iPr-Phenyl	572	1	S	4-NH_2-Phenyl
230	2	S	4-iPr-Phenyl	573	2	S	4-NH_2-Phenyl
231	3	S	4-iPr-Phenyl	574	3	S	4-NH_2-Phenyl
232	4	S	4-iPr-Phenyl	575	4	S	4-NH_2-Phenyl
233	1	SO	4-iPr-Phenyl	576	1	SO	4-NH_2-Phenyl
234	2	SO	4-iPr-Phenyl	577	2	SO	4-NH_2-Phenyl
235	3	SO	4-iPr-Phenyl	578	3	SO	4-NH_2-Phenyl
236	4	SO	4-iPr-Phenyl	579	4	SO	4-NH_2-Phenyl
237	1	SO_2	4-iPr-Phenyl	580	1	SO_2	4-NH_2-Phenyl
238	2	SO_2	4-iPr-Phenyl	581	2	SO_2	4-NH_2-Phenyl
239	3	SO_2	4-iPr-Phenyl	582	3	SO_2	4-NH_2-Phenyl
240	4	SO_2	4-iPr-Phenyl	583	4	SO_2	4-NH_2-Phenyl
241	1	O	3-NH_2-Phenyl	584	1	O	2-NH_2-Phenyl
242	2	O	3-NH_2-Phenyl	585	2	O	2-NH_2-Phenyl
243	3	O	3-NH_2-Phenyl	586	3	O	2-NH_2-Phenyl
244	4	O	3-NH_2-Phenyl	587	4	O	2-NH_2-Phenyl
245	1	S	3-NH_2-Phenyl	588	1	S	2-NH_2-Phenyl
246	2	S	3-NH_2-Phenyl	589	2	S	2-NH_2-Phenyl
247	3	S	3-NH_2-Phenyl	590	3	S	2-NH_2-Phenyl


248	1	SO	3-NH_2-Phenyl	591	1	SO	2-NH_2-Phenyl
249	2	SO	3-NH_2-Phenyl	592	2	SO	2-NH_2-Phenyl
250	3	SO	3-NH_2-Phenyl	593	3	SO	2-NH_2-Phenyl
251	4	SO	3-NH_2-Phenyl	594	4	SO	2-NH_2-Phenyl
252	1	SO_2	3-NH_2-Phenyl	595	1	SO_2	2-NH_2-Phenyl
253	2	SO_2	3-NH_2-Phenyl	596	2	SO_2	2-NH_2-Phenyl
254	3	SO_2	3-NH_2-Phenyl	597	3	SO_2	2-NH_2-Phenyl
255	4	SO_2	3-NH_2-Phenyl	598	4	SO_2	2-NH_2-Phenyl
256	1	O	2,4-di-Me-Phenyl	599	1	O	2,6-di-Me-Phenyl
257	2	O	2,4-di-Me-Phenyl	600	2	O	2,6-di-Me-Phenyl
258	3	O	2,4-di-Me-Phenyl	601	3	O	2,6-di-Me-Phenyl
259	4	O	2,4-di-Me-Phenyl	602	4	O	2,6-di-Me-Phenyl
260	1	S	2,4-di-Me-Phenyl	603	1	S	2,6-di-Me-Phenyl
261	2	S	2,4-di-Me-Phenyl	604	2	S	2,6-di-Me-Phenyl
262	3	S	2,4-di-Me-Phenyl	605	3	S	2,6-di-Me-Phenyl
263	4	S	2,4-di-Me-Phenyl	606	4	S	2,6-di-Me-Phenyl
264	1	SO	2,4-di-Me-Phenyl	607	1	SO	2,6-di-Me-Phenyl
265	2	SO	2,4-di-Me-Phenyl	608	2	SO	2,6-di-Me-Phenyl
266	3	SO	2,4-di-Me-Phenyl	609	3	SO	2,6-di-Me-Phenyl
267	4	SO	2,4-di-Me-Phenyl	610	4	SO	2,6-di-Me-Phenyl
268	1	SO_2	2,4-di-Me-Phenyl	611	1	SO_2	2,6-di-Me-Phenyl
269	2	SO_2	2,4-di-Me-Phenyl	612	2	SO_2	2,6-di-Me-Phenyl
270	3	SO_2	2,4-di-Me-Phenyl	613	3	SO_2	2,6-di-Me-Phenyl
271	4	SO_2	2,4-di-Me-Phenyl	614	4	SO_2	2,6-di-Me-Phenyl
272	1	O	2,6-di-iPr-Phenyl	615	1	O	2-Ph-Phenyl
273	2	O	2,6-di-iPr-Phenyl	616	2	O	2-Ph-Phenyl
274	3	O	2,6-di-iPr-Phenyl	617	3	O	2-Ph-Phenyl
275	4	O	2,6-di-iPr-Phenyl	618	4	O	2-Ph-Phenyl
276	1	S	2,6-di-iPr-Phenyl	619	1	S	2-Ph-Phenyl
277	2	S	2,6-di-iPr-Phenyl	620	2	S	2-Ph-Phenyl
278	3	S	2,6-di-iPr-Phenyl	621	3	S	2-Ph-Phenyl

279	4	S	2,6-di-iPr-Phenyl	622	4	S	2-Ph-Phenyl
280	1	SO	2,6-di-iPr-Phenyl	623	1	SO	2-Ph-Phenyl
281	2	SO	2,6-di-iPr-Phenyl	624	2	SO	2-Ph-Phenyl
282	3	SO	2,6-di-iPr-Phenyl	625	3	SO	2-Ph-Phenyl
283	4	SO	2,6-di-iPr-Phenyl	626	4	SO	2-Ph-Phenyl
284	1	SO_2	2,6-di-iPr-Phenyl	627	1	SO_2	2-Ph-Phenyl
285	2	SO_2	2,6-di-iPr-Phenyl	628	2	SO_2	2-Ph-Phenyl
286	3	SO_2	2,6-di-iPr-Phenyl	629	3	SO_2	2-Ph-Phenyl
287	4	SO_2	2,6-di-iPr-Phenyl	630	4	SO_2	2-Ph-Phenyl
288	1	O	3-Ph-Phenyl	631	1	O	4-Ph-Phenyl
289	2	O	3-Ph-Phenyl	632	2	O	4-Ph-Phenyl
290	3	O	3-Ph-Phenyl	633	3	O	4-Ph-Phenyl
291	4	O	3-Ph-Phenyl	634	4	O	4-Ph-Phenyl
292	1	S	3-Ph-Phenyl	635	1	S	4-Ph-Phenyl
293	2	S	3-Ph-Phenyl	636	2	S	4-Ph-Phenyl
294	3	S	3-Ph-Phenyl	637	3	S	4-Ph-Phenyl
295	4	S	3-Ph-Phenyl	638	4	S	4-Ph-Phenyl
296	1	SO	3-Ph-Phenyl	639	1	SO	4-Ph-Phenyl
297	2	SO	3-Ph-Phenyl	640	2	SO	4-Ph-Phenyl
298	3	SO	3-Ph-Phenyl	641	3	SO	4-Ph-Phenyl
299	4	SO	3-Ph-Phenyl	642	4	SO	4-Ph-Phenyl
300	1	SO_2	3-Ph-Phenyl	643	1	SO_2	4-Ph-Phenyl
301	2	SO_2	3-Ph-Phenyl	644	2	SO_2	4-Ph-Phenyl
302	3	SO_2	3-Ph-Phenyl	645	3	SO_2	4-Ph-Phenyl
303	4	SO_2	3-Ph-Phenyl	646	4	SO_2	4-Ph-Phenyl
304	1	O	2-morpholino-phenyl	647	1	O	3-morpholino-phenyl
305	2	O	2-morpholino-phenyl	648	2	O	3-morpholino-phenyl
306	3	O	2-morpholino-phenyl	649	3	O	3-morpholino-phenyl

307	4	O	2-morpholino-phenyl	650	4	O	3-morpholino-phenyl
308	1	S	2-morpholino-phenyl	651	1	S	3-morpholino-phenyl
309	2	S	2-morpholino-phenyl	652	2	S	3-morpholino-phenyl
310	3	S	2-morpholino-phenyl	653	3	S	3-morpholino-phenyl
311	4	S	2-morpholino-phenyl	654	4	S	3-morpholino-phenyl
312	1	SO	2-morpholino-phenyl	655	1	SO	3-morpholino-phenyl
313	2	SO	2-morpholino-phenyl	656	2	SO	3-morpholino-phenyl
314	3	SO	2-morpholino-phenyl	657	3	SO	3-morpholino-phenyl
315	4	SO	2-morpholino-phenyl	658	4	SO	3-morpholino-phenyl
316	1	SO_2	2-morpholino-phenyl	659	1	SO_2	3-morpholino-phenyl
317	2	SO_2	2-morpholino-phenyl	660	2	SO_2	3-morpholino-phenyl
318	3	SO_2	2-morpholino-phenyl	661	3	SO_2	3-morpholino-phenyl
319	4	SO_2	2-morpholino-phenyl	662	4	SO_2	3-morpholino-phenyl
320	1	O	4-morpholino-phenyl	663	1	S	4-morpholino-phenyl
321	2	O	4-morpholino-phenyl	664	2	S	4-morpholino-phenyl
322	3	O	4-morpholino-	665	3	S	4-morpholino-

			phenyl				phenyl
323	4	O	4-morpholino-phenyl	667	4	S	4-morpholino-phenyl
324	1	SO	4-morpholino-phenyl	668	1	SO_2	4-morpholino-phenyl
325	2	SO	4-morpholino-phenyl	669	2	SO_2	4-morpholino-phenyl
326	3	SO	4-morpholino-phenyl	670	3	SO_2	4-morpholino-phenyl
327	4	SO	4-morpholino-phenyl	671	4	SO_2	4-morpholino-phenyl
328	1	O	naphthylen-1-yl	672	1	O	naphthylen-2-yl
329	2	O	naphthylen-1-yl	673	2	O	naphthylen-2-yl
330	3	O	naphthylen-1-yl	674	3	O	naphthylen-2-yl
331	4	O	naphthylen-1-yl	675	4	O	naphthylen-2-yl
332	1	S	naphthylen-1-yl	676	1	S	naphthylen-2-yl
333	2	S	naphthylen-1-yl	678	2	S	naphthylen-2-yl
334	3	S	naphthylen-1-yl	679	3	S	naphthylen-2-yl
335	4	S	naphthylen-1-yl	680	4	S	naphthylen-2-yl
336	1	SO	naphthylen-1-yl	681	1	SO	naphthylen-2-yl
337	2	SO	naphthylen-1-yl	682	2	SO	naphthylen-2-yl
338	3	SO	naphthylen-1-yl	683	3	SO	naphthylen-2-yl
339	4	SO	naphthylen-1-yl	684	4	SO	naphthylen-2-yl
340	1	SO_2	naphthylen-1-yl	685	1	SO_2	naphthylen-2-yl
341	2	SO_2	naphthylen-1-yl	686	2	SO_2	naphthylen-2-yl
342	3	SO_2	naphthylen-1-yl	687	3	SO_2	naphthylen-2-yl
343	4	SO_2	naphthylen-1-yl	688	4	SO_2	naphthylen-2-yl

[01038] Exemplary embodiments include compounds having the formula (**XXXVII**)



(XXXVII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 30.

Table 30

Entry	n	X	R^3	Entry	n	X	R^3
1	1	O	Phenyl	344	1	O	4-OH-Phenyl
2	2	O	Phenyl	345	2	O	4-OH-Phenyl
3	3	O	Phenyl	346	3	O	4-OH-Phenyl
4	4	O	Phenyl	347	4	O	4-OH-Phenyl
5	1	S	Phenyl	348	1	S	4-OH-Phenyl
6	2	S	Phenyl	349	2	S	4-OH-Phenyl
7	3	S	Phenyl	350	3	S	4-OH-Phenyl
8	4	S	Phenyl	351	4	S	4-OH-Phenyl
9	1	SO	Phenyl	352	1	SO	4-OH-Phenyl
10	2	SO	Phenyl	353	2	SO	4-OH-Phenyl
11	3	SO	Phenyl	354	3	SO	4-OH-Phenyl
12	4	SO	Phenyl	355	4	SO	4-OH-Phenyl
13	1	SO_2	Phenyl	356	1	SO_2	4-OH-Phenyl
14	2	SO_2	Phenyl	357	2	SO_2	4-OH-Phenyl
15	3	SO_2	Phenyl	358	3	SO_2	4-OH-Phenyl
16	4	SO_2	Phenyl	359	4	SO_2	4-OH-Phenyl
17	1	O	3-OH-Phenyl	360	1	O	2-OH-Phenyl
18	2	O	3-OH-Phenyl	361	2	O	2-OH-Phenyl
19	3	O	3-OH-Phenyl	362	3	O	2-OH-Phenyl
20	4	O	3-OH-Phenyl	363	4	O	2-OH-Phenyl
21	1	S	3-OH-Phenyl	364	1	S	2-OH-Phenyl
22	2	S	3-OH-Phenyl	365	2	S	2-OH-Phenyl
23	3	S	3-OH-Phenyl	366	3	S	2-OH-Phenyl
24	4	S	3-OH-Phenyl	367	4	S	2-OH-Phenyl

25	1	SO	3-OH-Phenyl	368	1	SO	2-OH-Phenyl
26	2	SO	3-OH-Phenyl	369	2	SO	2-OH-Phenyl
27	3	SO	3-OH-Phenyl	370	3	SO	2-OH-Phenyl
28	4	SO	3-OH-Phenyl	371	4	SO	2-OH-Phenyl
29	1	SO_2	3-OH-Phenyl	372	1	SO_2	2-OH-Phenyl
30	2	SO_2	3-OH-Phenyl	373	2	SO_2	2-OH-Phenyl
31	3	SO_2	3-OH-Phenyl	374	3	SO_2	2-OH-Phenyl
32	4	SO_2	3-OH-Phenyl	375	4	SO_2	2-OH-Phenyl
33	1	O	4-NO_2-Phenyl	376	1	O	4-OMe-Phenyl
34	2	O	4-NO_2-Phenyl	377	2	O	4-OMe-Phenyl
35	3	O	4-NO_2-Phenyl	378	3	O	4-OMe-Phenyl
36	4	O	4-NO_2-Phenyl	379	4	O	4-OMe-Phenyl
37	1	S	4-NO_2-Phenyl	380	1	S	4-OMe-Phenyl
38	2	S	4-NO_2-Phenyl	381	2	S	4-OMe-Phenyl
39	3	S	4-NO_2-Phenyl	382	3	S	4-OMe-Phenyl
40	4	S	4-NO_2-Phenyl	383	4	S	4-OMe-Phenyl
41	1	SO	4-NO_2-Phenyl	384	1	SO	4-OMe-Phenyl
42	2	SO	4-NO_2-Phenyl	385	2	SO	4-OMe-Phenyl
43	3	SO	4-NO_2-Phenyl	386	3	SO	4-OMe-Phenyl
44	4	SO	4-NO_2-Phenyl	387	4	SO	4-OMe-Phenyl
45	1	SO_2	4-NO_2-Phenyl	388	1	SO_2	4-OMe-Phenyl
46	2	SO_2	4-NO_2-Phenyl	389	2	SO_2	4-OMe-Phenyl
47	3	SO_2	4-NO_2-Phenyl	390	3	SO_2	4-OMe-Phenyl
48	4	SO_2	4-NO_2-Phenyl	391	4	SO_2	4-OMe-Phenyl
49	1	O	3-OMe-Phenyl	392	1	O	2-OMe-Phenyl
50	2	O	3-OMe-Phenyl	393	2	O	2-OMe-Phenyl
51	3	O	3-OMe-Phenyl	394	3	O	2-OMe-Phenyl
52	4	O	3-OMe-Phenyl	395	4	O	2-OMe-Phenyl
53	1	S	3-OMe-Phenyl	396	1	S	2-OMe-Phenyl
54	2	S	3-OMe-Phenyl	397	2	S	2-OMe-Phenyl
55	3	S	3-OMe-Phenyl	398	3	S	2-OMe-Phenyl

56	4	S	3-OMe-Phenyl	399	4	S	2-OMe-Phenyl
57	1	SO	3-OMe-Phenyl	400	1	SO	2-OMe-Phenyl
58	2	SO	3-OMe-Phenyl	401	2	SO	2-OMe-Phenyl
59	3	SO	3-OMe-Phenyl	402	3	SO	2-OMe-Phenyl
60	4	SO	3-OMe-Phenyl	403	4	SO	2-OMe-Phenyl
61	1	SO_2	3-OMe-Phenyl	404	1	SO_2	2-OMe-Phenyl
62	2	SO_2	3-OMe-Phenyl	405	2	SO_2	2-OMe-Phenyl
63	3	SO_2	3-OMe-Phenyl	406	3	SO_2	2-OMe-Phenyl
64	4	SO_2	3-OMe-Phenyl	407	4	SO_2	2-OMe-Phenyl
65	1	O	4-CN-Phenyl	408	1	O	3-CN-Phenyl
66	2	O	4-CN-Phenyl	409	2	O	3-CN-Phenyl
67	3	O	4-CN-Phenyl	410	3	O	3-CN-Phenyl
68	4	O	4-CN-Phenyl	411	4	O	3-CN-Phenyl
69	1	S	4-CN-Phenyl	412	1	S	3-CN-Phenyl
70	2	S	4-CN-Phenyl	413	2	S	3-CN-Phenyl
71	3	S	4-CN-Phenyl	414	3	S	3-CN-Phenyl
72	4	S	4-CN-Phenyl	415	4	S	3-CN-Phenyl
73	1	SO	4-CN-Phenyl	416	1	SO	3-CN-Phenyl
74	2	SO	4-CN-Phenyl	417	2	SO	3-CN-Phenyl
75	3	SO	4-CN-Phenyl	418	3	SO	3-CN-Phenyl
76	4	SO	4-CN-Phenyl	419	4	SO	3-CN-Phenyl
77	1	SO_2	4-CN-Phenyl	420	1	SO_2	3-CN-Phenyl
78	2	SO_2	4-CN-Phenyl	421	2	SO_2	3-CN-Phenyl
79	3	SO_2	4-CN-Phenyl	422	3	SO_2	3-CN-Phenyl
80	4	SO_2	4-CN-Phenyl	423	4	SO_2	3-CN-Phenyl
81	1	O	2-CN-Phenyl	424	1	O	2-Me-Phenyl
82	2	O	2-CN-Phenyl	425	2	O	2-Me-Phenyl
83	3	O	2-CN-Phenyl	426	3	O	2-Me-Phenyl
84	4	O	2-CN-Phenyl	427	4	O	2-Me-Phenyl
85	1	S	2-CN-Phenyl	428	1	S	2-Me-Phenyl
86	2	S	2-CN-Phenyl	429	2	S	2-Me-Phenyl

87	3	S	2-CN-Phenyl	430	3	S	2-Me-Phenyl
88	4	S	2-CN-Phenyl	431	4	S	2-Me-Phenyl
89	1	SO	2-CN-Phenyl	432	1	SO	2-Me-Phenyl
90	2	SO	2-CN-Phenyl	433	2	SO	2-Me-Phenyl
91	3	SO	2-CN-Phenyl	434	3	SO	2-Me-Phenyl
92	4	SO	2-CN-Phenyl	435	4	SO	2-Me-Phenyl
93	1	SO_2	2-CN-Phenyl	436	1	SO_2	2-Me-Phenyl
94	2	SO_2	2-CN-Phenyl	437	2	SO_2	2-Me-Phenyl
95	3	SO_2	2-CN-Phenyl	438	3	SO_2	2-Me-Phenyl
96	4	SO_2	2-CN-Phenyl	439	4	SO_2	2-Me-Phenyl
97	1	O	3-Me-Phenyl	440	1	O	4-Me-Phenyl
98	2	O	3-Me-Phenyl	441	2	O	4-Me-Phenyl
99	3	O	3-Me-Phenyl	442	3	O	4-Me-Phenyl
100	4	O	3-Me-Phenyl	443	4	O	4-Me-Phenyl
101	1	S	3-Me-Phenyl	444	1	S	4-Me-Phenyl
102	2	S	3-Me-Phenyl	445	2	S	4-Me-Phenyl
103	3	S	3-Me-Phenyl	446	3	S	4-Me-Phenyl
104	4	S	3-Me-Phenyl	447	4	S	4-Me-Phenyl
105	1	SO	3-Me-Phenyl	448	1	SO	4-Me-Phenyl
106	2	SO	3-Me-Phenyl	449	2	SO	4-Me-Phenyl
107	3	SO	3-Me-Phenyl	450	3	SO	4-Me-Phenyl
108	4	SO	3-Me-Phenyl	451	4	SO	4-Me-Phenyl
109	1	SO_2	3-Me-Phenyl	452	1	SO_2	4-Me-Phenyl
110	2	SO_2	3-Me-Phenyl	453	2	SO_2	4-Me-Phenyl
111	3	SO_2	3-Me-Phenyl	454	3	SO_2	4-Me-Phenyl
112	4	SO_2	3-Me-Phenyl	455	4	SO_2	4-Me-Phenyl
113	1	O	2-F-Phenyl	456	1	O	3-F-Phenyl
114	2	O	2-F-Phenyl	457	2	O	3-F-Phenyl
115	3	O	2-F-Phenyl	458	3	O	3-F-Phenyl
116	4	O	2-F-Phenyl	459	4	O	3-F-Phenyl
117	1	S	2-F-Phenyl	460	1	S	3-F-Phenyl

118	2	S	2-F-Phenyl	461	2	S	3-F-Phenyl
119	3	S	2-F-Phenyl	462	3	S	3-F-Phenyl
120	4	S	2-F-Phenyl	463	4	S	3-F-Phenyl
121	1	SO	2-F-Phenyl	464	1	SO	3-F-Phenyl
122	2	SO	2-F-Phenyl	465	2	SO	3-F-Phenyl
123	3	SO	2-F-Phenyl	466	3	SO	3-F-Phenyl
124	4	SO	2-F-Phenyl	467	4	SO	3-F-Phenyl
125	1	SO_2	2-F-Phenyl	468	1	SO_2	3-F-Phenyl
126	2	SO_2	2-F-Phenyl	469	2	SO_2	3-F-Phenyl
127	3	SO_2	2-F-Phenyl	470	3	SO_2	3-F-Phenyl
128	4	SO_2	2-F-Phenyl	471	4	SO_2	3-F-Phenyl
129	1	O	4-F-Phenyl	472	1	O	2-Cl-Phenyl
130	2	O	4-F-Phenyl	473	2	O	2-Cl-Phenyl
131	3	O	4-F-Phenyl	474	3	O	2-Cl-Phenyl
132	4	O	4-F-Phenyl	475	4	O	2-Cl-Phenyl
133	1	S	4-F-Phenyl	476	1	S	2-Cl-Phenyl
134	2	S	4-F-Phenyl	477	2	S	2-Cl-Phenyl
135	3	S	4-F-Phenyl	478	3	S	2-Cl-Phenyl
136	4	S	4-F-Phenyl	479	4	S	2-Cl-Phenyl
137	1	SO	4-F-Phenyl	480	1	SO	2-Cl-Phenyl
138	2	SO	4-F-Phenyl	481	2	SO	2-Cl-Phenyl
139	3	SO	4-F-Phenyl	482	3	SO	2-Cl-Phenyl
140	4	SO	4-F-Phenyl	483	4	SO	2-Cl-Phenyl
141	1	SO_2	4-F-Phenyl	484	1	SO_2	2-Cl-Phenyl
142	2	SO_2	4-F-Phenyl	485	2	SO_2	2-Cl-Phenyl
143	3	SO_2	4-F-Phenyl	486	3	SO_2	2-Cl-Phenyl
144	4	SO_2	4-F-Phenyl	487	4	SO_2	2-Cl-Phenyl
145	1	O	3-Cl-Phenyl	488	1	O	4-Cl-Phenyl
146	2	O	3-Cl-Phenyl	489	2	O	4-Cl-Phenyl
147	3	O	3-Cl-Phenyl	490	3	O	4-Cl-Phenyl
148	4	O	3-Cl-Phenyl	491	4	O	4-Cl-Phenyl

149	1	S	3-Cl-Phenyl	492	1	S	4-Cl-Phenyl
150	2	S	3-Cl-Phenyl	493	2	S	4-Cl-Phenyl
151	3	S	3-Cl-Phenyl	494	3	S	4-Cl-Phenyl
152	4	S	3-Cl-Phenyl	495	4	S	4-Cl-Phenyl
153	1	SO	3-Cl-Phenyl	496	1	SO	4-Cl-Phenyl
154	2	SO	3-Cl-Phenyl	497	2	SO	4-Cl-Phenyl
155	3	SO	3-Cl-Phenyl	498	3	SO	4-Cl-Phenyl
156	4	SO	3-Cl-Phenyl	499	4	SO	4-Cl-Phenyl
157	1	SO_2	3-Cl-Phenyl	500	1	SO_2	4-Cl-Phenyl
158	2	SO_2	3-Cl-Phenyl	501	2	SO_2	4-Cl-Phenyl
159	3	SO_2	3-Cl-Phenyl	502	3	SO_2	4-Cl-Phenyl
160	4	SO_2	3-Cl-Phenyl	503	4	SO_2	4-Cl-Phenyl
161	1	O	2-Br-Phenyl	504	1	O	3-Br-Phenyl
162	2	O	2-Br-Phenyl	505	2	O	3-Br-Phenyl
163	3	O	2-Br-Phenyl	506	3	O	3-Br-Phenyl
164	4	O	2-Br-Phenyl	507	4	O	3-Br-Phenyl
165	1	S	2-Br-Phenyl	508	1	S	3-Br-Phenyl
166	2	S	2-Br-Phenyl	509	2	S	3-Br-Phenyl
167	3	S	2-Br-Phenyl	510	3	S	3-Br-Phenyl
168	4	S	2-Br-Phenyl	511	4	S	3-Br-Phenyl
169	1	SO	2-Br-Phenyl	512	1	SO	3-Br-Phenyl
170	2	SO	2-Br-Phenyl	513	2	SO	3-Br-Phenyl
171	3	SO	2-Br-Phenyl	514	3	SO	3-Br-Phenyl
172	4	SO	2-Br-Phenyl	515	4	SO	3-Br-Phenyl
173	1	SO_2	2-Br-Phenyl	516	1	SO_2	3-Br-Phenyl
174	2	SO_2	2-Br-Phenyl	517	2	SO_2	3-Br-Phenyl
175	3	SO_2	2-Br-Phenyl	518	3	SO_2	3-Br-Phenyl
176	4	SO_2	2-Br-Phenyl	519	4	SO_2	3-Br-Phenyl
177	1	O	4-Br-Phenyl	520	1	O	2-CF_3-Phenyl
178	2	O	4-Br-Phenyl	521	2	O	2-CF_3-Phenyl
179	3	O	4-Br-Phenyl	522	3	O	2-CF_3-Phenyl

180	4	O	4-Br-Phenyl	523	4	O	2-CF_3-Phenyl
181	1	S	4-Br-Phenyl	524	1	S	2-CF_3-Phenyl
182	2	S	4-Br-Phenyl	525	2	S	2-CF_3-Phenyl
183	3	S	4-Br-Phenyl	526	3	S	2-CF_3-Phenyl
184	4	S	4-Br-Phenyl	527	4	S	2-CF_3-Phenyl
185	1	SO	4-Br-Phenyl	528	1	SO	2-CF_3-Phenyl
186	2	SO	4-Br-Phenyl	529	2	SO	2-CF_3-Phenyl
187	3	SO	4-Br-Phenyl	530	3	SO	2-CF_3-Phenyl
188	4	SO	4-Br-Phenyl	531	4	SO	2-CF_3-Phenyl
189	1	SO_2	4-Br-Phenyl	532	1	SO_2	2-CF_3-Phenyl
190	2	SO_2	4-Br-Phenyl	533	2	SO_2	2-CF_3-Phenyl
191	3	SO_2	4-Br-Phenyl	534	3	SO_2	2-CF_3-Phenyl
192	4	SO_2	4-Br-Phenyl	535	4	SO_2	2-CF_3-Phenyl
193	1	O	3-CF_3-Phenyl	536	1	O	4-CF_3-Phenyl
194	2	O	3-CF_3-Phenyl	537	2	O	4-CF_3-Phenyl
195	3	O	3-CF_3-Phenyl	538	3	O	4-CF_3-Phenyl
196	4	O	3-CF_3-Phenyl	539	4	O	4-CF_3-Phenyl
197	1	S	3-CF_3-Phenyl	540	1	S	4-CF_3-Phenyl
198	2	S	3-CF_3-Phenyl	541	2	S	4-CF_3-Phenyl
199	3	S	3-CF_3-Phenyl	542	3	S	4-CF_3-Phenyl
200	4	S	3-CF_3-Phenyl	543	4	S	4-CF_3-Phenyl
201	1	SO	3-CF_3-Phenyl	544	1	SO	4-CF_3-Phenyl
202	2	SO	3-CF_3-Phenyl	545	2	SO	4-CF_3-Phenyl
203	3	SO	3-CF_3-Phenyl	546	3	SO	4-CF_3-Phenyl
204	4	SO	3-CF_3-Phenyl	547	4	SO	3-CF_3-Phenyl
205	1	SO_2	3-CF_3-Phenyl	548	1	SO_2	4-CF_3-Phenyl
206	2	SO_2	3-CF_3-Phenyl	549	2	SO_2	4-CF_3-Phenyl
207	3	SO_2	3-CF_3-Phenyl	550	3	SO_2	4-CF_3-Phenyl
208	4	SO_2	3-CF_3-Phenyl	551	4	SO_2	4-CF_3-Phenyl
209	1	O	2-iPr-Phenyl	552	1	O	3-iPr-Phenyl
210	2	O	2-iPr-Phenyl	553	2	O	3-iPr-Phenyl

211	3	O	2-iPr-Phenyl	554	3	O	3-iPr-Phenyl
212	4	O	2-iPr-Phenyl	555	4	O	3-iPr-Phenyl
213	1	S	2-iPr-Phenyl	556	1	S	3-iPr-Phenyl
214	2	S	2-iPr-Phenyl	557	2	S	3-iPr-Phenyl
215	3	S	2-iPr-Phenyl	558	3	S	3-iPr-Phenyl
216	4	S	2-iPr-Phenyl	559	4	S	3-iPr-Phenyl
217	1	SO	2-iPr-Phenyl	560	1	SO	3-iPr-Phenyl
218	2	SO	2-iPr-Phenyl	561	2	SO	3-iPr-Phenyl
219	3	SO	2-iPr-Phenyl	562	3	SO	3-iPr-Phenyl
220	4	SO	2-iPr-Phenyl	563	4	SO	3-iPr-Phenyl
221	1	SO_2	2-iPr-Phenyl	564	1	SO_2	3-iPr-Phenyl
222	2	SO_2	2-iPr-Phenyl	565	2	SO_2	3-iPr-Phenyl
223	3	SO_2	2-iPr-Phenyl	566	3	SO_2	3-iPr-Phenyl
224	4	SO_2	2-iPr-Phenyl	567	4	SO_2	3-iPr-Phenyl
225	1	O	4-iPr-Phenyl	568	1	O	4-NH_2-Phenyl
226	2	O	4-iPr-Phenyl	569	2	O	4-NH_2-Phenyl
227	3	O	4-iPr-Phenyl	570	3	O	4-NH_2-Phenyl
228	4	O	4-iPr-Phenyl	571	4	O	4-NH_2-Phenyl
229	1	S	4-iPr-Phenyl	572	1	S	4-NH_2-Phenyl
230	2	S	4-iPr-Phenyl	573	2	S	4-NH_2-Phenyl
231	3	S	4-iPr-Phenyl	574	3	S	4-NH_2-Phenyl
232	4	S	4-iPr-Phenyl	575	4	S	4-NH_2-Phenyl
233	1	SO	4-iPr-Phenyl	576	1	SO	4-NH_2-Phenyl
234	2	SO	4-iPr-Phenyl	577	2	SO	4-NH_2-Phenyl
235	3	SO	4-iPr-Phenyl	578	3	SO	4-NH_2-Phenyl
236	4	SO	4-iPr-Phenyl	579	4	SO	4-NH_2-Phenyl
237	1	SO_2	4-iPr-Phenyl	580	1	SO_2	4-NH_2-Phenyl
238	2	SO_2	4-iPr-Phenyl	581	2	SO_2	4-NH_2-Phenyl
239	3	SO_2	4-iPr-Phenyl	582	3	SO_2	4-NH_2-Phenyl
240	4	SO_2	4-iPr-Phenyl	583	4	SO_2	4-NH_2-Phenyl
241	1	O	3-NH_2-Phenyl	584	1	O	2-NH_2-Phenyl

242	2	O	3-NH_2-Phenyl	585	2	O	2-NH_2-Phenyl
243	3	O	3-NH_2-Phenyl	586	3	O	2-NH_2-Phenyl
244	4	O	3-NH_2-Phenyl	587	4	O	2-NH_2-Phenyl
245	1	S	3-NH_2-Phenyl	588	1	S	2-NH_2-Phenyl
246	2	S	3-NH_2-Phenyl	589	2	S	2-NH_2-Phenyl
247	3	S	3-NH_2-Phenyl	590	3	S	2-NH_2-Phenyl
248	1	SO	3-NH_2-Phenyl	591	1	SO	2-NH_2-Phenyl
249	2	SO	3-NH_2-Phenyl	592	2	SO	2-NH_2-Phenyl
250	3	SO	3-NH_2-Phenyl	593	3	SO	2-NH_2-Phenyl
251	4	SO	3-NH_2-Phenyl	594	4	SO	2-NH_2-Phenyl
252	1	SO_2	3-NH_2-Phenyl	595	1	SO_2	2-NH_2-Phenyl
253	2	SO_2	3-NH_2-Phenyl	596	2	SO_2	2-NH_2-Phenyl
254	3	SO_2	3-NH_2-Phenyl	597	3	SO_2	2-NH_2-Phenyl
255	4	SO_2	3-NH_2-Phenyl	598	4	SO_2	2-NH_2-Phenyl
256	1	O	2,4-di-Me-Phenyl	599	1	O	2,6-di-Me-Phenyl
257	2	O	2,4-di-Me-Phenyl	600	2	O	2,6-di-Me-Phenyl
258	3	O	2,4-di-Me-Phenyl	601	3	O	2,6-di-Me-Phenyl
259	4	O	2,4-di-Me-Phenyl	602	4	O	2,6-di-Me-Phenyl
260	1	S	2,4-di-Me-Phenyl	603	1	S	2,6-di-Me-Phenyl
261	2	S	2,4-di-Me-Phenyl	604	2	S	2,6-di-Me-Phenyl
262	3	S	2,4-di-Me-Phenyl	605	3	S	2,6-di-Me-Phenyl
263	4	S	2,4-di-Me-Phenyl	606	4	S	2,6-di-Me-Phenyl
264	1	SO	2,4-di-Me-Phenyl	607	1	SO	2,6-di-Me-Phenyl
265	2	SO	2,4-di-Me-Phenyl	608	2	SO	2,6-di-Me-Phenyl
266	3	SO	2,4-di-Me-Phenyl	609	3	SO	2,6-di-Me-Phenyl
267	4	SO	2,4-di-Me-Phenyl	610	4	SO	2,6-di-Me-Phenyl
268	1	SO_2	2,4-di-Me-Phenyl	611	1	SO_2	2,6-di-Me-Phenyl
269	2	SO_2	2,4-di-Me-Phenyl	612	2	SO_2	2,6-di-Me-Phenyl
270	3	SO_2	2,4-di-Me-Phenyl	613	3	SO_2	2,6-di-Me-Phenyl
271	4	SO_2	2,4-di-Me-Phenyl	614	4	SO_2	2,6-di-Me-Phenyl
272	1	O	2,6-di-iPr-Phenyl	615	1	O	2-Ph-Phenyl


273	2	O	2,6-di-iPr-Phenyl	616	2	O	2-Ph-Phenyl
274	3	O	2,6-di-iPr-Phenyl	617	3	O	2-Ph-Phenyl
275	4	O	2,6-di-iPr-Phenyl	618	4	O	2-Ph-Phenyl
276	1	S	2,6-di-iPr-Phenyl	619	1	S	2-Ph-Phenyl
277	2	S	2,6-di-iPr-Phenyl	620	2	S	2-Ph-Phenyl
278	3	S	2,6-di-iPr-Phenyl	621	3	S	2-Ph-Phenyl
279	4	S	2,6-di-iPr-Phenyl	622	4	S	2-Ph-Phenyl
280	1	SO	2,6-di-iPr-Phenyl	623	1	SO	2-Ph-Phenyl
281	2	SO	2,6-di-iPr-Phenyl	624	2	SO	2-Ph-Phenyl
282	3	SO	2,6-di-iPr-Phenyl	625	3	SO	2-Ph-Phenyl
283	4	SO	2,6-di-iPr-Phenyl	626	4	SO	2-Ph-Phenyl
284	1	SO_2	2,6-di-iPr-Phenyl	627	1	SO_2	2-Ph-Phenyl
285	2	SO_2	2,6-di-iPr-Phenyl	628	2	SO_2	2-Ph-Phenyl
286	3	SO_2	2,6-di-iPr-Phenyl	629	3	SO_2	2-Ph-Phenyl
287	4	SO_2	2,6-di-iPr-Phenyl	630	4	SO_2	2-Ph-Phenyl
288	1	O	3-Ph-Phenyl	631	1	O	4-Ph-Phenyl
289	2	O	3-Ph-Phenyl	632	2	O	4-Ph-Phenyl
290	3	O	3-Ph-Phenyl	633	3	O	4-Ph-Phenyl
291	4	O	3-Ph-Phenyl	634	4	O	4-Ph-Phenyl
292	1	S	3-Ph-Phenyl	635	1	S	4-Ph-Phenyl
293	2	S	3-Ph-Phenyl	636	2	S	4-Ph-Phenyl
294	3	S	3-Ph-Phenyl	637	3	S	4-Ph-Phenyl
295	4	S	3-Ph-Phenyl	638	4	S	4-Ph-Phenyl
296	1	SO	3-Ph-Phenyl	639	1	SO	4-Ph-Phenyl
297	2	SO	3-Ph-Phenyl	640	2	SO	4-Ph-Phenyl
298	3	SO	3-Ph-Phenyl	641	3	SO	4-Ph-Phenyl
299	4	SO	3-Ph-Phenyl	642	4	SO	4-Ph-Phenyl
300	1	SO_2	3-Ph-Phenyl	643	1	SO_2	4-Ph-Phenyl
301	2	SO_2	3-Ph-Phenyl	644	2	SO_2	4-Ph-Phenyl
302	3	SO_2	3-Ph-Phenyl	645	3	SO_2	4-Ph-Phenyl
303	4	SO_2	3-Ph-Phenyl	646	4	SO_2	4-Ph-Phenyl

304	1	O	2-morpholino-phenyl	647	1	O	3-morpholino-phenyl
305	2	O	2-morpholino-phenyl	648	2	O	3-morpholino-phenyl
306	3	O	2-morpholino-phenyl	649	3	O	3-morpholino-phenyl
307	4	O	2-morpholino-phenyl	650	4	O	3-morpholino-phenyl
308	1	S	2-morpholino-phenyl	651	1	S	3-morpholino-phenyl
309	2	S	2-morpholino-phenyl	652	2	S	3-morpholino-phenyl
310	3	S	2-morpholino-phenyl	653	3	S	3-morpholino-phenyl
311	4	S	2-morpholino-phenyl	654	4	S	3-morpholino-phenyl
312	1	SO	2-morpholino-phenyl	655	1	SO	3-morpholino-phenyl
313	2	SO	2-morpholino-phenyl	656	2	SO	3-morpholino-phenyl
314	3	SO	2-morpholino-phenyl	657	3	SO	3-morpholino-phenyl
315	4	SO	2-morpholino-phenyl	658	4	SO	3-morpholino-phenyl
316	1	SO_2	2-morpholino-phenyl	659	1	SO_2	3-morpholino-phenyl
317	2	SO_2	2-morpholino-phenyl	660	2	SO_2	3-morpholino-phenyl
318	3	SO_2	2-morpholino-phenyl	661	3	SO_2	3-morpholino-phenyl
319	4	SO_2	2-morpholino-	662	4	SO_2	3-morpholino-

			phenyl				phenyl
320	1	O	4-morpholino-phenyl	663	1	S	4-morpholino-phenyl
321	2	O	4-morpholino-phenyl	664	2	S	4-morpholino-phenyl
322	3	O	4-morpholino-phenyl	665	3	S	4-morpholino-phenyl
323	4	O	4-morpholino-phenyl	667	4	S	4-morpholino-phenyl
324	1	SO	4-morpholino-phenyl	668	1	SO_2	4-morpholino-phenyl
325	2	SO	4-morpholino-phenyl	669	2	SO_2	4-morpholino-phenyl
326	3	SO	4-morpholino-phenyl	670	3	SO_2	4-morpholino-phenyl
327	4	SO	4-morpholino-phenyl	671	4	SO_2	4-morpholino-phenyl
328	1	O	naphthylen-1-yl	672	1	O	naphthylen-2-yl
329	2	O	naphthylen-1-yl	673	2	O	naphthylen-2-yl
330	3	O	naphthylen-1-yl	674	3	O	naphthylen-2-yl
331	4	O	naphthylen-1-yl	675	4	O	naphthylen-2-yl
332	1	S	naphthylen-1-yl	676	1	S	naphthylen-2-yl
333	2	S	naphthylen-1-yl	678	2	S	naphthylen-2-yl
334	3	S	naphthylen-1-yl	679	3	S	naphthylen-2-yl
335	4	S	naphthylen-1-yl	680	4	S	naphthylen-2-yl
336	1	SO	naphthylen-1-yl	681	1	SO	naphthylen-2-yl
337	2	SO	naphthylen-1-yl	682	2	SO	naphthylen-2-yl
338	3	SO	naphthylen-1-yl	683	3	SO	naphthylen-2-yl
339	4	SO	naphthylen-1-yl	684	4	SO	naphthylen-2-yl
340	1	SO_2	naphthylen-1-yl	685	1	SO_2	naphthylen-2-yl
341	2	SO_2	naphthylen-1-yl	686	2	SO_2	naphthylen-2-yl

342	3	SO_2	naphthylen-1-yl	687	3	SO_2	naphthylen-2-yl
343	4	SO_2	naphthylen-1-yl	688	4	SO_2	naphthylen-2-yl

[01039] Exemplary embodiments include compounds having the formula **(XXXVIII)**



(XXXVIII)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 31

Table 31

Entry	n	R^3	R^{10c}
1	1	4-CH_3-phenyl	Ethyl
2	1	4-CH_3-phenyl	n-propyl
3	1	4-CH_3-phenyl	Isopropyl
4	1	4-CH_3-phenyl	-$CH_2CH(CH_3)_2$
5	1	4-CH_3-phenyl	CF_3
6	1	4-CH_3-phenyl	-CH_2CF_3
7	1	4-CH_3-phenyl	-$CH_2CH_2CF_3$
8	1	4-CH_3-phenyl	Cyclopropyl
9	1	4-CH_3-phenyl	Cyclobutyl
10	1	4-CH_3-phenyl	Cyclopentyl
11	1	4-CH_3-phenyl	Cyclohexyl
12	1	4-CH_3-phenyl	3-pyridyl
13	1	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
14	1	4-CH_3-phenyl	1H-imidazol-4-yl
15	1	4-CH_3-phenyl	2-furanyl
16	1	3-CH_3-phenyl	Ethyl
17	1	3-CH_3-phenyl	n-propyl
18	1	3-CH_3-phenyl	Isopropyl
19	1	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
20	1	3-CH_3-phenyl	CF_3
21	1	3-CH_3-phenyl	-CH_2CF_3

22	1	3-CH_3-phenyl	-$CH_2CH_2CF_3$
23	1	3-CH_3-phenyl	Cyclopropyl
24	1	3-CH_3-phenyl	Cyclobutyl
25	1	3-CH_3-phenyl	Cyclopentyl
26	1	3-CH_3-phenyl	Cyclohexyl
27	1	3-CH_3-phenyl	3-pyridyl
28	1	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
29	1	3-CH_3-phenyl	1H-imidazol-4-yl
30	1	3-CH_3-phenyl	2-furanyl
31	1	3-OH-Phenyl	Ethyl
32	1	3-OH-Phenyl	n-propyl
33	1	3-OH-Phenyl	Isopropyl
34	1	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
35	1	3-OH-Phenyl	CF_3
36	1	3-OH-Phenyl	-CH_2CF_3
37	1	3-OH-Phenyl	-$CH_2CH_2CF_3$
38	1	3-OH-Phenyl	Cyclopropyl
39	1	3-OH-Phenyl	Cyclobutyl
40	1	3-OH-Phenyl	Cyclopentyl
41	1	3-OH-Phenyl	Cyclohexyl
42	1	3-OH-Phenyl	3-pyridyl
43	1	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
44	1	3-OH-Phenyl	1H-imidazol-4-yl
45	1	3-OH-Phenyl	2-furanyl
46	1	4-OMe-Phenyl	Ethyl
47	1	4-OMe-Phenyl	n-propyl
48	1	4-OMe-Phenyl	Isopropyl
49	1	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
50	1	4-OMe-Phenyl	CF_3
51	1	4-OMe-Phenyl	-CH_2CF_3
52	1	4-OMe-Phenyl	-$CH_2CH_2CF_3$

53	1	4-OMe-Phenyl	Cyclopropyl
54	1	4-OMe-Phenyl	Cyclobutyl
55	1	4-OMe-Phenyl	Cyclopentyl
56	1	4-OMe-Phenyl	Cyclohexyl
57	1	4-OMe-Phenyl	3-pyridyl
58	1	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
59	1	4-OMe-Phenyl	1H-imidazol-4-yl
60	1	4-OMe-Phenyl	2-furanyl
61	1	2-OMe-Phenyl	Ethyl
62	1	2-OMe-Phenyl	n-propyl
63	1	2-OMe-Phenyl	Isopropyl
64	1	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
65	1	2-OMe-Phenyl	CF_3
66	1	2-OMe-Phenyl	$-CH_2CF_3$
67	1	2-OMe-Phenyl	$-CH_2CH_2CF_3$
68	1	2-OMe-Phenyl	Cyclopropyl
69	1	2-OMe-Phenyl	Cyclobutyl
70	1	2-OMe-Phenyl	Cyclopentyl
71	1	2-OMe-Phenyl	Cyclohexyl
72	1	2-OMe-Phenyl	3-pyridyl
73	1	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
74	1	2-OMe-Phenyl	1H-imidazol-4-yl
75	1	2-OMe-Phenyl	2-furanyl
76	1	3-CN-Phenyl	Ethyl
77	1	3-CN-Phenyl	n-propyl
78	1	3-CN-Phenyl	Isopropyl
79	1	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
80	1	3-CN-Phenyl	CF_3
81	1	3-CN-Phenyl	$-CH_2CF_3$
82	1	3-CN-Phenyl	$-CH_2CH_2CF_3$
83	1	3-CN-Phenyl	Cyclopropyl

84	1	3-CN-Phenyl	Cyclobutyl
85	1	3-CN-Phenyl	Cyclopentyl
86	1	3-CN-Phenyl	Cyclohexyl
87	1	3-CN-Phenyl	3-pyridyl
88	1	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
89	1	3-CN-Phenyl	1H-imidazol-4-yl
90	1	3-CN-Phenyl	2-furanyl
91	1	2-F-Phenyl	Ethyl
92	1	2-F-Phenyl	n-propyl
93	1	2-F-Phenyl	Isopropyl
94	1	2-F-Phenyl	$-CH_2CH(CH_3)_2$
95	1	2-F-Phenyl	CF_3
96	1	2-F-Phenyl	$-CH_2CF_3$
97	1	2-F-Phenyl	$-CH_2CH_2CF_3$
98	1	2-F-Phenyl	Cyclopropyl
99	1	2-F-Phenyl	Cyclobutyl
100	1	2-F-Phenyl	Cyclopentyl
101	1	2-F-Phenyl	Cyclohexyl
102	1	2-F-Phenyl	3-pyridyl
103	1	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
104	1	2-F-Phenyl	1H-imidazol-4-yl
105	1	2-F-Phenyl	2-furanyl
106	1	4-F-Phenyl	Ethyl
107	1	4-F-Phenyl	n-propyl
108	1	4-F-Phenyl	Isopropyl
109	1	4-F-Phenyl	$-CH_2CH(CH_3)_2$
110	1	4-F-Phenyl	CF_3
111	1	4-F-Phenyl	$-CH_2CF_3$
112	1	4-F-Phenyl	$-CH_2CH_2CF_3$
113	1	4-F-Phenyl	Cyclopropyl
114	1	4-F-Phenyl	Cyclobutyl

115	1	4-F-Phenyl	Cyclopentyl
116	1	4-F-Phenyl	Cyclohexyl
117	1	4-F-Phenyl	3-pyridyl
118	1	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
119	1	4-F-Phenyl	1H-imidazol-4-yl
120	1	4-F-Phenyl	2-furanyl
121	1	3-Cl-Phenyl	Ethyl
122	1	3-Cl-Phenyl	n-propyl
123	1	3-Cl-Phenyl	Isopropyl
124	1	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
125	1	3-Cl-Phenyl	CF_3
126	1	3-Cl-Phenyl	$-CH_2CF_3$
127	1	3-Cl-Phenyl	$-CH_2CH_2CF_3$
128	1	3-Cl-Phenyl	Cyclopropyl
129	1	3-Cl-Phenyl	Cyclobutyl
130	1	3-Cl-Phenyl	Cyclopentyl
131	1	3-Cl-Phenyl	Cyclohexyl
132	1	3-Cl-Phenyl	3-pyridyl
133	1	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
134	1	3-Cl-Phenyl	1H-imidazol-4-yl
135	1	3-Cl-Phenyl	2-furanyl
136	1	2-Br-Phenyl	ethyl
137	1	2-Br-Phenyl	n-propyl
138	1	2-Br-Phenyl	isopropyl
139	1	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
140	1	2-Br-Phenyl	CF_3
141	1	2-Br-Phenyl	$-CH_2CF_3$
142	1	2-Br-Phenyl	$-CH_2CH_2CF_3$
143	1	2-Br-Phenyl	cyclopropyl
144	1	2-Br-Phenyl	Cyclobutyl
145	1	2-Br-Phenyl	cyclopentyl

146	1	2-Br-Phenyl	cyclohexyl
147	1	2-Br-Phenyl	3-pyridyl
148	1	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
149	1	2-Br-Phenyl	1H-imidazol-4-yl
150	1	2-Br-Phenyl	2-furanyl
151	1	4-Br-Phenyl	ethyl
152	1	4-Br-Phenyl	n-propyl
153	1	4-Br-Phenyl	isopropyl
154	1	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
155	1	4-Br-Phenyl	CF_3
156	1	4-Br-Phenyl	$-CH_2CF_3$
157	1	4-Br-Phenyl	$-CH_2CH_2CF_3$
158	1	4-Br-Phenyl	cyclopropyl
159	1	4-Br-Phenyl	Cyclobutyl
160	1	4-Br-Phenyl	cyclopentyl
161	1	4-Br-Phenyl	cyclohexyl
162	1	4-Br-Phenyl	3-pyridyl
163	1	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
164	1	4-Br-Phenyl	1H-imidazol-4-yl
165	1	4-Br-Phenyl	2-furanyl
166	1	3-CF_3-Phenyl	ethyl
167	1	3-CF_3-Phenyl	n-propyl
168	1	3-CF_3-Phenyl	isopropyl
169	1	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
170	1	3-CF_3-Phenyl	CF_3
171	1	3-CF_3-Phenyl	$-CH_2CF_3$
172	1	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
173	1	3-CF_3-Phenyl	cyclopropyl
174	1	3-CF_3-Phenyl	Cyclobutyl
175	1	3-CF_3-Phenyl	cyclopentyl
176	1	3-CF_3-Phenyl	cyclohexyl

177	1	3-CF_3-Phenyl	3-pyridyl
178	1	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
179	1	3-CF_3-Phenyl	1H-imidazol-4-yl
180	1	3-CF_3-Phenyl	2-furanyl
181	1	2-iPr-Phenyl	ethyl
182	1	2-iPr-Phenyl	n-propyl
183	1	2-iPr-Phenyl	isopropyl
184	1	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
185	1	2-iPr-Phenyl	CF_3
186	1	2-iPr-Phenyl	-CH_2CF_3
187	1	2-iPr-Phenyl	-$CH_2CH_2CF_3$
188	1	2-iPr-Phenyl	cyclopropyl
189	1	2-iPr-Phenyl	Cyclobutyl
190	1	2-iPr-Phenyl	cyclopentyl
191	1	2-iPr-Phenyl	cyclohexyl
192	1	2-iPr-Phenyl	3-pyridyl
193	1	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
194	1	2-iPr-Phenyl	1H-imidazol-4-yl
195	1	2-iPr-Phenyl	2-furanyl
196	1	4-iPr-Phenyl	ethyl
197	1	4-iPr-Phenyl	n-propyl
198	1	4-iPr-Phenyl	isopropyl
199	1	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
200	1	4-iPr-Phenyl	CF_3
201	1	4-iPr-Phenyl	-CH_2CF_3
202	1	4-iPr-Phenyl	-$CH_2CH_2CF_3$
203	1	4-iPr-Phenyl	cyclopropyl
204	1	4-iPr-Phenyl	Cyclobutyl
205	1	4-iPr-Phenyl	cyclopentyl
206	1	4-iPr-Phenyl	cyclohexyl
207	1	4-iPr-Phenyl	3-pyridyl

208	1	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
209	1	4-iPr-Phenyl	1H-imidazol-4-yl
210	1	4-iPr-Phenyl	2-furanyl
211	1	3-morpholino-phenyl	ethyl
212	1	3-morpholino-phenyl	n-propyl
213	1	3-morpholino-phenyl	isopropyl
214	1	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
215	1	3-morpholino-phenyl	CF_3
216	1	3-morpholino-phenyl	$-CH_2CF_3$
217	1	3-morpholino-phenyl	$-CH_2CH_2CF_3$
218	1	3-morpholino-phenyl	cyclopropyl
219	1	3-morpholino-phenyl	Cyclobutyl
220	1	3-morpholino-phenyl	cyclopentyl
221	1	3-morpholino-phenyl	cyclohexyl
222	1	3-morpholino-phenyl	3-pyridyl
223	1	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
224	1	3-morpholino-phenyl	1H-imidazol-4-yl
225	1	3-morpholino-phenyl	2-furanyl
226	1	4-cyano-2-morpholino-phenyl	ethyl
227	1	4-cyano-2-morpholino-phenyl	n-propyl
228	1	4-cyano-2-morpholino-phenyl	isopropyl
229	1	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
230	1	4-cyano-2-morpholino-phenyl	CF_3
231	1	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
232	1	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
233	1	4-cyano-2-morpholino-phenyl	cyclopropyl
234	1	4-cyano-2-morpholino-phenyl	Cyclobutyl
235	1	4-cyano-2-morpholino-phenyl	cyclopentyl
236	1	4-cyano-2-morpholino-phenyl	cyclohexyl
237	1	4-cyano-2-morpholino-phenyl	3-pyridyl
238	1	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl

239	1	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
240	1	4-cyano-2-morpholino-phenyl	2-furanyl
241	1	4-hydroxy-2-morpholino-phenyl	ethyl
242	1	4-hydroxy-2-morpholino-phenyl	n-propyl
243	1	4-hydroxy-2-morpholino-phenyl	isopropyl
244	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
245	1	4-hydroxy-2-morpholino-phenyl	CF_3
246	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
247	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
248	1	4-hydroxy-2-morpholino-phenyl	cyclopropyl
249	1	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
250	1	4-hydroxy-2-morpholino-phenyl	cyclopentyl
251	1	4-hydroxy-2-morpholino-phenyl	cyclohexyl
252	1	4-hydroxy-2-morpholino-phenyl	3-pyridyl
253	1	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
254	1	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
255	1	4-hydroxy-2-morpholino-phenyl	2-furanyl
256	1	$2-CH_3$-phenyl	Ethyl
257	1	$2-CH_3$-phenyl	n-propyl
258	1	$2-CH_3$-phenyl	Isopropyl
259	1	$2-CH_3$-phenyl	$-CH_2CH(CH_3)_2$
260	1	$2-CH_3$-phenyl	CF_3
261	1	$2-CH_3$-phenyl	$-CH_2CF_3$
262	1	$2-CH_3$-phenyl	$-CH_2CH_2CF_3$
263	1	$2-CH_3$-phenyl	cyclopropyl
264	1	$2-CH_3$-phenyl	Cyclobutyl
265	1	$2-CH_3$-phenyl	cyclopentyl
266	1	$2-CH_3$-phenyl	cyclohexyl
267	1	$2-CH_3$-phenyl	3-pyridyl
268	1	$2-CH_3$-phenyl	1-methyl-1H-pyrazol-4-yl
269	1	$2-CH_3$-phenyl	1H-imidazol-4-yl

270	1	2-CH_3-phenyl	2-furanyl
271	1	4-OH-Phenyl	Ethyl
272	1	4-OH-Phenyl	n-propyl
273	1	4-OH-Phenyl	Isopropyl
274	1	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
275	1	4-OH-Phenyl	CF_3
276	1	4-OH-Phenyl	-CH_2CF_3
277	1	4-OH-Phenyl	-$CH_2CH_2CF_3$
278	1	4-OH-Phenyl	cyclopropyl
279	1	4-OH-Phenyl	Cyclobutyl
280	1	4-OH-Phenyl	cyclopentyl
281	1	4-OH-Phenyl	cyclohexyl
282	1	4-OH-Phenyl	3-pyridyl
283	1	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
284	1	4-OH-Phenyl	1H-imidazol-4-yl
285	1	4-OH-Phenyl	2-furanyl
286	1	2-OH-Phenyl	Ethyl
287	1	2-OH-Phenyl	n-propyl
288	1	2-OH-Phenyl	Isopropyl
289	1	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
290	1	2-OH-Phenyl	CF_3
291	1	2-OH-Phenyl	-CH_2CF_3
292	1	2-OH-Phenyl	-$CH_2CH_2CF_3$
293	1	2-OH-Phenyl	cyclopropyl
294	1	2-OH-Phenyl	Cyclobutyl
295	1	2-OH-Phenyl	cyclopentyl
296	1	2-OH-Phenyl	cyclohexyl
297	1	2-OH-Phenyl	3-pyridyl
298	1	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
299	1	2-OH-Phenyl	1H-imidazol-4-yl
300	1	2-OH-Phenyl	2-furanyl

301	1	3-OMe-Phenyl	Ethyl
302	1	3-OMe-Phenyl	n-propyl
303	1	3-OMe-Phenyl	Isopropyl
304	1	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
305	1	3-OMe-Phenyl	CF_3
306	1	3-OMe-Phenyl	$-CH_2CF_3$
307	1	3-OMe-Phenyl	$-CH_2CH_2CF_3$
308	1	3-OMe-Phenyl	cyclopropyl
309	1	3-OMe-Phenyl	Cyclobutyl
310	1	3-OMe-Phenyl	cyclopentyl
311	1	3-OMe-Phenyl	cyclohexyl
312	1	3-OMe-Phenyl	3-pyridyl
313	1	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
314	1	3-OMe-Phenyl	1H-imidazol-4-yl
315	1	3-OMe-Phenyl	2-furanyl
316	1	4-CN-Phenyl	Ethyl
317	1	4-CN-Phenyl	n-propyl
318	1	4-CN-Phenyl	Isopropyl
319	1	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
320	1	4-CN-Phenyl	CF_3
321	1	4-CN-Phenyl	$-CH_2CF_3$
322	1	4-CN-Phenyl	$-CH_2CH_2CF_3$
323	1	4-CN-Phenyl	cyclopropyl
324	1	4-CN-Phenyl	Cyclobutyl
325	1	4-CN-Phenyl	cyclopentyl
326	1	4-CN-Phenyl	cyclohexyl
327	1	4-CN-Phenyl	3-pyridyl
328	1	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
329	1	4-CN-Phenyl	1H-imidazol-4-yl
330	1	4-CN-Phenyl	2-furanyl
331	1	2-CN-Phenyl	Ethyl

332	1	2-CN-Phenyl	n-propyl
333	1	2-CN-Phenyl	Isopropyl
334	1	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
335	1	2-CN-Phenyl	CF_3
336	1	2-CN-Phenyl	$-CH_2CF_3$
337	1	2-CN-Phenyl	$-CH_2CH_2CF_3$
338	1	2-CN-Phenyl	cyclopropyl
339	1	2-CN-Phenyl	Cyclobutyl
340	1	2-CN-Phenyl	cyclopentyl
341	1	2-CN-Phenyl	cyclohexyl
342	1	2-CN-Phenyl	3-pyridyl
343	1	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
344	1	2-CN-Phenyl	1H-imidazol-4-yl
345	1	2-CN-Phenyl	2-furanyl
346	1	3-F-Phenyl	Ethyl
347	1	3-F-Phenyl	n-propyl
348	1	3-F-Phenyl	Isopropyl
349	1	3-F-Phenyl	$-CH_2CH(CH_3)_2$
350	1	3-F-Phenyl	CF_3
351	1	3-F-Phenyl	$-CH_2CF_3$
352	1	3-F-Phenyl	$-CH_2CH_2CF_3$
353	1	3-F-Phenyl	cyclopropyl
354	1	3-F-Phenyl	Cyclobutyl
355	1	3-F-Phenyl	cyclopentyl
356	1	3-F-Phenyl	cyclohexyl
357	1	3-F-Phenyl	3-pyridyl
358	1	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
359	1	3-F-Phenyl	1H-imidazol-4-yl
360	1	3-F-Phenyl	2-furanyl
361	1	2-Cl-Phenyl	Ethyl
362	1	2-Cl-Phenyl	n-propyl

363	1	2-Cl-Phenyl	Isopropyl
364	1	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
365	1	2-Cl-Phenyl	CF_3
366	1	2-Cl-Phenyl	$-CH_2CF_3$
367	1	2-Cl-Phenyl	$-CH_2CH_2CF_3$
368	1	2-Cl-Phenyl	cyclopropyl
369	1	2-Cl-Phenyl	Cyclobutyl
370	1	2-Cl-Phenyl	cyclopentyl
371	1	2-Cl-Phenyl	cyclohexyl
372	1	2-Cl-Phenyl	3-pyridyl
373	1	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
374	1	2-Cl-Phenyl	1H-imidazol-4-yl
375	1	2-Cl-Phenyl	2-furanyl
376	1	4-Cl-Phenyl	Ethyl
377	1	4-Cl-Phenyl	n-propyl
378	1	4-Cl-Phenyl	Isopropyl
379	1	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
380	1	4-Cl-Phenyl	CF_3
381	1	4-Cl-Phenyl	$-CH_2CF_3$
382	1	4-Cl-Phenyl	$-CH_2CH_2CF_3$
383	1	4-Cl-Phenyl	cyclopropyl
384	1	4-Cl-Phenyl	Cyclobutyl
385	1	4-Cl-Phenyl	cyclopentyl
386	1	4-Cl-Phenyl	cyclohexyl
387	1	4-Cl-Phenyl	3-pyridyl
388	1	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
389	1	4-Cl-Phenyl	1H-imidazol-4-yl
390	1	4-Cl-Phenyl	2-furanyl
391	1	3-Br-Phenyl	Ethyl
392	1	3-Br-Phenyl	n-propyl
393	1	3-Br-Phenyl	Isopropyl

394	1	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
395	1	3-Br-Phenyl	CF_3
396	1	3-Br-Phenyl	$-CH_2CF_3$
397	1	3-Br-Phenyl	$-CH_2CH_2CF_3$
398	1	3-Br-Phenyl	cyclopropyl
399	1	3-Br-Phenyl	Cyclobutyl
400	1	3-Br-Phenyl	cyclopentyl
401	1	3-Br-Phenyl	cyclohexyl
402	1	3-Br-Phenyl	3-pyridyl
403	1	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
404	1	3-Br-Phenyl	1H-imidazol-4-yl
405	1	3-Br-Phenyl	2-furanyl
406	1	2-CF_3-Phenyl	Ethyl
407	1	2-CF_3-Phenyl	n-propyl
408	1	2-CF_3-Phenyl	Isopropyl
409	1	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
410	1	2-CF_3-Phenyl	CF_3
411	1	2-CF_3-Phenyl	$-CH_2CF_3$
412	1	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
413	1	2-CF_3-Phenyl	cyclopropyl
414	1	2-CF_3-Phenyl	Cyclobutyl
415	1	2-CF_3-Phenyl	cyclopentyl
416	1	2-CF_3-Phenyl	cyclohexyl
417	1	2-CF_3-Phenyl	3-pyridyl
418	1	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
419	1	2-CF_3-Phenyl	1H-imidazol-4-yl
420	1	2-CF_3-Phenyl	2-furanyl
421	1	4-CF_3-Phenyl	Ethyl
422	1	4-CF_3-Phenyl	n-propyl
423	1	4-CF_3-Phenyl	Isopropyl
424	1	4-CF_3-Phenyl	$-CH_2CH(CH_3)_2$

425	1	4-CF_3-Phenyl	CF_3
426	1	4-CF_3-Phenyl	-CH_2CF_3
427	1	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
428	1	4-CF_3-Phenyl	cyclopropyl
429	1	4-CF_3-Phenyl	Cyclobutyl
430	1	4-CF_3-Phenyl	cyclopentyl
431	1	4-CF_3-Phenyl	cyclohexyl
432	1	4-CF_3-Phenyl	3-pyridyl
433	1	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
434	1	4-CF_3-Phenyl	1H-imidazol-4-yl
435	1	4-CF_3-Phenyl	2-furanyl
436	1	3-iPr-Phenyl	Ethyl
437	1	3-iPr-Phenyl	n-propyl
438	1	3-iPr-Phenyl	Isopropyl
439	1	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
440	1	3-iPr-Phenyl	CF_3
441	1	3-iPr-Phenyl	-CH_2CF_3
442	1	3-iPr-Phenyl	-$CH_2CH_2CF_3$
443	1	3-iPr-Phenyl	cyclopropyl
444	1	3-iPr-Phenyl	Cyclobutyl
445	1	3-iPr-Phenyl	cyclopentyl
446	1	3-iPr-Phenyl	cyclohexyl
447	1	3-iPr-Phenyl	3-pyridyl
448	1	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
449	1	3-iPr-Phenyl	1H-imidazol-4-yl
450	1	3-iPr-Phenyl	2-furanyl
451	1	2-morpholino-phenyl	Ethyl
452	1	2-morpholino-phenyl	n-propyl
453	1	2-morpholino-phenyl	isopropyl
454	1	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
455	1	2-morpholino-phenyl	CF_3

456	1	2-morpholino-phenyl	$-CH_2CF_3$
457	1	2-morpholino-phenyl	$-CH_2CH_2CF_3$
458	1	2-morpholino-phenyl	cyclopropyl
459	1	2-morpholino-phenyl	Cyclobutyl
460	1	2-morpholino-phenyl	cyclopentyl
461	1	2-morpholino-phenyl	cyclohexyl
462	1	2-morpholino-phenyl	3-pyridyl
463	1	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
464	1	2-morpholino-phenyl	1H-imidazol-4-yl
465	1	2-morpholino-phenyl	2-furanyl
466	1	4-morpholino-phenyl	ethyl
467	1	4-morpholino-phenyl	n-propyl
468	1	4-morpholino-phenyl	isopropyl
469	1	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
470	1	4-morpholino-phenyl	CF_3
471	1	4-morpholino-phenyl	$-CH_2CF_3$
472	1	4-morpholino-phenyl	$-CH_2CH_2CF_3$
473	1	4-morpholino-phenyl	cyclopropyl
474	1	4-morpholino-phenyl	Cyclobutyl
475	1	4-morpholino-phenyl	cyclopentyl
476	1	4-morpholino-phenyl	cyclohexyl
477	1	4-morpholino-phenyl	3-pyridyl
478	1	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
479	1	4-morpholino-phenyl	1H-imidazol-4-yl
480	1	4-morpholino-phenyl	2-furanyl
481	1	4-methyl-2-morpholino-phenyl	ethyl
482	1	4-methyl-2-morpholino-phenyl	n-propyl
483	1	4-methyl-2-morpholino-phenyl	isopropyl
484	1	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
485	1	4-methyl-2-morpholino-phenyl	CF_3
486	1	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$

487	1	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
488	1	4-methyl-2-morpholino-phenyl	cyclopropyl
489	1	4-methyl-2-morpholino-phenyl	Cyclobutyl
490	1	4-methyl-2-morpholino-phenyl	cyclopentyl
491	1	4-methyl-2-morpholino-phenyl	cyclohexyl
492	1	4-methyl-2-morpholino-phenyl	3-pyridyl
493	1	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
494	1	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
495	1	4-methyl-2-morpholino-phenyl	2-furanyl
496	2	4-CH_3-phenyl	ethyl
497	2	4-CH_3-phenyl	n-propyl
498	2	4-CH_3-phenyl	isopropyl
499	2	4-CH_3-phenyl	$-CH_2CH(CH_3)_2$
500	2	4-CH_3-phenyl	CF_3
501	2	4-CH_3-phenyl	$-CH_2CF_3$
502	2	4-CH_3-phenyl	$-CH_2CH_2CF_3$
503	2	4-CH_3-phenyl	cyclopropyl
504	2	4-CH_3-phenyl	Cyclobutyl
505	2	4-CH_3-phenyl	cyclopentyl
506	2	4-CH_3-phenyl	cyclohexyl
507	2	4-CH_3-phenyl	3-pyridyl
508	2	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
509	2	4-CH_3-phenyl	1H-imidazol-4-yl
510	2	4-CH_3-phenyl	2-furanyl
511	2	3-CH_3-phenyl	ethyl
512	2	3-CH_3-phenyl	n-propyl
513	2	3-CH_3-phenyl	isopropyl
514	2	3-CH_3-phenyl	$-CH_2CH(CH_3)_2$
515	2	3-CH_3-phenyl	CF_3
516	2	3-CH_3-phenyl	$-CH_2CF_3$
517	2	3-CH_3-phenyl	$-CH_2CH_2CF_3$

518	2	3-CH_3-phenyl	cyclopropyl
519	2	3-CH_3-phenyl	Cyclobutyl
520	2	3-CH_3-phenyl	cyclopentyl
521	2	3-CH_3-phenyl	cyclohexyl
522	2	3-CH_3-phenyl	3-pyridyl
523	2	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
524	2	3-CH_3-phenyl	1H-imidazol-4-yl
525	2	3-CH_3-phenyl	2-furanyl
526	2	3-OH-Phenyl	ethyl
527	2	3-OH-Phenyl	n-propyl
528	2	3-OH-Phenyl	isopropyl
529	2	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
530	2	3-OH-Phenyl	CF_3
531	2	3-OH-Phenyl	-CH_2CF_3
532	2	3-OH-Phenyl	-$CH_2CH_2CF_3$
533	2	3-OH-Phenyl	cyclopropyl
534	2	3-OH-Phenyl	Cyclobutyl
535	2	3-OH-Phenyl	cyclopentyl
536	2	3-OH-Phenyl	cyclohexyl
537	2	3-OH-Phenyl	3-pyridyl
538	2	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
539	2	3-OH-Phenyl	1H-imidazol-4-yl
540	2	3-OH-Phenyl	2-furanyl
541	2	4-OMe-Phenyl	ethyl
542	2	4-OMe-Phenyl	n-propyl
543	2	4-OMe-Phenyl	isopropyl
544	2	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
545	2	4-OMe-Phenyl	CF_3
546	2	4-OMe-Phenyl	-CH_2CF_3
547	2	4-OMe-Phenyl	-$CH_2CH_2CF_3$
548	2	4-OMe-Phenyl	cyclopropyl

549	2	4-OMe-Phenyl	Cyclobutyl
550	2	4-OMe-Phenyl	cyclopentyl
551	2	4-OMe-Phenyl	cyclohexyl
552	2	4-OMe-Phenyl	3-pyridyl
553	2	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
554	2	4-OMe-Phenyl	1H-imidazol-4-yl
555	2	4-OMe-Phenyl	2-furanyl
556	2	2-OMe-Phenyl	ethyl
557	2	2-OMe-Phenyl	n-propyl
558	2	2-OMe-Phenyl	isopropyl
559	2	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
560	2	2-OMe-Phenyl	CF_3
561	2	2-OMe-Phenyl	$-CH_2CF_3$
562	2	2-OMe-Phenyl	$-CH_2CH_2CF_3$
563	2	2-OMe-Phenyl	cyclopropyl
564	2	2-OMe-Phenyl	Cyclobutyl
565	2	2-OMe-Phenyl	cyclopentyl
566	2	2-OMe-Phenyl	cyclohexyl
567	2	2-OMe-Phenyl	3-pyridyl
568	2	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
569	2	2-OMe-Phenyl	1H-imidazol-4-yl
570	2	2-OMe-Phenyl	2-furanyl
571	2	3-CN-Phenyl	ethyl
572	2	3-CN-Phenyl	n-propyl
573	2	3-CN-Phenyl	isopropyl
574	2	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
575	2	3-CN-Phenyl	CF_3
576	2	3-CN-Phenyl	$-CH_2CF_3$
577	2	3-CN-Phenyl	$-CH_2CH_2CF_3$
578	2	3-CN-Phenyl	cyclopropyl
579	2	3-CN-Phenyl	Cyclobutyl

580	2	3-CN-Phenyl	cyclopentyl
581	2	3-CN-Phenyl	cyclohexyl
582	2	3-CN-Phenyl	3-pyridyl
583	2	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
584	2	3-CN-Phenyl	1H-imidazol-4-yl
585	2	3-CN-Phenyl	2-furanyl
586	2	2-F-Phenyl	ethyl
587	2	2-F-Phenyl	n-propyl
588	2	2-F-Phenyl	isopropyl
589	2	2-F-Phenyl	$-CH_2CH(CH_3)_2$
590	2	2-F-Phenyl	CF_3
591	2	2-F-Phenyl	$-CH_2CF_3$
592	2	2-F-Phenyl	$-CH_2CH_2CF_3$
593	2	2-F-Phenyl	cyclopropyl
594	2	2-F-Phenyl	Cyclobutyl
595	2	2-F-Phenyl	cyclopentyl
596	2	2-F-Phenyl	cyclohexyl
597	2	2-F-Phenyl	3-pyridyl
598	2	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
599	2	2-F-Phenyl	1H-imidazol-4-yl
600	2	2-F-Phenyl	2-furanyl
601	2	4-F-Phenyl	ethyl
602	2	4-F-Phenyl	n-propyl
603	2	4-F-Phenyl	isopropyl
604	2	4-F-Phenyl	$-CH_2CH(CH_3)_2$
605	2	4-F-Phenyl	CF_3
606	2	4-F-Phenyl	$-CH_2CF_3$
607	2	4-F-Phenyl	$-CH_2CH_2CF_3$
608	2	4-F-Phenyl	cyclopropyl
609	2	4-F-Phenyl	Cyclobutyl
610	2	4-F-Phenyl	cyclopentyl

611	2	4-F-Phenyl	cyclohexyl
612	2	4-F-Phenyl	3-pyridyl
613	2	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
614	2	4-F-Phenyl	1H-imidazol-4-yl
615	2	4-F-Phenyl	2-furanyl
616	2	3-Cl-Phenyl	ethyl
617	2	3-Cl-Phenyl	n-propyl
618	2	3-Cl-Phenyl	isopropyl
619	2	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
620	2	3-Cl-Phenyl	CF_3
621	2	3-Cl-Phenyl	$-CH_2CF_3$
622	2	3-Cl-Phenyl	$-CH_2CH_2CF_3$
623	2	3-Cl-Phenyl	cyclopropyl
624	2	3-Cl-Phenyl	Cyclobutyl
625	2	3-Cl-Phenyl	cyclopentyl
626	2	3-Cl-Phenyl	cyclohexyl
627	2	3-Cl-Phenyl	3-pyridyl
628	2	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
629	2	3-Cl-Phenyl	1H-imidazol-4-yl
630	2	3-Cl-Phenyl	2-furanyl
631	2	2-Br-Phenyl	ethyl
632	2	2-Br-Phenyl	n-propyl
633	2	2-Br-Phenyl	isopropyl
634	2	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
635	2	2-Br-Phenyl	CF_3
636	2	2-Br-Phenyl	$-CH_2CF_3$
637	2	2-Br-Phenyl	$-CH_2CH_2CF_3$
638	2	2-Br-Phenyl	cyclopropyl
639	2	2-Br-Phenyl	Cyclobutyl
640	2	2-Br-Phenyl	cyclopentyl
641	2	2-Br-Phenyl	cyclohexyl

642	2	2-Br-Phenyl	3-pyridyl
643	2	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
644	2	2-Br-Phenyl	1H-imidazol-4-yl
645	2	2-Br-Phenyl	2-furanyl
646	2	4-Br-Phenyl	ethyl
647	2	4-Br-Phenyl	n-propyl
648	2	4-Br-Phenyl	isopropyl
649	2	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
650	2	4-Br-Phenyl	CF_3
651	2	4-Br-Phenyl	$-CH_2CF_3$
652	2	4-Br-Phenyl	$-CH_2CH_2CF_3$
653	2	4-Br-Phenyl	cyclopropyl
654	2	4-Br-Phenyl	Cyclobutyl
655	2	4-Br-Phenyl	cyclopentyl
656	2	4-Br-Phenyl	cyclohexyl
657	2	4-Br-Phenyl	3-pyridyl
658	2	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
659	2	4-Br-Phenyl	1H-imidazol-4-yl
660	2	4-Br-Phenyl	2-furanyl
661	2	3-CF_3-Phenyl	ethyl
662	2	3-CF_3-Phenyl	n-propyl
663	2	3-CF_3-Phenyl	isopropyl
664	2	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
665	2	3-CF_3-Phenyl	CF_3
666	2	3-CF_3-Phenyl	$-CH_2CF_3$
667	2	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
668	2	3-CF_3-Phenyl	cyclopropyl
669	2	3-CF_3-Phenyl	Cyclobutyl
670	2	3-CF_3-Phenyl	cyclopentyl
671	2	3-CF_3-Phenyl	cyclohexyl
672	2	3-CF_3-Phenyl	3-pyridyl

673	2	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
674	2	3-CF_3-Phenyl	1H-imidazol-4-yl
675	2	3-CF_3-Phenyl	2-furanyl
676	2	2-iPr-Phenyl	ethyl
677	2	2-iPr-Phenyl	n-propyl
678	2	2-iPr-Phenyl	isopropyl
679	2	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
680	2	2-iPr-Phenyl	CF_3
681	2	2-iPr-Phenyl	-CH_2CF_3
682	2	2-iPr-Phenyl	-$CH_2CH_2CF_3$
683	2	2-iPr-Phenyl	cyclopropyl
684	2	2-iPr-Phenyl	Cyclobutyl
685	2	2-iPr-Phenyl	cyclopentyl
686	2	2-iPr-Phenyl	cyclohexyl
687	2	2-iPr-Phenyl	3-pyridyl
688	2	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
689	2	2-iPr-Phenyl	1H-imidazol-4-yl
690	2	2-iPr-Phenyl	2-furanyl
691	2	4-iPr-Phenyl	ethyl
692	2	4-iPr-Phenyl	n-propyl
693	2	4-iPr-Phenyl	isopropyl
694	2	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
695	2	4-iPr-Phenyl	CF_3
696	2	4-iPr-Phenyl	-CH_2CF_3
697	2	4-iPr-Phenyl	-$CH_2CH_2CF_3$
698	2	4-iPr-Phenyl	cyclopropyl
699	2	4-iPr-Phenyl	Cyclobutyl
700	2	4-iPr-Phenyl	cyclopentyl
701	2	4-iPr-Phenyl	cyclohexyl
702	2	4-iPr-Phenyl	3-pyridyl
703	2	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl

704	2	4-iPr-Phenyl	1H-imidazol-4-yl
705	2	4-iPr-Phenyl	2-furanyl
706	2	3-morpholino-phenyl	ethyl
707	2	3-morpholino-phenyl	n-propyl
708	2	3-morpholino-phenyl	isopropyl
709	2	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
710	2	3-morpholino-phenyl	CF_3
711	2	3-morpholino-phenyl	$-CH_2CF_3$
712	2	3-morpholino-phenyl	$-CH_2CH_2CF_3$
713	2	3-morpholino-phenyl	cyclopropyl
714	2	3-morpholino-phenyl	Cyclobutyl
715	2	3-morpholino-phenyl	cyclopentyl
716	2	3-morpholino-phenyl	cyclohexyl
717	2	3-morpholino-phenyl	3-pyridyl
718	2	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
719	2	3-morpholino-phenyl	1H-imidazol-4-yl
720	2	3-morpholino-phenyl	2-furanyl
721	2	4-cyano-2-morpholino-phenyl	ethyl
722	2	4-cyano-2-morpholino-phenyl	n-propyl
723	2	4-cyano-2-morpholino-phenyl	isopropyl
724	2	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
725	2	4-cyano-2-morpholino-phenyl	CF_3
726	2	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
727	2	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
728	2	4-cyano-2-morpholino-phenyl	cyclopropyl
729	2	4-cyano-2-morpholino-phenyl	Cyclobutyl
730	2	4-cyano-2-morpholino-phenyl	cyclopentyl
731	2	4-cyano-2-morpholino-phenyl	cyclohexyl
732	2	4-cyano-2-morpholino-phenyl	3-pyridyl
733	2	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
734	2	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl

735	2	4-cyano-2-morpholino-phenyl	2-furanyl
736	2	4-hydroxy-2-morpholino-phenyl	ethyl
737	2	4-hydroxy-2-morpholino-phenyl	n-propyl
738	2	4-hydroxy-2-morpholino-phenyl	isopropyl
739	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
740	2	4-hydroxy-2-morpholino-phenyl	CF_3
741	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
742	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
743	2	4-hydroxy-2-morpholino-phenyl	cyclopropyl
744	2	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
745	2	4-hydroxy-2-morpholino-phenyl	cyclopentyl
746	2	4-hydroxy-2-morpholino-phenyl	cyclohexyl
747	2	4-hydroxy-2-morpholino-phenyl	3-pyridyl
748	2	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
749	2	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
750	2	4-hydroxy-2-morpholino-phenyl	2-furanyl
751	2	2-CH_3-phenyl	Ethyl
752	2	2-CH_3-phenyl	n-propyl
753	2	2-CH_3-phenyl	Isopropyl
754	2	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
755	2	2-CH_3-phenyl	CF_3
756	2	2-CH_3-phenyl	$-CH_2CF_3$
757	2	2-CH_3-phenyl	$-CH_2CH_2CF_3$
758	2	2-CH_3-phenyl	cyclopropyl
759	2	2-CH_3-phenyl	Cyclobutyl
760	2	2-CH_3-phenyl	cyclopentyl
761	2	2-CH_3-phenyl	cyclohexyl
762	2	2-CH_3-phenyl	3-pyridyl
763	2	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
764	2	2-CH_3-phenyl	1H-imidazol-4-yl
765	2	2-CH_3-phenyl	2-furanyl

766	2	4-OH-Phenyl	Ethyl
767	2	4-OH-Phenyl	n-propyl
768	2	4-OH-Phenyl	Isopropyl
769	2	4-OH-Phenyl	$-CH_2CH(CH_3)_2$
770	2	4-OH-Phenyl	CF_3
771	2	4-OH-Phenyl	$-CH_2CF_3$
772	2	4-OH-Phenyl	$-CH_2CH_2CF_3$
773	2	4-OH-Phenyl	cyclopropyl
774	2	4-OH-Phenyl	Cyclobutyl
775	2	4-OH-Phenyl	cyclopentyl
776	2	4-OH-Phenyl	cyclohexyl
777	2	4-OH-Phenyl	3-pyridyl
778	2	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
779	2	4-OH-Phenyl	1H-imidazol-4-yl
780	2	4-OH-Phenyl	2-furanyl
781	2	2-OH-Phenyl	Ethyl
782	2	2-OH-Phenyl	n-propyl
783	2	2-OH-Phenyl	Isopropyl
784	2	2-OH-Phenyl	$-CH_2CH(CH_3)_2$
785	2	2-OH-Phenyl	CF_3
786	2	2-OH-Phenyl	$-CH_2CF_3$
787	2	2-OH-Phenyl	$-CH_2CH_2CF_3$
788	2	2-OH-Phenyl	cyclopropyl
789	2	2-OH-Phenyl	Cyclobutyl
790	2	2-OH-Phenyl	cyclopentyl
791	2	2-OH-Phenyl	cyclohexyl
792	2	2-OH-Phenyl	3-pyridyl
793	2	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
794	2	2-OH-Phenyl	1H-imidazol-4-yl
795	2	2-OH-Phenyl	2-furanyl
796	2	3-OMe-Phenyl	Ethyl

797	2	3-OMe-Phenyl	n-propyl
798	2	3-OMe-Phenyl	Isopropyl
799	2	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
800	2	3-OMe-Phenyl	CF_3
801	2	3-OMe-Phenyl	$-CH_2CF_3$
802	2	3-OMe-Phenyl	$-CH_2CH_2CF_3$
803	2	3-OMe-Phenyl	cyclopropyl
804	2	3-OMe-Phenyl	Cyclobutyl
805	2	3-OMe-Phenyl	cyclopentyl
806	2	3-OMe-Phenyl	cyclohexyl
807	2	3-OMe-Phenyl	3-pyridyl
808	2	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
809	2	3-OMe-Phenyl	1H-imidazol-4-yl
810	2	3-OMe-Phenyl	2-furanyl
811	2	4-CN-Phenyl	Ethyl
812	2	4-CN-Phenyl	n-propyl
813	2	4-CN-Phenyl	Isopropyl
814	2	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
815	2	4-CN-Phenyl	CF_3
816	2	4-CN-Phenyl	$-CH_2CF_3$
817	2	4-CN-Phenyl	$-CH_2CH_2CF_3$
818	2	4-CN-Phenyl	cyclopropyl
819	2	4-CN-Phenyl	Cyclobutyl
820	2	4-CN-Phenyl	cyclopentyl
821	2	4-CN-Phenyl	cyclohexyl
822	2	4-CN-Phenyl	3-pyridyl
823	2	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
824	2	4-CN-Phenyl	1H-imidazol-4-yl
825	2	4-CN-Phenyl	2-furanyl
826	2	2-CN-Phenyl	Ethyl
827	2	2-CN-Phenyl	n-propyl

828	2	2-CN-Phenyl	Isopropyl
829	2	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
830	2	2-CN-Phenyl	CF_3
831	2	2-CN-Phenyl	$-CH_2CF_3$
832	2	2-CN-Phenyl	$-CH_2CH_2CF_3$
833	2	2-CN-Phenyl	cyclopropyl
834	2	2-CN-Phenyl	Cyclobutyl
835	2	2-CN-Phenyl	cyclopentyl
836	2	2-CN-Phenyl	cyclohexyl
837	2	2-CN-Phenyl	3-pyridyl
838	2	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
839	2	2-CN-Phenyl	1H-imidazol-4-yl
840	2	2-CN-Phenyl	2-furanyl
841	2	3-F-Phenyl	Ethyl
842	2	3-F-Phenyl	n-propyl
843	2	3-F-Phenyl	Isopropyl
844	2	3-F-Phenyl	$-CH_2CH(CH_3)_2$
845	2	3-F-Phenyl	CF_3
846	2	3-F-Phenyl	$-CH_2CF_3$
847	2	3-F-Phenyl	$-CH_2CH_2CF_3$
848	2	3-F-Phenyl	cyclopropyl
849	2	3-F-Phenyl	Cyclobutyl
850	2	3-F-Phenyl	cyclopentyl
851	2	3-F-Phenyl	cyclohexyl
852	2	3-F-Phenyl	3-pyridyl
853	2	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
854	2	3-F-Phenyl	1H-imidazol-4-yl
855	2	3-F-Phenyl	2-furanyl
856	2	2-Cl-Phenyl	Ethyl
857	2	2-Cl-Phenyl	n-propyl
858	2	2-Cl-Phenyl	Isopropyl

859	2	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
860	2	2-Cl-Phenyl	CF_3
861	2	2-Cl-Phenyl	$-CH_2CF_3$
862	2	2-Cl-Phenyl	$-CH_2CH_2CF_3$
863	2	2-Cl-Phenyl	cyclopropyl
864	2	2-Cl-Phenyl	Cyclobutyl
865	2	2-Cl-Phenyl	cyclopentyl
866	2	2-Cl-Phenyl	cyclohexyl
867	2	2-Cl-Phenyl	3-pyridyl
868	2	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
869	2	2-Cl-Phenyl	1H-imidazol-4-yl
870	2	2-Cl-Phenyl	2-furanyl
871	2	4-Cl-Phenyl	Ethyl
872	2	4-Cl-Phenyl	n-propyl
873	2	4-Cl-Phenyl	Isopropyl
874	2	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
875	2	4-Cl-Phenyl	CF_3
876	2	4-Cl-Phenyl	$-CH_2CF_3$
877	2	4-Cl-Phenyl	$-CH_2CH_2CF_3$
878	2	4-Cl-Phenyl	cyclopropyl
879	2	4-Cl-Phenyl	Cyclobutyl
880	2	4-Cl-Phenyl	cyclopentyl
881	2	4-Cl-Phenyl	cyclohexyl
882	2	4-Cl-Phenyl	3-pyridyl
883	2	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
884	2	4-Cl-Phenyl	1H-imidazol-4-yl
885	2	4-Cl-Phenyl	2-furanyl
886	2	3-Br-Phenyl	Ethyl
887	2	3-Br-Phenyl	n-propyl
888	2	3-Br-Phenyl	Isopropyl
889	2	3-Br-Phenyl	$-CH_2CH(CH_3)_2$

890	2	3-Br-Phenyl	CF_3
891	2	3-Br-Phenyl	$-CH_2CF_3$
892	2	3-Br-Phenyl	$-CH_2CH_2CF_3$
893	2	3-Br-Phenyl	cyclopropyl
894	2	3-Br-Phenyl	Cyclobutyl
895	2	3-Br-Phenyl	cyclopentyl
896	2	3-Br-Phenyl	cyclohexyl
897	2	3-Br-Phenyl	3-pyridyl
898	2	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
899	2	3-Br-Phenyl	1H-imidazol-4-yl
900	2	3-Br-Phenyl	2-furanyl
901	2	2-CF_3-Phenyl	Ethyl
902	2	2-CF_3-Phenyl	n-propyl
903	2	2-CF_3-Phenyl	Isopropyl
904	2	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
905	2	2-CF_3-Phenyl	CF_3
906	2	2-CF_3-Phenyl	$-CH_2CF_3$
907	2	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
908	2	2-CF_3-Phenyl	cyclopropyl
909	2	2-CF_3-Phenyl	Cyclobutyl
910	2	2-CF_3-Phenyl	cyclopentyl
911	2	2-CF_3-Phenyl	cyclohexyl
912	2	2-CF_3-Phenyl	3-pyridyl
913	2	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
914	2	2-CF_3-Phenyl	1H-imidazol-4-yl
915	2	2-CF_3-Phenyl	2-furanyl
916	2	4-CF_3-Phenyl	Ethyl
917	2	4-CF_3-Phenyl	n-propyl
918	2	4-CF_3-Phenyl	Isopropyl
919	2	4-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
920	2	4-CF_3-Phenyl	CF_3

921	2	4-CF_3-Phenyl	-CH_2CF_3
922	2	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
923	2	4-CF_3-Phenyl	cyclopropyl
924	2	4-CF_3-Phenyl	Cyclobutyl
925	2	4-CF_3-Phenyl	cyclopentyl
926	2	4-CF_3-Phenyl	cyclohexyl
927	2	4-CF_3-Phenyl	3-pyridyl
928	2	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
929	2	4-CF_3-Phenyl	1H-imidazol-4-yl
930	2	4-CF_3-Phenyl	2-furanyl
931	2	3-iPr-Phenyl	Ethyl
932	2	3-iPr-Phenyl	n-propyl
933	2	3-iPr-Phenyl	Isopropyl
934	2	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
935	2	3-iPr-Phenyl	CF_3
936	2	3-iPr-Phenyl	-CH_2CF_3
937	2	3-iPr-Phenyl	-$CH_2CH_2CF_3$
938	2	3-iPr-Phenyl	cyclopropyl
939	2	3-iPr-Phenyl	Cyclobutyl
940	2	3-iPr-Phenyl	cyclopentyl
941	2	3-iPr-Phenyl	cyclohexyl
942	2	3-iPr-Phenyl	3-pyridyl
943	2	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
944	2	3-iPr-Phenyl	1H-imidazol-4-yl
945	2	3-iPr-Phenyl	2-furanyl
946	2	2-morpholino-phenyl	Ethyl
947	2	2-morpholino-phenyl	n-propyl
948	2	2-morpholino-phenyl	isopropyl
949	2	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
950	2	2-morpholino-phenyl	CF_3
951	2	2-morpholino-phenyl	-CH_2CF_3

952	2	2-morpholino-phenyl	$-CH_2CH_2CF_3$
953	2	2-morpholino-phenyl	cyclopropyl
954	2	2-morpholino-phenyl	Cyclobutyl
955	2	2-morpholino-phenyl	cyclopentyl
956	2	2-morpholino-phenyl	cyclohexyl
957	2	2-morpholino-phenyl	3-pyridyl
958	2	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
959	2	2-morpholino-phenyl	1H-imidazol-4-yl
960	2	2-morpholino-phenyl	2-furanyl
961	2	4-morpholino-phenyl	ethyl
962	2	4-morpholino-phenyl	n-propyl
963	2	4-morpholino-phenyl	isopropyl
964	2	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
965	2	4-morpholino-phenyl	CF_3
966	2	4-morpholino-phenyl	$-CH_2CF_3$
967	2	4-morpholino-phenyl	$-CH_2CH_2CF_3$
968	2	4-morpholino-phenyl	cyclopropyl
969	2	4-morpholino-phenyl	Cyclobutyl
970	2	4-morpholino-phenyl	cyclopentyl
971	2	4-morpholino-phenyl	cyclohexyl
972	2	4-morpholino-phenyl	3-pyridyl
973	2	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
974	2	4-morpholino-phenyl	1H-imidazol-4-yl
975	2	4-morpholino-phenyl	2-furanyl
976	2	4-methyl-2-morpholino-phenyl	ethyl
977	2	4-methyl-2-morpholino-phenyl	n-propyl
978	2	4-methyl-2-morpholino-phenyl	isopropyl
979	2	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
980	2	4-methyl-2-morpholino-phenyl	CF_3
981	2	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
982	2	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$

983	2	4-methyl-2-morpholino-phenyl	cyclopropyl
984	2	4-methyl-2-morpholino-phenyl	Cyclobutyl
985	2	4-methyl-2-morpholino-phenyl	cyclopentyl
986	2	4-methyl-2-morpholino-phenyl	cyclohexyl
987	2	4-methyl-2-morpholino-phenyl	3-pyridyl
988	2	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
989	2	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
990	2	4-methyl-2-morpholino-phenyl	2-furanyl
991	3	4-CH_3-phenyl	ethyl
992	3	4-CH_3-phenyl	n-propyl
993	3	4-CH_3-phenyl	isopropyl
994	3	4-CH_3-phenyl	-$CH_2CH(CH_3)_2$
995	3	4-CH_3-phenyl	CF_3
996	3	4-CH_3-phenyl	-CH_2CF_3
997	3	4-CH_3-phenyl	-$CH_2CH_2CF_3$
998	3	4-CH_3-phenyl	cyclopropyl
999	3	4-CH_3-phenyl	Cyclobutyl
1000	3	4-CH_3-phenyl	cyclopentyl
1001	3	4-CH_3-phenyl	cyclohexyl
1002	3	4-CH_3-phenyl	3-pyridyl
1003	3	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1004	3	4-CH_3-phenyl	1H-imidazol-4-yl
1005	3	4-CH_3-phenyl	2-furanyl
1006	3	3-CH_3-phenyl	ethyl
1007	3	3-CH_3-phenyl	n-propyl
1008	3	3-CH_3-phenyl	isopropyl
1009	3	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1010	3	3-CH_3-phenyl	CF_3
1011	3	3-CH_3-phenyl	-CH_2CF_3
1012	3	3-CH_3-phenyl	-$CH_2CH_2CF_3$
1013	3	3-CH_3-phenyl	cyclopropyl

1014	3	3-CH_3-phenyl	Cyclobutyl
1015	3	3-CH_3-phenyl	cyclopentyl
1016	3	3-CH_3-phenyl	cyclohexyl
1017	3	3-CH_3-phenyl	3-pyridyl
1018	3	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1019	3	3-CH_3-phenyl	1H-imidazol-4-yl
1020	3	3-CH_3-phenyl	2-furanyl
1021	3	3-OH-Phenyl	ethyl
1022	3	3-OH-Phenyl	n-propyl
1023	3	3-OH-Phenyl	isopropyl
1024	3	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
1025	3	3-OH-Phenyl	CF_3
1026	3	3-OH-Phenyl	-CH_2CF_3
1027	3	3-OH-Phenyl	-$CH_2CH_2CF_3$
1028	3	3-OH-Phenyl	cyclopropyl
1029	3	3-OH-Phenyl	Cyclobutyl
1030	3	3-OH-Phenyl	cyclopentyl
1031	3	3-OH-Phenyl	cyclohexyl
1032	3	3-OH-Phenyl	3-pyridyl
1033	3	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1034	3	3-OH-Phenyl	1H-imidazol-4-yl
1035	3	3-OH-Phenyl	2-furanyl
1036	3	4-OMe-Phenyl	ethyl
1037	3	4-OMe-Phenyl	n-propyl
1038	3	4-OMe-Phenyl	isopropyl
1039	3	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1040	3	4-OMe-Phenyl	CF_3
1041	3	4-OMe-Phenyl	-CH_2CF_3
1042	3	4-OMe-Phenyl	-$CH_2CH_2CF_3$
1043	3	4-OMe-Phenyl	cyclopropyl
1044	3	4-OMe-Phenyl	Cyclobutyl

1045	3	4-OMe-Phenyl	cyclopentyl
1046	3	4-OMe-Phenyl	cyclohexyl
1047	3	4-OMe-Phenyl	3-pyridyl
1048	3	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1049	3	4-OMe-Phenyl	1H-imidazol-4-yl
1050	3	4-OMe-Phenyl	2-furanyl
1051	3	2-OMe-Phenyl	ethyl
1052	3	2-OMe-Phenyl	n-propyl
1053	3	2-OMe-Phenyl	isopropyl
1054	3	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1055	3	2-OMe-Phenyl	CF_3
1056	3	2-OMe-Phenyl	$-CH_2CF_3$
1057	3	2-OMe-Phenyl	$-CH_2CH_2CF_3$
1058	3	2-OMe-Phenyl	cyclopropyl
1059	3	2-OMe-Phenyl	Cyclobutyl
1060	3	2-OMe-Phenyl	cyclopentyl
1061	3	2-OMe-Phenyl	cyclohexyl
1062	3	2-OMe-Phenyl	3-pyridyl
1063	3	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1064	3	2-OMe-Phenyl	1H-imidazol-4-yl
1065	3	2-OMe-Phenyl	2-furanyl
1066	3	3-CN-Phenyl	ethyl
1067	3	3-CN-Phenyl	n-propyl
1068	3	3-CN-Phenyl	isopropyl
1069	3	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
1070	3	3-CN-Phenyl	CF_3
1071	3	3-CN-Phenyl	$-CH_2CF_3$
1072	3	3-CN-Phenyl	$-CH_2CH_2CF_3$
1073	3	3-CN-Phenyl	cyclopropyl
1074	3	3-CN-Phenyl	Cyclobutyl
1075	3	3-CN-Phenyl	cyclopentyl

1076	3	3-CN-Phenyl	cyclohexyl
1077	3	3-CN-Phenyl	3-pyridyl
1078	3	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1079	3	3-CN-Phenyl	1H-imidazol-4-yl
1080	3	3-CN-Phenyl	2-furanyl
1081	3	2-F-Phenyl	ethyl
1082	3	2-F-Phenyl	n-propyl
1083	3	2-F-Phenyl	isopropyl
1084	3	2-F-Phenyl	$-CH_2CH(CH_3)_2$
1085	3	2-F-Phenyl	CF_3
1086	3	2-F-Phenyl	$-CH_2CF_3$
1087	3	2-F-Phenyl	$-CH_2CH_2CF_3$
1088	3	2-F-Phenyl	cyclopropyl
1089	3	2-F-Phenyl	Cyclobutyl
1090	3	2-F-Phenyl	cyclopentyl
1091	3	2-F-Phenyl	cyclohexyl
1092	3	2-F-Phenyl	3-pyridyl
1093	3	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1094	3	2-F-Phenyl	1H-imidazol-4-yl
1095	3	2-F-Phenyl	2-furanyl
1096	3	4-F-Phenyl	ethyl
1097	3	4-F-Phenyl	n-propyl
1098	3	4-F-Phenyl	isopropyl
1099	3	4-F-Phenyl	$-CH_2CH(CH_3)_2$
1100	3	4-F-Phenyl	CF_3
1101	3	4-F-Phenyl	$-CH_2CF_3$
1102	3	4-F-Phenyl	$-CH_2CH_2CF_3$
1103	3	4-F-Phenyl	cyclopropyl
1104	3	4-F-Phenyl	Cyclobutyl
1105	3	4-F-Phenyl	cyclopentyl
1106	3	4-F-Phenyl	cyclohexyl

1107	3	4-F-Phenyl	3-pyridyl
1108	3	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1109	3	4-F-Phenyl	1H-imidazol-4-yl
1110	3	4-F-Phenyl	2-furanyl
1111	3	3-Cl-Phenyl	ethyl
1112	3	3-Cl-Phenyl	n-propyl
1113	3	3-Cl-Phenyl	isopropyl
1114	3	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1115	3	3-Cl-Phenyl	CF_3
1116	3	3-Cl-Phenyl	$-CH_2CF_3$
1117	3	3-Cl-Phenyl	$-CH_2CH_2CF_3$
1118	3	3-Cl-Phenyl	cyclopropyl
1119	3	3-Cl-Phenyl	Cyclobutyl
1120	3	3-Cl-Phenyl	cyclopentyl
1121	3	3-Cl-Phenyl	cyclohexyl
1122	3	3-Cl-Phenyl	3-pyridyl
1123	3	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1124	3	3-Cl-Phenyl	1H-imidazol-4-yl
1125	3	3-Cl-Phenyl	2-furanyl
1126	3	2-Br-Phenyl	ethyl
1127	3	2-Br-Phenyl	n-propyl
1128	3	2-Br-Phenyl	isopropyl
1129	3	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
1130	3	2-Br-Phenyl	CF_3
1131	3	2-Br-Phenyl	$-CH_2CF_3$
1132	3	2-Br-Phenyl	$-CH_2CH_2CF_3$
1133	3	2-Br-Phenyl	cyclopropyl
1134	3	2-Br-Phenyl	Cyclobutyl
1135	3	2-Br-Phenyl	cyclopentyl
1136	3	2-Br-Phenyl	cyclohexyl
1137	3	2-Br-Phenyl	3-pyridyl

1138	3	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1139	3	2-Br-Phenyl	1H-imidazol-4-yl
1140	3	2-Br-Phenyl	2-furanyl
1141	3	4-Br-Phenyl	ethyl
1142	3	4-Br-Phenyl	n-propyl
1143	3	4-Br-Phenyl	isopropyl
1144	3	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
1145	3	4-Br-Phenyl	CF_3
1146	3	4-Br-Phenyl	$-CH_2CF_3$
1147	3	4-Br-Phenyl	$-CH_2CH_2CF_3$
1148	3	4-Br-Phenyl	cyclopropyl
1149	3	4-Br-Phenyl	Cyclobutyl
1150	3	4-Br-Phenyl	cyclopentyl
1151	3	4-Br-Phenyl	cyclohexyl
1152	3	4-Br-Phenyl	3-pyridyl
1153	3	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1154	3	4-Br-Phenyl	1H-imidazol-4-yl
1155	3	4-Br-Phenyl	2-furanyl
1156	3	3-CF_3-Phenyl	ethyl
1157	3	3-CF_3-Phenyl	n-propyl
1158	3	3-CF_3-Phenyl	isopropyl
1159	3	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1160	3	3-CF_3-Phenyl	CF_3
1161	3	3-CF_3-Phenyl	$-CH_2CF_3$
1162	3	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
1163	3	3-CF_3-Phenyl	cyclopropyl
1164	3	3-CF_3-Phenyl	Cyclobutyl
1165	3	3-CF_3-Phenyl	cyclopentyl
1166	3	3-CF_3-Phenyl	cyclohexyl
1167	3	3-CF_3-Phenyl	3-pyridyl
1168	3	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl

1169	3	3-CF_3-Phenyl	1H-imidazol-4-yl
1170	3	3-CF_3-Phenyl	2-furanyl
1171	3	2-iPr-Phenyl	ethyl
1172	3	2-iPr-Phenyl	n-propyl
1173	3	2-iPr-Phenyl	isopropyl
1174	3	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1175	3	2-iPr-Phenyl	CF_3
1176	3	2-iPr-Phenyl	-CH_2CF_3
1177	3	2-iPr-Phenyl	-$CH_2CH_2CF_3$
1178	3	2-iPr-Phenyl	cyclopropyl
1179	3	2-iPr-Phenyl	Cyclobutyl
1180	3	2-iPr-Phenyl	cyclopentyl
1181	3	2-iPr-Phenyl	cyclohexyl
1182	3	2-iPr-Phenyl	3-pyridyl
1183	3	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1184	3	2-iPr-Phenyl	1H-imidazol-4-yl
1185	3	2-iPr-Phenyl	2-furanyl
1186	3	4-iPr-Phenyl	ethyl
1187	3	4-iPr-Phenyl	n-propyl
1188	3	4-iPr-Phenyl	isopropyl
1189	3	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1190	3	4-iPr-Phenyl	CF_3
1191	3	4-iPr-Phenyl	-CH_2CF_3
1192	3	4-iPr-Phenyl	-$CH_2CH_2CF_3$
1193	3	4-iPr-Phenyl	cyclopropyl
1194	3	4-iPr-Phenyl	Cyclobutyl
1195	3	4-iPr-Phenyl	cyclopentyl
1196	3	4-iPr-Phenyl	cyclohexyl
1197	3	4-iPr-Phenyl	3-pyridyl
1198	3	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1199	3	4-iPr-Phenyl	1H-imidazol-4-yl

1200	3	4-iPr-Phenyl	2-furanyl
1201	3	3-morpholino-phenyl	ethyl
1202	3	3-morpholino-phenyl	n-propyl
1203	3	3-morpholino-phenyl	isopropyl
1204	3	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1205	3	3-morpholino-phenyl	CF_3
1206	3	3-morpholino-phenyl	$-CH_2CF_3$
1207	3	3-morpholino-phenyl	$-CH_2CH_2CF_3$
1208	3	3-morpholino-phenyl	cyclopropyl
1209	3	3-morpholino-phenyl	Cyclobutyl
1210	3	3-morpholino-phenyl	cyclopentyl
1211	3	3-morpholino-phenyl	cyclohexyl
1212	3	3-morpholino-phenyl	3-pyridyl
1213	3	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1214	3	3-morpholino-phenyl	1H-imidazol-4-yl
1215	3	3-morpholino-phenyl	2-furanyl
1216	3	4-cyano-2-morpholino-phenyl	ethyl
1217	3	4-cyano-2-morpholino-phenyl	n-propyl
1218	3	4-cyano-2-morpholino-phenyl	isopropyl
1219	3	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1220	3	4-cyano-2-morpholino-phenyl	CF_3
1221	3	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
1222	3	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1223	3	4-cyano-2-morpholino-phenyl	cyclopropyl
1224	3	4-cyano-2-morpholino-phenyl	Cyclobutyl
1225	3	4-cyano-2-morpholino-phenyl	cyclopentyl
1226	3	4-cyano-2-morpholino-phenyl	cyclohexyl
1227	3	4-cyano-2-morpholino-phenyl	3-pyridyl
1228	3	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1229	3	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
1230	3	4-cyano-2-morpholino-phenyl	2-furanyl

1231	3	4-hydroxy-2-morpholino-phenyl	ethyl
1232	3	4-hydroxy-2-morpholino-phenyl	n-propyl
1233	3	4-hydroxy-2-morpholino-phenyl	isopropyl
1234	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1235	3	4-hydroxy-2-morpholino-phenyl	CF_3
1236	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
1237	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1238	3	4-hydroxy-2-morpholino-phenyl	cyclopropyl
1239	3	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
1240	3	4-hydroxy-2-morpholino-phenyl	cyclopentyl
1241	3	4-hydroxy-2-morpholino-phenyl	cyclohexyl
1242	3	4-hydroxy-2-morpholino-phenyl	3-pyridyl
1243	3	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1244	3	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
1245	3	4-hydroxy-2-morpholino-phenyl	2-furanyl
1246	3	2-CH_3-phenyl	Ethyl
1247	3	2-CH_3-phenyl	n-propyl
1248	3	2-CH_3-phenyl	Isopropyl
1249	3	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1250	3	2-CH_3-phenyl	CF_3
1251	3	2-CH_3-phenyl	$-CH_2CF_3$
1252	3	2-CH_3-phenyl	$-CH_2CH_2CF_3$
1253	3	2-CH_3-phenyl	cyclopropyl
1254	3	2-CH_3-phenyl	Cyclobutyl
1255	3	2-CH_3-phenyl	cyclopentyl
1256	3	2-CH_3-phenyl	cyclohexyl
1257	3	2-CH_3-phenyl	3-pyridyl
1258	3	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1259	3	2-CH_3-phenyl	1H-imidazol-4-yl
1260	3	2-CH_3-phenyl	2-furanyl
1261	3	4-OH-Phenyl	Ethyl

1262	3	4-OH-Phenyl	n-propyl
1263	3	4-OH-Phenyl	Isopropyl
1264	3	4-OH-Phenyl	$-CH_2CH(CH_3)_2$
1265	3	4-OH-Phenyl	CF_3
1266	3	4-OH-Phenyl	$-CH_2CF_3$
1267	3	4-OH-Phenyl	$-CH_2CH_2CF_3$
1268	3	4-OH-Phenyl	cyclopropyl
1269	3	4-OH-Phenyl	Cyclobutyl
1270	3	4-OH-Phenyl	cyclopentyl
1271	3	4-OH-Phenyl	cyclohexyl
1272	3	4-OH-Phenyl	3-pyridyl
1273	3	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1274	3	4-OH-Phenyl	1H-imidazol-4-yl
1275	3	4-OH-Phenyl	2-furanyl
1276	3	2-OH-Phenyl	Ethyl
1277	3	2-OH-Phenyl	n-propyl
1278	3	2-OH-Phenyl	Isopropyl
1279	3	2-OH-Phenyl	$-CH_2CH(CH_3)_2$
1280	3	2-OH-Phenyl	CF_3
1281	3	2-OH-Phenyl	$-CH_2CF_3$
1282	3	2-OH-Phenyl	$-CH_2CH_2CF_3$
1283	3	2-OH-Phenyl	cyclopropyl
1284	3	2-OH-Phenyl	Cyclobutyl
1285	3	2-OH-Phenyl	cyclopentyl
1286	3	2-OH-Phenyl	cyclohexyl
1287	3	2-OH-Phenyl	3-pyridyl
1288	3	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1289	3	2-OH-Phenyl	1H-imidazol-4-yl
1290	3	2-OH-Phenyl	2-furanyl
1291	3	3-OMe-Phenyl	Ethyl
1292	3	3-OMe-Phenyl	n-propyl

1293	3	3-OMe-Phenyl	Isopropyl
1294	3	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1295	3	3-OMe-Phenyl	CF_3
1296	3	3-OMe-Phenyl	$-CH_2CF_3$
1297	3	3-OMe-Phenyl	$-CH_2CH_2CF_3$
1298	3	3-OMe-Phenyl	cyclopropyl
1299	3	3-OMe-Phenyl	Cyclobutyl
1300	3	3-OMe-Phenyl	cyclopentyl
1301	3	3-OMe-Phenyl	cyclohexyl
1302	3	3-OMe-Phenyl	3-pyridyl
1303	3	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1304	3	3-OMe-Phenyl	1H-imidazol-4-yl
1305	3	3-OMe-Phenyl	2-furanyl
1306	3	4-CN-Phenyl	Ethyl
1307	3	4-CN-Phenyl	n-propyl
1308	3	4-CN-Phenyl	Isopropyl
1309	3	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
1310	3	4-CN-Phenyl	CF_3
1311	3	4-CN-Phenyl	$-CH_2CF_3$
1312	3	4-CN-Phenyl	$-CH_2CH_2CF_3$
1313	3	4-CN-Phenyl	cyclopropyl
1314	3	4-CN-Phenyl	Cyclobutyl
1315	3	4-CN-Phenyl	cyclopentyl
1316	3	4-CN-Phenyl	cyclohexyl
1317	3	4-CN-Phenyl	3-pyridyl
1318	3	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1319	3	4-CN-Phenyl	1H-imidazol-4-yl
1320	3	4-CN-Phenyl	2-furanyl
1321	3	2-CN-Phenyl	Ethyl
1322	3	2-CN-Phenyl	n-propyl
1323	3	2-CN-Phenyl	Isopropyl

1324	3	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
1325	3	2-CN-Phenyl	CF_3
1326	3	2-CN-Phenyl	$-CH_2CF_3$
1327	3	2-CN-Phenyl	$-CH_2CH_2CF_3$
1328	3	2-CN-Phenyl	cyclopropyl
1329	3	2-CN-Phenyl	Cyclobutyl
1330	3	2-CN-Phenyl	cyclopentyl
1331	3	2-CN-Phenyl	cyclohexyl
1332	3	2-CN-Phenyl	3-pyridyl
1333	3	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1334	3	2-CN-Phenyl	1H-imidazol-4-yl
1335	3	2-CN-Phenyl	2-furanyl
1336	3	3-F-Phenyl	Ethyl
1337	3	3-F-Phenyl	n-propyl
1338	3	3-F-Phenyl	Isopropyl
1339	3	3-F-Phenyl	$-CH_2CH(CH_3)_2$
1340	3	3-F-Phenyl	CF_3
1341	3	3-F-Phenyl	$-CH_2CF_3$
1342	3	3-F-Phenyl	$-CH_2CH_2CF_3$
1343	3	3-F-Phenyl	cyclopropyl
1344	3	3-F-Phenyl	Cyclobutyl
1345	3	3-F-Phenyl	cyclopentyl
1346	3	3-F-Phenyl	cyclohexyl
1347	3	3-F-Phenyl	3-pyridyl
1348	3	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1349	3	3-F-Phenyl	1H-imidazol-4-yl
1350	3	3-F-Phenyl	2-furanyl
1351	3	2-Cl-Phenyl	Ethyl
1352	3	2-Cl-Phenyl	n-propyl
1353	3	2-Cl-Phenyl	Isopropyl
1354	3	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$

1355	3	2-Cl-Phenyl	CF_3
1356	3	2-Cl-Phenyl	$-CH_2CF_3$
1357	3	2-Cl-Phenyl	$-CH_2CH_2CF_3$
1358	3	2-Cl-Phenyl	cyclopropyl
1359	3	2-Cl-Phenyl	Cyclobutyl
1360	3	2-Cl-Phenyl	cyclopentyl
1361	3	2-Cl-Phenyl	cyclohexyl
1362	3	2-Cl-Phenyl	3-pyridyl
1363	3	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1364	3	2-Cl-Phenyl	1H-imidazol-4-yl
1365	3	2-Cl-Phenyl	2-furanyl
1366	3	4-Cl-Phenyl	Ethyl
1367	3	4-Cl-Phenyl	n-propyl
1368	3	4-Cl-Phenyl	Isopropyl
1369	3	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1370	3	4-Cl-Phenyl	CF_3
1371	3	4-Cl-Phenyl	$-CH_2CF_3$
1372	3	4-Cl-Phenyl	$-CH_2CH_2CF_3$
1373	3	4-Cl-Phenyl	cyclopropyl
1374	3	4-Cl-Phenyl	Cyclobutyl
1375	3	4-Cl-Phenyl	cyclopentyl
1376	3	4-Cl-Phenyl	cyclohexyl
1377	3	4-Cl-Phenyl	3-pyridyl
1378	3	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1379	3	4-Cl-Phenyl	1H-imidazol-4-yl
1380	3	4-Cl-Phenyl	2-furanyl
1381	3	3-Br-Phenyl	Ethyl
1382	3	3-Br-Phenyl	n-propyl
1383	3	3-Br-Phenyl	Isopropyl
1384	3	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
1385	3	3-Br-Phenyl	CF_3

1386	3	3-Br-Phenyl	$-CH_2CF_3$
1387	3	3-Br-Phenyl	$-CH_2CH_2CF_3$
1388	3	3-Br-Phenyl	cyclopropyl
1389	3	3-Br-Phenyl	Cyclobutyl
1390	3	3-Br-Phenyl	cyclopentyl
1391	3	3-Br-Phenyl	cyclohexyl
1392	3	3-Br-Phenyl	3-pyridyl
1393	3	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1394	3	3-Br-Phenyl	1H-imidazol-4-yl
1395	3	3-Br-Phenyl	2-furanyl
1396	3	2-CF_3-Phenyl	Ethyl
1397	3	2-CF_3-Phenyl	n-propyl
1398	3	2-CF_3-Phenyl	Isopropyl
1399	3	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1400	3	2-CF_3-Phenyl	CF_3
1401	3	2-CF_3-Phenyl	$-CH_2CF_3$
1402	3	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
1403	3	2-CF_3-Phenyl	cyclopropyl
1404	3	2-CF_3-Phenyl	Cyclobutyl
1405	3	2-CF_3-Phenyl	cyclopentyl
1406	3	2-CF_3-Phenyl	cyclohexyl
1407	3	2-CF_3-Phenyl	3-pyridyl
1408	3	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1409	3	2-CF_3-Phenyl	1H-imidazol-4-yl
1410	3	2-CF_3-Phenyl	2-furanyl
1411	3	4-CF_3-Phenyl	Ethyl
1412	3	4-CF_3-Phenyl	n-propyl
1413	3	4-CF_3-Phenyl	Isopropyl
1414	3	4-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1415	3	4-CF_3-Phenyl	CF_3
1416	3	4-CF_3-Phenyl	$-CH_2CF_3$

1417	3	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
1418	3	4-CF_3-Phenyl	cyclopropyl
1419	3	4-CF_3-Phenyl	Cyclobutyl
1420	3	4-CF_3-Phenyl	cyclopentyl
1421	3	4-CF_3-Phenyl	cyclohexyl
1422	3	4-CF_3-Phenyl	3-pyridyl
1423	3	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1424	3	4-CF_3-Phenyl	1H-imidazol-4-yl
1425	3	4-CF_3-Phenyl	2-furanyl
1426	3	3-iPr-Phenyl	Ethyl
1427	3	3-iPr-Phenyl	n-propyl
1428	3	3-iPr-Phenyl	Isopropyl
1429	3	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1430	3	3-iPr-Phenyl	CF_3
1431	3	3-iPr-Phenyl	-CH_2CF_3
1432	3	3-iPr-Phenyl	-$CH_2CH_2CF_3$
1433	3	3-iPr-Phenyl	cyclopropyl
1434	3	3-iPr-Phenyl	Cyclobutyl
1435	3	3-iPr-Phenyl	cyclopentyl
1436	3	3-iPr-Phenyl	cyclohexyl
1437	3	3-iPr-Phenyl	3-pyridyl
1438	3	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1439	3	3-iPr-Phenyl	1H-imidazol-4-yl
1440	3	3-iPr-Phenyl	2-furanyl
1441	3	2-morpholino-phenyl	Ethyl
1442	3	2-morpholino-phenyl	n-propyl
1443	3	2-morpholino-phenyl	isopropyl
1444	3	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
1445	3	2-morpholino-phenyl	CF_3
1446	3	2-morpholino-phenyl	-CH_2CF_3
1447	3	2-morpholino-phenyl	-$CH_2CH_2CF_3$

1448	3	2-morpholino-phenyl	cyclopropyl
1449	3	2-morpholino-phenyl	Cyclobutyl
1450	3	2-morpholino-phenyl	cyclopentyl
1451	3	2-morpholino-phenyl	cyclohexyl
1452	3	2-morpholino-phenyl	3-pyridyl
1453	3	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1454	3	2-morpholino-phenyl	1H-imidazol-4-yl
1455	3	2-morpholino-phenyl	2-furanyl
1456	3	4-morpholino-phenyl	ethyl
1457	3	4-morpholino-phenyl	n-propyl
1458	3	4-morpholino-phenyl	isopropyl
1459	3	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1460	3	4-morpholino-phenyl	CF_3
1461	3	4-morpholino-phenyl	$-CH_2CF_3$
1462	3	4-morpholino-phenyl	$-CH_2CH_2CF_3$
1463	3	4-morpholino-phenyl	cyclopropyl
1464	3	4-morpholino-phenyl	Cyclobutyl
1465	3	4-morpholino-phenyl	cyclopentyl
1466	3	4-morpholino-phenyl	cyclohexyl
1467	3	4-morpholino-phenyl	3-pyridyl
1468	3	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1469	3	4-morpholino-phenyl	1H-imidazol-4-yl
1470	3	4-morpholino-phenyl	2-furanyl
1471	3	4-methyl-2-morpholino-phenyl	ethyl
1472	3	4-methyl-2-morpholino-phenyl	n-propyl
1473	3	4-methyl-2-morpholino-phenyl	isopropyl
1474	3	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1475	3	4-methyl-2-morpholino-phenyl	CF_3
1476	3	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
1477	3	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1478	3	4-methyl-2-morpholino-phenyl	cyclopropyl

1479	3	4-methyl-2-morpholino-phenyl	Cyclobutyl
1480	3	4-methyl-2-morpholino-phenyl	cyclopentyl
1481	3	4-methyl-2-morpholino-phenyl	cyclohexyl
1482	3	4-methyl-2-morpholino-phenyl	3-pyridyl
1483	3	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1484	3	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
1485	3	4-methyl-2-morpholino-phenyl	2-furanyl
1486	4	4-CH_3-phenyl	ethyl
1487	4	4-CH_3-phenyl	n-propyl
1488	4	4-CH_3-phenyl	isopropyl
1489	4	4-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1490	4	4-CH_3-phenyl	CF_3
1491	4	4-CH_3-phenyl	-CH_2CF_3
1492	4	4-CH_3-phenyl	-$CH_2CH_2CF_3$
1493	4	4-CH_3-phenyl	cyclopropyl
1494	4	4-CH_3-phenyl	Cyclobutyl
1495	4	4-CH_3-phenyl	cyclopentyl
1496	4	4-CH_3-phenyl	cyclohexyl
1497	4	4-CH_3-phenyl	3-pyridyl
1498	4	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1499	4	4-CH_3-phenyl	1H-imidazol-4-yl
1500	4	4-CH_3-phenyl	2-furanyl
1501	4	3-CH_3-phenyl	ethyl
1502	4	3-CH_3-phenyl	n-propyl
1503	4	3-CH_3-phenyl	isopropyl
1504	4	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1505	4	3-CH_3-phenyl	CF_3
1506	4	3-CH_3-phenyl	-CH_2CF_3
1507	4	3-CH_3-phenyl	-$CH_2CH_2CF_3$
1508	4	3-CH_3-phenyl	cyclopropyl
1509	4	3-CH_3-phenyl	Cyclobutyl

1510	4	3-CH_3-phenyl	cyclopentyl
1511	4	3-CH_3-phenyl	cyclohexyl
1512	4	3-CH_3-phenyl	3-pyridyl
1513	4	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1514	4	3-CH_3-phenyl	1H-imidazol-4-yl
1515	4	3-CH_3-phenyl	2-furanyl
1516	4	3-OH-Phenyl	ethyl
1517	4	3-OH-Phenyl	n-propyl
1518	4	3-OH-Phenyl	isopropyl
1519	4	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
1520	4	3-OH-Phenyl	CF_3
1521	4	3-OH-Phenyl	-CH_2CF_3
1522	4	3-OH-Phenyl	-$CH_2CH_2CF_3$
1523	4	3-OH-Phenyl	cyclopropyl
1524	4	3-OH-Phenyl	Cyclobutyl
1525	4	3-OH-Phenyl	cyclopentyl
1526	4	3-OH-Phenyl	cyclohexyl
1527	4	3-OH-Phenyl	3-pyridyl
1528	4	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1529	4	3-OH-Phenyl	1H-imidazol-4-yl
1530	4	3-OH-Phenyl	2-furanyl
1531	4	4-OMe-Phenyl	ethyl
1532	4	4-OMe-Phenyl	n-propyl
1533	4	4-OMe-Phenyl	isopropyl
1534	4	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1535	4	4-OMe-Phenyl	CF_3
1536	4	4-OMe-Phenyl	-CH_2CF_3
1537	4	4-OMe-Phenyl	-$CH_2CH_2CF_3$
1538	4	4-OMe-Phenyl	cyclopropyl
1539	4	4-OMe-Phenyl	Cyclobutyl
1540	4	4-OMe-Phenyl	cyclopentyl

1541	4	4-OMe-Phenyl	cyclohexyl
1542	4	4-OMe-Phenyl	3-pyridyl
1543	4	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1544	4	4-OMe-Phenyl	1H-imidazol-4-yl
1545	4	4-OMe-Phenyl	2-furanyl
1546	4	2-OMe-Phenyl	ethyl
1547	4	2-OMe-Phenyl	n-propyl
1548	4	2-OMe-Phenyl	isopropyl
1549	4	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1550	4	2-OMe-Phenyl	CF_3
1551	4	2-OMe-Phenyl	$-CH_2CF_3$
1552	4	2-OMe-Phenyl	$-CH_2CH_2CF_3$
1553	4	2-OMe-Phenyl	cyclopropyl
1554	4	2-OMe-Phenyl	Cyclobutyl
1555	4	2-OMe-Phenyl	cyclopentyl
1556	4	2-OMe-Phenyl	cyclohexyl
1557	4	2-OMe-Phenyl	3-pyridyl
1558	4	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1559	4	2-OMe-Phenyl	1H-imidazol-4-yl
1560	4	2-OMe-Phenyl	2-furanyl
1561	4	3-CN-Phenyl	ethyl
1562	4	3-CN-Phenyl	n-propyl
1563	4	3-CN-Phenyl	isopropyl
1564	4	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
1565	4	3-CN-Phenyl	CF_3
1566	4	3-CN-Phenyl	$-CH_2CF_3$
1567	4	3-CN-Phenyl	$-CH_2CH_2CF_3$
1568	4	3-CN-Phenyl	cyclopropyl
1569	4	3-CN-Phenyl	Cyclobutyl
1570	4	3-CN-Phenyl	cyclopentyl
1571	4	3-CN-Phenyl	cyclohexyl

1572	4	3-CN-Phenyl	3-pyridyl
1573	4	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1574	4	3-CN-Phenyl	1H-imidazol-4-yl
1575	4	3-CN-Phenyl	2-furanyl
1576	4	2-F-Phenyl	ethyl
1577	4	2-F-Phenyl	n-propyl
1578	4	2-F-Phenyl	isopropyl
1579	4	2-F-Phenyl	$-CH_2CH(CH_3)_2$
1580	4	2-F-Phenyl	CF_3
1581	4	2-F-Phenyl	$-CH_2CF_3$
1582	4	2-F-Phenyl	$-CH_2CH_2CF_3$
1583	4	2-F-Phenyl	cyclopropyl
1584	4	2-F-Phenyl	Cyclobutyl
1585	4	2-F-Phenyl	cyclopentyl
1586	4	2-F-Phenyl	cyclohexyl
1587	4	2-F-Phenyl	3-pyridyl
1588	4	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1589	4	2-F-Phenyl	1H-imidazol-4-yl
1590	4	2-F-Phenyl	2-furanyl
1591	4	4-F-Phenyl	ethyl
1592	4	4-F-Phenyl	n-propyl
1593	4	4-F-Phenyl	isopropyl
1594	4	4-F-Phenyl	$-CH_2CH(CH_3)_2$
1595	4	4-F-Phenyl	CF_3
1596	4	4-F-Phenyl	$-CH_2CF_3$
1597	4	4-F-Phenyl	$-CH_2CH_2CF_3$
1598	4	4-F-Phenyl	cyclopropyl
1599	4	4-F-Phenyl	Cyclobutyl
1600	4	4-F-Phenyl	cyclopentyl
1601	4	4-F-Phenyl	cyclohexyl
1602	4	4-F-Phenyl	3-pyridyl

1603	4	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1604	4	4-F-Phenyl	1H-imidazol-4-yl
1605	4	4-F-Phenyl	2-furanyl
1606	4	3-Cl-Phenyl	ethyl
1607	4	3-Cl-Phenyl	n-propyl
1608	4	3-Cl-Phenyl	isopropyl
1609	4	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1610	4	3-Cl-Phenyl	CF_3
1611	4	3-Cl-Phenyl	$-CH_2CF_3$
1612	4	3-Cl-Phenyl	$-CH_2CH_2CF_3$
1613	4	3-Cl-Phenyl	cyclopropyl
1614	4	3-Cl-Phenyl	Cyclobutyl
1615	4	3-Cl-Phenyl	cyclopentyl
1616	4	3-Cl-Phenyl	cyclohexyl
1617	4	3-Cl-Phenyl	3-pyridyl
1618	4	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1619	4	3-Cl-Phenyl	1H-imidazol-4-yl
1620	4	3-Cl-Phenyl	2-furanyl
1621	4	2-Br-Phenyl	ethyl
1622	4	2-Br-Phenyl	n-propyl
1623	4	2-Br-Phenyl	isopropyl
1624	4	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
1625	4	2-Br-Phenyl	CF_3
1626	4	2-Br-Phenyl	$-CH_2CF_3$
1627	4	2-Br-Phenyl	$-CH_2CH_2CF_3$
1628	4	2-Br-Phenyl	cyclopropyl
1629	4	2-Br-Phenyl	Cyclobutyl
1630	4	2-Br-Phenyl	cyclopentyl
1631	4	2-Br-Phenyl	cyclohexyl
1632	4	2-Br-Phenyl	3-pyridyl
1633	4	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl

1634	4	2-Br-Phenyl	1H-imidazol-4-yl
1635	4	2-Br-Phenyl	2-furanyl
1636	4	4-Br-Phenyl	ethyl
1637	4	4-Br-Phenyl	n-propyl
1638	4	4-Br-Phenyl	isopropyl
1639	4	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
1640	4	4-Br-Phenyl	CF_3
1641	4	4-Br-Phenyl	$-CH_2CF_3$
1642	4	4-Br-Phenyl	$-CH_2CH_2CF_3$
1643	4	4-Br-Phenyl	cyclopropyl
1644	4	4-Br-Phenyl	Cyclobutyl
1645	4	4-Br-Phenyl	cyclopentyl
1646	4	4-Br-Phenyl	cyclohexyl
1647	4	4-Br-Phenyl	3-pyridyl
1648	4	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1649	4	4-Br-Phenyl	1H-imidazol-4-yl
1650	4	4-Br-Phenyl	2-furanyl
1651	4	3-CF_3-Phenyl	ethyl
1652	4	3-CF_3-Phenyl	n-propyl
1653	4	3-CF_3-Phenyl	isopropyl
1654	4	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1655	4	3-CF_3-Phenyl	CF_3
1656	4	3-CF_3-Phenyl	$-CH_2CF_3$
1657	4	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
1658	4	3-CF_3-Phenyl	cyclopropyl
1659	4	3-CF_3-Phenyl	Cyclobutyl
1660	4	3-CF_3-Phenyl	cyclopentyl
1661	4	3-CF_3-Phenyl	cyclohexyl
1662	4	3-CF_3-Phenyl	3-pyridyl
1663	4	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1664	4	3-CF_3-Phenyl	1H-imidazol-4-yl

1665	4	3-CF_3-Phenyl	2-furanyl
1666	4	2-iPr-Phenyl	ethyl
1667	4	2-iPr-Phenyl	n-propyl
1668	4	2-iPr-Phenyl	isopropyl
1669	4	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1670	4	2-iPr-Phenyl	CF_3
1671	4	2-iPr-Phenyl	-CH_2CF_3
1672	4	2-iPr-Phenyl	-$CH_2CH_2CF_3$
1673	4	2-iPr-Phenyl	cyclopropyl
1674	4	2-iPr-Phenyl	Cyclobutyl
1675	4	2-iPr-Phenyl	cyclopentyl
1676	4	2-iPr-Phenyl	cyclohexyl
1677	4	2-iPr-Phenyl	3-pyridyl
1678	4	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1679	4	2-iPr-Phenyl	1H-imidazol-4-yl
1680	4	2-iPr-Phenyl	2-furanyl
1681	4	4-iPr-Phenyl	ethyl
1682	4	4-iPr-Phenyl	n-propyl
1683	4	4-iPr-Phenyl	isopropyl
1684	4	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1685	4	4-iPr-Phenyl	CF_3
1686	4	4-iPr-Phenyl	-CH_2CF_3
1687	4	4-iPr-Phenyl	-$CH_2CH_2CF_3$
1688	4	4-iPr-Phenyl	cyclopropyl
1689	4	4-iPr-Phenyl	Cyclobutyl
1690	4	4-iPr-Phenyl	cyclopentyl
1691	4	4-iPr-Phenyl	cyclohexyl
1692	4	4-iPr-Phenyl	3-pyridyl
1693	4	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1694	4	4-iPr-Phenyl	1H-imidazol-4-yl
1695	4	4-iPr-Phenyl	2-furanyl

1696	4	3-morpholino-phenyl	ethyl
1697	4	3-morpholino-phenyl	n-propyl
1698	4	3-morpholino-phenyl	isopropyl
1699	4	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1700	4	3-morpholino-phenyl	CF_3
1701	4	3-morpholino-phenyl	$-CH_2CF_3$
1702	4	3-morpholino-phenyl	$-CH_2CH_2CF_3$
1703	4	3-morpholino-phenyl	cyclopropyl
1704	4	3-morpholino-phenyl	Cyclobutyl
1705	4	3-morpholino-phenyl	cyclopentyl
1706	4	3-morpholino-phenyl	cyclohexyl
1707	4	3-morpholino-phenyl	3-pyridyl
1708	4	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1709	4	3-morpholino-phenyl	1H-imidazol-4-yl
1710	4	3-morpholino-phenyl	2-furanyl
1711	4	4-cyano-2-morpholino-phenyl	ethyl
1712	4	4-cyano-2-morpholino-phenyl	n-propyl
1713	4	4-cyano-2-morpholino-phenyl	isopropyl
1714	4	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1715	4	4-cyano-2-morpholino-phenyl	CF_3
1716	4	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
1717	4	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1718	4	4-cyano-2-morpholino-phenyl	cyclopropyl
1719	4	4-cyano-2-morpholino-phenyl	Cyclobutyl
1720	4	4-cyano-2-morpholino-phenyl	cyclopentyl
1721	4	4-cyano-2-morpholino-phenyl	cyclohexyl
1722	4	4-cyano-2-morpholino-phenyl	3-pyridyl
1723	4	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1724	4	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
1725	4	4-cyano-2-morpholino-phenyl	2-furanyl
1726	4	4-hydroxy-2-morpholino-phenyl	ethyl

1727	4	4-hydroxy-2-morpholino-phenyl	n-propyl
1728	4	4-hydroxy-2-morpholino-phenyl	isopropyl
1729	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1730	4	4-hydroxy-2-morpholino-phenyl	CF_3
1731	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
1732	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1733	4	4-hydroxy-2-morpholino-phenyl	cyclopropyl
1734	4	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
1735	4	4-hydroxy-2-morpholino-phenyl	cyclopentyl
1736	4	4-hydroxy-2-morpholino-phenyl	cyclohexyl
1737	4	4-hydroxy-2-morpholino-phenyl	3-pyridyl
1738	4	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1739	4	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
1740	4	4-hydroxy-2-morpholino-phenyl	2-furanyl
1741	4	2-CH_3-phenyl	Ethyl
1742	4	2-CH_3-phenyl	n-propyl
1743	4	2-CH_3-phenyl	Isopropyl
1744	4	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1745	4	2-CH_3-phenyl	CF_3
1746	4	2-CH_3-phenyl	$-CH_2CF_3$
1747	4	2-CH_3-phenyl	$-CH_2CH_2CF_3$
1748	4	2-CH_3-phenyl	cyclopropyl
1749	4	2-CH_3-phenyl	Cyclobutyl
1750	4	2-CH_3-phenyl	cyclopentyl
1751	4	2-CH_3-phenyl	cyclohexyl
1752	4	2-CH_3-phenyl	3-pyridyl
1753	4	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1754	4	2-CH_3-phenyl	1H-imidazol-4-yl
1755	4	2-CH_3-phenyl	2-furanyl
1756	4	4-OH-Phenyl	Ethyl
1757	4	4-OH-Phenyl	n-propyl

1758	4	4-OH-Phenyl	Isopropyl
1759	4	4-OH-Phenyl	$-CH_2CH(CH_3)_2$
1760	4	4-OH-Phenyl	CF_3
1761	4	4-OH-Phenyl	$-CH_2CF_3$
1762	4	4-OH-Phenyl	$-CH_2CH_2CF_3$
1763	4	4-OH-Phenyl	cyclopropyl
1764	4	4-OH-Phenyl	Cyclobutyl
1765	4	4-OH-Phenyl	cyclopentyl
1766	4	4-OH-Phenyl	cyclohexyl
1767	4	4-OH-Phenyl	3-pyridyl
1768	4	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1769	4	4-OH-Phenyl	1H-imidazol-4-yl
1770	4	4-OH-Phenyl	2-furanyl
1771	4	2-OH-Phenyl	Ethyl
1772	4	2-OH-Phenyl	n-propyl
1773	4	2-OH-Phenyl	Isopropyl
1774	4	2-OH-Phenyl	$-CH_2CH(CH_3)_2$
1775	4	2-OH-Phenyl	CF_3
1776	4	2-OH-Phenyl	$-CH_2CF_3$
1777	4	2-OH-Phenyl	$-CH_2CH_2CF_3$
1778	4	2-OH-Phenyl	cyclopropyl
1779	4	2-OH-Phenyl	Cyclobutyl
1780	4	2-OH-Phenyl	cyclopentyl
1781	4	2-OH-Phenyl	cyclohexyl
1782	4	2-OH-Phenyl	3-pyridyl
1783	4	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1784	4	2-OH-Phenyl	1H-imidazol-4-yl
1785	4	2-OH-Phenyl	2-furanyl
1786	4	3-OMe-Phenyl	Ethyl
1787	4	3-OMe-Phenyl	n-propyl
1788	4	3-OMe-Phenyl	Isopropyl

1789	4	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1790	4	3-OMe-Phenyl	CF_3
1791	4	3-OMe-Phenyl	$-CH_2CF_3$
1792	4	3-OMe-Phenyl	$-CH_2CH_2CF_3$
1793	4	3-OMe-Phenyl	cyclopropyl
1794	4	3-OMe-Phenyl	Cyclobutyl
1795	4	3-OMe-Phenyl	cyclopentyl
1796	4	3-OMe-Phenyl	cyclohexyl
1797	4	3-OMe-Phenyl	3-pyridyl
1798	4	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1799	4	3-OMe-Phenyl	1H-imidazol-4-yl
1800	4	3-OMe-Phenyl	2-furanyl
1801	4	4-CN-Phenyl	Ethyl
1802	4	4-CN-Phenyl	n-propyl
1803	4	4-CN-Phenyl	Isopropyl
1804	4	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
1805	4	4-CN-Phenyl	CF_3
1806	4	4-CN-Phenyl	$-CH_2CF_3$
1807	4	4-CN-Phenyl	$-CH_2CH_2CF_3$
1808	4	4-CN-Phenyl	cyclopropyl
1809	4	4-CN-Phenyl	Cyclobutyl
1810	4	4-CN-Phenyl	cyclopentyl
1811	4	4-CN-Phenyl	cyclohexyl
1812	4	4-CN-Phenyl	3-pyridyl
1813	4	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1814	4	4-CN-Phenyl	1H-imidazol-4-yl
1815	4	4-CN-Phenyl	2-furanyl
1816	4	2-CN-Phenyl	Ethyl
1817	4	2-CN-Phenyl	n-propyl
1818	4	2-CN-Phenyl	Isopropyl
1819	4	2-CN-Phenyl	$-CH_2CH(CH_3)_2$

1820	4	2-CN-Phenyl	CF_3
1821	4	2-CN-Phenyl	$-CH_2CF_3$
1822	4	2-CN-Phenyl	$-CH_2CH_2CF_3$
1823	4	2-CN-Phenyl	cyclopropyl
1824	4	2-CN-Phenyl	Cyclobutyl
1825	4	2-CN-Phenyl	cyclopentyl
1826	4	2-CN-Phenyl	cyclohexyl
1827	4	2-CN-Phenyl	3-pyridyl
1828	4	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1829	4	2-CN-Phenyl	1H-imidazol-4-yl
1830	4	2-CN-Phenyl	2-furanyl
1831	4	3-F-Phenyl	Ethyl
1832	4	3-F-Phenyl	n-propyl
1833	4	3-F-Phenyl	Isopropyl
1834	4	3-F-Phenyl	$-CH_2CH(CH_3)_2$
1835	4	3-F-Phenyl	CF_3
1836	4	3-F-Phenyl	$-CH_2CF_3$
1837	4	3-F-Phenyl	$-CH_2CH_2CF_3$
1838	4	3-F-Phenyl	cyclopropyl
1839	4	3-F-Phenyl	Cyclobutyl
1840	4	3-F-Phenyl	cyclopentyl
1841	4	3-F-Phenyl	cyclohexyl
1842	4	3-F-Phenyl	3-pyridyl
1843	4	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1844	4	3-F-Phenyl	1H-imidazol-4-yl
1845	4	3-F-Phenyl	2-furanyl
1846	4	2-Cl-Phenyl	Ethyl
1847	4	2-Cl-Phenyl	n-propyl
1848	4	2-Cl-Phenyl	Isopropyl
1849	4	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1850	4	2-Cl-Phenyl	CF_3

1851	4	2-Cl-Phenyl	$-CH_2CF_3$
1852	4	2-Cl-Phenyl	$-CH_2CH_2CF_3$
1853	4	2-Cl-Phenyl	cyclopropyl
1854	4	2-Cl-Phenyl	Cyclobutyl
1855	4	2-Cl-Phenyl	cyclopentyl
1856	4	2-Cl-Phenyl	cyclohexyl
1857	4	2-Cl-Phenyl	3-pyridyl
1858	4	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1859	4	2-Cl-Phenyl	1H-imidazol-4-yl
1860	4	2-Cl-Phenyl	2-furanyl
1861	4	4-Cl-Phenyl	Ethyl
1862	4	4-Cl-Phenyl	n-propyl
1863	4	4-Cl-Phenyl	Isopropyl
1864	4	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1865	4	4-Cl-Phenyl	CF_3
1866	4	4-Cl-Phenyl	$-CH_2CF_3$
1867	4	4-Cl-Phenyl	$-CH_2CH_2CF_3$
1868	4	4-Cl-Phenyl	cyclopropyl
1869	4	4-Cl-Phenyl	Cyclobutyl
1870	4	4-Cl-Phenyl	cyclopentyl
1871	4	4-Cl-Phenyl	cyclohexyl
1872	4	4-Cl-Phenyl	3-pyridyl
1873	4	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1874	4	4-Cl-Phenyl	1H-imidazol-4-yl
1875	4	4-Cl-Phenyl	2-furanyl
1876	4	3-Br-Phenyl	Ethyl
1877	4	3-Br-Phenyl	n-propyl
1878	4	3-Br-Phenyl	Isopropyl
1879	4	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
1880	4	3-Br-Phenyl	CF_3
1881	4	3-Br-Phenyl	$-CH_2CF_3$

1882	4	3-Br-Phenyl	-$CH_2CH_2CF_3$
1883	4	3-Br-Phenyl	cyclopropyl
1884	4	3-Br-Phenyl	Cyclobutyl
1885	4	3-Br-Phenyl	cyclopentyl
1886	4	3-Br-Phenyl	cyclohexyl
1887	4	3-Br-Phenyl	3-pyridyl
1888	4	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1889	4	3-Br-Phenyl	1H-imidazol-4-yl
1890	4	3-Br-Phenyl	2-furanyl
1891	4	2-CF_3-Phenyl	Ethyl
1892	4	2-CF_3-Phenyl	n-propyl
1893	4	2-CF_3-Phenyl	Isopropyl
1894	4	2-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1895	4	2-CF_3-Phenyl	CF_3
1896	4	2-CF_3-Phenyl	-CH_2CF_3
1897	4	2-CF_3-Phenyl	-$CH_2CH_2CF_3$
1898	4	2-CF_3-Phenyl	cyclopropyl
1899	4	2-CF_3-Phenyl	Cyclobutyl
1900	4	2-CF_3-Phenyl	cyclopentyl
1901	4	2-CF_3-Phenyl	cyclohexyl
1902	4	2-CF_3-Phenyl	3-pyridyl
1903	4	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1904	4	2-CF_3-Phenyl	1H-imidazol-4-yl
1905	4	2-CF_3-Phenyl	2-furanyl
1906	4	4-CF_3-Phenyl	Ethyl
1907	4	4-CF_3-Phenyl	n-propyl
1908	4	4-CF_3-Phenyl	Isopropyl
1909	4	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1910	4	4-CF_3-Phenyl	CF_3
1911	4	4-CF_3-Phenyl	-CH_2CF_3
1912	4	4-CF_3-Phenyl	-$CH_2CH_2CF_3$

1913	4	4-CF_3-Phenyl	cyclopropyl
1914	4	4-CF_3-Phenyl	Cyclobutyl
1915	4	4-CF_3-Phenyl	cyclopentyl
1916	4	4-CF_3-Phenyl	cyclohexyl
1917	4	4-CF_3-Phenyl	3-pyridyl
1918	4	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1919	4	4-CF_3-Phenyl	1H-imidazol-4-yl
1920	4	4-CF_3-Phenyl	2-furanyl
1921	4	3-iPr-Phenyl	Ethyl
1922	4	3-iPr-Phenyl	n-propyl
1923	4	3-iPr-Phenyl	Isopropyl
1924	4	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1925	4	3-iPr-Phenyl	CF_3
1926	4	3-iPr-Phenyl	-CH_2CF_3
1927	4	3-iPr-Phenyl	-$CH_2CH_2CF_3$
1928	4	3-iPr-Phenyl	cyclopropyl
1929	4	3-iPr-Phenyl	Cyclobutyl
1930	4	3-iPr-Phenyl	cyclopentyl
1931	4	3-iPr-Phenyl	cyclohexyl
1932	4	3-iPr-Phenyl	3-pyridyl
1933	4	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1934	4	3-iPr-Phenyl	1H-imidazol-4-yl
1935	4	3-iPr-Phenyl	2-furanyl
1936	4	2-morpholino-phenyl	Ethyl
1937	4	2-morpholino-phenyl	n-propyl
1938	4	2-morpholino-phenyl	isopropyl
1939	4	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
1940	4	2-morpholino-phenyl	CF_3
1941	4	2-morpholino-phenyl	-CH_2CF_3
1942	4	2-morpholino-phenyl	-$CH_2CH_2CF_3$
1943	4	2-morpholino-phenyl	cyclopropyl

1944	4	2-morpholino-phenyl	Cyclobutyl
1945	4	2-morpholino-phenyl	cyclopentyl
1946	4	2-morpholino-phenyl	cyclohexyl
1947	4	2-morpholino-phenyl	3-pyridyl
1948	4	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1949	4	2-morpholino-phenyl	1H-imidazol-4-yl
1950	4	2-morpholino-phenyl	2-furanyl
1951	4	4-morpholino-phenyl	ethyl
1952	4	4-morpholino-phenyl	n-propyl
1953	4	4-morpholino-phenyl	isopropyl
1954	4	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1955	4	4-morpholino-phenyl	CF_3
1956	4	4-morpholino-phenyl	$-CH_2CF_3$
1957	4	4-morpholino-phenyl	$-CH_2CH_2CF_3$
1958	4	4-morpholino-phenyl	cyclopropyl
1959	4	4-morpholino-phenyl	Cyclobutyl
1960	4	4-morpholino-phenyl	cyclopentyl
1961	4	4-morpholino-phenyl	cyclohexyl
1962	4	4-morpholino-phenyl	3-pyridyl
1963	4	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1964	4	4-morpholino-phenyl	1H-imidazol-4-yl
1965	4	4-morpholino-phenyl	2-furanyl
1966	4	4-methyl-2-morpholino-phenyl	ethyl
1967	4	4-methyl-2-morpholino-phenyl	n-propyl
1968	4	4-methyl-2-morpholino-phenyl	isopropyl
1969	4	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1970	4	4-methyl-2-morpholino-phenyl	CF_3
1971	4	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
1972	4	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1973	4	4-methyl-2-morpholino-phenyl	cyclopropyl
1974	4	4-methyl-2-morpholino-phenyl	Cyclobutyl

1975	4	4-methyl-2-morpholino-phenyl	cyclopentyl
1976	4	4-methyl-2-morpholino-phenyl	cyclohexyl
1977	4	4-methyl-2-morpholino-phenyl	3-pyridyl
1978	4	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1979	4	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
1980	4	4-methyl-2-morpholino-phenyl	2-furanyl
1981	1	naphthylen-1-yl	Ethyl
1982	1	naphthylen-1-yl	n-propyl
1983	1	naphthylen-1-yl	Isopropyl
1984	1	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
1985	1	naphthylen-1-yl	CF_3
1986	1	naphthylen-1-yl	$-CH_2CF_3$
1987	1	naphthylen-1-yl	$-CH_2CH_2CF_3$
1988	1	naphthylen-1-yl	Cyclopropyl
1989	1	naphthylen-1-yl	Cyclobutyl
1990	1	naphthylen-1-yl	Cyclopentyl
1991	1	naphthylen-1-yl	Cyclohexyl
1992	1	naphthylen-1-yl	3-pyridyl
1993	1	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
1994	1	naphthylen-1-yl	1H-imidazol-4-yl
1995	1	naphthylen-1-yl	2-furanyl
1996	1	naphthylen-2-yl	Ethyl
1997	1	naphthylen-2-yl	n-propyl
1998	1	naphthylen-2-yl	Isopropyl
1999	1	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2000	1	naphthylen-2-yl	CF_3
2001	1	naphthylen-2-yl	$-CH_2CF_3$
2002	1	naphthylen-2-yl	$-CH_2CH_2CF_3$
2003	1	naphthylen-2-yl	Cyclopropyl
2004	1	naphthylen-2-yl	Cyclobutyl
2005	1	naphthylen-2-yl	Cyclopentyl
2006	1	naphthylen-2-yl	Cyclohexyl


2007	1	naphthylen-2-yl	3-pyridyl
2008	1	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2009	1	naphthylen-2-yl	1H-imidazol-4-yl
2010	1	naphthylen-2-yl	2-furanyl
2011	2	naphthylen-1-yl	Ethyl
2012	2	naphthylen-1-yl	n-propyl
2013	2	naphthylen-1-yl	Isopropyl
2014	2	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2015	2	naphthylen-1-yl	CF_3
2016	2	naphthylen-1-yl	$-CH_2CF_3$
2017	2	naphthylen-1-yl	$-CH_2CH_2CF_3$
2018	2	naphthylen-1-yl	Cyclopropyl
2019	2	naphthylen-1-yl	Cyclobutyl
2020	2	naphthylen-1-yl	Cyclopentyl
2021	2	naphthylen-1-yl	Cyclohexyl
2022	2	naphthylen-1-yl	3-pyridyl
2023	2	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2024	2	naphthylen-1-yl	1H-imidazol-4-yl
2025	2	naphthylen-1-yl	2-furanyl
2026	2	naphthylen-2-yl	Ethyl
2027	2	naphthylen-2-yl	n-propyl
2028	2	naphthylen-2-yl	Isopropyl
2029	2	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2030	2	naphthylen-2-yl	CF_3
2031	2	naphthylen-2-yl	$-CH_2CF_3$
2032	2	naphthylen-2-yl	$-CH_2CH_2CF_3$
2033	2	naphthylen-2-yl	Cyclopropyl
2034	2	naphthylen-2-yl	Cyclobutyl
2035	2	naphthylen-2-yl	Cyclopentyl
2036	2	naphthylen-2-yl	Cyclohexyl
2037	2	naphthylen-2-yl	3-pyridyl

2038	2	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2039	2	naphthylen-2-yl	1H-imidazol-4-yl
2040	2	naphthylen-2-yl	2-furanyl
2041	3	naphthylen-1-yl	Ethyl
2042	3	naphthylen-1-yl	n-propyl
2043	3	naphthylen-1-yl	Isopropyl
2044	3	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2045	3	naphthylen-1-yl	CF_3
2046	3	naphthylen-1-yl	$-CH_2CF_3$
2047	3	naphthylen-1-yl	$-CH_2CH_2CF_3$
2048	3	naphthylen-1-yl	Cyclopropyl
2049	3	naphthylen-1-yl	Cyclobutyl
2050	3	naphthylen-1-yl	Cyclopentyl
2051	3	naphthylen-1-yl	Cyclohexyl
2052	3	naphthylen-1-yl	3-pyridyl
2053	3	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2054	3	naphthylen-1-yl	1H-imidazol-4-yl
2055	3	naphthylen-1-yl	2-furanyl
2056	3	naphthylen-2-yl	Ethyl
2057	3	naphthylen-2-yl	n-propyl
2058	3	naphthylen-2-yl	Isopropyl
2059	3	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2060	3	naphthylen-2-yl	CF_3
2061	3	naphthylen-2-yl	$-CH_2CF_3$
2062	3	naphthylen-2-yl	$-CH_2CH_2CF_3$
2063	3	naphthylen-2-yl	Cyclopropyl
2064	3	naphthylen-2-yl	Cyclobutyl
2065	3	naphthylen-2-yl	Cyclopentyl
2066	3	naphthylen-2-yl	Cyclohexyl
2067	3	naphthylen-2-yl	3-pyridyl
2068	3	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl

2069	3	naphthylen-2-yl	1H-imidazol-4-yl
2070	3	naphthylen-2-yl	2-furanyl
2071	4	naphthylen-1-yl	Ethyl
2072	4	naphthylen-1-yl	n-propyl
2073	4	naphthylen-1-yl	Isopropyl
2074	4	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2075	4	naphthylen-1-yl	CF_3
2076	4	naphthylen-1-yl	$-CH_2CF_3$
2077	4	naphthylen-1-yl	$-CH_2CH_2CF_3$
2078	4	naphthylen-1-yl	Cyclopropyl
2079	4	naphthylen-1-yl	Cyclobutyl
2080	4	naphthylen-1-yl	Cyclopentyl
2081	4	naphthylen-1-yl	Cyclohexyl
2082	4	naphthylen-1-yl	3-pyridyl
2083	4	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2084	4	naphthylen-1-yl	1H-imidazol-4-yl
2085	4	naphthylen-1-yl	2-furanyl
2086	4	naphthylen-2-yl	Ethyl
2087	4	naphthylen-2-yl	n-propyl
2088	4	naphthylen-2-yl	Isopropyl
2089	4	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2090	4	naphthylen-2-yl	CF_3
2091	4	naphthylen-2-yl	$-CH_2CF_3$
2092	4	naphthylen-2-yl	$-CH_2CH_2CF_3$
2093	4	naphthylen-2-yl	Cyclopropyl
2094	4	naphthylen-2-yl	Cyclobutyl
2095	4	naphthylen-2-yl	Cyclopentyl
2096	4	naphthylen-2-yl	Cyclohexyl
2097	4	naphthylen-2-yl	3-pyridyl
2098	4	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2099	4	naphthylen-2-yl	1H-imidazol-4-yl

2100	4	naphthylen-2-yl	2-furanyl

[01040] Exemplary embodiments include compounds having the formula **(XXXIX)**



(XXXIX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 32.

Table 32

Entry	n	R^4	R^{10c}
1	1	4-CH_3-phenyl	Ethyl
2	1	4-CH_3-phenyl	n-propyl
3	1	4-CH_3-phenyl	Isopropyl
4	1	4-CH_3-phenyl	-$CH_2CH(CH_3)_2$
5	1	4-CH_3-phenyl	CF_3
6	1	4-CH_3-phenyl	-CH_2CF_3
7	1	4-CH_3-phenyl	-$CH_2CH_2CF_3$
8	1	4-CH_3-phenyl	Cyclopropyl
9	1	4-CH_3-phenyl	Cyclobutyl
10	1	4-CH_3-phenyl	Cyclopentyl
11	1	4-CH_3-phenyl	cyclohexyl
12	1	4-CH_3-phenyl	3-pyridyl
13	1	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
14	1	4-CH_3-phenyl	1H-imidazol-4-yl
15	1	4-CH_3-phenyl	2-furanyl
16	1	3-CH_3-phenyl	ethyl
17	1	3-CH_3-phenyl	n-propyl
18	1	3-CH_3-phenyl	isopropyl
19	1	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
20	1	3-CH_3-phenyl	CF_3
21	1	3-CH_3-phenyl	-CH_2CF_3
22	1	3-CH_3-phenyl	-$CH_2CH_2CF_3$
23	1	3-CH_3-phenyl	cyclopropyl
24	1	3-CH_3-phenyl	Cyclobutyl
25	1	3-CH_3-phenyl	cyclopentyl
26	1	3-CH_3-phenyl	cyclohexyl
27	1	3-CH_3-phenyl	3-pyridyl
28	1	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl

29	1	3-CH_3-phenyl	1H-imidazol-4-yl
30	1	3-CH_3-phenyl	2-furanyl
31	1	3-OH-Phenyl	ethyl
32	1	3-OH-Phenyl	n-propyl
33	1	3-OH-Phenyl	isopropyl
34	1	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
35	1	3-OH-Phenyl	CF_3
36	1	3-OH-Phenyl	-CH_2CF_3
37	1	3-OH-Phenyl	-$CH_2CH_2CF_3$
38	1	3-OH-Phenyl	cyclopropyl
39	1	3-OH-Phenyl	Cyclobutyl
40	1	3-OH-Phenyl	cyclopentyl
41	1	3-OH-Phenyl	cyclohexyl
42	1	3-OH-Phenyl	3-pyridyl
43	1	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
44	1	3-OH-Phenyl	1H-imidazol-4-yl
45	1	3-OH-Phenyl	2-furanyl
46	1	4-OMe-Phenyl	ethyl
47	1	4-OMe-Phenyl	n-propyl
48	1	4-OMe-Phenyl	isopropyl
49	1	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
50	1	4-OMe-Phenyl	CF_3
51	1	4-OMe-Phenyl	-CH_2CF_3
52	1	4-OMe-Phenyl	-$CH_2CH_2CF_3$
53	1	4-OMe-Phenyl	cyclopropyl
54	1	4-OMe-Phenyl	Cyclobutyl
55	1	4-OMe-Phenyl	cyclopentyl
56	1	4-OMe-Phenyl	cyclohexyl
57	1	4-OMe-Phenyl	3-pyridyl
58	1	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
59	1	4-OMe-Phenyl	1H-imidazol-4-yl
60	1	4-OMe-Phenyl	2-furanyl
61	1	2-OMe-Phenyl	ethyl
62	1	2-OMe-Phenyl	n-propyl
63	1	2-OMe-Phenyl	isopropyl
64	1	2-OMe-Phenyl	-$CH_2CH(CH_3)_2$
65	1	2-OMe-Phenyl	CF_3
66	1	2-OMe-Phenyl	-CH_2CF_3
67	1	2-OMe-Phenyl	-$CH_2CH_2CF_3$
68	1	2-OMe-Phenyl	cyclopropyl
69	1	2-OMe-Phenyl	Cyclobutyl
70	1	2-OMe-Phenyl	cyclopentyl
71	1	2-OMe-Phenyl	cyclohexyl

72	1	2-OMe-Phenyl	3-pyridyl
73	1	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
74	1	2-OMe-Phenyl	1H-imidazol-4-yl
75	1	2-OMe-Phenyl	2-furanyl
76	1	3-CN-Phenyl	ethyl
77	1	3-CN-Phenyl	n-propyl
78	1	3-CN-Phenyl	isopropyl
79	1	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
80	1	3-CN-Phenyl	CF_3
81	1	3-CN-Phenyl	$-CH_2CF_3$
82	1	3-CN-Phenyl	$-CH_2CH_2CF_3$
83	1	3-CN-Phenyl	cyclopropyl
84	1	3-CN-Phenyl	Cyclobutyl
85	1	3-CN-Phenyl	cyclopentyl
86	1	3-CN-Phenyl	cyclohexyl
87	1	3-CN-Phenyl	3-pyridyl
88	1	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
89	1	3-CN-Phenyl	1H-imidazol-4-yl
90	1	3-CN-Phenyl	2-furanyl
91	1	2-F-Phenyl	ethyl
92	1	2-F-Phenyl	n-propyl
93	1	2-F-Phenyl	isopropyl
94	1	2-F-Phenyl	$-CH_2CH(CH_3)_2$
95	1	2-F-Phenyl	CF_3
96	1	2-F-Phenyl	$-CH_2CF_3$
97	1	2-F-Phenyl	$-CH_2CH_2CF_3$
98	1	2-F-Phenyl	cyclopropyl
99	1	2-F-Phenyl	Cyclobutyl
100	1	2-F-Phenyl	cyclopentyl
101	1	2-F-Phenyl	cyclohexyl
102	1	2-F-Phenyl	3-pyridyl
103	1	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
104	1	2-F-Phenyl	1H-imidazol-4-yl
105	1	2-F-Phenyl	2-furanyl
106	1	4-F-Phenyl	ethyl
107	1	4-F-Phenyl	n-propyl
108	1	4-F-Phenyl	isopropyl
109	1	4-F-Phenyl	$-CH_2CH(CH_3)_2$
110	1	4-F-Phenyl	CF_3
111	1	4-F-Phenyl	$-CH_2CF_3$
112	1	4-F-Phenyl	$-CH_2CH_2CF_3$
113	1	4-F-Phenyl	cyclopropyl
114	1	4-F-Phenyl	Cyclobutyl
115	1	4-F-Phenyl	cyclopentyl

116	1	4-F-Phenyl	cyclohexyl
117	1	4-F-Phenyl	3-pyridyl
118	1	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
119	1	4-F-Phenyl	1H-imidazol-4-yl
120	1	4-F-Phenyl	2-furanyl
121	1	3-Cl-Phenyl	ethyl
122	1	3-Cl-Phenyl	n-propyl
123	1	3-Cl-Phenyl	isopropyl
124	1	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
125	1	3-Cl-Phenyl	CF_3
126	1	3-Cl-Phenyl	$-CH_2CF_3$
127	1	3-Cl-Phenyl	$-CH_2CH_2CF_3$
128	1	3-Cl-Phenyl	cyclopropyl
129	1	3-Cl-Phenyl	Cyclobutyl
130	1	3-Cl-Phenyl	cyclopentyl
131	1	3-Cl-Phenyl	cyclohexyl
132	1	3-Cl-Phenyl	3-pyridyl
133	1	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
134	1	3-Cl-Phenyl	1H-imidazol-4-yl
135	1	3-Cl-Phenyl	2-furanyl
136	1	2-Br-Phenyl	ethyl
137	1	2-Br-Phenyl	n-propyl
138	1	2-Br-Phenyl	isopropyl
139	1	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
140	1	2-Br-Phenyl	CF_3
141	1	2-Br-Phenyl	$-CH_2CF_3$
142	1	2-Br-Phenyl	$-CH_2CH_2CF_3$
143	1	2-Br-Phenyl	cyclopropyl
144	1	2-Br-Phenyl	Cyclobutyl
145	1	2-Br-Phenyl	cyclopentyl
146	1	2-Br-Phenyl	cyclohexyl
147	1	2-Br-Phenyl	3-pyridyl
148	1	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
149	1	2-Br-Phenyl	1H-imidazol-4-yl
150	1	2-Br-Phenyl	2-furanyl
151	1	4-Br-Phenyl	ethyl
152	1	4-Br-Phenyl	n-propyl
153	1	4-Br-Phenyl	isopropyl
154	1	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
155	1	4-Br-Phenyl	CF_3
156	1	4-Br-Phenyl	$-CH_2CF_3$
157	1	4-Br-Phenyl	$-CH_2CH_2CF_3$
158	1	4-Br-Phenyl	cyclopropyl
159	1	4-Br-Phenyl	Cyclobutyl

160	1	4-Br-Phenyl	cyclopentyl
161	1	4-Br-Phenyl	cyclohexyl
162	1	4-Br-Phenyl	3-pyridyl
163	1	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
164	1	4-Br-Phenyl	1H-imidazol-4-yl
165	1	4-Br-Phenyl	2-furanyl
166	1	3-CF_3-Phenyl	ethyl
167	1	3-CF_3-Phenyl	n-propyl
168	1	3-CF_3-Phenyl	isopropyl
169	1	3-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
170	1	3-CF_3-Phenyl	CF_3
171	1	3-CF_3-Phenyl	-CH_2CF_3
172	1	3-CF_3-Phenyl	-$CH_2CH_2CF_3$
173	1	3-CF_3-Phenyl	cyclopropyl
174	1	3-CF_3-Phenyl	Cyclobutyl
175	1	3-CF_3-Phenyl	cyclopentyl
176	1	3-CF_3-Phenyl	cyclohexyl
177	1	3-CF_3-Phenyl	3-pyridyl
178	1	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
179	1	3-CF_3-Phenyl	1H-imidazol-4-yl
180	1	3-CF_3-Phenyl	2-furanyl
181	1	2-iPr-Phenyl	ethyl
182	1	2-iPr-Phenyl	n-propyl
183	1	2-iPr-Phenyl	isopropyl
184	1	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
185	1	2-iPr-Phenyl	CF_3
186	1	2-iPr-Phenyl	-CH_2CF_3
187	1	2-iPr-Phenyl	-$CH_2CH_2CF_3$
188	1	2-iPr-Phenyl	cyclopropyl
189	1	2-iPr-Phenyl	Cyclobutyl
190	1	2-iPr-Phenyl	cyclopentyl
191	1	2-iPr-Phenyl	cyclohexyl
192	1	2-iPr-Phenyl	3-pyridyl
193	1	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
194	1	2-iPr-Phenyl	1H-imidazol-4-yl
195	1	2-iPr-Phenyl	2-furanyl
196	1	4-iPr-Phenyl	ethyl
197	1	4-iPr-Phenyl	n-propyl
198	1	4-iPr-Phenyl	isopropyl
199	1	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
200	1	4-iPr-Phenyl	CF_3
201	1	4-iPr-Phenyl	-CH_2CF_3

202	1	4-iPr-Phenyl	$-CH_2CH_2CF_3$
203	1	4-iPr-Phenyl	cyclopropyl
204	1	4-iPr-Phenyl	Cyclobutyl
205	1	4-iPr-Phenyl	cyclopentyl
206	1	4-iPr-Phenyl	cyclohexyl
207	1	4-iPr-Phenyl	3-pyridyl
208	1	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
209	1	4-iPr-Phenyl	1H-imidazol-4-yl
210	1	4-iPr-Phenyl	2-furanyl
211	1	3-morpholino-phenyl	ethyl
212	1	3-morpholino-phenyl	n-propyl
213	1	3-morpholino-phenyl	isopropyl
214	1	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
215	1	3-morpholino-phenyl	CF_3
216	1	3-morpholino-phenyl	$-CH_2CF_3$
217	1	3-morpholino-phenyl	$-CH_2CH_2CF_3$
218	1	3-morpholino-phenyl	cyclopropyl
219	1	3-morpholino-phenyl	Cyclobutyl
220	1	3-morpholino-phenyl	cyclopentyl
221	1	3-morpholino-phenyl	cyclohexyl
222	1	3-morpholino-phenyl	3-pyridyl
223	1	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
224	1	3-morpholino-phenyl	1H-imidazol-4-yl
225	1	3-morpholino-phenyl	2-furanyl
226	1	4-cyano-2-morpholino-phenyl	ethyl
227	1	4-cyano-2-morpholino-phenyl	n-propyl
228	1	4-cyano-2-morpholino-phenyl	isopropyl
229	1	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
230	1	4-cyano-2-morpholino-phenyl	CF_3
231	1	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
232	1	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
233	1	4-cyano-2-morpholino-phenyl	cyclopropyl
234	1	4-cyano-2-morpholino-phenyl	Cyclobutyl
235	1	4-cyano-2-morpholino-phenyl	cyclopentyl
236	1	4-cyano-2-morpholino-phenyl	cyclohexyl
237	1	4-cyano-2-morpholino-phenyl	3-pyridyl
238	1	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
239	1	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
240	1	4-cyano-2-morpholino-phenyl	2-furanyl
241	1	4-hydroxy-2-morpholino-phenyl	ethyl
242	1	4-hydroxy-2-morpholino-phenyl	n-propyl
243	1	4-hydroxy-2-morpholino-phenyl	isopropyl
244	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
245	1	4-hydroxy-2-morpholino-phenyl	CF_3

246	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
247	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
248	1	4-hydroxy-2-morpholino-phenyl	cyclopropyl
249	1	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
250	1	4-hydroxy-2-morpholino-phenyl	cyclopentyl
251	1	4-hydroxy-2-morpholino-phenyl	cyclohexyl
252	1	4-hydroxy-2-morpholino-phenyl	3-pyridyl
253	1	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
254	1	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
255	1	4-hydroxy-2-morpholino-phenyl	2-furanyl
256	1	2-CH_3-phenyl	Ethyl
257	1	2-CH_3-phenyl	n-propyl
258	1	2-CH_3-phenyl	Isopropyl
259	1	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
260	1	2-CH_3-phenyl	CF_3
261	1	2-CH_3-phenyl	$-CH_2CF_3$
262	1	2-CH_3-phenyl	$-CH_2CH_2CF_3$
263	1	2-CH_3-phenyl	cyclopropyl
264	1	2-CH_3-phenyl	Cyclobutyl
265	1	2-CH_3-phenyl	cyclopentyl
266	1	2-CH_3-phenyl	cyclohexyl
267	1	2-CH_3-phenyl	3-pyridyl
268	1	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
269	1	2-CH_3-phenyl	1H-imidazol-4-yl
270	1	2-CH_3-phenyl	2-furanyl
271	1	4-OH-Phenyl	Ethyl
272	1	4-OH-Phenyl	n-propyl
273	1	4-OH-Phenyl	Isopropyl
274	1	4-OH-Phenyl	$-CH_2CH(CH_3)_2$
275	1	4-OH-Phenyl	CF_3
276	1	4-OH-Phenyl	$-CH_2CF_3$
277	1	4-OH-Phenyl	$-CH_2CH_2CF_3$
278	1	4-OH-Phenyl	cyclopropyl
279	1	4-OH-Phenyl	Cyclobutyl
280	1	4-OH-Phenyl	cyclopentyl
281	1	4-OH-Phenyl	cyclohexyl
282	1	4-OH-Phenyl	3-pyridyl
283	1	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
284	1	4-OH-Phenyl	1H-imidazol-4-yl
285	1	4-OH-Phenyl	2-furanyl
286	1	2-OH-Phenyl	Ethyl
287	1	2-OH-Phenyl	n-propyl

288	1	2-OH-Phenyl	Isopropyl
289	1	2-OH-Phenyl	$-CH_2CH(CH_3)_2$
290	1	2-OH-Phenyl	CF_3
291	1	2-OH-Phenyl	$-CH_2CF_3$
292	1	2-OH-Phenyl	$-CH_2CH_2CF_3$
293	1	2-OH-Phenyl	cyclopropyl
294	1	2-OH-Phenyl	Cyclobutyl
295	1	2-OH-Phenyl	cyclopentyl
296	1	2-OH-Phenyl	cyclohexyl
297	1	2-OH-Phenyl	3-pyridyl
298	1	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
299	1	2-OH-Phenyl	1H-imidazol-4-yl
300	1	2-OH-Phenyl	2-furanyl
301	1	3-OMe-Phenyl	Ethyl
302	1	3-OMe-Phenyl	n-propyl
303	1	3-OMe-Phenyl	Isopropyl
304	1	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
305	1	3-OMe-Phenyl	CF_3
306	1	3-OMe-Phenyl	$-CH_2CF_3$
307	1	3-OMe-Phenyl	$-CH_2CH_2CF_3$
308	1	3-OMe-Phenyl	cyclopropyl
309	1	3-OMe-Phenyl	Cyclobutyl
310	1	3-OMe-Phenyl	cyclopentyl
311	1	3-OMe-Phenyl	cyclohexyl
312	1	3-OMe-Phenyl	3-pyridyl
313	1	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
314	1	3-OMe-Phenyl	1H-imidazol-4-yl
315	1	3-OMe-Phenyl	2-furanyl
316	1	4-CN-Phenyl	Ethyl
317	1	4-CN-Phenyl	n-propyl
318	1	4-CN-Phenyl	Isopropyl
319	1	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
320	1	4-CN-Phenyl	CF_3
321	1	4-CN-Phenyl	$-CH_2CF_3$
322	1	4-CN-Phenyl	$-CH_2CH_2CF_3$
323	1	4-CN-Phenyl	cyclopropyl
324	1	4-CN-Phenyl	Cyclobutyl
325	1	4-CN-Phenyl	cyclopentyl
326	1	4-CN-Phenyl	cyclohexyl
327	1	4-CN-Phenyl	3-pyridyl
328	1	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
329	1	4-CN-Phenyl	1H-imidazol-4-yl
330	1	4-CN-Phenyl	2-furanyl
331	1	2-CN-Phenyl	Ethyl

332	1	2-CN-Phenyl	n-propyl
333	1	2-CN-Phenyl	Isopropyl
334	1	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
335	1	2-CN-Phenyl	CF_3
336	1	2-CN-Phenyl	$-CH_2CF_3$
337	1	2-CN-Phenyl	$-CH_2CH_2CF_3$
338	1	2-CN-Phenyl	cyclopropyl
339	1	2-CN-Phenyl	Cyclobutyl
340	1	2-CN-Phenyl	cyclopentyl
341	1	2-CN-Phenyl	cyclohexyl
342	1	2-CN-Phenyl	3-pyridyl
343	1	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
344	1	2-CN-Phenyl	1H-imidazol-4-yl
345	1	2-CN-Phenyl	2-furanyl
346	1	3-F-Phenyl	Ethyl
347	1	3-F-Phenyl	n-propyl
348	1	3-F-Phenyl	Isopropyl
349	1	3-F-Phenyl	$-CH_2CH(CH_3)_2$
350	1	3-F-Phenyl	CF_3
351	1	3-F-Phenyl	$-CH_2CF_3$
352	1	3-F-Phenyl	$-CH_2CH_2CF_3$
353	1	3-F-Phenyl	cyclopropyl
354	1	3-F-Phenyl	Cyclobutyl
355	1	3-F-Phenyl	cyclopentyl
356	1	3-F-Phenyl	cyclohexyl
357	1	3-F-Phenyl	3-pyridyl
358	1	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
359	1	3-F-Phenyl	1H-imidazol-4-yl
360	1	3-F-Phenyl	2-furanyl
361	1	2-Cl-Phenyl	Ethyl
362	1	2-Cl-Phenyl	n-propyl
363	1	2-Cl-Phenyl	Isopropyl
364	1	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
365	1	2-Cl-Phenyl	CF_3
366	1	2-Cl-Phenyl	$-CH_2CF_3$
367	1	2-Cl-Phenyl	$-CH_2CH_2CF_3$
368	1	2-Cl-Phenyl	cyclopropyl
369	1	2-Cl-Phenyl	Cyclobutyl
370	1	2-Cl-Phenyl	cyclopentyl
371	1	2-Cl-Phenyl	cyclohexyl
372	1	2-Cl-Phenyl	3-pyridyl
373	1	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
374	1	2-Cl-Phenyl	1H-imidazol-4-yl
375	1	2-Cl-Phenyl	2-furanyl

376	1	4-Cl-Phenyl	Ethyl
377	1	4-Cl-Phenyl	n-propyl
378	1	4-Cl-Phenyl	Isopropyl
379	1	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
380	1	4-Cl-Phenyl	CF_3
381	1	4-Cl-Phenyl	$-CH_2CF_3$
382	1	4-Cl-Phenyl	$-CH_2CH_2CF_3$
383	1	4-Cl-Phenyl	cyclopropyl
384	1	4-Cl-Phenyl	Cyclobutyl
385	1	4-Cl-Phenyl	cyclopentyl
386	1	4-Cl-Phenyl	cyclohexyl
387	1	4-Cl-Phenyl	3-pyridyl
388	1	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
389	1	4-Cl-Phenyl	1H-imidazol-4-yl
390	1	4-Cl-Phenyl	2-furanyl
391	1	3-Br-Phenyl	Ethyl
392	1	3-Br-Phenyl	n-propyl
393	1	3-Br-Phenyl	Isopropyl
394	1	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
395	1	3-Br-Phenyl	CF_3
396	1	3-Br-Phenyl	$-CH_2CF_3$
397	1	3-Br-Phenyl	$-CH_2CH_2CF_3$
398	1	3-Br-Phenyl	cyclopropyl
399	1	3-Br-Phenyl	Cyclobutyl
400	1	3-Br-Phenyl	cyclopentyl
401	1	3-Br-Phenyl	cyclohexyl
402	1	3-Br-Phenyl	3-pyridyl
403	1	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
404	1	3-Br-Phenyl	1H-imidazol-4-yl
405	1	3-Br-Phenyl	2-furanyl
406	1	2-CF_3-Phenyl	Ethyl
407	1	2-CF_3-Phenyl	n-propyl
408	1	2-CF_3-Phenyl	Isopropyl
409	1	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
410	1	2-CF_3-Phenyl	CF_3
411	1	2-CF_3-Phenyl	$-CH_2CF_3$
412	1	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
413	1	2-CF_3-Phenyl	cyclopropyl
414	1	2-CF_3-Phenyl	Cyclobutyl
415	1	2-CF_3-Phenyl	cyclopentyl
416	1	2-CF_3-Phenyl	cyclohexyl
417	1	2-CF_3-Phenyl	3-pyridyl

418	1	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
419	1	2-CF_3-Phenyl	1H-imidazol-4-yl
420	1	2-CF_3-Phenyl	2-furanyl
421	1	4-CF_3-Phenyl	Ethyl
422	1	4-CF_3-Phenyl	n-propyl
423	1	4-CF_3-Phenyl	Isopropyl
424	1	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
425	1	4-CF_3-Phenyl	CF_3
426	1	4-CF_3-Phenyl	-CH_2CF_3
427	1	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
428	1	4-CF_3-Phenyl	cyclopropyl
429	1	4-CF_3-Phenyl	Cyclobutyl
430	1	4-CF_3-Phenyl	cyclopentyl
431	1	4-CF_3-Phenyl	cyclohexyl
432	1	4-CF_3-Phenyl	3-pyridyl
433	1	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
434	1	4-CF_3-Phenyl	1H-imidazol-4-yl
435	1	4-CF_3-Phenyl	2-furanyl
436	1	3-iPr-Phenyl	Ethyl
437	1	3-iPr-Phenyl	n-propyl
438	1	3-iPr-Phenyl	Isopropyl
439	1	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
440	1	3-iPr-Phenyl	CF_3
441	1	3-iPr-Phenyl	-CH_2CF_3
442	1	3-iPr-Phenyl	-$CH_2CH_2CF_3$
443	1	3-iPr-Phenyl	cyclopropyl
444	1	3-iPr-Phenyl	Cyclobutyl
445	1	3-iPr-Phenyl	cyclopentyl
446	1	3-iPr-Phenyl	cyclohexyl
447	1	3-iPr-Phenyl	3-pyridyl
448	1	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
449	1	3-iPr-Phenyl	1H-imidazol-4-yl
450	1	3-iPr-Phenyl	2-furanyl
451	1	2-morpholino-phenyl	Ethyl
452	1	2-morpholino-phenyl	n-propyl
453	1	2-morpholino-phenyl	isopropyl
454	1	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
455	1	2-morpholino-phenyl	CF_3
456	1	2-morpholino-phenyl	-CH_2CF_3
457	1	2-morpholino-phenyl	-$CH_2CH_2CF_3$
458	1	2-morpholino-phenyl	cyclopropyl
459	1	2-morpholino-phenyl	Cyclobutyl

460	1	2-morpholino-phenyl	cyclopentyl
461	1	2-morpholino-phenyl	cyclohexyl
462	1	2-morpholino-phenyl	3-pyridyl
463	1	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
464	1	2-morpholino-phenyl	1H-imidazol-4-yl
465	1	2-morpholino-phenyl	2-furanyl
466	1	4-morpholino-phenyl	ethyl
467	1	4-morpholino-phenyl	n-propyl
468	1	4-morpholino-phenyl	isopropyl
469	1	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
470	1	4-morpholino-phenyl	CF_3
471	1	4-morpholino-phenyl	$-CH_2CF_3$
472	1	4-morpholino-phenyl	$-CH_2CH_2CF_3$
473	1	4-morpholino-phenyl	cyclopropyl
474	1	4-morpholino-phenyl	Cyclobutyl
475	1	4-morpholino-phenyl	cyclopentyl
476	1	4-morpholino-phenyl	cyclohexyl
477	1	4-morpholino-phenyl	3-pyridyl
478	1	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
479	1	4-morpholino-phenyl	1H-imidazol-4-yl
480	1	4-morpholino-phenyl	2-furanyl
481	1	4-methyl-2-morpholino-phenyl	ethyl
482	1	4-methyl-2-morpholino-phenyl	n-propyl
483	1	4-methyl-2-morpholino-phenyl	isopropyl
484	1	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
485	1	4-methyl-2-morpholino-phenyl	CF_3
486	1	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
487	1	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
488	1	4-methyl-2-morpholino-phenyl	cyclopropyl
489	1	4-methyl-2-morpholino-phenyl	Cyclobutyl
490	1	4-methyl-2-morpholino-phenyl	cyclopentyl
491	1	4-methyl-2-morpholino-phenyl	cyclohexyl
492	1	4-methyl-2-morpholino-phenyl	3-pyridyl
493	1	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
494	1	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
495	1	4-methyl-2-morpholino-phenyl	2-furanyl
496	2	4-CH_3-phenyl	ethyl
497	2	4-CH_3-phenyl	n-propyl
498	2	4-CH_3-phenyl	isopropyl
499	2	4-CH_3-phenyl	$-CH_2CH(CH_3)_2$
500	2	4-CH_3-phenyl	CF_3
501	2	4-CH_3-phenyl	$-CH_2CF_3$
502	2	4-CH_3-phenyl	$-CH_2CH_2CF_3$

503	2	4-CH_3-phenyl	cyclopropyl
504	2	4-CH_3-phenyl	Cyclobutyl
505	2	4-CH_3-phenyl	cyclopentyl
506	2	4-CH_3-phenyl	cyclohexyl
507	2	4-CH_3-phenyl	3-pyridyl
508	2	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
509	2	4-CH_3-phenyl	1H-imidazol-4-yl
510	2	4-CH_3-phenyl	2-furanyl
511	2	3-CH_3-phenyl	ethyl
512	2	3-CH_3-phenyl	n-propyl
513	2	3-CH_3-phenyl	isopropyl
514	2	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
515	2	3-CH_3-phenyl	CF_3
516	2	3-CH_3-phenyl	-CH_2CF_3
517	2	3-CH_3-phenyl	-$CH_2CH_2CF_3$
518	2	3-CH_3-phenyl	cyclopropyl
519	2	3-CH_3-phenyl	Cyclobutyl
520	2	3-CH_3-phenyl	cyclopentyl
521	2	3-CH_3-phenyl	cyclohexyl
522	2	3-CH_3-phenyl	3-pyridyl
523	2	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
524	2	3-CH_3-phenyl	1H-imidazol-4-yl
525	2	3-CH_3-phenyl	2-furanyl
526	2	3-OH-Phenyl	ethyl
527	2	3-OH-Phenyl	n-propyl
528	2	3-OH-Phenyl	isopropyl
529	2	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
530	2	3-OH-Phenyl	CF_3
531	2	3-OH-Phenyl	-CH_2CF_3
532	2	3-OH-Phenyl	-$CH_2CH_2CF_3$
533	2	3-OH-Phenyl	cyclopropyl
534	2	3-OH-Phenyl	Cyclobutyl
535	2	3-OH-Phenyl	cyclopentyl
536	2	3-OH-Phenyl	cyclohexyl
537	2	3-OH-Phenyl	3-pyridyl
538	2	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
539	2	3-OH-Phenyl	1H-imidazol-4-yl
540	2	3-OH-Phenyl	2-furanyl
541	2	4-OMe-Phenyl	ethyl
542	2	4-OMe-Phenyl	n-propyl
543	2	4-OMe-Phenyl	isopropyl
544	2	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$

545	2	4-OMe-Phenyl	CF_3
546	2	4-OMe-Phenyl	$-CH_2CF_3$
547	2	4-OMe-Phenyl	$-CH_2CH_2CF_3$
548	2	4-OMe-Phenyl	cyclopropyl
549	2	4-OMe-Phenyl	Cyclobutyl
550	2	4-OMe-Phenyl	cyclopentyl
551	2	4-OMe-Phenyl	cyclohexyl
552	2	4-OMe-Phenyl	3-pyridyl
553	2	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
554	2	4-OMe-Phenyl	1H-imidazol-4-yl
555	2	4-OMe-Phenyl	2-furanyl
556	2	2-OMe-Phenyl	ethyl
557	2	2-OMe-Phenyl	n-propyl
558	2	2-OMe-Phenyl	isopropyl
559	2	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
560	2	2-OMe-Phenyl	CF_3
561	2	2-OMe-Phenyl	$-CH_2CF_3$
562	2	2-OMe-Phenyl	$-CH_2CH_2CF_3$
563	2	2-OMe-Phenyl	cyclopropyl
564	2	2-OMe-Phenyl	Cyclobutyl
565	2	2-OMe-Phenyl	cyclopentyl
566	2	2-OMe-Phenyl	cyclohexyl
567	2	2-OMe-Phenyl	3-pyridyl
568	2	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
569	2	2-OMe-Phenyl	1H-imidazol-4-yl
570	2	2-OMe-Phenyl	2-furanyl
571	2	3-CN-Phenyl	ethyl
572	2	3-CN-Phenyl	n-propyl
573	2	3-CN-Phenyl	isopropyl
574	2	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
575	2	3-CN-Phenyl	CF_3
576	2	3-CN-Phenyl	$-CH_2CF_3$
577	2	3-CN-Phenyl	$-CH_2CH_2CF_3$
578	2	3-CN-Phenyl	cyclopropyl
579	2	3-CN-Phenyl	Cyclobutyl
580	2	3-CN-Phenyl	cyclopentyl
581	2	3-CN-Phenyl	cyclohexyl
582	2	3-CN-Phenyl	3-pyridyl
583	2	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
584	2	3-CN-Phenyl	1H-imidazol-4-yl
585	2	3-CN-Phenyl	2-furanyl
586	2	2-F-Phenyl	ethyl
587	2	2-F-Phenyl	n-propyl
588	2	2-F-Phenyl	isopropyl

589	2	2-F-Phenyl	$-CH_2CH(CH_3)_2$
590	2	2-F-Phenyl	CF_3
591	2	2-F-Phenyl	$-CH_2CF_3$
592	2	2-F-Phenyl	$-CH_2CH_2CF_3$
593	2	2-F-Phenyl	cyclopropyl
594	2	2-F-Phenyl	Cyclobutyl
595	2	2-F-Phenyl	cyclopentyl
596	2	2-F-Phenyl	cyclohexyl
597	2	2-F-Phenyl	3-pyridyl
598	2	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
599	2	2-F-Phenyl	1H-imidazol-4-yl
600	2	2-F-Phenyl	2-furanyl
601	2	4-F-Phenyl	ethyl
602	2	4-F-Phenyl	n-propyl
603	2	4-F-Phenyl	isopropyl
604	2	4-F-Phenyl	$-CH_2CH(CH_3)_2$
605	2	4-F-Phenyl	CF_3
606	2	4-F-Phenyl	$-CH_2CF_3$
607	2	4-F-Phenyl	$-CH_2CH_2CF_3$
608	2	4-F-Phenyl	cyclopropyl
609	2	4-F-Phenyl	Cyclobutyl
610	2	4-F-Phenyl	cyclopentyl
611	2	4-F-Phenyl	cyclohexyl
612	2	4-F-Phenyl	3-pyridyl
613	2	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
614	2	4-F-Phenyl	1H-imidazol-4-yl
615	2	4-F-Phenyl	2-furanyl
616	2	3-Cl-Phenyl	ethyl
617	2	3-Cl-Phenyl	n-propyl
618	2	3-Cl-Phenyl	isopropyl
619	2	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
620	2	3-Cl-Phenyl	CF_3
621	2	3-Cl-Phenyl	$-CH_2CF_3$
622	2	3-Cl-Phenyl	$-CH_2CH_2CF_3$
623	2	3-Cl-Phenyl	cyclopropyl
624	2	3-Cl-Phenyl	Cyclobutyl
625	2	3-Cl-Phenyl	cyclopentyl
626	2	3-Cl-Phenyl	cyclohexyl
627	2	3-Cl-Phenyl	3-pyridyl
628	2	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
629	2	3-Cl-Phenyl	1H-imidazol-4-yl
630	2	3-Cl-Phenyl	2-furanyl
631	2	2-Br-Phenyl	ethyl
632	2	2-Br-Phenyl	n-propyl

633	2	2-Br-Phenyl	isopropyl
634	2	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
635	2	2-Br-Phenyl	CF_3
636	2	2-Br-Phenyl	$-CH_2CF_3$
637	2	2-Br-Phenyl	$-CH_2CH_2CF_3$
638	2	2-Br-Phenyl	cyclopropyl
639	2	2-Br-Phenyl	Cyclobutyl
640	2	2-Br-Phenyl	cyclopentyl
641	2	2-Br-Phenyl	cyclohexyl
642	2	2-Br-Phenyl	3-pyridyl
643	2	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
644	2	2-Br-Phenyl	1H-imidazol-4-yl
645	2	2-Br-Phenyl	2-furanyl
646	2	4-Br-Phenyl	ethyl
647	2	4-Br-Phenyl	n-propyl
648	2	4-Br-Phenyl	isopropyl
649	2	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
650	2	4-Br-Phenyl	CF_3
651	2	4-Br-Phenyl	$-CH_2CF_3$
652	2	4-Br-Phenyl	$-CH_2CH_2CF_3$
653	2	4-Br-Phenyl	cyclopropyl
654	2	4-Br-Phenyl	Cyclobutyl
655	2	4-Br-Phenyl	cyclopentyl
656	2	4-Br-Phenyl	cyclohexyl
657	2	4-Br-Phenyl	3-pyridyl
658	2	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
659	2	4-Br-Phenyl	1H-imidazol-4-yl
660	2	4-Br-Phenyl	2-furanyl
661	2	3-CF_3-Phenyl	ethyl
662	2	3-CF_3-Phenyl	n-propyl
663	2	3-CF_3-Phenyl	isopropyl
664	2	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
665	2	3-CF_3-Phenyl	CF_3
666	2	3-CF_3-Phenyl	$-CH_2CF_3$
667	2	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
668	2	3-CF_3-Phenyl	cyclopropyl
669	2	3-CF_3-Phenyl	Cyclobutyl
670	2	3-CF_3-Phenyl	cyclopentyl
671	2	3-CF_3-Phenyl	cyclohexyl
672	2	3-CF_3-Phenyl	3-pyridyl
673	2	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
674	2	3-CF_3-Phenyl	1H-imidazol-4-yl

675	2	3-CF_3-Phenyl	2-furanyl
676	2	2-iPr-Phenyl	ethyl
677	2	2-iPr-Phenyl	n-propyl
678	2	2-iPr-Phenyl	isopropyl
679	2	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
680	2	2-iPr-Phenyl	CF_3
681	2	2-iPr-Phenyl	-CH_2CF_3
682	2	2-iPr-Phenyl	-$CH_2CH_2CF_3$
683	2	2-iPr-Phenyl	cyclopropyl
684	2	2-iPr-Phenyl	Cyclobutyl
685	2	2-iPr-Phenyl	cyclopentyl
686	2	2-iPr-Phenyl	cyclohexyl
687	2	2-iPr-Phenyl	3-pyridyl
688	2	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
689	2	2-iPr-Phenyl	1H-imidazol-4-yl
690	2	2-iPr-Phenyl	2-furanyl
691	2	4-iPr-Phenyl	ethyl
692	2	4-iPr-Phenyl	n-propyl
693	2	4-iPr-Phenyl	isopropyl
694	2	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
695	2	4-iPr-Phenyl	CF_3
696	2	4-iPr-Phenyl	-CH_2CF_3
697	2	4-iPr-Phenyl	-$CH_2CH_2CF_3$
698	2	4-iPr-Phenyl	cyclopropyl
699	2	4-iPr-Phenyl	Cyclobutyl
700	2	4-iPr-Phenyl	cyclopentyl
701	2	4-iPr-Phenyl	cyclohexyl
702	2	4-iPr-Phenyl	3-pyridyl
703	2	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
704	2	4-iPr-Phenyl	1H-imidazol-4-yl
705	2	4-iPr-Phenyl	2-furanyl
706	2	3-morpholino-phenyl	ethyl
707	2	3-morpholino-phenyl	n-propyl
708	2	3-morpholino-phenyl	isopropyl
709	2	3-morpholino-phenyl	-$CH_2CH(CH_3)_2$
710	2	3-morpholino-phenyl	CF_3
711	2	3-morpholino-phenyl	-CH_2CF_3
712	2	3-morpholino-phenyl	-$CH_2CH_2CF_3$
713	2	3-morpholino-phenyl	cyclopropyl
714	2	3-morpholino-phenyl	Cyclobutyl
715	2	3-morpholino-phenyl	cyclopentyl
716	2	3-morpholino-phenyl	cyclohexyl
717	2	3-morpholino-phenyl	3-pyridyl

718	2	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
719	2	3-morpholino-phenyl	1H-imidazol-4-yl
720	2	3-morpholino-phenyl	2-furanyl
721	2	4-cyano-2-morpholino-phenyl	ethyl
722	2	4-cyano-2-morpholino-phenyl	n-propyl
723	2	4-cyano-2-morpholino-phenyl	isopropyl
724	2	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
725	2	4-cyano-2-morpholino-phenyl	CF_3
726	2	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
727	2	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
728	2	4-cyano-2-morpholino-phenyl	cyclopropyl
729	2	4-cyano-2-morpholino-phenyl	Cyclobutyl
730	2	4-cyano-2-morpholino-phenyl	cyclopentyl
731	2	4-cyano-2-morpholino-phenyl	cyclohexyl
732	2	4-cyano-2-morpholino-phenyl	3-pyridyl
733	2	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
734	2	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
735	2	4-cyano-2-morpholino-phenyl	2-furanyl
736	2	4-hydroxy-2-morpholino-phenyl	ethyl
737	2	4-hydroxy-2-morpholino-phenyl	n-propyl
738	2	4-hydroxy-2-morpholino-phenyl	isopropyl
739	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
740	2	4-hydroxy-2-morpholino-phenyl	CF_3
741	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
742	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
743	2	4-hydroxy-2-morpholino-phenyl	cyclopropyl
744	2	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
745	2	4-hydroxy-2-morpholino-phenyl	cyclopentyl
746	2	4-hydroxy-2-morpholino-phenyl	cyclohexyl
747	2	4-hydroxy-2-morpholino-phenyl	3-pyridyl
748	2	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
749	2	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
750	2	4-hydroxy-2-morpholino-phenyl	2-furanyl
751	2	2-CH_3-phenyl	Ethyl
752	2	2-CH_3-phenyl	n-propyl
753	2	2-CH_3-phenyl	Isopropyl
754	2	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
755	2	2-CH_3-phenyl	CF_3
756	2	2-CH_3-phenyl	$-CH_2CF_3$
757	2	2-CH_3-phenyl	$-CH_2CH_2CF_3$
758	2	2-CH_3-phenyl	cyclopropyl
759	2	2-CH_3-phenyl	Cyclobutyl
760	2	2-CH_3-phenyl	cyclopentyl

761	2	2-CH_3-phenyl	cyclohexyl
762	2	2-CH_3-phenyl	3-pyridyl
763	2	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
764	2	2-CH_3-phenyl	1H-imidazol-4-yl
765	2	2-CH_3-phenyl	2-furanyl
766	2	4-OH-Phenyl	Ethyl
767	2	4-OH-Phenyl	n-propyl
768	2	4-OH-Phenyl	Isopropyl
769	2	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
770	2	4-OH-Phenyl	CF_3
771	2	4-OH-Phenyl	-CH_2CF_3
772	2	4-OH-Phenyl	-$CH_2CH_2CF_3$
773	2	4-OH-Phenyl	cyclopropyl
774	2	4-OH-Phenyl	Cyclobutyl
775	2	4-OH-Phenyl	cyclopentyl
776	2	4-OH-Phenyl	cyclohexyl
777	2	4-OH-Phenyl	3-pyridyl
778	2	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
779	2	4-OH-Phenyl	1H-imidazol-4-yl
780	2	4-OH-Phenyl	2-furanyl
781	2	2-OH-Phenyl	Ethyl
782	2	2-OH-Phenyl	n-propyl
783	2	2-OH-Phenyl	Isopropyl
784	2	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
785	2	2-OH-Phenyl	CF_3
786	2	2-OH-Phenyl	-CH_2CF_3
787	2	2-OH-Phenyl	-$CH_2CH_2CF_3$
788	2	2-OH-Phenyl	cyclopropyl
789	2	2-OH-Phenyl	Cyclobutyl
790	2	2-OH-Phenyl	cyclopentyl
791	2	2-OH-Phenyl	cyclohexyl
792	2	2-OH-Phenyl	3-pyridyl
793	2	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
794	2	2-OH-Phenyl	1H-imidazol-4-yl
795	2	2-OH-Phenyl	2-furanyl
796	2	3-OMe-Phenyl	Ethyl
797	2	3-OMe-Phenyl	n-propyl
798	2	3-OMe-Phenyl	Isopropyl
799	2	3-OMe-Phenyl	-$CH_2CH(CH_3)_2$
800	2	3-OMe-Phenyl	CF_3
801	2	3-OMe-Phenyl	-CH_2CF_3
802	2	3-OMe-Phenyl	-$CH_2CH_2CF_3$
803	2	3-OMe-Phenyl	cyclopropyl

804	2	3-OMe-Phenyl	Cyclobutyl
805	2	3-OMe-Phenyl	cyclopentyl
806	2	3-OMe-Phenyl	cyclohexyl
807	2	3-OMe-Phenyl	3-pyridyl
808	2	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
809	2	3-OMe-Phenyl	1H-imidazol-4-yl
810	2	3-OMe-Phenyl	2-furanyl
811	2	4-CN-Phenyl	Ethyl
812	2	4-CN-Phenyl	n-propyl
813	2	4-CN-Phenyl	Isopropyl
814	2	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
815	2	4-CN-Phenyl	CF_3
816	2	4-CN-Phenyl	$-CH_2CF_3$
817	2	4-CN-Phenyl	$-CH_2CH_2CF_3$
818	2	4-CN-Phenyl	cyclopropyl
819	2	4-CN-Phenyl	Cyclobutyl
820	2	4-CN-Phenyl	cyclopentyl
821	2	4-CN-Phenyl	cyclohexyl
822	2	4-CN-Phenyl	3-pyridyl
823	2	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
824	2	4-CN-Phenyl	1H-imidazol-4-yl
825	2	4-CN-Phenyl	2-furanyl
826	2	2-CN-Phenyl	Ethyl
827	2	2-CN-Phenyl	n-propyl
828	2	2-CN-Phenyl	Isopropyl
829	2	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
830	2	2-CN-Phenyl	CF_3
831	2	2-CN-Phenyl	$-CH_2CF_3$
832	2	2-CN-Phenyl	$-CH_2CH_2CF_3$
833	2	2-CN-Phenyl	cyclopropyl
834	2	2-CN-Phenyl	Cyclobutyl
835	2	2-CN-Phenyl	cyclopentyl
836	2	2-CN-Phenyl	cyclohexyl
837	2	2-CN-Phenyl	3-pyridyl
838	2	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
839	2	2-CN-Phenyl	1H-imidazol-4-yl
840	2	2-CN-Phenyl	2-furanyl
841	2	3-F-Phenyl	Ethyl
842	2	3-F-Phenyl	n-propyl
843	2	3-F-Phenyl	Isopropyl
844	2	3-F-Phenyl	$-CH_2CH(CH_3)_2$
845	2	3-F-Phenyl	CF_3
846	2	3-F-Phenyl	$-CH_2CF_3$
847	2	3-F-Phenyl	$-CH_2CH_2CF_3$

848	2	3-F-Phenyl	cyclopropyl
849	2	3-F-Phenyl	Cyclobutyl
850	2	3-F-Phenyl	cyclopentyl
851	2	3-F-Phenyl	cyclohexyl
852	2	3-F-Phenyl	3-pyridyl
853	2	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
854	2	3-F-Phenyl	1H-imidazol-4-yl
855	2	3-F-Phenyl	2-furanyl
856	2	2-Cl-Phenyl	Ethyl
857	2	2-Cl-Phenyl	n-propyl
858	2	2-Cl-Phenyl	Isopropyl
859	2	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
860	2	2-Cl-Phenyl	CF_3
861	2	2-Cl-Phenyl	$-CH_2CF_3$
862	2	2-Cl-Phenyl	$-CH_2CH_2CF_3$
863	2	2-Cl-Phenyl	cyclopropyl
864	2	2-Cl-Phenyl	Cyclobutyl
865	2	2-Cl-Phenyl	cyclopentyl
866	2	2-Cl-Phenyl	cyclohexyl
867	2	2-Cl-Phenyl	3-pyridyl
868	2	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
869	2	2-Cl-Phenyl	1H-imidazol-4-yl
870	2	2-Cl-Phenyl	2-furanyl
871	2	4-Cl-Phenyl	Ethyl
872	2	4-Cl-Phenyl	n-propyl
873	2	4-Cl-Phenyl	Isopropyl
874	2	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
875	2	4-Cl-Phenyl	CF_3
876	2	4-Cl-Phenyl	$-CH_2CF_3$
877	2	4-Cl-Phenyl	$-CH_2CH_2CF_3$
878	2	4-Cl-Phenyl	cyclopropyl
879	2	4-Cl-Phenyl	Cyclobutyl
880	2	4-Cl-Phenyl	cyclopentyl
881	2	4-Cl-Phenyl	cyclohexyl
882	2	4-Cl-Phenyl	3-pyridyl
883	2	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
884	2	4-Cl-Phenyl	1H-imidazol-4-yl
885	2	4-Cl-Phenyl	2-furanyl
886	2	3-Br-Phenyl	Ethyl
887	2	3-Br-Phenyl	n-propyl
888	2	3-Br-Phenyl	Isopropyl
889	2	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
890	2	3-Br-Phenyl	CF_3
891	2	3-Br-Phenyl	$-CH_2CF_3$

892	2	3-Br-Phenyl	-$CH_2CH_2CF_3$
893	2	3-Br-Phenyl	cyclopropyl
894	2	3-Br-Phenyl	Cyclobutyl
895	2	3-Br-Phenyl	cyclopentyl
896	2	3-Br-Phenyl	cyclohexyl
897	2	3-Br-Phenyl	3-pyridyl
898	2	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
899	2	3-Br-Phenyl	1H-imidazol-4-yl
900	2	3-Br-Phenyl	2-furanyl
901	2	2-CF_3-Phenyl	Ethyl
902	2	2-CF_3-Phenyl	n-propyl
903	2	2-CF_3-Phenyl	Isopropyl
904	2	2-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
905	2	2-CF_3-Phenyl	CF_3
906	2	2-CF_3-Phenyl	-CH_2CF_3
907	2	2-CF_3-Phenyl	-$CH_2CH_2CF_3$
908	2	2-CF_3-Phenyl	cyclopropyl
909	2	2-CF_3-Phenyl	Cyclobutyl
910	2	2-CF_3-Phenyl	cyclopentyl
911	2	2-CF_3-Phenyl	cyclohexyl
912	2	2-CF_3-Phenyl	3-pyridyl
913	2	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
914	2	2-CF_3-Phenyl	1H-imidazol-4-yl
915	2	2-CF_3-Phenyl	2-furanyl
916	2	4-CF_3-Phenyl	Ethyl
917	2	4-CF_3-Phenyl	n-propyl
918	2	4-CF_3-Phenyl	Isopropyl
919	2	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
920	2	4-CF_3-Phenyl	CF_3
921	2	4-CF_3-Phenyl	-CH_2CF_3
922	2	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
923	2	4-CF_3-Phenyl	cyclopropyl
924	2	4-CF_3-Phenyl	Cyclobutyl
925	2	4-CF_3-Phenyl	cyclopentyl
926	2	4-CF_3-Phenyl	cyclohexyl
927	2	4-CF_3-Phenyl	3-pyridyl
928	2	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
929	2	4-CF_3-Phenyl	1H-imidazol-4-yl
930	2	4-CF_3-Phenyl	2-furanyl
931	2	3-iPr-Phenyl	Ethyl
932	2	3-iPr-Phenyl	n-propyl

933	2	3-iPr-Phenyl	Isopropyl
934	2	3-iPr-Phenyl	$-CH_2CH(CH_3)_2$
935	2	3-iPr-Phenyl	CF_3
936	2	3-iPr-Phenyl	$-CH_2CF_3$
937	2	3-iPr-Phenyl	$-CH_2CH_2CF_3$
938	2	3-iPr-Phenyl	cyclopropyl
939	2	3-iPr-Phenyl	Cyclobutyl
940	2	3-iPr-Phenyl	cyclopentyl
941	2	3-iPr-Phenyl	cyclohexyl
942	2	3-iPr-Phenyl	3-pyridyl
943	2	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
944	2	3-iPr-Phenyl	1H-imidazol-4-yl
945	2	3-iPr-Phenyl	2-furanyl
946	2	2-morpholino-phenyl	Ethyl
947	2	2-morpholino-phenyl	n-propyl
948	2	2-morpholino-phenyl	isopropyl
949	2	2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
950	2	2-morpholino-phenyl	CF_3
951	2	2-morpholino-phenyl	$-CH_2CF_3$
952	2	2-morpholino-phenyl	$-CH_2CH_2CF_3$
953	2	2-morpholino-phenyl	cyclopropyl
954	2	2-morpholino-phenyl	Cyclobutyl
955	2	2-morpholino-phenyl	cyclopentyl
956	2	2-morpholino-phenyl	cyclohexyl
957	2	2-morpholino-phenyl	3-pyridyl
958	2	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
959	2	2-morpholino-phenyl	1H-imidazol-4-yl
960	2	2-morpholino-phenyl	2-furanyl
961	2	4-morpholino-phenyl	ethyl
962	2	4-morpholino-phenyl	n-propyl
963	2	4-morpholino-phenyl	isopropyl
964	2	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
965	2	4-morpholino-phenyl	CF_3
966	2	4-morpholino-phenyl	$-CH_2CF_3$
967	2	4-morpholino-phenyl	$-CH_2CH_2CF_3$
968	2	4-morpholino-phenyl	cyclopropyl
969	2	4-morpholino-phenyl	Cyclobutyl
970	2	4-morpholino-phenyl	cyclopentyl
971	2	4-morpholino-phenyl	cyclohexyl
972	2	4-morpholino-phenyl	3-pyridyl
973	2	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
974	2	4-morpholino-phenyl	1H-imidazol-4-yl
975	2	4-morpholino-phenyl	2-furanyl
976	2	4-methyl-2-morpholino-phenyl	ethyl

977	2	4-methyl-2-morpholino-phenyl	n-propyl
978	2	4-methyl-2-morpholino-phenyl	isopropyl
979	2	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
980	2	4-methyl-2-morpholino-phenyl	CF_3
981	2	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
982	2	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
983	2	4-methyl-2-morpholino-phenyl	cyclopropyl
984	2	4-methyl-2-morpholino-phenyl	Cyclobutyl
985	2	4-methyl-2-morpholino-phenyl	cyclopentyl
986	2	4-methyl-2-morpholino-phenyl	cyclohexyl
987	2	4-methyl-2-morpholino-phenyl	3-pyridyl
988	2	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
989	2	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
990	2	4-methyl-2-morpholino-phenyl	2-furanyl
991	3	4-CH_3-phenyl	ethyl
992	3	4-CH_3-phenyl	n-propyl
993	3	4-CH_3-phenyl	isopropyl
994	3	4-CH_3-phenyl	$-CH_2CH(CH_3)_2$
995	3	4-CH_3-phenyl	CF_3
996	3	4-CH_3-phenyl	$-CH_2CF_3$
997	3	4-CH_3-phenyl	$-CH_2CH_2CF_3$
998	3	4-CH_3-phenyl	cyclopropyl
999	3	4-CH_3-phenyl	Cyclobutyl
1000	3	4-CH_3-phenyl	cyclopentyl
1001	3	4-CH_3-phenyl	cyclohexyl
1002	3	4-CH_3-phenyl	3-pyridyl
1003	3	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1004	3	4-CH_3-phenyl	1H-imidazol-4-yl
1005	3	4-CH_3-phenyl	2-furanyl
1006	3	3-CH_3-phenyl	ethyl
1007	3	3-CH_3-phenyl	n-propyl
1008	3	3-CH_3-phenyl	isopropyl
1009	3	3-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1010	3	3-CH_3-phenyl	CF_3
1011	3	3-CH_3-phenyl	$-CH_2CF_3$
1012	3	3-CH_3-phenyl	$-CH_2CH_2CF_3$
1013	3	3-CH_3-phenyl	cyclopropyl
1014	3	3-CH_3-phenyl	Cyclobutyl
1015	3	3-CH_3-phenyl	cyclopentyl
1016	3	3-CH_3-phenyl	cyclohexyl
1017	3	3-CH_3-phenyl	3-pyridyl

1018	3	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1019	3	3-CH_3-phenyl	1H-imidazol-4-yl
1020	3	3-CH_3-phenyl	2-furanyl
1021	3	3-OH-Phenyl	ethyl
1022	3	3-OH-Phenyl	n-propyl
1023	3	3-OH-Phenyl	isopropyl
1024	3	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
1025	3	3-OH-Phenyl	CF_3
1026	3	3-OH-Phenyl	-CH_2CF_3
1027	3	3-OH-Phenyl	-$CH_2CH_2CF_3$
1028	3	3-OH-Phenyl	cyclopropyl
1029	3	3-OH-Phenyl	Cyclobutyl
1030	3	3-OH-Phenyl	cyclopentyl
1031	3	3-OH-Phenyl	cyclohexyl
1032	3	3-OH-Phenyl	3-pyridyl
1033	3	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1034	3	3-OH-Phenyl	1H-imidazol-4-yl
1035	3	3-OH-Phenyl	2-furanyl
1036	3	4-OMe-Phenyl	ethyl
1037	3	4-OMe-Phenyl	n-propyl
1038	3	4-OMe-Phenyl	isopropyl
1039	3	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1040	3	4-OMe-Phenyl	CF_3
1041	3	4-OMe-Phenyl	-CH_2CF_3
1042	3	4-OMe-Phenyl	-$CH_2CH_2CF_3$
1043	3	4-OMe-Phenyl	cyclopropyl
1044	3	4-OMe-Phenyl	Cyclobutyl
1045	3	4-OMe-Phenyl	cyclopentyl
1046	3	4-OMe-Phenyl	cyclohexyl
1047	3	4-OMe-Phenyl	3-pyridyl
1048	3	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1049	3	4-OMe-Phenyl	1H-imidazol-4-yl
1050	3	4-OMe-Phenyl	2-furanyl
1051	3	2-OMe-Phenyl	ethyl
1052	3	2-OMe-Phenyl	n-propyl
1053	3	2-OMe-Phenyl	isopropyl
1054	3	2-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1055	3	2-OMe-Phenyl	CF_3
1056	3	2-OMe-Phenyl	-CH_2CF_3
1057	3	2-OMe-Phenyl	-$CH_2CH_2CF_3$
1058	3	2-OMe-Phenyl	cyclopropyl
1059	3	2-OMe-Phenyl	Cyclobutyl
1060	3	2-OMe-Phenyl	cyclopentyl

1061	3	2-OMe-Phenyl	cyclohexyl
1062	3	2-OMe-Phenyl	3-pyridyl
1063	3	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1064	3	2-OMe-Phenyl	1H-imidazol-4-yl
1065	3	2-OMe-Phenyl	2-furanyl
1066	3	3-CN-Phenyl	ethyl
1067	3	3-CN-Phenyl	n-propyl
1068	3	3-CN-Phenyl	isopropyl
1069	3	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
1070	3	3-CN-Phenyl	CF_3
1071	3	3-CN-Phenyl	$-CH_2CF_3$
1072	3	3-CN-Phenyl	$-CH_2CH_2CF_3$
1073	3	3-CN-Phenyl	cyclopropyl
1074	3	3-CN-Phenyl	Cyclobutyl
1075	3	3-CN-Phenyl	cyclopentyl
1076	3	3-CN-Phenyl	cyclohexyl
1077	3	3-CN-Phenyl	3-pyridyl
1078	3	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1079	3	3-CN-Phenyl	1H-imidazol-4-yl
1080	3	3-CN-Phenyl	2-furanyl
1081	3	2-F-Phenyl	ethyl
1082	3	2-F-Phenyl	n-propyl
1083	3	2-F-Phenyl	isopropyl
1084	3	2-F-Phenyl	$-CH_2CH(CH_3)_2$
1085	3	2-F-Phenyl	CF_3
1086	3	2-F-Phenyl	$-CH_2CF_3$
1087	3	2-F-Phenyl	$-CH_2CH_2CF_3$
1088	3	2-F-Phenyl	cyclopropyl
1089	3	2-F-Phenyl	Cyclobutyl
1090	3	2-F-Phenyl	cyclopentyl
1091	3	2-F-Phenyl	cyclohexyl
1092	3	2-F-Phenyl	3-pyridyl
1093	3	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1094	3	2-F-Phenyl	1H-imidazol-4-yl
1095	3	2-F-Phenyl	2-furanyl
1096	3	4-F-Phenyl	ethyl
1097	3	4-F-Phenyl	n-propyl
1098	3	4-F-Phenyl	isopropyl
1099	3	4-F-Phenyl	$-CH_2CH(CH_3)_2$
1100	3	4-F-Phenyl	CF_3
1101	3	4-F-Phenyl	$-CH_2CF_3$
1102	3	4-F-Phenyl	$-CH_2CH_2CF_3$
1103	3	4-F-Phenyl	cyclopropyl
1104	3	4-F-Phenyl	Cyclobutyl

1105	3	4-F-Phenyl	cyclopentyl
1106	3	4-F-Phenyl	cyclohexyl
1107	3	4-F-Phenyl	3-pyridyl
1108	3	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1109	3	4-F-Phenyl	1H-imidazol-4-yl
1110	3	4-F-Phenyl	2-furanyl
1111	3	3-Cl-Phenyl	ethyl
1112	3	3-Cl-Phenyl	n-propyl
1113	3	3-Cl-Phenyl	isopropyl
1114	3	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1115	3	3-Cl-Phenyl	CF_3
1116	3	3-Cl-Phenyl	$-CH_2CF_3$
1117	3	3-Cl-Phenyl	$-CH_2CH_2CF_3$
1118	3	3-Cl-Phenyl	cyclopropyl
1119	3	3-Cl-Phenyl	Cyclobutyl
1120	3	3-Cl-Phenyl	cyclopentyl
1121	3	3-Cl-Phenyl	cyclohexyl
1122	3	3-Cl-Phenyl	3-pyridyl
1123	3	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1124	3	3-Cl-Phenyl	1H-imidazol-4-yl
1125	3	3-Cl-Phenyl	2-furanyl
1126	3	2-Br-Phenyl	ethyl
1127	3	2-Br-Phenyl	n-propyl
1128	3	2-Br-Phenyl	isopropyl
1129	3	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
1130	3	2-Br-Phenyl	CF_3
1131	3	2-Br-Phenyl	$-CH_2CF_3$
1132	3	2-Br-Phenyl	$-CH_2CH_2CF_3$
1133	3	2-Br-Phenyl	cyclopropyl
1134	3	2-Br-Phenyl	Cyclobutyl
1135	3	2-Br-Phenyl	cyclopentyl
1136	3	2-Br-Phenyl	cyclohexyl
1137	3	2-Br-Phenyl	3-pyridyl
1138	3	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1139	3	2-Br-Phenyl	1H-imidazol-4-yl
1140	3	2-Br-Phenyl	2-furanyl
1141	3	4-Br-Phenyl	ethyl
1142	3	4-Br-Phenyl	n-propyl
1143	3	4-Br-Phenyl	isopropyl
1144	3	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
1145	3	4-Br-Phenyl	CF_3
1146	3	4-Br-Phenyl	$-CH_2CF_3$
1147	3	4-Br-Phenyl	$-CH_2CH_2CF_3$
1148	3	4-Br-Phenyl	cyclopropyl

1149	3	4-Br-Phenyl	Cyclobutyl
1150	3	4-Br-Phenyl	cyclopentyl
1151	3	4-Br-Phenyl	cyclohexyl
1152	3	4-Br-Phenyl	3-pyridyl
1153	3	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1154	3	4-Br-Phenyl	1H-imidazol-4-yl
1155	3	4-Br-Phenyl	2-furanyl
1156	3	3-CF_3-Phenyl	ethyl
1157	3	3-CF_3-Phenyl	n-propyl
1158	3	3-CF_3-Phenyl	isopropyl
1159	3	3-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1160	3	3-CF_3-Phenyl	CF_3
1161	3	3-CF_3-Phenyl	-CH_2CF_3
1162	3	3-CF_3-Phenyl	-$CH_2CH_2CF_3$
1163	3	3-CF_3-Phenyl	cyclopropyl
1164	3	3-CF_3-Phenyl	Cyclobutyl
1165	3	3-CF_3-Phenyl	cyclopentyl
1166	3	3-CF_3-Phenyl	cyclohexyl
1167	3	3-CF_3-Phenyl	3-pyridyl
1168	3	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1169	3	3-CF_3-Phenyl	1H-imidazol-4-yl
1170	3	3-CF_3-Phenyl	2-furanyl
1171	3	2-iPr-Phenyl	ethyl
1172	3	2-iPr-Phenyl	n-propyl
1173	3	2-iPr-Phenyl	isopropyl
1174	3	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1175	3	2-iPr-Phenyl	CF_3
1176	3	2-iPr-Phenyl	-CH_2CF_3
1177	3	2-iPr-Phenyl	-$CH_2CH_2CF_3$
1178	3	2-iPr-Phenyl	cyclopropyl
1179	3	2-iPr-Phenyl	Cyclobutyl
1180	3	2-iPr-Phenyl	cyclopentyl
1181	3	2-iPr-Phenyl	cyclohexyl
1182	3	2-iPr-Phenyl	3-pyridyl
1183	3	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1184	3	2-iPr-Phenyl	1H-imidazol-4-yl
1185	3	2-iPr-Phenyl	2-furanyl
1186	3	4-iPr-Phenyl	ethyl
1187	3	4-iPr-Phenyl	n-propyl
1188	3	4-iPr-Phenyl	isopropyl
1189	3	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1190	3	4-iPr-Phenyl	CF_3

1191	3	4-iPr-Phenyl	$-CH_2CF_3$
1192	3	4-iPr-Phenyl	$-CH_2CH_2CF_3$
1193	3	4-iPr-Phenyl	cyclopropyl
1194	3	4-iPr-Phenyl	Cyclobutyl
1195	3	4-iPr-Phenyl	cyclopentyl
1196	3	4-iPr-Phenyl	cyclohexyl
1197	3	4-iPr-Phenyl	3-pyridyl
1198	3	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1199	3	4-iPr-Phenyl	1H-imidazol-4-yl
1200	3	4-iPr-Phenyl	2-furanyl
1201	3	3-morpholino-phenyl	ethyl
1202	3	3-morpholino-phenyl	n-propyl
1203	3	3-morpholino-phenyl	isopropyl
1204	3	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1205	3	3-morpholino-phenyl	CF_3
1206	3	3-morpholino-phenyl	$-CH_2CF_3$
1207	3	3-morpholino-phenyl	$-CH_2CH_2CF_3$
1208	3	3-morpholino-phenyl	cyclopropyl
1209	3	3-morpholino-phenyl	Cyclobutyl
1210	3	3-morpholino-phenyl	cyclopentyl
1211	3	3-morpholino-phenyl	cyclohexyl
1212	3	3-morpholino-phenyl	3-pyridyl
1213	3	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1214	3	3-morpholino-phenyl	1H-imidazol-4-yl
1215	3	3-morpholino-phenyl	2-furanyl
1216	3	4-cyano-2-morpholino-phenyl	ethyl
1217	3	4-cyano-2-morpholino-phenyl	n-propyl
1218	3	4-cyano-2-morpholino-phenyl	isopropyl
1219	3	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1220	3	4-cyano-2-morpholino-phenyl	CF_3
1221	3	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
1222	3	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1223	3	4-cyano-2-morpholino-phenyl	cyclopropyl
1224	3	4-cyano-2-morpholino-phenyl	Cyclobutyl
1225	3	4-cyano-2-morpholino-phenyl	cyclopentyl
1226	3	4-cyano-2-morpholino-phenyl	cyclohexyl
1227	3	4-cyano-2-morpholino-phenyl	3-pyridyl
1228	3	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1229	3	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
1230	3	4-cyano-2-morpholino-phenyl	2-furanyl
1231	3	4-hydroxy-2-morpholino-phenyl	ethyl
1232	3	4-hydroxy-2-morpholino-phenyl	n-propyl
1233	3	4-hydroxy-2-morpholino-phenyl	isopropyl
1234	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$

1235	3	4-hydroxy-2-morpholino-phenyl	CF_3
1236	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
1237	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1238	3	4-hydroxy-2-morpholino-phenyl	cyclopropyl
1239	3	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
1240	3	4-hydroxy-2-morpholino-phenyl	cyclopentyl
1241	3	4-hydroxy-2-morpholino-phenyl	cyclohexyl
1242	3	4-hydroxy-2-morpholino-phenyl	3-pyridyl
1243	3	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1244	3	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
1245	3	4-hydroxy-2-morpholino-phenyl	2-furanyl
1246	3	2-CH_3-phenyl	Ethyl
1247	3	2-CH_3-phenyl	n-propyl
1248	3	2-CH_3-phenyl	Isopropyl
1249	3	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1250	3	2-CH_3-phenyl	CF_3
1251	3	2-CH_3-phenyl	$-CH_2CF_3$
1252	3	2-CH_3-phenyl	$-CH_2CH_2CF_3$
1253	3	2-CH_3-phenyl	cyclopropyl
1254	3	2-CH_3-phenyl	Cyclobutyl
1255	3	2-CH_3-phenyl	cyclopentyl
1256	3	2-CH_3-phenyl	cyclohexyl
1257	3	2-CH_3-phenyl	3-pyridyl
1258	3	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1259	3	2-CH_3-phenyl	1H-imidazol-4-yl
1260	3	2-CH_3-phenyl	2-furanyl
1261	3	4-OH-Phenyl	Ethyl
1262	3	4-OH-Phenyl	n-propyl
1263	3	4-OH-Phenyl	Isopropyl
1264	3	4-OH-Phenyl	$-CH_2CH(CH_3)_2$
1265	3	4-OH-Phenyl	CF_3
1266	3	4-OH-Phenyl	$-CH_2CF_3$
1267	3	4-OH-Phenyl	$-CH_2CH_2CF_3$
1268	3	4-OH-Phenyl	cyclopropyl
1269	3	4-OH-Phenyl	Cyclobutyl
1270	3	4-OH-Phenyl	cyclopentyl
1271	3	4-OH-Phenyl	cyclohexyl
1272	3	4-OH-Phenyl	3-pyridyl
1273	3	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1274	3	4-OH-Phenyl	1H-imidazol-4-yl
1275	3	4-OH-Phenyl	2-furanyl
1276	3	2-OH-Phenyl	Ethyl

1277	3	2-OH-Phenyl	n-propyl
1278	3	2-OH-Phenyl	Isopropyl
1279	3	2-OH-Phenyl	$-CH_2CH(CH_3)_2$
1280	3	2-OH-Phenyl	CF_3
1281	3	2-OH-Phenyl	$-CH_2CF_3$
1282	3	2-OH-Phenyl	$-CH_2CH_2CF_3$
1283	3	2-OH-Phenyl	cyclopropyl
1284	3	2-OH-Phenyl	Cyclobutyl
1285	3	2-OH-Phenyl	cyclopentyl
1286	3	2-OH-Phenyl	cyclohexyl
1287	3	2-OH-Phenyl	3-pyridyl
1288	3	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1289	3	2-OH-Phenyl	1H-imidazol-4-yl
1290	3	2-OH-Phenyl	2-furanyl
1291	3	3-OMe-Phenyl	Ethyl
1292	3	3-OMe-Phenyl	n-propyl
1293	3	3-OMe-Phenyl	Isopropyl
1294	3	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1295	3	3-OMe-Phenyl	CF_3
1296	3	3-OMe-Phenyl	$-CH_2CF_3$
1297	3	3-OMe-Phenyl	$-CH_2CH_2CF_3$
1298	3	3-OMe-Phenyl	cyclopropyl
1299	3	3-OMe-Phenyl	Cyclobutyl
1300	3	3-OMe-Phenyl	cyclopentyl
1301	3	3-OMe-Phenyl	cyclohexyl
1302	3	3-OMe-Phenyl	3-pyridyl
1303	3	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1304	3	3-OMe-Phenyl	1H-imidazol-4-yl
1305	3	3-OMe-Phenyl	2-furanyl
1306	3	4-CN-Phenyl	Ethyl
1307	3	4-CN-Phenyl	n-propyl
1308	3	4-CN-Phenyl	Isopropyl
1309	3	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
1310	3	4-CN-Phenyl	CF_3
1311	3	4-CN-Phenyl	$-CH_2CF_3$
1312	3	4-CN-Phenyl	$-CH_2CH_2CF_3$
1313	3	4-CN-Phenyl	cyclopropyl
1314	3	4-CN-Phenyl	Cyclobutyl
1315	3	4-CN-Phenyl	cyclopentyl
1316	3	4-CN-Phenyl	cyclohexyl
1317	3	4-CN-Phenyl	3-pyridyl
1318	3	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1319	3	4-CN-Phenyl	1H-imidazol-4-yl
1320	3	4-CN-Phenyl	2-furanyl

1321	3	2-CN-Phenyl	Ethyl
1322	3	2-CN-Phenyl	n-propyl
1323	3	2-CN-Phenyl	Isopropyl
1324	3	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
1325	3	2-CN-Phenyl	CF_3
1326	3	2-CN-Phenyl	$-CH_2CF_3$
1327	3	2-CN-Phenyl	$-CH_2CH_2CF_3$
1328	3	2-CN-Phenyl	cyclopropyl
1329	3	2-CN-Phenyl	Cyclobutyl
1330	3	2-CN-Phenyl	cyclopentyl
1331	3	2-CN-Phenyl	cyclohexyl
1332	3	2-CN-Phenyl	3-pyridyl
1333	3	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1334	3	2-CN-Phenyl	1H-imidazol-4-yl
1335	3	2-CN-Phenyl	2-furanyl
1336	3	3-F-Phenyl	Ethyl
1337	3	3-F-Phenyl	n-propyl
1338	3	3-F-Phenyl	Isopropyl
1339	3	3-F-Phenyl	$-CH_2CH(CH_3)_2$
1340	3	3-F-Phenyl	CF_3
1341	3	3-F-Phenyl	$-CH_2CF_3$
1342	3	3-F-Phenyl	$-CH_2CH_2CF_3$
1343	3	3-F-Phenyl	cyclopropyl
1344	3	3-F-Phenyl	Cyclobutyl
1345	3	3-F-Phenyl	cyclopentyl
1346	3	3-F-Phenyl	cyclohexyl
1347	3	3-F-Phenyl	3-pyridyl
1348	3	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1349	3	3-F-Phenyl	1H-imidazol-4-yl
1350	3	3-F-Phenyl	2-furanyl
1351	3	2-Cl-Phenyl	Ethyl
1352	3	2-Cl-Phenyl	n-propyl
1353	3	2-Cl-Phenyl	Isopropyl
1354	3	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1355	3	2-Cl-Phenyl	CF_3
1356	3	2-Cl-Phenyl	$-CH_2CF_3$
1357	3	2-Cl-Phenyl	$-CH_2CH_2CF_3$
1358	3	2-Cl-Phenyl	cyclopropyl
1359	3	2-Cl-Phenyl	Cyclobutyl
1360	3	2-Cl-Phenyl	cyclopentyl
1361	3	2-Cl-Phenyl	cyclohexyl
1362	3	2-Cl-Phenyl	3-pyridyl
1363	3	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1364	3	2-Cl-Phenyl	1H-imidazol-4-yl

1365	3	2-Cl-Phenyl	2-furanyl
1366	3	4-Cl-Phenyl	Ethyl
1367	3	4-Cl-Phenyl	n-propyl
1368	3	4-Cl-Phenyl	Isopropyl
1369	3	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1370	3	4-Cl-Phenyl	CF_3
1371	3	4-Cl-Phenyl	$-CH_2CF_3$
1372	3	4-Cl-Phenyl	$-CH_2CH_2CF_3$
1373	3	4-Cl-Phenyl	cyclopropyl
1374	3	4-Cl-Phenyl	Cyclobutyl
1375	3	4-Cl-Phenyl	cyclopentyl
1376	3	4-Cl-Phenyl	cyclohexyl
1377	3	4-Cl-Phenyl	3-pyridyl
1378	3	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1379	3	4-Cl-Phenyl	1H-imidazol-4-yl
1380	3	4-Cl-Phenyl	2-furanyl
1381	3	3-Br-Phenyl	Ethyl
1382	3	3-Br-Phenyl	n-propyl
1383	3	3-Br-Phenyl	Isopropyl
1384	3	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
1385	3	3-Br-Phenyl	CF_3
1386	3	3-Br-Phenyl	$-CH_2CF_3$
1387	3	3-Br-Phenyl	$-CH_2CH_2CF_3$
1388	3	3-Br-Phenyl	cyclopropyl
1389	3	3-Br-Phenyl	Cyclobutyl
1390	3	3-Br-Phenyl	cyclopentyl
1391	3	3-Br-Phenyl	cyclohexyl
1392	3	3-Br-Phenyl	3-pyridyl
1393	3	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1394	3	3-Br-Phenyl	1H-imidazol-4-yl
1395	3	3-Br-Phenyl	2-furanyl
1396	3	2-CF_3-Phenyl	Ethyl
1397	3	2-CF_3-Phenyl	n-propyl
1398	3	2-CF_3-Phenyl	Isopropyl
1399	3	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1400	3	2-CF_3-Phenyl	CF_3
1401	3	2-CF_3-Phenyl	$-CH_2CF_3$
1402	3	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
1403	3	2-CF_3-Phenyl	cyclopropyl
1404	3	2-CF_3-Phenyl	Cyclobutyl
1405	3	2-CF_3-Phenyl	cyclopentyl
1406	3	2-CF_3-Phenyl	cyclohexyl
1407	3	2-CF_3-Phenyl	3-pyridyl

1408	3	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1409	3	2-CF_3-Phenyl	1H-imidazol-4-yl
1410	3	2-CF_3-Phenyl	2-furanyl
1411	3	4-CF_3-Phenyl	Ethyl
1412	3	4-CF_3-Phenyl	n-propyl
1413	3	4-CF_3-Phenyl	Isopropyl
1414	3	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1415	3	4-CF_3-Phenyl	CF_3
1416	3	4-CF_3-Phenyl	-CH_2CF_3
1417	3	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
1418	3	4-CF_3-Phenyl	cyclopropyl
1419	3	4-CF_3-Phenyl	Cyclobutyl
1420	3	4-CF_3-Phenyl	cyclopentyl
1421	3	4-CF_3-Phenyl	cyclohexyl
1422	3	4-CF_3-Phenyl	3-pyridyl
1423	3	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1424	3	4-CF_3-Phenyl	1H-imidazol-4-yl
1425	3	4-CF_3-Phenyl	2-furanyl
1426	3	3-iPr-Phenyl	Ethyl
1427	3	3-iPr-Phenyl	n-propyl
1428	3	3-iPr-Phenyl	Isopropyl
1429	3	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1430	3	3-iPr-Phenyl	CF_3
1431	3	3-iPr-Phenyl	-CH_2CF_3
1432	3	3-iPr-Phenyl	-$CH_2CH_2CF_3$
1433	3	3-iPr-Phenyl	cyclopropyl
1434	3	3-iPr-Phenyl	Cyclobutyl
1435	3	3-iPr-Phenyl	cyclopentyl
1436	3	3-iPr-Phenyl	cyclohexyl
1437	3	3-iPr-Phenyl	3-pyridyl
1438	3	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1439	3	3-iPr-Phenyl	1H-imidazol-4-yl
1440	3	3-iPr-Phenyl	2-furanyl
1441	3	2-morpholino-phenyl	Ethyl
1442	3	2-morpholino-phenyl	n-propyl
1443	3	2-morpholino-phenyl	isopropyl
1444	3	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
1445	3	2-morpholino-phenyl	CF_3
1446	3	2-morpholino-phenyl	-CH_2CF_3
1447	3	2-morpholino-phenyl	-$CH_2CH_2CF_3$
1448	3	2-morpholino-phenyl	cyclopropyl
1449	3	2-morpholino-phenyl	Cyclobutyl

1450	3	2-morpholino-phenyl	cyclopentyl
1451	3	2-morpholino-phenyl	cyclohexyl
1452	3	2-morpholino-phenyl	3-pyridyl
1453	3	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1454	3	2-morpholino-phenyl	1H-imidazol-4-yl
1455	3	2-morpholino-phenyl	2-furanyl
1456	3	4-morpholino-phenyl	ethyl
1457	3	4-morpholino-phenyl	n-propyl
1458	3	4-morpholino-phenyl	isopropyl
1459	3	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1460	3	4-morpholino-phenyl	CF_3
1461	3	4-morpholino-phenyl	$-CH_2CF_3$
1462	3	4-morpholino-phenyl	$-CH_2CH_2CF_3$
1463	3	4-morpholino-phenyl	cyclopropyl
1464	3	4-morpholino-phenyl	Cyclobutyl
1465	3	4-morpholino-phenyl	cyclopentyl
1466	3	4-morpholino-phenyl	cyclohexyl
1467	3	4-morpholino-phenyl	3-pyridyl
1468	3	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1469	3	4-morpholino-phenyl	1H-imidazol-4-yl
1470	3	4-morpholino-phenyl	2-furanyl
1471	3	4-methyl-2-morpholino-phenyl	ethyl
1472	3	4-methyl-2-morpholino-phenyl	n-propyl
1473	3	4-methyl-2-morpholino-phenyl	isopropyl
1474	3	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1475	3	4-methyl-2-morpholino-phenyl	CF_3
1476	3	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
1477	3	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1478	3	4-methyl-2-morpholino-phenyl	cyclopropyl
1479	3	4-methyl-2-morpholino-phenyl	Cyclobutyl
1480	3	4-methyl-2-morpholino-phenyl	cyclopentyl
1481	3	4-methyl-2-morpholino-phenyl	cyclohexyl
1482	3	4-methyl-2-morpholino-phenyl	3-pyridyl
1483	3	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1484	3	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
1485	3	4-methyl-2-morpholino-phenyl	2-furanyl
1486	4	4-CH_3-phenyl	ethyl
1487	4	4-CH_3-phenyl	n-propyl
1488	4	4-CH_3-phenyl	isopropyl
1489	4	4-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1490	4	4-CH_3-phenyl	CF_3
1491	4	4-CH_3-phenyl	$-CH_2CF_3$
1492	4	4-CH_3-phenyl	$-CH_2CH_2CF_3$

1493	4	4-CH_3-phenyl	cyclopropyl
1494	4	4-CH_3-phenyl	Cyclobutyl
1495	4	4-CH_3-phenyl	cyclopentyl
1496	4	4-CH_3-phenyl	cyclohexyl
1497	4	4-CH_3-phenyl	3-pyridyl
1498	4	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1499	4	4-CH_3-phenyl	1H-imidazol-4-yl
1500	4	4-CH_3-phenyl	2-furanyl
1501	4	3-CH_3-phenyl	ethyl
1502	4	3-CH_3-phenyl	n-propyl
1503	4	3-CH_3-phenyl	isopropyl
1504	4	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1505	4	3-CH_3-phenyl	CF_3
1506	4	3-CH_3-phenyl	-CH_2CF_3
1507	4	3-CH_3-phenyl	-$CH_2CH_2CF_3$
1508	4	3-CH_3-phenyl	cyclopropyl
1509	4	3-CH_3-phenyl	Cyclobutyl
1510	4	3-CH_3-phenyl	cyclopentyl
1511	4	3-CH_3-phenyl	cyclohexyl
1512	4	3-CH_3-phenyl	3-pyridyl
1513	4	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1514	4	3-CH_3-phenyl	1H-imidazol-4-yl
1515	4	3-CH_3-phenyl	2-furanyl
1516	4	3-OH-Phenyl	ethyl
1517	4	3-OH-Phenyl	n-propyl
1518	4	3-OH-Phenyl	isopropyl
1519	4	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
1520	4	3-OH-Phenyl	CF_3
1521	4	3-OH-Phenyl	-CH_2CF_3
1522	4	3-OH-Phenyl	-$CH_2CH_2CF_3$
1523	4	3-OH-Phenyl	cyclopropyl
1524	4	3-OH-Phenyl	Cyclobutyl
1525	4	3-OH-Phenyl	cyclopentyl
1526	4	3-OH-Phenyl	cyclohexyl
1527	4	3-OH-Phenyl	3-pyridyl
1528	4	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1529	4	3-OH-Phenyl	1H-imidazol-4-yl
1530	4	3-OH-Phenyl	2-furanyl
1531	4	4-OMe-Phenyl	ethyl
1532	4	4-OMe-Phenyl	n-propyl
1533	4	4-OMe-Phenyl	isopropyl
1534	4	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$

1535	4	4-OMe-Phenyl	CF_3
1536	4	4-OMe-Phenyl	$-CH_2CF_3$
1537	4	4-OMe-Phenyl	$-CH_2CH_2CF_3$
1538	4	4-OMe-Phenyl	cyclopropyl
1539	4	4-OMe-Phenyl	Cyclobutyl
1540	4	4-OMe-Phenyl	cyclopentyl
1541	4	4-OMe-Phenyl	cyclohexyl
1542	4	4-OMe-Phenyl	3-pyridyl
1543	4	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1544	4	4-OMe-Phenyl	1H-imidazol-4-yl
1545	4	4-OMe-Phenyl	2-furanyl
1546	4	2-OMe-Phenyl	ethyl
1547	4	2-OMe-Phenyl	n-propyl
1548	4	2-OMe-Phenyl	isopropyl
1549	4	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1550	4	2-OMe-Phenyl	CF_3
1551	4	2-OMe-Phenyl	$-CH_2CF_3$
1552	4	2-OMe-Phenyl	$-CH_2CH_2CF_3$
1553	4	2-OMe-Phenyl	cyclopropyl
1554	4	2-OMe-Phenyl	Cyclobutyl
1555	4	2-OMe-Phenyl	cyclopentyl
1556	4	2-OMe-Phenyl	cyclohexyl
1557	4	2-OMe-Phenyl	3-pyridyl
1558	4	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1559	4	2-OMe-Phenyl	1H-imidazol-4-yl
1560	4	2-OMe-Phenyl	2-furanyl
1561	4	3-CN-Phenyl	ethyl
1562	4	3-CN-Phenyl	n-propyl
1563	4	3-CN-Phenyl	isopropyl
1564	4	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
1565	4	3-CN-Phenyl	CF_3
1566	4	3-CN-Phenyl	$-CH_2CF_3$
1567	4	3-CN-Phenyl	$-CH_2CH_2CF_3$
1568	4	3-CN-Phenyl	cyclopropyl
1569	4	3-CN-Phenyl	Cyclobutyl
1570	4	3-CN-Phenyl	cyclopentyl
1571	4	3-CN-Phenyl	cyclohexyl
1572	4	3-CN-Phenyl	3-pyridyl
1573	4	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1574	4	3-CN-Phenyl	1H-imidazol-4-yl
1575	4	3-CN-Phenyl	2-furanyl
1576	4	2-F-Phenyl	ethyl
1577	4	2-F-Phenyl	n-propyl
1578	4	2-F-Phenyl	isopropyl

1579	4	2-F-Phenyl	-$CH_2CH(CH_3)_2$
1580	4	2-F-Phenyl	CF_3
1581	4	2-F-Phenyl	-CH_2CF_3
1582	4	2-F-Phenyl	-$CH_2CH_2CF_3$
1583	4	2-F-Phenyl	cyclopropyl
1584	4	2-F-Phenyl	Cyclobutyl
1585	4	2-F-Phenyl	cyclopentyl
1586	4	2-F-Phenyl	cyclohexyl
1587	4	2-F-Phenyl	3-pyridyl
1588	4	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1589	4	2-F-Phenyl	1H-imidazol-4-yl
1590	4	2-F-Phenyl	2-furanyl
1591	4	4-F-Phenyl	ethyl
1592	4	4-F-Phenyl	n-propyl
1593	4	4-F-Phenyl	isopropyl
1594	4	4-F-Phenyl	-$CH_2CH(CH_3)_2$
1595	4	4-F-Phenyl	CF_3
1596	4	4-F-Phenyl	-CH_2CF_3
1597	4	4-F-Phenyl	-$CH_2CH_2CF_3$
1598	4	4-F-Phenyl	cyclopropyl
1599	4	4-F-Phenyl	Cyclobutyl
1600	4	4-F-Phenyl	cyclopentyl
1601	4	4-F-Phenyl	cyclohexyl
1602	4	4-F-Phenyl	3-pyridyl
1603	4	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1604	4	4-F-Phenyl	1H-imidazol-4-yl
1605	4	4-F-Phenyl	2-furanyl
1606	4	3-Cl-Phenyl	ethyl
1607	4	3-Cl-Phenyl	n-propyl
1608	4	3-Cl-Phenyl	isopropyl
1609	4	3-Cl-Phenyl	-$CH_2CH(CH_3)_2$
1610	4	3-Cl-Phenyl	CF_3
1611	4	3-Cl-Phenyl	-CH_2CF_3
1612	4	3-Cl-Phenyl	-$CH_2CH_2CF_3$
1613	4	3-Cl-Phenyl	cyclopropyl
1614	4	3-Cl-Phenyl	Cyclobutyl
1615	4	3-Cl-Phenyl	cyclopentyl
1616	4	3-Cl-Phenyl	cyclohexyl
1617	4	3-Cl-Phenyl	3-pyridyl
1618	4	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1619	4	3-Cl-Phenyl	1H-imidazol-4-yl
1620	4	3-Cl-Phenyl	2-furanyl
1621	4	2-Br-Phenyl	ethyl
1622	4	2-Br-Phenyl	n-propyl

1623	4	2-Br-Phenyl	isopropyl
1624	4	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
1625	4	2-Br-Phenyl	CF_3
1626	4	2-Br-Phenyl	$-CH_2CF_3$
1627	4	2-Br-Phenyl	$-CH_2CH_2CF_3$
1628	4	2-Br-Phenyl	cyclopropyl
1629	4	2-Br-Phenyl	Cyclobutyl
1630	4	2-Br-Phenyl	cyclopentyl
1631	4	2-Br-Phenyl	cyclohexyl
1632	4	2-Br-Phenyl	3-pyridyl
1633	4	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1634	4	2-Br-Phenyl	1H-imidazol-4-yl
1635	4	2-Br-Phenyl	2-furanyl
1636	4	4-Br-Phenyl	ethyl
1637	4	4-Br-Phenyl	n-propyl
1638	4	4-Br-Phenyl	isopropyl
1639	4	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
1640	4	4-Br-Phenyl	CF_3
1641	4	4-Br-Phenyl	$-CH_2CF_3$
1642	4	4-Br-Phenyl	$-CH_2CH_2CF_3$
1643	4	4-Br-Phenyl	cyclopropyl
1644	4	4-Br-Phenyl	Cyclobutyl
1645	4	4-Br-Phenyl	cyclopentyl
1646	4	4-Br-Phenyl	cyclohexyl
1647	4	4-Br-Phenyl	3-pyridyl
1648	4	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1649	4	4-Br-Phenyl	1H-imidazol-4-yl
1650	4	4-Br-Phenyl	2-furanyl
1651	4	3-CF_3-Phenyl	ethyl
1652	4	3-CF_3-Phenyl	n-propyl
1653	4	3-CF_3-Phenyl	isopropyl
1654	4	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1655	4	3-CF_3-Phenyl	CF_3
1656	4	3-CF_3-Phenyl	$-CH_2CF_3$
1657	4	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
1658	4	3-CF_3-Phenyl	cyclopropyl
1659	4	3-CF_3-Phenyl	Cyclobutyl
1660	4	3-CF_3-Phenyl	cyclopentyl
1661	4	3-CF_3-Phenyl	cyclohexyl
1662	4	3-CF_3-Phenyl	3-pyridyl
1663	4	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1664	4	3-CF_3-Phenyl	1H-imidazol-4-yl

1665	4	3-CF_3-Phenyl	2-furanyl
1666	4	2-iPr-Phenyl	ethyl
1667	4	2-iPr-Phenyl	n-propyl
1668	4	2-iPr-Phenyl	isopropyl
1669	4	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1670	4	2-iPr-Phenyl	CF_3
1671	4	2-iPr-Phenyl	-CH_2CF_3
1672	4	2-iPr-Phenyl	-$CH_2CH_2CF_3$
1673	4	2-iPr-Phenyl	cyclopropyl
1674	4	2-iPr-Phenyl	Cyclobutyl
1675	4	2-iPr-Phenyl	cyclopentyl
1676	4	2-iPr-Phenyl	cyclohexyl
1677	4	2-iPr-Phenyl	3-pyridyl
1678	4	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1679	4	2-iPr-Phenyl	1H-imidazol-4-yl
1680	4	2-iPr-Phenyl	2-furanyl
1681	4	4-iPr-Phenyl	ethyl
1682	4	4-iPr-Phenyl	n-propyl
1683	4	4-iPr-Phenyl	isopropyl
1684	4	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1685	4	4-iPr-Phenyl	CF_3
1686	4	4-iPr-Phenyl	-CH_2CF_3
1687	4	4-iPr-Phenyl	-$CH_2CH_2CF_3$
1688	4	4-iPr-Phenyl	cyclopropyl
1689	4	4-iPr-Phenyl	Cyclobutyl
1690	4	4-iPr-Phenyl	cyclopentyl
1691	4	4-iPr-Phenyl	cyclohexyl
1692	4	4-iPr-Phenyl	3-pyridyl
1693	4	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1694	4	4-iPr-Phenyl	1H-imidazol-4-yl
1695	4	4-iPr-Phenyl	2-furanyl
1696	4	3-morpholino-phenyl	ethyl
1697	4	3-morpholino-phenyl	n-propyl
1698	4	3-morpholino-phenyl	isopropyl
1699	4	3-morpholino-phenyl	-$CH_2CH(CH_3)_2$
1700	4	3-morpholino-phenyl	CF_3
1701	4	3-morpholino-phenyl	-CH_2CF_3
1702	4	3-morpholino-phenyl	-$CH_2CH_2CF_3$
1703	4	3-morpholino-phenyl	cyclopropyl
1704	4	3-morpholino-phenyl	Cyclobutyl
1705	4	3-morpholino-phenyl	cyclopentyl
1706	4	3-morpholino-phenyl	cyclohexyl
1707	4	3-morpholino-phenyl	3-pyridyl

1708	4	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1709	4	3-morpholino-phenyl	1H-imidazol-4-yl
1710	4	3-morpholino-phenyl	2-furanyl
1711	4	4-cyano-2-morpholino-phenyl	ethyl
1712	4	4-cyano-2-morpholino-phenyl	n-propyl
1713	4	4-cyano-2-morpholino-phenyl	isopropyl
1714	4	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1715	4	4-cyano-2-morpholino-phenyl	CF_3
1716	4	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
1717	4	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1718	4	4-cyano-2-morpholino-phenyl	cyclopropyl
1719	4	4-cyano-2-morpholino-phenyl	Cyclobutyl
1720	4	4-cyano-2-morpholino-phenyl	cyclopentyl
1721	4	4-cyano-2-morpholino-phenyl	cyclohexyl
1722	4	4-cyano-2-morpholino-phenyl	3-pyridyl
1723	4	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1724	4	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
1725	4	4-cyano-2-morpholino-phenyl	2-furanyl
1726	4	4-hydroxy-2-morpholino-phenyl	ethyl
1727	4	4-hydroxy-2-morpholino-phenyl	n-propyl
1728	4	4-hydroxy-2-morpholino-phenyl	isopropyl
1729	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1730	4	4-hydroxy-2-morpholino-phenyl	CF_3
1731	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
1732	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1733	4	4-hydroxy-2-morpholino-phenyl	cyclopropyl
1734	4	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
1735	4	4-hydroxy-2-morpholino-phenyl	cyclopentyl
1736	4	4-hydroxy-2-morpholino-phenyl	cyclohexyl
1737	4	4-hydroxy-2-morpholino-phenyl	3-pyridyl
1738	4	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1739	4	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
1740	4	4-hydroxy-2-morpholino-phenyl	2-furanyl
1741	4	2-CH_3-phenyl	Ethyl
1742	4	2-CH_3-phenyl	n-propyl
1743	4	2-CH_3-phenyl	Isopropyl
1744	4	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1745	4	2-CH_3-phenyl	CF_3
1746	4	2-CH_3-phenyl	$-CH_2CF_3$
1747	4	2-CH_3-phenyl	$-CH_2CH_2CF_3$
1748	4	2-CH_3-phenyl	cyclopropyl
1749	4	2-CH_3-phenyl	Cyclobutyl
1750	4	2-CH_3-phenyl	cyclopentyl

1751	4	2-CH_3-phenyl	cyclohexyl
1752	4	2-CH_3-phenyl	3-pyridyl
1753	4	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1754	4	2-CH_3-phenyl	1H-imidazol-4-yl
1755	4	2-CH_3-phenyl	2-furanyl
1756	4	4-OH-Phenyl	Ethyl
1757	4	4-OH-Phenyl	n-propyl
1758	4	4-OH-Phenyl	Isopropyl
1759	4	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
1760	4	4-OH-Phenyl	CF_3
1761	4	4-OH-Phenyl	-CH_2CF_3
1762	4	4-OH-Phenyl	-$CH_2CH_2CF_3$
1763	4	4-OH-Phenyl	cyclopropyl
1764	4	4-OH-Phenyl	Cyclobutyl
1765	4	4-OH-Phenyl	cyclopentyl
1766	4	4-OH-Phenyl	cyclohexyl
1767	4	4-OH-Phenyl	3-pyridyl
1768	4	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1769	4	4-OH-Phenyl	1H-imidazol-4-yl
1770	4	4-OH-Phenyl	2-furanyl
1771	4	2-OH-Phenyl	Ethyl
1772	4	2-OH-Phenyl	n-propyl
1773	4	2-OH-Phenyl	Isopropyl
1774	4	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
1775	4	2-OH-Phenyl	CF_3
1776	4	2-OH-Phenyl	-CH_2CF_3
1777	4	2-OH-Phenyl	-$CH_2CH_2CF_3$
1778	4	2-OH-Phenyl	cyclopropyl
1779	4	2-OH-Phenyl	Cyclobutyl
1780	4	2-OH-Phenyl	cyclopentyl
1781	4	2-OH-Phenyl	cyclohexyl
1782	4	2-OH-Phenyl	3-pyridyl
1783	4	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1784	4	2-OH-Phenyl	1H-imidazol-4-yl
1785	4	2-OH-Phenyl	2-furanyl
1786	4	3-OMe-Phenyl	Ethyl
1787	4	3-OMe-Phenyl	n-propyl
1788	4	3-OMe-Phenyl	Isopropyl
1789	4	3-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1790	4	3-OMe-Phenyl	CF_3
1791	4	3-OMe-Phenyl	-CH_2CF_3
1792	4	3-OMe-Phenyl	-$CH_2CH_2CF_3$
1793	4	3-OMe-Phenyl	cyclopropyl

1794	4	3-OMe-Phenyl	Cyclobutyl
1795	4	3-OMe-Phenyl	cyclopentyl
1796	4	3-OMe-Phenyl	cyclohexyl
1797	4	3-OMe-Phenyl	3-pyridyl
1798	4	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1799	4	3-OMe-Phenyl	1H-imidazol-4-yl
1800	4	3-OMe-Phenyl	2-furanyl
1801	4	4-CN-Phenyl	Ethyl
1802	4	4-CN-Phenyl	n-propyl
1803	4	4-CN-Phenyl	Isopropyl
1804	4	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
1805	4	4-CN-Phenyl	CF_3
1806	4	4-CN-Phenyl	$-CH_2CF_3$
1807	4	4-CN-Phenyl	$-CH_2CH_2CF_3$
1808	4	4-CN-Phenyl	cyclopropyl
1809	4	4-CN-Phenyl	Cyclobutyl
1810	4	4-CN-Phenyl	cyclopentyl
1811	4	4-CN-Phenyl	cyclohexyl
1812	4	4-CN-Phenyl	3-pyridyl
1813	4	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1814	4	4-CN-Phenyl	1H-imidazol-4-yl
1815	4	4-CN-Phenyl	2-furanyl
1816	4	2-CN-Phenyl	Ethyl
1817	4	2-CN-Phenyl	n-propyl
1818	4	2-CN-Phenyl	Isopropyl
1819	4	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
1820	4	2-CN-Phenyl	CF_3
1821	4	2-CN-Phenyl	$-CH_2CF_3$
1822	4	2-CN-Phenyl	$-CH_2CH_2CF_3$
1823	4	2-CN-Phenyl	cyclopropyl
1824	4	2-CN-Phenyl	Cyclobutyl
1825	4	2-CN-Phenyl	cyclopentyl
1826	4	2-CN-Phenyl	cyclohexyl
1827	4	2-CN-Phenyl	3-pyridyl
1828	4	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1829	4	2-CN-Phenyl	1H-imidazol-4-yl
1830	4	2-CN-Phenyl	2-furanyl
1831	4	3-F-Phenyl	Ethyl
1832	4	3-F-Phenyl	n-propyl
1833	4	3-F-Phenyl	Isopropyl
1834	4	3-F-Phenyl	$-CH_2CH(CH_3)_2$
1835	4	3-F-Phenyl	CF_3
1836	4	3-F-Phenyl	$-CH_2CF_3$
1837	4	3-F-Phenyl	$-CH_2CH_2CF_3$

1838	4	3-F-Phenyl	cyclopropyl
1839	4	3-F-Phenyl	Cyclobutyl
1840	4	3-F-Phenyl	cyclopentyl
1841	4	3-F-Phenyl	cyclohexyl
1842	4	3-F-Phenyl	3-pyridyl
1843	4	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1844	4	3-F-Phenyl	1H-imidazol-4-yl
1845	4	3-F-Phenyl	2-furanyl
1846	4	2-Cl-Phenyl	Ethyl
1847	4	2-Cl-Phenyl	n-propyl
1848	4	2-Cl-Phenyl	Isopropyl
1849	4	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1850	4	2-Cl-Phenyl	CF_3
1851	4	2-Cl-Phenyl	$-CH_2CF_3$
1852	4	2-Cl-Phenyl	$-CH_2CH_2CF_3$
1853	4	2-Cl-Phenyl	cyclopropyl
1854	4	2-Cl-Phenyl	Cyclobutyl
1855	4	2-Cl-Phenyl	cyclopentyl
1856	4	2-Cl-Phenyl	cyclohexyl
1857	4	2-Cl-Phenyl	3-pyridyl
1858	4	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1859	4	2-Cl-Phenyl	1H-imidazol-4-yl
1860	4	2-Cl-Phenyl	2-furanyl
1861	4	4-Cl-Phenyl	Ethyl
1862	4	4-Cl-Phenyl	n-propyl
1863	4	4-Cl-Phenyl	Isopropyl
1864	4	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1865	4	4-Cl-Phenyl	CF_3
1866	4	4-Cl-Phenyl	$-CH_2CF_3$
1867	4	4-Cl-Phenyl	$-CH_2CH_2CF_3$
1868	4	4-Cl-Phenyl	cyclopropyl
1869	4	4-Cl-Phenyl	Cyclobutyl
1870	4	4-Cl-Phenyl	cyclopentyl
1871	4	4-Cl-Phenyl	cyclohexyl
1872	4	4-Cl-Phenyl	3-pyridyl
1873	4	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1874	4	4-Cl-Phenyl	1H-imidazol-4-yl
1875	4	4-Cl-Phenyl	2-furanyl
1876	4	3-Br-Phenyl	Ethyl
1877	4	3-Br-Phenyl	n-propyl
1878	4	3-Br-Phenyl	Isopropyl
1879	4	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
1880	4	3-Br-Phenyl	CF_3
1881	4	3-Br-Phenyl	$-CH_2CF_3$

1882	4	3-Br-Phenyl	$-CH_2CH_2CF_3$
1883	4	3-Br-Phenyl	cyclopropyl
1884	4	3-Br-Phenyl	Cyclobutyl
1885	4	3-Br-Phenyl	cyclopentyl
1886	4	3-Br-Phenyl	cyclohexyl
1887	4	3-Br-Phenyl	3-pyridyl
1888	4	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1889	4	3-Br-Phenyl	1H-imidazol-4-yl
1890	4	3-Br-Phenyl	2-furanyl
1891	4	2-CF_3-Phenyl	Ethyl
1892	4	2-CF_3-Phenyl	n-propyl
1893	4	2-CF_3-Phenyl	Isopropyl
1894	4	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1895	4	2-CF_3-Phenyl	CF_3
1896	4	2-CF_3-Phenyl	$-CH_2CF_3$
1897	4	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
1898	4	2-CF_3-Phenyl	cyclopropyl
1899	4	2-CF_3-Phenyl	Cyclobutyl
1900	4	2-CF_3-Phenyl	cyclopentyl
1901	4	2-CF_3-Phenyl	cyclohexyl
1902	4	2-CF_3-Phenyl	3-pyridyl
1903	4	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1904	4	2-CF_3-Phenyl	1H-imidazol-4-yl
1905	4	2-CF_3-Phenyl	2-furanyl
1906	4	4-CF_3-Phenyl	Ethyl
1907	4	4-CF_3-Phenyl	n-propyl
1908	4	4-CF_3-Phenyl	Isopropyl
1909	4	4-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1910	4	4-CF_3-Phenyl	CF_3
1911	4	4-CF_3-Phenyl	$-CH_2CF_3$
1912	4	4-CF_3-Phenyl	$-CH_2CH_2CF_3$
1913	4	4-CF_3-Phenyl	cyclopropyl
1914	4	4-CF_3-Phenyl	Cyclobutyl
1915	4	4-CF_3-Phenyl	cyclopentyl
1916	4	4-CF_3-Phenyl	cyclohexyl
1917	4	4-CF_3-Phenyl	3-pyridyl
1918	4	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1919	4	4-CF_3-Phenyl	1H-imidazol-4-yl
1920	4	4-CF_3-Phenyl	2-furanyl
1921	4	3-iPr-Phenyl	Ethyl
1922	4	3-iPr-Phenyl	n-propyl


1923	4	3-iPr-Phenyl	Isopropyl
1924	4	3-iPr-Phenyl	$-CH_2CH(CH_3)_2$
1925	4	3-iPr-Phenyl	CF_3
1926	4	3-iPr-Phenyl	$-CH_2CF_3$
1927	4	3-iPr-Phenyl	$-CH_2CH_2CF_3$
1928	4	3-iPr-Phenyl	cyclopropyl
1929	4	3-iPr-Phenyl	Cyclobutyl
1930	4	3-iPr-Phenyl	cyclopentyl
1931	4	3-iPr-Phenyl	cyclohexyl
1932	4	3-iPr-Phenyl	3-pyridyl
1933	4	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1934	4	3-iPr-Phenyl	1H-imidazol-4-yl
1935	4	3-iPr-Phenyl	2-furanyl
1936	4	2-morpholino-phenyl	Ethyl
1937	4	2-morpholino-phenyl	n-propyl
1938	4	2-morpholino-phenyl	isopropyl
1939	4	2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1940	4	2-morpholino-phenyl	CF_3
1941	4	2-morpholino-phenyl	$-CH_2CF_3$
1942	4	2-morpholino-phenyl	$-CH_2CH_2CF_3$
1943	4	2-morpholino-phenyl	cyclopropyl
1944	4	2-morpholino-phenyl	Cyclobutyl
1945	4	2-morpholino-phenyl	cyclopentyl
1946	4	2-morpholino-phenyl	cyclohexyl
1947	4	2-morpholino-phenyl	3-pyridyl
1948	4	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1949	4	2-morpholino-phenyl	1H-imidazol-4-yl
1950	4	2-morpholino-phenyl	2-furanyl
1951	4	4-morpholino-phenyl	ethyl
1952	4	4-morpholino-phenyl	n-propyl
1953	4	4-morpholino-phenyl	isopropyl
1954	4	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1955	4	4-morpholino-phenyl	CF_3
1956	4	4-morpholino-phenyl	$-CH_2CF_3$
1957	4	4-morpholino-phenyl	$-CH_2CH_2CF_3$
1958	4	4-morpholino-phenyl	cyclopropyl
1959	4	4-morpholino-phenyl	Cyclobutyl
1960	4	4-morpholino-phenyl	cyclopentyl
1961	4	4-morpholino-phenyl	cyclohexyl
1962	4	4-morpholino-phenyl	3-pyridyl
1963	4	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1964	4	4-morpholino-phenyl	1H-imidazol-4-yl
1965	4	4-morpholino-phenyl	2-furanyl
1966	4	4-methyl-2-morpholino-phenyl	ethyl

1967	4	4-methyl-2-morpholino-phenyl	n-propyl
1968	4	4-methyl-2-morpholino-phenyl	isopropyl
1969	4	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1970	4	4-methyl-2-morpholino-phenyl	CF_3
1971	4	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
1972	4	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1973	4	4-methyl-2-morpholino-phenyl	cyclopropyl
1974	4	4-methyl-2-morpholino-phenyl	Cyclobutyl
1975	4	4-methyl-2-morpholino-phenyl	cyclopentyl
1976	4	4-methyl-2-morpholino-phenyl	cyclohexyl
1977	4	4-methyl-2-morpholino-phenyl	3-pyridyl
1978	4	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1979	4	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
1980	4	4-methyl-2-morpholino-phenyl	2-furanyl
1981	1	naphthylen-1-yl	Ethyl
1982	1	naphthylen-1-yl	n-propyl
1983	1	naphthylen-1-yl	Isopropyl
1984	1	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
1985	1	naphthylen-1-yl	CF_3
1986	1	naphthylen-1-yl	$-CH_2CF_3$
1987	1	naphthylen-1-yl	$-CH_2CH_2CF_3$
1988	1	naphthylen-1-yl	Cyclopropyl
1989	1	naphthylen-1-yl	Cyclobutyl
1990	1	naphthylen-1-yl	Cyclopentyl
1991	1	naphthylen-1-yl	Cyclohexyl
1992	1	naphthylen-1-yl	3-pyridyl
1993	1	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
1994	1	naphthylen-1-yl	1H-imidazol-4-yl
1995	1	naphthylen-1-yl	2-furanyl
1996	1	naphthylen-2-yl	Ethyl
1997	1	naphthylen-2-yl	n-propyl
1998	1	naphthylen-2-yl	Isopropyl
1999	1	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2000	1	naphthylen-2-yl	CF_3
2001	1	naphthylen-2-yl	$-CH_2CF_3$
2002	1	naphthylen-2-yl	$-CH_2CH_2CF_3$
2003	1	naphthylen-2-yl	Cyclopropyl
2004	1	naphthylen-2-yl	Cyclobutyl
2005	1	naphthylen-2-yl	Cyclopentyl
2006	1	naphthylen-2-yl	Cyclohexyl
2007	1	naphthylen-2-yl	3-pyridyl
2008	1	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2009	1	naphthylen-2-yl	1H-imidazol-4-yl
2010	1	naphthylen-2-yl	2-furanyl
2011	2	naphthylen-1-yl	Ethyl

2012	2	naphthylen-1-yl	n-propyl
2013	2	naphthylen-1-yl	Isopropyl
2014	2	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2015	2	naphthylen-1-yl	CF_3
2016	2	naphthylen-1-yl	$-CH_2CF_3$
2017	2	naphthylen-1-yl	$-CH_2CH_2CF_3$
2018	2	naphthylen-1-yl	Cyclopropyl
2019	2	naphthylen-1-yl	Cyclobutyl
2020	2	naphthylen-1-yl	Cyclopentyl
2021	2	naphthylen-1-yl	Cyclohexyl
2022	2	naphthylen-1-yl	3-pyridyl
2023	2	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2024	2	naphthylen-1-yl	1H-imidazol-4-yl
2025	2	naphthylen-1-yl	2-furanyl
2026	2	naphthylen-2-yl	Ethyl
2027	2	naphthylen-2-yl	n-propyl
2028	2	naphthylen-2-yl	Isopropyl
2029	2	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2030	2	naphthylen-2-yl	CF_3
2031	2	naphthylen-2-yl	$-CH_2CF_3$
2032	2	naphthylen-2-yl	$-CH_2CH_2CF_3$
2033	2	naphthylen-2-yl	Cyclopropyl
2034	2	naphthylen-2-yl	Cyclobutyl
2035	2	naphthylen-2-yl	Cyclopentyl
2036	2	naphthylen-2-yl	Cyclohexyl
2037	2	naphthylen-2-yl	3-pyridyl
2038	2	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2039	2	naphthylen-2-yl	1H-imidazol-4-yl
2040	2	naphthylen-2-yl	2-furanyl
2041	3	naphthylen-1-yl	Ethyl
2042	3	naphthylen-1-yl	n-propyl
2043	3	naphthylen-1-yl	Isopropyl
2044	3	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2045	3	naphthylen-1-yl	CF_3
2046	3	naphthylen-1-yl	$-CH_2CF_3$
2047	3	naphthylen-1-yl	$-CH_2CH_2CF_3$
2048	3	naphthylen-1-yl	Cyclopropyl
2049	3	naphthylen-1-yl	Cyclobutyl
2050	3	naphthylen-1-yl	Cyclopentyl
2051	3	naphthylen-1-yl	Cyclohexyl
2052	3	naphthylen-1-yl	3-pyridyl
2053	3	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2054	3	naphthylen-1-yl	1H-imidazol-4-yl
2055	3	naphthylen-1-yl	2-furanyl
2056	3	naphthylen-2-yl	Ethyl

2057	3	naphthylen-2-yl	n-propyl
2058	3	naphthylen-2-yl	Isopropyl
2059	3	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2060	3	naphthylen-2-yl	CF_3
2061	3	naphthylen-2-yl	$-CH_2CF_3$
2062	3	naphthylen-2-yl	$-CH_2CH_2CF_3$
2063	3	naphthylen-2-yl	Cyclopropyl
2064	3	naphthylen-2-yl	Cyclobutyl
2065	3	naphthylen-2-yl	Cyclopentyl
2066	3	naphthylen-2-yl	Cyclohexyl
2067	3	naphthylen-2-yl	3-pyridyl
2068	3	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2069	3	naphthylen-2-yl	1H-imidazol-4-yl
2070	3	naphthylen-2-yl	2-furanyl
2071	4	naphthylen-1-yl	Ethyl
2072	4	naphthylen-1-yl	n-propyl
2073	4	naphthylen-1-yl	Isopropyl
2074	4	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2075	4	naphthylen-1-yl	CF_3
2076	4	naphthylen-1-yl	$-CH_2CF_3$
2077	4	naphthylen-1-yl	$-CH_2CH_2CF_3$
2078	4	naphthylen-1-yl	Cyclopropyl
2079	4	naphthylen-1-yl	Cyclobutyl
2080	4	naphthylen-1-yl	Cyclopentyl
2081	4	naphthylen-1-yl	Cyclohexyl
2082	4	naphthylen-1-yl	3-pyridyl
2083	4	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2084	4	naphthylen-1-yl	1H-imidazol-4-yl
2085	4	naphthylen-1-yl	2-furanyl
2086	4	naphthylen-2-yl	Ethyl
2087	4	naphthylen-2-yl	n-propyl
2088	4	naphthylen-2-yl	Isopropyl
2089	4	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2090	4	naphthylen-2-yl	CF_3
2091	4	naphthylen-2-yl	$-CH_2CF_3$
2092	4	naphthylen-2-yl	$-CH_2CH_2CF_3$
2093	4	naphthylen-2-yl	Cyclopropyl
2094	4	naphthylen-2-yl	Cyclobutyl
2095	4	naphthylen-2-yl	Cyclopentyl
2096	4	naphthylen-2-yl	Cyclohexyl
2097	4	naphthylen-2-yl	3-pyridyl
2098	4	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2099	4	naphthylen-2-yl	1H-imidazol-4-yl
2100	4	naphthylen-2-yl	2-furanyl

[01041] Exemplary embodiments include compounds having the formula **(XXXX)**



(XXXX)

or a pharmaceutically acceptable salt form thereof defined herein below in Table 33.

Table 33

Entry	n	R^5	R^{10c}
1	1	4-CH_3-phenyl	Ethyl
2	1	4-CH_3-phenyl	n-propyl
3	1	4-CH_3-phenyl	Isopropyl
4	1	4-CH_3-phenyl	-$CH_2CH(CH_3)_2$
5	1	4-CH_3-phenyl	CF_3
6	1	4-CH_3-phenyl	-CH_2CF_3
7	1	4-CH_3-phenyl	-$CH_2CH_2CF_3$
8	1	4-CH_3-phenyl	Cyclopropyl
9	1	4-CH_3-phenyl	Cyclobutyl
10	1	4-CH_3-phenyl	Cyclopentyl
11	1	4-CH_3-phenyl	Cyclohexyl
12	1	4-CH_3-phenyl	3-pyridyl
13	1	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
14	1	4-CH_3-phenyl	1H-imidazol-4-yl
15	1	4-CH_3-phenyl	2-furanyl
16	1	3-CH_3-phenyl	Ethyl
17	1	3-CH_3-phenyl	n-propyl
18	1	3-CH_3-phenyl	Isopropyl
19	1	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
20	1	3-CH_3-phenyl	CF_3
21	1	3-CH_3-phenyl	-CH_2CF_3
22	1	3-CH_3-phenyl	-$CH_2CH_2CF_3$
23	1	3-CH_3-phenyl	Cyclopropyl
24	1	3-CH_3-phenyl	Cyclobutyl
25	1	3-CH_3-phenyl	Cyclopentyl
26	1	3-CH_3-phenyl	cyclohexyl
27	1	3-CH_3-phenyl	3-pyridyl
28	1	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
29	1	3-CH_3-phenyl	1H-imidazol-4-yl
30	1	3-CH_3-phenyl	2-furanyl
31	1	3-OH-Phenyl	ethyl

32	1	3-OH-Phenyl	n-propyl
33	1	3-OH-Phenyl	isopropyl
34	1	3-OH-Phenyl	$-CH_2CH(CH_3)_2$
35	1	3-OH-Phenyl	CF_3
36	1	3-OH-Phenyl	$-CH_2CF_3$
37	1	3-OH-Phenyl	$-CH_2CH_2CF_3$
38	1	3-OH-Phenyl	cyclopropyl
39	1	3-OH-Phenyl	Cyclobutyl
40	1	3-OH-Phenyl	cyclopentyl
41	1	3-OH-Phenyl	cyclohexyl
42	1	3-OH-Phenyl	3-pyridyl
43	1	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
44	1	3-OH-Phenyl	1H-imidazol-4-yl
45	1	3-OH-Phenyl	2-furanyl
46	1	4-OMe-Phenyl	ethyl
47	1	4-OMe-Phenyl	n-propyl
48	1	4-OMe-Phenyl	isopropyl
49	1	4-OMe-Phenyl	$-CH_2CH(CH_3)_2$
50	1	4-OMe-Phenyl	CF_3
51	1	4-OMe-Phenyl	$-CH_2CF_3$
52	1	4-OMe-Phenyl	$-CH_2CH_2CF_3$
53	1	4-OMe-Phenyl	cyclopropyl
54	1	4-OMe-Phenyl	Cyclobutyl
55	1	4-OMe-Phenyl	cyclopentyl
56	1	4-OMe-Phenyl	cyclohexyl
57	1	4-OMe-Phenyl	3-pyridyl
58	1	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
59	1	4-OMe-Phenyl	1H-imidazol-4-yl
60	1	4-OMe-Phenyl	2-furanyl
61	1	2-OMe-Phenyl	ethyl
62	1	2-OMe-Phenyl	n-propyl
63	1	2-OMe-Phenyl	isopropyl
64	1	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
65	1	2-OMe-Phenyl	CF_3
66	1	2-OMe-Phenyl	$-CH_2CF_3$
67	1	2-OMe-Phenyl	$-CH_2CH_2CF_3$
68	1	2-OMe-Phenyl	cyclopropyl
69	1	2-OMe-Phenyl	Cyclobutyl
70	1	2-OMe-Phenyl	cyclopentyl
71	1	2-OMe-Phenyl	cyclohexyl
72	1	2-OMe-Phenyl	3-pyridyl
73	1	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
74	1	2-OMe-Phenyl	1H-imidazol-4-yl
75	1	2-OMe-Phenyl	2-furanyl

76	1	3-CN-Phenyl	ethyl
77	1	3-CN-Phenyl	n-propyl
78	1	3-CN-Phenyl	isopropyl
79	1	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
80	1	3-CN-Phenyl	CF_3
81	1	3-CN-Phenyl	$-CH_2CF_3$
82	1	3-CN-Phenyl	$-CH_2CH_2CF_3$
83	1	3-CN-Phenyl	cyclopropyl
84	1	3-CN-Phenyl	Cyclobutyl
85	1	3-CN-Phenyl	cyclopentyl
86	1	3-CN-Phenyl	cyclohexyl
87	1	3-CN-Phenyl	3-pyridyl
88	1	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
89	1	3-CN-Phenyl	1H-imidazol-4-yl
90	1	3-CN-Phenyl	2-furanyl
91	1	2-F-Phenyl	ethyl
92	1	2-F-Phenyl	n-propyl
93	1	2-F-Phenyl	isopropyl
94	1	2-F-Phenyl	$-CH_2CH(CH_3)_2$
95	1	2-F-Phenyl	CF_3
96	1	2-F-Phenyl	$-CH_2CF_3$
97	1	2-F-Phenyl	$-CH_2CH_2CF_3$
98	1	2-F-Phenyl	cyclopropyl
99	1	2-F-Phenyl	Cyclobutyl
100	1	2-F-Phenyl	cyclopentyl
101	1	2-F-Phenyl	cyclohexyl
102	1	2-F-Phenyl	3-pyridyl
103	1	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
104	1	2-F-Phenyl	1H-imidazol-4-yl
105	1	2-F-Phenyl	2-furanyl
106	1	4-F-Phenyl	ethyl
107	1	4-F-Phenyl	n-propyl
108	1	4-F-Phenyl	isopropyl
109	1	4-F-Phenyl	$-CH_2CH(CH_3)_2$
110	1	4-F-Phenyl	CF_3
111	1	4-F-Phenyl	$-CH_2CF_3$
112	1	4-F-Phenyl	$-CH_2CH_2CF_3$
113	1	4-F-Phenyl	cyclopropyl
114	1	4-F-Phenyl	Cyclobutyl
115	1	4-F-Phenyl	cyclopentyl
116	1	4-F-Phenyl	cyclohexyl
117	1	4-F-Phenyl	3-pyridyl
118	1	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
119	1	4-F-Phenyl	1H-imidazol-4-yl

120	1	4-F-Phenyl	2-furanyl
121	1	3-Cl-Phenyl	ethyl
122	1	3-Cl-Phenyl	n-propyl
123	1	3-Cl-Phenyl	isopropyl
124	1	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
125	1	3-Cl-Phenyl	CF_3
126	1	3-Cl-Phenyl	$-CH_2CF_3$
127	1	3-Cl-Phenyl	$-CH_2CH_2CF_3$
128	1	3-Cl-Phenyl	cyclopropyl
129	1	3-Cl-Phenyl	Cyclobutyl
130	1	3-Cl-Phenyl	cyclopentyl
131	1	3-Cl-Phenyl	cyclohexyl
132	1	3-Cl-Phenyl	3-pyridyl
133	1	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
134	1	3-Cl-Phenyl	1H-imidazol-4-yl
135	1	3-Cl-Phenyl	2-furanyl
136	1	2-Br-Phenyl	ethyl
137	1	2-Br-Phenyl	n-propyl
138	1	2-Br-Phenyl	isopropyl
139	1	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
140	1	2-Br-Phenyl	CF_3
141	1	2-Br-Phenyl	$-CH_2CF_3$
142	1	2-Br-Phenyl	$-CH_2CH_2CF_3$
143	1	2-Br-Phenyl	cyclopropyl
144	1	2-Br-Phenyl	Cyclobutyl
145	1	2-Br-Phenyl	cyclopentyl
146	1	2-Br-Phenyl	cyclohexyl
147	1	2-Br-Phenyl	3-pyridyl
148	1	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
149	1	2-Br-Phenyl	1H-imidazol-4-yl
150	1	2-Br-Phenyl	2-furanyl
151	1	4-Br-Phenyl	ethyl
152	1	4-Br-Phenyl	n-propyl
153	1	4-Br-Phenyl	isopropyl
154	1	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
155	1	4-Br-Phenyl	CF_3
156	1	4-Br-Phenyl	$-CH_2CF_3$
157	1	4-Br-Phenyl	$-CH_2CH_2CF_3$
158	1	4-Br-Phenyl	cyclopropyl
159	1	4-Br-Phenyl	Cyclobutyl
160	1	4-Br-Phenyl	cyclopentyl
161	1	4-Br-Phenyl	cyclohexyl
162	1	4-Br-Phenyl	3-pyridyl
163	1	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl

164	1	4-Br-Phenyl	1H-imidazol-4-yl
165	1	4-Br-Phenyl	2-furanyl
166	1	3-CF_3-Phenyl	ethyl
167	1	3-CF_3-Phenyl	n-propyl
168	1	3-CF_3-Phenyl	isopropyl
169	1	3-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
170	1	3-CF_3-Phenyl	CF_3
171	1	3-CF_3-Phenyl	-CH_2CF_3
172	1	3-CF_3-Phenyl	-$CH_2CH_2CF_3$
173	1	3-CF_3-Phenyl	cyclopropyl
174	1	3-CF_3-Phenyl	Cyclobutyl
175	1	3-CF_3-Phenyl	cyclopentyl
176	1	3-CF_3-Phenyl	cyclohexyl
177	1	3-CF_3-Phenyl	3-pyridyl
178	1	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
179	1	3-CF_3-Phenyl	1H-imidazol-4-yl
180	1	3-CF_3-Phenyl	2-furanyl
181	1	2-iPr-Phenyl	ethyl
182	1	2-iPr-Phenyl	n-propyl
183	1	2-iPr-Phenyl	isopropyl
184	1	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
185	1	2-iPr-Phenyl	CF_3
186	1	2-iPr-Phenyl	-CH_2CF_3
187	1	2-iPr-Phenyl	-$CH_2CH_2CF_3$
188	1	2-iPr-Phenyl	cyclopropyl
189	1	2-iPr-Phenyl	Cyclobutyl
190	1	2-iPr-Phenyl	cyclopentyl
191	1	2-iPr-Phenyl	cyclohexyl
192	1	2-iPr-Phenyl	3-pyridyl
193	1	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
194	1	2-iPr-Phenyl	1H-imidazol-4-yl
195	1	2-iPr-Phenyl	2-furanyl
196	1	4-iPr-Phenyl	ethyl
197	1	4-iPr-Phenyl	n-propyl
198	1	4-iPr-Phenyl	isopropyl
199	1	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
200	1	4-iPr-Phenyl	CF_3
201	1	4-iPr-Phenyl	-CH_2CF_3
202	1	4-iPr-Phenyl	-$CH_2CH_2CF_3$
203	1	4-iPr-Phenyl	cyclopropyl
204	1	4-iPr-Phenyl	Cyclobutyl
205	1	4-iPr-Phenyl	cyclopentyl

206	1	4-iPr-Phenyl	cyclohexyl
207	1	4-iPr-Phenyl	3-pyridyl
208	1	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
209	1	4-iPr-Phenyl	1H-imidazol-4-yl
210	1	4-iPr-Phenyl	2-furanyl
211	1	3-morpholino-phenyl	ethyl
212	1	3-morpholino-phenyl	n-propyl
213	1	3-morpholino-phenyl	isopropyl
214	1	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
215	1	3-morpholino-phenyl	CF_3
216	1	3-morpholino-phenyl	$-CH_2CF_3$
217	1	3-morpholino-phenyl	$-CH_2CH_2CF_3$
218	1	3-morpholino-phenyl	cyclopropyl
219	1	3-morpholino-phenyl	Cyclobutyl
220	1	3-morpholino-phenyl	cyclopentyl
221	1	3-morpholino-phenyl	cyclohexyl
222	1	3-morpholino-phenyl	3-pyridyl
223	1	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
224	1	3-morpholino-phenyl	1H-imidazol-4-yl
225	1	3-morpholino-phenyl	2-furanyl
226	1	4-cyano-2-morpholino-phenyl	ethyl
227	1	4-cyano-2-morpholino-phenyl	n-propyl
228	1	4-cyano-2-morpholino-phenyl	isopropyl
229	1	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
230	1	4-cyano-2-morpholino-phenyl	CF_3
231	1	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
232	1	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
233	1	4-cyano-2-morpholino-phenyl	cyclopropyl
234	1	4-cyano-2-morpholino-phenyl	Cyclobutyl
235	1	4-cyano-2-morpholino-phenyl	cyclopentyl
236	1	4-cyano-2-morpholino-phenyl	cyclohexyl
237	1	4-cyano-2-morpholino-phenyl	3-pyridyl
238	1	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
239	1	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
240	1	4-cyano-2-morpholino-phenyl	2-furanyl
241	1	4-hydroxy-2-morpholino-phenyl	ethyl
242	1	4-hydroxy-2-morpholino-phenyl	n-propyl
243	1	4-hydroxy-2-morpholino-phenyl	isopropyl
244	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
245	1	4-hydroxy-2-morpholino-phenyl	CF_3
246	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
247	1	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
248	1	4-hydroxy-2-morpholino-phenyl	cyclopropyl
249	1	4-hydroxy-2-morpholino-phenyl	Cyclobutyl

250	1	4-hydroxy-2-morpholino-phenyl	cyclopentyl
251	1	4-hydroxy-2-morpholino-phenyl	cyclohexyl
252	1	4-hydroxy-2-morpholino-phenyl	3-pyridyl
253	1	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
254	1	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
255	1	4-hydroxy-2-morpholino-phenyl	2-furanyl
256	1	2-CH_3-phenyl	Ethyl
257	1	2-CH_3-phenyl	n-propyl
258	1	2-CH_3-phenyl	Isopropyl
259	1	2-CH_3-phenyl	-$CH_2CH(CH_3)_2$
260	1	2-CH_3-phenyl	CF_3
261	1	2-CH_3-phenyl	-CH_2CF_3
262	1	2-CH_3-phenyl	-$CH_2CH_2CF_3$
263	1	2-CH_3-phenyl	cyclopropyl
264	1	2-CH_3-phenyl	Cyclobutyl
265	1	2-CH_3-phenyl	cyclopentyl
266	1	2-CH_3-phenyl	cyclohexyl
267	1	2-CH_3-phenyl	3-pyridyl
268	1	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
269	1	2-CH_3-phenyl	1H-imidazol-4-yl
270	1	2-CH_3-phenyl	2-furanyl
271	1	4-OH-Phenyl	Ethyl
272	1	4-OH-Phenyl	n-propyl
273	1	4-OH-Phenyl	Isopropyl
274	1	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
275	1	4-OH-Phenyl	CF_3
276	1	4-OH-Phenyl	-CH_2CF_3
277	1	4-OH-Phenyl	-$CH_2CH_2CF_3$
278	1	4-OH-Phenyl	cyclopropyl
279	1	4-OH-Phenyl	Cyclobutyl
280	1	4-OH-Phenyl	cyclopentyl
281	1	4-OH-Phenyl	cyclohexyl
282	1	4-OH-Phenyl	3-pyridyl
283	1	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
284	1	4-OH-Phenyl	1H-imidazol-4-yl
285	1	4-OH-Phenyl	2-furanyl
286	1	2-OH-Phenyl	Ethyl
287	1	2-OH-Phenyl	n-propyl
288	1	2-OH-Phenyl	Isopropyl
289	1	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
290	1	2-OH-Phenyl	CF_3
291	1	2-OH-Phenyl	-CH_2CF_3

292	1	2-OH-Phenyl	$-CH_2CH_2CF_3$
293	1	2-OH-Phenyl	cyclopropyl
294	1	2-OH-Phenyl	Cyclobutyl
295	1	2-OH-Phenyl	cyclopentyl
296	1	2-OH-Phenyl	cyclohexyl
297	1	2-OH-Phenyl	3-pyridyl
298	1	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
299	1	2-OH-Phenyl	1H-imidazol-4-yl
300	1	2-OH-Phenyl	2-furanyl
301	1	3-OMe-Phenyl	Ethyl
302	1	3-OMe-Phenyl	n-propyl
303	1	3-OMe-Phenyl	Isopropyl
304	1	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
305	1	3-OMe-Phenyl	CF_3
306	1	3-OMe-Phenyl	$-CH_2CF_3$
307	1	3-OMe-Phenyl	$-CH_2CH_2CF_3$
308	1	3-OMe-Phenyl	cyclopropyl
309	1	3-OMe-Phenyl	Cyclobutyl
310	1	3-OMe-Phenyl	cyclopentyl
311	1	3-OMe-Phenyl	cyclohexyl
312	1	3-OMe-Phenyl	3-pyridyl
313	1	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
314	1	3-OMe-Phenyl	1H-imidazol-4-yl
315	1	3-OMe-Phenyl	2-furanyl
316	1	4-CN-Phenyl	Ethyl
317	1	4-CN-Phenyl	n-propyl
318	1	4-CN-Phenyl	Isopropyl
319	1	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
320	1	4-CN-Phenyl	CF_3
321	1	4-CN-Phenyl	$-CH_2CF_3$
322	1	4-CN-Phenyl	$-CH_2CH_2CF_3$
323	1	4-CN-Phenyl	cyclopropyl
324	1	4-CN-Phenyl	Cyclobutyl
325	1	4-CN-Phenyl	cyclopentyl
326	1	4-CN-Phenyl	cyclohexyl
327	1	4-CN-Phenyl	3-pyridyl
328	1	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
329	1	4-CN-Phenyl	1H-imidazol-4-yl
330	1	4-CN-Phenyl	2-furanyl
331	1	2-CN-Phenyl	Ethyl
332	1	2-CN-Phenyl	n-propyl
333	1	2-CN-Phenyl	Isopropyl
334	1	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
335	1	2-CN-Phenyl	CF_3

336	1	2-CN-Phenyl	$-CH_2CF_3$
337	1	2-CN-Phenyl	$-CH_2CH_2CF_3$
338	1	2-CN-Phenyl	cyclopropyl
339	1	2-CN-Phenyl	Cyclobutyl
340	1	2-CN-Phenyl	cyclopentyl
341	1	2-CN-Phenyl	cyclohexyl
342	1	2-CN-Phenyl	3-pyridyl
343	1	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
344	1	2-CN-Phenyl	1H-imidazol-4-yl
345	1	2-CN-Phenyl	2-furanyl
346	1	3-F-Phenyl	Ethyl
347	1	3-F-Phenyl	n-propyl
348	1	3-F-Phenyl	Isopropyl
349	1	3-F-Phenyl	$-CH_2CH(CH_3)_2$
350	1	3-F-Phenyl	CF_3
351	1	3-F-Phenyl	$-CH_2CF_3$
352	1	3-F-Phenyl	$-CH_2CH_2CF_3$
353	1	3-F-Phenyl	cyclopropyl
354	1	3-F-Phenyl	Cyclobutyl
355	1	3-F-Phenyl	cyclopentyl
356	1	3-F-Phenyl	cyclohexyl
357	1	3-F-Phenyl	3-pyridyl
358	1	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
359	1	3-F-Phenyl	1H-imidazol-4-yl
360	1	3-F-Phenyl	2-furanyl
361	1	2-Cl-Phenyl	Ethyl
362	1	2-Cl-Phenyl	n-propyl
363	1	2-Cl-Phenyl	Isopropyl
364	1	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
365	1	2-Cl-Phenyl	CF_3
366	1	2-Cl-Phenyl	$-CH_2CF_3$
367	1	2-Cl-Phenyl	$-CH_2CH_2CF_3$
368	1	2-Cl-Phenyl	cyclopropyl
369	1	2-Cl-Phenyl	Cyclobutyl
370	1	2-Cl-Phenyl	cyclopentyl
371	1	2-Cl-Phenyl	cyclohexyl
372	1	2-Cl-Phenyl	3-pyridyl
373	1	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
374	1	2-Cl-Phenyl	1H-imidazol-4-yl
375	1	2-Cl-Phenyl	2-furanyl
376	1	4-Cl-Phenyl	Ethyl
377	1	4-Cl-Phenyl	n-propyl
378	1	4-Cl-Phenyl	Isopropyl
379	1	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$

380	1	4-Cl-Phenyl	CF_3
381	1	4-Cl-Phenyl	$-CH_2CF_3$
382	1	4-Cl-Phenyl	$-CH_2CH_2CF_3$
383	1	4-Cl-Phenyl	cyclopropyl
384	1	4-Cl-Phenyl	Cyclobutyl
385	1	4-Cl-Phenyl	cyclopentyl
386	1	4-Cl-Phenyl	cyclohexyl
387	1	4-Cl-Phenyl	3-pyridyl
388	1	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
389	1	4-Cl-Phenyl	1H-imidazol-4-yl
390	1	4-Cl-Phenyl	2-furanyl
391	1	3-Br-Phenyl	Ethyl
392	1	3-Br-Phenyl	n-propyl
393	1	3-Br-Phenyl	Isopropyl
394	1	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
395	1	3-Br-Phenyl	CF_3
396	1	3-Br-Phenyl	$-CH_2CF_3$
397	1	3-Br-Phenyl	$-CH_2CH_2CF_3$
398	1	3-Br-Phenyl	cyclopropyl
399	1	3-Br-Phenyl	Cyclobutyl
400	1	3-Br-Phenyl	cyclopentyl
401	1	3-Br-Phenyl	cyclohexyl
402	1	3-Br-Phenyl	3-pyridyl
403	1	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
404	1	3-Br-Phenyl	1H-imidazol-4-yl
405	1	3-Br-Phenyl	2-furanyl
406	1	2-CF_3-Phenyl	Ethyl
407	1	2-CF_3-Phenyl	n-propyl
408	1	2-CF_3-Phenyl	Isopropyl
409	1	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
410	1	2-CF_3-Phenyl	CF_3
411	1	2-CF_3-Phenyl	$-CH_2CF_3$
412	1	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
413	1	2-CF_3-Phenyl	cyclopropyl
414	1	2-CF_3-Phenyl	Cyclobutyl
415	1	2-CF_3-Phenyl	cyclopentyl
416	1	2-CF_3-Phenyl	cyclohexyl
417	1	2-CF_3-Phenyl	3-pyridyl
418	1	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
419	1	2-CF_3-Phenyl	1H-imidazol-4-yl
420	1	2-CF_3-Phenyl	2-furanyl
421	1	4-CF_3-Phenyl	Ethyl

422	1	4-CF_3-Phenyl	n-propyl
423	1	4-CF_3-Phenyl	Isopropyl
424	1	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
425	1	4-CF_3-Phenyl	CF_3
426	1	4-CF_3-Phenyl	-CH_2CF_3
427	1	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
428	1	4-CF_3-Phenyl	cyclopropyl
429	1	4-CF_3-Phenyl	Cyclobutyl
430	1	4-CF_3-Phenyl	cyclopentyl
431	1	4-CF_3-Phenyl	cyclohexyl
432	1	4-CF_3-Phenyl	3-pyridyl
433	1	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
434	1	4-CF_3-Phenyl	1H-imidazol-4-yl
435	1	4-CF_3-Phenyl	2-furanyl
436	1	3-iPr-Phenyl	Ethyl
437	1	3-iPr-Phenyl	n-propyl
438	1	3-iPr-Phenyl	Isopropyl
439	1	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
440	1	3-iPr-Phenyl	CF_3
441	1	3-iPr-Phenyl	-CH_2CF_3
442	1	3-iPr-Phenyl	-$CH_2CH_2CF_3$
443	1	3-iPr-Phenyl	cyclopropyl
444	1	3-iPr-Phenyl	Cyclobutyl
445	1	3-iPr-Phenyl	cyclopentyl
446	1	3-iPr-Phenyl	cyclohexyl
447	1	3-iPr-Phenyl	3-pyridyl
448	1	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
449	1	3-iPr-Phenyl	1H-imidazol-4-yl
450	1	3-iPr-Phenyl	2-furanyl
451	1	2-morpholino-phenyl	Ethyl
452	1	2-morpholino-phenyl	n-propyl
453	1	2-morpholino-phenyl	isopropyl
454	1	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
455	1	2-morpholino-phenyl	CF_3
456	1	2-morpholino-phenyl	-CH_2CF_3
457	1	2-morpholino-phenyl	-$CH_2CH_2CF_3$
458	1	2-morpholino-phenyl	cyclopropyl
459	1	2-morpholino-phenyl	Cyclobutyl
460	1	2-morpholino-phenyl	cyclopentyl
461	1	2-morpholino-phenyl	cyclohexyl
462	1	2-morpholino-phenyl	3-pyridyl
463	1	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl

464	1	2-morpholino-phenyl	1H-imidazol-4-yl
465	1	2-morpholino-phenyl	2-furanyl
466	1	4-morpholino-phenyl	ethyl
467	1	4-morpholino-phenyl	n-propyl
468	1	4-morpholino-phenyl	isopropyl
469	1	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
470	1	4-morpholino-phenyl	CF_3
471	1	4-morpholino-phenyl	$-CH_2CF_3$
472	1	4-morpholino-phenyl	$-CH_2CH_2CF_3$
473	1	4-morpholino-phenyl	cyclopropyl
474	1	4-morpholino-phenyl	Cyclobutyl
475	1	4-morpholino-phenyl	cyclopentyl
476	1	4-morpholino-phenyl	cyclohexyl
477	1	4-morpholino-phenyl	3-pyridyl
478	1	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
479	1	4-morpholino-phenyl	1H-imidazol-4-yl
480	1	4-morpholino-phenyl	2-furanyl
481	1	4-methyl-2-morpholino-phenyl	ethyl
482	1	4-methyl-2-morpholino-phenyl	n-propyl
483	1	4-methyl-2-morpholino-phenyl	isopropyl
484	1	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
485	1	4-methyl-2-morpholino-phenyl	CF_3
486	1	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
487	1	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
488	1	4-methyl-2-morpholino-phenyl	cyclopropyl
489	1	4-methyl-2-morpholino-phenyl	Cyclobutyl
490	1	4-methyl-2-morpholino-phenyl	cyclopentyl
491	1	4-methyl-2-morpholino-phenyl	cyclohexyl
492	1	4-methyl-2-morpholino-phenyl	3-pyridyl
493	1	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
494	1	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
495	1	4-methyl-2-morpholino-phenyl	2-furanyl
496	2	4-CH_3-phenyl	ethyl
497	2	4-CH_3-phenyl	n-propyl
498	2	4-CH_3-phenyl	isopropyl
499	2	4-CH_3-phenyl	$-CH_2CH(CH_3)_2$
500	2	4-CH_3-phenyl	CF_3
501	2	4-CH_3-phenyl	$-CH_2CF_3$
502	2	4-CH_3-phenyl	$-CH_2CH_2CF_3$
503	2	4-CH_3-phenyl	cyclopropyl
504	2	4-CH_3-phenyl	Cyclobutyl
505	2	4-CH_3-phenyl	cyclopentyl
506	2	4-CH_3-phenyl	cyclohexyl

507	2	4-CH_3-phenyl	3-pyridyl
508	2	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
509	2	4-CH_3-phenyl	1H-imidazol-4-yl
510	2	4-CH_3-phenyl	2-furanyl
511	2	3-CH_3-phenyl	ethyl
512	2	3-CH_3-phenyl	n-propyl
513	2	3-CH_3-phenyl	isopropyl
514	2	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
515	2	3-CH_3-phenyl	CF_3
516	2	3-CH_3-phenyl	-CH_2CF_3
517	2	3-CH_3-phenyl	-$CH_2CH_2CF_3$
518	2	3-CH_3-phenyl	cyclopropyl
519	2	3-CH_3-phenyl	Cyclobutyl
520	2	3-CH_3-phenyl	cyclopentyl
521	2	3-CH_3-phenyl	cyclohexyl
522	2	3-CH_3-phenyl	3-pyridyl
523	2	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
524	2	3-CH_3-phenyl	1H-imidazol-4-yl
525	2	3-CH_3-phenyl	2-furanyl
526	2	3-OH-Phenyl	ethyl
527	2	3-OH-Phenyl	n-propyl
528	2	3-OH-Phenyl	isopropyl
529	2	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
530	2	3-OH-Phenyl	CF_3
531	2	3-OH-Phenyl	-CH_2CF_3
532	2	3-OH-Phenyl	-$CH_2CH_2CF_3$
533	2	3-OH-Phenyl	cyclopropyl
534	2	3-OH-Phenyl	Cyclobutyl
535	2	3-OH-Phenyl	cyclopentyl
536	2	3-OH-Phenyl	cyclohexyl
537	2	3-OH-Phenyl	3-pyridyl
538	2	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
539	2	3-OH-Phenyl	1H-imidazol-4-yl
540	2	3-OH-Phenyl	2-furanyl
541	2	4-OMe-Phenyl	ethyl
542	2	4-OMe-Phenyl	n-propyl
543	2	4-OMe-Phenyl	isopropyl
544	2	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
545	2	4-OMe-Phenyl	CF_3
546	2	4-OMe-Phenyl	-CH_2CF_3
547	2	4-OMe-Phenyl	-$CH_2CH_2CF_3$
548	2	4-OMe-Phenyl	cyclopropyl

549	2	4-OMe-Phenyl	Cyclobutyl
550	2	4-OMe-Phenyl	cyclopentyl
551	2	4-OMe-Phenyl	cyclohexyl
552	2	4-OMe-Phenyl	3-pyridyl
553	2	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
554	2	4-OMe-Phenyl	1H-imidazol-4-yl
555	2	4-OMe-Phenyl	2-furanyl
556	2	2-OMe-Phenyl	ethyl
557	2	2-OMe-Phenyl	n-propyl
558	2	2-OMe-Phenyl	isopropyl
559	2	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
560	2	2-OMe-Phenyl	CF_3
561	2	2-OMe-Phenyl	$-CH_2CF_3$
562	2	2-OMe-Phenyl	$-CH_2CH_2CF_3$
563	2	2-OMe-Phenyl	cyclopropyl
564	2	2-OMe-Phenyl	Cyclobutyl
565	2	2-OMe-Phenyl	cyclopentyl
566	2	2-OMe-Phenyl	cyclohexyl
567	2	2-OMe-Phenyl	3-pyridyl
568	2	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
569	2	2-OMe-Phenyl	1H-imidazol-4-yl
570	2	2-OMe-Phenyl	2-furanyl
571	2	3-CN-Phenyl	ethyl
572	2	3-CN-Phenyl	n-propyl
573	2	3-CN-Phenyl	isopropyl
574	2	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
575	2	3-CN-Phenyl	CF_3
576	2	3-CN-Phenyl	$-CH_2CF_3$
577	2	3-CN-Phenyl	$-CH_2CH_2CF_3$
578	2	3-CN-Phenyl	cyclopropyl
579	2	3-CN-Phenyl	Cyclobutyl
580	2	3-CN-Phenyl	cyclopentyl
581	2	3-CN-Phenyl	cyclohexyl
582	2	3-CN-Phenyl	3-pyridyl
583	2	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
584	2	3-CN-Phenyl	1H-imidazol-4-yl
585	2	3-CN-Phenyl	2-furanyl
586	2	2-F-Phenyl	ethyl
587	2	2-F-Phenyl	n-propyl
588	2	2-F-Phenyl	isopropyl
589	2	2-F-Phenyl	$-CH_2CH(CH_3)_2$
590	2	2-F-Phenyl	CF_3
591	2	2-F-Phenyl	$-CH_2CF_3$
592	2	2-F-Phenyl	$-CH_2CH_2CF_3$

593	2	2-F-Phenyl	cyclopropyl
594	2	2-F-Phenyl	Cyclobutyl
595	2	2-F-Phenyl	cyclopentyl
596	2	2-F-Phenyl	cyclohexyl
597	2	2-F-Phenyl	3-pyridyl
598	2	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
599	2	2-F-Phenyl	1H-imidazol-4-yl
600	2	2-F-Phenyl	2-furanyl
601	2	4-F-Phenyl	ethyl
602	2	4-F-Phenyl	n-propyl
603	2	4-F-Phenyl	isopropyl
604	2	4-F-Phenyl	$-CH_2CH(CH_3)_2$
605	2	4-F-Phenyl	CF_3
606	2	4-F-Phenyl	$-CH_2CF_3$
607	2	4-F-Phenyl	$-CH_2CH_2CF_3$
608	2	4-F-Phenyl	cyclopropyl
609	2	4-F-Phenyl	Cyclobutyl
610	2	4-F-Phenyl	cyclopentyl
611	2	4-F-Phenyl	cyclohexyl
612	2	4-F-Phenyl	3-pyridyl
613	2	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
614	2	4-F-Phenyl	1H-imidazol-4-yl
615	2	4-F-Phenyl	2-furanyl
616	2	3-Cl-Phenyl	ethyl
617	2	3-Cl-Phenyl	n-propyl
618	2	3-Cl-Phenyl	isopropyl
619	2	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
620	2	3-Cl-Phenyl	CF_3
621	2	3-Cl-Phenyl	$-CH_2CF_3$
622	2	3-Cl-Phenyl	$-CH_2CH_2CF_3$
623	2	3-Cl-Phenyl	cyclopropyl
624	2	3-Cl-Phenyl	Cyclobutyl
625	2	3-Cl-Phenyl	cyclopentyl
626	2	3-Cl-Phenyl	cyclohexyl
627	2	3-Cl-Phenyl	3-pyridyl
628	2	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
629	2	3-Cl-Phenyl	1H-imidazol-4-yl
630	2	3-Cl-Phenyl	2-furanyl
631	2	2-Br-Phenyl	ethyl
632	2	2-Br-Phenyl	n-propyl
633	2	2-Br-Phenyl	isopropyl
634	2	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
635	2	2-Br-Phenyl	CF_3
636	2	2-Br-Phenyl	$-CH_2CF_3$

637	2	2-Br-Phenyl	-$CH_2CH_2CF_3$
638	2	2-Br-Phenyl	cyclopropyl
639	2	2-Br-Phenyl	Cyclobutyl
640	2	2-Br-Phenyl	cyclopentyl
641	2	2-Br-Phenyl	cyclohexyl
642	2	2-Br-Phenyl	3-pyridyl
643	2	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
644	2	2-Br-Phenyl	1H-imidazol-4-yl
645	2	2-Br-Phenyl	2-furanyl
646	2	4-Br-Phenyl	ethyl
647	2	4-Br-Phenyl	n-propyl
648	2	4-Br-Phenyl	isopropyl
649	2	4-Br-Phenyl	-$CH_2CH(CH_3)_2$
650	2	4-Br-Phenyl	CF_3
651	2	4-Br-Phenyl	-CH_2CF_3
652	2	4-Br-Phenyl	-$CH_2CH_2CF_3$
653	2	4-Br-Phenyl	cyclopropyl
654	2	4-Br-Phenyl	Cyclobutyl
655	2	4-Br-Phenyl	cyclopentyl
656	2	4-Br-Phenyl	cyclohexyl
657	2	4-Br-Phenyl	3-pyridyl
658	2	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
659	2	4-Br-Phenyl	1H-imidazol-4-yl
660	2	4-Br-Phenyl	2-furanyl
661	2	3-CF_3-Phenyl	ethyl
662	2	3-CF_3-Phenyl	n-propyl
663	2	3-CF_3-Phenyl	isopropyl
664	2	3-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
665	2	3-CF_3-Phenyl	CF_3
666	2	3-CF_3-Phenyl	-CH_2CF_3
667	2	3-CF_3-Phenyl	-$CH_2CH_2CF_3$
668	2	3-CF_3-Phenyl	cyclopropyl
669	2	3-CF_3-Phenyl	Cyclobutyl
670	2	3-CF_3-Phenyl	cyclopentyl
671	2	3-CF_3-Phenyl	cyclohexyl
672	2	3-CF_3-Phenyl	3-pyridyl
673	2	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
674	2	3-CF_3-Phenyl	1H-imidazol-4-yl
675	2	3-CF_3-Phenyl	2-furanyl
676	2	2-iPr-Phenyl	ethyl
677	2	2-iPr-Phenyl	n-propyl
678	2	2-iPr-Phenyl	isopropyl

679	2	2-iPr-Phenyl	$-CH_2CH(CH_3)_2$
680	2	2-iPr-Phenyl	CF_3
681	2	2-iPr-Phenyl	$-CH_2CF_3$
682	2	2-iPr-Phenyl	$-CH_2CH_2CF_3$
683	2	2-iPr-Phenyl	cyclopropyl
684	2	2-iPr-Phenyl	Cyclobutyl
685	2	2-iPr-Phenyl	cyclopentyl
686	2	2-iPr-Phenyl	cyclohexyl
687	2	2-iPr-Phenyl	3-pyridyl
688	2	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
689	2	2-iPr-Phenyl	1H-imidazol-4-yl
690	2	2-iPr-Phenyl	2-furanyl
691	2	4-iPr-Phenyl	ethyl
692	2	4-iPr-Phenyl	n-propyl
693	2	4-iPr-Phenyl	isopropyl
694	2	4-iPr-Phenyl	$-CH_2CH(CH_3)_2$
695	2	4-iPr-Phenyl	CF_3
696	2	4-iPr-Phenyl	$-CH_2CF_3$
697	2	4-iPr-Phenyl	$-CH_2CH_2CF_3$
698	2	4-iPr-Phenyl	cyclopropyl
699	2	4-iPr-Phenyl	Cyclobutyl
700	2	4-iPr-Phenyl	cyclopentyl
701	2	4-iPr-Phenyl	cyclohexyl
702	2	4-iPr-Phenyl	3-pyridyl
703	2	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
704	2	4-iPr-Phenyl	1H-imidazol-4-yl
705	2	4-iPr-Phenyl	2-furanyl
706	2	3-morpholino-phenyl	ethyl
707	2	3-morpholino-phenyl	n-propyl
708	2	3-morpholino-phenyl	isopropyl
709	2	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
710	2	3-morpholino-phenyl	CF_3
711	2	3-morpholino-phenyl	$-CH_2CF_3$
712	2	3-morpholino-phenyl	$-CH_2CH_2CF_3$
713	2	3-morpholino-phenyl	cyclopropyl
714	2	3-morpholino-phenyl	Cyclobutyl
715	2	3-morpholino-phenyl	cyclopentyl
716	2	3-morpholino-phenyl	cyclohexyl
717	2	3-morpholino-phenyl	3-pyridyl
718	2	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
719	2	3-morpholino-phenyl	1H-imidazol-4-yl
720	2	3-morpholino-phenyl	2-furanyl
721	2	4-cyano-2-morpholino-phenyl	ethyl
722	2	4-cyano-2-morpholino-phenyl	n-propyl

723	2	4-cyano-2-morpholino-phenyl	isopropyl
724	2	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
725	2	4-cyano-2-morpholino-phenyl	CF_3
726	2	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
727	2	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
728	2	4-cyano-2-morpholino-phenyl	cyclopropyl
729	2	4-cyano-2-morpholino-phenyl	Cyclobutyl
730	2	4-cyano-2-morpholino-phenyl	cyclopentyl
731	2	4-cyano-2-morpholino-phenyl	cyclohexyl
732	2	4-cyano-2-morpholino-phenyl	3-pyridyl
733	2	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
734	2	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
735	2	4-cyano-2-morpholino-phenyl	2-furanyl
736	2	4-hydroxy-2-morpholino-phenyl	ethyl
737	2	4-hydroxy-2-morpholino-phenyl	n-propyl
738	2	4-hydroxy-2-morpholino-phenyl	isopropyl
739	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
740	2	4-hydroxy-2-morpholino-phenyl	CF_3
741	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
742	2	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
743	2	4-hydroxy-2-morpholino-phenyl	cyclopropyl
744	2	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
745	2	4-hydroxy-2-morpholino-phenyl	cyclopentyl
746	2	4-hydroxy-2-morpholino-phenyl	cyclohexyl
747	2	4-hydroxy-2-morpholino-phenyl	3-pyridyl
748	2	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
749	2	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
750	2	4-hydroxy-2-morpholino-phenyl	2-furanyl
751	2	2-CH_3-phenyl	Ethyl
752	2	2-CH_3-phenyl	n-propyl
753	2	2-CH_3-phenyl	Isopropyl
754	2	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
755	2	2-CH_3-phenyl	CF_3
756	2	2-CH_3-phenyl	$-CH_2CF_3$
757	2	2-CH_3-phenyl	$-CH_2CH_2CF_3$
758	2	2-CH_3-phenyl	cyclopropyl
759	2	2-CH_3-phenyl	Cyclobutyl
760	2	2-CH_3-phenyl	cyclopentyl
761	2	2-CH_3-phenyl	cyclohexyl
762	2	2-CH_3-phenyl	3-pyridyl
763	2	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
764	2	2-CH_3-phenyl	1H-imidazol-4-yl

765	2	2-CH_3-phenyl	2-furanyl
766	2	4-OH-Phenyl	Ethyl
767	2	4-OH-Phenyl	n-propyl
768	2	4-OH-Phenyl	Isopropyl
769	2	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
770	2	4-OH-Phenyl	CF_3
771	2	4-OH-Phenyl	-CH_2CF_3
772	2	4-OH-Phenyl	-$CH_2CH_2CF_3$
773	2	4-OH-Phenyl	cyclopropyl
774	2	4-OH-Phenyl	Cyclobutyl
775	2	4-OH-Phenyl	cyclopentyl
776	2	4-OH-Phenyl	cyclohexyl
777	2	4-OH-Phenyl	3-pyridyl
778	2	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
779	2	4-OH-Phenyl	1H-imidazol-4-yl
780	2	4-OH-Phenyl	2-furanyl
781	2	2-OH-Phenyl	Ethyl
782	2	2-OH-Phenyl	n-propyl
783	2	2-OH-Phenyl	Isopropyl
784	2	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
785	2	2-OH-Phenyl	CF_3
786	2	2-OH-Phenyl	-CH_2CF_3
787	2	2-OH-Phenyl	-$CH_2CH_2CF_3$
788	2	2-OH-Phenyl	cyclopropyl
789	2	2-OH-Phenyl	Cyclobutyl
790	2	2-OH-Phenyl	cyclopentyl
791	2	2-OH-Phenyl	cyclohexyl
792	2	2-OH-Phenyl	3-pyridyl
793	2	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
794	2	2-OH-Phenyl	1H-imidazol-4-yl
795	2	2-OH-Phenyl	2-furanyl
796	2	3-OMe-Phenyl	Ethyl
797	2	3-OMe-Phenyl	n-propyl
798	2	3-OMe-Phenyl	Isopropyl
799	2	3-OMe-Phenyl	-$CH_2CH(CH_3)_2$
800	2	3-OMe-Phenyl	CF_3
801	2	3-OMe-Phenyl	-CH_2CF_3
802	2	3-OMe-Phenyl	-$CH_2CH_2CF_3$
803	2	3-OMe-Phenyl	cyclopropyl
804	2	3-OMe-Phenyl	Cyclobutyl
805	2	3-OMe-Phenyl	cyclopentyl
806	2	3-OMe-Phenyl	cyclohexyl
807	2	3-OMe-Phenyl	3-pyridyl

808	2	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
809	2	3-OMe-Phenyl	1H-imidazol-4-yl
810	2	3-OMe-Phenyl	2-furanyl
811	2	4-CN-Phenyl	Ethyl
812	2	4-CN-Phenyl	n-propyl
813	2	4-CN-Phenyl	Isopropyl
814	2	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
815	2	4-CN-Phenyl	CF_3
816	2	4-CN-Phenyl	$-CH_2CF_3$
817	2	4-CN-Phenyl	$-CH_2CH_2CF_3$
818	2	4-CN-Phenyl	cyclopropyl
819	2	4-CN-Phenyl	Cyclobutyl
820	2	4-CN-Phenyl	cyclopentyl
821	2	4-CN-Phenyl	cyclohexyl
822	2	4-CN-Phenyl	3-pyridyl
823	2	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
824	2	4-CN-Phenyl	1H-imidazol-4-yl
825	2	4-CN-Phenyl	2-furanyl
826	2	2-CN-Phenyl	Ethyl
827	2	2-CN-Phenyl	n-propyl
828	2	2-CN-Phenyl	Isopropyl
829	2	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
830	2	2-CN-Phenyl	CF_3
831	2	2-CN-Phenyl	$-CH_2CF_3$
832	2	2-CN-Phenyl	$-CH_2CH_2CF_3$
833	2	2-CN-Phenyl	cyclopropyl
834	2	2-CN-Phenyl	Cyclobutyl
835	2	2-CN-Phenyl	cyclopentyl
836	2	2-CN-Phenyl	cyclohexyl
837	2	2-CN-Phenyl	3-pyridyl
838	2	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
839	2	2-CN-Phenyl	1H-imidazol-4-yl
840	2	2-CN-Phenyl	2-furanyl
841	2	3-F-Phenyl	Ethyl
842	2	3-F-Phenyl	n-propyl
843	2	3-F-Phenyl	Isopropyl
844	2	3-F-Phenyl	$-CH_2CH(CH_3)_2$
845	2	3-F-Phenyl	CF_3
846	2	3-F-Phenyl	$-CH_2CF_3$
847	2	3-F-Phenyl	$-CH_2CH_2CF_3$
848	2	3-F-Phenyl	cyclopropyl
849	2	3-F-Phenyl	Cyclobutyl
850	2	3-F-Phenyl	cyclopentyl
851	2	3-F-Phenyl	cyclohexyl

852	2	3-F-Phenyl	3-pyridyl
853	2	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
854	2	3-F-Phenyl	1H-imidazol-4-yl
855	2	3-F-Phenyl	2-furanyl
856	2	2-Cl-Phenyl	Ethyl
857	2	2-Cl-Phenyl	n-propyl
858	2	2-Cl-Phenyl	Isopropyl
859	2	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
860	2	2-Cl-Phenyl	CF_3
861	2	2-Cl-Phenyl	$-CH_2CF_3$
862	2	2-Cl-Phenyl	$-CH_2CH_2CF_3$
863	2	2-Cl-Phenyl	cyclopropyl
864	2	2-Cl-Phenyl	Cyclobutyl
865	2	2-Cl-Phenyl	cyclopentyl
866	2	2-Cl-Phenyl	cyclohexyl
867	2	2-Cl-Phenyl	3-pyridyl
868	2	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
869	2	2-Cl-Phenyl	1H-imidazol-4-yl
870	2	2-Cl-Phenyl	2-furanyl
871	2	4-Cl-Phenyl	Ethyl
872	2	4-Cl-Phenyl	n-propyl
873	2	4-Cl-Phenyl	Isopropyl
874	2	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
875	2	4-Cl-Phenyl	CF_3
876	2	4-Cl-Phenyl	$-CH_2CF_3$
877	2	4-Cl-Phenyl	$-CH_2CH_2CF_3$
878	2	4-Cl-Phenyl	cyclopropyl
879	2	4-Cl-Phenyl	Cyclobutyl
880	2	4-Cl-Phenyl	cyclopentyl
881	2	4-Cl-Phenyl	cyclohexyl
882	2	4-Cl-Phenyl	3-pyridyl
883	2	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
884	2	4-Cl-Phenyl	1H-imidazol-4-yl
885	2	4-Cl-Phenyl	2-furanyl
886	2	3-Br-Phenyl	Ethyl
887	2	3-Br-Phenyl	n-propyl
888	2	3-Br-Phenyl	Isopropyl
889	2	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
890	2	3-Br-Phenyl	CF_3
891	2	3-Br-Phenyl	$-CH_2CF_3$
892	2	3-Br-Phenyl	$-CH_2CH_2CF_3$
893	2	3-Br-Phenyl	cyclopropyl
894	2	3-Br-Phenyl	Cyclobutyl
895	2	3-Br-Phenyl	cyclopentyl

896	2	3-Br-Phenyl	cyclohexyl
897	2	3-Br-Phenyl	3-pyridyl
898	2	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
899	2	3-Br-Phenyl	1H-imidazol-4-yl
900	2	3-Br-Phenyl	2-furanyl
901	2	2-CF_3-Phenyl	Ethyl
902	2	2-CF_3-Phenyl	n-propyl
903	2	2-CF_3-Phenyl	Isopropyl
904	2	2-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
905	2	2-CF_3-Phenyl	CF_3
906	2	2-CF_3-Phenyl	-CH_2CF_3
907	2	2-CF_3-Phenyl	-$CH_2CH_2CF_3$
908	2	2-CF_3-Phenyl	cyclopropyl
909	2	2-CF_3-Phenyl	Cyclobutyl
910	2	2-CF_3-Phenyl	cyclopentyl
911	2	2-CF_3-Phenyl	cyclohexyl
912	2	2-CF_3-Phenyl	3-pyridyl
913	2	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
914	2	2-CF_3-Phenyl	1H-imidazol-4-yl
915	2	2-CF_3-Phenyl	2-furanyl
916	2	4-CF_3-Phenyl	Ethyl
917	2	4-CF_3-Phenyl	n-propyl
918	2	4-CF_3-Phenyl	Isopropyl
919	2	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
920	2	4-CF_3-Phenyl	CF_3
921	2	4-CF_3-Phenyl	-CH_2CF_3
922	2	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
923	2	4-CF_3-Phenyl	cyclopropyl
924	2	4-CF_3-Phenyl	Cyclobutyl
925	2	4-CF_3-Phenyl	cyclopentyl
926	2	4-CF_3-Phenyl	cyclohexyl
927	2	4-CF_3-Phenyl	3-pyridyl
928	2	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
929	2	4-CF_3-Phenyl	1H-imidazol-4-yl
930	2	4-CF_3-Phenyl	2-furanyl
931	2	3-iPr-Phenyl	Ethyl
932	2	3-iPr-Phenyl	n-propyl
933	2	3-iPr-Phenyl	Isopropyl
934	2	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
935	2	3-iPr-Phenyl	CF_3
936	2	3-iPr-Phenyl	-CH_2CF_3

937	2	3-iPr-Phenyl	$-CH_2CH_2CF_3$
938	2	3-iPr-Phenyl	cyclopropyl
939	2	3-iPr-Phenyl	Cyclobutyl
940	2	3-iPr-Phenyl	cyclopentyl
941	2	3-iPr-Phenyl	cyclohexyl
942	2	3-iPr-Phenyl	3-pyridyl
943	2	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
944	2	3-iPr-Phenyl	1H-imidazol-4-yl
945	2	3-iPr-Phenyl	2-furanyl
946	2	2-morpholino-phenyl	Ethyl
947	2	2-morpholino-phenyl	n-propyl
948	2	2-morpholino-phenyl	isopropyl
949	2	2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
950	2	2-morpholino-phenyl	CF_3
951	2	2-morpholino-phenyl	$-CH_2CF_3$
952	2	2-morpholino-phenyl	$-CH_2CH_2CF_3$
953	2	2-morpholino-phenyl	cyclopropyl
954	2	2-morpholino-phenyl	Cyclobutyl
955	2	2-morpholino-phenyl	cyclopentyl
956	2	2-morpholino-phenyl	cyclohexyl
957	2	2-morpholino-phenyl	3-pyridyl
958	2	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
959	2	2-morpholino-phenyl	1H-imidazol-4-yl
960	2	2-morpholino-phenyl	2-furanyl
961	2	4-morpholino-phenyl	ethyl
962	2	4-morpholino-phenyl	n-propyl
963	2	4-morpholino-phenyl	isopropyl
964	2	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
965	2	4-morpholino-phenyl	CF_3
966	2	4-morpholino-phenyl	$-CH_2CF_3$
967	2	4-morpholino-phenyl	$-CH_2CH_2CF_3$
968	2	4-morpholino-phenyl	cyclopropyl
969	2	4-morpholino-phenyl	Cyclobutyl
970	2	4-morpholino-phenyl	cyclopentyl
971	2	4-morpholino-phenyl	cyclohexyl
972	2	4-morpholino-phenyl	3-pyridyl
973	2	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
974	2	4-morpholino-phenyl	1H-imidazol-4-yl
975	2	4-morpholino-phenyl	2-furanyl
976	2	4-methyl-2-morpholino-phenyl	ethyl
977	2	4-methyl-2-morpholino-phenyl	n-propyl
978	2	4-methyl-2-morpholino-phenyl	isopropyl
979	2	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
980	2	4-methyl-2-morpholino-phenyl	CF_3

981	2	4-methyl-2-morpholino-phenyl	-CH_2CF_3
982	2	4-methyl-2-morpholino-phenyl	-$CH_2CH_2CF_3$
983	2	4-methyl-2-morpholino-phenyl	cyclopropyl
984	2	4-methyl-2-morpholino-phenyl	Cyclobutyl
985	2	4-methyl-2-morpholino-phenyl	cyclopentyl
986	2	4-methyl-2-morpholino-phenyl	cyclohexyl
987	2	4-methyl-2-morpholino-phenyl	3-pyridyl
988	2	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
989	2	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
990	2	4-methyl-2-morpholino-phenyl	2-furanyl
991	3	4-CH_3-phenyl	ethyl
992	3	4-CH_3-phenyl	n-propyl
993	3	4-CH_3-phenyl	isopropyl
994	3	4-CH_3-phenyl	-$CH_2CH(CH_3)_2$
995	3	4-CH_3-phenyl	CF_3
996	3	4-CH_3-phenyl	-CH_2CF_3
997	3	4-CH_3-phenyl	-$CH_2CH_2CF_3$
998	3	4-CH_3-phenyl	cyclopropyl
999	3	4-CH_3-phenyl	Cyclobutyl
1000	3	4-CH_3-phenyl	cyclopentyl
1001	3	4-CH_3-phenyl	cyclohexyl
1002	3	4-CH_3-phenyl	3-pyridyl
1003	3	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1004	3	4-CH_3-phenyl	1H-imidazol-4-yl
1005	3	4-CH_3-phenyl	2-furanyl
1006	3	3-CH_3-phenyl	ethyl
1007	3	3-CH_3-phenyl	n-propyl
1008	3	3-CH_3-phenyl	isopropyl
1009	3	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1010	3	3-CH_3-phenyl	CF_3
1011	3	3-CH_3-phenyl	-CH_2CF_3
1012	3	3-CH_3-phenyl	-$CH_2CH_2CF_3$
1013	3	3-CH_3-phenyl	cyclopropyl
1014	3	3-CH_3-phenyl	Cyclobutyl
1015	3	3-CH_3-phenyl	cyclopentyl
1016	3	3-CH_3-phenyl	cyclohexyl
1017	3	3-CH_3-phenyl	3-pyridyl
1018	3	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1019	3	3-CH_3-phenyl	1H-imidazol-4-yl
1020	3	3-CH_3-phenyl	2-furanyl
1021	3	3-OH-Phenyl	ethyl

1022	3	3-OH-Phenyl	n-propyl
1023	3	3-OH-Phenyl	isopropyl
1024	3	3-OH-Phenyl	$-CH_2CH(CH_3)_2$
1025	3	3-OH-Phenyl	CF_3
1026	3	3-OH-Phenyl	$-CH_2CF_3$
1027	3	3-OH-Phenyl	$-CH_2CH_2CF_3$
1028	3	3-OH-Phenyl	cyclopropyl
1029	3	3-OH-Phenyl	Cyclobutyl
1030	3	3-OH-Phenyl	cyclopentyl
1031	3	3-OH-Phenyl	cyclohexyl
1032	3	3-OH-Phenyl	3-pyridyl
1033	3	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1034	3	3-OH-Phenyl	1H-imidazol-4-yl
1035	3	3-OH-Phenyl	2-furanyl
1036	3	4-OMe-Phenyl	ethyl
1037	3	4-OMe-Phenyl	n-propyl
1038	3	4-OMe-Phenyl	isopropyl
1039	3	4-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1040	3	4-OMe-Phenyl	CF_3
1041	3	4-OMe-Phenyl	$-CH_2CF_3$
1042	3	4-OMe-Phenyl	$-CH_2CH_2CF_3$
1043	3	4-OMe-Phenyl	cyclopropyl
1044	3	4-OMe-Phenyl	Cyclobutyl
1045	3	4-OMe-Phenyl	cyclopentyl
1046	3	4-OMe-Phenyl	cyclohexyl
1047	3	4-OMe-Phenyl	3-pyridyl
1048	3	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1049	3	4-OMe-Phenyl	1H-imidazol-4-yl
1050	3	4-OMe-Phenyl	2-furanyl
1051	3	2-OMe-Phenyl	ethyl
1052	3	2-OMe-Phenyl	n-propyl
1053	3	2-OMe-Phenyl	isopropyl
1054	3	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1055	3	2-OMe-Phenyl	CF_3
1056	3	2-OMe-Phenyl	$-CH_2CF_3$
1057	3	2-OMe-Phenyl	$-CH_2CH_2CF_3$
1058	3	2-OMe-Phenyl	cyclopropyl
1059	3	2-OMe-Phenyl	Cyclobutyl
1060	3	2-OMe-Phenyl	cyclopentyl
1061	3	2-OMe-Phenyl	cyclohexyl
1062	3	2-OMe-Phenyl	3-pyridyl
1063	3	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1064	3	2-OMe-Phenyl	1H-imidazol-4-yl
1065	3	2-OMe-Phenyl	2-furanyl

1066	3	3-CN-Phenyl	ethyl
1067	3	3-CN-Phenyl	n-propyl
1068	3	3-CN-Phenyl	isopropyl
1069	3	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
1070	3	3-CN-Phenyl	CF_3
1071	3	3-CN-Phenyl	$-CH_2CF_3$
1072	3	3-CN-Phenyl	$-CH_2CH_2CF_3$
1073	3	3-CN-Phenyl	cyclopropyl
1074	3	3-CN-Phenyl	Cyclobutyl
1075	3	3-CN-Phenyl	cyclopentyl
1076	3	3-CN-Phenyl	cyclohexyl
1077	3	3-CN-Phenyl	3-pyridyl
1078	3	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1079	3	3-CN-Phenyl	1H-imidazol-4-yl
1080	3	3-CN-Phenyl	2-furanyl
1081	3	2-F-Phenyl	ethyl
1082	3	2-F-Phenyl	n-propyl
1083	3	2-F-Phenyl	isopropyl
1084	3	2-F-Phenyl	$-CH_2CH(CH_3)_2$
1085	3	2-F-Phenyl	CF_3
1086	3	2-F-Phenyl	$-CH_2CF_3$
1087	3	2-F-Phenyl	$-CH_2CH_2CF_3$
1088	3	2-F-Phenyl	cyclopropyl
1089	3	2-F-Phenyl	Cyclobutyl
1090	3	2-F-Phenyl	cyclopentyl
1091	3	2-F-Phenyl	cyclohexyl
1092	3	2-F-Phenyl	3-pyridyl
1093	3	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1094	3	2-F-Phenyl	1H-imidazol-4-yl
1095	3	2-F-Phenyl	2-furanyl
1096	3	4-F-Phenyl	ethyl
1097	3	4-F-Phenyl	n-propyl
1098	3	4-F-Phenyl	isopropyl
1099	3	4-F-Phenyl	$-CH_2CH(CH_3)_2$
1100	3	4-F-Phenyl	CF_3
1101	3	4-F-Phenyl	$-CH_2CF_3$
1102	3	4-F-Phenyl	$-CH_2CH_2CF_3$
1103	3	4-F-Phenyl	cyclopropyl
1104	3	4-F-Phenyl	Cyclobutyl
1105	3	4-F-Phenyl	cyclopentyl
1106	3	4-F-Phenyl	cyclohexyl
1107	3	4-F-Phenyl	3-pyridyl
1108	3	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1109	3	4-F-Phenyl	1H-imidazol-4-yl

1110	3	4-F-Phenyl	2-furanyl
1111	3	3-Cl-Phenyl	ethyl
1112	3	3-Cl-Phenyl	n-propyl
1113	3	3-Cl-Phenyl	isopropyl
1114	3	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1115	3	3-Cl-Phenyl	CF_3
1116	3	3-Cl-Phenyl	$-CH_2CF_3$
1117	3	3-Cl-Phenyl	$-CH_2CH_2CF_3$
1118	3	3-Cl-Phenyl	cyclopropyl
1119	3	3-Cl-Phenyl	Cyclobutyl
1120	3	3-Cl-Phenyl	cyclopentyl
1121	3	3-Cl-Phenyl	cyclohexyl
1122	3	3-Cl-Phenyl	3-pyridyl
1123	3	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1124	3	3-Cl-Phenyl	1H-imidazol-4-yl
1125	3	3-Cl-Phenyl	2-furanyl
1126	3	2-Br-Phenyl	ethyl
1127	3	2-Br-Phenyl	n-propyl
1128	3	2-Br-Phenyl	isopropyl
1129	3	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
1130	3	2-Br-Phenyl	CF_3
1131	3	2-Br-Phenyl	$-CH_2CF_3$
1132	3	2-Br-Phenyl	$-CH_2CH_2CF_3$
1133	3	2-Br-Phenyl	cyclopropyl
1134	3	2-Br-Phenyl	Cyclobutyl
1135	3	2-Br-Phenyl	cyclopentyl
1136	3	2-Br-Phenyl	cyclohexyl
1137	3	2-Br-Phenyl	3-pyridyl
1138	3	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1139	3	2-Br-Phenyl	1H-imidazol-4-yl
1140	3	2-Br-Phenyl	2-furanyl
1141	3	4-Br-Phenyl	ethyl
1142	3	4-Br-Phenyl	n-propyl
1143	3	4-Br-Phenyl	isopropyl
1144	3	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
1145	3	4-Br-Phenyl	CF_3
1146	3	4-Br-Phenyl	$-CH_2CF_3$
1147	3	4-Br-Phenyl	$-CH_2CH_2CF_3$
1148	3	4-Br-Phenyl	cyclopropyl
1149	3	4-Br-Phenyl	Cyclobutyl
1150	3	4-Br-Phenyl	cyclopentyl
1151	3	4-Br-Phenyl	cyclohexyl
1152	3	4-Br-Phenyl	3-pyridyl
1153	3	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl

1154	3	4-Br-Phenyl	1H-imidazol-4-yl
1155	3	4-Br-Phenyl	2-furanyl
1156	3	3-CF_3-Phenyl	ethyl
1157	3	3-CF_3-Phenyl	n-propyl
1158	3	3-CF_3-Phenyl	isopropyl
1159	3	3-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1160	3	3-CF_3-Phenyl	CF_3
1161	3	3-CF_3-Phenyl	-CH_2CF_3
1162	3	3-CF_3-Phenyl	-$CH_2CH_2CF_3$
1163	3	3-CF_3-Phenyl	cyclopropyl
1164	3	3-CF_3-Phenyl	Cyclobutyl
1165	3	3-CF_3-Phenyl	cyclopentyl
1166	3	3-CF_3-Phenyl	cyclohexyl
1167	3	3-CF_3-Phenyl	3-pyridyl
1168	3	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1169	3	3-CF_3-Phenyl	1H-imidazol-4-yl
1170	3	3-CF_3-Phenyl	2-furanyl
1171	3	2-iPr-Phenyl	ethyl
1172	3	2-iPr-Phenyl	n-propyl
1173	3	2-iPr-Phenyl	isopropyl
1174	3	2-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1175	3	2-iPr-Phenyl	CF_3
1176	3	2-iPr-Phenyl	-CH_2CF_3
1177	3	2-iPr-Phenyl	-$CH_2CH_2CF_3$
1178	3	2-iPr-Phenyl	cyclopropyl
1179	3	2-iPr-Phenyl	Cyclobutyl
1180	3	2-iPr-Phenyl	cyclopentyl
1181	3	2-iPr-Phenyl	cyclohexyl
1182	3	2-iPr-Phenyl	3-pyridyl
1183	3	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1184	3	2-iPr-Phenyl	1H-imidazol-4-yl
1185	3	2-iPr-Phenyl	2-furanyl
1186	3	4-iPr-Phenyl	ethyl
1187	3	4-iPr-Phenyl	n-propyl
1188	3	4-iPr-Phenyl	isopropyl
1189	3	4-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1190	3	4-iPr-Phenyl	CF_3
1191	3	4-iPr-Phenyl	-CH_2CF_3
1192	3	4-iPr-Phenyl	-$CH_2CH_2CF_3$
1193	3	4-iPr-Phenyl	cyclopropyl
1194	3	4-iPr-Phenyl	Cyclobutyl
1195	3	4-iPr-Phenyl	cyclopentyl

1196	3	4-iPr-Phenyl	cyclohexyl
1197	3	4-iPr-Phenyl	3-pyridyl
1198	3	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1199	3	4-iPr-Phenyl	1H-imidazol-4-yl
1200	3	4-iPr-Phenyl	2-furanyl
1201	3	3-morpholino-phenyl	ethyl
1202	3	3-morpholino-phenyl	n-propyl
1203	3	3-morpholino-phenyl	isopropyl
1204	3	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1205	3	3-morpholino-phenyl	CF_3
1206	3	3-morpholino-phenyl	$-CH_2CF_3$
1207	3	3-morpholino-phenyl	$-CH_2CH_2CF_3$
1208	3	3-morpholino-phenyl	cyclopropyl
1209	3	3-morpholino-phenyl	Cyclobutyl
1210	3	3-morpholino-phenyl	cyclopentyl
1211	3	3-morpholino-phenyl	cyclohexyl
1212	3	3-morpholino-phenyl	3-pyridyl
1213	3	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1214	3	3-morpholino-phenyl	1H-imidazol-4-yl
1215	3	3-morpholino-phenyl	2-furanyl
1216	3	4-cyano-2-morpholino-phenyl	ethyl
1217	3	4-cyano-2-morpholino-phenyl	n-propyl
1218	3	4-cyano-2-morpholino-phenyl	isopropyl
1219	3	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1220	3	4-cyano-2-morpholino-phenyl	CF_3
1221	3	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
1222	3	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1223	3	4-cyano-2-morpholino-phenyl	cyclopropyl
1224	3	4-cyano-2-morpholino-phenyl	Cyclobutyl
1225	3	4-cyano-2-morpholino-phenyl	cyclopentyl
1226	3	4-cyano-2-morpholino-phenyl	cyclohexyl
1227	3	4-cyano-2-morpholino-phenyl	3-pyridyl
1228	3	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1229	3	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
1230	3	4-cyano-2-morpholino-phenyl	2-furanyl
1231	3	4-hydroxy-2-morpholino-phenyl	ethyl
1232	3	4-hydroxy-2-morpholino-phenyl	n-propyl
1233	3	4-hydroxy-2-morpholino-phenyl	isopropyl
1234	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1235	3	4-hydroxy-2-morpholino-phenyl	CF_3
1236	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
1237	3	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1238	3	4-hydroxy-2-morpholino-phenyl	cyclopropyl
1239	3	4-hydroxy-2-morpholino-phenyl	Cyclobutyl

1240	3	4-hydroxy-2-morpholino-phenyl	cyclopentyl
1241	3	4-hydroxy-2-morpholino-phenyl	cyclohexyl
1242	3	4-hydroxy-2-morpholino-phenyl	3-pyridyl
1243	3	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1244	3	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
1245	3	4-hydroxy-2-morpholino-phenyl	2-furanyl
1246	3	2-CH_3-phenyl	Ethyl
1247	3	2-CH_3-phenyl	n-propyl
1248	3	2-CH_3-phenyl	Isopropyl
1249	3	2-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1250	3	2-CH_3-phenyl	CF_3
1251	3	2-CH_3-phenyl	-CH_2CF_3
1252	3	2-CH_3-phenyl	-$CH_2CH_2CF_3$
1253	3	2-CH_3-phenyl	cyclopropyl
1254	3	2-CH_3-phenyl	Cyclobutyl
1255	3	2-CH_3-phenyl	cyclopentyl
1256	3	2-CH_3-phenyl	cyclohexyl
1257	3	2-CH_3-phenyl	3-pyridyl
1258	3	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1259	3	2-CH_3-phenyl	1H-imidazol-4-yl
1260	3	2-CH_3-phenyl	2-furanyl
1261	3	4-OH-Phenyl	Ethyl
1262	3	4-OH-Phenyl	n-propyl
1263	3	4-OH-Phenyl	Isopropyl
1264	3	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
1265	3	4-OH-Phenyl	CF_3
1266	3	4-OH-Phenyl	-CH_2CF_3
1267	3	4-OH-Phenyl	-$CH_2CH_2CF_3$
1268	3	4-OH-Phenyl	cyclopropyl
1269	3	4-OH-Phenyl	Cyclobutyl
1270	3	4-OH-Phenyl	cyclopentyl
1271	3	4-OH-Phenyl	cyclohexyl
1272	3	4-OH-Phenyl	3-pyridyl
1273	3	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1274	3	4-OH-Phenyl	1H-imidazol-4-yl
1275	3	4-OH-Phenyl	2-furanyl
1276	3	2-OH-Phenyl	Ethyl
1277	3	2-OH-Phenyl	n-propyl
1278	3	2-OH-Phenyl	Isopropyl
1279	3	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
1280	3	2-OH-Phenyl	CF_3
1281	3	2-OH-Phenyl	-CH_2CF_3

1282	3	2-OH-Phenyl	$-CH_2CH_2CF_3$
1283	3	2-OH-Phenyl	cyclopropyl
1284	3	2-OH-Phenyl	Cyclobutyl
1285	3	2-OH-Phenyl	cyclopentyl
1286	3	2-OH-Phenyl	cyclohexyl
1287	3	2-OH-Phenyl	3-pyridyl
1288	3	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1289	3	2-OH-Phenyl	1H-imidazol-4-yl
1290	3	2-OH-Phenyl	2-furanyl
1291	3	3-OMe-Phenyl	Ethyl
1292	3	3-OMe-Phenyl	n-propyl
1293	3	3-OMe-Phenyl	Isopropyl
1294	3	3-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1295	3	3-OMe-Phenyl	CF_3
1296	3	3-OMe-Phenyl	$-CH_2CF_3$
1297	3	3-OMe-Phenyl	$-CH_2CH_2CF_3$
1298	3	3-OMe-Phenyl	cyclopropyl
1299	3	3-OMe-Phenyl	Cyclobutyl
1300	3	3-OMe-Phenyl	cyclopentyl
1301	3	3-OMe-Phenyl	cyclohexyl
1302	3	3-OMe-Phenyl	3-pyridyl
1303	3	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1304	3	3-OMe-Phenyl	1H-imidazol-4-yl
1305	3	3-OMe-Phenyl	2-furanyl
1306	3	4-CN-Phenyl	Ethyl
1307	3	4-CN-Phenyl	n-propyl
1308	3	4-CN-Phenyl	Isopropyl
1309	3	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
1310	3	4-CN-Phenyl	CF_3
1311	3	4-CN-Phenyl	$-CH_2CF_3$
1312	3	4-CN-Phenyl	$-CH_2CH_2CF_3$
1313	3	4-CN-Phenyl	cyclopropyl
1314	3	4-CN-Phenyl	Cyclobutyl
1315	3	4-CN-Phenyl	cyclopentyl
1316	3	4-CN-Phenyl	cyclohexyl
1317	3	4-CN-Phenyl	3-pyridyl
1318	3	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1319	3	4-CN-Phenyl	1H-imidazol-4-yl
1320	3	4-CN-Phenyl	2-furanyl
1321	3	2-CN-Phenyl	Ethyl
1322	3	2-CN-Phenyl	n-propyl
1323	3	2-CN-Phenyl	Isopropyl
1324	3	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
1325	3	2-CN-Phenyl	CF_3

1326	3	2-CN-Phenyl	$-CH_2CF_3$
1327	3	2-CN-Phenyl	$-CH_2CH_2CF_3$
1328	3	2-CN-Phenyl	cyclopropyl
1329	3	2-CN-Phenyl	Cyclobutyl
1330	3	2-CN-Phenyl	cyclopentyl
1331	3	2-CN-Phenyl	cyclohexyl
1332	3	2-CN-Phenyl	3-pyridyl
1333	3	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1334	3	2-CN-Phenyl	1H-imidazol-4-yl
1335	3	2-CN-Phenyl	2-furanyl
1336	3	3-F-Phenyl	Ethyl
1337	3	3-F-Phenyl	n-propyl
1338	3	3-F-Phenyl	Isopropyl
1339	3	3-F-Phenyl	$-CH_2CH(CH_3)_2$
1340	3	3-F-Phenyl	CF_3
1341	3	3-F-Phenyl	$-CH_2CF_3$
1342	3	3-F-Phenyl	$-CH_2CH_2CF_3$
1343	3	3-F-Phenyl	cyclopropyl
1344	3	3-F-Phenyl	Cyclobutyl
1345	3	3-F-Phenyl	cyclopentyl
1346	3	3-F-Phenyl	cyclohexyl
1347	3	3-F-Phenyl	3-pyridyl
1348	3	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1349	3	3-F-Phenyl	1H-imidazol-4-yl
1350	3	3-F-Phenyl	2-furanyl
1351	3	2-Cl-Phenyl	Ethyl
1352	3	2-Cl-Phenyl	n-propyl
1353	3	2-Cl-Phenyl	Isopropyl
1354	3	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1355	3	2-Cl-Phenyl	CF_3
1356	3	2-Cl-Phenyl	$-CH_2CF_3$
1357	3	2-Cl-Phenyl	$-CH_2CH_2CF_3$
1358	3	2-Cl-Phenyl	cyclopropyl
1359	3	2-Cl-Phenyl	Cyclobutyl
1360	3	2-Cl-Phenyl	cyclopentyl
1361	3	2-Cl-Phenyl	cyclohexyl
1362	3	2-Cl-Phenyl	3-pyridyl
1363	3	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1364	3	2-Cl-Phenyl	1H-imidazol-4-yl
1365	3	2-Cl-Phenyl	2-furanyl
1366	3	4-Cl-Phenyl	Ethyl
1367	3	4-Cl-Phenyl	n-propyl
1368	3	4-Cl-Phenyl	Isopropyl
1369	3	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$

1370	3	4-Cl-Phenyl	CF_3
1371	3	4-Cl-Phenyl	$-CH_2CF_3$
1372	3	4-Cl-Phenyl	$-CH_2CH_2CF_3$
1373	3	4-Cl-Phenyl	cyclopropyl
1374	3	4-Cl-Phenyl	Cyclobutyl
1375	3	4-Cl-Phenyl	cyclopentyl
1376	3	4-Cl-Phenyl	cyclohexyl
1377	3	4-Cl-Phenyl	3-pyridyl
1378	3	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1379	3	4-Cl-Phenyl	1H-imidazol-4-yl
1380	3	4-Cl-Phenyl	2-furanyl
1381	3	3-Br-Phenyl	Ethyl
1382	3	3-Br-Phenyl	n-propyl
1383	3	3-Br-Phenyl	Isopropyl
1384	3	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
1385	3	3-Br-Phenyl	CF_3
1386	3	3-Br-Phenyl	$-CH_2CF_3$
1387	3	3-Br-Phenyl	$-CH_2CH_2CF_3$
1388	3	3-Br-Phenyl	cyclopropyl
1389	3	3-Br-Phenyl	Cyclobutyl
1390	3	3-Br-Phenyl	cyclopentyl
1391	3	3-Br-Phenyl	cyclohexyl
1392	3	3-Br-Phenyl	3-pyridyl
1393	3	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1394	3	3-Br-Phenyl	1H-imidazol-4-yl
1395	3	3-Br-Phenyl	2-furanyl
1396	3	2-CF_3-Phenyl	Ethyl
1397	3	2-CF_3-Phenyl	n-propyl
1398	3	2-CF_3-Phenyl	Isopropyl
1399	3	2-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1400	3	2-CF_3-Phenyl	CF_3
1401	3	2-CF_3-Phenyl	$-CH_2CF_3$
1402	3	2-CF_3-Phenyl	$-CH_2CH_2CF_3$
1403	3	2-CF_3-Phenyl	cyclopropyl
1404	3	2-CF_3-Phenyl	Cyclobutyl
1405	3	2-CF_3-Phenyl	cyclopentyl
1406	3	2-CF_3-Phenyl	cyclohexyl
1407	3	2-CF_3-Phenyl	3-pyridyl
1408	3	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1409	3	2-CF_3-Phenyl	1H-imidazol-4-yl
1410	3	2-CF_3-Phenyl	2-furanyl
1411	3	4-CF_3-Phenyl	Ethyl

1412	3	4-CF_3-Phenyl	n-propyl
1413	3	4-CF_3-Phenyl	Isopropyl
1414	3	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1415	3	4-CF_3-Phenyl	CF_3
1416	3	4-CF_3-Phenyl	-CH_2CF_3
1417	3	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
1418	3	4-CF_3-Phenyl	cyclopropyl
1419	3	4-CF_3-Phenyl	Cyclobutyl
1420	3	4-CF_3-Phenyl	cyclopentyl
1421	3	4-CF_3-Phenyl	cyclohexyl
1422	3	4-CF_3-Phenyl	3-pyridyl
1423	3	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1424	3	4-CF_3-Phenyl	1H-imidazol-4-yl
1425	3	4-CF_3-Phenyl	2-furanyl
1426	3	3-iPr-Phenyl	Ethyl
1427	3	3-iPr-Phenyl	n-propyl
1428	3	3-iPr-Phenyl	Isopropyl
1429	3	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1430	3	3-iPr-Phenyl	CF_3
1431	3	3-iPr-Phenyl	-CH_2CF_3
1432	3	3-iPr-Phenyl	-$CH_2CH_2CF_3$
1433	3	3-iPr-Phenyl	cyclopropyl
1434	3	3-iPr-Phenyl	Cyclobutyl
1435	3	3-iPr-Phenyl	cyclopentyl
1436	3	3-iPr-Phenyl	cyclohexyl
1437	3	3-iPr-Phenyl	3-pyridyl
1438	3	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1439	3	3-iPr-Phenyl	1H-imidazol-4-yl
1440	3	3-iPr-Phenyl	2-furanyl
1441	3	2-morpholino-phenyl	Ethyl
1442	3	2-morpholino-phenyl	n-propyl
1443	3	2-morpholino-phenyl	isopropyl
1444	3	2-morpholino-phenyl	-$CH_2CH(CH_3)_2$
1445	3	2-morpholino-phenyl	CF_3
1446	3	2-morpholino-phenyl	-CH_2CF_3
1447	3	2-morpholino-phenyl	-$CH_2CH_2CF_3$
1448	3	2-morpholino-phenyl	cyclopropyl
1449	3	2-morpholino-phenyl	Cyclobutyl
1450	3	2-morpholino-phenyl	cyclopentyl
1451	3	2-morpholino-phenyl	cyclohexyl
1452	3	2-morpholino-phenyl	3-pyridyl
1453	3	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl

1454	3	2-morpholino-phenyl	1H-imidazol-4-yl
1455	3	2-morpholino-phenyl	2-furanyl
1456	3	4-morpholino-phenyl	ethyl
1457	3	4-morpholino-phenyl	n-propyl
1458	3	4-morpholino-phenyl	isopropyl
1459	3	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1460	3	4-morpholino-phenyl	CF_3
1461	3	4-morpholino-phenyl	$-CH_2CF_3$
1462	3	4-morpholino-phenyl	$-CH_2CH_2CF_3$
1463	3	4-morpholino-phenyl	cyclopropyl
1464	3	4-morpholino-phenyl	Cyclobutyl
1465	3	4-morpholino-phenyl	cyclopentyl
1466	3	4-morpholino-phenyl	cyclohexyl
1467	3	4-morpholino-phenyl	3-pyridyl
1468	3	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1469	3	4-morpholino-phenyl	1H-imidazol-4-yl
1470	3	4-morpholino-phenyl	2-furanyl
1471	3	4-methyl-2-morpholino-phenyl	ethyl
1472	3	4-methyl-2-morpholino-phenyl	n-propyl
1473	3	4-methyl-2-morpholino-phenyl	isopropyl
1474	3	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1475	3	4-methyl-2-morpholino-phenyl	CF_3
1476	3	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
1477	3	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1478	3	4-methyl-2-morpholino-phenyl	cyclopropyl
1479	3	4-methyl-2-morpholino-phenyl	Cyclobutyl
1480	3	4-methyl-2-morpholino-phenyl	cyclopentyl
1481	3	4-methyl-2-morpholino-phenyl	cyclohexyl
1482	3	4-methyl-2-morpholino-phenyl	3-pyridyl
1483	3	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1484	3	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
1485	3	4-methyl-2-morpholino-phenyl	2-furanyl
1486	4	4-CH_3-phenyl	ethyl
1487	4	4-CH_3-phenyl	n-propyl
1488	4	4-CH_3-phenyl	isopropyl
1489	4	4-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1490	4	4-CH_3-phenyl	CF_3
1491	4	4-CH_3-phenyl	$-CH_2CF_3$
1492	4	4-CH_3-phenyl	$-CH_2CH_2CF_3$
1493	4	4-CH_3-phenyl	cyclopropyl
1494	4	4-CH_3-phenyl	Cyclobutyl
1495	4	4-CH_3-phenyl	cyclopentyl
1496	4	4-CH_3-phenyl	cyclohexyl

1497	4	4-CH_3-phenyl	3-pyridyl
1498	4	4-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1499	4	4-CH_3-phenyl	1H-imidazol-4-yl
1500	4	4-CH_3-phenyl	2-furanyl
1501	4	3-CH_3-phenyl	ethyl
1502	4	3-CH_3-phenyl	n-propyl
1503	4	3-CH_3-phenyl	isopropyl
1504	4	3-CH_3-phenyl	-$CH_2CH(CH_3)_2$
1505	4	3-CH_3-phenyl	CF_3
1506	4	3-CH_3-phenyl	-CH_2CF_3
1507	4	3-CH_3-phenyl	-$CH_2CH_2CF_3$
1508	4	3-CH_3-phenyl	cyclopropyl
1509	4	3-CH_3-phenyl	Cyclobutyl
1510	4	3-CH_3-phenyl	cyclopentyl
1511	4	3-CH_3-phenyl	cyclohexyl
1512	4	3-CH_3-phenyl	3-pyridyl
1513	4	3-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1514	4	3-CH_3-phenyl	1H-imidazol-4-yl
1515	4	3-CH_3-phenyl	2-furanyl
1516	4	3-OH-Phenyl	ethyl
1517	4	3-OH-Phenyl	n-propyl
1518	4	3-OH-Phenyl	isopropyl
1519	4	3-OH-Phenyl	-$CH_2CH(CH_3)_2$
1520	4	3-OH-Phenyl	CF_3
1521	4	3-OH-Phenyl	-CH_2CF_3
1522	4	3-OH-Phenyl	-$CH_2CH_2CF_3$
1523	4	3-OH-Phenyl	cyclopropyl
1524	4	3-OH-Phenyl	Cyclobutyl
1525	4	3-OH-Phenyl	cyclopentyl
1526	4	3-OH-Phenyl	cyclohexyl
1527	4	3-OH-Phenyl	3-pyridyl
1528	4	3-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1529	4	3-OH-Phenyl	1H-imidazol-4-yl
1530	4	3-OH-Phenyl	2-furanyl
1531	4	4-OMe-Phenyl	ethyl
1532	4	4-OMe-Phenyl	n-propyl
1533	4	4-OMe-Phenyl	isopropyl
1534	4	4-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1535	4	4-OMe-Phenyl	CF_3
1536	4	4-OMe-Phenyl	-CH_2CF_3
1537	4	4-OMe-Phenyl	-$CH_2CH_2CF_3$
1538	4	4-OMe-Phenyl	cyclopropyl

1539	4	4-OMe-Phenyl	Cyclobutyl
1540	4	4-OMe-Phenyl	cyclopentyl
1541	4	4-OMe-Phenyl	cyclohexyl
1542	4	4-OMe-Phenyl	3-pyridyl
1543	4	4-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1544	4	4-OMe-Phenyl	1H-imidazol-4-yl
1545	4	4-OMe-Phenyl	2-furanyl
1546	4	2-OMe-Phenyl	ethyl
1547	4	2-OMe-Phenyl	n-propyl
1548	4	2-OMe-Phenyl	isopropyl
1549	4	2-OMe-Phenyl	$-CH_2CH(CH_3)_2$
1550	4	2-OMe-Phenyl	CF_3
1551	4	2-OMe-Phenyl	$-CH_2CF_3$
1552	4	2-OMe-Phenyl	$-CH_2CH_2CF_3$
1553	4	2-OMe-Phenyl	cyclopropyl
1554	4	2-OMe-Phenyl	Cyclobutyl
1555	4	2-OMe-Phenyl	cyclopentyl
1556	4	2-OMe-Phenyl	cyclohexyl
1557	4	2-OMe-Phenyl	3-pyridyl
1558	4	2-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1559	4	2-OMe-Phenyl	1H-imidazol-4-yl
1560	4	2-OMe-Phenyl	2-furanyl
1561	4	3-CN-Phenyl	ethyl
1562	4	3-CN-Phenyl	n-propyl
1563	4	3-CN-Phenyl	isopropyl
1564	4	3-CN-Phenyl	$-CH_2CH(CH_3)_2$
1565	4	3-CN-Phenyl	CF_3
1566	4	3-CN-Phenyl	$-CH_2CF_3$
1567	4	3-CN-Phenyl	$-CH_2CH_2CF_3$
1568	4	3-CN-Phenyl	cyclopropyl
1569	4	3-CN-Phenyl	Cyclobutyl
1570	4	3-CN-Phenyl	cyclopentyl
1571	4	3-CN-Phenyl	cyclohexyl
1572	4	3-CN-Phenyl	3-pyridyl
1573	4	3-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1574	4	3-CN-Phenyl	1H-imidazol-4-yl
1575	4	3-CN-Phenyl	2-furanyl
1576	4	2-F-Phenyl	ethyl
1577	4	2-F-Phenyl	n-propyl
1578	4	2-F-Phenyl	isopropyl
1579	4	2-F-Phenyl	$-CH_2CH(CH_3)_2$
1580	4	2-F-Phenyl	CF_3
1581	4	2-F-Phenyl	$-CH_2CF_3$
1582	4	2-F-Phenyl	$-CH_2CH_2CF_3$

1583	4	2-F-Phenyl	cyclopropyl
1584	4	2-F-Phenyl	Cyclobutyl
1585	4	2-F-Phenyl	cyclopentyl
1586	4	2-F-Phenyl	cyclohexyl
1587	4	2-F-Phenyl	3-pyridyl
1588	4	2-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1589	4	2-F-Phenyl	1H-imidazol-4-yl
1590	4	2-F-Phenyl	2-furanyl
1591	4	4-F-Phenyl	ethyl
1592	4	4-F-Phenyl	n-propyl
1593	4	4-F-Phenyl	isopropyl
1594	4	4-F-Phenyl	$-CH_2CH(CH_3)_2$
1595	4	4-F-Phenyl	CF_3
1596	4	4-F-Phenyl	$-CH_2CF_3$
1597	4	4-F-Phenyl	$-CH_2CH_2CF_3$
1598	4	4-F-Phenyl	cyclopropyl
1599	4	4-F-Phenyl	Cyclobutyl
1600	4	4-F-Phenyl	cyclopentyl
1601	4	4-F-Phenyl	cyclohexyl
1602	4	4-F-Phenyl	3-pyridyl
1603	4	4-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1604	4	4-F-Phenyl	1H-imidazol-4-yl
1605	4	4-F-Phenyl	2-furanyl
1606	4	3-Cl-Phenyl	ethyl
1607	4	3-Cl-Phenyl	n-propyl
1608	4	3-Cl-Phenyl	isopropyl
1609	4	3-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1610	4	3-Cl-Phenyl	CF_3
1611	4	3-Cl-Phenyl	$-CH_2CF_3$
1612	4	3-Cl-Phenyl	$-CH_2CH_2CF_3$
1613	4	3-Cl-Phenyl	cyclopropyl
1614	4	3-Cl-Phenyl	Cyclobutyl
1615	4	3-Cl-Phenyl	cyclopentyl
1616	4	3-Cl-Phenyl	cyclohexyl
1617	4	3-Cl-Phenyl	3-pyridyl
1618	4	3-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1619	4	3-Cl-Phenyl	1H-imidazol-4-yl
1620	4	3-Cl-Phenyl	2-furanyl
1621	4	2-Br-Phenyl	ethyl
1622	4	2-Br-Phenyl	n-propyl
1623	4	2-Br-Phenyl	isopropyl
1624	4	2-Br-Phenyl	$-CH_2CH(CH_3)_2$
1625	4	2-Br-Phenyl	CF_3
1626	4	2-Br-Phenyl	$-CH_2CF_3$

1627	4	2-Br-Phenyl	$-CH_2CH_2CF_3$
1628	4	2-Br-Phenyl	cyclopropyl
1629	4	2-Br-Phenyl	Cyclobutyl
1630	4	2-Br-Phenyl	cyclopentyl
1631	4	2-Br-Phenyl	cyclohexyl
1632	4	2-Br-Phenyl	3-pyridyl
1633	4	2-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1634	4	2-Br-Phenyl	1H-imidazol-4-yl
1635	4	2-Br-Phenyl	2-furanyl
1636	4	4-Br-Phenyl	ethyl
1637	4	4-Br-Phenyl	n-propyl
1638	4	4-Br-Phenyl	isopropyl
1639	4	4-Br-Phenyl	$-CH_2CH(CH_3)_2$
1640	4	4-Br-Phenyl	CF_3
1641	4	4-Br-Phenyl	$-CH_2CF_3$
1642	4	4-Br-Phenyl	$-CH_2CH_2CF_3$
1643	4	4-Br-Phenyl	cyclopropyl
1644	4	4-Br-Phenyl	Cyclobutyl
1645	4	4-Br-Phenyl	cyclopentyl
1646	4	4-Br-Phenyl	cyclohexyl
1647	4	4-Br-Phenyl	3-pyridyl
1648	4	4-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1649	4	4-Br-Phenyl	1H-imidazol-4-yl
1650	4	4-Br-Phenyl	2-furanyl
1651	4	3-CF_3-Phenyl	ethyl
1652	4	3-CF_3-Phenyl	n-propyl
1653	4	3-CF_3-Phenyl	isopropyl
1654	4	3-CF_3-Phenyl	$-CH_2CH(CH_3)_2$
1655	4	3-CF_3-Phenyl	CF_3
1656	4	3-CF_3-Phenyl	$-CH_2CF_3$
1657	4	3-CF_3-Phenyl	$-CH_2CH_2CF_3$
1658	4	3-CF_3-Phenyl	cyclopropyl
1659	4	3-CF_3-Phenyl	Cyclobutyl
1660	4	3-CF_3-Phenyl	cyclopentyl
1661	4	3-CF_3-Phenyl	cyclohexyl
1662	4	3-CF_3-Phenyl	3-pyridyl
1663	4	3-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1664	4	3-CF_3-Phenyl	1H-imidazol-4-yl
1665	4	3-CF_3-Phenyl	2-furanyl
1666	4	2-iPr-Phenyl	ethyl
1667	4	2-iPr-Phenyl	n-propyl
1668	4	2-iPr-Phenyl	isopropyl

1669	4	2-iPr-Phenyl	$-CH_2CH(CH_3)_2$
1670	4	2-iPr-Phenyl	CF_3
1671	4	2-iPr-Phenyl	$-CH_2CF_3$
1672	4	2-iPr-Phenyl	$-CH_2CH_2CF_3$
1673	4	2-iPr-Phenyl	cyclopropyl
1674	4	2-iPr-Phenyl	Cyclobutyl
1675	4	2-iPr-Phenyl	cyclopentyl
1676	4	2-iPr-Phenyl	cyclohexyl
1677	4	2-iPr-Phenyl	3-pyridyl
1678	4	2-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1679	4	2-iPr-Phenyl	1H-imidazol-4-yl
1680	4	2-iPr-Phenyl	2-furanyl
1681	4	4-iPr-Phenyl	ethyl
1682	4	4-iPr-Phenyl	n-propyl
1683	4	4-iPr-Phenyl	isopropyl
1684	4	4-iPr-Phenyl	$-CH_2CH(CH_3)_2$
1685	4	4-iPr-Phenyl	CF_3
1686	4	4-iPr-Phenyl	$-CH_2CF_3$
1687	4	4-iPr-Phenyl	$-CH_2CH_2CF_3$
1688	4	4-iPr-Phenyl	cyclopropyl
1689	4	4-iPr-Phenyl	Cyclobutyl
1690	4	4-iPr-Phenyl	cyclopentyl
1691	4	4-iPr-Phenyl	cyclohexyl
1692	4	4-iPr-Phenyl	3-pyridyl
1693	4	4-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1694	4	4-iPr-Phenyl	1H-imidazol-4-yl
1695	4	4-iPr-Phenyl	2-furanyl
1696	4	3-morpholino-phenyl	ethyl
1697	4	3-morpholino-phenyl	n-propyl
1698	4	3-morpholino-phenyl	isopropyl
1699	4	3-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1700	4	3-morpholino-phenyl	CF_3
1701	4	3-morpholino-phenyl	$-CH_2CF_3$
1702	4	3-morpholino-phenyl	$-CH_2CH_2CF_3$
1703	4	3-morpholino-phenyl	cyclopropyl
1704	4	3-morpholino-phenyl	Cyclobutyl
1705	4	3-morpholino-phenyl	cyclopentyl
1706	4	3-morpholino-phenyl	cyclohexyl
1707	4	3-morpholino-phenyl	3-pyridyl
1708	4	3-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1709	4	3-morpholino-phenyl	1H-imidazol-4-yl
1710	4	3-morpholino-phenyl	2-furanyl
1711	4	4-cyano-2-morpholino-phenyl	ethyl
1712	4	4-cyano-2-morpholino-phenyl	n-propyl

1713	4	4-cyano-2-morpholino-phenyl	isopropyl
1714	4	4-cyano-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1715	4	4-cyano-2-morpholino-phenyl	CF_3
1716	4	4-cyano-2-morpholino-phenyl	$-CH_2CF_3$
1717	4	4-cyano-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1718	4	4-cyano-2-morpholino-phenyl	cyclopropyl
1719	4	4-cyano-2-morpholino-phenyl	Cyclobutyl
1720	4	4-cyano-2-morpholino-phenyl	cyclopentyl
1721	4	4-cyano-2-morpholino-phenyl	cyclohexyl
1722	4	4-cyano-2-morpholino-phenyl	3-pyridyl
1723	4	4-cyano-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1724	4	4-cyano-2-morpholino-phenyl	1H-imidazol-4-yl
1725	4	4-cyano-2-morpholino-phenyl	2-furanyl
1726	4	4-hydroxy-2-morpholino-phenyl	ethyl
1727	4	4-hydroxy-2-morpholino-phenyl	n-propyl
1728	4	4-hydroxy-2-morpholino-phenyl	isopropyl
1729	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1730	4	4-hydroxy-2-morpholino-phenyl	CF_3
1731	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CF_3$
1732	4	4-hydroxy-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1733	4	4-hydroxy-2-morpholino-phenyl	cyclopropyl
1734	4	4-hydroxy-2-morpholino-phenyl	Cyclobutyl
1735	4	4-hydroxy-2-morpholino-phenyl	cyclopentyl
1736	4	4-hydroxy-2-morpholino-phenyl	cyclohexyl
1737	4	4-hydroxy-2-morpholino-phenyl	3-pyridyl
1738	4	4-hydroxy-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1739	4	4-hydroxy-2-morpholino-phenyl	1H-imidazol-4-yl
1740	4	4-hydroxy-2-morpholino-phenyl	2-furanyl
1741	4	2-CH_3-phenyl	Ethyl
1742	4	2-CH_3-phenyl	n-propyl
1743	4	2-CH_3-phenyl	Isopropyl
1744	4	2-CH_3-phenyl	$-CH_2CH(CH_3)_2$
1745	4	2-CH_3-phenyl	CF_3
1746	4	2-CH_3-phenyl	$-CH_2CF_3$
1747	4	2-CH_3-phenyl	$-CH_2CH_2CF_3$
1748	4	2-CH_3-phenyl	cyclopropyl
1749	4	2-CH_3-phenyl	Cyclobutyl
1750	4	2-CH_3-phenyl	cyclopentyl
1751	4	2-CH_3-phenyl	cyclohexyl
1752	4	2-CH_3-phenyl	3-pyridyl
1753	4	2-CH_3-phenyl	1-methyl-1H-pyrazol-4-yl
1754	4	2-CH_3-phenyl	1H-imidazol-4-yl

1755	4	2-CH_3-phenyl	2-furanyl
1756	4	4-OH-Phenyl	Ethyl
1757	4	4-OH-Phenyl	n-propyl
1758	4	4-OH-Phenyl	Isopropyl
1759	4	4-OH-Phenyl	-$CH_2CH(CH_3)_2$
1760	4	4-OH-Phenyl	CF_3
1761	4	4-OH-Phenyl	-CH_2CF_3
1762	4	4-OH-Phenyl	-$CH_2CH_2CF_3$
1763	4	4-OH-Phenyl	cyclopropyl
1764	4	4-OH-Phenyl	Cyclobutyl
1765	4	4-OH-Phenyl	cyclopentyl
1766	4	4-OH-Phenyl	cyclohexyl
1767	4	4-OH-Phenyl	3-pyridyl
1768	4	4-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1769	4	4-OH-Phenyl	1H-imidazol-4-yl
1770	4	4-OH-Phenyl	2-furanyl
1771	4	2-OH-Phenyl	Ethyl
1772	4	2-OH-Phenyl	n-propyl
1773	4	2-OH-Phenyl	Isopropyl
1774	4	2-OH-Phenyl	-$CH_2CH(CH_3)_2$
1775	4	2-OH-Phenyl	CF_3
1776	4	2-OH-Phenyl	-CH_2CF_3
1777	4	2-OH-Phenyl	-$CH_2CH_2CF_3$
1778	4	2-OH-Phenyl	cyclopropyl
1779	4	2-OH-Phenyl	Cyclobutyl
1780	4	2-OH-Phenyl	cyclopentyl
1781	4	2-OH-Phenyl	cyclohexyl
1782	4	2-OH-Phenyl	3-pyridyl
1783	4	2-OH-Phenyl	1-methyl-1H-pyrazol-4-yl
1784	4	2-OH-Phenyl	1H-imidazol-4-yl
1785	4	2-OH-Phenyl	2-furanyl
1786	4	3-OMe-Phenyl	Ethyl
1787	4	3-OMe-Phenyl	n-propyl
1788	4	3-OMe-Phenyl	Isopropyl
1789	4	3-OMe-Phenyl	-$CH_2CH(CH_3)_2$
1790	4	3-OMe-Phenyl	CF_3
1791	4	3-OMe-Phenyl	-CH_2CF_3
1792	4	3-OMe-Phenyl	-$CH_2CH_2CF_3$
1793	4	3-OMe-Phenyl	cyclopropyl
1794	4	3-OMe-Phenyl	Cyclobutyl
1795	4	3-OMe-Phenyl	cyclopentyl
1796	4	3-OMe-Phenyl	cyclohexyl
1797	4	3-OMe-Phenyl	3-pyridyl

1798	4	3-OMe-Phenyl	1-methyl-1H-pyrazol-4-yl
1799	4	3-OMe-Phenyl	1H-imidazol-4-yl
1800	4	3-OMe-Phenyl	2-furanyl
1801	4	4-CN-Phenyl	Ethyl
1802	4	4-CN-Phenyl	n-propyl
1803	4	4-CN-Phenyl	Isopropyl
1804	4	4-CN-Phenyl	$-CH_2CH(CH_3)_2$
1805	4	4-CN-Phenyl	CF_3
1806	4	4-CN-Phenyl	$-CH_2CF_3$
1807	4	4-CN-Phenyl	$-CH_2CH_2CF_3$
1808	4	4-CN-Phenyl	cyclopropyl
1809	4	4-CN-Phenyl	Cyclobutyl
1810	4	4-CN-Phenyl	cyclopentyl
1811	4	4-CN-Phenyl	cyclohexyl
1812	4	4-CN-Phenyl	3-pyridyl
1813	4	4-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1814	4	4-CN-Phenyl	1H-imidazol-4-yl
1815	4	4-CN-Phenyl	2-furanyl
1816	4	2-CN-Phenyl	Ethyl
1817	4	2-CN-Phenyl	n-propyl
1818	4	2-CN-Phenyl	Isopropyl
1819	4	2-CN-Phenyl	$-CH_2CH(CH_3)_2$
1820	4	2-CN-Phenyl	CF_3
1821	4	2-CN-Phenyl	$-CH_2CF_3$
1822	4	2-CN-Phenyl	$-CH_2CH_2CF_3$
1823	4	2-CN-Phenyl	cyclopropyl
1824	4	2-CN-Phenyl	Cyclobutyl
1825	4	2-CN-Phenyl	cyclopentyl
1826	4	2-CN-Phenyl	cyclohexyl
1827	4	2-CN-Phenyl	3-pyridyl
1828	4	2-CN-Phenyl	1-methyl-1H-pyrazol-4-yl
1829	4	2-CN-Phenyl	1H-imidazol-4-yl
1830	4	2-CN-Phenyl	2-furanyl
1831	4	3-F-Phenyl	Ethyl
1832	4	3-F-Phenyl	n-propyl
1833	4	3-F-Phenyl	Isopropyl
1834	4	3-F-Phenyl	$-CH_2CH(CH_3)_2$
1835	4	3-F-Phenyl	CF_3
1836	4	3-F-Phenyl	$-CH_2CF_3$
1837	4	3-F-Phenyl	$-CH_2CH_2CF_3$
1838	4	3-F-Phenyl	cyclopropyl
1839	4	3-F-Phenyl	Cyclobutyl
1840	4	3-F-Phenyl	cyclopentyl
1841	4	3-F-Phenyl	cyclohexyl

1842	4	3-F-Phenyl	3-pyridyl
1843	4	3-F-Phenyl	1-methyl-1H-pyrazol-4-yl
1844	4	3-F-Phenyl	1H-imidazol-4-yl
1845	4	3-F-Phenyl	2-furanyl
1846	4	2-Cl-Phenyl	Ethyl
1847	4	2-Cl-Phenyl	n-propyl
1848	4	2-Cl-Phenyl	Isopropyl
1849	4	2-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1850	4	2-Cl-Phenyl	CF_3
1851	4	2-Cl-Phenyl	$-CH_2CF_3$
1852	4	2-Cl-Phenyl	$-CH_2CH_2CF_3$
1853	4	2-Cl-Phenyl	cyclopropyl
1854	4	2-Cl-Phenyl	Cyclobutyl
1855	4	2-Cl-Phenyl	cyclopentyl
1856	4	2-Cl-Phenyl	cyclohexyl
1857	4	2-Cl-Phenyl	3-pyridyl
1858	4	2-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1859	4	2-Cl-Phenyl	1H-imidazol-4-yl
1860	4	2-Cl-Phenyl	2-furanyl
1861	4	4-Cl-Phenyl	Ethyl
1862	4	4-Cl-Phenyl	n-propyl
1863	4	4-Cl-Phenyl	Isopropyl
1864	4	4-Cl-Phenyl	$-CH_2CH(CH_3)_2$
1865	4	4-Cl-Phenyl	CF_3
1866	4	4-Cl-Phenyl	$-CH_2CF_3$
1867	4	4-Cl-Phenyl	$-CH_2CH_2CF_3$
1868	4	4-Cl-Phenyl	cyclopropyl
1869	4	4-Cl-Phenyl	Cyclobutyl
1870	4	4-Cl-Phenyl	cyclopentyl
1871	4	4-Cl-Phenyl	cyclohexyl
1872	4	4-Cl-Phenyl	3-pyridyl
1873	4	4-Cl-Phenyl	1-methyl-1H-pyrazol-4-yl
1874	4	4-Cl-Phenyl	1H-imidazol-4-yl
1875	4	4-Cl-Phenyl	2-furanyl
1876	4	3-Br-Phenyl	Ethyl
1877	4	3-Br-Phenyl	n-propyl
1878	4	3-Br-Phenyl	Isopropyl
1879	4	3-Br-Phenyl	$-CH_2CH(CH_3)_2$
1880	4	3-Br-Phenyl	CF_3
1881	4	3-Br-Phenyl	$-CH_2CF_3$
1882	4	3-Br-Phenyl	$-CH_2CH_2CF_3$
1883	4	3-Br-Phenyl	cyclopropyl
1884	4	3-Br-Phenyl	Cyclobutyl
1885	4	3-Br-Phenyl	cyclopentyl

1886	4	3-Br-Phenyl	cyclohexyl
1887	4	3-Br-Phenyl	3-pyridyl
1888	4	3-Br-Phenyl	1-methyl-1H-pyrazol-4-yl
1889	4	3-Br-Phenyl	1H-imidazol-4-yl
1890	4	3-Br-Phenyl	2-furanyl
1891	4	2-CF_3-Phenyl	Ethyl
1892	4	2-CF_3-Phenyl	n-propyl
1893	4	2-CF_3-Phenyl	Isopropyl
1894	4	2-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1895	4	2-CF_3-Phenyl	CF_3
1896	4	2-CF_3-Phenyl	-CH_2CF_3
1897	4	2-CF_3-Phenyl	-$CH_2CH_2CF_3$
1898	4	2-CF_3-Phenyl	cyclopropyl
1899	4	2-CF_3-Phenyl	Cyclobutyl
1900	4	2-CF_3-Phenyl	cyclopentyl
1901	4	2-CF_3-Phenyl	cyclohexyl
1902	4	2-CF_3-Phenyl	3-pyridyl
1903	4	2-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1904	4	2-CF_3-Phenyl	1H-imidazol-4-yl
1905	4	2-CF_3-Phenyl	2-furanyl
1906	4	4-CF_3-Phenyl	Ethyl
1907	4	4-CF_3-Phenyl	n-propyl
1908	4	4-CF_3-Phenyl	Isopropyl
1909	4	4-CF_3-Phenyl	-$CH_2CH(CH_3)_2$
1910	4	4-CF_3-Phenyl	CF_3
1911	4	4-CF_3-Phenyl	-CH_2CF_3
1912	4	4-CF_3-Phenyl	-$CH_2CH_2CF_3$
1913	4	4-CF_3-Phenyl	cyclopropyl
1914	4	4-CF_3-Phenyl	Cyclobutyl
1915	4	4-CF_3-Phenyl	cyclopentyl
1916	4	4-CF_3-Phenyl	cyclohexyl
1917	4	4-CF_3-Phenyl	3-pyridyl
1918	4	4-CF_3-Phenyl	1-methyl-1H-pyrazol-4-yl
1919	4	4-CF_3-Phenyl	1H-imidazol-4-yl
1920	4	4-CF_3-Phenyl	2-furanyl
1921	4	3-iPr-Phenyl	Ethyl
1922	4	3-iPr-Phenyl	n-propyl
1923	4	3-iPr-Phenyl	Isopropyl
1924	4	3-iPr-Phenyl	-$CH_2CH(CH_3)_2$
1925	4	3-iPr-Phenyl	CF_3
1926	4	3-iPr-Phenyl	-CH_2CF_3


1927	4	3-iPr-Phenyl	$-CH_2CH_2CF_3$
1928	4	3-iPr-Phenyl	cyclopropyl
1929	4	3-iPr-Phenyl	Cyclobutyl
1930	4	3-iPr-Phenyl	cyclopentyl
1931	4	3-iPr-Phenyl	cyclohexyl
1932	4	3-iPr-Phenyl	3-pyridyl
1933	4	3-iPr-Phenyl	1-methyl-1H-pyrazol-4-yl
1934	4	3-iPr-Phenyl	1H-imidazol-4-yl
1935	4	3-iPr-Phenyl	2-furanyl
1936	4	2-morpholino-phenyl	Ethyl
1937	4	2-morpholino-phenyl	n-propyl
1938	4	2-morpholino-phenyl	isopropyl
1939	4	2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1940	4	2-morpholino-phenyl	CF_3
1941	4	2-morpholino-phenyl	$-CH_2CF_3$
1942	4	2-morpholino-phenyl	$-CH_2CH_2CF_3$
1943	4	2-morpholino-phenyl	cyclopropyl
1944	4	2-morpholino-phenyl	Cyclobutyl
1945	4	2-morpholino-phenyl	cyclopentyl
1946	4	2-morpholino-phenyl	cyclohexyl
1947	4	2-morpholino-phenyl	3-pyridyl
1948	4	2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1949	4	2-morpholino-phenyl	1H-imidazol-4-yl
1950	4	2-morpholino-phenyl	2-furanyl
1951	4	4-morpholino-phenyl	ethyl
1952	4	4-morpholino-phenyl	n-propyl
1953	4	4-morpholino-phenyl	isopropyl
1954	4	4-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1955	4	4-morpholino-phenyl	CF_3
1956	4	4-morpholino-phenyl	$-CH_2CF_3$
1957	4	4-morpholino-phenyl	$-CH_2CH_2CF_3$
1958	4	4-morpholino-phenyl	cyclopropyl
1959	4	4-morpholino-phenyl	Cyclobutyl
1960	4	4-morpholino-phenyl	cyclopentyl
1961	4	4-morpholino-phenyl	cyclohexyl
1962	4	4-morpholino-phenyl	3-pyridyl
1963	4	4-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1964	4	4-morpholino-phenyl	1H-imidazol-4-yl
1965	4	4-morpholino-phenyl	2-furanyl
1966	4	4-methyl-2-morpholino-phenyl	ethyl
1967	4	4-methyl-2-morpholino-phenyl	n-propyl
1968	4	4-methyl-2-morpholino-phenyl	isopropyl
1969	4	4-methyl-2-morpholino-phenyl	$-CH_2CH(CH_3)_2$
1970	4	4-methyl-2-morpholino-phenyl	CF_3

1971	4	4-methyl-2-morpholino-phenyl	$-CH_2CF_3$
1972	4	4-methyl-2-morpholino-phenyl	$-CH_2CH_2CF_3$
1973	4	4-methyl-2-morpholino-phenyl	Cyclopropyl
1974	4	4-methyl-2-morpholino-phenyl	Cyclobutyl
1975	4	4-methyl-2-morpholino-phenyl	Cyclopentyl
1976	4	4-methyl-2-morpholino-phenyl	Cyclohexyl
1977	4	4-methyl-2-morpholino-phenyl	3-pyridyl
1978	4	4-methyl-2-morpholino-phenyl	1-methyl-1H-pyrazol-4-yl
1979	4	4-methyl-2-morpholino-phenyl	1H-imidazol-4-yl
1980	4	4-methyl-2-morpholino-phenyl	2-furanyl
1981	1	naphthylen-1-yl	Ethyl
1982	1	naphthylen-1-yl	n-propyl
1983	1	naphthylen-1-yl	Isopropyl
1984	1	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
1985	1	naphthylen-1-yl	CF_3
1986	1	naphthylen-1-yl	$-CH_2CF_3$
1987	1	naphthylen-1-yl	$-CH_2CH_2CF_3$
1988	1	naphthylen-1-yl	Cyclopropyl
1989	1	naphthylen-1-yl	Cyclobutyl
1990	1	naphthylen-1-yl	Cyclopentyl
1991	1	naphthylen-1-yl	Cyclohexyl
1992	1	naphthylen-1-yl	3-pyridyl
1993	1	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
1994	1	naphthylen-1-yl	1H-imidazol-4-yl
1995	1	naphthylen-1-yl	2-furanyl
1996	1	naphthylen-2-yl	Ethyl
1997	1	naphthylen-2-yl	n-propyl
1998	1	naphthylen-2-yl	Isopropyl
1999	1	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2000	1	naphthylen-2-yl	CF_3
2001	1	naphthylen-2-yl	$-CH_2CF_3$
2002	1	naphthylen-2-yl	$-CH_2CH_2CF_3$
2003	1	naphthylen-2-yl	Cyclopropyl
2004	1	naphthylen-2-yl	Cyclobutyl
2005	1	naphthylen-2-yl	Cyclopentyl
2006	1	naphthylen-2-yl	Cyclohexyl
2007	1	naphthylen-2-yl	3-pyridyl
2008	1	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2009	1	naphthylen-2-yl	1H-imidazol-4-yl
2010	1	naphthylen-2-yl	2-furanyl
2011	2	naphthylen-1-yl	Ethyl
2012	2	naphthylen-1-yl	n-propyl
2013	2	naphthylen-1-yl	Isopropyl
2014	2	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2015	2	naphthylen-1-yl	CF_3

2016	2	naphthylen-1-yl	$-CH_2CF_3$
2017	2	naphthylen-1-yl	$-CH_2CH_2CF_3$
2018	2	naphthylen-1-yl	Cyclopropyl
2019	2	naphthylen-1-yl	Cyclobutyl
2020	2	naphthylen-1-yl	Cyclopentyl
2021	2	naphthylen-1-yl	Cyclohexyl
2022	2	naphthylen-1-yl	3-pyridyl
2023	2	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2024	2	naphthylen-1-yl	1H-imidazol-4-yl
2025	2	naphthylen-1-yl	2-furanyl
2026	2	naphthylen-2-yl	Ethyl
2027	2	naphthylen-2-yl	n-propyl
2028	2	naphthylen-2-yl	Isopropyl
2029	2	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2030	2	naphthylen-2-yl	CF_3
2031	2	naphthylen-2-yl	$-CH_2CF_3$
2032	2	naphthylen-2-yl	$-CH_2CH_2CF_3$
2033	2	naphthylen-2-yl	Cyclopropyl
2034	2	naphthylen-2-yl	Cyclobutyl
2035	2	naphthylen-2-yl	Cyclopentyl
2036	2	naphthylen-2-yl	Cyclohexyl
2037	2	naphthylen-2-yl	3-pyridyl
2038	2	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2039	2	naphthylen-2-yl	1H-imidazol-4-yl
2040	2	naphthylen-2-yl	2-furanyl
2041	3	naphthylen-1-yl	Ethyl
2042	3	naphthylen-1-yl	n-propyl
2043	3	naphthylen-1-yl	Isopropyl
2044	3	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2045	3	naphthylen-1-yl	CF_3
2046	3	naphthylen-1-yl	$-CH_2CF_3$
2047	3	naphthylen-1-yl	$-CH_2CH_2CF_3$
2048	3	naphthylen-1-yl	Cyclopropyl
2049	3	naphthylen-1-yl	Cyclobutyl
2050	3	naphthylen-1-yl	Cyclopentyl
2051	3	naphthylen-1-yl	Cyclohexyl
2052	3	naphthylen-1-yl	3-pyridyl
2053	3	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2054	3	naphthylen-1-yl	1H-imidazol-4-yl
2055	3	naphthylen-1-yl	2-furanyl
2056	3	naphthylen-2-yl	Ethyl
2057	3	naphthylen-2-yl	n-propyl
2058	3	naphthylen-2-yl	Isopropyl
2059	3	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2060	3	naphthylen-2-yl	CF_3


2061	3	naphthylen-2-yl	$-CH_2CF_3$
2062	3	naphthylen-2-yl	$-CH_2CH_2CF_3$
2063	3	naphthylen-2-yl	Cyclopropyl
2064	3	naphthylen-2-yl	Cyclobutyl
2065	3	naphthylen-2-yl	Cyclopentyl
2066	3	naphthylen-2-yl	Cyclohexyl
2067	3	naphthylen-2-yl	3-pyridyl
2068	3	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2069	3	naphthylen-2-yl	1H-imidazol-4-yl
2070	3	naphthylen-2-yl	2-furanyl
2071	4	naphthylen-1-yl	Ethyl
2072	4	naphthylen-1-yl	n-propyl
2073	4	naphthylen-1-yl	Isopropyl
2074	4	naphthylen-1-yl	$-CH_2CH(CH_3)_2$
2075	4	naphthylen-1-yl	CF_3
2076	4	naphthylen-1-yl	$-CH_2CF_3$
2077	4	naphthylen-1-yl	$-CH_2CH_2CF_3$
2078	4	naphthylen-1-yl	Cyclopropyl
2079	4	naphthylen-1-yl	Cyclobutyl
2080	4	naphthylen-1-yl	Cyclopentyl
2081	4	naphthylen-1-yl	Cyclohexyl
2082	4	naphthylen-1-yl	3-pyridyl
2083	4	naphthylen-1-yl	1-methyl-1H-pyrazol-4-yl
2084	4	naphthylen-1-yl	1H-imidazol-4-yl
2085	4	naphthylen-1-yl	2-furanyl
2086	4	naphthylen-2-yl	Ethyl
2087	4	naphthylen-2-yl	n-propyl
2088	4	naphthylen-2-yl	Isopropyl
2089	4	naphthylen-2-yl	$-CH_2CH(CH_3)_2$
2090	4	naphthylen-2-yl	CF_3
2091	4	naphthylen-2-yl	$-CH_2CF_3$
2092	4	naphthylen-2-yl	$-CH_2CH_2CF_3$
2093	4	naphthylen-2-yl	Cyclopropyl
2094	4	naphthylen-2-yl	Cyclobutyl
2095	4	naphthylen-2-yl	Cyclopentyl
2096	4	naphthylen-2-yl	Cyclohexyl
2097	4	naphthylen-2-yl	3-pyridyl
2098	4	naphthylen-2-yl	1-methyl-1H-pyrazol-4-yl
2099	4	naphthylen-2-yl	1H-imidazol-4-yl
2100	4	naphthylen-2-yl	2-furanyl

[01042] For the purposes of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:




has the chemical name 8-(methylsulfonyl)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one.

[01043] For the purposes of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:




has the chemical name 8-(methylsulfonyl)-3-(2-(5-phenylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one.

[01044] For the purposes of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:




[01045] has the chemical name 8-(methylsulfonyl)-3-(2-(4-phenylpiperidin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one


[01046] For the purposes of the present invention, a compound depicted by the racemic formula, for example:



will stand equally well for either of the two enantiomers having the formula:



or the formula:



or mixtures thereof, or in the case where a second chiral center is present, all diastereomers.

[01047] In all of the embodiments provided herein, examples of suitable optional substituents are not intended to limit the scope of the claimed invention. The compounds of the invention may contain any of the substituents, or combinations of substituents, provided herein.

Process for preparing the 5-hydroxytryptamine receptor 7 activity modulators of the invention

[01048] The present invention further relates to a process for preparing the 5-hydroxytryptamine receptor 7 activity modulators of the present invention.

[01049] Compounds of the present teachings can be prepared in accordance with the procedures outlined herein, from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions can vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented can be varied for the purpose of optimizing the formation of the compounds described herein.

[01050] The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ^{1}H or ^{13}C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatography such as high pressure liquid chromatograpy (HPLC), gas chromatography (GC), gel-permeation chromatography (GPC), or thin layer chromatography (TLC).

[01051] Preparation of the compounds can involve protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene et al., *Protective Groups in Organic Synthesis*, 2d. Ed. (Wiley & Sons, 1991), the entire disclosure of which is incorporated by reference herein for all purposes.

[01052] The reactions or the processes described herein can be carried out in suitable solvents which can be readily selected by one skilled in the art of organic synthesis. Suitable solvents typically are substantially nonreactive with the reactants, intermediates, and/or products at the temperatures at which the reactions are carried out, i.e., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.


[01053] The compounds of these teachings can be prepared by methods known in the art of organic chemistry. The reagents used in the preparation of the compounds of these teachings can be either commercially obtained or can be prepared by standard procedures described in the literature. For example, compounds of the present invention can be prepared according to the method illustrated in the General Synthetic Schemes:

General Synthetic Schemes for Preparation of Compounds

[01054] The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. In accordance with this invention, compounds in the genus may be produced by one of the following reaction schemes. Accordingly, the invention further features any of the synthetic intermediates or processes as described herein.


[01055] Compounds of the disclosure may be prepared according to the process outlined in Scheme 1-

Scheme 1



[01056] A suitably substituted compound of formula (**1**), a known compound or a compound prepared by known methods wherein PG is a protecting selected from the group consisting of benzyl, tert-butyl carbonate, benzyl carbonate, and tert-butyldimethylsilyl, is reacted with a compound of the formula (**2**), a known compound or a compound prepared by known methods, in the presence of $BnNEt_3Cl$, in the presence of a base such as potassium carbonate, sodium carbonate, cesium carbonate, lithium carbonate, sodium hydroxide, potassium hydroxide, cesium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, acetonitrile, methanol, ethanol, isopropanol, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compounds of the formula (3). A compounds of the formula (3) is reacted with a compounds of the formula (4) a known compound or compound prepared by known methods in which Z^1 is selected from the group consisting of methyl, trifluoromethyl, para-tolyl, and para-NO_2-phenyl, in the presence of a base such as pyridine, 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (5). A compound of the formula (5) is reacted with a base such as potassium carbonate, sodium carbonate, cesium carbonate, lithium carbonate, and the like, in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (6)


Scheme 2



[01057] A compound of formula (**6**) is reacted with a compound of the formula (7), a known compound or a compound prepared by known methods, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as

tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (8). A compound of the formula (8) is reacted with an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, para-toluenesulfonic acid, acetic acid, trifluoracetic acid, and the like, in a solvent such as benzene, toluene, para-xylene, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (9). A compound of the formula (9) is reacted with a compound of the formula (10), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (11).


Scheme 3



[01058] A compound of formula **(11)** is reacted with sodium in the presence of naphthalene in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(12)**. A compound of the formula **(12)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula **(13)**. Alternatively, a compound of the formula **(12)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide,

N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(13)**. Alternatively, a compound of the formula (12) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(13)**. A compound of the **(13)** is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(14)**. A compound of the formula **(14)** is reacted with a compound of the formula **(15)**, a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(16)**.


Scheme 4



[01059] A compound of formula **(6)** is reacted with a compound of the formula **(17)**, a known compound or a compound prepared by known methods, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(18)**. A compound of the formula **(18)** is reacted with an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, para-toluenesulfonic acid, acetic acid, trifluoracetic acid, and the like, in a solvent such as benzene, toluene, para-xylene, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, acetonitrile, N,N-dimethylformamide, N,N-

dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(19)**. A compound of the formula **(19)** is reacted with a compound of the formula (20), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(21)**. A compound of the formula **(21)** is reacted with a compound of the formula **(22)**, a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(11)**.

Scheme 5




[01060] A compound of the formula **(19)** is reacted with a compound of the formula **(23)**, a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate and wherein Q^1 is selected from the group consisting of 1 and 2, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(24)**.

A compound of the formula (**24**) is reacted with a compound of the formula (**25**), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate and wherein Q^2 is selected from the group consisting of 1 and 2, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**26**). A compound of the formula (**26**) is reacted with a ruthenium catalyst such as benzylidene-bis(tricyclohexylphosphine)dichlororuthenium, (1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexyl phosphine)ruthenium, (1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxy phenylmethylene)ruthenium, dichloro(2-isopropoxyphenylmethylene)(tricyclohexylphosphine) ruthenium(II), [1,3-bis(2-methylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene) (tricyclohexyl phosphine) ruthenium(II), dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene](benzylidene) bis(3-bromopyridine)ruthenium(II), dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene](3-methyl-2-butenylidene) (tricyclohexylphosphine)ruthenium(II), dichloro[1,3-bis(2-methylphenyl)-2-imidazolidinylidene](2-isopropoxyphenylmethylene)ruthenium(II), [1,3-dimesityl-2-imidazolidinylidene] dichloro[3-(2-pyridinyl)propylidene]ruthenium(II), dichloro[1,3-bis(2,6-isopropylphenyl)-2-imidazolidinylidene](2-isopropoxyphenylmethylene)ruthenium(II), dichloro(tricyclohexylphosphine) [(tricyclohexylphosphoranyl)methylidene]ruthenium tetrafluoroborate, dichloro[1,3-bis(2,4,6-trimethyl phenyl)-2-imidazolidinylidene][(tricyclohexylphosphoranyl)methylidene]ruthenium(II) tetrafluoroborate, [2-(1-methylethoxy-O)phenylmethyl-C](nitrato-O,O′){rel-(2R,5R,7R)-adamantane-2,1-diyl[3-(2,4,6-trimethylphenyl)-1-imidazolidinyl-2-ylidene]}ruthenium, dichloro[1,3-bis(2,6-isopropylphenyl)-2-imidazolidinylidene](benzylidene)(tricyclohexylphosphine)ruthenium(II), [1,3-bis(2-methylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium(II), dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene][3-(2-pyridinyl)propylidene]ruthenium(II), and the like in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-

diethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**27**).


Scheme 6



[01061] A compound of the formula (**27**) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula (**28**). A compound of the formula (**28**) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula (**29**). Alternatively, a compound of the formula (**28**) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**29**). Alternatively, a compound of the formula (**28**) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**29**). A compound of formula (**29**) is reacted with sodium in the presence of naphthalene in a solvent such as tetrahydrofuran, 1,4-dioxane,


1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**30**).

Scheme 7




[01062] Alternatively, a compound of formula (**27**) is reacted with sodium in the presence of naphthalene in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**31**). A compound of the formula (**31**) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula (**32**). A compound of the formula (**32**) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula (**30**). Alternatively, a compound of the formula (**32**) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**30**). Alternatively, a compound of the formula (**32**) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**30**).

Scheme 8



[01063] A compound of the **(30)** is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(33)**. A compound of the formula **(33)** is reacted with a compound of the formula **(34)**, a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(35)**.


Scheme 9



[01064] A compound of the formula **(31)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula **(36)**. Alternatively, a compound of the formula **(31)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide,

N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**36**). Alternatively, a compound of the formula (**31**) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**36**). A compound of the (**36**) is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**37**). A compound of the formula (**37**) is reacted with a compound of the formula (**38**), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**39**).

Scheme 10




[01065] A compound of the formula (**26**) is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with triphenyl phosphine in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula (**40**). Alternatively, a compound of the formula (**26**) is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-

dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with dimethyl sulfide in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(40)**. Alternatively, a compound of the formula **(26)** is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(40)**. Alternatively, a compound of the formula **(26)** is reacted with potassium osmate dehydrate in the presence of potassium ferricyanide, optionally in the presence of potassium carbonate, optionally in the presence of a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(40)**. Alternatively, a compound of the formula **(26)** is reacted with osmium tetraoxide in the presence of sodium periodate, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of a base such as pyridine, 2,6-lutidine, 2,6-di-tert-butylpyridine, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(40)**. Alternatively, a compound of the formula **(26)** is reacted with osmium tetraoxide in the presence of N-methylmorpholine N-oxide, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(40)**. A compound of the formula **(40)** is reacted with benzyl amine in the presence of a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium

cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(41)**. A compound of the formula **(41)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula **(42)**.


Scheme 11



[01066] A compound of the formula **(42)** is reacted with Di-tert-butyl dicarbonate in the presence of a base such as such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(43)**. A compound of formula **(43)** is reacted with sodium in the presence of naphthalene in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(44)**. A compound of the formula **(44)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula **(45)**. Alternatively, a compound of the formula **(44)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a


solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**45**). Alternatively, a compound of the formula (**44**) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**45**).

Scheme 12




[01067] A compound of the (**45**) is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**46**). A compound of the formula (**46**) is reacted with a compound of the formula (**47**), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**48**). A compound of the formula (**48**) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**49**).

Scheme 13




[01068] A compound of the formula **(49)** is reacted with a compound of the formula **(50)**, a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(51)**.

Scheme 14



[01069] A compound of the formula **(49)** is reacted with a compound of the formula **(52)**, a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(53)**.


Scheme 15



[01070] A compound of the formula **(49)** is reacted with a compound of the formula **(54)**, a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-


dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**55**).

Scheme 16




[01071] A compound of the formula (**49**) is reacted with a compound of the formula (**56**), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**57**).

Scheme 17



[01072] A compound of the formula (**49**) is reacted with a compound of the formula (**58**), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**59**).


Scheme 18



[01073] A compound of the formula (**49**) is reacted with a compound of the formula (**60**), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene

chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(61)**.


Scheme 19



[01074] A compound of the formula **(62)** is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with triphenyl phosphine in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(63)**. Alternatively, a compound of the formula **(62)** is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with dimethyl sulfide in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(63)**. Alternatively, a compound of the formula **(62)** is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(63)**. Alternatively, a compound of the formula **(62)** is reacted with potassium osmate dehydrate in the presence of potassium ferricyanide, optionally in the presence of potassium carbonate, optionally in the presence of a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and the

like, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(63)**. Alternatively, a compound of the formula **(62)** is reacted with osmium tetraoxide in the presence of sodium periodate, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of a base such as pyridine, 2,6-lutidine, 2,6-di-tert-butylpyridine, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(63)**. Alternatively, a compound of the formula **(62)** is reacted with osmium tetraoxide in the presence of N-methylmorpholine N-oxide, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(63)**.

Scheme 20




[01075] A compound of the formula **(64)** is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with triphenyl phosphine in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(65)**. Alternatively, a compound of the formula **(64)** is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-

dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with dimethyl sulfide in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(65)**. Alternatively, a compound of the formula **(64)** is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(65)**. Alternatively, a compound of the formula **(64)** is reacted with potassium osmate dehydrate in the presence of potassium ferricyanide, optionally in the presence of potassium carbonate, optionally in the presence of a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(65)**. Alternatively, a compound of the formula **(64)** is reacted with osmium tetraoxide in the presence of sodium periodate, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of a base such as pyridine, 2,6-lutidine, 2,6-di-tert-butylpyridine, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(65)**. Alternatively, a compound of the formula **(64)** is reacted with osmium tetraoxide in the presence of N-methylmorpholine N-oxide, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(65)**. A compound of the formula **(65)** is reacted with benzyl amine in the presence of a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium

cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(66)**. A compound of the formula **(66)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula **(67)**.

Scheme 21




[01076] A compound of the formula **(68)** is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(69)**. Alternatively, a compound of the formula **(68)** is reacted with a compound of the formula ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-

dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with dimethyl sulfide in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(68a)**. Alternatively, a compound of the formula **(68)** is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(68a)**. Alternatively, a compound of the formula **(68)** is reacted with potassium osmate dehydrate in the presence of potassium ferricyanide, optionally in the presence of potassium carbonate, optionally in the presence of a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula **(68a)**. Alternatively, a compound of the formula **(68)** is reacted with osmium tetraoxide in the presence of sodium periodate, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of a base such as pyridine, 2,6-lutidine, 2,6-di-tert-butylpyridine, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(68a)**. Alternatively, a compound of the formula **(68)** is reacted with osmium tetraoxide in the presence of N-methylmorpholine N-oxide, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(68a)**. A compound of the formula **(68a)** is reacted with a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium cyanoborohydride and the like, in the

presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**69**). A compound of the (**69**) is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**70**). Alternatively, a compound of the formula (**69**) is reacted with bromine in the presence of triphenylphosphine, in the presence of a base such as pyridine 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**70**). Alternatively, a compound of the formula (**69**) is reacted with dibromotriphenylphosphorane, optionally in the presence of a base such as pyridine 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**70**). A compound of the formula (**70**) is reacted with sodium sulfide in the presence of a solvent such as ethanol, methanol, isopropanol, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**71**).


Scheme 22



[01077] A compound of the formula (**71**) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II),

and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula (**72**). Alternatively, a compound of the formula (**71**) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**72**). Alternatively, a compound of the formula (**71**) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**72**). A compound of the (**72**) is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**73**). A compound of the formula (**73**) is reacted with a compound of the formula (**74**), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**75**).


Scheme 23



[01078] A compound of the formula (**75**) is reacted with an oxidizing agent such as *m*-chloroperoxybenzoic acid, monoperphthalic acid, peracetic acid, perpropionic acid, pertrifluoroacetic acid, potassium periodate, sodium metaperiodate, sodium perborate, potassium

peroxymonosulfate (Oxone®), potassium peroxydisulfate, dimethyldioxirane, and the like, in the presence of a solvent such as tetrahydrofuran, ether, 1,4-dioxane, acetone, acetonitrile, methanol, ethanol, isopropanol, water, and the like, optionally with heating, optionally with microwave irradiation to provide compounds of the formula (**76**) and (**77**). Alternatively, a formula of the compound (**75**) is reacted with a sulfoxide such as diphenyl sulfoxide, dimethyl sulfoxide, and the like, in the presence of a rhenium catalyst such as $ReOCl_3(PPh_3)_2$, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, chloroform, tetrahydrofuran, ether, 1,4-dioxane, acetone, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide compounds of the formula (**76**) and (**77**). Alternatively, a formula of the compound (**75**) is reacted with a urea hydrogen peroxide complex in the presence of a rhenium catalyst such as $ReOCl_3(PPh_3)_2$, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, chloroform, tetrahydrofuran, ether, 1,4-dioxane, acetone, acetonitrile, *N,N*-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide compounds of the formula (**76**) and (**77**). Alternatively, a compound of the formula (**75**) is reacted with hydrogen peroxide in the presence titanium (IV) isopropoxide-diethyltartarate, optionally in the presence of an amino alcohol such as 2-amino-3-phenylpropan-1-ol, 2-amino-4-methylpentan-1-ol, 2-amino-4-(methylthio)butan-1-ol, 2-aminopropan-1-ol, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, chloroform, tetrahydrofuran, ether, 1,4-dioxane, acetone, acetonitrile, *N,N*-dimethylformamide, and the like optionally with heating, optionally with microwave irradiation to provide compounds of the formula (**76**) and (**77**). It is understood that one skilled in the art would readily understand that the ratio of products (**76**) and (**77**) will be controlled by the amount of oxidant added and would adjust the amount of oxidant accordingly to produce the desired ration of products.

Scheme 24




[01079] A suitably substituted compound of the formula (**78**), a known compound or a compound prepared by known methods wherein PG is a protecting selected from the group consisting of benzyl, tert-butyl carbonate, benzyl carbonate, and tert-butyldimethylsilyl, is reacted with a compound of the formula (**79**), a known compound or a compound prepared by known methods in which PG^1 is a protecting group selected from the group consisting of benzyl, tert-butyl carbonate, benzyl carbonate, and tert-butyldimethylsilyl, and wherein the LG is

selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(80)**. A compound of the formula **(80)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula **(81)**. Alternatively, a compound of the formula **(80)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(81)**. Alternatively, a compound of the formula **(80)** is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(81)**. A compound of the formula **(81)** is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(82)**. Alternatively, a compound of the formula **(81)** is reacted with bromine in the presence of triphenylphosphine, in the presence of a base such as pyridine 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(82)**. Alternatively, a compound of

the formula **(81)** is reacted with dibromotriphenylphosphorane, optionally in the presence of a base such as pyridine 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(82)**.


Scheme 25



[01080] A compound of the formula **(82)**, is reacted with a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(83)**. A compound of formula **(83)** is reacted with sodium in the presence of naphthalene in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(84)**. A compound of the formula **(84)** is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, optionally with heating, to provide a compound of the formula **(85)**. Alternatively, a compound of the formula **(84)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(85)**. Alternatively, a compound of the formula

(84) is reacted with tetrabutyl ammonium fluoride in the presence of a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (85).


Scheme 26



[01081] A compound of the formula (85) is reacted with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (86). Alternatively, a compound of the formula (85) is reacted with bromine in the presence of triphenylphosphine, in the presence of a base such as pyridine 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (86). Alternatively, a compound of the formula (85) is reacted with dibromotriphenylphosphorane, optionally in the presence of a base such as pyridine 2,6-dimethyl pyridine, 2,6-di-tert-butyl pyridine, triethylamine, diisopropylethyl amine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (86). A compound of the formula (86) is reacted with a compound of the formula (87), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol,


ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(88)**.

Scheme 26



[01082] Diethanolamine **(89)** is reacted with 4-nitrobenzenesulfonyl chloride (NosCl) in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride and the like to provide a compound of the formula **(90)**. A compound of the formula **(90)** is then reacted with a compound of the formula **(91)**, a known compound or one prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like, in a solvent such as acetonitrile, methanol, ethanol, dimethyl formamide, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(92)**. A compound of the formula **(92)** is reacted with a thiophenol in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, acetonitrile and the like, optionally in the presence of dimethylsulfoxide, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula **(93)**.


Scheme 27



[01083] A compound of the formula **(94)**, a known compound or a compound prepared by known methods, is reacted with a compound of the formula **(95)**, a known compound or a compound prepared by known methods in which X^3 is selected from the group consisting of chlorine, bromine, iodine, and methanetrifluorosulfonate, in the presence of a base such as sodium tert-butoxide, lithium tert-butoxide, potassium tert-butoxide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethyl amine, pyridine, 2,6-lutidine, and the like, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II),


tris(dibenzylideneacetone)dipalladium(0), and the like, in the presence of a solvent such as toluene, benzene, methylene chloride, 1,2-dichloroethae, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (**96**). A compound of the formula (**96**) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**97**).

Scheme 28




[01084] A compound of the formula (**98**), a known compound or a compound prepared by known methods, is reacted with a compound of the formula (**99**), a known compound or a compound prepared by known methods in which X^3 is selected from the group consisting of chlorine, bromine, iodine, and methanetrifluorosulfonate, in the presence of a base such as sodium tert-butoxide, lithium tert-butoxide, potassium tert-butoxide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethyl amine, pyridine, 2,6-lutidine, and the like, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), tris(dibenzylideneacetone)dipalladium(0), and the like, in the presence of a solvent such as toluene, benzene, methylene chloride, 1,2-dichloroethae, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (**100**). A compound of the formula (**100**) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**101**).

Scheme 29




[01085] A compound of the formula (**102**), a known compound or a compound prepared by known methods, is reacted with tert-butylchlorodimethylsilane in the presence of a base such as imidazole, 4-dimethylaminopyridine, potassium carbonate, sodium carbonate, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**103**). A compound of the formula (**103**) is reacted with di-tert-butyl dicarbonate in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**104**). A compound of the formula (**104**) is reacted with a compound of the formula (**105**), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**106**). A compound of the formula (**106**) is reacted with a compound of the formula (**107**), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**108**).

Scheme 30



[01086] A compound of the formula (**108**) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**109**). A compound of the formula (**109**) is reacted with 4-methylbenzenesulfonyl chloride in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**110**). A compound of the formula (**110**) is reacted with a compound of the formula (**111**), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**112**).

Scheme 31




[01087] A compound of the formula (**113**), a known compound or a compound prepared by known methods, is reacted with 4-methylbenzenesulfonyl chloride in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-

diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**114**). A compound of the formula (**114**) is reacted with a source of cyanide such as potassium cyanide, sodium cyanide, lithium cyanide, tetrabutylammonium cyanide, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**115**). A compound of the formula (**115**) is reacted with an acid such as as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**116**) where R^Z is H. Alternatively, a compound of the formula of the formula (**115**) can be treated with acid and a suitable alcoholic solvent to provide the compound of the formula (**116**) that is a carboxylic acid ester (e.g., where R^Z is a C_{1-6} alkyl): suitable conditions include using 6M HCl in methanol to provide ester compounds of the formula (**116**) where R^Z is methyl. A compound of the formula (**116**) is reacted with a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**117**). A compound of the formula (**117**) is reacted with tert-butylchlorodimethylsilane in the presence of a base such as imidazole, 4-dimethylaminopyridine, potassium carbonate, sodium carbonate, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**118**). A compound of the formula (**118**) is reacted with di-tert-butyl dicarbonate in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like,

optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**119**).


Scheme 32



[01088] A compound of the formula (**119**) is reacted with a compound of the formula (**120**), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate and wherein Q^1 is selected from the group consisting of 1 and 2, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**121**). A compound of the formula (**121**) is reacted with a compound of the formula (**122**), a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate and wherein Q^2 is selected from the group consisting of 1 and 2, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**123**). A compound of the formula (**123**) is reacted with a ruthenium catalyst such as benzylidene-bis(tricyclohexylphosphine)dichlororuthenium, (1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexyl phosphine)ruthenium, (1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxy phenylmethylene)ruthenium, dichloro(2-isopropoxyphenylmethylene)(tricyclohexylphosphine) ruthenium(II), [1,3-bis(2-methylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene) (tricyclohexyl phosphine) ruthenium(II), dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene](benzylidene) bis(3-bromopyridine)ruthenium(II), dichloro[1,3-bis(2,4,6-

trimethylphenyl)-2-imidazolidinylidene](3-methyl-2-butenylidene) (tricyclohexylphosphine)ruthenium(II), dichloro[1,3-bis(2-methylphenyl)-2-imidazolidinylidene](2-isopropoxyphenylmethylene)ruthenium(II), [1,3-dimesityl-2-imidazolidinylidene] dichloro[3-(2-pyridinyl)propylidene]ruthenium(II), dichloro[1,3-bis(2,6-isopropylphenyl)-2-imidazolidinylidene](2-isopropoxyphenylmethylene)ruthenium(II), dichloro(tricyclohexylphosphine) [(tricyclohexylphosphoranyl)methylidene]ruthenium tetrafluoroborate, dichloro[1,3-bis(2,4,6-trimethyl phenyl)-2-imidazolidinylidene][(tricyclohexylphosphoranyl)methylidene]ruthenium(II) tetrafluoroborate, [2-(1-methylethoxy-O)phenylmethyl-C](nitrato-O,O′){rel-(2R,5R,7R)-adamantane-2,1-diyl[3-(2,4,6-trimethylphenyl)-1-imidazolidinyl-2-ylidene]}ruthenium, dichloro[1,3-bis(2,6-isopropylphenyl)-2-imidazolidinylidene](benzylidene)(tricyclohexylphosphine)ruthenium(II), [1,3-bis(2-methylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium(II), dichloro[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene][3-(2-pyridinyl)propylidene]ruthenium(II), and the like in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**124**).

Scheme 33




[01089] A compound of the formula (**124**) is reacted with ozone in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with triphenyl phosphine in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula (**125**). Alternatively, a compound of the formula (**124**) is reacted with a ozone in the presence of a solvent such as

methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation. The resulting material is then treated with dimethyl sulfide in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating optionally with microwave irradiation to provide a compound of the formula (**125**). Alternatively, a compound of the formula (**124**) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula (**125**). Alternatively, a compound of the formula (**124**) is reacted with potassium osmate dehydrate in the presence of potassium ferricyanide, optionally in the presence of potassium carbonate, optionally in the presence of a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating optionally with microwave irradiation to provide a compound of the formula (**125**). Alternatively, a compound of the formula (**124**) is reacted with osmium tetraoxide in the presence of sodium periodate, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of a base such as pyridine, 2,6-lutidine, 2,6-di-tert-butylpyridine, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**125**). Alternatively, a compound of the formula (**124**) is reacted with osmium tetraoxide in the presence of N-methylmorpholine N-oxide, in the presence of a solvent such as methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, acetone, ethyl acetate, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**125**). A compound of the formula (**125**) is reacted with benzyl amine in the presence of a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium


cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**126**). A compound of the formula (**126**) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula (**127**).

Scheme 34




[01090] A compound of the formula (**127**) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**128**). A compound of the formula (**128**) is reacted with di-tert-butyl dicarbonate in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**129**). A compound of the formula (**129**) is reacted with 4-methylbenzenesulfonyl chloride in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**130**).

Scheme 35



[01091] A compound of the formula **(130)** is reacted with a compound of the formula **(131)**, a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(132)**. A compound of the formula **(132)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(133)**.


Scheme 36



[01092] A compound of the formula **(134)** wherein n is selected from the group consisting 1 and 2, a known compound or a compound prepared by known methods, is reacted with 4-methylbenzenesulfonyl chloride in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(135)**. A compound of the formula **(135)** is reacted with di-tert-butyl malonate in the presence of a base such as potassium tert-butoxide, sodium tert-butoxide, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium

bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**136**). A compound of the formula (**136**) an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**137**). A compound of the formula (**137**) is reacted with methanol in the presence of an acid such as hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**138**). Alternatively, a compound of the formula (**137**) is reacted with methanol in the presence of a coupling agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, *N,N'*-dicyclohexylcarbodiimide, *O*-benzotriazole-*N,N,N',N'*-tetramethyl-uronium-hexafluoro-phosphate, *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like, optionally in the presence of 4-*N,N*-dimethylaminopyridine, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**138**). Alternatively, a compound of the formula (**137**) is reacted with (diazomethyl)trimethylsilane in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**138**).


Scheme 37



[01093] A compound of the formula **(138)** is reacted with a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(139)**. A compound of the formula **(139)** is reacted with tert-butylchlorodimethylsilane in the presence of a base such as imidazole, 4-dimethylaminopyridine, potassium carbonate, sodium carbonate, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(140)**. A compound of the formula **(140)** is reacted with di-tert-butyl dicarbonate in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(141)**. A compound of the formula **(141)** is reacted with a compound of the formula **(142)**, a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(143)**. A compound of the formula **(143)** is reacted with a compound of the formula **(144)**, a known compound or a compound prepared by known methods wherein LG is selected from the group consisting of bromine, chlorine, methansulfonate, and para-tolylsufonate, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, potassium hydride, lithium hydride, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, 1,2-diethoxyethane, and the


like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**145**).

Scheme 38



[01094] A compound of the formula (**145**) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**146**). A compound of the formula (**146**) is reacted with 4-methylbenzenesulfonyl chloride in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**147**). A compound of the formula (**147**) is reacted with a compound of the formula (**148**), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (**149**).

Scheme 39



[01095] Intermediate **(130)** of Scheme 34 can also be used in methods that allow the further homologation of the alkylene linker group. An exemplary method is shown in Scheme 39.

[01096] A compound of the formula **(130)** is reacted with a source of cyanide such as potassium cyanide, sodium cyanide, lithium cyanide, tetrabutylammonium cyanide, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(150)**.

[01097] A compound of the formula **(150)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(151)**.

[01098] A group corresponding to R^7 as described herein can be introduced according to methods known in the art (e.g., as described in Scheme 13). For example, a compound of the formula **(151)** can be reacted with a compound of the formula **(50)**, a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(152)**, where R^7 is SO_2R^{10c}.

Alternatively, a compound of the formula **(151)** can be used as a starting material in the exemplary methods of Schemes 14 and 15 to provide respectively a compound of the formula **(152)**, where R^7 is COR^8 or CO_2R^9.

[01099] A compound of the formula **(152)** is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(153)** where R^Z is H. Alternatively, a compound of the formula of the formula **(152)** can be treated with acid and a suitable alcoholic solvent to provide the compound of the formula **(153)** that is a carboxylic acid ester (e.g., where R^Z is a C_{1-6} alkyl): suitable conditions include using 6M HCl in methanol to provide ester compounds of the formula **(153)** where R^Z is methyl.

[01100] A compound of the formula **(153)** is reacted with a reducing agent such as sodium borohydride, sodium triacetoxy borohydride, sodium cyanoborohydride, lithium borohydride, lithium triacetoxy borohydride, lithium cyanoborohydride and the like, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, methanol, ethanol, isopropanol, tert-butanol, 1,4-dioxane, tetrahydrofuran, 1,2-dimethoxtethane, benzene toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(154)**.

[01101] A compound of the formula **(154)** is reacted with 4-methylbenzenesulfonyl chloride in the presence of 4-dimethylaminopyridine, in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(155)**.

[01102] A compound of the formula **(155)** is reacted with a compound of the formula **(131)**, a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula **(156)**.


[01103] The Examples provided below provide representative methods for preparing exemplary compounds of the present invention. The skilled practitioner will know how to substitute the appropriate reagents, starting materials and purification methods known to those skilled in the art, in order to prepare the compounds of the present invention.

EXAMPLES

[01104] The practice of the invention is illustrated by the following non-limiting examples. The Examples provided below provide representative methods for preparing exemplary compounds of the present invention. The skilled practitioner will know how to substitute the appropriate reagents, starting materials and purification methods known to those skilled in the art, in order to prepare the compounds of the present invention.


[01105] In the examples that follow, ^{1}H-NMR spectra were obtained on a Varian Mercury 300-MHz NMR. Purity (%) and mass spectral data were determined with a Waters Alliance 2695 HPLC/MS (Waters Symmetry C18, 4.6 x 75 mm, 3.5 μm) with a 2996 diode array detector from 210-400 nm.

Example 1: Compound Synthesis




[01106] Preparation of tert-butyl (R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidine-1-carboxylate: To a stirred solution of (R)-(-)-5-(hydroxymethyl)-2-pyrrolidinone (1.0 g, 8.68 mmol, 1.0 equiv) and tert-butyldimethylsilyl chloride (1.44 g, 9.54 mmol, 1.1 equiv.) in dichloromethane (17.3 mL) was added imidazole (0.650 g, 9.54 mmol, 1.1 equiv.). The resulting mixture was then allowed to stirred at 23 °C for 2 hours before being diluted with deionized H_2O (25 mL) and extracted with diethyl ether (3x25 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum to give a crude intermediate which was then dissolved in acetonitrile (43 mL). To the resulting solution was added triethylamine (1.75 g, 17.3 mmol, 2 equiv.), 4-dimethylaminopyridine (0.212 g, 1.73 mmol, 0.2 equiv.) and di-tert-butyl dicarbonate (2.6 g, 16.5 mmol, 1.9 equiv.). The reaction solution was then allowed to stir at 23 °C for 2 hours before being diluted with saturated aqueous NH_4Cl (25 mL) and extracted with ethyl acetate (3x25 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column

chromatography (Ethyl acetate/Hexanes, 20% ~ 30%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 4.13 (m, 1H), 3.88 (dd, J = 4.0, 10.3 Hz, 1H), 3.65 (dd, J= 2.2, 10.3 Hz, 1H), 2.66 (m, 1H), 2.33 (m, 1H), 2.13-1.92 (m, 2H), 1.49 (s, 9H), 0.84 (s, 9H), 0.00 (d, J= 5.3 Hz, 6H).




[01107] Preparation of tert-butyl (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate: To a dry round bottom flask under N_2 atmosphere was added tert-butyl (R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidine-1-carboxylate (2.63 g, 7.98 mmol, 1.0 equiv.) and then dissolved in dry tetrahydrofuran (11.5 mL). The resulting solution was then cooled to -78 ^{O}C and 1 M Lithium bis(trimethylsilyl)amide solution (tetrahydrofuran, 16.8 mL, 16.8 mmol, 2.1 equiv.) was added dropwise. The resulting solution was allowed to gradually warm to -20 ^{O}C before being cooled back to -78 ^{O}C and followed by dropwise addition of iodoethane (3.12 g, 20 mmol, 2.5 equiv.). The reaction solution was then allowed to gradually warm to 0 ^{O}C and stir at that temperature for 2 hours before being warmed to 23 ^{o}C and allowed to stir for an additional 2 hours. The resulting solution was diluted with saturated aq. NH_4Cl (25 mL) and extracted with ethyl acetate (3x25 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 3.94 (m, 1H), 3.83 (dd, J = 5.2, 10.0 Hz, 1H), 3.67 (dd, J= 2.5, 10.0 Hz, 1H), 1.95 (dd, J= 6.3, 13.4 Hz, 1H), 1.79 (dd, J= 9.0, 13.4 Hz, 1H), 1.65-1.40 (m, 13H), 0.90-0.75 (m, 15H), 0.00 (d, J= 3.3 Hz, 6H).




[01108] Preparation of (R)-3,3-diethyl-5-(hydroxymethyl)pyrrolidin-2-one: A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (4.8 mL) to methanol (12 mL). To a small round bottom flask was added tert-butyl (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate (0.875 g, 2.65 mmol, 1.0 equiv.) and 1 mL of methanol. The prepared methanolic HCl solution was then added dropwise (12 mL) and the resulting mixture was allowed to stir at 23 ^{o}C for 30 min before being diluted with methanol and concentrated in vacuum to produce a crude product that was used in


the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.61 (b, 1H), 4.96 (b, 1H), 3.69-3.48 (m, 2H), 3.33 (dd, J= 8.1, 11.2 Hz, 1H), 1.84 (dd, J= 7.8, 13.3 Hz, 1H), 1.58-1.31 (m, 5H), 0.80 (dt, J= 7.5, 21.9 Hz, 6H).




[01109] Preparation of (R)-(4,4-diethyl-5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate: To a stirred solution of (R)-3,3-diethyl-5-(hydroxymethyl)pyrrolidin-2-one (0.367 g, 2.14 mmol, 1.0 equiv) and triethylamine (0.240 g, 2.36 mmol, 1.1 equiv) in dichloromethane (3.3 mL), 4-methylbenzenesulfonyl chloride (0.450 g, 2.36 mmol, 1.1 equiv) and 4-dimethylaminopyridine (0.053 g, 0.428 mmol, 0.2 equiv.) were subsequently added at 0 °C. The resulting mixture was stirred at 0 °C for 10 minutes and allowed to stir overnight at 23 °C. Then, the reaction mixture was diluted with dichloromethane (25 mL), washed with 1N HCl (1x5 mL) and deionized H_2O (2x5 mL), dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.71 (d, J= 8.3 Hz, 2H), 7.28 (d, J= 8.1 Hz, 2H), 6.57 (b, 1H), 3.96 (dd, J= 4.0, 9.6 Hz, 1H), 3.82-3.67 (m, 2H), 2.37 (s, 3H), 1.90 (dd, J= 7.9, 13.5 Hz, 1H), 1.52 (dd, J= 7.1, 13.6 Hz, 1H) 1.49-1.31 (m, 4H), 0.75 (dt, J= 7.4, 26.5 Hz, 6H).




[01110] Preparation of (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate: To a small vial was added (R)-(4,4-diethyl-5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate (75 mg, 0.23 mmol, 1 equiv.) and 1-phenylpiperazine (79 mg, 0.48 mmol, 2.1 equiv.) then both were dissolved in acetonitrile (2.3 mL). Then K_2CO_3 (80 mg, 0.57 mmol, 2.5 equiv.) was added, the reaction mixture was allowed to stir at 80 °C for 3 days, and then cooled to 23 °C. The mixture was filtered, washed with acetonitrile, and the filtrate was concentrated in vacuum to give a crude product which was further purified by HPLC (CH_3CN/H_2O, 0.1% Formic acid), 0%~100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.19 (m, 2H), 6.85 (d, J= 8.3 Hz, 2H), 6.79 (t, J= 7.0 Hz, 1H), 6.42 (b, 1H), 3.70 (m, 1H), 3.12 (m, 4H), 2.70 (m, 2H), 2.50 (m, 2H), 2.41 (dd, J= 3.6, 12.4 Hz, 1H), 2.29 (dd, J= 9.8, 12.4 Hz, 1H), 1.93 (dd, J= 7.6, 13.5 Hz, 1H), 1.57-1.37 (m, 5H), 0.84 (dt, J= 7.4, 19.6 Hz, 6H). LC/MS [M+H] = m/z 316.2.




[01111] Preparation of (R)-3,3-diethyl-5-((4-(p-tolyl)piperazin-1-yl)methyl)pyrrolidin-2-one formate: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate, except 1-(4-methylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.09 (d, J= 8.2 Hz, 2H), 6.85 (d, J= 8.5 Hz, 2H), 6.47 (b, 1H), 3.78 (m, 1H), 3.15 (m, 4H), 2.78 (m, 2H), 2.59 (m, 2H), 2.49 (dd, J= 3.6, 12.4 Hz, 1H), 2.38 (dd, J= 9.9, 12.4 Hz, 1H), 2.28 (s, 3H), 2.01 (dd, J= 7.6, 13.1 Hz, 1H), 1.67-1.45 (m, 5H), 0.93 (dt, J= 7.4, 19.6 Hz, 6H). LC/MS [M+H] = m/z 330.2.




[01112] Preparation of (R)-5-((4-(3-chlorophenyl)piperazin-1-yl)methyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate, except 1-(3-chlorophenyl)piperazine hydrochloride was substituted for 1-phenylpiperazine and 5 equiv. of K_2CO_3 used instead of 2.5 equiv. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.09 (t, J= 8.1 Hz, 1H), 6.79 (t, J= 2.0 Hz, 1H), 6.74 (dd, J= 1.8, 7.7 Hz, 1H), 6.70 (dd, J= 2.3, 8.3 Hz, 1H), 6.36 (b, 1H), 3.69 (m, 1H), 3.11 (m, 4H), 2.67 (m, 2H), 2.47 (m, 2H), 2.39 (dd, J= 3.5, 12.3 Hz, 1H), 2.28 (dd, J= 10.0, 12.4 Hz, 1H), 1.92 (dd, J= 7.8, 13.2 Hz, 1H), 1.58-1.38 (m, 5H), 0.84 (dt, J= 7.5, 20.2 Hz, 6H). LC/MS [M+H] = m/z 350.2.




[01113] Preparation of (R)-3,3-diethyl-5-((4-(4-fluorophenyl)piperazin-1-yl)methyl)pyrrolidin-2-one formate: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate, except 1-(4-fluorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.97 (m, 2H), 6.92-6.77 (m, 3H), 3.81 (m, 1H), 3.15 (m, 4H), 2.82 (m, 2H), 2.65 (m, 2H), 2.53 (dd, J= 3.5, 12.4 Hz, 1H), 2.44 (dd, J= 9.6, 12.4 Hz, 1H), 2.03 (dd, J= 7.6, 13.3 Hz, 1H), 1.68-1.44 (m, 5H), 0.92 (dt, J= 7.5, 18.9 Hz, 6H). LC/MS [M+H] = m/z 334.2.



[01114] Preparation of (R)-3,3-diethyl-5-((4-(pyridin-2-yl)piperazin-1-yl)methyl)pyrrolidin-2-one formate: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate, except 1-(2-pyridyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.19 (m, 1H), 7.50 (m, 1H), 6.86 (b, 1H) 6.65 (m, 2H), 3.81 (m, 1H), 3.57 (m, 4H), 2.77 (m, 2H), 2.59 (m, 2H), 2.51 (dd, J= 3.8, 12.6 Hz, 1H), 2.43 (dd, J= 9.4, 12.5 Hz, 1H), 2.02 (dd, J= 7.7, 13.2 Hz, 1H), 1.66-1.44 (m, 5H), 0.90 (dt, J= 7.4, 20.0 Hz, 6H). LC/MS [M+H] = m/z 317.2.




[01115] Preparation of (R)-3,3-diethyl-5-((4-(2-isopropylphenyl)piperazin-1-yl)methyl)pyrrolidin-2-one formate: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate, except 1-(2-isopropylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.18 (m, 1H), 7.12-6.99 (m, 3H), 6.34 (b, 1H), 3.71 (m, 1H), 3.40 (sept, J= 6.8 Hz, 1H), 2.83 (m, 4H), 2.71 (b, 2H), 2.60-2.39 (b, 3H), 2.32 (m, 1H), 1.94 (dd, J= 7.5, 13.2 Hz, 1H), 1.60-1.36 (m, 5H), 1.12 (d, J= 6.9 Hz, 6H), 0.84 (dt, J= 7.4, 18.3 Hz, 6H). LC/MS [M+H] = m/z 358.2.




[01116] Preparation of (R)-3,3-diethyl-5-((4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)methyl)pyrrolidin-2-one formate: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one formate, except 1-(4-methyl-2-morpholinophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.73 (m, 2H), 6.63 (b, 1H), 6.45 (b, 1H) 3.82-3.64 (m, 5H), 3.31-2.84


(b, 8H), 2.68 (b, 2H), 2.57-2.38 (b, 3H), 2.32 (m, 1H), 2.21 (s, 3H), 1.94 (dd, J= 7.4, 13.0 Hz, 1H), 1.59-1.38 (m, 5H), 0.84 (dt, J= 7.4, 18.8 Hz, 6H). LC/MS [M+H] = m/z 415.2.




[01117] Preparation of (S)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide: To a stirred solution of (S)-2-(2-(benzyloxy)ethyl)oxirane (0.5 g, 2.8 mmo, 1.0 equiv.) in 1,4-dioxane (11.25 mL) was added p-toluenesulfonamide (0.96 g, 5.6 mmol, 2.0 equiv.), benzyltriethylammonium chloride (0.064 g, 0.28 mmol, 0.1 equiv.) and Cs_2CO_3 (0.092 g, 0.28 mmol, 0.1 equiv.). The resulting mixture was then stirred at 90 ^{o}C for 48 hours. The reaction was then allowed to cool to 23 ^{o}C and concentrated in vacuum to give a crude product which was further purified by HPLC (CH_3CN/H_2O, 0.1% Formic acid), 0%~100%). Desired fractions were further purified by column chromatography (Ethyl acetate/Hexanes, 10% ~ 100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.73 (d, J= 8.2 Hz, 2H), 7.44-7.22 (m, 7H), 5.00 (t, J= 6.2 Hz, 1H), 4.50 (s, 2H), 3.93 (m, 1H), 3.66 (m, 2H), 3.07 (m, 1H), 2.87 (m, 1H), 2.43 (s, 3H), 1.83 (m, 1H), 1.70 (m, 1H).



[01118] Preparation of (R)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide: The title compound was prepared according to the procedure for (S)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide, except (R)-2-(2-(benzyloxy)ethyl)oxirane was substituted for (S)-2-(2-(benzyloxy)ethyl)oxirane. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.64 (d, J= 8.2 Hz, 2H), 7.31-7.16 (m, 7H), 4.90 (t, J= 6.1 Hz, 1H), 4.41 (s, 2H), 3.84 (m, 1H), 3.57 (m, 2H), 2.98 (m, 1H), 2.78 (m, 1H), 2.34 (s, 3H), 1.74 (m, 1H), 1.60 (m, 1H).




[01119] Preparation of N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide: The title compound was prepared according to the procedure for (S)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide, except (rac)-2-(2-(benzyloxy)ethyl)oxirane was substituted for (S)-2-(2-(benzyloxy)ethyl)oxirane. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.66 (d, J= 8.2 Hz, 2H), 7.35-7.18 (m, 7H), 4.92 (t, J= 6.1 Hz, 1H), 4.43 (s, 2H), 3.89 (m, 1H), 3.60 (m, 2H), 3.02 (m, 1H), 2.80 (m, 1H), 2.38 (s, 3H), 1.77 (m, 1H), 1.63 (m, 1H).




[01120] Preparation of (R)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a stirred solution of pyridine (1.57 g, 19.9 mmol, 5.0 equiv.) and methanesulfonyl chloride (2.28 g, 19.9 mmol, 5.0 equiv.) in dry dichloromethane (22.5 mL) at 0°C was added a solution of (S)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide (1.4 g, 3.99 mmol, 1.0 equiv.) in dry dichloromethane (22.5 mL). The resulting solution was stirred at reflux overnight, cooled to 23 °C, and washed with brine (50 mL). The organic layer was dried over Na_2SO_4 and concentrated in vacuo to give crude mesylate which was further purified by column chromatography (Ethyl acetate/Hexanes, 10% ~ 50%).

[01121] The purified mesylate was then dissolved in acetonitrile (45 mL) and K_2CO_3 (2.22 g, 16.0 mmol, 4.0 equiv.) was added. The resulting mixture was allowed to stir at 45 °C overnight before being cooled to 23 °C and filtered. The filtrate was concentrated in vacuo to give crude product which was purified by column chromatography (Ethyl acetate/Hexanes, 10% ~ 20%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.84 (d, J= 8.2 Hz, 2H), 7.45-7.19 (m, 7H), 4.39 (s, 2H), 3.46 (dt, J= 3.7, 9.2 Hz, 1H), 3.35 (m, 1H), 2.93 (m, 1H), 2.70 (d, J= 7.1 Hz, 1H), 2.45 (s, 3H), 2.15 (d, J= 4.6 Hz, 1H), 1.94 (m, 1H), 1.58 (m, 1H).




[01122] Preparation of (S)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine: The title compound was prepared according to the procedure for (R)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine, except (R)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide was substituted for (S)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.84 (d, J= 8.3 Hz, 2H), 7.43-7.23 (m, 7H), 4.39 (s, 2H), 3.46 (dt, J= 3.8, 9.3 Hz, 1H), 3.35 (m, 1H), 2.93 (m, 1H), 2.69 (d, J= 7.0 Hz, 1H), 2.45 (s, 3H), 2.15 (d, J= 4.5 Hz, 1H), 1.94 (m, 1H), 1.59 (m, 1H).




[01123] Preparation of 2-(2-(benzyloxy)ethyl)-1-tosylaziridine: The title compound was prepared according to the procedure for (R)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine, except (rac)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide was substituted for (S)-N-(4-(benzyloxy)-2-hydroxybutyl)-4-methylbenzenesulfonamide. ^{1}H NMR (400 MHz, $CDCl_3$) δ


7.84 (d, J= 8.3 Hz, 2H), 7.41-7.26 (m, 7H), 4.39 (s, 2H), 3.46 (dt, J= 3.8, 9.3 Hz, 1H), 3.35 (m, 1H), 2.93 (m, 1H), 2.69 (d, J= 7.0 Hz, 1H), 2.45 (s, 3H), 2.15 (d, J= 4.6 Hz, 1H), 1.93 (m, 1H), 1.59 (m, 1H).




[01124] Preparation of (S)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido) hexanamide: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a cooled solution of dry N, N-dimethylacetamide (0.527 g, 6.05 mmol, 1.1 equiv.) and dry tetrahydrofuran (18 mL) at -78 ^{O}C was added dropwise a 1M Lithium diisopropylamide solution (tetrahydrofuran/Hexanes, 7.26 mL, 7.26 mmol, 1.3 equiv.). The resulting solution was then stirred at -78 ^{O}C for 30 minutes before being allowed to warm to 0 ^{O}C. At 0 ^{O}C, a solution of (R)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine (1.82 g, 5.5 mmol, 1.0 equiv.) in dry tetrahydrofuran (18 mL) was added to the solution. The reaction was stirred at 0 ^{O}C for 20 minutes and then allowed to warm to 23 ^{o}C and stir overnight. The reaction was quenched with sat. NH_4Cl (40 mL) and extracted with ethyl acetate (3x30 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 40% ~ 100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.72 (d, J= 8.2 Hz, 2H), 7.41-7.19 (m, 7H), 5.91 (d, J= 7.5 Hz, 1H), 4.40 (q, J= 9.3 Hz, 2H), 3.56 (m, 1H), 3.40 (m, 2H), 2.93 (s, 3H), 2.90 (s, 3H), 2.48-2.35 (m, 4H), 2.21 (dt, J= 6.6, 16.6 Hz, 1H), 1.88-1.69 (m, 2H), 1.68-1.55 (m, 2H).




[01125] Preparation of (R)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido) hexanamide: The title compound was prepared according to the procedure for (S)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide, except (S)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine was substituted for (R)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.71 (d, J= 8.2 Hz, 2H), 7.41-7.18 (m, 7H), 5.91 (d, J= 7.5 Hz, 1H), 4.40 (q, J= 8.9 Hz, 2H), 3.54 (m, 1H), 3.40 (m, 2H), 2.94 (s, 3H), 2.91 (s, 3H), 2.47-2.35 (m, 4H), 2.21 (dt, J= 6.6, 16.6 Hz, 1H), 1.87-1.68 (m, 2H), 1.67-1.52 (m, 2H).




[01126] Preparation of 6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido) hexanamide: The title compound was prepared according to the procedure for (S)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide, except (rac)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine was substituted for (R)-2-(2-(benzyloxy)ethyl)-1-tosylaziridine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.72 (d, J= 8.2 Hz, 2H), 7.42-7.21 (m, 7H), 5.90 (d, J= 7.5 Hz, 1H), 4.41 (q, J= 9.3 Hz, 2H), 3.57 (m, 1H), 3.40 (m, 2H), 2.95 (s, 3H), 2.93 (s, 3H), 2.50-2.36 (m, 4H), 2.23 (dt, J= 6.6, 16.6 Hz, 1H), 1.88-1.70 (m, 2H), 1.69-1.57 (m, 2H).




[01127] Preparation of (S)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one: (S)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide (0.565g, 1.35 mmol, 1.0 equiv.) was mixed with p-toluenesulfonic acid monohydrate (0.282g, 1.48 mmol, 1.1 equiv.) and toluene (5.65 mL) in a microwave vial. The mixture was then heated in a microwave reactor at 190 °C for 2 hours. The mixture was then neutralized with sat. $NaHCO_3$ and extracted with ethyl acetate (3x15 mL). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 40%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.96 (d, J= 8.2 Hz, 2H), 7.42-7.26 (m, 7H), 4.59-4.42 (m, 3H), 3.65-3.54 (m, 2H), 2.62-2.50 (m, 1H), 2.45 (s, 3H), 2.42-2.27 (m, 2H), 2.25-2.12 (m, 1H), 2.11-1.89 (m, 2H).




[01128] Preparation of (R)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one: The title compound was prepared according to the procedure for (S)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one, except (R)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide was substituted for (S)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.95 (d, J= 8.4 Hz, 2H), 7.39-7.25 (m, 7H), 4.59-4.42 (m, 3H), 3.67-3.53 (m, 2H), 2.61-2.47 (m, 1H), 2.42 (s, 3H), 2.40-2.23 (m, 2H), 2.22-2.09 (m, 1H), 2.07-1.89 (m, 2H).




[01129] Preparation of 5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one: The title compound was prepared according to the procedure for (S)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one, except (rac)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide was substituted for (S)-6-(benzyloxy)-N,N-dimethyl-4-((4-methylphenyl)sulfonamido)hexanamide. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.96 (d, J= 8.3 Hz, 2H), 7.41-7.25 (m, 7H), 4.60-4.42 (m, 3H), 3.64-3.54 (m, 2H), 2.62-2.49 (m, 1H), 2.44 (s, 3H), 2.42-2.26 (m, 2H), 2.24-2.11 (m, 1H), 2.10-1.88 (m, 2H).




[01130] Preparation of (R)-(5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate: To a cooled mixture of (R)-(-)-5-(hydroxymethyl)-2-pyrrolidinone (10.0 g, 87 mmol, 1.0 equiv.) and triethylamine (9.68 g, 95.7 mmol, 1.1 equiv.) in methylene chloride (134 mL) at 0 ^{O}C was added 4-toluenesulfonyl chloride (18.25 g, 95.7 mmol, 1.1 equiv.) followed by 4-dimethylaminopyridine (2.12 g, 17.3 mmol, 0.2 equiv.). The resulting reaction mixture was stirred at 0 ^{O}C for 5 minutes before being warmed to 23 ^{o}C and allowed to stir overnight. Then, the reaction mixture was diluted with dichloromethane (200 mL), washed with 1N HCl (1x200 mL) and deionized H_2O (2x150 mL), dried over Na_2SO_4 and concentrated in vacuum to give a crude product which used in the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.77 (d, J= 8.2 Hz, 2H), 7.35 (d, J= 8.2 Hz, 2H), 6.76 (b, 1H), 4.01 (dd, J= 3.6, 9.7 Hz, 1H), 3.86 (m, 1H), 3.80 (dd, J= 7.4, 9.6 Hz, 1H), 2.44 (s, 3H), 2.37-2.12 (m, 3H), 1.77 (m, 1H)




[01131] Preparation of (S)-(5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate: The title compound was prepared according to the procedure for (R)-(5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate, except L-pyroglutaminol was substituted for (R)-(-)-5-(hydroxymethyl)-2-pyrrolidinone. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.71 (d, J= 8.3 Hz, 2H), 7.30 (d, J= 8.2 Hz, 2H), 5.77 (b, 1H), 3.99 (dd, J= 3.5, 9.7 Hz, 1H), 3.86 (m, 1H), 3.79 (dd, J= 7.4, 9.6 Hz, 1H), 2.39 (s, 3H), 2.29-2.11 (m, 3H), 1.69 (m, 1H).




[01132] Preparation of (R)-2-(5-oxopyrrolidin-2-yl)acetonitrile: To a solution of (R)-(5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate (21.25 g, 79 mmol, 1.0 equiv.) in acetonitrile (335 mL) was added potassium cyanide (12.86 g, 197 mmol, 2.5 equiv.). The resulting reaction mixture was then heated to reflux and allowed to reflux overnight. After cooling to 23 °C, the reaction mixture was filtered thru a plug of Celite and concentrated in vacuum to give a crude product which was further purified by column chromatography (MeOH/Ethyl acetate, 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.23 (b, 1H), 3.93 (m, 1H), 2.54 (d, J= 5.7 Hz, 2H), 2.48-2.24 (m, 3H), 1.88 (m, 1H).




[01133] Preparation of (S)-2-(5-oxopyrrolidin-2-yl)acetonitrile: The title compound was prepared according to the procedure for (R)-2-(5-oxopyrrolidin-2-yl)acetonitrile, except (S)-(5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate was substituted for (R)-(5-oxopyrrolidin-2-yl)methyl 4-methylbenzenesulfonate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.47 (b, 1H), 3.92 (m, 1H), 2.55 (d, J= 5.6 Hz, 2H), 2.47-2.24 (m, 3H), 1.86 (m, 1H).




[01134] Preparation of methyl (R)-2-(5-oxopyrrolidin-2-yl)acetate: A 6 M HCl in methanol solution was prepared via the addition of acetyl chloride (33 mL) to methanol (77 mL). (R)-2-(5-oxopyrrolidin-2-yl)acetonitrile (4.73 g, 38 mmol, 1.0 equiv.) was dissolved in the prepared 6 M methanolic HCl solution (77 mL) and stirred at 23 °C overnight. The reaction mixture was diluted with deionized H_2O (100 mL) and methylene chloride (100 mL) and layers were seperated. The aqueous layer was backwashed with methylene chloride (8x100 mL). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuum to give a crude product that was used in the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.40 (b, 1H), 3.94 (m, 1H), 3.64 (s, 3H), 2.52 (dd, J= 4.5, 16.5 Hz, 1H), 2.43 (dd, J= 9.0, 16.5 Hz, 1H), 2.35-2.19 (m, 3H), 1.68 (m, 1H).




[01135] Preparation of methyl (S)-2-(5-oxopyrrolidin-2-yl)acetate: The title compound was prepared according to the procedure for methyl (R)-2-(5-oxopyrrolidin-2-yl)acetate, except (S)-2-(5-oxopyrrolidin-2-yl)acetonitrile was substituted for (R)-2-(5-oxopyrrolidin-2-yl)acetonitrile. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.25 (b, 1H), 3.94 (m, 1H), 3.64 (s, 3H), 2.52 (dd, J= 4.3, 16.4 Hz, 1H), 2.42 (dd, J= 9.2, 16.5 Hz, 1H), 2.32-2.23 (m, 3H), 1.68 (m, 1H).



[01136] Preparation of (R)-5-(2-hydroxyethyl)pyrrolidin-2-one: To a stirred solution of methyl (R)-2-(5-oxopyrrolidin-2-yl)acetate (0.525 g, 3.3 mmol, 1.0 equiv.) in ethanol (13.4 mL) was added $NaBH_4$ (0.380 g, 10 mmol, 3.0 equiv.) and the resulting mixture was stirred at 23 °C for 5 minutes then at reflux for 1 hour. After cooling to 23 °C, the reaction mixture was quenched with 1 mL of acetic acid and the filtered while washing with methanol. The filtrate was concentrated in vacuum to give a crude product which was further purified by column chromatography (MeOH/methanol, 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.36 (b, 1H), 4.86-4.09 (b, 1H), 3.82-3.54 (m, 3H), 2.32-2.14 (m, 3H), 1.74-1.53 (m, 3H).




[01137] Preparation of (S)-5-(2-hydroxyethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-5-(2-hydroxyethyl)pyrrolidin-2-one, except methyl (S)-2-(5-oxopyrrolidin-2-yl)acetate was substituted for methyl (R)-2-(5-oxopyrrolidin-2-yl)acetate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.04 (b, 1H), 3.81-3.59 (m, 3H), 3.35-2.88 (b, 1H), 2.31-2.14 (m, 3H), 1.75-1.57 (m, 3H).




[01138] Preparation of tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate: To a stirred solution of (R)-5-(2-hydroxyethyl)pyrrolidin-2-one (3.41 g, 26.4 mmol, 1.0 equiv.) in methylene chloride (50 mL) was added tert-

butylchlorodimethylsilane (4.37 g, 29 mmol, 1.1 equiv.) followed by imidazole (1.98 g, 29 mmol, 1.1 equiv.). The resulting mixture was then stirred at 23 °C for 2 hr before being diluted with diethyl ether (100 mL) and washed with deionized H_2O (50 mL). The aqueous layer was backwashed with diethyl ether (2x20 mL). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuum to give a crude intermediate that was dissolved in acetonitrile (132 mL). Triethylamine (5.34 g, 52.8 mmol, 2.0 equiv.), di-tert-butyl dicarbonate (10.95 g, 50.2 mmol, 1.9 equiv.) and 4-dimethylaminopyridine (0.645 g, 5.28 mmol, 0.2 equiv.) were then added and the resulting solution was stirred at 23 °C for 2 hrs. The reaction was diluted with ethyl acetate (200 mL) and washed with sat. NH_4Cl (100 mL). The aqueous layer was backwashed with ethyl acetate (2x20 mL) and the combined organic phase was dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 20-30%). ^1H NMR (400 MHz, $CDCl_3$) δ 4.18 (m, 1H), 3.66 (t, J= 6.2 Hz, 2H), 2.54 (ddd, J= 9.2, 11.3, 17.6 Hz, 1H), 2.36 (ddd, J= 2.4, 9.2, 17.6 Hz, 1H), 2.13-1.82 (m, 3H), 1.66 (m, 1H), 1.47 (s, 9H), 0.83 (s, 9H), 0.00 (s, 6H).




[01139] Preparation of tert-butyl (S)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate, except (S)-5-(2-hydroxyethyl)pyrrolidin-2-one was substituted for (R)-5-(2-hydroxyethyl)pyrrolidin-2-one. ^1H NMR (400 MHz, $CDCl_3$) δ 4.18 (m, 1H), 3.66 (t, J= 6.3 Hz, 2H), 2.54 (ddd, J= 9.1, 11.3, 17.6 Hz, 1H), 2.36 (ddd, J= 2.4, 9.2, 17.6 Hz, 1H), 2.12-1.85 (m, 3H), 1.66 (m, 1H), 1.47 (s, 9H), 0.83 (s, 9H), 0.00 (s, 6H).




[01140] Preparation of tert-butyl (R)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. A stirred solution of tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate (8.0 g, 23.2 mmol, 1.0 equiv.) in dry tetrahydrofuran (35 mL) was cooled to -78 °C and 1M lithium bis(trimethylsilyl)amide solution (tetrahydrofuran, 51 mL, 51 mmol, 2.2 equiv.) was added dropwise while maintaining


the reaction temperature below -70 ^{O}C. The resulting solution was allowed to slowly warm to -30 ^{O}C before being cooled back to -78 ^{O}C at which iodoethane (8.48 g, 50.5 mmol, 2.15 equiv.) was slowly added dropwise. The resulting solution was slowly warmed to -15 ^{O}C and allowed to stir at this temperature for 2 hr before being warmed to 23 ^{o}C and allowed to stir for an additional 2.5 hr. The reaction was quenched with sat. NH_4Cl (40 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 3.97 (m, 1H), 3.65 (t, J= 5.9 Hz, 2H), 2.23 (m, 1H), 1.95 (dd, J= 8.6, 13.5 Hz, 1H), 1.66 (dd, J= 6.1, 13.5 Hz, 1H), 1.58-1.39 (m, 14H), 0.90-0.74 (m, 15H), 0.00 (s, 3H).




[01141] Preparation of (R)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one: The title compound was prepared according to the procedure for tert-butyl (R)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate, except (R)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one was substituted for tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.84 (d, J= 8.4 Hz, 2H), 7.33-7.16 (m, 7H), 4.44 (dd, J= 12.0, 32.0 Hz, 2H), 4.21 (m, 1H), 3.54 (t, J= 5.5 Hz, 2H), 2.69 (m, 1H), 2.34 (s, 3H), 1.95 (dd, J= 8.1, 13.5 Hz, 1H), 1.81-1.64 (m, 2H), 1.41 (q, J= 7.5 Hz, 2H), 1.33-1.13 (m, 2H), 0.71 (t, J= 7.5 Hz, 3H), 0.48 (t, J= 7.5 Hz, 3H).




[01142] Preparation of (S)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one: The title compound was prepared according to the procedure for tert-butyl (R)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate, except (S)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one was substituted for tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.93 (d, J= 8.2 Hz, 2H), 7.40-7.24 (m, 7H), 4.53 (dd, J= 11.9, 32.6 Hz, 2H), 4.31 (m, 1H), 3.63 (t, J= 5.8 Hz, 2H), 2.78 (m, 1H), 2.42 (s, 3H), 2.04 (dd, J= 8.6, 13.5 Hz, 1H), 1.90-1.74 (m, 2H), 1.50 (q, J= 7.7 Hz, 2H), 1.44-1.23 (m, 2H), 0.80 (t, J= 7.4 Hz, 3H), 0.57 (t, J= 7.4 Hz, 3H).



[01143] Preparation of 5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one: The title compound was prepared according to the procedure for tert-butyl (R)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate, except (rac)-5-(2-(benzyloxy)ethyl)-1-tosylpyrrolidin-2-one was substituted for tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.93 (d, J= 8.3 Hz, 2H), 7.41-7.24 (m, 7H), 4.52 (dd, J= 12.0, 32.4 Hz, 2H), 4.30 (m, 1H), 3.62 (t, J= 5.7 Hz, 2H), 2.78 (m, 1H), 2.41 (s, 3H), 2.04 (dd, J= 8.6, 13.5 Hz, 1H), 1.89-1.72 (m, 2H), 1.49 (q, J= 7.6 Hz, 2H), 1.43-1.19 (m, 2H), 0.80 (t, J= 7.4 Hz, 3H), 0.56 (t, J= 7.4 Hz, 3H).




[01144] Preparation of (R)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. A mixture of Na metal (800 mg) and dry tetrahydrofuran (100 mL) was stirred at 23 ^{0}C for 45 minutes. The reaction mixture was cooled to -78 ^{O}C followed by the addition of a solution of (R)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one (1.48 g, 3.45 mmol, 1.0 equiv.) in dry tetrahydrofuran (51 mL). The resulting mixture was allowed to stir at -78 ^{O}C for 1.5 hours before being quenched with sat. NH_4Cl (50 mL) and extracted with ethyl acetate (3x40 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuum to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.31-7.14 (m, 5H), 6.59 (b, 1H), 4.40 (s, 2H), 3.60-3.37 (m, 3H), 1.93 (dd, J= 7.5, 13.3 Hz, 1H), 1.75-1.58 (m, 2H), 1.57-1.32 (m, 5H), 0.80 (dt, J= 7.6, 18.3 Hz, 6H).




[01145] Preparation of (S)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one, except (S)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one was substituted for (R)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one. ^{1}H NMR


(400 MHz, $CDCl_3$) δ 7.35-7.13 (m, 5H), 6.06 (b, 1H), 4.42 (s, 2H), 3.62-3.36 (m, 3H), 1.95 (dd, J= 7.5, 13.3 Hz, 1H), 1.75-1.59 (m, 2H), 1.57-1.36 (m, 5H), 0.80 (dt, J= 7.6, 18.3 Hz, 6H)



[01146] Preparation of 5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one, except (rac)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one was substituted for (R)-5-(2-(benzyloxy)ethyl)-3,3-diethyl-1-tosylpyrrolidin-2-one. ^1H NMR (400 MHz, $CDCl_3$) δ 7.28-7.10 (m, 5H), 6.17 (b, 1H), 4.36 (s, 2H), 3.58-3.32 (m, 3H), 1.89 (dd, J= 7.3, 13.3 Hz, 1H), 1.68-1.53 (m, 2H), 1.52-1.28 (m, 5H), 0.76 (dt, J= 7.4, 19.8 Hz, 6H)




[01147] Preparation of (R)-5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one: To a round bottom flask was added 10% Pd/C (175 mg, 20% wt) followed by a solution of (R)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one (876 mg, 3.19 mmol, 1 equiv.) in ethanol (17 mL). The system was put under H_2 (1 atm) using a balloon and allowed to stir at 23 °C under a H_2 atmosphere overnight. The reaction was filtered through a plug of Celite and concentrated under reduced pressure. The crude alcohol was dissolved in tetrahydrofuran (12.8 mL) and then triphenylphosphine (1.35 g, 5.13 mmol, 1.6 equiv.) and carbon tetrabromide (1.70 g, 5.13 mmol, 1.6 equiv.) were sequentially added and the reaction was allowed to stir at 23 °C for ~3 hours. The resulting mixture was filtered and concentrated in vacuum to give a crude product which was further purified by column chromatography (100% Hexanes then Ethyl acetate/Hexanes, 30% ~ 50%). ^1H NMR (400 MHz, $CDCl_3$) δ 7.31 (b, 1H), 3.65 (p, J= 6.8 Hz, 1H), 3.38 (t, J= 6.7 Hz, 2H), 2.12-1.85 (m, 3H), 1.62-1.32 (m, 5H), 0.82 (dt, J= 7.5, 17.8 Hz, 6H).




[01148] Preparation of (S)-5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one, except (S)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one was substituted for (R)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one. ^1H NMR (400 MHz,


$CDCl_3$) δ 7.16 (b, 1H), 3.66 (p, J= 6.8 Hz, 1H), 3.38 (t, J= 6.8 Hz, 2H), 2.08-1.88 (m, 3H), 1.59-1.35 (m, 5H), 0.82 (dt, J= 7.5, 17.8 Hz, 6H).



[01149] Preparation of 5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one, except 5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one was substituted for (R)-5-(2-(benzyloxy)ethyl)-3,3-diethylpyrrolidin-2-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.06 (b, 1H), 3.64 (p, J= 6.5 Hz, 1H), 3.40 (t, J= 6.8 Hz, 2H), 2.06-1.86 (m, 3H), 1.58-1.34 (m, 5H), 0.81 (dt, J= 7.5, 16.8 Hz, 6H).




[01150] Preparation of (R)-3,3-diethyl-5-(2-hydroxyethyl)pyrrolidin-2-one: A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (18 mL) to methanol (45 mL). tert-Butyl (R)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3,3-diethyl-2-oxopyrrolidine-1-carboxylate (3.98 g, 10 mmol, 1.0 equiv.) was dissolved in the prepared 6M methanolic HCl solution (45 mL) and stirred at 23 °C for 30 minutes. The resulting reaction solution was diluted with methanol and then concentrated in vacuo to give a crude product which used in the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.28 (b, 1H), 3.82 (m, 2H), 3.68 (m, 1H), 2.07 (dd, J= 7.7, 13.4 Hz, 1H), 1.70 (m, 2H), 1.61 (dd, J= 7.7, 13.3 Hz, 1H), 1.57-1.39 (m, 4H), 0.84 (dt, J= 7.5, 18.0 Hz, 6H).




[01151] Preparation of (R)-2-(4,4-diethyl-5-oxopyrrolidin-2-yl)ethyl 4-methylbenzenesulfonate: To a cooled solution of (R)-3,3-diethyl-5-(2-hydroxyethyl)pyrrolidin-2-one (1.85 g, 10 mmol, 1.0 equiv.) and triethylamine (2.02 g, 20 mmol, 2.0 equiv.) in tetrahydrofuran/methylene chloride (50 mL:50 mL) at 0 °C was added 4-toluenesulfonyl chloride (2.85 g, 15 mmol, 1.5 equiv.) followed by 4-dimethylaminopyridine (0.122 g, 1 mmol, 0.2 equiv.). The resulting reaction mixture was stirred at 0 °C for 5 minutes before being warmed to 23 °C and allowed to stir for 72 hours. Then, the reaction mixture was diluted with


dichloromethane (50 mL), washed with 1N HCl (1x50 mL) and deionized H_2O (2x50 mL), dried over Na_2SO_4 and concentrated in vacuo to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 20% ~ 75%). ^1H NMR (400 MHz, $CDCl_3$) δ 7.22 (d, J= 8.2 Hz, 2H), 7.29 (d, J= 7.9 Hz, 2H), 6.05 (b, 1H), 4.04 (t, J= 5.8 Hz, 2H), 3.53 (p, J= 6.8 Hz, 1H), 2.38 (s, 3H), 1.94 (dd, J= 7.6, 13.2 Hz, 1H), 1.75 (q, J= 6.0 Hz, 2H), 1.53-1.32 (m, 5H), 0.78 (dt, J= 7.5, 21.5 Hz, 6H).




[01152] Preparation of 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one: To a small vial was added 5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one (50 mg, 0.201 mmol, 1 equiv.), 1-phenylpiperazine (69 mg, 0.422 mmol, 2.1 eq.) and tetrahydrofuran (3.5 mL). The reaction mixture was allowed to reflux overnight was then cooled to 23 °C. The mixture was filtered, washed with tetrahydrofuran, and the filtrate was concentrated in vacuo to give a crude product which was further purified by column chromatography (MeOH/DCM, 0% ~ 10%). ^1H NMR (400 MHz, $CDCl_3$) δ 7.26 (m, 2H), 6.93 (d, J= 8.1 Hz, 2H), 6.86 (t, J= 7.2 Hz, 1H), 6.76 (b, 1H), 3.58 (m, 1H), 3.22 (t, J= 5.0 Hz, 4H), 2.69 (m, 2H), 2.60-2.40 (m, 4H), 2.06 (dd, J= 7.2, 13.1 Hz, 1H), 1.78-1.43 (m, 7H), 0.91 (dt, J= 7.5, 13.5 Hz, 6H). LC/MS [M+H] = m/z 330.2




[01153] Preparation of 3,3-diethyl-5-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-methylphenyl)piperazine was substituted for 1-phenylpiperazine. ^1H NMR (400 MHz, $CDCl_3$) δ 7.07 (d, J= 8.1 Hz, 2H), 6.84 (d, J= 8.6 Hz, 2H), 6.74 (b, 1H), 3.58 (m, 1H), 3.16 (t, J= 5.0 Hz, 4H), 2.69 (m, 2H), 2.56-2.40 (m, 4H), 2.27 (s, 3H), 2.05 (dd, J= 7.3, 13.3 Hz, 1H), 1.78-1.43 (m, 7H), 0.91 (dt, J= 7.4, 13.8 Hz, 6H). LC/MS [M+H] = m/z 344.2




[01154] Preparation of 3,3-diethyl-5-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-hydroxyphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.23 (b, 1H), 6.73 (d, J= 9.1 Hz, 2H), 6.68 (d, J= 9.0 Hz, 2H), 3.59 (m, 1H), 3.04-2.87 (b, 4H), 2.69 (m, 2H), 2.57 (m, 1H), 2.45 (m, 3H), 2.06 (dd, J= 7.4, 13.2 Hz, 1H), 1.75-1.43 (m, 7H), 0.91 (dt, J= 7.5, 14.3 Hz, 6H). LC/MS [M+H] = m/z 346.2




[01155] Preparation of 3,3-diethyl-5-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(2-isopropylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.26 (d, J= 7.5 Hz, 1H), 7.20-7.04 (m, 3H), 6.79 (b, 1H), 3.59 (m, 1H), 3.49 (sept. J= 6.8 Hz, 1H), 2.93 (t, J= 4.6 Hz, 4H), 2.83-2.60 (b, 2H), 2.60-2.42 (m, 4H), 2.07 (dd, J= 7.4, 13.1 Hz, 1H), 1.78-1.45 (m, 7H), 1.23 (dd, J= 2.4, 6.9 Hz, 6H), 0.92 (dt, J= 7.4, 18.3 Hz, 6H). LC/MS [M+H] = m/z 372.2




[01156] Preparation of 5-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-chlorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.19 (d, J= 9.0 Hz, 2H), 6.83 (d, J= 9.0 Hz, 2H), 6.73 (b, 1H), 3.57 (m, 1H), 3.17 (t, J= 5.0 Hz, 4H), 2.68 (m, 2H), 2.58-2.40 (m, 4H), 2.05 (dd, J= 7.4, 13.2 Hz, 1H), 1.76-1.42 (m, 7H), 0.90 (dt, J= 7.4, 13.7 Hz, 6H). LC/MS [M+H] = m/z 364.2




[01157] Preparation of 3,3-diethyl-5-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-fluorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.99-6.90 (m, 2H), 6.89-6.83 (m, 2H), 6.79 (b, 1H), 3.56 (m, 1H), 3.12 (t, J= 4.9 Hz, 4H), 2.68 (m, 2H), 2.58-2.39 (m, 4H), 2.04 (dd, J= 7.5, 13.2 Hz, 1H), 1.74-1.42 (m, 7H), 0.89 (dt, J= 7.4, 13.9 Hz, 6H). LC/MS [M+H] = m/z 348.2




[01158] Preparation of 3,3-diethyl-5-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 4-(2-(piperazin-1-yl)phenyl)morpholine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.91-6.84 (m, 2H), 6.84-6.74 (m, 2H), 6.51 (b, 1H), 3.71 (t, J= 4.8 Hz, 4H), 3.46 (m, 1H), 3.36-2.77 (b, 8H), 2.74-2.07 (b, 6H), 1.94 (dd, J= 7.5, 13.2 Hz, 1H), 1.65-1.31 (m, 7H), 0.79 (dt, J= 7.3, 15.9 Hz, 6H). LC/MS [M+H] = m/z 415.2




[01159] Preparation of 3,3-diethyl-5-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.88-6.78 (m, 2H), 6.77-6.67 (m, 2H), 3.84 (t, J= 4.6 Hz, 4H), 3.59 (m, 1H), 3.42-2.86 (b, 8H), 2.80-2.32 (b, 6H), 2.29 (s, 3H), 2.06 (dd, J= 7.5, 13.3 Hz, 1H), 1.78-1.44 (m, 7H), 0.92 (dt, J= 7.4, 15.6 Hz, 6H). LC/MS [M+H] = m/z 429.2




[01160] Preparation of (R)-3,3-diethyl-5-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except (R)-5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one was substituted 5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one and 1-(4-methylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.07 (d, J= 8.2 Hz, 2H), 6.84 (d, J= 8.5 Hz, 2H), 6.41 (b, 1H), 3.57 (m, 1H), 3.16 (t, J= 4.9 Hz, 4H), 2.69 (m, 2H), 2.58-2.40 (m, 4H), 2.27 (s, 3H), 2.05 (dd, J= 7.3, 13.1 Hz, 1H), 1.77-1.43 (m, 7H), 0.91 (dt, J= 7.4, 13.7 Hz, 6H). LC/MS [M+H] = m/z 344.2




[01161] Preparation of (S)-3,3-diethyl-5-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except (S)-5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one was substituted 5-(2-bromoethyl)-3,3-diethylpyrrolidin-2-one and 1-(4-methylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.00 (d, J= 8.5 Hz, 2H), 6.76 (d, J= 8.5 Hz, 2H), 6.41 (b, 1H), 3.50 (m, 1H), 3.09 (t, J= 5.1 Hz, 4H), 2.64 (m, 2H), 2.54-2.32 (m, 4H), 2.19 (s, 3H), 1.98 (dd, J= 7.3, 13.1 Hz, 1H), 1.69-1.69 (m, 7H), 0.83 (dt, J= 7.4, 14.5 Hz, 6H). LC/MS [M+H] = m/z 344.2




[01162] Preparation of (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one: To a small vial was added (R)-2-(4,4-diethyl-5-oxopyrrolidin-2-yl)ethyl 4-methylbenzenesulfonate (75 mg, 0.22 mmol, 1 equiv.) and 1-phenylpiperazine (76 mg, 0.46 mmol, 2.1 equiv.) then both were dissolved in acetonitrile (2.2 mL). Then K_2CO_3 (77 mg, 0.55 mmol, 2.5 equiv.) was added, the reaction was allowed to stir at 80 °C overnight, and then cooled to 23 °C. The mixture was filtered, washed with acetonitrile and the filtrate was concentrated in vacuo to give a crude product which was by further purified by column chromatography (MeOH/DCM, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.27 (m, 2H), 6.94 (d, J= 8.1 Hz, 2H), 6.87 (t, J= 7.2 Hz, 1H), 6.65 (b, 1H), 3.59 (m, 1H), 3.23 (t, J= 5.0 Hz, 4H), 2.71 (m, 2H), 2.61-2.41 (m, 4H), 2.07 (dd, J= 7.4, 13.1 Hz, 1H), 1.77-1.45 (m, 7H), 0.92 (dt, J= 7.4, 14.0 Hz, 6H). LC/MS [M+H] = m/z 330.2.




[01163] Preparation of (R)-3,3-diethyl-5-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-fluorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.00-6.91 (m, 2H), 6.91-6.82 (m, 2H), 6.74 (b, 1H), 3.57 (m, 1H), 3.13 (t, J= 5.0 Hz, 4H), 2.70 (m, 2H), 2.60-2.41 (m, 4H), 2.05 (dd, J= 7.3, 13.1 Hz, 1H), 1.76-1.44 (m, 7H), 0.90 (dt, J= 7.5, 14.1 Hz, 6H). LC/MS [M+H] = m/z 348.2




[01164] Preparation of (R)-5-(2-(4-(3,4-dichlorophenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(3,4-dichlorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.26 (d, J= 9.0 Hz, 1H), 6.95 (d, J= 2.9 Hz, 1H), 6.79-2.67 (b, 2H), 3.58 (m, 1H), 3.18 (t, J= 5.0 Hz, 4H), 2.67 (m, 2H), 2.59-2.39 (m, 4H), 2.05 (dd, J= 7.4, 13.1 Hz, 1H), 1.75-1.42 (m, 7H), 0.90 (dt, J= 7.4, 13.7 Hz, 6H). LC/MS [M+H] = m/z 398.2.




[01165] Preparation of (R)-5-(2-(4-(3-chloro-4-fluorophenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(3-chloro-4-fluorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.01 (t, J= 8.8 Hz, 1H), 6.91 (dd, J= 2.9, 6.2 Hz, 1H), 6.79-6.66 (b, 2H), 3.57 (m, 1H), 3.14 (t, J= 5.0 Hz, 4H), 2.68 (m, 2H), 2.60-2.40 (m, 4H), 2.05 (dd, J= 7.5, 13.2 Hz, 1H), 1.75-1.43 (m, 7H), 0.90 (dt, J= 7.3, 13.9 Hz, 6H). LC/MS [M+H] = m/z 382.2.




[01166] Preparation of (R)-5-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(3-chlorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.16 (t, J= 8.1 Hz, 1H), 6.87 (t, J= 2.1 Hz, 1H), 6.83-6.75 (m, 2H), 6.71 (b, 1H), 3.58 (m, 1H), 3.21 (t, J= 5.0 Hz, 4H), 2.68 (m, 2H), 2.60-2.40 (m, 4H), 2.06 (dd, J= 7.2, 13.1 Hz, 1H), 1.76-1.44 (m, 7H), 0.91 (dt, J= 7.4, 13.8 Hz, 6H). LC/MS [M+H] = m/z 364.2




[01167] Preparation of (R)-5-(2-(4-(2-chlorophenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(2-chlorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.27 (dd, J= 1.5, 7.9 Hz, 1H), 7.14 (td, J= 1.5, 7.7 Hz, 1H), 6.98 (dd, J= 1.5, 8.0 Hz, 1H), 6.89 (td, J= 1.5, 7.7 Hz, 1H), 6.63 (b, 1H), 3.50 (m, 1H), 3.18-2.83 (b, 4H), 2.77-2.56 (b, 2H), 2.55-2.31 (m, 4H), 1.98 (dd, J= 7.4, 13.1 Hz, 1H), 1.69-1.36 (m, 7H), 0.83 (dt, J= 7.4, 16.9 Hz, 6H). LC/MS [M+H] = m/z 364.2




[01168] Preparation of (R)-5-(2-(4-(3-fluorophenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(3-fluorophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.10 (m, 1H), 6.64-6.54 (b, 2H), 6.50 (dt, J= 2.4, 12.4 Hz, 1H), 6.45 (td, J= 2.3, 8.2 Hz, 1H), 3.50 (m, 1H), 3.14 (t, J= 5.0 Hz, 4H), 2.60 (m, 2H), 2.51-2.30 (m, 4H), 1.98 (dd, J= 7.3, 13.2 Hz, 1H), 1.67-1.36 (m, 7H), 0.83 (dt, J= 7.3, 14.0 Hz, 6H). LC/MS [M+H] = m/z 348.2



[01169] Preparation of (R)-5-(2-(4-(2-methylphenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(2-methylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.17 (m, 2H), 7.04 (dd, J= 1.2, 8.5 Hz, 1H), 6.99 (td, J= 1.2, 7.4 Hz, 1H), 6.73 (b, 1H), 3.59 (m, 1H), 3.03-2.89 (b, 4H), 2.83-2.62 (b, 2H), 2.62-2.38 (m, 4H), 2.31 (s, 3H), 2.07 (dd, J= 7.5, 13.1 Hz, 1H), 1.77-1.45 (m, 7H), 0.92 (dt, J= 7.5, 17.5 Hz, 6H). LC/MS [M+H] = m/z 344.2




[01170] Preparation of (R)-5-(2-(4-(3-methylphenyl)piperazin-1-yl)ethyl)-3,3-diethylpyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(3-methylphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.16 (t, J= 7.8 Hz, 1H), 6.80-6.68 (m, 3H), 6.63 (b, 1H), 3.59 (m, 1H), 3.22 (t, J= 5.0 Hz, 4H), 2.71 (m, 2H), 2.61-2.41 (m, 4H), 2.33 (s, 3H), 2.07 (dd, J= 7.4, 13.2 Hz, 1H), 1.78-1.45 (m, 7H), 0.92 (dt, J= 7.4, 14.0 Hz, 6H). LC/MS [M+H] = m/z 344.2




[01171] Preparation of tert-butyl (R)-3,3-diallyl-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxopyrrolidine-1-carboxylate: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. A stirred solution of tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate (10.0 g, 29.0 mmol, 1.0 equiv.) in dry tetrahydrofuran (43 mL) was cooled to -78 ^{O}C and 1M lithium bis(trimethylsilyl)amide solution (tetrahydrofuran, 63.8 mL, 63.8 mmol, 2.2 equiv.) was added dropwise while maintaining the reaction temperature below -70 ^{O}C. The resulting solution was allowed to slowly warm to -30 ^{O}C before being cooled back to -78 ^{O}C at which time allyl iodide (10.71 g, 63.8 mmol, 2.2 equiv.) was slowly added dropwise. The resulting solution was slowly warmed to -20 ^{O}C and then quenched with sat. NH_4Cl (75 mL) and extracted with ethyl acetate (3x75 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuo to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 5.77-5.58 (m, 2H), 5.12-4.99 (m, 4H), 3.96 (m, 1H), 3.63


(t, J= 6.2 Hz, 2H), 2.40-2.09 (m, 5H), 2.01 (dd, J= 8.6, 13.6 Hz, 1H), 1.70 (dd, J= 6.4, 13.6 Hz, 1H), 1.57-1.42 (m, 10H), 0.84 (s, 9H), 0.00 (s, 6H).



[01172] Preparation of tert-butyl (S)-3,3-diallyl-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxopyrrolidine-1-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-3,3-diallyl-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxopyrrolidine-1-carboxylate, except tert-butyl (S)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate was substituted for tert-butyl (R)-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-oxopyrrolidine-1-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 5.79-5.60 (m, 2H), 5.13-4.98 (m, 4H), 3.96 (m, 1H), 3.62 (t, J= 6.2 Hz, 2H), 2.40-2.10 (m, 5H), 2.00 (dd, J= 8.6, 13.6 Hz, 1H), 1.69 (dd, J= 6.3, 13.6 Hz, 1H), 1.58-1.42 (m, 10H), 0.83 (s, 9H), 0.00 (s, 6H).




[01173] Preparation of tert-butyl (R)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate: To a stirred solution of tert-butyl (R)-3,3-diallyl-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxopyrrolidine-1-carboxylate (10.03 g, 23.6 mmol, 1.0 equiv.) in methylene chloride (200 mL) was added benzylidene-bis(tricyclohexyl(phophine) dichlororuthenium (0.388 g, 0.472 mmol, 2 mol%). The resulting solution was allowed to stir at 23 °C for 4 hours before being concentrated in vacuo to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0% ~ 20%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 5.56 (m, 2H), 4.08 (m, 1H), 3.66 (t, J= 6.1 Hz, 2H), 2.86 (m, 2H), 2.36 (m, 1H), 2.29-2.14 (m, 2H), 2.09 (dd, J= 8.0, 13.0 Hz, 1H), 1.98 (dd, J= 3.9, 13.0 Hz, 1H), 1.60 (m, 1H), 1.48 (s, 9H), 0.83 (s, 9H), 0.00 (s, 6H).




[01174] Preparation of tert-butyl (S)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate, except tert-butyl (S)-3,3-diallyl-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-

oxopyrrolidine-1-carboxylate was substituted for tert-butyl (R)-3,3-diallyl-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxopyrrolidine-1-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 5.56 (m, 2H), 4.08 (m, 1H), 3.66 (t, J= 6.1 Hz, 2H), 2.87 (m, 2H), 2.36 (m, 1H), 2.30-2.14 (m, 2H), 2.09 (dd, J= 8.0, 13.1 Hz, 1H), 1.98 (dd, J= 3.9, 13.1 Hz, 1H), 1.60 (m, 1H), 1.48 (s, 9H), 0.83 (s, 9H), 0.00 (s, 6H).




[01175] Preparation of tert-butyl (R)-8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-2-carboxylate: A stirred solution of tert-butyl (R)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate (9.04 g, 22.8 mmol, 1.0 equiv.) in methylene chloride (235 mL) and methanol (7.7 mL) was cooled to -78 ^{O}C and a gaseous stream of O_3/O_2 was bubbled through the solution until the color developed a purple tint (45 minutes). Residual O_3 was removed by bubbling O_2 through the solution for 10 minutes. At -78 ^{O}C, $NaBH(OAc)_3$ (4.93 g, 23.2 mmol, 1.02 equiv.) was added and the reaction mixture was allowed to warm to 23 ^{o}C and stir for 45 minutes. Next, $BnNH_2$ (2.70 g, 25.2 mmol, 1.1 equiv.) and $NaBH(OAc)_3$ (9.72 g, 45.8 mmol, 2.0 equiv.) were sequentially added and the reaction was stirred at 23 ^{o}C overnight. The resulting mixture was filtered and concentrated in vacuo to give a crude product which was further purified by column chromatography (2M Ammonia in MeOH/methylene chloride, 0% ~ 2%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.34-7.19 (m, 5H), 4.03 (m, 1H), 3.65 (t, J= 5.9 Hz, 2H) 3.54 (b, 2H), 2.94 (b, 2H), 2.41 (b, 2H), 2.19 (m, 1H), 2.08-1.86 (m, 3H), 1.79 (dd, J= 4.7, 13.5 Hz, 1H), 1.60-1.40 (m, 12H), 0.84 (s, 9H), 0.00 (s, 6H).




[01176] Preparation of tert-butyl (S)-8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-2-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-2-carboxylate, except tert-butyl (S)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate was substituted for tert-butyl (R)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.32-7.14 (m, 5H), 4.02 (m, 1H), 3.65 (t, J= 5.9 Hz,

2H) 3.54 (b, 2H), 2.84 (b, 2H), 2.41 (b, 2H), 2.19 (m, 1H), 2.05-1.86 (m, 3H), 1.80 (dd, J= 4.7, 13.3 Hz, 1H), 1.60-1.39 (m, 12H), 0.84 (s, 9H), 0.00 (s, 6H).




[01177] Preparation of (R)-3-(2-hydroxyethyl)-2,8-diazaspiro[4.5]decan-1-one: To a round bottom flask was added 10% Pd/C (1.27 g, 20% by weight) followed by a solution of tert-butyl (R)-8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-2-carboxylate (6.32 g, 12.5 mmol, 1 equiv.) in methanol (83 mL). The reaction was put under H_2 (1 atm) using a balloon and stirred at 23 °C overnight. The reaction was filtered through a plug of Celite and concentrated filtrate under reduced pressure to give a crude intermediate.


[01178] A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (60 mL) to methanol (160 mL). The crude intermediate was dissolved in the prepared 6M methanolic HCl solution (160 mL) and stirred at 23 °C for 30 minutes before being diluted with methanol and concentrated in vacuo to produce a crude product as an HCl salt. The product was free based by stirring with Amberlite IRN-78 base resin in methanol (~150 mL) for 15 minutes followed by filtration and concentrated in vacuo to produce a crude product that was used in the next step without further purification. ^{1}H NMR (400 MHz, MeOD) δ 3.82-3.61 (m, 3H), 3.02 (m, 2H), 2.76 (td, J= 2.9, 12.9 Hz, 1H), 2.64 (td, J= 2.9, 12.9 Hz, 1H), 2.46 (dd, J= 7.0, 13.0 Hz, 1H), 1.93 (td, J= 4.4, 12.7 Hz, 1H), 1.86-1.74 (m, 1H), 1.74-1.64 (m, 2H), 1.60 (dd, J= 8.2, 12.9 Hz, 1H), 1.49 (d, J= 13.2 Hz, 1H), 1.36 (d, J= 13.6 Hz, 1H).




[01179] Preparation of (S)-3-(2-hydroxyethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-hydroxyethyl)-2,8-diazaspiro[4.5]decan-1-one, except tert-butyl (R)-8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-2-carboxylate was substituted for tert-butyl (S)-8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-2-carboxylate. ^{1}H NMR (400 MHz, MeOD) δ 3.82-3.60 (m, 3H), 3.02 (m, 2H), 2.76 (td, J= 2.9, 12.9 Hz, 1H), 2.64 (td, J= 2.9, 12.9 Hz, 1H), 2.46 (dd, J= 7.1, 13.2 Hz, 1H), 1.93 (td, J= 3.7, 12.3 Hz, 1H), 1.86-1.75 (m, 1H), 1.75-1.64 (m, 2H), 1.60 (dd, J= 8.0, 12.7 Hz, 1H), 1.49 (d, J= 13.1 Hz, 1H), 1.37 (d, J= 13.0 Hz, 1H).



[01180] Preparation of tert-butyl (R)-3-(2-hydroxyethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: To a solution of (R)-3-(2-hydroxyethyl)-2,8-diazaspiro[4.5]decan-1-one (2.2 g, 11.0 mmol, 1.0 equiv.) and triethylamine (1.12 g, 11.0 mmol, 1.0 equiv.) in methylene chloride (113 mL) and methanol (3 mL) was added di-tert-butyl dicarbonate (2.4 g, 11.0 mmol, 1.0 equiv.). The resulting solution was allowed to stir at 23 °C overnight before being concentrated in vacuo to produce a crude product that was used in the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.93 (b, 1H), 4.15-3.55 (b, 6H), 3.15-2.74 (m, 2H), 2.29 (dd, J= 6.7, 12.5 H, 1H), 2.00-1.82 (m, 1H), 1.80-1.60 (m, 3H), 1.58-1.29 (m, 12).




[01181] Preparation of tert-butyl (S)-3-(2-hydroxyethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for (tert-butyl (R)-3-(2-hydroxyethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate, except (S)-3-(2-hydroxyethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-hydroxyethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.53 (b, 1H), 4.06-3.56 (b, 6H), 3.05-2.77 (m, 2H), 2.25 (dd, J= 6.7, 12.9 H, 1H), 1.93-1.80 (m, 1H), 1.74-1.56 (m, 3H), 1.52-1.24 (m, 12).




[01182] Preparation of (S)-3-(2-hydroxyethyl)-2-azaspiro[4.4]nonan-1-one: To a round bottom flask was added 10% Pd/C (0.60 g, 20% by wieght) followed by a solution of tert-butyl (S)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate (0.30 g, 0.758 mmol, 1 equiv.) in methanol (7.5 mL). The reaction was put under H_2 (1 atm) using a balloon and stirred at 23 °C for 4 hrs. The reaction was filtered through a plug of Celite and concentrated filtrate under reduced pressure to give a crude intermediate.

[01183] A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (3 mL) to methanol (7.5 mL). The crude intermediate was dissolved in the prepared 6M methanolic HCl solution (7.5 mL) and stirred at 23 °C for 30 minutes before being diluted with


methanol and concentrated in vacuo to produce a crude product was used in the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.95 (b, 1H), 3.99 (b, 1H), 3.76 (m, 1H), 3.64 (m, 2H), 2.09 (dd, J= 6.6, 12.6 Hz, 1H), 2.01 (m, 1H), 1.81-1.45 (m, 9H), 1.37 (m, 1H).




[01184] Preparation of (S)-3-(2-hydroxyethyl)-2-azaspiro[4.4]non-7-en-1-one: A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (3 mL) to methanol (7.5 mL). tert-Butyl (S)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-azaspiro[4.4]non-7-ene-2-carboxylate (0.30 g, 0.758 mmol, 1 equiv.) was dissolved in the prepared 6M methanolic HCl solution (7.5 mL) and stirred at 23 °C for ~30 minutes before being diluted with methanol and concentrated in vacuo to produce a crude product was used in the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.04 (b, 1H), 5.62 (m, 1H), 5.52 (m, 1H), 3.83-3.71 (m, 2H), 3.70-3.57 (m, 2H), 2.90 (dp, J= 2.4, 16.6 Hz, 1H), 2.58 (dp, J= 2.4, 16.3 Hz, 1H), 2.33 (d, J= 16.4 Hz, 1H), 2.22 (dd, J= 6.2, 12.4 Hz, 1H), 2.14 (d, J= 16.2 Hz, 1H), 1.71-1.54 (m, 3H).




[01185] Preparation of tert-butyl (R)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate: To a cooled solution of tert-butyl (R)-3-(2-hydroxyethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (3.2 g, 10.7 mmol, 1.0 equiv.) and triethylamine (2.16 g, 21.4 mmol, 2.0 equiv.) in tetrahydrofuran/methylene chloride (46 mL:46 mL) at 0 °C was added 4-toluenesulfonyl chloride (3.06 g, 16 mmol, 1.5 equiv.) followed by 4-dimethylaminopyridine (0.131 g, 1.07 mmol, 0.2 equiv.). The resulting reaction mixture was stirred at 0 °C for 5 minutes before being warmed to 23 °C and allowed to stir overnight. Then, the reaction mixture was diluted with dichloromethane (50 mL) and washed with deionized H_2O (1x50 mL). The aqueous layer was backwashed with methylene chloride (2x50 mL). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuo to give a crude product which was further purified by HPLC (CH_3CN/H_2O, 0.1% Formic acid), 0%~100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.81 (d, J= 8.3 Hz, 2H), 7.38 (d, J= 8.2 Hz, 2H), 6.11 (b, 1H), 4.14 (m, 2H), 4.07-3.89 (b, 2H), 3.72 (p, J= 6.8 Hz, 1H), 2.97 (m, 2H), 2.48 (s, 3H), 2.28 (dd, J= 6.9, 12.8 Hz, 1H), 1.97-1.83 (m, 3H), 1.75 (m, 1H), 1.56-1.30 (m, 12H).



[01186] Preparation of tert-butyl (S)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate, except tert-butyl (S)-3-(2-hydroxyethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for tert-butyl (R)-3-(2-hydroxyethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.77 (d, J= 8.3 Hz, 2H), 7.34 (d, J= 8.2 Hz, 2H), 7.05 (b, 1H), 4.11 (m, 2H), 4.05-3.78 (b, 2H), 3.68 (p, J= 6.8 Hz, 1H), 2.92 (m, 2H), 2.43 (s, 3H), 2.22 (dd, J= 6.8, 12.9 Hz, 1H), 1.93-1.76 (m, 3H), 1.68 (m, 1H), 1.53-1.24 (m, 12H).




[01187] Preparation of (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate: To a cooled solution of (S)-3-(2-hydroxyethyl)-2-azaspiro[4.4]non-7-en-1-one (0.140 g, 0.758 mmol, 1.0 equiv.) and N-methylimidazole (0.312 g, 3.8 mmol, 5.0 equiv.) in methylene chloride (2.5 mL) at 0°C was added a solution of 4-toluenesulfonyl chloride (0.217 g, 1.14 mmol, 1.5 equiv.) in methylene chloride (3.5 mL). The resulting reaction mixture was stirred at 0 ^{O}C for 5 min utesbefore being warmed to 23 ^{o}C and allowed to stir overnight. Then, the reaction mixture was quenched with 1N HCl (1x5 mL) and extracted with methylene chloride (3x15 mL). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuo to give a crude product which was further by column chromatography (Ethyl acetate/Hexanes, 40% ~ 100%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.71 (d, J= 8.3 Hz, 2H), 7.27 (d, J= 8.1 Hz, 2H), 6.97 (b, 1H), 5.58 (m, 1H), 5.51 (m, 1H), 4.04 (m, 2H), 3.58 (p, J= 6.8 Hz, 1H), 2.86 (dp, J= 2.3, 16.5 Hz, 1H), 2.58 (dp, J= 2.3, 16.3 Hz, 1H), 2.37 (s, 3H), 2.25 (d, J= 16.1 Hz, 1H), 2.19-2.04 (m, 2H), 1.86-1.67 (m, 2H), 1.54 (dd, J= 7.7, 12.5 Hz, 1H).




[01188] Preparation of (S)-2-(1-oxo-2-azaspiro[4.4]nonan-3-yl)ethyl 4-methylbenzenesulfonate: The title compound was prepared according to the procedure for (S)-2-


(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate, except (S)-3-(2-hydroxyethyl)-2-azaspiro[4.4]nonan-1-one was substituted for (S)-3-(2-hydroxyethyl)-2-azaspiro[4.4]non-7-en-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.78 (d, J= 8.2 Hz, 2H), 7.34 (d, J= 8.1 Hz, 2H), 6.87 (b, 1H), 4.10 (m, 2H), 3.60 (p, J= 6.7 Hz, 1H), 2.44 (s, 3H), 2.12-1.97 (m, 2H), 1.94-1.68 (m, 5H), 1.66-1.45 (m, 4H), 1.40 (m, 1H).




[01189] Preparation of (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one: To a small vial was added (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate (50 mg, 0.15 mmol, 1 equiv.) and 1-(4-fluorophenyl)piperazine (57 mg, 0.31 mmol, 2.1 equiv.) then both were dissolved in acetonitrile (1.5 mL). Then K_2CO_3 (52 mg, 0.37 mmol, 2.5 equiv.) was added, the reaction was allowed to stir at 80 °C overnight, and then cooled to 23 °C. The mixture was filtered, washed with acetonitrile and filtrate was concentrated in vacuo to give a crude product which was by further purified by column chromatography (MeOH/methylene chloride, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.00-6.82 (m, 5H), 5.70 (m, 1H), 5.59 (m, 1H), 3.63 (m, 1H), 3.13 (t, J= 4.9 Hz, 4H), 3.02 (dp, J= 2.5, 16.5 Hz, 1H), 2.76-2.62 (m, 3H), 2.61-2.43 (m, 4H), 2.39 (d, J= 16.6 Hz, 1H), 2.29 (dd, J= 6.1, 12.4 Hz, 1H), 2.20 (d, J= 16.4 Hz, 1H), 1.80-1.57 (m, 3H). LC/MS [M+H] = m/z 344.2




[01190] Preparation of (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except 1-(3-chlorophenyl)piperazine was substituted for 1-(4-fluorophenyl)piperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.08 (t, J= 8.0 Hz, 1H), 6.79 (t, J= 2.1 Hz, 1H), 6.77-6.65 (m, 3H). 5.60 (m, 1H), 5.51 (m, 1H), 3.56 (m, 1H), 3.13 (t, J= 5.1 Hz, 4H), 2.95 (dp, J= 2.4, 16.6 Hz, 1H), 2.68-2.54 (m, 3H), 2.54-2.35 (m, 4H), 2.31 (d, J= 16.0 Hz, 1H), 2.22 (dd, J= 6.1, 12.3 Hz, 1H), 2.13 (d, J= 16.5 Hz, 1H), 1.72-1.49 (m, 3H). LC/MS [M+H] = m/z 360.2.



[01191] Preparation of (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]nonan-1-one: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except (S)-2-(1-oxo-2-azaspiro[4.4]nonan-3-yl)ethyl 4-methylbenzenesulfonate was substituted for (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.00-6.91 (m, 2H), 6.90-6.74 (m, 3H), 3.59 (m, 1H), 3.12 (t, J= 4.9 Hz, 4H), 2.69 (m, 2H), 2.60-2.44 (m, 4H), 2.19-2.06 (m, 2H), 1.86-1.51 (m, 9H), 1.44 (m, 1H). LC/MS [M+H] = m/z 346.2.




[01192] Preparation of (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]nonan-1-one: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except (S)-2-(1-oxo-2-azaspiro[4.4]nonan-3-yl)ethyl 4-methylbenzenesulfonate was substituted for (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate and 1-(3-chlorophenyl)piperazine was substituted for 1-(4-fluorophenyl)piperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.16 (t, J= 8.0 Hz, 1H), 6.88 (t, J= 2.1 Hz, 1H), 6.81 (dd, J= 1.7, 7.8 Hz, 1H), 6.78 (dd, J= 2.3, 8.3 Hz, 1H), 6.69 (b, 1H), 3.60 (m, 1H), 3.22 (t, J= 5.0 Hz, 4H), 2.69 (m, 2H), 2.61-2.39 (m, 4H), 2.23-2.08 (m, 2H), 1.87-1.55 (m, 9H), 1.46 (m, 1H). LC/MS [M+H] = m/z 362.2.




[01193] Preparation of tert-butyl (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except tert-butyl (R)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate and 1-(3-chlorophenyl)piperazine was substituted for 1-(4-fluorophenyl)piperazine. ^{1}H NMR (400


MHz, $CDCl_3$) δ 7.15 (t, J= 7.9 Hz, 1H), 7.06 (b, 1H), 6.84 (t, J= 2.0 Hz, 1H), 6.79 (dd, J= 1.6, 7.6 Hz, 1H), 6.74 (dd, J= 2.1, 8.3 Hz, 1H), 4.13-3.82 (b, 2H), 3.63 (p, J= 7.0 Hz, 1H), 3.20 (t, J= 4.8 Hz, 4H), 3.10-2.83 (m, 2H), 2.67 (m, 2H), 2.60-2.40 (m, 4H), 2.29 (dd, J= 6.7, 12.8 Hz, 1H), 1.96 (m, 1H), 1.80-1.62 (m, 3H), 1.58-1.30 (m, 12H). LC/MS [M+H] = m/z 478.2.




[01194] Preparation of tert-butyl (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except tert-butyl (R)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate. ^1H NMR (400 MHz, $CDCl_3$) δ 7.02 (b, 1H), 6.97-6.90 (m, 2H), 6.90-6.80 (m, 2H), 4.23-3.78 (b, 2H), 3.63 (p, J= 6.5 Hz, 1H), 3.12 (t, J= 4.7 Hz, 4H), 3.07-2.82 (m, 2H), 2.68 (m, 2H), 2.60-2.40 (m, 4H), 2.28 (dd, J= 6.7, 12.7 Hz, 1H), 1.95 (m, 1H), 1.80-1.61 (m, 3H), 1.58-1.29 (m, 12H). LC/MS [M+H] = m/z 461.2.




[01195] Preparation of tert-butyl (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except tert-butyl (S)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate and 1-(3-chlorophenyl)piperazine was substituted for 1-(4-fluorophenyl)piperazine. ^1H NMR (400 MHz, $CDCl_3$) δ 7.14 (t, J= 8.0 Hz, 1H), 7.04 (b, 1H), 6.85 (t, J= 2.0 Hz, 1H), 6.79 (dd, J= 1.6, 7.7 Hz, 1H), 6.76 (dd, J= 2.1, 8.3 Hz, 1H), 4.13-3.83 (b, 2H), 3.63 (p, J= 7.0 Hz, 1H), 3.19 (t, J= 4.8 Hz, 4H), 3.09-2.80 (m, 2H), 2.67 (m, 2H), 2.60-2.39 (m, 4H), 2.29 (dd, J= 6.6, 12.8 Hz, 1H), 1.95 (m, 1H), 1.80-1.63 (m, 3H), 1.57-1.30 (m, 12H). LC/MS [M+H] = m/z 478.2




[01196] Preparation of tert-butyl (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-azaspiro[4.4]non-7-en-1-one, except tert-butyl (S)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for (S)-2-(1-oxo-2-azaspiro[4.4]non-7-en-3-yl)ethyl 4-methylbenzenesulfonate. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.01 (b, 1H), 6.97-6.89 (m, 2H), 6.89-6.80 (m, 2H), 4.21-3.76 (b, 2H), 3.63 (p, J= 6.5 Hz, 1H), 3.11 (t, J= 4.7 Hz, 4H), 3.06-2.82 (m, 2H), 2.69 (m, 2H), 2.61-2.41 (m, 4H), 2.29 (dd, J= 6.7, 12.8 Hz, 1H), 1.94 (m, 1H), 1.80-1.60 (m, 3H), 1.57-1.28 (m, 12H). LC/MS [M+H] = m/z 461.




[01197] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (1.2 mL) to methanol (3 mL). tert-Butyl (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (0.127 g, 0.266 mmol, 1.0 equiv.) was dissolved in the prepared 6M methanolic HCl solution (3 mL) and let stir at 23 °C for 30 minutes before being diluted with methanol and concentrated in vacuo to produce a crude product as an HCl salt. The product was free based by stirring with Amberlite IRN-78 base resin in methanol (~10 mL) for 15 minutes followed by filtration and concentrated in vacuo to produce a crude product that was used in the next step without further purification. ^{1}H NMR (400 MHz, MeOD) δ 7.21 (t, J= 8.3 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 8.5 Hz, 1H), 6.81 (d, J= 7.7 Hz, 1H), 3.68 (m, 1H), 3.29-3.13 (m, 4H), 3.01 (m, 2H), 2.81-2.38 (m, 9H), 1.93 (m, 1H), 1.86-1.64 (m, 3H), 1.60 (dd, J= 7.6, 12.7 Hz, 1H), 1.49 (d, J= 13.2 Hz, 1H), 1.38 (d, J= 12.8 Hz, 1H). LC/MS [M+H] = m/z 377.



[01198] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one, except tert-butyl (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for tert-butyl (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate. ^{1}H NMR (400 MHz, MeOD) δ 7.08-6.92 (m, 4H), 3.68 (m, 1H), 3.23-3.09 (m, 4H), 3.01 (m, 2H), 2.81-2.38 (m, 9H), 1.93 (m, 1H), 1.86-1.62 (m, 3H), 1.60 (dd, J= 7.6, 12.5 Hz, 1H), 1.48 (d, J= 13.5 Hz, 1H), 1.37 (d, J= 13.5 Hz, 1H). LC/MS [M+H] = m/z 361.




[01199] Preparation of (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one, except tert-butyl (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for tert-butyl (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate. ^{1}H NMR (400 MHz, MeOD) δ 7.20 (t, J= 8.2 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J= 8.5 Hz, 1H), 6.80 (d, J= 7.7 Hz, 1H), 3.68 (m, 1H), 3.28-3.13 (m, 4H), 3.02 (m, 2H), 2.80-2.36 (m, 9H), 1.93 (m, 1H), 1.85-1.64 (m, 3H), 1.59 (dd, J= 7.6, 12.7 Hz, 1H), 1.48 (d, J= 13.2 Hz, 1H), 1.37 (d, J= 12.8 Hz, 1H). LC/MS [M+H] = m/z 377.




[01200] Preparation of (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for

(R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one, except tert-butyl (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate was substituted for tert-butyl (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate. ^{1}H NMR (400 MHz, MeOD) δ 7.07-6.91 (m, 4H), 3.68 (m, 1H), 3.22-3.09 (m, 4H), 3.02 (m, 2H), 2.81-2.37 (m, 9H), 1.93 (m, 1H), 1.86-1.63 (m, 3H), 1.59 (dd, J= 7.6, 12.5 Hz, 1H), 1.48 (d, J= 13.5 Hz, 1H), 1.38 (d, J= 13.5 Hz, 1H). LC/MS [M+H] = m/z 361.2.




[01201] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: A solution of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one (28 mg, 0.074 mmol, 1 equiv.), dichloromethane (0.85 mL) and triethylamine (15.7 mg, 0.155 mmol, 2.1 eq.) was cooled to 0 °C before methanesulfonyl chloride (12.7 mg. 0.111 mmol, 1.5 equiv.) was added to the solution. The reaction solution was allowed to warm to 23 °C and stir for 15 minutes. The reaction was diluted with methanol (~2 mL), concentrated in vacuo and further purified by flash column chromatography (methanol/dichloromethane, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.17 (t, J= 8.2 Hz, 1H), 6.88 (t, J= 2.1 Hz, 1H), 6.83 (dd, J= 1.7, 7.8 Hz, 1H), 6.81-6.72 (m, 2H), 3.81-3.61 (m, 2H), 3.50 (m, 1H), 3.32-3.11 (m, 6H), 2.82 (s, 3H), 2.73 (m, 2H), 2.66-2.42 (m, 4H), 2.20 (dd, J= 6.5, 12.7 Hz, 1H), 2.04 (m, 1H), 1.96 (m, 1H), 1.79-1.50 (m, 5H); MS (LC/MS, $M+H^+$): 456.2.




[01202] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one, except (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-


yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.07-6.93 (m, 2H), 6.92-6.84 (m, 2H), 6.80 (b, 1H), 3.80-3.62 (m, 2H), 3.49 (m, 1H), 3.27 (m, 1H), 3.22-3.08 (m, 5H), 2.82 (s, 3H), 2.75 (m, 2H), 2.66-2.43 (m, 4H), 2.20 (dd, J= 6.4, 12.7 Hz, 1H), 2.04 (m, 1H), 1.96 (m, 1H), 1.79-1.48 (m, 5H); MS (LC/MS, $M+H^+$): 439.2.




[01203] Preparation of (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one, except (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.09 (t, J= 8.1 Hz, 1H), 6.79 (t, J= 2.1 Hz, 1H), 6.74 (dd, J= 1.7, 7.7 Hz, 1H), 6.72-6.65 (m, 2H), 3.72-3.53 (m, 2H), 3.41 (m, 1H), 3.23-3.04 (m, 6H), 2.73 (s, 3H), 2.64 (m, 2H), 2.57-2.33 (m, 4H), 2.12 (dd, J= 6.4, 12.8 Hz, 1H), 1.95 (m, 1H), 1.88 (m, 1H), 1.70-1.42 (m, 5H); MS (LC/MS, $M+H^+$): 456.2.




[01204] Preparation of (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one, except (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.94-6.84 (m, 2H), 6.83-6.76 (m, 2H), 6.74 (b, 1H), 3.71-3.54 (m, 2H), 3.41 (m, 1H), 3.17 (m, 1H), 3.13-2.99 (m, 5H), 2.73 (s, 3H), 2.65 (m, 2H), 2.57-2.34 (m, 4H), 2.11 (dd, J= 6.4, 12.7 Hz, 1H), 1.95 (m, 1H), 1.87 (m, 1H), 1.70-1.39 (m, 5H); MS (LC/MS, $M+H^+$): 439.2




[01205] Preparation of (R)-8-acetyl-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: A solution of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one (21 mg, 0.056 mmol, 1 equiv.), dichloromethane (0.725 mL) and triethylamine (12 mg, 0.118 mmol, 2.1 eq.) was cooled to 0 °C before acetyl chloride (12.7 mg. 0.057 mmol, 1.01 equiv.) was added to the solution. The reaction solution was allowed to warm to 23 °C and stir for 15 minutes. The reaction was diluted with methanol (~2 mL), concentrated in vacuo and further purified by flash column chromatography (methanol/methylene chloride, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.09 (t, J= 8.1 Hz, 1H), 6.80 (t, J= 2.2 Hz, 1H), 6.77-6.65 (m, 3H), 4.26 (dt, J= 4.8, 13.4 Hz, 0.5H), 4.12 (dt, J= 5.0, 13.8 Hz, 0.5H), 3.82 (dt, J= 4.5, 13.5 Hz, 0.5H), 3.69 (dt, J= 4.9, 13.8 Hz, 0.5H), 3.60 (m, 1H), 3.27-3.03 (m, 5.5H), 2.97 (m, 0.5H), 2.63 (m, 2H), 2.57-2.31 (m, 4H), 2.23 (m, 1H), 2.02 (s, 3H), 1.98-1.80 (m, 1H), 1.80-1.56 (m, 3H), 1.55-1.29 (m, 3H); MS (LC/MS, M+H$^+$): 419.2




[01206] Preparation of (R)-8-acetyl-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-8-acetyl-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one, except (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.93-6.84 (m, 2H), 6.83-6.70 (m, 3H), 4.26 (dt, J= 5.2, 13.5 Hz, 0.5H), 4.12 (dt, J= 5.0, 13.5 Hz, 0.5H), 3.82 (dt, J= 5.0, 13.7 Hz, 0.5H), 3.69 (dt, J= 5.0, 13.7 Hz, 0.5H), 3.59 (m, 1H), 3.27-2.91 (m, 6H), 2.65 (m, 2H), 2.58-2.33 (m, 4H), 2.23 (m, 1H), 2.02 (s, 3H), 1.99-1.82 (m, 1H), 1.80-1.55 (m, 3H), 1.54-1.30 (m, 3H); MS (LC/MS, M+H$^+$): 403.2




[01207] Preparation of (S)-8-acetyl-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-8-acetyl-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one, except (S)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.09 (t, J= 8.1 Hz, 1H), 6.80 (t, J= 2.2 Hz, 1H), 6.77-6.66 (m, 3H), 4.26 (dt, J= 4.8, 13.4 Hz, 0.5H), 4.12 (dt, J= 5.0, 13.8 Hz, 0.5H), 3.82 (dt, J= 4.5, 13.5 Hz, 0.5H), 3.69 (dt, J= 4.9, 13.8 Hz, 0.5H), 3.60 (m, 1H), 3.25-3.08 (m, 5.5H), 2.98 (m, 0.5H), 2.63 (m, 2H), 2.56-2.34 (m, 4H), 2.23 (m, 1H), 2.02 (s, 3H), 1.98-1.83 (m, 1H), 1.81-1.56 (m, 3H), 1.54-1.30 (m, 3H); MS (LC/MS, M+H$^+$): 419.2




[01208] Preparation of (S)-8-acetyl-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-8-acetyl-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one, except (S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2,8-diazaspiro[4.5]decan-1-one. ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.93-6.84 (m, 2H), 6.83-6.73 (m, 3H), 4.26 (dt, J= 5.2, 13.5 Hz, 0.5H), 4.12 (dt, J= 5.0, 13.5 Hz, 0.5H), 3.82 (dt, J= 5.0, 13.7 Hz, 0.5H), 3.69 (dt, J= 5.0, 13.7 Hz, 0.5H), 3.59 (m, 1H), 3.26-2.91 (m, 6H), 2.65 (m, 2H), 2.57-2.32 (m, 4H), 2.23 (m, 1H), 2.02 (s, 3H), 1.98-1.82 (m, 1H), 1.81-1.55 (m, 3H), 1.54-1.30 (m, 3H); MS (LC/MS, M+H$^+$): 403.2




[01209] Preparation of (R)-3,3-diethyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(2-pyridyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.18 (dd, J= 2.1, 4.8 Hz, 1H), 7.47 (m, 1H), 6.73 (b, 1H), 6.66-6.57 (m, 2H), 3.64-3.47 (m, 5H), 2.63 (m, 2H), 2.58-2.36 (m, 4H), 2.05 (dd, J= 7.4, 13.0 Hz, 1H), 1.76-1.43 (m, 7H), 0.90 (dt, J= 7.4, 14.5 Hz, 6H). LC/MS [M+H] = m/z 331.2




[01210] Preparation of (R)-3,3-diethyl-5-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(2-methoxyphenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.04-6.88 (m, 3H), 6.85 (dd, J= 1.1, 8.0 Hz, 1H), 6.72 (b, 1H), 3.86 (s, 3H), 3.58 (m, 1H), 3.28-2.90 (b, 4H), 2.84-2.65 (b, 2H), 2.64-2.41 (m, 4H), 2.05 (dd, J= 7.3, 13.1 Hz, 1H), 1.76-1.43 (m, 7H), 0.91 (dt, J= 7.5, 16.1 Hz, 6H). LC/MS [M+H] = m/z 360.2




[01211] Preparation of (R)-4-(4-(2-(4,4-diethyl-5-oxopyrrolidin-2-yl)ethyl)piperazin-1-yl)benzonitrile: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-cyanophenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.48 (d, J= 9.0 Hz, 2H), 6.85 (d, J= 9.0 Hz, 2H), 6.73 (b, 1H), 3.58 (m, 1H), 3.34 (t, J= 5.1 Hz, 4H), 2.67 (m, 2H), 2.60-2.38 (m, 4H), 2.06 (dd, J= 7.6, 13.2 Hz, 1H), 1.75-1.42 (m, 7H), 0.90 (dt, J= 7.4, 14.0 Hz, 6H). LC/MS [M+H] = m/z 355.2



[01212] Preparation of (R)-3,3-diethyl-5-(2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 1-(4-(trifluoromethyl)phenyl)piperazine was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.36 (d, J= 8.6 Hz, 2H), 6.80 (d, J= 8.6 Hz, 2H), 6.58 (b, 1H), 3.47 (m, 1H), 3.18 (t, J= 5.0 Hz, 4H), 2.57 (m, 2H), 2.49-2.28 (m, 4H), 1.95 (dd, J= 7.4, 13.1 Hz, 1H), 1.64-1.32 (m, 7H), 0.79 (dt, J= 7.3, 13.8 Hz, 6H). LC/MS [M+H] = m/z 398.2




[01213] Preparation of (5R)-3,3-diethyl-5-(2-(5-phenylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethyl)pyrrolidin-2-one: The title compound was prepared according to the procedure for (R)-3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)pyrrolidin-2-one, except 2-phenyloctahydropyrrolo[3,4-c]pyrrole was substituted for 1-phenylpiperazine. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.11 (m, 2H), 6.61 (t, J= 7.4 Hz, 1H), 6.56 (d, J= 8.6 Hz, 2H), 6.44 (b, 1H), 3.42 (m, 1H), 3.20-3.05 (m, 4H), 2.91 (m, 1H), 2.87-2.70 (m, 3H), 2.51 (m, 1H), 2.34-2.15 (m, 2H), 2.07 (dd, J= 4.7, 8.5 Hz, 1H), 1.91 (dd, J= 7.4, 13.1 Hz, 1H), 1.58-1.28 (m, 7H), 0.77 (m, 6H). LC/MS [M+H] = m/z 356.2




[01214] Preparation of tert-butyl (S)-3-(2-cyanoethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate: To a solution of tert-butyl (R)-1-oxo-3-(2-(tosyloxy)ethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate (0.2 g, 0.44 mmol, 1.0 equiv.) in acetonitrile (1.9 mL) was added potassium cyanide (0.72 g, 1.1 mmol, 2.5 equiv.). The resulting reaction mixture was then allowed to reflux for 16 hours. After cooling to 23°C, the reaction mixture was filtered thru a plug of Celite and concentrated in vacuo to give a crude product which was further purified by

column chromatography (MeOH/dichloromethane, 0% ~ 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.08 (b, 1H), 4.11-3.79 (b, 2H), 3.72 (p, J= 6.6 Hz, 1H), 3.00 (t, J= 11.3 Hz, 1H), 2.91 (t, J= 11.3 Hz, 1H), 2.49 (td, J= 1.2, 7.4 Hz, 2H), 2.32 (dd, J= 7.0, 13.0 Hz, 1H), 1.97-1.78 (m, 3H), 1.72 (m, 1H), 1.52 (dd, J= 7.8, 12.9 Hz, 1H), 1.48-1.29 (m, 11H).




[01215] Preparation of (S)-3-(8-(methylsulfonyl)-1-oxo-2,8-diazaspiro[4.5]decan-3-yl)propanenitrile: To a solution of tert-butyl (S)-3-(2-cyanoethyl)-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (0.1 g, 0.35 mmol, 1.0 equiv.) in dichloromethane (2.75 mL) was added trifluoroacetic acid (0.5 mL). The resulting solution was allowed to stir at 23°C for 45 minutes before being concentrated in vacuo. The residue was dissolved in MeOH (5 mL) followed by the addition of Amberlite IRN-78 base resin (0.5 g). This mixture was stirred vigorously for 15 minutes, filtered and the filtrate was concentrated in vacuo to give a crude intermediate that was then dissolved in dichloromethane (3.75 mL). The resulting solution was then cooled to 0°C before the sequential addition of triethylamine (0.72 g, 0.70 mmol, 2.0 eq.) and methanesulfonyl chloride (0.6 g. 0.53 mmol, 1.5 equiv.). The reaction solution was allowed to warm to 23°C and stir for 15 minutes. The reaction was diluted with MeOH (2 mL), concentrated in vacuo and further purified by flash column chromatography (MeOH w/ 2M ammonia/dichloromethane, 0% - 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 6.56 (b, 1H), 3.81 (p, J= 6.8 Hz, 1H), 3.72 (m, 1H), 3.53 (m, 1H), 3.32-3.15 (m, 2H), 2.83 (s, 3H), 2.49 (t, J= 6.8 Hz, 2H), 2.29 (dd, J= 6.9, 12.9 Hz, 1H), 2.09-1.82 (m, 4H), 1.75-1.59 (m, 3H).




[01216] Preparation of methyl (S)-3-(8-(methylsulfonyl)-1-oxo-2,8-diazaspiro[4.5]decan-3-yl)propanoate: A 6M HCl in methanol solution was prepared via the addition of acetyl chloride (0.48 mL) to MeOH (1 mL). (S)-3-(8-(methylsulfonyl)-1-oxo-2,8-diazaspiro[4.5]decan-3-yl)propanenitrile (91 mg, 0.32 mmol, 1.0 equiv.) was dissolved in the prepared 6M methanolic HCl solution (0.64 mL) and stirred at 23 °C overnight. The reaction mixture was diluted with MeOH (1 mL) and concentrated in vacuo. The resulting residue was suspended in sat. aqueous

$NaHCO_3$ and extracted with dichloromethane (4x15 mL). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuo to give a crude product that was used in the next step without further purification. ^1H NMR (400 MHz, $CDCl_3$) δ 7.13 (b, 1H), 3.75-3.57 (m, 5H), 3.50 (m, 1H), 3.23-3.02 (m, 2H), 2.79 (s, 3H), 2.40 (td, J= 1.7, 7.2 Hz, 2H), 2.18 (dd, J= 6.8, 13.0 Hz, 1H), 2.01 (m, 1H), 1.92 (m, 1H), 1.83 (q, J= 6.9 Hz, 2H), 1.68-1.45 (m, 3H).




[01217] Preparation of (S)-3-(3-hydroxypropyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a stirred solution of methyl (S)-3-(8-(methylsulfonyl)-1-oxo-2,8-diazaspiro[4.5]decan-3-yl)propanoate (80 mg, 0.25 mmol, 1.0 equiv.) in dry tetrahydrofuran (1.2 mL) at 0^oC was added $LiBH_4$ (2M in tetrahydrofuran, 0.25 mL, 0.5 mmol, 2.0 equiv.) and the resulting solution was stirred at 23 ^oC for 6 hours. The reaction was then quenched with 0.5 mL of acetic acid and then filtered while washing with MeOH. The filtrate was concentrated in vacuo to give a crude product which was further purified by column chromatography (MeOH/dichloromethane, 10%). ^1H NMR (400 MHz, MeOD) δ 3.74-3.55 (m, 5H), 3.02 (td, J= 3.0, 11.2 Hz, 1H), 2.92 (td, J= 2.9, 11.5 Hz, 1H), 2.86 (s, 3H), 2.39 (dd, J= 7.0, 13.1 Hz, 1H), 2.08-1.97 (m, 1H), 1.89-1.78 (m, 1H), 1.71-1.50 (m, 7H).




[01218] Preparation of (S)-3-(8-(methylsulfonyl)-1-oxo-2,8-diazaspiro[4.5]decan-3-yl)propyl 4-methylbenzenesulfonate: To a cooled mixture of (S)-3-(3-hydroxypropyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one (55 mg, 0.19 mmol, 1.0 equiv.) and triethylamine (40 mg, 0.38 mmol, 2.0 equiv.) in dichloromethane:dimethylformamide (2.0 mL:0.2 mL) at 0 ^oC was added 4-toluenesulfonyl chloride (55 mg, 0.28 mmol, 1.5 equiv.) followed by 4-dimethylaminopyridine (3 mg, 0.02 mmol, 0.1 equiv.). The resulting reaction mixture was stirred at 0 ^oC for 5 minutes before being warmed to 23 ^oC and allowed to stir for 24 hours. Then, the reaction mixture was diluted with dichloromethane (5 mL), washed with 1N HCl (1x5 mL). The aqueous layer was backwashed with dichloromethane (2x5 mL). The

combined organic layers were dried over Na_2SO_4 and concentrated in vacuo to give a crude product which was further purified by HPLC (CH_3CN/H_2O, 0.1% Formic acid), 0%~100%). ^1H NMR (400 MHz, $CDCl_3$) δ 7.78 (d, J= 8.2 Hz, 2H), 7.37 (d, J= 8.0 Hz, 2H), 6.84 (b, 1H), 4.04 (t, J= 5.9 Hz, 2H), 3.70 (m, 1H), 3.64-3.44 (m, 2H), 3.21-3.00 (m, 2H), 2.80 (s, 3H), 2.46 (s, 3H), 2.17 (dd, J= 6.8, 12.8 Hz, 1H), 2.01 (m, 1H), 1.91 (m, 1H), 1.81-1.66 (m, 2H), 1.66-1.44 (m, 5H).



[01219] Preparation of (S)-3-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: To a small vial was added (S)-3-(8-(methylsulfonyl)-1-oxo-2,8-diazaspiro[4.5]decan-3-yl)propyl 4-methylbenzenesulfonate (16 mg, 0.036 mmol, 1 equiv.) and 1-(4-fluorophenyl)piperazine (13.5 mg, 0.75 mmol, 2.1 equiv.) then both were dissolved in acetonitrile (0.4 mL). Then K_2CO_3 (13 mg, 0.089 mmol, 2.5 equiv.) was added and the reaction mixture was stirred at 80 °C overnight and then cooled to 23°C. The mixture was filtered, washed with acetonitrile and filtrate was concentrated in vacuo to give a crude product which was by further purified by column chromatography (MeOH/dichloromethane, 0% ~ 10%). ^1H NMR (400 MHz, $CDCl_3$) δ 7.02-6.92 (m, 3H), 6.92-6.84 (m, 2H), 3.72 (m, 1H), 3.59 (m, 1H), 3.50 (m, 1H), 3.31-3.09 (m, 6H), 2.81 (s, 3H), 2.74-2.56 (m, 4H), 2.46 (t, J= 6.2 Hz, 2H), 2.18 (dd, J= 6.6, 12.8 Hz, 1H), 2.09-1.90 (m, 2H), 1.74-1.43 (m, 7H). LC/MS [M+H] = m/z 453.2



[01220] Preparation of (S)-3-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (S)-3-(3-(4-(4-fluorophenyl)piperazin-1-yl)propyl)-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decan-1-one, except 1-(3-chlorophenyl)piperazine was substituted for 1-(4-fluorophenyl)piperazine. ^1H NMR (400 MHz, $CDCl_3$) δ 7.17 (t, J= 8.2 Hz, 1H), 6.92-6.85 (m, 2H), 6.84-6.76 (m, 2H), 3.72 (m, 1H), 3.60 (m, 1H), 3.50 (m, 1H), 3.32-3.13 (m, 6H), 2.81 (s,

3H), 2.71-2.55 (m, 4H), 2.45 (t, J= 6.3 Hz, 2H), 2.19 (dd, J= 6.7, 12.8 Hz, 1H), 2.09-1.90 (m, 2H), 1.73-1.44 (m, 7H). LC/MS [M+H] = m/z 469.2

Example 2: Exemplary Formulations

[01221] The present invention also relates to compositions or formulations which comprise the 5-hydroxytryptamine receptor 7 activity modulators according to the present invention. In general, the compositions of the present invention comprise an effective amount of one or more compounds of the disclosure and salts thereof according to the present invention which are effective for providing modulation of 5-hydroxytryptamine receptor 7 activity; and one or more excipients.

[01222] For the purposes of the present invention the term "excipient" and "carrier" are used interchangeably throughout the description of the present invention and said terms are defined herein as, "ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition."

[01223] The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.

[01224] The present teachings also provide pharmaceutical compositions that include at least one compound described herein and one or more pharmaceutically acceptable carriers, excipients, or diluents. Examples of such carriers are well known to those skilled in the art and can be prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in *Remington's Pharmaceutical Sciences*, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), the entire disclosure of which is incorporated by reference herein for all purposes. As used herein, "pharmaceutically acceptable" refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient. Accordingly, pharmaceutically acceptable carriers are those that are compatible with the other ingredients in

the formulation and are biologically acceptable. Supplementary active ingredients can also be incorporated into the pharmaceutical compositions.

[01225] Compounds of the present teachings can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents, or encapsulating materials. The compounds can be formulated in conventional manner, for example, in a manner similar to that used for known 5-hydroxytryptamine receptor 7 activity modulators. Oral formulations containing a compound disclosed herein can comprise any conventionally used oral form, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. In powders, the carrier can be a finely divided solid, which is an admixture with a finely divided compound. In tablets, a compound disclosed herein can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets can contain up to 99 % of the compound.

[01226] Capsules can contain mixtures of one or more compound(s) disclosed herein with inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.

[01227] Useful tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidine, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, and ion exchange resins. Surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations herein can utilize standard delay or

time-release formulations to alter the absorption of the compound(s). The oral formulation can also consist of administering a compound disclosed herein in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed.

[01228] Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups, elixirs, and for inhaled delivery. A compound of the present teachings can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a mixture of both, or a pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators. Examples of liquid carriers for oral and parenteral administration include, but are not limited to, water (particularly containing additives as described herein, e.g., cellulose derivatives such as a sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration, the carrier can be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants.

[01229] Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration can be in either liquid or solid form.

[01230] Preferably the pharmaceutical composition is in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the pharmaceutical composition can be sub-divided in unit dose(s) containing appropriate quantities of the compound. The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. Alternatively, the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. Such unit dosage form can contain from about 1 mg/kg of compound to about 500 mg/kg of compound, and can be given in a single dose or in two or more doses. Such doses can be administered in any manner useful in directing the compound(s) to the recipient’ s bloodstream, including orally, via implants, parenterally

(including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.

[01231] When administered for the treatment or inhibition of a particular disease state or disorder, it is understood that an effective dosage can vary depending upon the particular compound utilized, the mode of administration, and severity of the condition being treated, as well as the various physical factors related to the individual being treated. In therapeutic applications, a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications. The dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician. The variables involved include the specific condition and its state as well as the size, age and response pattern of the patient.

[01232] In some cases it may be desirable to administer a compound directly to the airways of the patient, using devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multidose dry-powder inhalers, pumps, squeeze-actuated nebulized spray dispensers, aerosol dispensers, and aerosol nebulizers. For administration by intranasal or intrabronchial inhalation, the compounds of the present teachings can be formulated into a liquid composition, a solid composition, or an aerosol composition. The liquid composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser. The solvents can be, for example, isotonic saline or bacteriostatic water. The solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation. The aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device. The propellants can be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other propellants that are physiologically and environmentally acceptable.]

[01233] Compounds described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or a pharmaceutically acceptable

salts, hydrates, or esters thereof can be prepared in water suitably mixed with a surfactant such as hydroxyl-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms.

[01234] The pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form can sterile and its viscosity permits it to flow through a syringe. The form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[01235] Compounds described herein can be administered transdermally, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administration can be carried out using the compounds of the present teachings including pharmaceutically acceptable salts, hydrates, or esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).

[01236] Transdermal administration can be accomplished through the use of a transdermal patch containing a compound, such as a compound disclosed herein, and a carrier that can be inert to the compound, can be non-toxic to the skin, and can allow delivery of the compound for systemic absorption into the blood stream via the skin. The carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the compound can also be suitable. A variety of occlusive devices can be used to release the compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound. Other occlusive devices are known in the literature.

[01237] Compounds described herein can be administered rectally or vaginally in the form of a conventional suppository. Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository’s melting

point, and glycerin. Water-soluble suppository bases, such as polyethylene glycols of various molecular weights, can also be used.

[01238] Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells either *in vitro* or *in vivo*. Lipid formulations and nanocapsules can be prepared by methods known in the art.

[01239] To increase the effectiveness of compounds of the present teachings, it can be desirable to combine a compound with other agents effective in the treatment of the target disease. For example, other active compounds (i.e., other active ingredients or agents) effective in treating the target disease can be administered with compounds of the present teachings. The other agents can be administered at the same time or at different times than the compounds disclosed herein.

[01240] Compounds of the present teachings can be useful for the treatment or inhibition of a pathological condition or disorder in a mammal, for example, a human subject. The present teachings accordingly provide methods of treating or inhibiting a pathological condition or disorder by providing to a mammal a compound of the present teachings including its pharmaceutically acceptable salt) or a pharmaceutical composition that includes one or more compounds of the present teachings in combination or association with pharmaceutically acceptable carriers. Compounds of the present teachings can be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment or inhibition of the pathological condition or disorder.

[01241] Non-limiting examples of compositions according to the present invention include from about 0.001 mg to about 1000 mg of one or more compounds of the disclosure according to the present invention and one or more excipients; from about 0.01 mg to about 100 mg of one or more compounds of the disclosure according to the present invention and one or more excipients; and from about 0.1 mg to about 10 mg of one or more compounds of the disclosure according to the present invention; and one or more excipients.

Example 3: General Biochemical Procedures

[01242] The following procedures can be utilized in evaluating and selecting compounds as 5-hydroxytryptamine receptor 7 activity modulators.

Radiolabel Binding Studies for Serotonin 5HT7 receptors, method 1:

[01243] A solution of the compound of the disclosure to be tested is prepared as a 1-mg/ml stock in Assay Buffer or DMSO according to its solubility. A similar stock of the

reference compound chlorpromazine is also prepared as a positive control. Eleven dilutions (5 x assay concentration) of the compound of the disclosure and chlorpromazine are prepared in the Assay Buffer by serial dilution to yield final corresponding assay concentrations ranging from 10 pM to 10 μM.

[01244] A stock concentration of 5 nM [^{3}H]LSD (lysergic acid diethyl amide) is prepared in 50 mM Tris-HCl, 10 mM $MgCl_2$, 1 mM EDTA, pH 7.4 (Assay Buffer). Aliquots (50 μl) of radioligand are dispensed into the wells of a 96-well plate containing 100 μl of Assay Buffer. Duplicate 50-μl aliquots of the compound of the disclosure test and chlorpromazine positive control reference compound serial dilutions are added.

[01245] Membrane fractions of cells expressing recombinant $5HT_7$ receptors (50μL) are dispensed into each well. The membranes are prepared from stably transfected cell lines expressing $5HT_7$ receptors cultured on 10-cm plates by harvesting PBS-rinsed monolayers, resuspending and lysing in chilled, hypotonic 50 mM Tris-HCl, pH 7.4, centrifuging at 20,000 x *g*, decanting the supernatant and storing at -80 ^{0}C; the membrane preparations are resuspended in 3 ml of chilled Assay Buffer and homogenized by several passages through a 26 gauge needle before using in the assay.

[01246] The 250-μl reactions are incubated at room temperature for 1.5 hours, then harvested by rapid filtration onto 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester. Four rapid 500-μl washes are performed with chilled Assay Buffer to reduce non-specific binding. The filter mats are dried, then scintillant is added to the filters and the radioactivity retained on the filters is counted in a Microbeta scintillation counter.

[01247] Raw data (dpm) representing total radioligand binding (*i.e.*, specific + non-specific binding) are plotted as a function of the logarithm of the molar concentration of the competitor (*i.e.*, test or reference compound). Non-linear regression of the normalized (*i.e.*, percent radioligand binding compared to that observed in the absence of test or reference compound) raw data is performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model describing ligand competition binding to radioligand-labeled sites:

$y = bottom + [(top-bottom)/(1 + 10x-logIC_{50})]$

where bottom equals the residual radioligand binding measured in the presence of 10 μM reference compound (*i.e.*, non-specific binding) and top equals the total radioligand binding observed in the absence of competitor. The log IC_{50} (*i.e.*, the log of the ligand concentration that reduces radioligand binding by 50%) is thus estimated from the data and used to obtain the *K*i by applying the Cheng-Prusoff approximation:

$Ki = IC_{50}/(1 + [ligand]/KD)$

where [ligand] equals the assay radioligand concentration and *K*D equals the affinity constant of the radioligand for the target receptor.

[01248] Compounds of the disclosure are also screened at a single concentration of 10 μM using the same method described for the Radiolabel Binding Studies for Serotonin $5HT_7$ receptors to determine the percent inhibition of [^{3}H]LSD binding.

Radiolabel Binding Studies for Serotonin 5-HT7 receptors, method 2:

[01249] A solution of the compound of the disclosure to be tested is prepared as a 1-mg/ml stock in Assay Buffer or DMSO according to its solubility. A similar stock of the reference compound chlorpromazine is also prepared as a positive control. Eleven dilutions (5 x assay concentration) of the compound of the disclosure and chlorpromazine are prepared in the Assay Buffer by serial dilution to yield final corresponding assay concentrations ranging from 10 pM to 10 μM.

[01250] A stock concentration of 5 nM [^{3}H]-5-Hydroxytryptamine ([^{3}H]-5HT) is prepared in 50 mM Tris-HCl, 10 mM $MgCl_2$, 1 mM EDTA, pH 7.4 (Assay Buffer). Aliquots (50 μl) of radioligand are dispensed into the wells of a 96-well plate containing 100 μl of Assay Buffer. Duplicate 50-μl aliquots of the compound of the disclosure test and chlorpromazine positive control reference compound serial dilutions are added.

[01251] Membrane fractions of cells expressing recombinant $5HT_7$ receptors (50μL) are dispensed into each well. The membranes are prepared from stably transfected cell lines expressing $5HT_7$ receptors cultured on 10-cm plates by harvesting PBS-rinsed monolayers, resuspending and lysing in chilled, hypotonic 50 mM Tris-HCl, pH 7.4, centrifuging at 20,000 x *g*, decanting the supernatant and storing at -80 ^{0}C; the membrane preparations are resuspended in 3 ml of chilled Assay Buffer and homogenized by several passages through a 26 gauge needle before using in the assay.

[01252] The 250-μl reactions are incubated at room temperature for 1.5 hours, then harvested by rapid filtration onto 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester. Four rapid 500-μl washes are performed with chilled Assay Buffer to reduce non-specific binding. The filter mats are dried, then scintillant is added to the filters and the radioactivity retained on the filters is counted in a Microbeta scintillation counter.

[01253] Raw data (dpm) representing total radioligand binding (*i.e.*, specific + non-specific binding) are plotted as a function of the logarithm of the molar concentration of the

competitor (*i.e.*, test or reference compound). Non-linear regression of the normalized (*i.e.*, percent radioligand binding compared to that observed in the absence of test or reference compound) raw data is performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model describing ligand competition binding to radioligand-labeled sites:

$y = bottom + [(top-bottom)/(1 + 10x\text{-}logIC_{50})]$

where bottom equals the residual radioligand binding measured in the presence of 10 μM reference compound (*i.e.*, non-specific binding) and top equals the total radioligand binding observed in the absence of competitor. The log IC_{50} (*i.e.*, the log of the ligand concentration that reduces radioligand binding by 50%) is thus estimated from the data and used to obtain the *K*i by applying the Cheng-Prusoff approximation:

$Ki = IC_{50}/(1 + [ligand]/KD)$

where [ligand] equals the assay radioligand concentration and *K*D equals the affinity constant of the radioligand for the target receptor.

[01254] Compounds of the disclosure are also screened at a single concentration of 10 μM using the same method described for the Radiolabel Binding Studies for Serotonin $5HT_7$ receptors to determine the percent inhibition of [^{3}H]-5HT binding.

[01255] Functional Serotonin $5HT_7$ assay, method 1:

[01256] Cell lines stably expressing human $5HT_7$ receptors are seeded in 96-well, poly-L-lysine-coated plates 48 hours prior to the assay (40,000 cells per well) in Dulbecco's Modified Eagle Medium (DMEM) containing 5% dialyzed serum. Twenty hours prior to the assay, the medium is changed to serum-free DMEM. On the day of the assay, the DMEM is washed and replaced with 30 μl of assay buffer (1X Krebs-Ringer bicarbonate glucose buffer, 0.75 mM IBMX, pH 7.4). A 10-min pre-incubation is performed in a 37-degree centigrade, humidified incubator. Then, the cells are stimulated by addition of 30 μl of 2X dilutions of compounds of the disclosure or chlorpromazine (final concentrations ranging from 0.1 nM to 10 μM, each concentration assayed in triplicate). A positive control (100 μM forskolin) is also included. Accumulation of cAMP is allowed to continue for 15 min, after which the buffer is removed and the cells are lysed with Cell Lysis Buffer (CatchPoint cAMP Assay Kit, Molecular Devices). Next, the lysates are transferred to 96-well, glass-bottom plates coated with goat anti-rabbit IgG and adsorbed with rabbit anti-cAMP (Molecular Devices). Following a 5 minute incubation, horseradish peroxidase-cAMP conjugate is added (Molecular Devices) and a 2-hour incubation is performed at room temperature. Then, after three washes with Wash Buffer (Molecular Devices), Stoplight Red substrate (Molecular Devices), reconstituted in Substrate Buffer

(Molecular Devices) containing freshly-added 1 mM H_2O_2, is added and, after a 15-min incubation at room temperature, fluorescence is measured (excitation 510-545 nm, emission 565-625 nm). For each assay, a cAMP calibration curve is generated and controls without lysate and without antibody are included.

[01257] For agonist tests, raw data (maximum fluorescence, fluorescence units) for each concentration of the compounds of the disclosure or chlorpromazine are normalized to the basal (vehicle-stimulated) fluorescence (reported as fold increase over basal) and plotted as a function of the logarithm of the molar concentration of the drug (i.e., test or reference compound). Non-linear regression of the normalized data is performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model (i.e., sigmoidal concentration-response) describing agonist-stimulated activation of one receptor population:

y = bottom + [(top-bottom)/(1 + 10x-logEC50)]

where bottom equals the best-fit basal fluorescence and top equals the best-fit maximal fluorescence stimulated by the compound of the disclosure or chlorpromazine. The log EC_{50} (i.e., the log of the drug concentration that increases fluorescence by 50% of the maximum fluorescence observed for the compound of the disclosure or chlorpromazine is thus estimated from the data, and the EC_{50} (agonist potency) is obtained. To obtain an estimate of the relative efficacy of the test compound (Rel. Emax), its best-fit top is compared to and expressed as a ratio of that for the chlorpromazine (Rel. Emax of the reference agonist is 1.00).

[01258] To ascertain whether compounds of the disclosure are antagonists, a double-addition paradigm is employed. First, 30 µl of a compound of the disclosure (20 µM) is added (10 µM final concentration) and a 15 minute incubation is performed. Then, 30 µl of chlorpromazine (3X; EC_{90}) is added (final concentration of agonist is EC30) and cAMP accumulation is allowed to proceed for 15 minutes. The samples are then processed for cAMP measurements as detailed above. Measurements of chlorpromazine -induced cAMP accumulation are compared to the signals elicited by the chlorpromazine following addition of vehicle instead of test compound and expressed as a ratio. 'Hits' (compounds that antagonize chlorpromazine -stimulated increases in baseline-normalized fluorescence by at least 50%) are then characterized by a modified Schild analysis.

[01259] For modified Schild analysis, a family of chlorpromazine concentration-response isotherms is generated in the absence and presence of graded concentrations of test compound (added 15 min prior to reference agonist). Theoretically, compounds that are competitive

antagonists cause a dextral shift of agonist concentration-response isotherms without reducing the maximum response to agonist (i.e., surmountable antagonism). However, on occasion, factors such as non-competitive antagonism, hemiequilibria, and/or receptor reserve cause apparent insurmountable antagonism. To account for such deviations, we apply the modified Lew-Angus method to ascertain antagonist potency (Christopoulos et al., 1999). Briefly, equieffective concentrations of agonist (concentrations of agonist that elicit a response equal to the $EC_{25\%}$ of the agonist control curve) are plotted as a function of the compound of the disclosure concentration present in the wells in which they were measured. Non-linear regression of the baseline-normalized data is performed in Prism 4.0 using the following equation:

pEC25% = -log ([B] + 10-pK) - log c

where EC25% equals the concentration of agonist that elicits a response equal to 25% of the maximum agonist control curve response and [B] equals the antagonist concentration; K, c, and s are fit parameters. The parameter s is equal to the Schild slope factor. If s is not significantly different from unity, pK equals pKB; otherwise, pA2 is calculated (pA2 = pK/s). The parameter c equals the ratio $EC_{25\%}$/[B].

Functional efficacy assay for 5-HT_7 receptors method 2:

[01260] Functional efficacy of the compounds of the disclosure on 5-HT_7 serotonin receptors were measured in a cell based cAMP enzyme fragment complementation assay using the HitHunter cAMP assay (DiscoveRx). Cells stably expressing human $5HT_7$ receptors were plated in 96-well plates at 4000 cells/well, 16-20 hours prior to assay in growth media (Ultraculture medium, 2 mM GlutaMax and G418 1 mg/mL. Serial dilutions of the agonist, 5-Carboxamidotryptamine (5-CT), were prepared in a final concentration range of 10 μM to 10 nM. Compounds of the disclosure were prepared in 3-fold serial dilutions to obtain a final concentration range of 10μM to 0.1 nM. Compounds of the disclosure are tested for agonist activity in the absence of 5-CT and antagonist activity in the presence of 5-CT. For the cAMP assay, the protocol was followed according to the instructions provided by the supplier. Briefly, cells were incubated with a compound of the disclosure for 30 minutes at 37 °C prior to addition of EC_{70} concentration of 5-CT. After an additional 30 minutes, cAMP antibody/cell lysis solution was added (20 μL/well) and incubated for 60 minutes at room temperature. cAMP XS + EA reagent is added (20 μL/well) and incubated for 2 hours at room temperature. Luminescence was read on the Envision Multilabel plate reader.

[01261] The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

[01262] While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Example 4: Biochemical Experiments

Methods:

[1]Radiolabeled Binding (IC_{50} and K_I)

[01263] A solution of the compound of the disclosure to be tested was prepared as a 1-mg/ml stock in Assay Buffer or DMSO according to its solubility. A similar stock of the reference compound chlorpromazine was also prepared as a positive control. Eleven dilutions (5 x assay concentration) of the compound of the disclosure and chlorpromazine were prepared in the Assay Buffer by serial dilution to yield final corresponding assay concentrations ranging from 10 pM to 10 μM.

[01264] A stock concentration of 5 nM [^{3}H]LSD (lysergic acid diethyl amide) was prepared in 50 mM Tris-HCl, 10 mM $MgCl_2$, 1 mM EDTA, pH 7.4 (Assay Buffer). Aliquots (50 μl) of radioligand were dispensed into the wells of a 96-well plate containing 100 μl of Assay Buffer. Duplicate 50-μl aliquots of the compound of the disclosure test and chlorpromazine positive control reference compound serial dilutions were added.

[01265] Membrane fractions of cells expressing recombinant $5HT_7$ receptors (50μL) were dispensed into each well. The membranes were prepared from stably transfected cell lines expressing $5HT_7$ receptors cultured on 10-cm plates by harvesting PBS-rinsed monolayers, resuspending and lysing in chilled, hypotonic 50 mM Tris-HCl, pH 7.4, centrifuging at 20,000 x *g*, decanting the supernatant and storing at -80 ^{0}C; the membrane preparations were resuspended in 3 ml of chilled Assay Buffer and homogenized by several passages through a 26 gauge needle before using in the assay.

[01266] The 250-μl reactions were incubated at room temperature for 1.5 hours, then harvested by rapid filtration onto 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester. Four rapid 500-μl washes were performed with chilled Assay Buffer to reduce non-specific binding. The filter mats were dried, then scintillant is added to the filters and the radioactivity retained on the filters was counted in a Microbeta scintillation counter.

[01267] Raw data (dpm) representing total radioligand binding (*i.e.*, specific + non-specific binding) was plotted as a function of the logarithm of the molar concentration of the competitor (*i.e.*, test or reference compound). Non-linear regression of the normalized (*i.e.*,

percent radioligand binding compared to that observed in the absence of test or reference compound) raw data was performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model describing ligand competition binding to radioligand-labeled sites:

$$y = \text{bottom} + [(\text{top-bottom})/(1 + 10^{x\text{-log}IC_{50}})]$$

where bottom equals the residual radioligand binding measured in the presence of 10 μM reference compound (*i.e.*, non-specific binding) and top equals the total radioligand binding observed in the absence of competitor. The log IC_{50} (*i.e.*, the log of the ligand concentration that reduces radioligand binding by 50%) was thus estimated from the data and used to obtain the *K*i by applying the Cheng-Prusoff approximation:


$$Ki = IC_{50}/(1 + [\text{ligand}]/KD)$$

where [ligand] equals the assay radioligand concentration and *K*D equals the affinity constant of the radioligand for the target receptor.

Functional Data (K_b)

[01268] Functional efficacy of the compounds of the disclosure on 5-HT_7 serotonin receptors were measured in a cell based cAMP enzyme fragment complementation assay using the HitHunter cAMP assay (DiscoveRx). Cells stably expressing human $5HT_7$ receptors were plated in 96-well plates at 4000 cells/well, 16-20 hours prior to assay in growth media (Ultraculture medium, 2 mM GlutaMax and G418 1 mg/mL. Serial dilutions of the agonist, 5-hydroxytryptamine (5-HT), were prepared in a final concentration range of 10 μM to 10 nM. Compounds of the disclosure were prepared in 3-fold serial dilutions to obtain a final concentration range of 10μM to 0.1 nM. Compounds of the disclosure are tested for agonist activity in the absence of 5-HT and antagonist activity in the presence of 5-HT. For the cAMP assay, the protocol was followed according to the instructions provided by the supplier. Briefly, cells were incubated with a compound of the disclosure for 30 minutes at 37 °C prior to addition of EC_{70} concentration of 5-HT. After an additional 30 minutes, cAMP antibody/cell lysis solution was added (20 μL/well) and incubated for 60 minutes at room temperature. cAMP XS + EA reagent is added (20 μL/well) and incubated for 2 hours at room temperature. Luminescence was read on the Envision Multilabel plate reader.


Results



(XLI)

Table 34:

n	R^1	R^2	R^3	IC_{50} (nM)[1]	K_i (nM)[1]	K_b (nM)[2]	TPSA
2	Ethyl	Ethyl	4-F-Phenyl		8.5	8.98	35.6
2	Ethyl	Ethyl	4-Cl-Phenyl		13	54.6	35.6
2	Ethyl	Ethyl	2-iPr-phenyl		23	163	35.6
2	Ethyl	Ethyl	2-morpholino-phenyl		24	32.3	48.1
2	Ethyl	Ethyl	4-Me-Phenyl		28	24.1	35.6
2	Ethyl	Ethyl	4-OH-Phenyl		34	50	55.8
2	Ethyl	Ethyl	Phenyl		68	17.8	35.6
2	Ethyl	Ethyl	4-Me-2-morpholino-phenyl		74	59.3	48.1




(XLII)

Table 35:

n	R^1	R^2	R^3	IC_{50} (nM)[1]	K_i (nM)[1]	K_b (nM)[2]	TPSA
1	Ethyl	Ethyl	2-iPr-phenyl		121		35.6
1	Ethyl	Ethyl	4-Me-2-morpholino-phenyl		132	43.8	48.1
1	Ethyl	Ethyl	4-F-Phenyl		243		35.6
1	Ethyl	Ethyl	4-Me-Phenyl		249		35.6
1	Ethyl	Ethyl	2-pyridyl		669		48.5


1	Ethyl	Ethyl	Phenyl		819		35.6
1	Ethyl	Ethyl	3-Cl-Phenyl		1087		35.6
2	Ethyl	Ethyl	4-Me-Phenyl		11	8.43	35.6
2	Ethyl	Ethyl	4-F-Phenyl	12.34		0.81	35.6
2	Ethyl	Ethyl	3,4-di-Cl-Phenyl	82.8		6.19	35.6
2	Ethyl	Ethyl	4-F-3-Cl-Phenyl	8.7		1.92	35.6
2	Ethyl	Ethyl	3-Cl-Phenyl	9.9		1.38	35.6
2	Ethyl	Ethyl	Phenyl			6.59	35.6
2	Ethyl	Ethyl	2-Cl-Phenyl			109	35.6
2	Ethyl	Ethyl	3-F-Phenyl			9.89	35.6
2	Ethyl	Ethyl	2-Me-Phenyl			127	35.6
2	Ethyl	Ethyl	3-Me-Phenyl			1.65	35.6
2	Ethyl	Ethyl	2-pyridyl			4.91	48.5
2	Ethyl	Ethyl	2-OMe-Phenyl			230	44.8
2	Ethyl	Ethyl	4-CN-Phenyl			544	59.4
2	Ethyl	Ethyl	4-CF_3-Phenyl			137	35.6



(XLIII)

Table 36:


n	R^1	R^2	R^3	IC_{50} (nM)[1]	K_i (nM)[1]	K_b (nM)[2]	TPSA
2	Ethyl	Ethyl	4-Me-Phenyl		79	58.1	35.6
2	- $CH_2CH=CHCH_2$-		4-F-Phenyl			46.2	35.6
2	- $CH_2CH=CHCH_2$-		3-Cl-Phenyl			36.3	35.6
2	- $CH_2CH_2CH_2CH_2$-		4-F-Phenyl			52.6	35.6
2	- $CH_2CH_2CH_2CH_2$-		3-Cl-Phenyl			48.4	35.6



(XLIV)

Table 37:


n	R^3	R^7	IC_{50} (nM)[1]	K_i (nM)[1]	K_b (nM)[2]	TPSA
2	3-Cl-Phenyl	Acetyl		63	5.04	55.9
2	4-F-Phenyl	Acetyl		76	14.4	55.9
2	4-F-Phenyl	$MeSO_2$		89	30.7	81.3
2	3-Cl-Phenyl	$MeSO_2$		107	13.5	81.3
3	3-Cl-Phenyl	$MeSO_2$			321	81.3
3	4-F-Phenyl	$MeSO_2$			526	81.3



(XLV)

Table 38:

n	R^3	R^7	IC_{50} (nM)[1]	K_i (nM)[1]	K_b (nM)[2]	TPSA
2	3-Cl-Phenyl	$MeSO_2$		117		81.3
2	4-F-Phenyl	$MeSO_2$		167	74.2	81.3
2	3-Cl-Phenyl	Acetyl		214		55.9
2	4-F-Phenyl	Acetyl		325		55.9



(XLVI)

Table 39:

n	R^1	R^2	R^3	IC_{50} (nM)[1]	K_i (nM)[1]	K_b (nM)[2]	TPSA
2	Ethyl	Ethyl	Phenyl			144	35.6


[01269] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

[01270] All references, patents or applications, U.S. or foreign, cited in the application are hereby incorporated by reference as if written herein in their entireties. Where any inconsistencies arise, material literally disclosed herein controls.

CLAIMS



WHAT IS CLAIMED IS:

1. A compound having formula **(I)**:



(I),

including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

A is selected from a group consisting of  , and  ;


R^1 is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl;


R^2 is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl;

or R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having from 5 to 7 ring atoms, optionally containing a double bond;

or R^1 and R^2 are taken together with the atoms to which they are bound to form a ring having from 6 to 8 ring atoms containing a moiety selected from the group consisting of O, S, SO, SO_2, and NR^7;

R^3 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl, and  ;

R^4 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl and  ;

R^5 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl and  ;

R^6 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthylen-1-yl, optionally substituted naphthylen-2-yl, optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, and optionally substituted 4-pyridyl;













R^7 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, COR^8, CO_2R^9, $CONR^{10a}R^{10b}$, $SO_2NR^{10a}R^{10b}$, and SO_2R^{10c};

R^8 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^9 is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10a} is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10b} is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{10c} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, $-(CH_2)_qCN$, $-(CH_2)_qSO_2R^{11}$, $-(CH_2)_qOR^{12}$,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  ;

R^{11} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{12} is selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^{1e} are at each occurrence independently selected from the group consisting of H, OH, NO_2, halogen, CN, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, -S(C_{1-6} linear alkyl), S(C_{3-7} branched alkyl), -S(C_{3-7} cycloalkyl), COR^{13}, CO_2R^{14}, $CONR^{15a}R^{15b}$, $SO_2NR^{15a}R^{15b}$, $NR^{16a}R^{16b}$, $NR^{16a}COR^{17}$, $NR^{16a}SO_2R^{18}$, and $NR^{16a}SO_2NR^{19a}R^{19b}$;

R^{13} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{14} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{15a} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{15b} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{16a} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{16b} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{17} is at each occurrence independently selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{18} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{19a} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{19b} is at each occurrence independently selected from the group consisting of C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

n is 1, 2, 3, or 4;

m is 1, 2, or 3.

2. The compound of claim 1, wherein:

A is  ;

each R^1 and R^2 is independently C_{1-6} linear alkyl or C_{3-7} branched alkyl; or R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring,

wherein said 5- to 8-membered ring is saturated or comprises a carbon-carbon double bond, and/or a ring atom that is O, S, SO, SO_2, or NR^7

each R^3, R^4, and R^5 is independently optionally substituted phenyl, optionally optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, or optionally substituted 4-pyridyl;

R^6 is independently optionally substituted phenyl, optionally optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, or optionally substituted 4-pyridyl;

R^7 is independently H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, COR^8, or SO_2R^{10c};

R^8 is selected from the group consisting of H, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{10c} is C_{1-6} linear alkyl or C_{3-7} branched alkyl;

n is 1, 2, 3, or 4; and

m is 1, 2, or 3.

3. The compound of claim 1 or 2, wherein n is 1, 2 ,or 3.


4. The compound of any one of claims 1-3, having the formula **(II)**:



(II)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

5. The compound of claim 4, having the formula **(XXXXII)**:




(XXXXII) or a pharmaceutically acceptable salt thereof.

6. The compound of claim 4, having the formula (**XXXXIII**):




(XXXXIII) or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, having the formula (**IIa**):



(IIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

8. The compound of claim 1, having the formula **(IIe)**:



(IIe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

9. The compound of claim 1, having the formula (**IIi**):



(IIi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, –NO_2, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

10. The compound of claim 1, having the formula **(IIm)**:



(IIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20cd}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

11. The compound of claim 1, having the formula **(IIq)**:



(IIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

12. The compound of claim 1, having the formula **(IIu)**:



(IIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.


13. The compound of claim 1, having the formula **(III)**:



(III)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

14. The compound of claim 1, having the formula **(IIIa)**:



(IIIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

15. The compound of claim 1, having the formula **(IIIe)**:



(IIIe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

16. The compound of claim 1, having the formula **(IIIi)**:



(IIIi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

17. The compound of claim 1, having the formula **(IIIm)**:



(IIIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

18. The compound of claim 1, having the formula **(IIIq)**:



(IIIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

19. The compound of claim 1, having the formula **(IIIu)**:



(IIIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.


20. The compound of claim 1, having the formula **(IV)**:



(IV)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

21. The compound of claim 20, having the following formula,




, or a pharmaceutically acceptable salt thereof.

22. The compound of claim 20, having the following formula,



, or a pharmaceutically acceptable salt thereof.


23. The compound of claim 1, having the formula **(IVa)**:



(IVa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-}

$_{7}$cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

24. The compound of claim 1, having the formula **(IVe)**:



(IVe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

25. The compound of claim 1, having the formula **(IVi)**:



(IVi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

26. The compound of claim 1, having the formula **(IVm)**:



(IVm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

27. The compound of claim 1, having the formula **(IVq)**:



(IVq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

28. The compound of claim 1, having the formula **(IVu)**:



(IVu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.


29. The compound of claim 1, having the formula **(V)**:



(V)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

30. The compound of claim 1, having the formula **(Va)**:



(Va)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

31. The compound of claim 1, having the formula **(Vb)**:




(Vb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

Q^1 is 1 or 2;

and Q^2 is 1 or 2.


32. The compound of claim 1, having the formula **(Ve)**:



(Ve)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-}

$_{7}$cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

33. The compound of claim 1, having the formula **(Vi)**:



(Vi)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

34. The compound of claim 1, having the formula **(Vm)**:



(Vm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

35. The compound of claim 1, having the formula **(Vq)**:



(Vq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

36. The compound of claim 1, having the formula **(Vu)**:



(Vu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.


37. The compound of claim 1, having the formula **(VI)**:



(VI)


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

38. The compound of claim 37, having the formula **(XXXXVI)**:




(XXXXVI) , or a pharmaceutically acceptable salt thereof.

39. The compound of claim 37, having the formula:




, or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1, having the formula **(VIa)**:



(VIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

41. The compound of claim 1, having the formula **(VIe)**:



(VIe)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, –NO_2, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.


42. The compound of claim 1, having the formula (**VIi**):



(VIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, –NO_2, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched

haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.


43. The compound of claim 1, having the formula **(VIm)**:



(VIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof, wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-}

$_{7}$cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

44. The compound of claim 1, having the formula (**VIq**):



(VIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

45. The compound of claim 1, having the formula (**VIu**):



(VIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.


46. The compound of claim 1, having the formula **(VII)**:



(VII)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


47. The compound of claim 1, having the formula **(VIIa)**:



(VIIa)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-}

$_{7}$cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 3 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, and R^{20e} are hydrogen.

48. The compound of claim 1, having the formula **(VIIe)**:



(VIIb)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20d} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

49. The compound of claim 1, having the formula **(VIIi)**:



(VIIc)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20e} are hydrogen.

50. The compound of claim 1, having the formula **(VIIm)**:



(VIIm)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20d}, and R^{20e} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 2 of R^{20a}, R^{20b}, R^{20c}, and R^{20d} are hydrogen.

51. The compound of claim 1, having the formula **(VIIq)**:



(VIIq)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and 

;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;


and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

52. The compound of claim 1, having the formula **(VIIu)**:



(VIIu)

Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof wherein

R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are independently selected from the group consisting of hydrogen, –CN, $–NO_2$, -OH, halogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{3-7} cycloalkyl, C_{1-6} linear alkoxy, C_{3-7} branched alkoxy, C_{3-7} cycloalkoxy, C_{1-6} linear haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} linear haloalkoxy, C_{3-7} branched haloalkoxy, SH, SC_{1-6} linear alkyl, SC_{3-7} branched alkyl, SC_{3-7}cycloalkyl, SO_2C_{1-6} linear alkyl, SO_2C_{3-7} branched alkyl, SO_2C_{3-7}cycloalkyl, SO_2NH_2, SO_2NHR^{21}, $NHSO_2R^{22}$, $-NR^{23a}R^{23b}$, $NHC(O)R^{24}$, $C(O)NHR^{24}$, $C(O)N(R^{24})_2$, morpholino, and  ;

R^{21} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{22} at each occurrence is independently selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23a} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{23b} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{24} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

R^{25} at each occurrence is independently is selected from the group consisting of hydrogen, C_{1-6} linear alkyl, C_{3-7} branched alkyl, and C_{3-7} cycloalkyl;

and at least 5 of R^{20a}, R^{20b}, R^{20c}, R^{20d}, R^{20e}, R^{20f}, and R^{20g} are hydrogen.

53. The compound of any one of claims 1-52, wherein R^1 and R^2 are each independently C_{1-6} linear alkyl or C_{3-7} branched alkyl.


54. The compound of claim 53, wherein each of R^1 and R^2 is ethyl.

55. The compound of any one of claims 1-52, wherein R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring, optionally containing one carbon-carbon double bonds and/or a ring atom selected from the group consisting of O, S, SO, SO_2, and NR^7.

56. The compound of claim 55, wherein R^1 and R^2 are taken together with the atoms to which they are bound to form a C_3-C_8 cycloalkyl or a C_5-C_8 cycloalkenyl.

57. The compound of claim 56 wherein R^1 and R^2 are taken together with the atoms to which they are bound to form a cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, or cyclooctenyl.

58. The compound of any one of claims 55-57, having the formula **(XLIIIa)**:



(XLIIIa) , or

a pharmaceutically acceptable salt thereof, wherein ------ represents a single or double bond.

59. The compound of claim 58, wherein ------ represents a single bond.

60. The compound of claim 58, wherein ------ represents a double bond.

61. The compound of claim 55, wherein R^1 and R^2 are taken together with the atoms to which they are bound to form a 5- to 8-membered ring containing a ring atom that is NR^7.

62. The compound of claim 61, wherein R^1 and R^2 are taken together to form a pyrrolidinyl or piperidinyl group where the nitrogen atom is NR^7.


63. The compound of claim 61 or 62, wherein R^7 is COR^8, and R^8 is C_{1-6} linear alkyl.

64. The compound of claim 63, wherein R^7 is acetyl.

65. The compound of claim 61 or 62, wherein R^7 is SO_2R^{10c}, and R^{10c} is C_{1-6} linear alkyl.

66. The compound of claim 65, wherein R^{10c} is methyl.


67. The compound of any one of claims 61-66, having the formula **(XLIIIb)**:



(XLIIIb)

, or a pharmaceutically acceptable salt thereof.


68. The compound of claim 67, having the formula **(XLIV)**:



(XLIV)

, or a pharmaceutically acceptable salt thereof.

69. The compound of claim 67, having the formula **(XLV)**:



(XLV)


, or a pharmaceutically acceptable salt thereof.

70. The compound of any one of claims 53-69, wherein R^3 is unsubstituted phenyl.


71. The compound of any one of claims 53-69, wherein R^3 is substituted phenyl, wherein the substitutents are selected from the group consisting of hydroxyl, halo, cyano, C_{1-6} alkoxy, C_{1-6} linear alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, and heterocylyl.

72. The compound of claim 71, wherein R^3 is selected from the group consisting of 4-hydroxyphenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-fluoro-3-chlorophenyl, 4-cyanophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl, 4-trifluoromethylphenyl, 2-morpholinophenyl, and 4-methyl-2-morpholinophenyl.

73. The compound of any one of claims 53-69, wherein R^3 is 2-pyridyl.

74. The compound of any one of claims 53-56 and 61-62, wherein A is  , and R^5 is optionally substituted phenyl.


75. The compound of claim 74, having the formula **(XLVI)**,



(XLVI)

, or a pharmaceutically acceptable salt thereof.

76. The compound of claim 74, having the formula **(XLVIa)**,



(XLVIa)

, or a pharmaceutically acceptable salt thereof.

77. The compound of claim 74, wherein R^5 is unsubstituted phenyl.

78. The compound of claim 74, wherein R^5 is selected from the group consisting of 4-hydroxyphenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-

dichlorophenyl, 4-fluoro-3-chlorophenyl, 4-cyanophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl, 4-trifluoromethylphenyl, 2-morpholinophenyl, and 4-methyl-2-morpholinophenyl.

79. The compound of any one of claims 1-78, or a pharmaceutically acceptable salt thereof.

80. The compound of claim 79, wherein the compound is a compound described in any one of Tables 1-39, or a pharmaceutically acceptable salt thereof.

81. The compound of claim 80, wherein the compound is a compound described in any one of Tables 34-39, or a pharmaceutically acceptable salt thereof.

82. A composition comprising an effective amount of at least one compound according to any one of claims 1–81, or a pharmaceutically acceptable salt thereof.

83. A composition according to claim 82, further comprising at least one excipient.

84. A method of treating a disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, said method comprising administering to a subject an effective amount of at least one compound according to any one of claims 1–81, or a pharmaceutically acceptable salt thereof.

85. The method of claim 84, wherein the at least one compound, or a pharmaceutically acceptable salt thereof, is administered in a composition further comprising at least one excipient.

86. The method of claim 84 or 85, wherein the disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity is selected from the group consisting of circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention

deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestine neuroendocrine tumors, and lung injury.

87. The method of claim 84 or 85, wherein the disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity is inflammatory bowel disease (IBD) or intestinal inflammation.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2019/031824

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D207/20 C07D209/96 C07D401/06 C07D401/12 C07D471/10
C07D487/04 A61P25/00 A61K31/497 A61K31/4015
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 066 651 A (REGNIR GILBERT [FR] ET AL) 19 November 1991 (1991-11-19)	1-7,14
A	compounds of formula (II) column 2; claims; examples 5,6	8-13, 15-87

Y	WO 2016/040554 A1 (UNIV TEMPLE [US]) 17 March 2016 (2016-03-17) claims; examples; table 2	1-87

Y	BALAZS VOLK ET AL.: "Optimization of the (Arylpiperazinylbutyl)oxindoles Exhibiting Selective 5-HT7 Receptor Antagonist Activity", J.MED.CHEM., vol. 54, 2011, pages 6657-6669, XP002793163, DOI: dc.doi.org/10.1021/jm200547z the whole document	1-87

	-/--	

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 July 2019	05/08/2019

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Gavriliu, Daniela

1

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2019/031824

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DÍAZ-CERVANTES ERIK ET AL: "In vitro and in silico evaluation of twelve newly-synthesized 1-acetamide-5-methoxy-2-oxindoles as 5-Ht7receptor ligands", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 25, no. 7, 13 February 2015 (2015-02-13), pages 1580-1585, XP029148565, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2015.02.008 the whole document -----	1-87

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2019/031824

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5066651 A	19-11-1991	AT 119149 T	15-03-1995
		AU 617945 B2	05-12-1991
		CA 2017044 A1	30-11-1990
		DE 69017265 D1	06-04-1995
		DE 69017265 T2	19-10-1995
		DK 0401093 T3	10-07-1995
		EP 0401093 A1	05-12-1990
		ES 2071793 T3	01-07-1995
		FR 2647785 A1	07-12-1990
		IE 67060 B1	21-02-1996
		JP H0320259 A	29-01-1991
		JP H0688972 B2	09-11-1994
		NZ 233618 A	26-11-1991
		OA 9451 A	15-10-1992
		PT 94196 A	08-02-1991
		US 5066651 A	19-11-1991
		ZA 9003944 B	27-03-1991
WO 2016040554 A1	17-03-2016	EP 3200589 A1	09-08-2017
		US 2017298037 A1	19-10-2017
		WO 2016040554 A1	17-03-2016